<SEC-DOCUMENT>0001558370-25-003406.txt : 20250321
<SEC-HEADER>0001558370-25-003406.hdr.sgml : 20250321
<ACCEPTANCE-DATETIME>20250320203234
ACCESSION NUMBER:		0001558370-25-003406
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250321
DATE AS OF CHANGE:		20250320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Armata Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37544
		FILM NUMBER:		25758305

	BUSINESS ADDRESS:	
		STREET 1:		5005 MCCONNELL AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90066
		BUSINESS PHONE:		310-665-2928

	MAIL ADDRESS:	
		STREET 1:		5005 MCCONNELL AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90066

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AmpliPhi Biosciences Corp
		DATE OF NAME CHANGE:	20130222

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>armp-20241231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/21/2025 12:13:17 AM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: f5abd67a-2148-471f-877a-401d760c476e -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:armp="http://www.armatapharma.com/20241231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>ARMATA PHARMACEUTICALS, INC._December 31, 2024</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" xs:nil="true" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" name="us-gaap:CommitmentsAndContingencies" id="Hidden_QxxCRg4_J0WVs2POc4bI3Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" xs:nil="true" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_CgMkDhwOWkOK21k_ANT1Ew"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityCentralIndexKey" id="Tc_tdUaBHS_U0OBCW6dE6O9oQ_2_1">0000921114</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:DocumentFiscalPeriodFocus" id="Tc_fLf6ZcVOL0e97AOJPQoXmg_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:AmendmentFlag" id="Tc_NvxguUVOmku9UYunf92P4Q_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_6QVF5TJnNUu6xhAL_qid-w" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_XOwD5nV2WEyBnp53UOQlCw">http://fasb.org/us-gaap/2024#RevenueNotFromContractWithCustomer</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_kA-sXj9xmUyv5HjdSnfDDQ" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_4FqYFdy5Z0uAKDas3B1bxA">http://fasb.org/us-gaap/2024#RevenueNotFromContractWithCustomer</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" id="Hidden_-Eh2dCRyZEObk0oB6hPNcg">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lY150wsNP02MP9zqV76jPQ" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_xUrXavuJzEKCYO2cJuMBNA">http://fasb.org/us-gaap/2024#GainsLossesOnExtinguishmentOfDebt</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__36xUotZ3Emz9Qt3QZqLDQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_GZ0DQ00E2US7iMhH9yvSLg">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_Bf3h2ZhloEidThSSRPvQFw" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Hidden_gW2qZueRtk-fdI8-fDXRnA">P1Y10M24D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_f3OfRucBq0qiXxxXxag-WQ" name="us-gaap:GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration" id="Hidden_jN3anHbpa0isGOdK9gp3IA">http://fasb.org/us-gaap/2024#OtherAssetsCurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="armp-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_reOzmK0NOUyOz-GslMRWRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K4ieWmLnSUyd7TzJckLcIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lRVURMKV0SoOkMJkefoHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TdUVPQRZ90GLDTkGnv6akw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_z3NSngTeFUqo0EjEQOAFlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1Rw3csLgjECALBKYfsINwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EqQhMtDQN0uq2op06-vOIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WYP4LOLiVE2vVMYho8f0Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H4YKiME1IEWZOdKMpzlX5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_T8FTsTcprUy8rKzW-XC3EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_gGZqSnGwP0OUUcdXV26XfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_PdC_SAUxUUK65xSOy8LXqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_NG9OliLZLUqYSqXnApcGDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_umBgF7ml2kCrfw0hSCQoPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_2hEBCqxGoUqgVYfZknvwGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_pJH1VOMu10ubY-ejaciVcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_8COWQsEZn0Wg7V4VXWyPng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GhrtbpfWc0emjiaVORy1SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_QarzicNc2kSX3wxOAwoMJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_f61X9uE-N0-LLpqFLPWZgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__36xUotZ3Emz9Qt3QZqLDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ct6tmhYJKEW98JUYWA7SAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_X0p3Xo14WU6gPCeyKpTmXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_F1-n7zRE20q0EmkRbZO3CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_aDlY3wA3nk6hKsCmJ4oMww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_TwxvP62zB0uMlwhQkUWi8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_16WVW7L1UEKVDZzpv4Vrkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Tfkx6Pkwf02KkxOhwrASHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_aI2oyISraU2WBXG-8aXVKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_3TzGv1YAjkGo6HRjhuGnGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_5Jnw-tluDEu-Kx_JvwRpgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_p7FgB_AuUke_7o5Nlzb6Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Osvcwobb1UGHl_jI9F_1uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kYqBxC16p0K1mZ2qlRBw6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_D0CIVBrcHkCADcgqae2kVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_iIfGtoSfVkOyLJgO8EHWrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_qx3dYJjAE0ynK7mpFACMVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_CQpyd18Ds0qh3m21NnuflA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_iRtQVHneb02Vlx_hfCVCVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_yrOpWPoZBU2cuEPXaihZtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6Y5SYi_BTUa8vlarva5peg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_12iaGKNXCkqYkhajskEVlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b2xRzt0_BUqhKZ6JbrdY4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_OwnershipAxis_armp_ArmataPharmaceuticalsIncMember_Gv-ymKjfckGEyekgNJZuSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">armp:ArmataPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_10_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9MsN49-EsUuh7lrZcuBNDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-10</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_RBZa_N6QqUyQ2oiWdEiprQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_lYQF9icj1kuOL4xigHQzKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_KilvybAjfU2MMseKFQN_pA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_ISHRxxWU70-yPTo0clBZbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_AUoppBe8TkmxEisCXjCy5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_XpvWEZpmi0eXkPlF_gpoDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_e8KlhRKgsU2__dqtJNLl0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_15_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_2_29PgfsbkCQszk3gpXeEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_13_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_HJ-pxCwh90SIPJv_UoUV2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_f3OfRucBq0qiXxxXxag-WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_29_2022_To_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_V-g9tOqDXE2fXuEN9aCnWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-29</xbrli:startDate><xbrli:endDate>2022-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_kA-sXj9xmUyv5HjdSnfDDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_47SSxi3ckE-kheHf6e3v9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_6QVF5TJnNUu6xhAL_qid-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_6TQEKKE2Ck6FoFOmzAl5OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lY150wsNP02MP9zqV76jPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_pSgow0Qc80SpSp1cz46FaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_fPQyy0HqVEuM1qduhYrYog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_Bf3h2ZhloEidThSSRPvQFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_yDGzdtvVaUO97cPKrXci4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_PC5IfPM4Q02DNCet-1_Lag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_MIv8wWRsbkmUV0mdcTFmZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_OTR9ruU8jEO4DamnlHKFLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:CreditAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sVGisjCvnEiEB93bLojreA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_YvPw907mK0udlp6KfJ8QZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_htSBHjfgekaRHkMRgsz1MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_7LahToXqk0ys3Hj-vViLrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_Q2agB-03uEiWytISvo0nvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_8NNrUB98dU6nTV1W_TbZEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_8bhT2JsMPEe7lORCk6OgzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_HyGAt6Tz506l49Pgkj8m9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_aSkSzFIw6E6liVy6b0eAVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_5m5du7ROvkCWkfWMS1O-UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_igNvzFb5yESqV8OvL7Pg4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_bAIh_tiMI0Kax823zmexkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_wEUJtdyPwUmF7kwBsHNYtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_FRPlVpNZ5UGLs3JJR-cB7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_rohFuA_mlUuMJvakf51DjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_SxAfTk9NBUeYICYKsOhlgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_XkThMChsq06Wh5OxvIKHaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_Zs1AsV-ToEOMh54dXGkq3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_SharesIssuableUponConversionOfConvertibleLoanMember_h0Z_P8CvIEq0cw1j1Kdi6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:SharesIssuableUponConversionOfConvertibleLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_VsjRlp7C00anCfXheLFsLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_YbvCeB-0yEWBm5JrBGygig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Wnx7hledV0aiY-1RCUHzlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kBMGpinIEUqZVp0QH9Oswg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tiRew-3WXUazY4UJ_rsE2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_28_2024_8KTFkLOAWUee7jQTUCnIkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2025_0UmROVpvLkiJOl5Q8Bvc_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_xBgryqct0E6Zilf1u8G51w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_JaLL1iLkyEWNgBPCSHnOpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_zidty5XO8kGAipBpidYvpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_8Mc5U6Ck2kSpYcYSeCnQCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_feeJaveXFUOGLBI6iniUiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_3r_X0vA_sEGsQPwLdkNqvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_elsHS6ydWEONtGpKI5VfjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_4FQlAocYb0208Y7SDKNP4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-10</xbrli:startDate><xbrli:endDate>2023-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_gXm3SotZZkifgZITvucSLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_u_Te-bqUOEC1eghs9nZXfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_lvqDhuhNuUSizIHbky_dog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XXu-NcK_bkaDqHPx0csY9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_PYldRmX4ZUyocSelgjrlsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_qzQd7EpFYkq8oeUwINwivg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_hHfphnzRoUq3UB_-E3jFQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-10</xbrli:startDate><xbrli:endDate>2023-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_ProstheticJointInfectionMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_cMxrWzKqB0aDivLktL7xSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:ProstheticJointInfectionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_NonCysticFibrosisBronchiectasisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_Na4M3PweMUi2iIIsCkq_3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:NonCysticFibrosisBronchiectasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_CysticFibrosisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_-n5s3ugSiUWuw4UgnftWDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:CysticFibrosisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_BacteremiaMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_nENRXrCZwUmEuUIiI0n0aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:BacteremiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_ProstheticJointInfectionMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_v56oVy0tEEyLTBl6m8fpVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:ProstheticJointInfectionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_NonCysticFibrosisBronchiectasisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_QTrcE4TKsUW11OtCkzUlvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:NonCysticFibrosisBronchiectasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_CysticFibrosisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_DQ9wJoe1u0-IR7_CKaA1Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:CysticFibrosisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_BacteremiaMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_O6wXLenwPkqANS08n0zSCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:BacteremiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_BApNk3n5XkaOpKH7-XGdqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_QpjN1Yhr0kCLe-x9CNhQkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_83vS_dwiSkeNsun5DvCQfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_zHKl8i7YW0il2SCbZ7ryrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_jVO24CHTHEOIiO_ECZ6bIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_q3iOc3hnOEKxXvfRp4uwBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ieNv8UfQuEu5yQKAxjemyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_-pt2ThZhNkOtRzUxqgRzhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_AE_R59dgSk29aRazyIh1uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Tan8oCbxTkeDxokgzAn6TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_wDGF0KSNh0K-ZOkC4X8kag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember__ONSzE2PXE2dEzLteS-O5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Dse-ebonN0CTM7ve3ne8_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ubx-9CKJgEWrllUJcWFg7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Nx2W3bvlQUKPamjde55oCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_jj6a-hSvJkuGs24AQOWWHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_pLXRlxUf9kGKDnBAIaplzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N9_1XuuLQ0-lsYc-TWi-NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_UqehtnWrBEGyotCU0pk1bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_N2i004GY7UqD_LBRSb5cDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_TkXtmRTW0kmojBMn9BVCTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_rOsiQMIXrkabber6Gcmk5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_T0i7nyaWzEq2E47alJJZLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_pPPFgT2uxECtGLDgw4ehFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_AyLQnVZhREiEwFcrl82R0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_kRX4vihrCkaUsg38VT2Fag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KZNkSs3clkaJtabzbT5F9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_p_w3bZ_ln0aJdZk7_GgZHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_uW8GX-eYnUeHey_7S13JXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_JqCSzztJk0uu3fT9ol6LJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_37d8n_o0P0-p2FnUWFQIOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lyiDqRxypkiQAz7M1AbxDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N0tx2XrUDkeZnYUXCzfq4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_8HLlfMA8zkmvRWpKnH3qMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_NLLKe9dPJkWGOD2819Wd7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-10</xbrli:startDate><xbrli:endDate>2023-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_RangeAxis_srt_MinimumMember_1gX74jz0bEaW8OFMI4iC9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_13_2020_To_3_13_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_kfgQS3Y8DEmi378_OnwJhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-13</xbrli:startDate><xbrli:endDate>2020-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_r5Xr-teAaUaiHHiDICZQPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg"><xbrli:measure>armp:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA"><xbrli:measure>armp:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_sNn8LuEmwE69rUms--yKEA"><xbrli:measure>armp:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:10.35pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:0pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_adaca254_0600_4d08_8676_018a1c00543a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:3pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:DocumentType" id="Narr_VOFMKC8dq0yx4P4Txxz-6Q"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">(Mark&#160;One)</p><a id="_0c44c818_c17a_4219_82c4_c382607a4e5d"></a><a id="Tc_md5Z6GVHU0qIInt5-mkyvg_0_1"></a><a id="Tc_AIWuCBiidUOZIOf7-IeAyg_1_0"></a><a id="Tc_CAlqhO1TJkmiBp2FafYTUA_2_1"></a><a id="Tc_aQh_OXUC2UGH2tFX0Qm30w_3_1"></a><a id="Tc_1jObe2Q6bkSR0_T8kxJlbA_4_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:DocumentAnnualReport" id="Tc_gKEBpBnrAkK9n1F_Z2DPzA_0_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:DocumentPeriodEndDate" id="Narr_E65qHgZvW0W_jcM6LuXy8g"><ix:nonNumeric format="ixt:date-monthname-day-en" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:CurrentFiscalYearEndDate" id="Narr_k9kWw8YtJk2TmF8LC7oWaA"><b style="font-size:9pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:DocumentFiscalYearFocus" id="Narr_R9oQGsWI1kaHoLNyukb8Tg"><b style="font-size:9pt;font-weight:bold;">2024</b></ix:nonNumeric></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">or</b></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:DocumentTransitionReport" id="Tc_dwsBEkDnjEimLTGd8cmNWA_3_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityFileNumber" id="Narr__iqJWiZiOEqHkl17MA9hNg"><b style="font-size:9pt;font-weight:bold;">001-37544</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityRegistrantName" id="Narr_RXy04Js-LEK8dn6lvEXZDg"><b style="font-size:9pt;font-weight:bold;">ARMATA PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_d761a948_8d19_417f_a17a_5c7a20383030"></a><a id="Tc_lRvo34am3UOZ8xrGEsQA7w_2_0"></a><a id="Tc_XLQcban9TkugxkvGDIc1nw_2_2"></a><a id="Tc_ubv12B4-SUewzgCNGN5bkA_3_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:48.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityIncorporationStateCountryCode" id="Tc_htdrjDt0jUmP3q8uAyaYcA_0_0"><b style="font-size:9pt;font-weight:bold;">Washington</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityTaxIdentificationNumber" id="Tc_fPjJxQFBoUuXD4yC1PV4Gg_0_2"><b style="font-size:9pt;font-weight:bold;">91-1549568</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.99%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(State or other jurisdiction of</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">incorporation and organization)</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityAddressAddressLine1" id="Narr_F-0Lic1BBUa1DV38gFSXOA"><b style="font-size:9pt;font-weight:bold;">5005 McConnell Avenue</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityAddressCityOrTown" id="Narr_BgjmiSxdvUOVQZwd60vOzA"><b style="font-size:9pt;font-weight:bold;">Los Angeles</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityAddressStateOrProvince" id="Narr_aUtfYb-Blk6aaMr1IztMAA"><b style="font-size:9pt;font-weight:bold;">CA</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;white-space:pre-wrap;">  </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityAddressPostalZipCode" id="Narr_u_slVe-bJEee4D3DVrsF_g"><b style="font-size:9pt;font-weight:bold;">90066</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices, including zip code)</p></td><td style="vertical-align:top;width:50.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:CityAreaCode" id="Narr_GWZdCikDkk2mLHRfuiYZkA"><b style="font-size:9pt;font-weight:bold;">310</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:LocalPhoneNumber" id="Narr_WHNdaiqQxUGirBSy7Ae8bw"><b style="font-size:9pt;font-weight:bold;">665-2928</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p></td></tr><tr><td style="vertical-align:top;width:49.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:50.14%;margin:0pt;padding:0pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_2e875ddc_c1e8_42c1_8e36_2381b7e0f850"></a><a id="Tc_AjsINMfwn0mQ7N6YaOFFnQ_0_0"></a><a id="Tc_YMX-ty4yB0WtPH-W_HaGLg_0_2"></a><a id="Tc_IxgrdU4quUm-4wbvY8geRQ_0_4"></a><a id="Tc_wG4pfFK9JkaJmdJosjuP2w_1_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:10.45pt;"><td style="vertical-align:bottom;width:29.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Title of each class</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr style="height:11.75pt;"><td style="vertical-align:bottom;width:29.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:Security12bTitle" id="Narr_nVDDPb_XKU-ZPD6ceGzW7A"><span style="font-size:8pt;">Common Stock</span></ix:nonNumeric><span style="font-size:8pt;">, par value $0.01 per share</span></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:TradingSymbol" id="Tc_qdinGrhIEEiivKWG7o1YaA_1_2"><span style="font-size:8pt;">ARMP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:SecurityExchangeName" id="Tc_gze0eW158Eyoj1Y8LMYzSw_1_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">Securities registered pursuant to Section 12(g) of the Act: None. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_hBg_0unnLki8Hrxn4L7dWw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act. &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityVoluntaryFilers" id="Narr_n8NJeeH1GkCVY_fboME6OQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityCurrentReportingStatus" id="Narr_BxSL-Qzx60S6XZPiEj8NjQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityInteractiveDataCurrent" id="Narr_YIlIkmi450KafpP_-HFmyQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;">Large accelerated filer&#160;&#160;&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">Accelerated filer&#160;&#160;&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityFilerCategory" id="Narr_gvaqVCxMf0-qCrK_SnQwUA"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntitySmallBusiness" id="Narr_JHiHheS2zk2h36TqL1zVAw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityEmergingGrowthCompany" id="Narr_rV30r2AwvUOKruO_kMo6Cw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:IcfrAuditorAttestationFlag" id="Narr_p0Y_zaC9D0uFIbrdNJKHeQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.24;text-indent:18pt;margin:0pt 2.9pt 5pt 0pt;"><span style="color:#231f20;font-size:8pt;">I</span><span style="font-size:8pt;">f securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_6IIMLrrL80SLQihq86sT8w"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.23;text-indent:18pt;margin:0pt 2.85pt 0pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.23;text-indent:18pt;margin:0pt 2.85pt 0pt 0pt;"><span style="font-size:4pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:EntityShellCompany" id="Narr_VqOpVkQG4USs0iC9m0eGrQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">As of June&#160;30, 2024, the aggregate market value of voting stock held by non-affiliates of the Registrant, based on the closing price of the common stock on June&#160;28, 2024 (the last business day of the Registrant&#8217;s most recently completed second quarter) as quoted on the NYSE American, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" format="ixt:num-dot-decimal" scale="6" contextRef="As_Of_6_28_2024_8KTFkLOAWUee7jQTUCnIkg" decimals="-5" name="dei:EntityPublicFloat" id="Narr_QfmqYS9kyUq7mPeWfUQ5uw">30.3</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;">As of February 28, 2025, <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_2_28_2025_0UmROVpvLkiJOl5Q8Bvc_w" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_adV86kWd3UaRZH65LGz8Qw">36,183,067</ix:nonFraction> shares of the Registrant&#8217;s common stock were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Document Incorporated by Reference</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_rwkcKcVDAUCfuD9fioc_Wg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the registrant&#8217;s fiscal&#160;year ended December&#160;31, 2024, are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="TOC"></a><a id="_6983c7c5_489f_4def_9e6e_1a48ae9fd1ec"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 9pt 0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 9pt 0pt;">ARMATA PHARMACEUTICALS, INC. </p><a id="Item12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page&#160;No.</b></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTI_129284"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUSINESS_806208"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUSINESS_806208"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6 </p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1ARiskFactors_490547"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1ARiskFactors_490547"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">40</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUNRESOLVEDSTAFFCOMMENTS_454967"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUNRESOLVEDSTAFFCOMMENTS_454967"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">62</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Item 1C.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">62</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">63</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item3LEGALPROCEEDINGS_563299"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item3LEGALPROCEEDINGS_563299"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">63</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item4MINESAFETYDISCLOSURES_516138"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item4MINESAFETYDISCLOSURES_516138"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">64</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTII_630154"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">64</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">64</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">64</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">75</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">75</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9AControlsAndProcedures"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9AControlsAndProcedures"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9BOTHERINFORMATION_104987"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9BOTHERINFORMATION_104987"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">104</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9CDISCLOSUREREGARDINGFOREIGNJURISDIC"><span style="font-style:normal;font-weight:normal;">Item&#160;9C.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9CDISCLOSUREREGARDINGFOREIGNJURISDIC"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">105</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTIII_156407"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">106</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item11EXECUTIVECOMPENSATION_44857"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item11EXECUTIVECOMPENSATION_44857"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">106</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#_Item_12._"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#_Item_12._"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">106</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">106</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">106</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTIV_519682"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item15EXHIBITS_865142"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item15EXHIBITS_865142"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">107</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item16Form10KSummary_988645"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item16Form10KSummary_988645"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">112</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#SIGNATURES_275590"><span style="font-style:normal;font-weight:normal;">Signatures</span><span style="font-style:normal;font-weight:normal;"> </span><span style="font-style:normal;font-weight:normal;">and Power of Attorney</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">113</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="FLS"></a><a id="_ab69fcce_0d9b_49e3_a762_795c79714a90"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) and certain information incorporated herein by reference contain forward-looking statements, which are provided under the &#8220;safe harbor&#8221; protection of the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements regarding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding anticipated operating losses, capital requirements and needs for additional funds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise additional capital when needed and to continue as a going concern;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manufacture, or otherwise secure the manufacture of, sufficient amounts of our product candidates for our preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our clinical development plans, including planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our research and development plans, including our clinical development plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to select combinations of phages to formulate our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our development of bacteriophage-based therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential use of bacteriophages to treat bacterial infections; </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential future of antibiotic resistance;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability for bacteriophage therapies to disrupt and destroy biofilms and restore sensitivity to antibiotics; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our planned development strategy, presenting data to regulatory agencies and defining planned clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected timing of additional clinical trials, including Phase 1b/Phase 2 or registrational clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manufacture and secure sufficient quantities of our product candidates for clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drug product candidates to be supplied by us for clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for bacteriophage technology being uniquely positioned to address the global threat of antibiotic resistance; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety and efficacy of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our anticipated regulatory pathways for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the activities to be performed by specific parties in connection with clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our pursuit of additional indications;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the content and timing of submissions to and decisions made by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and other regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to leverage the experience of our management team and to attract and retain management and other key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the capacities and performance of our suppliers, manufacturers, contract research organizations (&#8220;CROs&#8221;) and other third parties over whom we have limited control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to staff and maintain our Los Angeles production facility under fully compliant current Good Manufacturing Practices (&#8220;cGMP&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the actions of our competitors and success of competing drugs or other therapies that are or may become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations with respect to future growth and investments in our infrastructure, and our ability to effectively manage any such growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and potential growth of the markets for any of our product candidates, and our ability to capture share in or impact the size of those markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the benefits of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential market growth and market and industry trends;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining collaborations with third parties including our partnerships with the Cystic Fibrosis Foundation (&#8220;CFF&#8221;), and the U.S. Department of Defense (the &#8220;DoD&#8221;); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential future collaborations with third parties and the potential markets and market opportunities for product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve our vision, including improvements through engineering and success of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to meet anticipated milestones in the development and testing of the relevant product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to be a leader in the development of phage-based therapeutics; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected use of proceeds from the $21.6 million DoD award; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of government regulation and regulatory developments, and our ability and the ability of the third parties with whom we engage to comply with applicable regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of our estimates regarding future expenses, revenues, capital requirements and need for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding future planned expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve and maintain effective internal control over financial reporting in accordance with Section&#160;404 of the Sarbanes-Oxley Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of any of our products and product candidates; </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to protect our intellectual property, including pending and issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to operate our business without infringing the intellectual property rights of others; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to advance our clinical development programs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of ongoing conflicts between Ukraine and Russia and in the Middle East, the recent and potential future bank failures or other geopolitical events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential economic and regulatory impacts on the biotechnology, pharmaceutical and drug manufacturing industries;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of artificial intelligence on our business and the industry as a whole; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statements of belief and any statement of assumptions underlying any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, you can identify these statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions. These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail in the section entitled &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain. Given these uncertainties, you should not place undue reliance on any of the forward-looking statements included in this Annual Report. In addition, this Annual Report also contains estimates, projections and other information concerning our industry, our business, and the markets for our product candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events, or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report includes trademarks and registered trademarks of Armata Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As used in this Annual Report, unless the context requires otherwise, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Armata Pharmaceuticals, Inc. and its wholly owned subsidiaries.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fb086711_6ed5_4c29_adbe_687f739e8534"></a><a id="PARTI_129284"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1BUSINESS_806208"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;&#160;BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Overview </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are a clinical-stage biotechnology company having completed three Phase 2 trials focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics. Bacteriophages or &#8220;phages&#8221; have a powerful and highly differentiated mechanism of action that enables binding to and killing of specific targeted bacteria while uniquely preserving the normal human microbiome or &#8220;healthy bacteria&#8221;. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as <i style="font-style:italic;">Clostridium difficile</i> (&#8220;<i style="font-style:italic;">C. difficile&#8221;)</i>. We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or &#8220;superbug&#8221; strains of bacteria. We are a leading developer of clinical-stage phage therapeutics of high purity, and believe we are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. We have completed three critical Phase 2 trials, utilizing two distinct phage cocktails against two different bacterial pathogens with the potential to treat chronic pulmonary disease complicated by bacterial infection, as well as acute systemic bacterial infection. We believe we are on a critical pathway towards pivotal Phase 3 clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered (synthetic) bacteriophages with our proprietary phage-specific host-engineered current good manufacturing practice (&#8220;cGMP&#8221;) manufacturing capabilities to advance a target pipeline of high-quality bacteriophage product candidates for late-stage clinical development. We have improved our manufacturing processes by significantly increasing phage titers and improving production efficiency with the goal of ensuring commercial viability. We believe that we are uniquely advancing two lead candidates, referred to as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our first lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to <i style="font-style:italic;">Pseudomonas aeruginosa </i>(<i style="font-style:italic;">&#8220;</i><i style="font-style:italic;">P. aeruginosa</i><i style="font-style:italic;">&#8221;</i>). On October 14, 2020, we received the approval to proceed from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for our Investigational New Drug (&#8220;IND&#8221;) application for AP-PA02. In the first quarter of 2023, we announced positive topline results from the completed &#8220;SWARM-<i style="font-style:italic;">P.a.</i>&#8221; study &#8211; a Phase 1b/2a, multicenter, double-blind, randomized, placebo-controlled, single ascending dose and multiple ascending dose clinical trial to evaluate the safety and tolerability of inhaled AP-PA02 in subjects with cystic fibrosis (&#8220;CF&#8221;) and chronic pulmonary&#160;<i style="font-style:italic;">P. aeruginosa&#160;</i>infection. Data indicate that AP-PA02 was well-tolerated with a treatment emergent adverse event profile similar to placebo. Pharmacokinetcs (&#8220;PK&#8221;) findings confirm that AP-PA02 can be effectively delivered to the lungs through nebulization with minimal systemic exposure, with single ascending doses and multiple ascending doses resulting in a proportional increase in exposure as measured in induced sputum. AP-PA02 exposures were generally consistent across subjects. Additionally, bacterial levels of&#160;<i style="font-style:italic;">P. aeruginosa&#160;</i>in the sputum measured at several timepoints suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment as compared to placebo after ten days of dosing. In addition, a correlation was seen between increasing phage dose (higher AP-PA02 exposures) and reduction in the bacterial load, supporting the biologic plausibility of a bacterial specific mechanism of action and creating the opportunity for phage as a therapeutic alternative to inhaled antibiotics. This study was supported by the Cystic Fibrosis Foundation (&#8220;CFF&#8221;)<span style="white-space:pre-wrap;">, which granted us a Therapeutics Development Award of $5.0 million. We received the full award&#8217;s amount, including the final payment of $0.3 million, in January 2024. Following the promising Phase 1b/2a results of favorable safety and tolerability profile and plausible mechanism of action, an additional confirmatory Phase 2 trial was initiated in non-cystic fibrosis Bronchiectasis (&#8220;NCFB&#8221;)  patients with similar chronic pulmonary disease with infections due to&#160;</span><i style="font-style:italic;">P. aeruginosa</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On February 22, 2022, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-PA02, in a second indication, NCFB. On December 19, 2024, Armata announced encouraging results from the completed &#8220;Tail<i style="font-style:italic;">wind</i>&#8221; study &#8211; a Phase 2 multicenter, double-blind, randomized, placebo-controlled study to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 in subjects with NCFB and chronic pulmonary <i style="font-style:italic;">P. aeruginosa</i> infection. Data indicated that inhaled AP-PA02 provides a durable reduction of <i style="font-style:italic;">P. aeruginosa</i> in the lung, with a favorable safety and tolerability profile. The Tail<i style="font-style:italic;">wind</i> study was conducted in two cohorts running in parallel: subjects in one cohort (cohort A) received inhaled AP-PA02 as monotherapy, while subjects in another cohort (cohort B) received inhaled AP-PA02 in combination with inhaled anti-pseudomonal antibiotic treatment. Subjects in both cohorts were dosed at home by nebulization with study drug administered every 12 hours for 10 days and were followed for approximately four weeks after receiving their last dose of study drug. The primary efficacy endpoint was the reduction in <i style="font-style:italic;">P. aeruginosa</i> colony forming units (&#8220;CFUs&#8221;) in lung sputum at one week following completion of dosing (day 17) compared to baseline. Per the statistical analysis plan, efficacy analysis of each independent cohort showed no significant difference between subjects treated with AP-PA02 and placebo due to small numbers of subjects in each cohort. Notably, a post-hoc intent-to-treat analysis (n=33 active and n=15 placebo; all subjects from both cohorts) demonstrated a statistically significant reduction of <i style="font-style:italic;">P. aeruginosa</i> CFUs in the lung at day 17 (AP-PA02 vs. placebo; P=0.05). The reduction in <i style="font-style:italic;">P. aeruginosa</i> CFUs persisted two weeks following completion of dosing with AP-PA02 when compared with placebo at day 24 (AP-PA02 vs. placebo; P=0.015). Additionally, paired analysis of <i style="font-style:italic;">P. aeruginosa</i> CFU density at baseline compared to day 10 (P=0.03), day 11 (P=0.01), day 17 (P=0.003) and day 24 (P=0.018) was significant in the AP-PA02-treated cohort. We believe the data suggest that AP-PA02 alone is as effective as the combination therapy of phage and antibiotics in reducing <i style="font-style:italic;">P. aeruginosa</i> CFUs in the lung. Additionally, approximately one-third of subjects treated with phage monotherapy exhibited at least a 2-log CFU reduction in <i style="font-style:italic;">P. aeruginosa</i> compared to no reduction in placebo treated subjects. Safety data indicate that inhaled AP-PA02 was well-tolerated with treatment-emergent adverse events mild and self-limiting. There was one possibly related serious adverse event that was linked to an acute pulmonary event requiring hospitalization that was responsive to antibiotics. We believe the safety and tolerability of AP-PA02 offers a promising profile for treating chronically infected NCFB patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Results from the Phase 2 Tail<i style="font-style:italic;">wind</i> study demonstrate the potential of Armata&#8217;s high-purity phage cocktail, AP-PA02, as a new monotherapy treatment alternative for chronic pulmonary disease caused by <i style="font-style:italic;">P. aeruginosa</i> infection, including drug-resistant bacteria, and indicate the potential for phage therapy to reduce reliance on chronic antibiotic use. The Phase 2 Tail<i style="font-style:italic;">wind</i> study represents the second successful clinical trial for AP-PA02,&#160;Armata&#8217;s lead pulmonary candidate, which was first evaluated in people with cystic fibrosis in the Phase&#160;1b/2a SWARM-<i style="font-style:italic;">P.a.&#160;</i>trial that completed in 2023. We believe the learnings on dose-schedule regimens gained from the two completed Phase 2 studies position us to define a safe and promising biologic correlation for a Phase 3 definitive trial which will aim to evaluate inhaled AP-PA02 as an alternative to antibiotics in chronic pulmonary <i style="font-style:italic;">P. aeruginosa </i>infection. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In parallel to developing novel phage therapeutics that target chronic bacterial infections, we have an acute bacterial infection clinical development plan focused on <i style="font-style:italic;">Staphylococcus aureus</i> (&#8220;<i style="font-style:italic;">S. aureus</i>&#8221;) bacteremia, a difficult-to-treat and often life-threatening human infection that can result in high morbidity and mortality and for which bacterial resistance to antibiotics is growing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">A key advantage of our phage manufacturing expertise is the purity profiles of our phage products, including AP-SA02, our phage product candidate for <i style="font-style:italic;">S. aureus</i>; this has enabled us to pursue treatment of complicated <i style="font-style:italic;">S. aureus</i> bacteremia, where repetitive intravenous dosing is required. On June 15, 2020, we entered into an agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which we received a $15.0 million award and entered into a multi-year program administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (&#8220;NMRC&#8221;) &#8211; Naval Advanced Medical Development (&#8220;NAMD&#8221;) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the second half of 2024. In July 2024, the MTEC Agreement was modified to increase the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025. We are using the award to partially fund a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled dose escalation study that will assess the safety, tolerability and efficacy of our phage-based candidate, AP-SA02, for the treatment of adults with <i style="font-style:italic;">S. aureus </i>(the &#8220;diSArm study&#8221;)<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On November 17, 2021, we announced that we had received approval from the FDA to proceed with our IND application for AP-SA02. On November 12, 2024, we announced completion of enrollment of the Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for <i style="font-style:italic;">S. aureus</i> bacteremia. The last patient final follow-up visit </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">was completed on January 14, 2025. During the Phase 2a portion of diSArm, Armata focused on evaluating clinical safety of higher intravenous doses of AP-SA02 and accelerating enrollment to arrive at topline data expeditiously. The manufacture of highly purified phages using Armata&#8217;s proprietary methods enabled dose escalation to 5E10 PFU every six hours (2E11 PFU every 24 hours) for five days without clinically significant adverse events. In parallel with dose escalation, the evolution of two distinct blinded subsets of subjects receiving phage has been observed. One subset, comprising approximately half of the treated group, has evidence of persistence of detectable phage in the blood providing early evidence of <i style="font-style:italic;">in vivo</i> phage amplification and resultant release of phage progeny. The Company anticipates topline data from the diSArm study in the first half of 2025 where it can explore the two aforementioned subsets in an unblinded manner. Topline results are also expected to inform the optimal dose of AP-SA02 to be evaluated in a larger definitive efficacy study. Data from this Phase 1b/2a study will be invaluable for a follow-on trial that is being designed to demonstrate efficacy of AP-SA02 in treating <i style="font-style:italic;">S. aureus</i> bacteremia. We anticipate findings from the Phase 1b/2a study will provide the basis for constructing a robust trial strategy for registration which can be the basis for an End-of-Phase-2 meeting with the FDA that enables us to obtain agreement on a path to approval. We are committed to developing a definitive efficacy trial focused on phage as an alternative to broad-spectrum antibiotics and/or antibiotic sparing to decrease the utilization of broad-spectrum antibiotics and their detrimental impact on the normal human microbiome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">On August 1, 2022, we announced FDA approval to proceed with our IND application for AP-SA02 in a second indication, prosthetic joint infections (&#8220;PJI&#8221;) with <i style="font-style:italic;">S. aureus</i>. We had planned to initiate a Phase 1b/2a trial; however, in light of the growing concerns of both PJI and wound infections, we are considering revising the protocol to include both indications. Driven by data from the bacteremia study, and with sufficient funding, we may in the future initiate a Phase 1b/2a trial to assess the safety and tolerability of intravenous and intra-articular AP-SA02 as an adjunct to standard of care antibiotics in adults undergoing treatment of periprosthetic joint infections and/or wound infections caused by <i style="font-style:italic;">S. aureus</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">We remain committed to our mission to evaluate phage-based therapeutics in randomized controlled clinical trials that evaluate safety and efficiacy required to support potential regulatory approval and commercialization of our phage products as alternatives to traditional antibiotics, providing a potential method of treating patients suffering from drug-resistant and difficult-to-treat bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In parallel to the critical pathway Phase 2 trials, Armata has also focused on the validation of the lot release assays to ensure consistency and potency as well as improvement in cGMP manufacturing efficiencies and extension of phage shelf life using specific excipients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">  </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recent </b><b style="font-family:'Times New Roman;font-weight:bold;">Financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2025 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On March 12, 2025, the Company entered into a credit and security agreement (the &#8220;2025 Credit Agreement&#8221;) for a loan in an aggregate amount of $10.0&#160;million (the &#8220;2025 Loan&#8221;) with </span>Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA), our principal stockholder and a related party (collectively, &#8220;Innoviva&#8221;)<span style="background:#ffffff;">. The 2025 Loan bears interest at an annual rate of&#160;14.0% and matures on March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2025 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Concurrently with the execution of the 2025 Credit Agreement, the Company entered into amendments to (i) its existing convertible loan (the &#8220;Convertible Loan&#8221;) and secured credit and security agreement, dated January 10, 2023, with Innoviva (the &#8220;Convertible Credit Agreement&#8221;), (ii) its existing secured term loan facility (the &#8220;2023 Loan&#8221;) and credit and security agreement, dated July 10, 2023, with Innoviva (the &#8220;2023 Credit Agreement&#8221;) and (iii) its existing secured term loan facility (the &#8220;2024 Loan&#8221;) and credit and security agreement, dated March 4, 2024, with Innoviva (the &#8220;2024 Credit Agreement&#8221;), which, among other things, extended the maturity date of each loan to March 12, 2026.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="color:#231f20;font-style:italic;">2024 Credit </i><i style="font-family:'Times New Roman;font-style:italic;">Agreement</i><i style="color:#231f20;font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 4, 2024, the Company entered into the 2024 Credit Agreement for the 2024 Loan in an aggregate amount of $35.0&#160;million with Innoviva. The 2024 Loan bears interest at an annual rate of&#160;14.0% and was scheduled to mature on June 4, 2025. Principal and accrued interest are payable at maturity. Repayment of the 2024 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors. Concurrently with the execution of the 2024 Credit Agreement, the Company amended certain provisions of the Convertible Loan and Convertible Credit Agreement and the 2023 Loan and 2023 Credit Agreement, to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;">On March 12, 2025, the Company executed an amendment to the 2024 Credit Agreement which, among other things, extended the 2024 Loan maturity date to March 12, 2026.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2023 Credit Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On July 10, 2023, the Company entered into the 2023 Credit Agreement. The 2023 Credit Agreement provides for the 2023 Loan, a secured term loan facility in an aggregate amount of $25.0&#160;million at an interest rate of&#160;14.0% per annum, and was scheduled to mature on January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the 2023 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the 2023 Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 12, 2024, the Company executed an amendment to the 2023 Credit Agreement, which, among other things, extended the 2023 Loan maturity date to January 10, 2026. On March 12, 2025, the Company executed a subsequent amendment to the 2023 Credit Agreement which, among other things, extended the 2023 Loan maturity date to March 12, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;font-style:italic;margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">Convertible Credit Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 10, 2023, the Company received the Convertible Loan in the aggregate amount of $30.0&#160;million from Innoviva pursuant to the Convertible Credit Agreement. The Convertible Loan bears interest at a rate of&#160;8.0% per annum and was scheduled to mature on January 10, 2024. The Convertible Credit Agreement was amended on July 10, 2023, in connection with the Company&#8217;s entry into the 2023 Credit Agreement, to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. Subsequently, on November 12, 2024, the Company executed another amendment to the Convertible Credit Agreement, which, among other things, extended the Convertible Credit Agreement maturity date to January 10, 2026. Then, on March 12, 2025, the Company executed a subsequent amendment to the Convertible Credit Agreement which, among other things, extended the Convertible Loan maturity date to March 12, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Convertible Loan principal and accrued interest are payable at maturity. Repayment of the Convertible Loan is guaranteed by the Company&#8217;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Convertible Credit Agreement provides that if there is a financing from new investors of at least $30.0&#160;million (a &#8220;Qualified Financing&#8221;), the outstanding principal amount of and all accrued and unpaid interest on the Convertible Loan shall be converted into shares of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;), at a price per share equal to a&#160;15.0% discount to the lowest price per share for Common Stock paid by investors in such Qualified Financing. The Convertible Credit Agreement also required the Company to file a registration statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender&#8217;s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52&#160;(as may be appropriately adjusted for any stock split, combination or similar act).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:145.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following chart summarizes the status of our phage product candidate development programs and partners. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="armp-20241231x10k003.jpg" alt="Graphic" style="display:inline-block;height:142.1pt;left:0.31%;padding-bottom:1.9pt;position:relative;top:0pt;width:468.2pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our strategy is to demonstrate the safety, tolerability and definitive efficacy of multiple phage products in randomized controlled clinical trials required for FDA approval and to support commercialization in both acute and chronic indications of high unmet medical need, including bacterial infections caused by multidrug-resistant and difficult-to-treat pathogens. Our fully integrated product development capabilities from bench to clinic enable the discovery of optimal phage product candidates, and include the effective adaptation of phages to uniquely engineered host cells, essential for efficient process development and resulting in improved purity, stability, and manufacturability, to power rigorous clinical trials. Our microbiological surveillance and synthetic biology capabilities drive long-term product life cycle management. We intend to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Advance clinical trials of AP-PA02 in patients with CF </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and NCFB, both chronic pulmonary </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">P. aeruginosa </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infections, as an alternative to inhaled antibiotics.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Advance clinical trials of AP-SA02 in patients with bacteremia due to acute infection with </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, including methicillin-resistant </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (&#8220;MRSA&#8221;), as an alternative to antibiotics or to significantly limit duration of antibiotic use.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Develop AP-SA02 for the treatment of other antibiotic-resistant and difficult-to-treat </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> infections such as PJI and wound infections.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Develop other bacteriophage therapeutics, potentially including AP-PA03, for the treatment of other antibiotic-resistant and difficult-to-treat </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">P. aeruginosa </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infections such as acute bacterial pneumonia. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Need for New Anti-Infective Therapies </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The introduction of penicillin in the early 1940s marked the start of the antibiotic discovery era, during which more than 20 new classes of antibiotic were marketed over a period of three decades. The first case of the &#8220;superbug&#8221;, MRSA, in the United States occurred in 1968. A void in the discovery of new classes of antibiotics lasting approximately 30&#160;years drove the emergence and spread of antibiotic-resistant bacteria, including vancomycin-resistant <i style="font-style:italic;">enterococci</i> </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:181.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(&#8220;VRE&#8221;), and pandrug-resistant strains of <i style="font-style:italic;">Acinetobacter baumannii</i>, <i style="font-style:italic;">P. aeruginosa</i>, <i style="font-style:italic;">Escherichia coli</i> and <i style="font-style:italic;">Klebsiella pneumoniae</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20241231x10k004.jpg" alt="Graphic" style="display:inline-block;height:178.35pt;left:0.31%;padding-bottom:1.65pt;position:relative;top:0pt;width:417pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">MRSA: methicillin-resistant <i style="font-style:italic;">Staphylococcus aureus</i>; VRE: vancomycin resistant enterococci; PDR: pandrug-resistant; AMR: antimicrobial resistance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The dramatic and continuous emergence of antibiotic-resistant bacteria, and the lack of novel next generation antibiotics in the pipeline, has prompted calls to action from many of the world&#8217;s major health bodies such as the U.S. Centers for Disease Control and Prevention (the &#8220;CDC&#8221;), and the World Health Organization (the &#8220;WHO&#8221;), who warn of an &#8220;antibiotic cliff&#8221; and a &#8220;post-antibiotic era.&#8221; A growing list of infections&#160;&#8211; such as pneumonia, tuberculosis, bacteremia/septicemia, gonorrhea, and foodborne diseases&#160;&#8211; are becoming harder, and sometimes impossible, to treat as antibiotics become less effective. In 2009, the European Antimicrobial Resistance Surveillance System concluded that &#8220;the loss of effective antimicrobial therapy increasingly threatens the delivery of crucial health services in hospitals and in the community.&#8221; This conclusion was reinforced by The Antimicrobial Availability Task Force of the Infectious Diseases Society of America (the &#8220;IDSA&#8221;), and the European Centre for Disease Prevention and Control in conjunction with the European Medicines Agency (the &#8220;EMA&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The IDSA and the WHO regard antimicrobial resistance as one of the greatest threats to human health worldwide. The Review on Antimicrobial Resistance, a global project commissioned by the British government and the Wellcome Trust, reports that at least 700,000 people die each&#160;year of drug resistance in illnesses that include bacterial infections. The report predicts that, by 2050, 10 million lives a&#160;year worldwide (more people than currently die from cancer) and a cumulative $100 trillion of economic output are at risk due to the rise of drug-resistant infections. The CDC estimates that at least 2 million people in the United States develop infections due to resistant bacteria resulting in more than 23,000 deaths each&#160;year. A 2018 study from the Washington University School of Medicine indicated that the number of deaths would be between 153,113 and 162,044, which suggests that the CDC estimates may be dramatic underestimations. It is estimated that 50% of hospital-acquired infections are resistant to first-line anti-infective therapies. The cumulative annual healthcare costs for treating drug-resistant bacterial infections in the United States alone is calculated at $21 billion to $34 billion, with over 8 million additional hospital&#160;days. It is for these reasons that we believe there is a critical and pressing need to develop new and novel antibacterial therapies to combat the rise in antibiotic-resistance bacteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Increased public funding as well as foundation funding will be essential to bring new approaches forward through full cycle development. Definitive controlled clinical trials to test promising novel therapeutics as alternatives to traditional antibiotics must be funded in order to combat the growing issue of drug-resistant bacterial infections across the globe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anti-Infective Therapeutics Market </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The market opportunity for antibiotics is large, with the market estimated to exceed $58 billion in annual sales globally by 2027. Almost one in every five deaths worldwide occurs as a result of infection and, according to the WHO, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">many bacterial infections will become difficult or impossible to cure as the efficacy of current standard-of-care antibiotics wanes. Despite the advances in antimicrobial and vaccine development, infectious diseases still remain the third-leading cause of death in the United States and the second-leading cause of death worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of new antibiotics approved by the FDA and other global regulatory authorities has declined consistently over the last two decades. A recent review from WHO on the number of new antibiotics currently in the pipeline shows that just 12 new antibiotics have entered the market in the five years from 2017-21, and there are fewer than 30 under development in clinical trials against pathogens considered critical by WHO such as&#160;<i style="font-style:italic;">P. aeruginosa.</i> This is compared with more than 2,000 new product candidates in the drug pipeline for cancer. Historically, the success rate from Phase 1 to marketing approval is only one in five for infectious disease products. We, therefore, believe there is a need for new approaches to treat serious and life-threatening bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Hospital-acquired (nosocomial) infections are a major healthcare problem throughout the world, affecting developed countries as well as resource-poor countries. The WHO reports that hospital-acquired infections are among the major causes of death and increased morbidity among hospitalized patients. In the United States alone, the CDC estimates that hospital-acquired infections account for ~1.7 million infections and 99,000 associated deaths each year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compounding the above situations is the alarming and continuing rise in the prevalence of multidrug-resistant bacterial infections. This, coupled with the lack of new antibiotics in current discovery and development pipelines, has generated a significant clinical management problem worldwide, leading to increases in morbidity and mortality due to these antibiotic-resistant bacteria as well as increases in healthcare costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Bacteriophage therapy has the potential to be an alternative to antibiotics in treating bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Bacteriophage Therapy </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Bacteriophages, also known as phages, are ubiquitous viruses, found wherever bacteria exist. It is estimated there are more bacteriophages than every other organism on Earth combined. Phages are natural predators of bacteria, and the name &#8220;bacteriophage&#8221; translates as &#8220;eaters of bacteria&#8221;. Phages infect and rapidly kill the bacterial host by multiplying inside and then bursting through the cell membrane in order to release the next generation of phages into the surrounding environment, ready to infect and kill additional nearby target bacterial cells until the bacteria have been eliminated. When there are no target bacteria left for the phages to infect, the phages are removed through the body&#8217;s natural clearance processes. In contrast to broad-spectrum antibiotics, phages are highly targeted to specific bacteria, and do not attack the normal human microbiome on the skin, the gut or other areas critical to maintaining our defenses against more opportunistic infections like <i style="font-style:italic;">C. difficile</i>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:214.65pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="armp-20241231x10k005.jpg" alt="Graphic" style="display:inline-block;height:214.65pt;width:430.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Phages have the potential to provide both an alternative to, and/or a synergistic approach with, antibiotic therapy. Phages offer several differentiating attributes compared to classic antibiotics:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Highly specific/selective bactericidal agents, sparing the normal human microbiome</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Since each strain of phage specifically binds and kills only a particular bacterial host, phages may be a precision tool to reduce or eliminate specific strains of harmful bacteria without exposing patients to risks of eliminating the beneficial bacteria of our microbiomes through the use of current standard of care antibiotics. Such risks could include serious opportunistic infections such as </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">C. difficile</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> infection and VRE infection.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No known toxicities associated with chemical structures.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Antibiotic use is often associated with toxicities (e.g., kidneys, bone marrow, hearing). Phages are highly unlikely to carry structural features or be metabolized by the body to produce structural elements that confer chemical toxicities associated with small molecules.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distinct mechanism of bactericidal action.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Since phages use different mechanisms of action, their activity is independent of antibiotic resistance and as such could provide much needed therapy for multi-drug resistant infections.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Replication competent.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> It is possible that phage replication at the site of infection facilitates effective dosing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">High potential for added functionality through genetic engineering.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Phage genomes can be modified to confer benefits that address limitations, if any, that are observed during clinical development. Traits such as host range, burst size and biofilm disruption can be improved. These potential improvements help to assure phage therapeutics efficacy in difficult settings and over time as new isolates emerge.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Phages were discovered in 1915 at the Pasteur Institute and were shown to kill bacteria taken from patients suffering from dysentery. Furthermore, it was noted that phage numbers rose as patients recovered from infection, suggesting a direct association. Throughout the pre-antibiotic era, phages were widely used as an effective therapeutic agent to combat a variety of bacterial infections. However, phage use was displaced by the common use of broad-spectrum antibiotics in the early 1940s, with antibiotics being seen for many&#160;years as the superior treatment to combat bacterial disease, particularly in Western medicine. This attitude persisted until the development of the wide-ranging, and in some cases total, resistance to antibiotics seen within the last 10&#160;years. We believe that the continuing emergence of antibiotic-resistant bacteria provides the opportunity to revitalize phage use.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are hundreds of cases published in the scientific and medical literature describing the use of phage therapy in human medicine over more than 90&#160;years, mostly in the former Soviet Union and Eastern Europe. Phage therapy is still commonly used today in Russia, Poland and Georgia, with numerous reports of success in treating serious infectious diseases caused by many pathogenic bacterial species. However, the safety and effectiveness of these therapies have not been conclusively established due to the lack of randomized controlled clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">More recently, Western medicine has seen a rise in the clinical evaluation of phages. In the United Kingdom, two early-stage clinical trials of <i style="font-style:italic;">P. aeruginosa</i> phage cocktails showed no adverse effects in patients. One study (Phase 1/2a) demonstrated efficacy in a small trial of 12 patients with chronic multidrug-resistant <i style="font-style:italic;">P. aeruginosa</i> otitis treated with a cocktail of six natural phages. Since 2016, there have been a number of &#8220;compassionate use&#8221; cases in which patients suffering from various serious or life-threatening infections have been treated with phage therapy under physician-sponsored Emergency Investigational New Drug Applications with high rates of success and no adverse effects attributable to the therapy. Most notable was the well-documented case in 2016 of Tom Patterson, whose disseminated multidrug-resistant <i style="font-style:italic;">Acinetobacter baumannii</i> infection was successfully treated with phage-based therapeutic cocktails administered intravenously and intraperitoneally. An 82-year-old male with an aortic graft (heart implant) infected with pandrug-resistant <i style="font-style:italic;">P. aeruginosa</i> was successfully treated with a single application of phage, marking Yale University&#8217;s first case using phage therapy under Emergency IND. By early 2019, Yale University had treated more than half-a-dozen compassionate use cases, the majority individuals with CF with antibiotic-resistant lung infection. In 2018, a 15-year-old CF patient with a disseminated <i style="font-style:italic;">Mycobacterium abscessus</i> lung infection was treated intravenously with a three-phage cocktail following lung transplantation. That patient&#8217;s case represents another milestone for phage therapy &#8211; the first person to be treated with genetically modified phages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A consistent takeaway from these early phage therapy uses, and from the more recent clinical trials and compassionate use cases, is that phage therapy is generally well tolerated, with generally no reports of serious adverse events when administered by inhalation. Intravenous use of phage has been more limited due to bacterial cell wall and other contaminants in the final phage product. Phages have previously received approvals for use in cleaning food facilities and as a food additive for human consumption by the FDA and the EMA, and as agricultural bacterial pest treatments by the United States Department of Agriculture. Phages have met the criteria to be considered as &#8220;generally recognized as safe&#8221;, or &#8220;GRAS&#8221;, in the food and food contact surface categories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the growing problem of antimicrobial resistance, we believe it is essential that phage safety and efficacy be demonstrated by conducting rigorous well-powered clinical trials required for FDA approval, in order to move toward commercialization of phage therapy as an alternative to traditional antibiotics and to bring a potential solution to all patients suffering from drug-resistant bacterial infections. Armata has been focused on enhancing the overall quality of its manufactured phages through engineering and adaptation to maximize production titers while ensuring high level of purity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Target Markets and Medical Need</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pulmonary Bacterial Infections</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">P. aeruginosa</i> is consistently recognized by the CDC, and other public health agencies, as among the most dangerous and difficult-to-treat pathogens associated with significant impacts on health, quality of life, and economic burden. Regular standard-of-care antibiotics treatments often fail to completely eradicate the pathogen, and the problem is further complicated by rising rates of antibiotic resistance due to a growing number of multidrug-resistant isolates emerging, particularly with long term use. <i style="font-style:italic;">P. aeruginosa</i> is particularly problematic for CF patients given that their already compromised immune system leads to chronic infections. In addition to CF lung infections, <i style="font-style:italic;">P. aeruginosa</i> is responsible for other respiratory infections with high unmet medical need, including NCFB and hospitalized pneumonia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">P. aeruginosa Infection is a Major Cause of Morbidity and Mortality in Cystic Fibrosis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">CF is a genetic disease caused by mutations in the CF transmembrane conductance regulator (&#8220;CFTR&#8221;) gene. CF affects over 40,000 people in the United States (105,000 people worldwide) with approximately 1,000 new diagnoses per&#160;year. Dysfunction of the CFTR gene leads to dysfunction in multiple organs, but particularly the lungs, where a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">failure of hydration of airway secretions results in thick mucus, chronic inflammation, airway remodeling, and recurrent infections. Lung function continues to decline over time, punctuated by pulmonary exacerbations with increased cough, shortness of breath, and infections that result in rapid declines in lung function. For these reasons, CF remains the most common fatal hereditary lung disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outcomes for people with CF have improved significantly in recent&#160;years through early screening, the development and use of CFTR modulators, and other therapies. However, people with CF still suffer significant morbidity and mortality due to pulmonary infection with <i style="font-style:italic;">P. aeruginosa</i>. Chronic <i style="font-style:italic;">P. aeruginosa</i> infections occur in 45% of CF patients by age 40, and are strongly associated with worsening lung function, frequent pulmonary exacerbations, and increased mortality. In 2022, the median predicted survival age was 68&#160;years. Although many patients with chronic <i style="font-style:italic;">P. aeruginosa</i> benefit from routine suppressive inhaled antibiotic therapy, large numbers of CF patients still experience clinical deterioration despite these treatments, hence the need for more effective therapies, ideally with a different mechanism of action compared to traditional antibiotics, for the treatment of chronic <i style="font-style:italic;">P. aeruginosa</i> infection. GlobalData projects that total antibiotic sales in the CF market will exceed $900 million in the United States in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-Cystic Fibrosis Bronchiectasis: No approved therapy for NCFB P. aeruginosa</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NCFB is a chronic progressive pulmonary disease with 422,000 prevalent cases and 90,000 incident cases in the United States, expanding at a compound annual growth rate of 3.5%. NCFB is a condition characterized by recurrent respiratory infections that lead to a vicious cycle of impaired mucociliary clearance, chronic infection, bronchial inflammation, structural damage, and progressive lung function loss. <i style="font-style:italic;">P. aeruginosa</i> is the most prevalent pathogen responsible for these recurrent infections. Approximately 30% of NCFB patients are colonized with <i style="font-style:italic;">P. aeruginosa</i>, resulting in enhanced disease progression and poorer outcomes, including decreased lung function and lower quality of life, more frequent acute exacerbations, 7-fold increase in hospitalizations, and 3-fold increase in death. The average annual healthcare costs for an NCFB patient colonized with <i style="font-style:italic;">P. aeruginosa</i> exceeds $200,000, 175% higher compared to non-colonized patients. NCFB patients frequently become chronically colonized with multidrug-resistant strains of <i style="font-style:italic;">P. aeruginosa</i> because of the need for repeated courses of antibiotic treatment. There are currently no FDA-approved medications for the treatment of NCFB patients with chronic <i style="font-style:italic;">P. aeruginosa</i> respiratory infection, including inhaled antibiotics or therapeutics that address antibiotic resistance and reduce exacerbations. Advantages of bacteriophages include exquisite specificity for the target bacterial pathogen (e.g., <i style="font-style:italic;">P. aeruginosa</i>), minimal risks of dysbiosis compared to broad-spectrum antibiotics (e.g., to lung and gut microbiomes), mitigation of antimicrobial resistance, and lower risk of off-target effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Hospitalized Pneumonia</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Hospital-acquired pneumonia and ventilated-associated pneumonia is one of the most common causes of death among all hospital&#8208;acquired infections, with approximately 300,000 hospitalizations each year in the United States due to <i style="font-style:italic;">Pseudomonas</i>. Infection with <i style="font-style:italic;">Pseudomonas</i> results in mortality rates ranging as high as 35&#8208;50%, drives considerable healthcare costs (in excess of $40,000 per patient), and accounts for around 50% of all intensive care unit antibiotics. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Staphylococcus aureus Infections</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Bacteremia</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Bacteremia is a bacterial infection of the bloodstream. A common diagnosis, the CDC estimates that up to 1.7 million people in the United States develop bacteremia each year. <i style="font-style:italic;">S. aureus</i> is the most commonly identified pathogen in both hospital- and community-acquired bloodstream infections. Annually in the United States there are approximately 200,000 hospitalizations for <i style="font-style:italic;">S. aureus</i> bacteremia (&#8220;SAB&#8221;). Despite conventional antibiotics, mortality in SAB results in the death of up to 40% of all cases and 57% of patients over the age of 85. Patients with comorbidities such as alcoholism, malignancy, diabetes, end-stage renal disease requiring hemodialysis, and immunosuppression are at even higher risk for death when SAB develops. Age-adjusted mortality assessments show that SAB mortality is higher than that of AIDS, tuberculosis, or viral hepatitis, and comparable to mortality rates for breast or prostate cancer. Outcomes are even poorer for SAB due to MRSA, classified as a serious threat to global health by the CDC and a high priority threat by the WHO, with higher rates of complications and increased mortality as compared to methicillin-susceptible <i style="font-style:italic;">S. </i></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:54pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">aureus</i> (&#8220;MSSA&#8221;). Average hospital costs to patients with nosocomial SAB ranges between $40,000 (MSSA) and $114,000 (MRSA). Treatment failures are common in SAB, with highest rates due to MRSA. These failures can be attributed in part to poor penetration of some tissues by antibiotics, slow onset of bactericidal effects, emerging resistance patterns, and biofilm formation. While biofilms can render traditional antibiotics ineffective, phages may have the ability to penetrate the biofilm allowing rapid and efficient infection of the host and amplification at the site of infection. Until 2024, daptomycin (approved in 2006; based on clinical cure rates of less than 50%) and vancomycin were the only two FDA-approved antibiotics with label indications in the United States for the treatment of SAB, and the emergence of drug-resistant <i style="font-style:italic;">S.&#160;aureus</i> isolates, including to these two standard of care drugs, represents a major threat in terms of increasing morbidity, mortality and health care utilization. In April 2024, the FDA approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with SAB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prosthetic Joint Infection and Wound Infection</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total number of PJI-related revision surgeries is expected to more than double from 70,000 in 2020 to 144,000 in 2040 in the United States and European Union Five (France, Germany, Italy, Spain, and the United Kingdom), at an annual growth rate of 5.6% due to a growing elderly population. The United States is the largest market for PJI, accounting for 61% of PJI-related revision surgery in 2020 (estimated to be 71% by 2040), each estimated to cost $150,000. <i style="font-style:italic;">S. aureus</i> PJI infections are among the most commonly observed, accounting for up to 47% of all infections. PJI caused by biofilm-forming bacteria, such as <i style="font-style:italic;">S. aureus</i>, is challenging to treat and requires both surgery and long-term antibiotic use. Lack of efficacy against biofilms is a common cause of re-infection or treatment failure in PJI. Moreover, growing antibiotic resistance complicates treatment strategies and antibiotic choice for the treatment of PJI. Phage therapy has been successful in patients who have failed conventional antibiotic treatment, including two 2020 case studies in which phages were administered by intravenous or intraarticular routes and shown to be generally well tolerated. Similarly, secondary and tertiary wound infections due to <i style="font-style:italic;">S. aureus </i>are a growing issue worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Platform Technologies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Synthetic Phage Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Phages, natural predators of bacteria, have been in an uninterrupted battle for millions of&#160;years&#160;&#8211; evolving to kill or evade. These powerful natural well-adapted phages can be purposely engineered to be more efficient killers. The use of synthetic biology tools enables us to precisely engineer natural phages in ways that further improve their pharmacological properties and antimicrobial activity. Attributes of engineered phages can include expanded host range, improved potency which is a fundamental drug property that can translate into improved clinical efficacy, and importantly, biofilm disruption, which is a critical aspect of serious infections that needs to be addressed.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:89.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:86.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20241231x10k006.jpg" alt="Graphic" style="display:inline-block;height:53.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:43.8pt;"/></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Phage Discovery and Phenotyping:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Development of synthetic phage products that target a specific pathogen begins with the isolation of powerful natural phages from environmental and clinical samples. Our large library of multidrug-resistant pathogens and microbiome targets aids in the identification of the optimal phage candidates for downstream engineering.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20241231x10k007.jpg" alt="Graphic" style="display:inline-block;height:45pt;width:43.8pt;"/></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Bioinformatics Powers Engineering:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We employ next-generation sequencing, proprietary sequencing databases and software, bioinformatics, and comparative genomics, for the analyses of our phages.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20241231x10k008.jpg" alt="Graphic" style="display:inline-block;height:52.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:42pt;"/></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Engineering Host and Phage to Confer Desirable Properties:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depending on the target pathogen, identified natural phages are engineered to enable desirable phenotypes such as wide host range, payload expression, biofilm degradation, resistance prevention, and bioactive peptide display. Engineered phages are evaluated both in vitro and in vivo to determine pharmacological and toxicological parameters to confirm their potential in the clinic. Engineering the host is critical to decreasing drug product contaminents.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:58.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20241231x10k009.jpg" alt="Graphic" style="display:inline-block;height:58.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:43.8pt;"/></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Formulation Development and Chemistry, Manufacturing, and Controls:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have developed and acquired highly skilled process development and phage manufacturing expertise to manage our proprietary platforms with proven capabilities from the bench to clinic. Our research and development facilities are equipped with cGMP compliant manufacturing suites enabling the production, purification, testing and release of reproducible batches of phage clinical trial material exhibiting high purity and high titer designed to be tolerated for both intravenous and inhaled administration.</p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preclinical and Clinical Development Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Overview</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are committed to developing novel phage therapies, with drug development expertise and product development capabilities that span bench to clinic, including in-house phage-specific cGMP manufacturing. We believe our phage discovery platform in which we screen panels of clinically-relevant isolates against our extensive phage library utilizing proprietary methods that identify phage combinations with superior attributes, together with our phage-specific cGMP compliant manufacturing facilities, uniquely enables us to efficiently identify optimal product candidates. Our microbiological surveillance and synthetic biology capabilities drive long-term product life cycle management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our therapeutic phage candidates aim to address areas of significant unmet medical need, by targeting key drug-resistant bacteria, including those on the WHO&#8217;s global priority pathogens list, and the priority pathogens list issued by the CDC. The long-term potential for phage therapy is broad reaching, including potential use as front-line therapy. However, first indications will be as adjunct therapy in indications with high unmet need, which demands careful patient population selection to assure that a treatment effect with the phage cocktail can be observed over and above the efficacy of standard-of-care antibiotics. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for <i style="font-style:italic;">P. aeruginosa</i> and <i style="font-style:italic;">S. aureus</i>, two bacterial pathogens known to have significant morbidity and mortality despite standard-of-care antibiotic usage. <i style="font-style:italic;">P. aeruginosa</i> and <i style="font-style:italic;">S. aureus</i> are causative agents for difficult-to-treat infections: <i style="font-style:italic;">P. aeruginosa</i>, with its mucoid and multidrug-resistant strains, is a dominant culprit in chronic respiratory infections in CF and NCFB patients as well as acute pneumonia in hospitalized patients; <i style="font-style:italic;">S. aureus</i>, with its heteroresistant and MRSA strains, has been implicated in systemic (e.g., bacteremia) as well as prosthetic-related and wound infections. By advancing randomized controlled clinical trials using <i style="font-style:italic;">P. aeruginosa</i> and <i style="font-style:italic;">S. aureus</i> natural phage cocktails, Armata will gain experience treating site-specific as well as systemic infections. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pseudomonas aeruginosa Phage Product Candidate, AP-PA02</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Historical Background </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AP-PA02 was developed as a next-generation replacement for AP-PA01 (previously known as AB-PA01). A total of 10 patients with serious or life-threatening <i style="font-style:italic;">P. aeruginosa</i> infections not responding to antibiotic therapy were treated with AP-PA01, along with antibiotics, under single-patient expanded access programs in the United States (authorized under Emergency INDs by the FDA) and in Australia (authorized under the Special Access Scheme by the Australian Therapeutic Goods Administration). The treated patients&#8217; infections included bacteremia, native and prosthetic valve endocarditis, recurrent pneumonia (CF, post-transplant), ventilated-associated pneumonia, prosthetic joint infection, ventricular assist device infection, and septicemia due to burns. Investigators concluded that intravenous and nebulized administration of AP-PA01 was well-tolerated with no treatment-related serious adverse events. One of these cases was published in August 2019, in the peer-reviewed journal Infection, after AP-PA01 was used to successfully treat a CF patient who had developed a multidrug-resistant <i style="font-style:italic;">P. aeruginosa</i> infection. Another success with AP-PA01, used to treat a 77-year-old with ventilated-associated pneumonia and empyema, was published in November 2019, in the American Journal of Respiratory and Critical Care Medicine. We no longer offer AP-PA01 through any expanded access program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2018, we held a Type B pre-IND meeting with the U.S. FDA regarding a proposed Phase 1/2 clinical study of AP-PA01 for the treatment of <i style="font-style:italic;">P. aeruginosa</i> respiratory infections (ventilated-associated pneumonia). Feedback from the FDA in September 2018 included: agreement on product specifications, manufacturing and analytical plan, and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">a stability program. Furthermore, the FDA noted that preclinical toxicology studies are not required for AP-PA01 to enter clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Human exposure through treatment of single patients with AP-PA01 under the expanded access program has been helpful in demonstrating the promise and safety of phage therapy. Feedback from the pre-IND meeting has been insightful for the regulatory path required for phage therapeutics in general, and specifically for a phage product candidate intended for respiratory infection. We, therefore, have leveraged our experiences with AP-PA01 to derive a development plan for the next-generation product candidate, AP-PA02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Development of AP-PA02</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AP-PA02 is one example of the novel candidates to emerge from our robust research and development capabilities, and significantly improves upon our original <i style="font-style:italic;">P. aeruginosa</i> phage product candidate, AP-PA01. The phages that comprise AP-PA02 were selected with desired attributes for a product candidate targeting <i style="font-style:italic;">P. aeruginosa </i>lung infections. Different methods were deployed, including microbiological, bioinformatics and comparative genomics, in order to identify optimal attributes for the product candidate. Susceptibility, killing kinetics, and biofilm eradication, was assessed using <i style="font-style:italic;">P. aeruginosa</i> isolates from CF patients to determine antimicrobial activity and potency of AP-PA02. Viability in relevant biological fluids, and compatibility with current standard of care therapies for CF patients, was verified to confirm suitability of AP-PA02 for clinical use in this patient population. Immune stimulation was assessed to assure the lack of inflammatory impact by AP-PA02. Animal studies were conducted to provide insight into safe and efficacious dose levels that would support the expectation of pharmacological activity (i.e., antimicrobial potential of phage) in the lung compartment following an inhaled route of administration. In parallel, we initiated manufacturing feasibility and process optimization efforts with the goal of achieving high-quality phage product free of endotoxin and host cell proteins whilst maintaining adequate phage titers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">AP-PA02 is comprised of a cocktail of adapted natural <i style="font-style:italic;">P. aeruginosa</i> phages originating from distinct families and subfamilies, targeting multiple receptor classes, functioning with compatibility (i.e., the phages do not interfere with one another) and cooperativity (i.e., the phages work together for a better outcome), and further characterized by being highly potent and having a broad host range and overlap. Prior to initiating the SWARM-<i style="font-style:italic;">P.a.</i> trial (described below), our clinical isolate screening and phage collections yielded a three-phage AP-PA02 cocktail with compelling host-range coverage. We subsequently modified AP-PA02 to include additional phage genera that increase potency and broaden coverage of strains of <i style="font-style:italic;">P. aeruginosa</i> found in CF patients. The optimized five-phage AP-PA02 cocktail provided coverage against at least 90% of tested CF clinical isolates and has shown superior <i style="font-style:italic;">in vitro</i> potency as well as improved efficacy in an animal model of infection. The improvements in AP-PA02 reflect our core strategy of utilizing clinical isolate surveillance data to drive enhancement of product composition. Screening <i style="font-style:italic;">P. aeruginosa</i> isolates from people </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:177pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">diagnosed with NCFB revealed that the five-phage AP-PA02 cocktail offers broad coverage and robust potency in this indication as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="armp-20241231x10k010.jpg" alt="Graphic" style="display:inline-block;height:176.45pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:223.4pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical highlights of AP-PA02 include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significantly reduced </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">P. aeruginosa</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> biofilm mass </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vitro</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Persistence of active phage particles in the lung;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Limited systemic and off-target organ distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significantly decreased mortality in a murine model of acute </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">P. aeruginosa</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> lung infection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Components are stable in blood and sputum;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Not antagonistic with tobramycin nor aztreonam; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Components maintain activity in the presence of other CF therapies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have developed AP-PA02 as a sterile liquid formulation, suitable for delivery by inhalation. Through the end of 2024, clinical trial material of AP-PA02 was manufactured under cGMP at our production facility in Marina del Rey, California. As of 2025, clinicial trial material of AP-PA02 is being manufactured under cGMP at our production facility in Los Angeles, California to support the required regulatory filing(s)&#160;for clinical entry both inside and outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development of AP-PA02 in Cystic Fibrosis</i>:<i style="font-style:italic;"> </i><i style="font-style:italic;">Completed Phase 1b/2a Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On October 14, 2020, Armata received approval for the study to proceed from the FDA for its IND to initiate the &#8220;SWARM-<i style="font-style:italic;">P.a.</i>&#8221; study &#8211; a Phase 1b/2a, multicenter, double-blind, randomized, placebo-controlled, single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) clinical trial to evaluate the safety, tolerability and phage recovery profile of AP-PA02 administered by inhalation in subjects with cystic fibrosis and chronic pulmonary <i style="font-style:italic;">P. aeruginosa</i> infection. Primary Endpoints (SAD and MAD) included incidence and severity of treatment-emergent, adverse events. Secondary Endpoints (MAD) included changes in <i style="font-style:italic;">P. aeruginosa</i> colony-forming units. We looked at clinical parameters </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">as a part of exploratory endpoints for the SAD and MAD cohorts. The SWARM-<i style="font-style:italic;">P.a.</i> study was supported by a $5 million Therapeutics Development Award from the CFF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the first quarter of 2023, Armata announced positive topline results from the completed &#8220;SWARM-<i style="font-style:italic;">P.a.</i>&#8221; study. Data indicate that AP-PA02 was well-tolerated with a treatment emergent adverse event profile similar to placebo. Pharmacokinetcs (PK) findings confirm that AP-PA02 can be effectively delivered to the lungs through nebulization with minimal systemic exposure, with single ascending doses and multiple ascending doses resulting in a proportional increase in exposure as measured in induced sputum and exposure achievement relatively consistent across patient subjects. Additionally, bacterial levels of <i style="font-style:italic;">P. aeruginosa </i>in the sputum measured at several timepoints suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment as compared to placebo after ten days of dosing. Moreover, correlation was seen between increasing phage dose and reduction in the bacterial load supporting the biologic plausibility of a bacterial specific mechanism of action and creating the opportunity for phage as a therapeutic alternative to inhaled antibiotics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">With positive outcomes from this first clinical study, SWARM-<i style="font-style:italic;">P.a.</i>, we initiated a follow-on Phase 2 study investigating AP-PA02 in NCFB patients chronically infected with <i style="font-style:italic;">P. aeruginosa.</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis: Completed Phase 2 Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On February 22, 2022, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis (&#8220;NCFB&#8221;). On December 19, 2024, Armata announced encouraging results from the completed &#8220;Tail<i style="font-style:italic;">wind</i>&#8221; study &#8211; a Phase 2 multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 in subjects with NCFB and chronic pulmonary <i style="font-style:italic;">P. aeruginosa</i> infection. Data indicated that inhaled AP-PA02 provides a durable reduction of <i style="font-style:italic;">P. aeruginosa</i> in the lung, with a favorable safety and tolerability profile. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Tail<i style="font-style:italic;">wind</i> study was conducted in two cohorts running in parallel: subjects in one cohort (cohort A) received inhaled AP-PA02 as monotherapy, while subjects in another cohort (cohort B) received inhaled AP-PA02 in combination with inhaled anti-pseudomonal antibiotic treatment. Subjects in both cohorts were dosed at home by nebulization with study drug administered every 12 hours for 10 days and were followed for approximately four weeks after receiving their last dose of study drug. The primary efficacy endpoint was the reduction in <i style="font-style:italic;">P. aeruginosa</i> colony forming units ("CFUs") in lung sputum at one week following completion of dosing (day 17) compared to baseline. Per the statistical analysis plan, efficacy analysis of each independent cohort showed no significant difference between subjects treated with AP-PA02 and placebo due to small numbers of subjects in each cohort. Notably, a post-hoc intent-to-treat analysis (n=33 active and n=15 placebo; all subjects from both cohorts) demonstrated a statistically significant reduction of <i style="font-style:italic;">P. aeruginosa</i> CFUs in the lung at day 17 (AP-PA02 vs. placebo; P=0.05). The reduction in <i style="font-style:italic;">P. aeruginosa</i> CFUs persisted two weeks following completion of dosing with AP-PA02 when compared with placebo at day 24 (AP-PA02 vs. placebo; P=0.015). Additionally, paired analysis of <i style="font-style:italic;">P. aeruginosa</i> CFU density at baseline compared to day 10 (P=0.03), day 11 (P=0.01), day 17 (P=0.003) and day 24 (P=0.018) was significant in the AP-PA02-treated cohort. We believe the data suggest that AP-PA02 alone is as effective as the combination therapy of phage and antibiotics in reducing <i style="font-style:italic;">P. aeruginosa</i> CFUs in the lung. Additionally, approximately one-third of subjects treated with phage monotherapy exhibited at least a 2-log CFU reduction in <i style="font-style:italic;">P. aeruginosa</i> compared to no reduction in placebo treated subjects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The relationship between phage dose and microbiological impact on <i style="font-style:italic;">P. aeruginosa</i> confirms the findings in the cystic fibrosis SWARM-<i style="font-style:italic;">P.a.</i> Phase 2a trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Safety data from the Tail<i style="font-style:italic;">wind</i> study indicate that inhaled AP-PA02 was well-tolerated with treatment-emergent adverse events mild and self-limiting. There was one possibly related serious adverse event that was linked to an acute pulmonary event requiring hospitalization that was responsive to antibiotics. We believe the safety and tolerability of AP-PA02 offers a promising profile for treating chronically infected NCFB patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Results from the Phase 2 Tail<i style="font-style:italic;">wind</i> study demonstrate the potential of Armata&#8217;s high-purity phage cocktail, AP-PA02, as a new monotherapy treatment alternative for chronic pulmonary disease caused by <i style="font-style:italic;">P. aeruginosa</i> infection, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">including drug-resistant bacteria, and indicate the potential for phage therapy to reduce reliance on chronic antibiotic use. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Phase 2 Tail<i style="font-style:italic;">wind</i> study represents the second successful clinical trial for AP-PA02,&#160;Armata&#8217;s lead pulmonary candidate, which was first evaluated in people with cystic fibrosis in the Phase&#160;1b/2a SWARM-<i style="font-style:italic;">P.a.&#160;</i>trial that completed in 2023. We believe the learnings on dose-schedule regimens gained from the two completed Phase 2 studies position us to define a safe and promising biologic correlation for a Phase 3 definitive study which will aim to evaluate inhaled AP-PA02 as an alternative to antibiotics in chronic pulmonary <i style="font-style:italic;">P. aeruginosa</i> infection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">AP-PA03 for Antibiotic-Resistant and Difficult-to-Treat Acute Bacterial Pneumonia</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Conversely and representing the different physiology of acute pneumonia lung infections as compared to chronic CF and NCFB respiratory infections, a novel cocktail is in development for the clinical indication of acute hospitalized pneumonia. We have deployed our extensive <i style="font-style:italic;">P. aeruginosa</i> clinical isolate collection and phage library to identify a candidate phage cocktail, AP-PA03.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Staphylococcus aureus Phage Product Candidate, AP-SA02</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Historical Background</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AP-SA02 was developed as a more advanced version of AP-SA01 (previously known as AB-SA01).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The therapeutic potential of AP-SA01 has been demonstrated through:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Efficacy in murine methicillin-resistant and methicillin-susceptible </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> pneumonia models, and sheep sinus biofilm model.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Demonstration of safety and tolerability in two completed investigator-initiated Phase 1 studies (topical administration: intact skin of healthy adults; intrasinal administration: patients suffering from </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-derived chronic rhinosinusitis).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AP-SA01 was provided for use under single-patient expanded access programs in the United States (Emergency INDs, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per the Food and Drug Administration</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) or Australia (Special Access Scheme, per the Australian Therapeutic Goods Administration). A total of 18 patients with serious or life-threatening </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> infections (including bacteremia, endocarditis, ventricular-assist device infection, prosthetic joint infection) not responding to standard-of-care antibiotic therapy were treated with AP-SA01. AP-SA01 was administered intravenously, with most patients treated for 14&#160;days, every 12 hours as an adjunct to antibiotic therapy. Investigators concluded that intravenous administration of AP-SA01 was well-tolerated with no </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">treatment-related serious adverse events.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We no longer offer AP-SA01 through any expanded access program.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Human exposure through treatment of single patients with AP-SA01 under the expanded access program has been helpful in demonstrating the promise of phage therapy and warrants further study to support safety and efficacy through randomized controlled trials required to support registration. Feedback from a Type B pre-IND meeting with the FDA in August&#160;2018 has been insightful for the regulatory path required for phage therapeutics in general, and specifically for a phage product candidate intended for systemic delivery. We therefore have leveraged our experiences with AP-SA01 to derive a development plan for AP-SA02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Optimization: Development of AP-SA02</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AP-SA02 is a novel biologic product candidate comprised of a cocktail of adapted natural lytic phages that target the problematic pathogen, <i style="font-style:italic;">S. aureus</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical highlights of AP-SA02 include:</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potent antimicrobial activity against approximately 95% of </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> clinical isolates tested, including drug-resistant isolates (MRSA: methicillin-resistant </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and VRSA: vancomycin-resistant </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unique mechanism of action offers independent or synergistic benefit with standard of care antibiotics; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Component phages are stable and retain infectivity after exposure to relevant biological fluids; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Penetrates pre-existing </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> biofilms.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have developed AP-SA02 as a sterile solution, suitable for delivery by intravenous administration. Through the end of 2024, clinical trial material of AP-SA02 was manufactured under cGMP at our production facility in Marina del Rey, California. As of 2025, clinicial trial material of AP-SA02 is being manufactured under cGMP at our production facility in Los Angeles, California to support the required regulatory filing(s)&#160;for clinical entry both inside and outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We combine our proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered bacteriophages with our proprietary phage-specific host-engineered cGMP manufacturing capabilities to advance high-quality bacteriophage product candidates for late-stage clinical development. We believe a key advantage of our phage manufacturing expertise is the purity profiles of our phage products, including AP-SA02, our phage product candidate targeting <i style="font-style:italic;">S. aureus</i>; this has enabled us to pursue treatment of complicated <i style="font-style:italic;">S. aureus</i> bacteremia, where repetitive intravenous dosing is required. Throughout the past 12 months, improvements in our proprietary upstream manufacturing processes have resulted in a ten-fold increase in phage titer. Additionally, significant improvements in recovery throughout our processes has resulted in five-fold more doses from a single production run. We have improved our overall production efficiency with the goal of ensuring commercial viability. The Los Angeles site&#8217;s approximately 10,000 square foot cGMP facility enables us to bring more efficient manufacturing processes on line and allows for full commercialization from the current facility, streamlining the timeline from potential successful pivotal trial to a Biologics License Application (&#8220;BLA&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development of AP-SA02 in Bacteremia: Completed Phase 1b/2a Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 17, 2021, Armata received approval for the study to proceed from the FDA for its IND to initiate the &#8220;diSArm&#8221; study &#8211; a Phase 1b/2a, randomized, double&#8208;blind, placebo&#8208;controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP&#8208;SA02 as an adjunct to best available antibiotic therapy compared to best available antibiotic therapy alone for the treatment of adults with bacteremia due to <i style="font-style:italic;">Staphylococcus aureus</i>. The objectives of this study are to: (i)&#160;demonstrate safety and tolerability of multiple different dose levels of AP-SA02; (ii)&#160;evaluate optimal dosing through safety, pharmacokinetics and microbial efficacy; and (iii)&#160;explore efficacy through evaluation of key meaningful endpoints. The study is being conducted at sites in the United States and also at sites abroad in Australia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Phase 1b/2a study is partially funded by a $15.0 million&#160;award administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (NMRC) &#8211; Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. <span style="background:#ffffff;">On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3&#160;million to $16.3&#160;million and extend the term into the second half of 2024.</span> In July 2024, the MTEC Agreement was modified to increase the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 12, 2024, we announced completion of enrollment of the Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for <i style="font-style:italic;">S. aureus</i> bacteremia. The last patient final follow-up visit was completed on January 14, 2025. During the Phase 2a portion of diSArm, Armata focused on evaluating clinical safety of higher intravenous doses of AP-SA02 and accelerating enrollment to arrive at topline data expeditiously. The manufacture of highly purified phages using Armata's proprietary methods enabled dose escalation to 5E10 PFU every six hours (2E11 PFU every 24 hours) for five days without clinically significant adverse events. In parallel with dose escalation, the evolution of two distinct blinded subsets of subjects receiving phage has been observed. One subset, comprising approximately half of the treated group, has evidence of persistence of detectable phage in the blood providing early </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">evidence of <i style="font-style:italic;">in vivo</i> phage amplification and resultant release of phage progeny. The Company anticipates topline data from the diSArm study in the first half of 2025 where it can explore the two aforementioned subsets in an unblinded manner. Topline results are also expected to inform the optimal dose of AP-SA02 to be evaluated in a larger definitive efficacy study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Data from this Phase 1b/2a study will be invaluable for a follow-on trial that is being designed to demonstrate efficacy of AP-SA02 in treating <i style="font-style:italic;">S. aureus</i> bacteremia. We anticipate findings from the Phase 1b/2a study will provide the basis for constructing a robust trial strategy for registration which can be the basis for an End-of-Phase-2 meeting with the FDA that enables us to obtain agreement on a path to approval. We are committed to developing a definitive efficacy trial focused on phage as an alternative to broad-spectrum antibiotics and/or antibiotic sparing to decrease the utilization of broad-spectrum antibiotics and their detrimental impact on the normal human microbiome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">Additional Clinical Indications for AP-SA02</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Improved patient outcomes are needed for other <i style="font-style:italic;">Staphylococcal</i> infections, in settings such as PJI and wound infections, for which antimicrobial resistance is a growing concern. We believe AP-SA02 could also have a meaningful impact in these indications, particularly infections caused by methicillin-resistant <i style="font-style:italic;">S. aureus</i> (&#8220;MRSA&#8221;). On August 1, 2022, we announced that we had received from the FDA the approval to proceed for our IND application for AP-SA02, in a second indication, PJI. We had planned to initiate a Phase 1b/2a trial; however, in light of the growing concerns of both PJI and wound infection, we are considering revising the protocol to include both indications. Driven by data from the bacteremia study, and with sufficient funding, we may in the future initiate a Phase 1b/2a trial to assess the safety and tolerability of intravenous and intra-articular AP-SA02 as an adjunct to standard of care antibiotics in adults undergoing treatment of periprosthetic joint infections and/or wound infections caused by <i style="font-style:italic;">S. aureus</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Discovery Research</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to developing our more advanced pipeline programs described above, we continue phage discovery efforts by screening other interesting bacterial targets against our phage library in order to further expand our pipeline. <i style="font-style:italic;">Klebsiella pneumoniae</i> phage, for example, is a potentially important addition to treatment options for serious lung infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our team of microbiologists and synthetic biologists hunt for natural phages and evaluate the suitability of these natural phages for engineering and adaptation using our synthetic phage platform. These powerful natural well-adapted phages can be purposely engineered to be more efficient killers. The use of synthetic biology tools enables us to precisely engineer natural phages in ways that further improve their pharmacological properties and antimicrobial activity. Attributes of engineered phages can include expanded host range, improved potency which is a fundamental drug property that can translate into improved clinical efficacy, and importantly, biofilm disruption, which is a critical aspect of serious infections that needs to be addressed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Through the end of 2024, we produced, tested and released clinical quantities of each of our bacteriophage product candidates at our cGMP-compliant manufacturing facility in Marina del Rey, California. This facility has approximately 35,500 square feet of laboratory and office space, including 3,000 square feet of cGMP laboratory space and is licensed by the California Department of Public Health for drug manufacturing. In the fourth quarter of 2024, manufacturing was fully relocated to our new research and development and manufacturing facility, and corporate headquarters, located in Los Angeles, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our Los Angeles facility consists of approximately 56,500 square feet of office, research and development and manufacturing space. Office space and research laboratories have been occupied since the third quarter of 2023, and construction of the cGMP manufacturing space (~10,000 square feet) was completed in the third quarter of 2024. Our Los Angeles facility is licensed by the California Department of Public Health for drug manufacturing and is subject to periodic, unannounced inspections for compliance with cGMP and other state and federal laws and regulations. The facility is subject to periodic inspections by the City of Los Angeles and Los Angeles County for fire hazard and waste </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">management and is in compliance with all applicable regulations. Our facility is staffed with an independent Quality Unit (Quality Assurance and Quality Control) and manufacturing and facilities personnel trained under cGMPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We operate in-house process development activities through the production, purification, formulation, and release of our therapeutic phage cocktails for use in human clinical trials. Our current formulations for our <i style="font-style:italic;">P. aeruginosa </i>and <i style="font-style:italic;">S. aureus</i> phage product candidates are intended for inhaled and intravenous delivery, both requiring our drug products to be sterile. Our manufacturing facility is capable of producing sterile drug products, utilizing ISO-certified cleanrooms. The facility also houses an ISO 5-certified closed system isolator. We may further optimize future formulations of our product candidates which may or may not require assurance of sterility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For our manufacturing facility we have been able to access and hire highly skilled process development and phage manufacturing expertise and believe that we have control of our proprietary platform from phage identification through final product fill and finish and release. Manufacturing campaigns are managed by a specialist team of our internal staff, which is designed to promote compliance with the technical aspects and regulatory requirements of the manufacturing process. We have developed a cGMP-compliant manufacturing process that utilizes both industry standard and proprietary methods for the manufacture of our product candidates. Our process is designed to be scalable to meet our clinical study needs, and to fulfill the requirements of regulators for human studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although our facility is capable of manufacturing our phage product candidates, we rely on, and may continue to rely on, third-party contract manufacturers for the manufacture of certain raw materials, components, or packaging of the product candidates that may be developed for clinical testing, as well as for commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our goal is to protect the proprietary technology that we believe is important to our business, including to obtain, maintain and enforce patent protection for our product candidates, formulations, processes, methods and any other proprietary technologies, preserve our trade secrets and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our current product candidates and any future product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the United States and abroad. However, patent protection may not afford us with complete protection against competitors who seek to circumvent our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also rely on trademarks, trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position. We also depend upon the skills, knowledge, experience and know-how of our management and research and development personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary processes and know-how, which is not patentable, and for inventions for which patents may be difficult to enforce, we currently and will in the future rely on trade secret protection and contractual obligations with third parties to protect our interests and to develop and maintain our competitive position. To this end, we require all of our employees, consultants, advisors and other contractors to enter into agreements with contractual obligations that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success in preserving market exclusivity for our product candidates relies on patent protection, including extensions to this where appropriate, and on data exclusivity relating to an approved biologic. This may be extended by orphan drug and/or pediatric use protection where appropriate. Once any regulatory period of data exclusivity expires, depending on the status of our patent coverage, we may not be able to prevent others from marketing and selling biosimilar versions of our product candidates. We are also dependent upon the diligence of our appointed agents in national jurisdictions, acting for and on our behalf, which manage the prosecution of pending domestic and foreign patent applications and maintain granted domestic and foreign patents.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18&#160;months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries and patent application filings, we cannot be certain of the priority of inventions covered by pending patent applications. Accordingly, we may not have been the first to invent the subject matter disclosed in some of our patent applications or the first to file patent applications covering such subject matter, and we may have to participate in interference proceedings or derivation proceedings declared by the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) to determine priority of invention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Bacteriophage Patent Portfolio</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we owned or had exclusive license rights to a total of 152 patents and applications: 11 U.S. patents, 12 U.S. patent applications, 73 foreign patents, and 56 foreign patent applications, with nominal expiration on various dates between 2024 and 2045. Patent term adjustments or patent term extensions could result in later expiration dates. We believe these patents and applications cover our lead phage therapeutic programs and use thereof, synthetic phage and methods of manufacture thereof, beneficial effects of bacteriophage treatment - including treatment and prevention of bacteria-associated cancers, bacteriophage combinations, the sequential use of bacteriophages in combination with conventional antibiotics, genetic sequence variations, methods to reduce antibiotic resistance, methods to treat bacterial biofilms, methods to design therapeutic combination panels of bacteriophage, disinfection methods using bacteriophages, and bacteriophage mutants having increased bacterial host spectra.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of new drugs is highly competitive. We face competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions all seeking to develop novel treatment modalities for bacterial infections. Many of our competitors have significantly greater financial, product development, manufacturing and marketing resources than us. Large pharmaceutical companies have extensive experience in clinical development and obtaining regulatory approval for drug products. In addition, many universities and private and public research institutes are active in antibacterial research, some in direct competition with us. We also may compete with these organizations to recruit scientists and clinical development personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to compete successfully will depend largely on our ability to leverage our collective experience in drug discovery, development and commercialization to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discover and develop medicines that are differentiated from other products in the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain patent and/or proprietary protection for our products and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain required regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain a commercial partner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercialize our drugs, if approved; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract and retain high-quality research, development and commercial personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key factors affecting the success of any approved product include its efficacy, safety profile, drug interactions, method of administration, pricing, reimbursement and level of promotional activity relative to those of competing drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The majority of phage companies are focused on aspects outside of human health such as agriculture, food, environmental, veterinary, biocontrol, manufacturing, and diagnostics. There are a handful of small biotechnology companies developing bacteriophage products to treat human diseases. To our knowledge, several biotechnology companies in the United States and Europe, including BiomX, Inc. (merged with Adaptive Phage Therapeutics in 1Q </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2024), Intralytix, Inc., Locus Biosciences, Inc., TechnoPhage, SA, as well as academic institutions, have discovery stage or clinical programs utilizing naturally occurring phages or synthetic biology approaches to genetically modify bacteriophages to remove or input genes to improve therapeutic properties such as increases to the bacterial host range to infect a larger number of bacterial strains and decrease the need for using multiple phages in a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our bacteriophage programs may compete with or be synergistic with currently approved antibiotics, and experimental approaches such as novel antibiotics, antimicrobial peptides, antimicrobial vaccines, metals, antisense, monoclonal antibodies and possibly microbiome manipulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sales and Marketing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have full worldwide commercial rights to all of our phage-based product candidates to treat drug-resistant bacterial infections, including our product candidates: AP-PA02 and AP-PA03 for the treatment of <i style="font-style:italic;">P. aeruginosa</i> infections, and AP-SA02 for the treatment of <i style="font-style:italic;">S. aureus</i> infections. We believe we can maximize the value of our company by retaining substantial global commercialization rights to these product candidates and, where appropriate, entering into partnerships to develop and commercialize these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not yet established a sales, marketing or product distribution infrastructure because our lead candidates are still in early clinical development. Subject to receiving marketing approvals or earlier, we intend to either partner the commercial rights to our products with existing companies that have the wherewithal and resources to commercialize building the necessary marketing and sales infrastructure to market and sell our current product candidates. We also intend to explore the use of a variety of distribution agreements and commercial partnerships in those territories where we do not establish a sales force for any of our product candidates that obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Material Agreements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Strategic Alliances and Research Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MTEC Grant</i><span style="display:inline-block;width:101.74pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2020, we entered into a Research Project Award agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which we received a $15.0 million award and entered into a multi-year program administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (NMRC) &#8211; Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the second half of 2024. In July 2024, the MTEC Agreement was modified to increase the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025. We are using the award to partially fund a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled dose escalation study that will assess the safety, tolerability and efficacy of our phage-based candidate, AP-SA02, for the treatment of adults with <i style="font-style:italic;">S. aureus </i>(&#8220;diSArm&#8221; study)<i style="font-style:italic;">.</i> The MTEC Agreement specifies that the award is paid to the Company over the term of the award through a cost reimbursable model, based on agreed-upon cost share percentages, and the money received is not refundable to MTEC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MTEC Agreement is effective through August 15, 2025. The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CFF Therapeutics Development Award</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 13, 2020, the Company entered into an award agreement (the &#8220;Award Agreement&#8221;) with CFF, pursuant to which the Company received a Therapeutics Development Award of $5.0 million (the &#8220;CFF Award&#8221;). The CFF Award has funded a portion of the Company&#8217;s Phase 1b/2a clinical trial of the <i style="font-style:italic;">Pseudomonas aeruginosa</i> (&#8220;<i style="font-style:italic;">P. aeruginosa</i>&#8221;) phage candidate, AP-PA02, as a treatment for airway infections in people with cystic fibrosis (&#8220;CF&#8221;).&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The first payment under the Award Agreement, in the amount of $1.0 million, became due upon signing the Award Agreement and was received in April 2020. The remainder of the Award was paid to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement. The final milestone was achieved in the fourth quarter of 2023 and the milestone payment was received in the first quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other product (as defined in the Award Agreement), for a period of 360 days (an &#8220;Interruption&#8221;) and fails to resume the development of the product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the product for use in treating infections in CF patients (the &#8220;CF Field&#8221;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the product, to the extent necessary to commercialize the Product in the CF Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon commercialization by the Company of any product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the product in the CF Field, or if the Company enters into a change of control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company&#8217;s material failure to achieve certain development milestones. The Company&#8217;s payment obligations survive the termination of the Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters are located in Los Angeles, California, with an address of 5005 McConnell Avenue, Los Angeles, CA 90066 (the &#8220;McConnell Facility&#8221;). On October 28, 2021, we entered into a lease for approximately 56,300 square feet of office, research and development and manufacturing space under a non-cancellable lease (the &#8220;2021 Lease&#8221;). The 2021 Lease payment start date was May 1, 2022, and the total lease term is for&#160;16 years&#160;and runs through 2038. Office space and research laboratories have been occupied since the third quarter of 2023, with cGMP manufacturing space (~10,000 square feet) fully constructed and occupied in the second half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also have a facility located in Marina del Rey, California, with an address of 4503 Glencoe Avenue, Marina del Rey, CA 90292, where we currently lease approximately 35,500 square feet of office, research and development and manufacturing space (the &#8220;Marina del Rey Lease&#8221;). The Marina del Rey Lease expires on December 31, 2031. The facility includes 19,500 square feet of BSL2 laboratory space and approximately 3,000 square feet of cGMP laboratory space. We are actively seeking a sub-tenant to take over the remaining term of the Marina del Rey Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we lease a 5,000 square foot facility located in Sydney, Australia, which includes 4,000 square feet of laboratory space providing capabilities to support phage product development and manufacturing process development. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that our facilities are adequate for our current and long-term needs. Additionally, we believe the newly constructed McConnell facility, offering expanded manufacturing capacity, will allow us to pursue contract manufacturing opportunities for phage and potentially other advanced biologics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we are a party to certain litigation that is either judged to be not material or that arises in the ordinary course of business. We intend to vigorously defend our interests in these matters. We expect that the resolution of these matters will not have a material adverse effect on our business, financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this Annual Report, we are not subject to any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products such as those we are developing. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety, efficacy, purity, and/or potency must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority where the product is intended to be marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">United States Product Development Process</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable FDA requirements at any time during the product development process or approval process, or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of preclinical laboratory tests, animal studies and formulation studies according to good laboratory practice requirements (&#8220;GLP&#8221;) or other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an IND application, which must be granted before human clinical trials may begin in the United States or internationally if submitting results to the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices (&#8220;GCPs&#8221;) and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use or uses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of a Biologics License Application (&#8220;BLA&#8221;) for a new biological product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with the FDA&#8217;s cGMP regulations, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potential FDA inspection of the nonclinical study sites and clinical trial sites that generated the data in support of the BLA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA&#8217;s approval of the BLA, which must occur before a biological product can be marketed or sold in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources even when approvals are inherently uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The strategies, nature, and technologies of bacteriophage products are different from those of conventional antibiotic therapy products. From the regulatory requirements established to ensure the safety, efficacy and quality of bacteriophage preparations, there are several major points to consider during the development, manufacturing, characterization, preclinical study and clinical trial of bacteriophage products. The major issues include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phage preparation design (single agent versus phage mixes and wild-type phage versus genetically engineered phage);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Proof of concept in development of phage products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Selectivity of bacteriophage replication and targeting to specific species of bacteria;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Relevant animal models in preclinical studies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical safety and efficacy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Studies and IND</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before testing any compounds with potential therapeutic value in humans, the biological product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product biology, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the biological product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practices described in 21 CFR Part&#160;58 (GLP). The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND application. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA places the IND on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be certain that submission of an IND application will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by the sponsor. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject inclusion and exclusion criteria and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA. Clinical trials must be conducted in accordance with GCP requirements. Further, each clinical trial must be reviewed and approved by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee if conducted outside of the United States, at or servicing each institution at which the clinical trial will be conducted. An IRB or ethics committee is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB or ethics committee also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. We intend to use third-party CROs </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to administer and conduct our planned clinical trials and will rely upon such CROs, as well as medical institutions, clinical investigators and consultants, to conduct our trials in accordance with our clinical protocols. The failure by any of such third parties to meet expected timelines, adhere to our protocols or meet regulatory standards could adversely impact the subject product development program and we remain legally responsible for compliance with applicable laws and regulations governing the conduct of these clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1: The product candidate is initially introduced into healthy human subjects and tested primarily for safety and dosage tolerance. Absorption, metabolism, distribution and excretion may also be tested.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2: The product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3: Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA and other regulatory authorities for approval of a marketing application.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Post-approval studies, or Phase 4 clinical trials, may be requested by the FDA as a condition of approval and are conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted annually to the FDA and written safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggest that there may be a significant risk for human subjects. The FDA or the sponsor or, if used, the sponsor&#8217;s data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB or ethics committee can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s or ethics committee&#8217;s requirements or if the pharmaceutical product has been associated with unexpected serious harm to patients. Suspension of a clinical trial due to safety risks attributed to the investigational product will result in termination of the trial and possibly others that are underway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or other impurities with the use of biological products, the Public Health Service Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency, and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FDA Review and Approval Processes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In order to obtain approval to market a biological product in the United States, a BLA that provides data establishing to the FDA&#8217;s satisfaction the safety and effectiveness of the investigational product candidate for the proposed indication must be submitted to the FDA. The application includes all data available from nonclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s manufacture and composition, and proposed labeling, among other things. The testing and approval processes </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Prescription Drug User Fee Act, as amended (&#8220;PDUFA&#8221;), each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has 60&#160;days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. After the BLA is accepted for filing, the FDA reviews it to determine, among other things, whether the proposed product is safe and effective for its intended use, has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency, and purity. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10&#160;months from the filing date in which to complete its initial review of an original BLA and respond to the applicant, and six&#160;months from the filing date of an original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process is often extended by FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before approving a BLA, the FDA will conduct a preapproval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel product candidates or those that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA may ultimately decide that the BLA does not satisfy the criteria for approval. If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Drug Designation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation for a biologic must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If a product that has orphan designation subsequently receives the first FDA approval for the rare disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven&#160;years from the date of such approval. Additionally, the sponsor can benefit from certain financial incentives, including opportunities for grant funding towards clinical trial costs, research and development tax credits, and user fee waivers. If the same drug has already been approved, the proposed drug needs to demonstrate clinical superiority to obtain orphan exclusivity for the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">same indication, such as by means of greater effectiveness, greater safety or providing a major contribution to patient care, or in instances of drug supply issues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven&#160;years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act, a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the biologic for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (&#8220;PSP&#8221;) within 60&#160;days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Special FDA Expedited Review and Approval Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has various programs, including Fast Track designation, Limited Population, accelerated approval and priority review, that are intended to expedite the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs and biological products to patients earlier than under standard FDA review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be eligible for a Fast Track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need, or if the drug or biological product qualifies as a qualified infectious disease product under the Generating Antibiotic Incentives Now Act. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapies based on efficacy or safety factors. We intend to request Fast Track designation for our product candidates if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biological may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review, accelerated approval, and, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">for antibacterial and antifungal therapies, approval under the Limited Population Pathway. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or if there is a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefits, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The limited population pathway for antibacterial and antifungal drugs or biologics (&#8220;LPAD&#8221;) may enable the streamlined development of safe and effective medicines that overcome the unmet needs of a limited population of patients with serious bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a condition of approval, the FDA may require a sponsor of a drug or biological product receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biological product may be subject to accelerated withdrawal procedures. In addition, the FDA currently requires as a condition for accelerated approval and approval under LPAD pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. Approval under LPAD is for a limited population of patients; labeling statements for the limited use of the product are removed when supplemental data substantiates expansion of the patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Eligibility for a drug or biologic product to be licensed under LPAD includes treatment of a serious or life-threatening infection in a limited population of patients with unmet medical need. FDA also considers the severity, rarity or prevalence of the infection and the lack of alternative treatment in the limited population the therapeutic is intended for. It is possible for qualifying therapies to complete a streamlined clinical program to demonstrate substantial evidence of effectiveness and safety in the limited population. Drugs or biological products approved under LPAD can also receive fast track and breakthrough designations as well as accelerated and priority review of the marketing application. LPAD-required limitations of labeling are removed when supplemental data demonstrating a favorable benefit-risk profile in a broader population corroborates label expansion. We intend to request approval under LPAD in the BLA for our product candidates if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor can also request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug or biological product that is intended, alone or in combination with one or more other drugs or biological products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the biological product or drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biological products designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. We intend to request &#8220;breakthrough therapy&#8221; designation for our product candidates if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FDA Post-Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Maintaining substantial compliance with applicable federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of new products continues after approval, particularly with respect to cGMP. We may rely on third parties for the production of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercial quantities of any products that we may commercialize. We and third-party manufacturers of our products are required to comply with applicable requirements in the cGMPs, including quality control and quality assurance and maintenance of records and documentation. We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP and other FDA requirements. Other post-approval requirements applicable to biological products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements, by us or our suppliers, may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Biological product manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their facilities with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs and other laws. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Labeling, Marketing and Promotion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the labeling, marketing and promotion of drugs and biological products, including direct-to-consumer advertising, promotional activities involving the internet, and industry-sponsored scientific and educational activities. While doctors are free to prescribe any product approved by the FDA for any use, a company can only make claims relating to safety and efficacy of a product that are consistent with FDA approval, and the company is allowed to actively market a product only for the particular use and treatment approved by the FDA. In addition, any claims we make for our products in advertising or promotion must be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, injunctions and potential civil and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Patent Term Restoration and Extension</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, including the United States, the base term is 20&#160;years from the filing date of the earliest-filed non-provisional patent application from which the patent claims priority. The term of a U.S. patent can be lengthened by patent term adjustment, which compensates the owner of the patent for administrative delays at the USPTO. Depending upon the timing, duration and specifics of FDA approval of our drugs, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one half the time between the effective date of an IND, and the submission date of an NDA or BLA, plus the time between the submission date of an NDA or BLA and the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Biologics Price Competition and Innovation Act of 2009: Biosimilars and Interchangeable Biologic Products</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Biologics Price Competition and Innovation Act of 2009 amended the Public Health Service Act to create an abbreviated approval pathway for two types of &#8220;generic&#8221; biologics &#8212; biosimilars and interchangeable biologic products, and provides for a twelve-year data exclusivity period for the first approved biological product, or reference product, against which a biosimilar or interchangeable application is evaluated; however, if pediatric clinical trials are performed and accepted by the FDA, the twelve-year data exclusivity period will be extended for an additional six months. A biosimilar product is defined as one that is highly similar to a reference product notwithstanding minor differences in clinically inactive components and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. An interchangeable product is a biosimilar product that may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biosimilar applicant must demonstrate that the product is biosimilar based on data from (1)&#160;analytical studies showing that the biosimilar product is highly similar to the reference product; (2)&#160;animal studies (including toxicity); and (3)&#160;one or more clinical trials to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An application for a biosimilar product may not be submitted until four&#160;years after the date on which the reference product was first approved. The first approved interchangeable biologic product will be granted an exclusivity period of up to one&#160;year after it is first commercially marketed, but the exclusivity period may be shortened under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is a type of marketing exclusivity available in the United States under the Best Pharmaceuticals for Children Act, which provides for an additional six months of marketing exclusivity and may be available if a sponsor conducts clinical trials in children in response to a written request from the FDA (the &#8220;Written Request&#8221;). If the Written Request does not include clinical trials in neonates, the FDA is required to include its rationale for not requesting those clinical trials. The FDA may request studies on approved or unapproved indications in separate Written Requests. The issuance of a Written Request does not require the sponsor to undertake the described clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Diagnostics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may employ companion diagnostics to help us to more accurately identify patients within a particular bacterial strain, both during our clinical trials and in connection with the commercialization of our product candidates that we are developing or may in the future develop. Companion diagnostics can identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA and, as such, require either clearance or approval prior to commercialization. The level of risk combined with available controls to mitigate risk determines whether a companion diagnostic device requires Premarket Approval Application approval or is cleared through the 510(k)&#160;premarket notification process. For a novel therapeutic product for which a companion diagnostic device is essential for the safe and effective use of the product, the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">companion diagnostic device should be developed and approved or 510(k)-cleared contemporaneously with the therapeutic. The use of the companion diagnostic device will be stipulated in the labeling of the therapeutic product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other U.S. Healthcare Laws and Compliance Requirements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to FDA restrictions on the marketing of pharmaceutical products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our business or financial arrangements and relationships through which we market, sell and distribute the products, if any, for which we obtain approval. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs&#894; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties statute&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws and civil monetary penalties laws, such as the federal False Claims Act, which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent&#894; making, using or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government&#894; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state governmental program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters&#894; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and covered subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information&#894;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal transparency requirements under the Affordable Care Act (the &#8220;ACA&#8221;), including the provision commonly referred to as the Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April&#160;2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements, and if we fail to comply with an applicable state law requirement, we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines, imprisonment and/or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the federal False Claims Act as well as under the false claims laws of several states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which may also adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Additional Regulation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Foreign Corrupt Practices Act</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The U.S. Foreign Corrupt Practices Act, to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Healthcare Reform</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March&#160;2010, the ACA was enacted, which has substantially changed healthcare financing and delivery by both governmental and private insurers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been a number of amendments and legal and political challenges to certain aspects of the ACA. For example, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and any additional healthcare reform measures will impact the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015 led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal&#160;year that will remain in effect through 2032 unless additional Congressional action is taken. More recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The current administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) and related agencies. These actions may propose policy changes that may create additional uncertainty for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that additional foreign, federal and state healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Government Regulation Outside of the United States</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials of drug products as well as the approval, manufacture and distribution of our product candidates. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pricing and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although none of our product candidates has been commercialized for any indication, if they are approved for marketing, commercial success of our product candidates will depend, in part, upon the availability of third-party reimbursement from payors at the federal, state and private levels. Third-party payors include government healthcare programs, such as Medicare and Medicaid, private health insurers and managed-care plans. We anticipate third-party payors will provide reimbursement for our products. However, these third-party payors are increasingly challenging the price and examining the cost effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost effectiveness of our products. Our product candidates may not be considered cost effective. It is time consuming and expensive for us to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we seek regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Additionally, we may develop companion diagnostic tests for use with our current and future product candidates. We will be required to obtain coverage and reimbursement for these tests separately and apart from the coverage and reimbursement we may seek for our current and future potential product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employees and Human Capital </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of February 28, 2025, we had 60 full-time employees. Of the 60 full-time employees, 52 were engaged in research and development activities and 8 employees were engaged in finance, legal, human resources, facilities and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">general management. We have no collective bargaining agreements with our employees, we have not experienced any work stoppages&#160;and we believe our relations with our employees are good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">Our human resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and prospective employees. The principal purposes of our incentive plans are to attract, retain and motivate selected employees, consultants, advisors and directors through the granting of stock-based compensation awards and cash-based performance awards, as applicable. We provide a comprehensive benefits package to help employees manage their health, well-being, finances, and life outside of work, including health insurance, dental and vision insurance, life insurance, accidental death and dismemberment issuance, short-term and long-term disability insurance, paid sick leave, a defined contribution plan, an employee stock purchase plan, a flexible spending account program, and paid vacation time. We value the health, safety, and wellbeing of our employees and their families.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Compensation and Benefits</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are committed to equitable pay practices for employees based on role, education, experience, performance, and location and Armata conducts pay equity reviews on an annual basis. We believe that we must offer and maintain market competitive compensation and benefit programs for our employees in order to attract and retain qualified personnel. In addition to cash compensation, we provide equity compensation, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, and employee assistance programs. We also have a defined contribution plan in the United States, enabling eligible employees to contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="color:#500050;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">All periodic and current reports and other filings that we are required to file with the Securities and Exchange Commission (&#8220;SEC&#8221;), including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant Section 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge from the SEC&#8217;s website (www.sec.gov) or through our Investor Relations website at https://investor.armatapharma.com. Our corporate headquarters are located in Los Angeles, California, with an address of 5005 McConnell Avenue, Los Angeles, CA 90066, and our telephone number is +1 (310) 665-2928. We maintain a website at https://www.armatapharma.com, to which we regularly post copies of our press releases as well as additional information about us. The information on our website is not incorporated by reference into this Annual Report on Form 10-K or in any other report or document we submit to the SEC, and any references to our website are intended to be inactive textual references only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:58.4pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_b77679e7_ec72_4cef_8dd6_78d1d41f7024"></a><a id="Item1ARiskFactors_490547"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">You should consider carefully the following information about the risks described below, together with the other information contained in this Annual Report and in our other public filings in evaluating our business. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties.&#160;Additionally, our business is subject to general risks applicable to any company, such as economic conditions, geopolitical events, trade restrictions, extreme weather and natural disasters. If known or unknown risks or uncertainties materialize, our business, financial condition, results of operations, cash flows, access to liquidity and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our Common Stock would likely decline. The following discussion of risk factors contains forward-looking statements, as discussed in the Special Note Regarding&#160;</i>Forward-Looking Statements<i style="font-style:italic;">&#160;section in this Annual Report on Form 10-K.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Summary of Risk Factors </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Below is a summary of the principal factors that make an investment in our Common Stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered, together with </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">other information in this Annual Report on Form 10-K and our other filings with the SEC before making an investment decision regarding our Common Stock.</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There is substantial doubt about our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail our operations. We will need substantial additional financing to develop our product candidates and implement our operating plans, including to support one or more pivotal trials in 2025 and beyond. If we fail to obtain additional financing, we may be delayed or unable to complete the development and commercialization of our product candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to develop and maintain proper and effective processes and operating procedures as a non-traditional government contractor, our ability to adhere to the DoD and related entity standards could impact our ongoing and future development financing awards from the U.S. government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are seeking to develop antibacterial agents using bacteriophage and synthetic phage technology, a novel approach, which makes it difficult to predict the time and cost of development. No bacteriophage products have been approved in the United States or elsewhere.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results from interim, &#8220;topline,&#8221; and preliminary data, or preclinical studies and Phase 1 or 2 clinical trials of our product candidates or from single-patient expanded access treatments may not be predictive of the results of later stage clinical trials and are subject to audit and verification procedures that could result in material changes in the final data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We must continue to develop manufacturing processes for our product candidates and any delay in or our inability to do so would result in delays in our clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our clinical trials and to obtain materials or supplies necessary to conduct trials or to manufacture our product candidates, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face potential risks associated with future changes in laws and policies, including the availability of government funding for grants, staffing and funding of regulatory agencies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The use or anticipated use of artificial intelligence (&#8220;AI&#8221;) technologies, including generative AI, by us or third parties, may increase or create new operational risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business operations and current and future relationships with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Innoviva, our principal stockholder, beneficially owns greater than 50% of our outstanding shares of Common Stock, which causes us to be deemed a &#8220;controlled company&#8221; under the rules of the New York Stock Exchange (the &#8220;NYSE&#8221;). In addition, Innoviva&#8217;s interests in our business may be different than our other stockholders.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:6pt 0pt 0pt 60.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Condition and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:10pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is substantial doubt about our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail our operations. We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be delayed or unable to complete the development and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt;">The audited consolidated financial statements and accompanying notes thereto included disclosures that our recurring losses and negative cash flows from operations raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements as of December 31, 2024 and December 31, 2023 were prepared under the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. As of December 31, 2024, we had unrestricted cash and cash equivalents of $9.3 million, and we have had recurring losses from operations and negative operating cash flows since inception. In March 2024, we received an additional loan from Innoviva of $35.0 million. Our outstanding term loans, which comprise of $60.0 million of principal and $9.4 million of accrued interest, mature in January 2026 and in June 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt;">We will need to raise additional capital to support our operations and product development activities. Our ability to raise additional capital via equity or debt financing may be adversely impacted by potential worsening global economic conditions and the disruptions to, and volatility in, financial markets in the United States and worldwide. We may also seek funds through arrangements with collaborators, grant agencies or others that may require us to relinquish rights to the product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to secure additional funds when needed or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition of our company by a third party at a price that may result in a loss on investment for our stockholders, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt;">While we believe that our existing resources will be sufficient to fund our planned operations into fiscal year 2025, we cannot provide assurances that our estimates will be accurate, that our plans will not change or that changed circumstances will not result in the depletion of our capital resources more rapidly than we currently anticipate. Our future funding requirements will depend on many factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of our research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and cost of our clinical trials and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing costs associated with our targeted phage therapies strategy and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any collaborative, licensing, acquisition or other arrangements that we may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and when we receive future Australian tax rebates, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent applications, claims, patents and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of lawsuits involving us or our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the continued availability of government funding for grants.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part, on the success of our product development activities, including our targeted phage therapies strategy and any clinical trials we initiate, regulatory events, our ability to identify and enter into in-licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, political, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trials and activities associated with discovery research are costly. We do not expect to generate any revenue from the commercial sales of our product candidates in the near term, and we expect to continue to have significant losses for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our ability to generate meaningful revenue and achieve profitability depends on successfully completing the development of, and obtaining the regulatory approvals necessary to, commercialize our product candidates. If any of our product candidates fail in clinical trials or if any of our product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our ability to generate future revenues from product sales depends heavily on our success in:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing research and preclinical and clinical development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking and obtaining regulatory and marketing approvals for product candidates for which we complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing a sustainable, scalable, reproducible, and transferable manufacturing process for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching and commercializing product candidates for which we obtain regulatory and marketing approval, either by establishing a sales force, marketing and distribution infrastructure, or by collaborating with a partner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining market acceptance of any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implementing additional internal systems and infrastructure, as needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying and validating new product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring and retaining qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or other foreign regulatory authorities to perform clinical trials and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024, our accumulated deficit was $327.7 million and we expect to incur losses for the foreseeable future. We have devoted, and will continue to devote for the foreseeable future, substantially all of our resources to research and development of our product candidates. Additional information regarding our results of operations may be found in our consolidated financial statements included in Item 8 in this Annual Report and in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Item 7 in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to develop and maintain proper and effective processes and operating procedures as a non-traditional government contractor, our ability to adhere to the Department of Defense and related entity standards could impact our ongoing and future development financing awards from the U.S. government. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">       On June 15, 2020, we entered into an agreement with the Medical Technology Enterprise Consortium (&#8220;MTEC Agreement&#8221;), pursuant to which we received a </span>$15.0 million award and have entered into a multi-year program administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (NMRC) &#8211; Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the third quarter of 2024. In July 2024, the MTEC Agreement was modified to increase the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025. We are using the award to partially fund a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled dose escalation study that will assess the safety, tolerability and efficacy of our phage-based candidate, AP-SA02, for the treatment of adults with <i style="font-style:italic;">S. aureus </i>(&#8220;diSArm&#8221; study)<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;background:#ffffff;margin:0pt;">Government contracts and grants normally contain additional requirements that may increase our costs of doing business and expose us to liability for failure to comply with these terms and conditions. These requirements have historically included and may continue to include, for example:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tracking of contract costs and maintenance of effective controls over tracking of such costs; </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion and submission of periodic reporting packages;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">mandatory financial audits and potential liability for failing such audits; and  </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination, and affirmative action programs, and environmental compliance requirements. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      While we believe we are in compliance with all requirements under the MTEC Agreement, potential failure to maintain such compliance could result in reduction of the grant or termination of the contract, which could in turn negatively impact our business.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Business</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are seeking to develop antibacterial agents using bacteriophage and synthetic phage technology, a novel approach, which makes it difficult to predict the time and cost of development. No bacteriophage products have been approved in the United States or elsewhere.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are developing our product candidates with bacteriophage and synthetic phage technology. We have not, nor to our knowledge has any other company, received regulatory approval from the FDA or equivalent foreign agencies for a pharmaceutical drug based on this approach. While<i style="font-style:italic;"> in vitro</i> studies have characterized the behavior of bacteriophages in cell cultures and there exists a body of literature regarding the use of phage therapy in humans, the safety and efficacy of phage therapy in humans has not been extensively studied in well-controlled modern clinical trials. Most of the prior research on phage-based therapy was conducted in the former Soviet Union prior to and immediately after World War II and lacked appropriate control group design or lacked control groups at all. Furthermore, the standard of care has changed substantially during the ensuing decades since those studies were performed, diminishing the relevance of prior claims of improved cure rates. We cannot be certain that our approach will lead to the development of approvable or marketable drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Developing phage-based therapies on a commercial scale will also require developing new manufacturing processes and techniques. We and our third-party collaborators may experience delays in developing manufacturing capabilities for our product candidates and may not be able to do so at the scale required to efficiently conduct the clinical trials required </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to obtain regulatory approval of our product candidates, or to manufacture commercial quantities of our products, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of drugs based on these approaches, which could lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Results from interim, &#8220;top-line,&#8221; and preliminary data, or preclinical studies and Phase 1 or 2 clinical trials of our product candidates or from single-patient expanded access treatments may not be predictive of the results of later stage clinical trials and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, we may publicly disclose interim,&#160;top-line&#160;or preliminary data from our preclinical studies and clinical trials, based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publicly disclose such data. As a result, any interim,&#160;top-line&#160;or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or&#160;top-line&#160;data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim,&#160;top-line&#160;and preliminary data should be viewed with caution until the final data are available. In addition, preliminary or interim data from ongoing clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between any preliminary or interim data we disclose and final data could significantly harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by investors or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim,&#160;top-line&#160;or preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Preclinical studies, including studies of our product candidates in animal disease models, may not accurately predict the result of human clinical trials of those product candidates. In particular, promising animal studies suggesting the efficacy of prototype phage products in the treatment of bacterial infections, such as<i style="font-style:italic;">&#160;P. aeruginosa&#160;</i>and<i style="font-style:italic;">&#160;S. aureus,</i> may not predict the ability of these products to treat similar infections in humans. Despite promising data in our completed Phase 1 clinical trials, our phage technology may be found not to be safe or efficacious in treating bacterial infections alone or in combination with other agents, when studied in later-stage clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, we have used our bacteriophage technology in the area of targeted medicine under single-patient expanded access guidelines, which permit the use of phage therapy outside of clinical trials, in the United States and Australia. Despite prior single-patient expanded access successes, no assurance can be given that we will have similar single-patient expanded access treatment successes in the future. Single-patient expanded access is a term that is used to refer to the use of an investigational drug or therapy outside of a clinical trial to treat a patient with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options. Regulators often allow single-patient expanded access on a case-by-case basis for an individual patient or for defined groups of patients with similar treatment needs. In some countries, such as Australia, the treating physician can </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">administer treatment under single-patient expanded access guidelines without pre-approval from the applicable regulatory authority.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To satisfy FDA or foreign regulatory approval standards for the commercial sale of our product candidates, we must demonstrate in adequate and controlled clinical trials that our product candidates are safe and effective. Success in early clinical trials, including Phase 1 and Phase 2 trials, or in our single-patient expanded access program does not ensure that later clinical trials will be successful. Our initial results from early stage clinical trials or our single-patient expanded access program also may not be confirmed by later analysis or subsequent larger clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials and most product candidates that commence clinical trials are never approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delays in our clinical trials could result in us not achieving anticipated developmental milestones when expected, increased costs and delay our ability to obtain regulatory approval for and commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Delays in our ability to commence or enroll patients for our clinical trials could result in us not meeting anticipated clinical milestones and could materially impact our product development costs and delay regulatory approval of our product candidates. Planned clinical trials may not be commenced or completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the development of manufacturing capabilities for our product candidates to enable their consistent production at clinical trial scale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failures in our internal manufacturing operations that result in our inability to consistently and timely produce bacteriophages in sufficient quantities to support our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of financial resources to commence and complete our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with clinical investigators on study design;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with regulatory agencies on trial design or in obtaining regulatory approval to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the FDA and foreign regulatory approval processes, staffing, resources or perspectives that may delay or prevent the approval of future products and result in lost market opportunity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining clinical materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected patient recruitment for participation in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by clinical trial sites, other third parties, or us to adhere to clinical trial agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching agreement on acceptable clinical trial agreement terms with prospective sites or obtaining institutional review board approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse safety events experienced during our clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Completion of clinical trials depends, among other things, on our ability to enroll a sufficient number of patients, which is a function of many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the therapeutic endpoints chosen for evaluation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived benefit of the product candidate under study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the clinical trial&#8217;s therapeutic endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators and sites with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition for patients from clinical trials for other treatments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Difficulties in enrolling patients in our clinical trials, could increase the costs or affect the timing or outcome of these clinical trials. This is particularly true with respect to diseases with relatively small patient populations. If we do not successfully commence or complete our clinical trials on schedule, the price of our Common Stock may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We must continue to develop manufacturing processes for our product candidates and any delay in or our inability to do so would result in delays in our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are continuing to develop novel manufacturing processes for our phage product candidates at our facility in Los Angeles, California. Construction of the new manufacturing facility in Los Angeles, California was completed in the second half of 2024. The manufacturing processes for our product candidates, and the scale-up of such processes for clinical trials, are novel, and there can be no assurance that we will be able to complete this work in a timely manner, if at all. The manufacture of our product candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. If we were to encounter any of these difficulties, our ability to provide our products to patients in our clinical trials or to commercially launch a product would be jeopardized. Any delay or interruption could postpone the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program, and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any delay in the development or scale up of these manufacturing processes could delay the start of clinical trials and harm our business. In the event our facility in Los Angeles, California, does not receive a satisfactory cGMP inspection for the manufacture of our product candidates, we may need to fund additional modifications to our manufacturing process, conduct additional validation studies, or find alternative manufacturing facilities, any of which would result in significant cost to us as well as a delay of up to several&#160;years in obtaining approval for such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our manufacturing facility will be subject to ongoing periodic inspection by the FDA&#160;for compliance with cGMP regulations. Compliance with these regulations and standards is complex and costly, and there can be no assurance that we will be able to comply. Any failure to comply with applicable regulations could result in sanctions being imposed (including fines, injunctions and civil penalties), failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecution. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if we fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain FDA approval of our products, we will not be able to commercialize our products in the United States. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;">We need FDA approval prior to marketing our product candidates in the United States. If we fail to obtain FDA approval to market our product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;">This regulatory review and approval process, which includes evaluation of pre-clinical studies and clinical trials of our product candidates as well as the evaluation of our manufacturing processes, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our product candidates are both safe and effective for each indication for which approval is sought. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals, including approval for an Investigational New Drug application (&#8220;IND application&#8221;), for any of our product candidates currently under development, other than for our product candidates AP-PA02 and AP-SA02, for which we received FDA clearance of our respective IND applications. Moreover, approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;">The FDA has substantial discretion in the approval process and may either refuse to consider any of our applications for substantive review or may form the opinion after review of our data that one or more of our applications are insufficient to approve our product candidates. If the FDA does not consider or approve any of our applications, it may require that we conduct additional clinical, pre-clinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may conduct clinical trials for our products or product candidates outside the United States and the FDA may not accept data from such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We completed an investigator-sponsored clinical trial of AP-SA01 at the University of Adelaide in Australia for CRS in December&#160;2016. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example, the study must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The study population must also adequately represent the U.S. population, and the data must be applicable to the United States population and U.S. medical practice in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical studies conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, such studies would be subject to the applicable local laws and FDA acceptance of the data would be dependent upon its determination that the studies also complied with all applicable U.S. laws and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. Further, with respect to AP-SA01, we have changed the product formulation to AP-SA02 and any work related to AP-SA01 may not be relevant to the FDA or other international regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to significant regulatory approval requirements, which could delay, prevent or limit our ability to market our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development activities, preclinical studies, clinical trials and the anticipated manufacturing and marketing of our product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in Europe and elsewhere. There can be no assurance that our manufacturing facilities will satisfy the requirements of the FDA or comparable foreign authorities. We require the approval of the relevant regulatory authorities before we may commence commercial sales of our product candidates in a given market. The regulatory approval process is expensive and time-consuming, and the timing of receipt of regulatory approval is difficult to predict. Our product candidates could require a significantly longer time to gain regulatory approval than expected, or may never gain approval. We cannot be certain that, even after expending substantial time and financial resources, we will obtain regulatory approval for any of our product candidates. A delay or denial of regulatory approval could delay or prevent our ability to generate product revenues and to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in regulatory approval policies during the development period of any of our product candidates, changes in, or the enactment of, additional regulations or statutes, changes in regulatory review practices for a submitted product application, or changes in regulatory staffing and funding may cause a delay in obtaining approval or result in the rejection of an application for regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory approval, if obtained, may be made subject to limitations on the indicated uses for which we may market a product. These limitations could adversely affect our potential product revenues. Regulatory approval may also require costly post-marketing follow-up studies. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping related to the product will be subject to extensive ongoing regulatory requirements. Furthermore, for any marketed product, its manufacturer and its manufacturing facilities will be subject to continual review and periodic inspections by the FDA or other regulatory authorities. Failure to comply with applicable regulatory requirements may, among other things, result in fines, suspensions of regulatory approvals, product recalls, product seizures, operating restrictions and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials and to obtain materials or supplies necessary to conduct trials or to manufacture our product candidates, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We use third parties, such as clinical research organizations, to assist in conducting our clinical trials and for many aspects of our manufacturing process development of our product candidates. However, we may face delays outside of our control if these parties do not perform their obligations in a timely or competent fashion or if we are forced to change service providers. This risk is heightened for clinical trials conducted outside of the United States, where it may be more difficult to ensure that clinical trials are conducted in compliance with FDA requirements. Any third party that we hire to conduct clinical trials may also provide services to our competitors, which could compromise the performance of their obligations to us. If we experience significant delays in the progress of our clinical trials and in our plans to submit Biologics License Applications, the commercial prospects for product candidates could be harmed and our ability to generate product revenue would be delayed or prevented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:10pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business operations and current and future relationships with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Our business operations and current and future arrangements with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">arrangements and relationships through which we conduct our operations, including how we market, sell, and distribute our product candidates, if approved. Such laws include, but are not limited to, the U.S. Anti-Kickback Statute, U.S. civil and criminal false claims laws, the U.S. federal Beneficiary Inducement Statute, HIPAA, and state and local laws and regulations. Some of these laws may apply differently to, and may have different requirements for, and effects on, our business, rendering compliance complex and possibly burdensome. We cannot predict how future changes to these laws may impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, may not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties; damages; fines; exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other jurisdictions; integrity oversight and reporting obligations to resolve allegations of non-compliance; disgorgement; individual imprisonment; contractual damages; reputational harm; diminished profits; and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Furthermore, defending against any of these actions can be costly, time-consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:10pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face potential liability related to the privacy of health information we may obtain from the patients in our clinical trials if we fail to comply with privacy laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Most healthcare providers are subject to privacy and security regulations promulgated under HIPAA, as amended by HITECH, as well as similar state laws governing the collection, use, and disclosure of health-related information. We are not currently classified as a covered entity or business associate under HIPAA and thus are not subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial negative consequences &#8211; including criminal penalties, regulatory fines, reputational damage, and other harmful effects &#8211; if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, if we receive sensitive personally identifiable information, including health information, we may be subject to state laws governing the use, security, and disclosure of such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">We cannot assure you that we, our CROs, our clinical trial sites, and our clinical trial principal investigators with access to personally identifiable and other sensitive or confidential information relating to the patients in our clinical trials will not breach contractual obligations, or that we or they will not experience data security breaches or attempts thereof. This could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations as discussed above, which could in turn adversely affect our business, financial condition, results of operations, and prospects. We also cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage, and transmission of such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which could have a material adverse effect on our business, financial condition, results of operations, or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">The regulatory framework for the collection, use, safeguarding, sharing, transfer, and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, many jurisdictions have established their own data security and privacy frameworks. In the United States, there are a broad variety of data protection laws that are either currently in place or under way and a wide range of enforcement agencies </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">at both the state and federal levels have the authority to review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission (&#8220;FTC&#8221;), and state Attorneys General have been aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which went into effect on January 1, 2020, provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. There also is the threat of consumer class actions related to these laws and the overall protection of personal data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, the CCPA was amended by the California Privacy Rights Act, which significantly amends the CCPA and imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations, which could result in increased privacy and information security enforcement. The majority of the provisions went into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in, or are being considered by, other states. The enactment of such laws in other states could result in potentially conflicting requirements, which would make compliance challenging and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FTC and many state attorneys general continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. We may also be subject to new state laws governing the privacy of consumer health data, including information concerning individual health conditions and treatment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union (the &#8220;EU&#8221;), including personal health data, is subject to the General Data Protection Regulation, (EU) 2016/679 (the &#8220;GDPR&#8221;). The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR has expanded the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial patients and investigators. In addition, the GDPR imposes strict rules on the transfer of personal data to countries outside the EU, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the European Economic Area should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information or impose substantial fines for violations of the GDPR, which can be up to 4% of global revenues or &#8364;20 million, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that EU member states may make their own additional laws and regulations limiting the processing of personal data, including genetic, biometric, or health data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>Furthermore, since the United Kingdom is no longer part of the EU, its data protection regulatory regime is independent of the EU. From January 1, 2021, companies have had to comply with both the GDPR and the United Kingdom GDPR, which, together with the amended United Kingdom Data Protection Act 2018, retains the GDPR in UK national law. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear. In addition, the longer term economic, legal, political, regulatory, and social framework to be put in place between the United Kingdom and the EU has had, and may continue to have, a material and adverse effect on global economic conditions and the stability of global financial markets and may significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these factors </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">could depress economic activity and restrict our access to capital, which could materially and adversely affect our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We face potential risks associated with future changes in laws and policies, including the availability of government funding for grants, staffing and funding of regulatory agencies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the United States, changes in the U.S. government between administrations have resulted in potential changes in regulations, fiscal policy, social programs, domestic and foreign relations and international trade policies. Our ability to respond to these developments or comply with any resulting new legal or regulatory requirements, including those involving economic and trade sanctions, could increase our costs of doing business, reduce our financial flexibility and otherwise have a material adverse effect on our business, financial condition and results of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our operations, including research, development, and clinical programs and trials, are largely dependent on government grants (for example, the MTEC Agreement, which is paid over the term of the award), meaning any substantial policy shift or executive action that restricts or diminishes the availability of these funds could materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The use or anticipated use of artificial intelligence (&#8220;AI&#8221;) technologies, including generative AI, by us or third parties, may increase or create new operational risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">AI technologies offer numerous potential benefits, such as creating or increasing operational efficiencies, and we expect an increase in the use of AI and generative AI by us, third parties on our behalf, and other market actors, including our competitors. However, the deployment of such technologies also poses certain risks, including that the algorithms may be flawed, misused or otherwise function in an unexpected manner; data sets may be insufficient, of poor quality, or contain biased information; and inappropriate or controversial data practices by data scientists, engineers, and end-users could impair results. The relative newness of the technology, the speed at which it is being adopted, and the paucity of laws, regulations or standards expressly and specifically governing its use increases these risks. If the analyses that AI-based applications assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability and brand or reputational harm. Our competitors may also adopt AI or generative AI more quickly or more effectively than we do, which could cause competitive harm. Furthermore, use of AI-based software may lead to the release of confidential information which may impact our ability to realize the benefits of our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technology and product candidates. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which could harm our business and ability to achieve profitability. To protect our proprietary positions, we file patent applications in the United States and abroad related to our novel technologies and product candidates that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>The patent application and prosecution process is expensive and time-consuming. We, our current licensees, or any future licensors and licensees may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We or our current licensees, or any future licensors or licensees may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with our best interests. It is possible that defects of form in the preparation or filing of our patents or patent applications </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If our current licensees, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised, and we might not be able to prevent third parties from making, using and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and/or unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. For example, European patent law currently restricts the patentability of methods of treatment of the human body more than United States law does. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws in the United States, including the America Invents Act of 2011, may affect the scope, strength and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#8239;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly, should we own any patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for the inventions claimed in such patents or patent applications. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) or become involved in derivation, ex-parte reexamination, or inter partes review proceedings in the USPTO or similar proceedings elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection against competing products or processes sufficient to achieve our business objectives, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable and/or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate, a patent being held unenforceable, and/or in one or more patent claims being narrowed or invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our technology or product candidates, including interference proceedings before the USPTO. Intellectual property disputes arise in several areas including with respect to patents, use of other proprietary rights and the contractual terms of license arrangements. Third parties may assert claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are found to infringe a third-party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In some cases, we may not be able to obtain patent protection for certain licensed technology outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and preclinical programs and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties prior to beginning research or disclosing proprietary information. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Despite these efforts and the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information due to our reliance on third parties, increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Industry</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is a high rate of failure inherent in drug discovery and development, and failure can occur at any point in the process, including in later stages after substantial investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">New product candidates that appear promising in development or prior to being acquired may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payor reimbursement or coverage, failure to obtain placement on guidelines or recommendations published by third-party organizations that are commensurate with clinical data, the application of pricing controls, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of newer better, or more cost-effective competitive products, difficulty or excessive costs to manufacture, insufficient infrastructure to support detection, diagnostic or other requisites for treatment, ineffectiveness in reaching healthcare professionals, including digitally given the increase in virtual engagements, or infringement of the patents or intellectual property rights of others. We may also fail to allocate research and development resources efficiently, fail to pursue or invest sufficiently in product candidates or indications that may have been successful, or fail to optimally balance trial design, conduct, and speed to accomplish desired outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delay, uncertainty, unpredictability, and inconsistency in drug approval processes across markets and agencies can result in delays in product launches, lost market opportunities, impairment of inventories, and other negative impacts. In addition, it can be very difficult to predict revenue growth rates of, or variability in demand for, new products and indications, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">which in some cases leads to difficult meeting product demand or, on the other hand, excess inventory and related financial charges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The development and commercialization of new drug products is highly competitive. We face competition from major multi-national pharmaceutical companies, biotechnology companies, specialty pharmaceutical companies and generic drug companies with respect to our current and future product candidates. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of drug-resistant infections. Potential competitors also include academic institutions, government agencies and other public and private research organizations. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, more effectively marketed and sold or less costly than our product candidates, which could render our product candidates non-competitive and obsolete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our competitors obtain marketing approval from the FDA, the EMA or other comparable regulatory authorities for their product candidates more rapidly than we do, it could result in our competitors establishing a strong market position before we are able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulation of generic and biosimilar products varies around the world and such regulation is complex and subject to ongoing interpretation and implementation by regulatory agencies and courts. Particularly for biosimilars, health authority guidelines and legislative actions could make it less burdensome for competitor products to enter the market and further incentivize uptake of biosimilars. In the United States, the FDA has issued several &#8220;interchangeability&#8221; designations for biosimilar products, and is expected to continue doing so in the future. These designations could, subject to state law requirements, enable pharmacies to substitute biosimilars for innovator biological products. Given the importance of biologic products to our clinical-stage pipeline, such regulation could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of our competitors have greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do as an organization. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our competitors also may obtain approval from the FDA, the EMA or other comparable regulatory agencies for their product candidates more rapidly than we may obtain approval for ours, which could result in product approval delays if a competitor obtains market exclusivity from the FDA or the EMA, or our competitors establish a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs. Additional drugs may become available on a generic basis over the coming years. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>reduced resources of our management to pursue our business strategy;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>decreased demand for any product candidates or products that we may develop;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>injury to our reputation and significant negative media attention;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>withdrawal of clinical trial participants;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>initiation of investigations by regulators;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>product recalls, withdrawals or labeling, marketing or promotional restrictions;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>significant costs to defend the resulting litigation;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>substantial monetary awards paid to clinical trial participants or patients;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>loss of revenue; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inability to commercialize any drugs that we may develop.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently hold product liability insurance coverage in an amount that may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which would negatively affect our ability to achieve profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any approved products will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential advantages or disadvantages over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price of the product, both in absolute terms and relative to alternative treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficient third-party coverage or reimbursement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our product candidates receive regulatory approval but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate product revenues sufficient to attain profitability.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current and future healthcare reform measures may affect our results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the United States, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our future products may be prescribed, purchased and reimbursed, which may adversely affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the European Union and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures may adversely affect our future revenue and business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our business is subject to increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our results of operations, reputation or business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Public and private payors continue to take aggressive steps to control their expenditures for pharmaceuticals by placing restrictions on pricing and reimbursement for, and patient access to, medicines. Governments and private payors worldwide have intensified their scrutiny of, and actions intended to address, pricing, reimbursement, and access to pharmaceutical products and are demanding greater commercial and clinical value from pharmaceutical companies in the form of strong product differentiation and demonstrated value. The effect of reducing prices and reimbursement would significantly impact potential future revenues and business opportunities. Within the United States, state level transparency initiatives, importation rules, reporting requirements, and mandated programs, may also increase administrative costs, in some cases, compromise confidential business practices and otherwise detrimentally impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Heightened governmental scrutiny over the manner in which drug manufacturers price their marketed products and the practices of pharmacy benefit managers and other supply chain entities has also resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, require advance notice of list price increases, establish upper payment limits or other restrictions by drug affordability review boards, allow the importation of drugs from other countries, address pharmacy benefit manager practices, and reform government program reimbursement methodologies for drug products. In particular, the IRA contains provisions designed to limit the prices paid by Medicare for various prescription drugs. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Outside of the United States, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Innoviva, our principal </span><span style="font-style:italic;font-weight:bold;">stockholder</span><span style="font-style:italic;font-weight:bold;">, beneficially owns greater than 50% of our outstanding shares of Common Stock, which causes us to be deemed a &#8220;controlled company&#8221; under the rules of NYSE. In addition, Innoviva&#8217;s interests in our business may be different than our other </span><span style="font-style:italic;font-weight:bold;">stockholder</span><span style="font-style:italic;font-weight:bold;">s.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024, Innoviva owns 69.3% of our outstanding shares and 19,364,647 warrants to purchase shares of our Common Stock. If Innoviva were to exercise the warrants held by them, they would hold approximately </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">80.0% of our issued and outstanding shares of Common Stock. As a result, Innoviva owns more than 50% of our outstanding shares, and as such, we are a &#8220;controlled company&#8221; under the rules of the NYSE. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group or another company is a &#8220;controlled company&#8221; and, as such, may elect to be exempt from certain corporate governance requirements, including requirements that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_5"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a majority of the board of directors consist of independent directors;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_6"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the board of directors maintain a nominating and corporate governance comprised solely of independent directors and with a written charter addressing the committee&#8217;s purpose and responsibilities; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_7"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the board of directors maintain a compensation committee comprised solely of independent directors and with a written charter addressing the committee&#8217;s purpose and responsibilities.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As a &#8220;controlled company,&#8221; we may elect to rely on some or all of these exemptions, however, we do not intend to take advantage of any of these exemptions. Despite the fact we do not intend to take advantage of these exemptions, our status as a controlled company could make our Common Stock less attractive to some investors or otherwise harm our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Innoviva&#8217;s large ownership stake may allow it to exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support, including amendments to our articles of incorporation, adoption of measures that could delay or prevent a change in control or impede a merger, takeover, or other business combination involving us, and approval of other major corporate transactions. In addition, Innoviva&#8217;s stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us, which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price. Accordingly, our stockholders other than Innoviva may be unable to influence management and exercise control over our business. Furthermore, any sales by Innoviva of a substantial number of shares of our Common Stock, or the expectation of such sales, could cause a significant reduction in the market price of our Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The price of our securities has been volatile and may continue to be so, and purchasers of our securities could incur substantial losses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The price of our securities has been volatile and may continue to be so. Between January 1, 2024 and December 31, 2024, the high and low sales prices of our Common Stock as reported on NYSE varied between $1.85 and $4.18 per share. The stock market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the companies&#8217; operating performance, in particular during the last several years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024, we had outstanding common warrants to purchase an aggregate of 19,365,847 shares of our Common Stock at a weighted-average exercise price of $3.59 per share. We also have outstanding options to exercise 3,755,965 shares of our Common Stock at a weighted-average exercise price of $3.74 per share. To the extent any of our outstanding warrants or options are exercised, additional shares of our Common Stock will be issued which will result in dilution to our security holders and could also have an adverse effect on the market price of our Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:10pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations, and/or require us to relinquish rights to our technologies or product candidates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Until such time, if ever, that we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, and strategic collaboration and licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our Common Stock to decline. Debt financing, if available, may involve agreements that include covenants limiting or restricting our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ability to take specific actions, such as incurring additional debt, making capital expenditures, licensing or assigning our intellectual property rights, declaring dividends, and possibly other restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">To the extent that we raise additional capital through the sale of equity or convertible loan securities, our stockholders&#8217; interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our Common Stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Attempting to secure additional financing may also divert our management from our day-to-day activities, which could impair or delay our ability to develop our product candidates. Furthermore, if, in the future, one or more banks or financial institutions enter receivership or become insolvent in response to financial conditions affecting the banking system or financial markets, our ability to access our existing cash, cash equivalents, and marketable securities may be threatened and could have a material impact on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts. Alternatively, we could be required to seek collaborators for our product candidates at an earlier stage than would otherwise be desirable or on terms that are less favorable than might otherwise be available. We might need to relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development and commercialization ourselves, or to license our intellectual property to others who could develop products that will compete with our products. Any of these actions could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General Risk Factors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and trade disputes or other factors, may adversely affect our business and financial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Our business is sensitive to global economic conditions, which can be adversely affected by epidemics and other public health crises, political and military conflict, trade and other international disputes (including tariffs, embargoes, sanctions or other trade restrictions), significant natural disasters (including as a result of climate change) or other events that disrupt macroeconomic conditions. Pandemics, such as the COVID-19 pandemic, have in the past impacted and may in the future impact our business, operations and financial condition and results. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, us and our business partners and suppliers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Further, military conflicts or wars (such as the ongoing conflicts between Russia and Ukraine&#160;</span>and in the Middle East<span style="background:#ffffff;">) can cause exacerbated volatility and disruptions to various aspects of the global economy. The uncertain nature, magnitude, and duration of hostilities stemming from such conflicts, including the potential effects of sanctions and counter-sanctions, or retaliatory&#160;cyber-attacks on the world economy and markets, have contributed to increased market volatility and uncertainty, which could have an adverse impact on macroeconomic factors that affect our business and operations, such as worldwide supply chain issues. It is not possible to predict the short- and long-term implications of military conflicts or wars or geopolitical tensions which could include further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices,&#160;cyber-attacks, supply chain challenges and adverse effects on currency exchange rates and financial markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Additionally, the operations of our suppliers and manufacturers may be located in areas that are prone to earthquakes, wildfires and other natural disasters. Such operations and facilities are also subject to the risk of interruption by drought, power shortages, nuclear power plant accidents and other industrial accidents, terrorist attacks and other hostile acts, ransomware and other cybersecurity attacks, labor disputes, public health crises, trade restrictions (including tariffs, embargoes and sanctions), and other events beyond the Company&#8217;s control. Global climate change is resulting in certain types of natural disasters occurring more frequently or with more intense effects. Such events can create delays or </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">interruptions to the Company&#8217;s development efforts and inefficiencies in the Company&#8217;s supply and manufacturing chain. Significant delays in our development efforts could materially impact our ability to obtain regulatory approval and to commercialize our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Without limiting the foregoing, we have experienced and/or may in the future experience:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving authorization from regulatory authorities to initiate any planned clinical trials, inspections, reviews and approvals of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties enrolling patients in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or disruptions to the conduct of preclinical programs and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">constraints on the movement of products and supplies through the supply chain, which can disrupt our ability to conduct clinical trials and develop our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">price increases in raw materials and capital equipment, as well as increasing price competition in our markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse impacts on our workforce and/or key employees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our operations could be disrupted by failure of our information systems or by successful&#160;cyber-attacks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations could be disrupted if our information systems&#8212;or those of our vendors&#8212; fail, if we or our vendors are unsuccessful in implementing necessary upgrades, or if we or our vendors are subject to successful&#160;cyber-attacks. Our business depends on the efficient and uninterrupted operation of our computer and communications systems and networks, hardware and software systems and our other information technology. We collect and maintain information, which includes confidential and proprietary information as well as personal information regarding our employees and others, in digital form. Data maintained in digital form is subject to risk of&#160;cyber-attacks, which could include the deployment of harmful malware, viruses, worms, and other means to affect service reliability and threaten data confidentiality, integrity and availability. Despite our efforts to monitor and safeguard our systems to prevent data compromise (as discussed below in Item 1C), such attacks are increasing in frequency and sophistication, and the possibility of a future data compromise, and risks associated with intrusion, tampering, and theft, cannot be eliminated entirely. We have experienced cyber-attacks in various forms, including phishing and other attempts to compromise our systems, but none of these has resulted in a material incident. A failure of our systems, or an inability to successfully expand the capacity of these systems, or an inability to successfully integrate new technologies into our existing systems could have a material adverse effect on our business, results of operations, financial condition, and cash flows. Further, our cybersecurity controls may not function as intended or our logging may be insufficient to fully investigate an incident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A system failure, accident or security breach may also result in a material disruption of our independent drug development programs. For example, the loss of clinical trial data from ongoing or future clinical trials for any of our product candidates could result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data. Our information security systems are also subject to laws and regulations requiring that we take measures to protect the privacy and security of certain information we gather and use in our business. For example, federal and state laws, including, without limitation, state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and storage of personal information. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of confidential or proprietary information or personal health information, we could incur substantial liability, our reputation would be damaged and the further development of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">&#160;The Company&#8217;s and its vendors&#8217; sophisticated information technology operations are spread across multiple, sometimes inconsistent, platforms, which pose difficulties in maintaining data integrity across systems. The ever-</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional or improper dissemination or destruction of confidential information stored in the Company&#8217;s systems. A compromise of the security or integrity of any of these systems could adversely affect our security posture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any breach of our security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse of trade secrets, proprietary information or other confidential information, whether as a result of theft, hacking, fraud, trickery or other forms of deception, or for any other cause, could adversely affect our business position. Further, any such interruption, security breach, loss or disclosure of confidential information could result in financial, legal, business and reputational harm to the Company and could have a material adverse effect on our business, financial condition, results of operations, cash flows and stock price.</p><a id="_95714717_db82_450b_bd89_820c7231c812"></a><a id="Item1BUNRESOLVEDSTAFFCOMMENTS_454967"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;1B.&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_467d17c3_f508_4efd_a7b1_e58e0a8a4532"></a><a id="Item1CCybersecurity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Item&#160;1C.&#160;&#160;&#160;</b><b style="font-weight:bold;">Cybersecurity</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_pr07zUuWBE2R0bJxs5EQDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cybersecurity Risk Management and Strategy</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_-edTutcEbUmd3X4nG2irKQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_Q0UZ6Hh9UESHeX4Ah-P8gw">We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. </ix:nonNumeric>These risks include operational risks, intellectual property or trade secret theft, improper disclosure of confidential information, fraud, extortion, harm to employees or customers, and violation of data privacy or security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cybersecurity risks related to our business, technical operations, privacy, and compliance issues are identified and addressed through a multi-faceted approach <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_oYSkoZ-84UywbFYJZuuVoQ">including third-party assessments</ix:nonNumeric>, internal information technology (&#8220;IT&#8221;) audits, and IT security reviews. To defend, detect, and respond to cybersecurity incidents, we perform cybersecurity reviews of systems and applications; audits of applicable data policies; vulnerability assessments and penetration testing using external third-party tools to test security control; security incident and event management; continuous monitoring, and threat intelligence gathering; conduct employee training; and implement appropriate changes. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We leverage <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_iqYKt4Tb9ES5pDpZKVTsAQ">third-party expertise</ix:nonNumeric> to audit and test our cybersecurity program and perform employee awareness training. These include periodic reviews of cybersecurity threats and related controls, including review of periodic penetration testing conducted by independent third parties. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We maintain a cyber liability insurance plan underwritten by multiple insurance companies, which provides protection against certain potential losses arising from cybersecurity incidents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Our business strategy, results of operations and financial condition <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_3oWbLVd7D06D-k_YOqsABw">have not been materially affected by risks from cybersecurity threats</ix:nonNumeric>, including as a result of previously identified cybersecurity incidents, but we cannot provide assurance that they will not be materially affected in the future by such risks or any future material incidents. For more information on our cybersecurity related risks, see Item 1A Risk Factors of this Annual Report on Form 10-K.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_uIR60Mo6jkGea_Nkc4O1tA" continuedAt="Tb_uIR60Mo6jkGea_Nkc4O1tA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cybersecurity Governance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cybersecurity is an important part of our risk management processes and an area of focus for our Board of Directors (&#8220;Board of Directors&#8221;) and management. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_tesg-yqLpkqp4Vmx5OITQQ" continuedAt="Tb_tesg-yqLpkqp4Vmx5OITQQ_cont1" escape="true">Our Board of Directors delegated oversight of Cybersecurity to the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_3uMo76rNQk-UvysvEl3YzQ" escape="true">Audit Committee</ix:nonNumeric>. Members of our Board of Directors receive reports and presentations on data privacy and security, which address relevant cybersecurity issues, and which can span a wide range of topics, including but not limited to, recent developments, evolving standards, vulnerability assessments, review of risks from third parties such as service providers and suppliers, and the current threat environment. These updates are presented by IT third-party experts, finance, and </ix:nonNumeric></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_uIR60Mo6jkGea_Nkc4O1tA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:continuation id="Tb_tesg-yqLpkqp4Vmx5OITQQ_cont1">legal departments. Members of our Board of Directors also engage in ad hoc conversations with management on cybersecurity-related news events and updates to our cybersecurity risk management and strategy programs.</ix:continuation> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Group_TM2gY7NfVUGRtF7nBs40MA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Audit Committee&#8217;s cybersecurity-related oversight includes the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Receiving notice of, and providing guidance with respect to, material cybersecurity incidents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing our risks and cybersecurity programs and policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Overseeing our management and mitigation of cybersecurity risks and potential breach incidents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing reports and key metrics on the Company&#8217;s cybersecurity and related risk management programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing the progress of major technology-related proposals, plans, projects and architecture decisions to ensure that these projects and decisions support our overall business strategy.</span></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Tb_Qtb6mRT7nUuabGjV6mYz0A" escape="true">Our <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_lIMoHZbsNkW7nvcXFPMwrg"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_AsCnugKohEyKu3Bqb2fhYQ" escape="true">management</ix:nonNumeric> engages with third-party experts</ix:nonNumeric> who have significant <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_v6swIXV4EkWLEG571OIfLw">IT expertise</ix:nonNumeric> and broad cybersecurity experience, including in cybersecurity threat management, cybersecurity training and education, incident response, cyber forensics, insider threats, business continuity and disaster recovery, and regulatory compliance.</ix:nonNumeric> Such <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_e4cyUP1h30a_vAGntzHcFw" escape="true">individuals have significant prior work experience in various roles involving IT security, auditing, compliance, systems, and programming. These individuals are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents and design.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_647e330c_1c33_46fe_8dd9_df2784da6f66"></a><a id="Item2Properties"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;&#160;PROPERTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters are located in Los Angeles, California, with an address of 5005 McConnell Avenue, Los Angeles, CA 90066. On October 28, 2021, we entered into a lease for approximately 56,300 square feet of office, research and development and manufacturing space under a non-cancellable lease. The 2021 Lease payment start date was May 1, 2022, and the total lease term is for&#160;16 years&#160;and runs through 2038. Office space and research laboratories have been occupied since the third quarter of 2023, with cGMP manufacturing space (~10,000 square feet) fully constructed and occupied in the second half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also have a facility located in Marina del Rey, California, with an address of 4503 Glencoe Avenue, Marina del Rey, CA 90292, where we currently lease approximately 35,500 square feet of laboratory and office space. The Marina del Rey Lease expires on December 31, 2031. The facility includes 19,500 square feet of BSL2 laboratory space, and approximately 3,000 square feet of cGMP laboratory space. We are actively seeking a sub-tenant to take over the remaining term of the Marina del Rey Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we lease a 5,000 square foot facility located in Sydney, Australia, which includes 4,000 square feet of laboratory space providing capabilities to support phage product development and manufacturing process development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe that our existing office and laboratory space is sufficient to meet our needs for the foreseeable future. Additionally, we believe the newly constructed McConnell Facility, offering expanded manufacturing capacity, will allow us to pursue contract manufacturing opportunities for phage and potentially other advanced biologics. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><a id="_df65ea38_079a_4e60_9406_3b1e7c02f8d1"></a><a id="Item3LEGALPROCEEDINGS_563299"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject us to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4c68ffab_6f5b_4c4c_8cd2_b2beab8eda41"></a><a id="Item4MINESAFETYDISCLOSURES_516138"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_ef687bc2_a4a3_4e2d_bf0d_afa97fe898ba"></a><a id="PARTII_630154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:42.5pt;text-indent:-42.5pt;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Common Stock is traded on the NYSE American under the symbol &#8220;ARMP.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Holders of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of February 28, 2025, there were 70 holders of record of our Common Stock. As of such date, there were 36,183,067 shares of our Common Stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our Common Stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our Board of Directors may deem relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.4pt;margin:0pt 0pt 10pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans: See Part III, Item 12 of this Form 10-K for additional information required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e8655e33_eedd_4e56_9251_308ecb0f90f6"></a><a id="Item6SELECTEDFINANCIALDATA_873680"></a><a id="Item6Reserved"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;&#160;&#160;&#160;[Reserved]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None. </p><a id="_b569102d_8ec5_494e_bdf9_f92c5e7d8dc7"></a><a id="Item7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:42.5pt;text-indent:-42.5pt;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes contained elsewhere in this Annual Report </i><i style="font-style:italic;">on Form 10-K</i><i style="font-style:italic;">. Some of the information contained in this discussion and analysis are set forth elsewhere in this Annual Report </i><i style="font-style:italic;">on Form 10-K</i><i style="font-style:italic;">, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Our actual results may differ substantially from those referred to herein due to a number of factors, including but not limited to risks described in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report </i><i style="font-style:italic;">on Form 10-K</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:16.2pt;margin:0pt 4pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Overview</b></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacteria using our proprietary bacteriophage-based technology. We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics. Bacteriophages or &#8220;phages&#8221; have a powerful and highly differentiated mechanism of action that enables binding to and killing of specific targeted bacteria while uniquely preserving the normal human microbiome or &#8220;healthy bacteria&#8221;. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as <i style="font-style:italic;">C. difficile</i>. We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or &#8220;superbug&#8221; strains of bacteria. We are a leading developer of clinical-stage phage therapeutics of high purity, and believe we are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. We have completed three critical Phase 2 trials, utilizing two distinct phage cocktails against two different bacterial pathogens with the potential to treat chronic pulmonary disease complicated by bacterial infection, as well as acute systemic bacterial infection. We believe we are on a critical pathway towards pivotal Phase 3 clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered (synthetic) bacteriophages with our proprietary phage-specific host-engineered cGMP manufacturing capabilities to advance a target pipeline of high-quality bacteriophage product candidates for late-stage clinical development. We have improved our manufacturing processes by significantly increasing phage titers and improving production efficiency with the goal of ensuring commercial viability. We believe that we are uniquely advancing two lead candidates, referred to as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our first lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to <i style="font-style:italic;">P. aeruginosa</i>. On October 14, 2020, we received the approval to proceed from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for our Investigational New Drug (&#8220;IND&#8221;) application for AP-PA02. In the first quarter of 2023, we announced positive topline results from the completed &#8220;SWARM-<i style="font-style:italic;">P.a.</i>&#8221; study &#8211; a Phase 1b/2a, multicenter, double-blind, randomized, placebo-controlled, single ascending dose and multiple ascending dose clinical trial to evaluate the safety and tolerability of inhaled AP-PA02 in subjects with cystic fibrosis and chronic pulmonary&#160;<i style="font-style:italic;">P. aeruginosa&#160;</i>infection. Data indicate that AP-PA02 was well-tolerated with a treatment emergent adverse event profile similar to placebo. Pharmacokinetics findings confirm that AP-PA02 can be effectively delivered to the lungs through nebulization with minimal systemic exposure, with single ascending doses and multiple ascending doses resulting in a proportional increase in exposure as measured in induced sputum. AP-PA02 exposures were generally consistent across subjects. Additionally, bacterial levels of&#160;<i style="font-style:italic;">P. aeruginosa&#160;</i>in the sputum measured at several timepoints suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment as compared to placebo after ten days of dosing. In addition, a correlation was seen between increasing phage dose (higher AP-PA02 exposures) and reduction in the bacterial load, supporting the biologic plausibility of a bacterial specific mechanism of action and creating the opportunity for phage as a therapeutic alternative to inhaled antibiotics. This study was supported by the CFF, which granted us a Therapeutics Development Award of $5.0 million. We received the full award&#8217;s amount, including the final payment of $0.3 million, in January 2024. Following the promising Phase 1b/2a results of favorable safety and tolerability profile and plausible mechanism of action, an additional confirmatory Phase 2 trial was initiated in non-cystic fibrosis Bronchiectasis (&#8220;NCFB&#8221;) patients with similar chronic pulmonary disease with infections due to&#160;<i style="font-style:italic;">P. aeruginosa</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On February 22, 2022, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis (&#8220;NCFB&#8221;). On December 19, 2024, Armata announced encouraging results from the completed &#8220;Tail<i style="font-style:italic;">wind</i>&#8221; study &#8211; a Phase 2 multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 in subjects with NCFB and chronic pulmonary <i style="font-style:italic;">P. aeruginosa</i> infection. Data indicated that inhaled AP-PA02 provides a durable reduction of <i style="font-style:italic;">P. aeruginosa</i> in the lung, with a favorable safety and tolerability profile. The Tail<i style="font-style:italic;">wind</i> study was conducted in two cohorts running in parallel: subjects in one cohort (cohort A) received inhaled AP-PA02 as monotherapy, while subjects in another cohort (cohort B) received inhaled AP-PA02 in combination with inhaled anti-pseudomonal antibiotic treatment. Subjects in both cohorts were dosed at home by nebulization with study drug </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">administered every 12 hours for 10 days and were followed for approximately four weeks after receiving their last dose of study drug. The primary efficacy endpoint was the reduction in <i style="font-style:italic;">P. aeruginosa</i> colony forming units ("CFUs") in lung sputum at one week following completion of dosing (day 17) compared to baseline. Per the statistical analysis plan, efficacy analysis of each independent cohort showed no significant difference between subjects treated with AP-PA02 and placebo due to small numbers of subjects in each cohort. Notably, a post-hoc intent-to-treat analysis (n=33 active and n=15 placebo; all subjects from both cohorts) demonstrated a statistically significant reduction of <i style="font-style:italic;">P. aeruginosa</i> CFUs in the lung at day 17 (AP-PA02 vs. placebo; P=0.05). The reduction in <i style="font-style:italic;">P. aeruginosa</i> CFUs persisted two weeks following completion of dosing with AP-PA02 when compared with placebo at day 24 (AP-PA02 vs. placebo; P=0.015). Additionally, paired analysis of <i style="font-style:italic;">P. aeruginosa</i> CFU density at baseline compared to day 10 (P=0.03), day 11 (P=0.01), day 17 (P=0.003) and day 24 (P=0.018) was significant in the AP-PA02-treated cohort. We believe the data suggest that AP-PA02 alone is as effective as the combination therapy of phage and antibiotics in reducing <i style="font-style:italic;">P. aeruginosa</i> CFUs in the lung. Additionally, approximately one-third of subjects treated with phage monotherapy exhibited at least a 2-log CFU reduction in <i style="font-style:italic;">P. aeruginosa</i> compared to no reduction in placebo treated subjects. Safety data indicate that inhaled AP-PA02 was well-tolerated with treatment-emergent adverse events mild and self-limiting. There was one possibly related serious adverse event that was linked to an acute pulmonary event requiring hospitalization that was responsive to antibiotics. We believe the safety and tolerability of AP-PA02 offers a promising profile for treating chronically infected NCFB patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Results from the Phase 2 Tail<i style="font-style:italic;">wind</i> study demonstrate the potential of Armata&#8217;s high-purity phage cocktail, AP-PA02, as a new monotherapy treatment alternative for chronic pulmonary disease caused by <i style="font-style:italic;">P. aeruginosa</i> infection, including drug-resistant bacteria, and indicate the potential for phage therapy to reduce reliance on chronic antibiotic use. The Phase 2 Tail<i style="font-style:italic;">wind</i> study represents the second successful clinical trial for AP-PA02,&#160;Armata&#8217;s lead pulmonary candidate, which was first evaluated in people with cystic fibrosis in the Phase&#160;1b/2a SWARM-<i style="font-style:italic;">P.a.&#160;</i>trial that completed in 2023. We believe the learnings on dose-schedule regimens gained from the two completed Phase 2 studies position us to define a safe and promising biologic correlation for a Phase 3 definitive trial which will aim to evaluate inhaled AP-PA02 as an alternative to antibiotics in chronic pulmonary <i style="font-style:italic;">P. aeruginosa </i>infection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">In parallel to developing novel phage therapeutics that target chronic bacterial infections, we have an acute bacterial infection clinical development plan focused on <i style="font-style:italic;">Staphylococcus aureus</i> (&#8220;<i style="font-style:italic;">S. aureus</i>&#8221;) bacteremia, a difficult-to-treat and often life-threatening human infection that can result in high morbidity and mortality and for which bacterial resistance to antibiotics is growing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">A key advantage of our phage manufacturing expertise is the purity profiles of our phage products, including AP-SA02, our phage product candidate for <i style="font-style:italic;">S. aureus</i>; this has enabled us to pursue treatment of complicated <i style="font-style:italic;">S. aureus</i> bacteremia, where repetitive intravenous dosing is required. On June 15, 2020, we entered into an agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which we received a $15.0 million award and entered into a multi-year program administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (NMRC) &#8211; Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the second half of 2024. In July 2024, the MTEC Agreement was modified to increase the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025. We are using the award to partially fund a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled dose escalation study that will assess the safety, tolerability and efficacy of our phage-based candidate, AP-SA02, for the treatment of adults with <i style="font-style:italic;">S. aureus </i>(&#8220;diSArm&#8221; study)<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On November 17, 2021, we announced that we had received approval from the FDA to proceed with our IND application for AP-SA02. On November 12, 2024, we announced completion of enrollment of the Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for <i style="font-style:italic;">S. aureus</i> bacteremia. The last patient final follow-up visit was completed on January 14, 2025. During the Phase 2a portion of diSArm, Armata focused on evaluating clinical safety of higher intravenous doses of AP-SA02 and accelerating enrollment to arrive at topline data expeditiously. The manufacture of highly purified phages using Armata's proprietary methods enabled dose escalation to 5E10 PFU every six hours (2E11 PFU every 24 hours) for five days without clinically significant adverse events. In parallel with dose escalation, the evolution of two distinct blinded subsets of subjects receiving phage has been observed. One subset, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:138.03pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">comprising approximately half of the treated group, has evidence of persistence of detectable phage in the blood providing early evidence of <i style="font-style:italic;">in vivo</i> phage amplification and resultant release of phage progeny. The Company anticipates topline data from the diSArm study in the first half of 2025 where it can explore the two aforementioned subsets in an unblinded manner. Topline results are also expected to inform the optimal dose of AP-SA02 to be evaluated in a larger definitive efficacy study. Data from this Phase 1b/2a study will be invaluable for a follow-on trial that is being designed to demonstrate efficacy of AP-SA02 in treating <i style="font-style:italic;">S. aureus</i> bacteremia. We anticipate findings from the Phase 1b/2a study will provide the basis for constructing a robust trial strategy for registration which can be the basis for an End-of-Phase-2 meeting with the FDA that enables us to obtain agreement on a path to approval. We are committed to developing a definitive efficacy trial focused on phage as an alternative to broad-spectrum antibiotics and/or antibiotic sparing to decrease the utilization of broad-spectrum antibiotics and their detrimental impact on the normal human microbiome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">On August 1, 2022, we announced FDA approval to proceed with our IND application for AP-SA02 in a second indication, prosthetic joint infections (&#8220;PJI&#8221;) with <i style="font-style:italic;">S. aureus</i>. We had planned to initiate a Phase 1b/2a trial; however, in light of the growing concerns of both PJI and wound infections, we are considering revising the protocol to include both indications. Driven by data from the bacteremia study, and with sufficient funding, we may in the future initiate a Phase 1b/2a trial to assess the safety and tolerability of intravenous and intra-articular AP-SA02 as an adjunct to standard of care antibiotics in adults undergoing treatment of periprosthetic joint infections and/or wound infections caused by <i style="font-style:italic;">S. aureus</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We remain committed to our mission to evaluate phage-based therapeutics in randomized controlled clinical trials that evaluate safety and efficiacy required to support potential regulatory approval and commercialization of our phage products as alternatives to traditional antibiotics, providing a potential method of treating patients suffering from drug-resistant and difficult-to-treat bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following chart summarizes the status of our phage product candidate development programs and partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:13.5pt;margin:0pt;"><img src="armp-20241231x10k011.jpg" alt="Graphic" style="display:inline-block;height:135.38pt;left:0.31%;padding-bottom:1.15pt;position:relative;top:0pt;width:446.08pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">We have incurred net losses since our inception and our operations to date have been primarily limited to research and development and raising capital. As of December 31, 2024, we had an accumulated deficit of $327.7 million. We currently expect to use our existing cash and cash equivalents for the focused research and development of our current product candidates and for working capital and other general corporate purposes. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the development of and seeking to obtain regulatory approval for our product candidates. We do not expect to generate product revenue unless and until we successfully complete development and obtain marketing approval for at least one of our product candidates. We may also use a portion of our existing cash and cash equivalents for the potential acquisition of, or investment in, product candidates, technologies, formulations or companies that complement our business, although we have no current understandings, commitments or agreements to do so. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our existing cash and cash equivalents of $9.3 million as of December 31, 2024 will not be sufficient to enable us to complete all necessary development of any potential product candidates and fund our operations for the next twelve months from the date the consolidated financial statements included elsewhere in this Annual Report on Form 10-K are </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">issued. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Accordingly, we will be required to obtain further funding through one or more other public or private equity offerings, debt financings, collaboration, strategic financing, grants or government contract awards, licensing arrangements or other sources. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and potential disruptions to, and volatility in, financial markets in the United States and worldwide. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of assets, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations and result in a loss of investment by our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">MTEC Agreement Modification</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman;">In July 2024, we extended the MTEC Agreement to August 2025 and increased the amount of the award by $5.3 million to a total of $21.6 million. We will recognize an increase in grant revenue from the third quarter of 2024 until the full amount of the amended award is utilized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">2025 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">On March 12, 2025, the Company entered the 2025 Credit Agreement for the 2025 Loan in an aggregate amount of $10.0 million. The 2025 Loan bears interest at an annual rate of 14.0% and matures on March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2025 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors. Concurrently with the execution of the 2025 Credit Agreement, the Company entered into amendments to (i) the Convertible Loan and Convertible Credit Agreement, (ii) the 2023 Loan and 2023 Credit Agreement, and (iii) the 2024 Loan and 2024 Credit Agreement, which, among other things, extended the maturity date of the Convertible Loan, 2023 Loan and 2024 Loan, respectively, to March 12, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">2024 Credit </i><i style="font-style:italic;">Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 4, 2024, the Company entered into the 2024 Credit Agreement for the 2024 Loan in an aggregate amount of $35.0&#160;million. The 2024 Loan bears interest at an annual rate of&#160;14.0% and was scheduled to mature on June 4, 2025. Principal and accrued interest are payable at maturity. Repayment of the 2024 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors. Concurrently with the execution of the 2024 Credit Agreement, the Company amended certain provisions of the Convertible Loan and Convertible Credit Agreement and the 2023 Loan and 2023 Credit Agreement to, among other things, conform certain terms relating to permitted indebtedness and permitted liens. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 12, 2025, the Company executed an amendment to the 2024 Credit Agreement which, among other things, extended the 2024 Loan maturity date to March 12, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2023 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">On July 10, 2023, the Company entered into the 2023 Credit Agreement. The 2023 Credit Agreement provides for the 2023 Loan, a secured term loan facility in an aggregate amount of $25.0 million at an interest rate of 14.0% per annum, and was scheduled to mature on January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the 2023 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the 2023 Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">On November 12, 2024, the Company executed an amendment to the 2023 Credit Agreement, which, among other things, extended the 2023 Loan maturity date to January 10, 2026. On March 12, 2025, the Company executed a </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">subsequent amendment to the 2023 Credit Agreement which, among other things, extended the 2023 Loan maturity date to March 12, 2026.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.27;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of years ended December 31, 2024 and 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">The following table summarizes our results of operations for the years ended December 31, 2024 and 2023 (dollars in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Grant revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,174</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,529</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 645</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">14.2%</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,770</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 656</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1.9%</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,184</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,649</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,535</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">13.2%</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,610</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,419</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,191</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.8%</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42,436)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (40,890)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,546)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">3.8%</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 697</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 179</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 518</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">289.4%</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,742)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,626)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,116)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">309.1%</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of the Convertible Loan </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,399</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (21,845)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53,244</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(243.7%)</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain (loss) on debt and the Convertible Loan extinguishments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,166</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,863)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,029</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(156.1%)</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total other income (expense), net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,520</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,155)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,675</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(183.5%)</p></td></tr><tr><td style="vertical-align:bottom;width:41.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18,916)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (69,045)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,129</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(72.6%)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized $5.2 million and $4.5 million of grant revenue for the years ended December 31, 2024 and 2023, respectively, which represents MTEC&#8217;s share of the clinical development costs incurred for our AP-SA02 program for the treatment of&#160;<i style="font-style:italic;">S. aureus</i>&#160;bacteremia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The following table summarizes our research and development expenses for the years ended December 31, 2024 and 2023 (dollars in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">External costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,278</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,982</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 296</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.0%</p></td></tr><tr><td style="vertical-align:middle;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other research and development costs, including consulting, laboratory supplies and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,418</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,665</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,247)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(26.7%)</p></td></tr><tr><td style="vertical-align:middle;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,696</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,647</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (951)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(6.5%)</p></td></tr><tr><td style="vertical-align:middle;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Internal costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Personnel-related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,925</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,665</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,260</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">13.0%</p></td></tr><tr><td style="vertical-align:middle;width:41.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Facilities and overhead costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,805</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,458</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 347</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.7%</p></td></tr><tr><td style="vertical-align:middle;width:41.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total research and development expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,426</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,770</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 656</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.9%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Research and development expenses increased by $0.6 million, from $33.8 million for the year ended December 31, 2023 to $34.4 million for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trial costs increased by $0.3 million, from $10.0 million for the year ended December 31, 2023, to $10.3 million for the year ended December 31, 2024. The increase is primarily due to a $2.2 million increase in the AP-PA02 NCFB study as the study is at an active stage with significant developments during the year ended December 31, 2024, offset by a $1.9 million decrease in other clinical trial expenses, based on the progress of our clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other external research and development costs decreased by $1.3 million from $4.7 million for the year ended December 31, 2023 to $3.4 million for the year ended December 31, 2024. We recognized zero and $0.3 million credits to research and development expenses related to the CFF grant for the years ended December 31, 2024 and 2023, respectively. Our consultant expenses decreased by $0.9 million, spending on outsource service contracts decreased by $0.4 million, laboratory supplies decreased by $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our external research and development expenses by project for the years ended December 31, 2024 and 2023 were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:19.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:43.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;width:63.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:19.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.31%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:19.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:middle;width:43.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Project name </b></p></td><td style="vertical-align:middle;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:17.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:19.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AP-PA02</p></td><td style="vertical-align:middle;width:43.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-Cystic Fibrosis Bronchiectasis</p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,840</p></td><td style="vertical-align:middle;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,922</p></td></tr><tr><td style="vertical-align:middle;width:19.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AP-PA02</p></td><td style="vertical-align:middle;width:43.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cystic Fibrosis</p></td><td style="vertical-align:middle;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">236</p></td><td style="vertical-align:middle;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,692</p></td></tr><tr><td style="vertical-align:middle;width:19.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AP-SA02</p></td><td style="vertical-align:middle;width:43.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bacteremia</p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,177</p></td><td style="vertical-align:middle;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,789</p></td></tr><tr><td style="vertical-align:middle;width:19.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AP-SA02</p></td><td style="vertical-align:middle;width:43.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prosthetic Joint Infection</p></td><td style="vertical-align:middle;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">35</p></td><td style="vertical-align:middle;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">202</p></td></tr><tr><td style="vertical-align:middle;width:19.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expenses not allocated by projects*</p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.87%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,408</p></td><td style="vertical-align:middle;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.06%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3,042</p></td></tr><tr><td style="vertical-align:middle;width:19.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:43.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total external costs</p></td><td style="vertical-align:bottom;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;$</p></td><td style="vertical-align:middle;width:12.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">13,696</p></td><td style="vertical-align:middle;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;$</p></td><td style="vertical-align:middle;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">14,647</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-indent:-4.5pt;margin:0pt 0pt 0pt 18pt;">* Expenses not allocated by projects include consultants, lab supplies and outsource service expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Personnel-related costs, including employee payroll and related expenses, increased by $1.3 million, from $9.7 million for the year ended December 31, 2023 to $11.0 million for the year ended December 31, 2024, largely due to an increase of $0.9 million in incentive compensation expense, whereas no such expense was incurred during the year ended December 31, 2023, an increase of $0.7 million in severance expense, offset by a decrease of $0.3 million in employee stock-based compensation expenses, which was primarily due to the full vesting of awards issued in prior periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Facilities and overheads increased by $0.3 million from $9.5 million for the year ended December 31, 2023 to $9.8 million for the year ended December 31, 2024, largely as a result of an increase in lease expense of $1.0 million, partially offset by a decrease of $0.7 million in expensed noncapitalizable lab equipment, lab equipment maintenance and other research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $13.1 million and $11.7 million for the years ended December 31, 2024 and 2023, respectively. The increase of $1.4 million is primarily related to an increase of $2.1 million in personnel related costs, including $2.3 million in stock-based compensation expense, mainly related to the awards granted in March 2024, an increase of $0.7 million in salaries, an increase of $0.2 million in incentive compensation expense, offset by a $1.1 million decrease in severance expense. The increase in general and administrative expenses was also attributable to an increase of $0.5 million in lease expenses, an increase of $0.8 million in other facilities, general, administrative and overhead expenses, partially offset by a decrease of $2.0 million in legal, accounting and other consulting expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Income</i></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest income for the years ended December 31, 2024 and 2023 was $0.7 million and $0.2 million, respectively, which was related to interest income earned on our cash, cash equivalents and restricted cash balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized interest expense of $10.7 million and $2.6 million for the years ended December 31, 2024 and 2023, respectively, which relates to the interest and the amortization of debt discount and issuance costs for the 2023 Loan and 2024 Loan received from Innoviva in July 2023 and March 2024, respectively. Interest expense is accrued at each period end and is payable at the loan maturity. Refer to Note 8, &#8220;<i style="font-style:italic;">Term Debt</i>&#8221;, in our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Change in Fair Value of Convertible Loan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized a fair value of the Convertible Loan gain of $31.4 million for the year ended December 31, 2024 and the Convertible Loan loss of $21.8 million for the year ended December 31, 2023. The Convertible Loan is accounted at fair value using a weighted probability of various settlement scenarios of the Convertible Loan during its term discounted to each reporting date. Conversion option scenarios are valued using an option pricing model with significant assumptions and estimates such as volatility, expected term and risk-free interest rates. Refer to Note 7, &#8220;<i style="font-style:italic;">Convertible Loan</i>&#8221;, in our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Gain (Loss) on Debt and Convertible </i>Loan<i style="font-style:italic;"> Extinguishments</i><span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized a gain of $2.2 million on debt extinguishment for the year ended December 31, 2024, which relates to the amendments to the 2023 Loan and Convertible Loan on November 12, 2024. The gain was estimated as the difference between the carrying value of the 2023 Loan and Convertible Loan before the modification and the fair value of the 2023 Loan and Convertible Loan after the modification. Refer to Note 8, &#8220;<i style="font-style:italic;">Term Debt</i>&#8221; and Note 7, &#8220;<i style="font-style:italic;">Convertible Loan</i>&#8221;, in our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional details. We recognized a loss of $3.9 million on the Convertible Loan extinguishment for the year ended December 31, 2023, which relates to the amendment to the Convertible Loan on July 10, 2023. Refer to Note 7, &#8220;<i style="font-style:italic;">Convertible Loan&#8221;</i>, in our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liquidity, Capital Resources and Financial Condition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;margin:0pt;"><span style="font-size:11.45pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have incurred net losses since our inception and have negative operating cash flows. Our cash and cash equivalents of $9.3 million as of December 31, 2024, will not be sufficient to fund our operations for the next 12 months from the date the consolidated financial statements included elsewhere in this Annual Report on Form 10-K are issued. We plan to control our expenses and to raise additional capital through a combination of public and private equity, debt financings, strategic alliances, and grant arrangements. These circumstances raise substantial doubt about our ability to continue as a going concern. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. We may not be able to secure additional financing in a timely manner or on favorable terms, if at all<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 12, 2025, the Company entered the 2025 Credit Agreement for the 2025 Loan in an aggregate amount of $10.0 million. The 2025 Loan bears interest at an annual rate of 14.0% and matures on March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2025 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors. Concurrently with the execution of the 2025 Credit Agreement, the Company entered into amendments to (i) the Convertible Loan and Convertible Credit Agreement, (ii) the 2023 Loan and 2023 Credit Agreement, and (iii) the 2024 Loan and 2024 Credit Agreement, which, among other things, extended the maturity date of the Convertible Loan, 2023 Loan and 2024 Loan, respectively, to March 12, 2026.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2024, we amended the MTEC Agreement and increased the amount of the award by $5.3 million to a total of $21.6 million. We will recognize grant revenue from the third quarter of 2024 until the full amount of the amended award is utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Future Capital Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;margin:0pt;"><span style="font-size:11.45pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will need to raise additional capital in the future to continue to fund our operations. Our future funding requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of our research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and cost of our clinical trials and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing costs associated with our targeted phage therapies strategy and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting and enforcing any patent applications, claims, patents and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of potential lawsuits involving us or our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek to raise capital through a variety of sources, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the public equity market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">private equity or debt financings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborative arrangements, </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">government grants; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic financings. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Any additional fundraising efforts may divert our management team from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part, on the success of our product development activities, including our targeted phage therapies strategy and any clinical trials we initiate, regulatory events, our ability to identify and enter into in-licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on acceptable terms. If we are unable to secure additional funds on a timely basis or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition of our company by a third party at a price that may result in a loss on investment for our stockholders, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations, increase the risk of insolvency and loss of investment by our stockholders. To the extent that additional capital is raised through the sale of equity or convertible loan securities, the issuance of such securities could result in dilution to our existing stockholders. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our sources and uses of cash for the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37,551)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (47,423)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,879)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (8,134)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 34,958</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 53,988</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,472)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,569)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows Used in Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Net cash used in operating activities was $37.6&#160;million and $47.4 million for the years ended December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities in the year ended December 31, 2024 was primarily due to our net loss for the period of $18.9 million, adjusted by non-cash net changes of $16.5 million and a net change of $2.1 million in our net operating assets and liabilities. The non-cash items consist of $31.4 million related to a gain from change in fair value of our Convertible Loan, $2.2 million extinguishment gain related to the extension of our Convertible Loan and 2023 Loan maturity to January 10, 2026, $10.8 million of non-cash interest expense on outstanding balances of the 2023 Loan and the 2024 Loan, $1.3 million related to depreciation and amortization expense, $2.1 million related to change in right-of-use asset, $2.9 million related to stock-based compensation expense. The changes in our net operating assets and liabilities were primarily due to a decrease of $5.0 million in operating lease liability, mainly related to payments for our new leased facility construction, which was completed in 2024, and rent payments, $3.8 million decrease in accounts payable and accrued liabilities, partially offset by a decrease of $5.1 million in prepaid expenses and other assets and an increase of $1.5 million in accrued compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities in the year ended December 31, 2023 was primarily due to our net loss for the period of $69.0 million, adjusted by non-cash net expenses of $31.3 million and a net change of $9.7 million in our net operating assets and liabilities. The non-cash items consist of $21.8 million related to a loss from change in fair value of the Convertible Loan, $3.9 million related to the Convertible Loan extinguishment loss, $2.6 million of non-cash interest expense on the Convertible Loan, $1.0 million related to depreciation and amortization expense, $1.0 million related to change in right-of-use asset, $0.9 million related to stock-based compensation expense. The changes in our net operating assets and liabilities were primarily due to a decrease of $13.5 million in operating lease liability, mainly related to payments for our new leased facility construction, and rent payments, a decrease of $1.1 million in accrued compensation, partially offset by a decrease of $4.8 million in prepaid expenses and other assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows Used in Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $1.9 million and $8.1 million for the years ended December 31, 2024 and 2023, respectively, which is mostly attributable to purchases of laboratory and manufacturing equipment acquired for our new manufacturing facility. We expect our spending for property and equipment to decrease as the construction of our manufacturing facility was completed as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows from Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities for the year ended December 31, 2024 was $34.9 million, which consisted primarily of net proceeds from the issuance of the 2024 Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities for the year ended December 31, 2023 was $54.0 million, which consisted primarily of net proceeds from the issuance of the Convertible Loan of $29.1 million and net proceeds from the issuance of long-term debt of $24.9 million.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we did not have any off-balance sheet arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;text-indent:18pt;margin:0pt;"><span style="font-size:11.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements as of December 31, 2024 and December 31, 2023, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate estimates and assumptions, including but not limited to those related to the fair value estimate of the Convertible Loan, stock-based compensation expense, accruals for research and development costs, impairment of goodwill and intangible assets and impairment of long-lived assets. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Although our significant accounting policies are described in more detail in Note 3, &#8220;<i style="font-style:italic;">Significant Accounting Policies&#8221;</i>, to our consolidated financial statements included in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt;"><span style="font-size:11.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Accrued Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services) and in-process research and development expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We record accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, we accrue the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Judgments and estimates are made in determining the accrued balances at the end of the reporting period. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Estimate of the Convertible </span>Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2023, we entered into the Convertible Credit Agreement with Innoviva, which was amended in July 2023 and November 2024. The Convertible Loan includes various conversion and repayment options, including the conversion of principal and accrued interest into shares of our Common Stock upon a Qualified Financing and our option to repay the Convertible Loan prior to maturity. Refer to Note 7, &#8220;<i style="font-style:italic;">Convertible </i><i style="font-style:italic;">Loan</i>&#8221;, in the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We account for the Convertible Loan at fair value and changes in fair value are included in other income (expense) in the consolidated statements of operations in each reporting period. We estimate the fair value using a weighted probability of various settlement scenarios during the Convertible Loan term discounted to each reporting date. To </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">estimate the fair value of the conversion option scenarios, we use an option pricing model with assumptions, such as volatility, expected term and risk-free interest rates. Changes in the fair value of our Common Stock and probabilities of scenarios significantly impact the fair value of the Convertible Loan. We expect to continue making these estimates until the Convertible Loan conversion or its maturity in January 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we estimated the fair value of the Convertible Loan to be $32.9 million. For the year ended December 31, 2024, we recognized a change in fair value gain of $31.4 million in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;margin:0pt;"><span style="font-size:11.45pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Refer to Note 3, &#8220;<i style="font-style:italic;">Significant Accounting Policies</i>&#8221;, of the notes to the consolidated financial statements contained elsewhere in this Annual Report on Form 10-K.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><a id="_086a8db7_39ef_4d9b_a40f_77e966b49f74"></a><a id="Item7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company as defined by Rule&#160;12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.</p><a id="_84c5a57c_e3b0_420e_828f_ff3de1d3d7c6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;8.&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p><a id="Item8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_abef2d86_a3d5_4865_a86f_5687cada32cf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ARMATA PHARMACEUTICALS, INC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Armata Pharmaceuticals, Inc. </b></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORT_OF_INDEPENDENT_AUDITORS"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (Ernst &amp; Young, LLP; San Diego, CA; PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:AuditorFirmId" id="Narr_4uqgdvDwQkOTeCxUDvekRQ">42</ix:nonNumeric>) </p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_283036"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11pt;text-indent:-11pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;Years Ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11pt;text-indent:-11pt;margin:0pt;"><a href="#ConsolidatedStatementsofStockholdersDef"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; </span><span style="font-style:normal;font-weight:normal;">Deficit</span><span style="font-style:normal;font-weight:normal;"> for the&#160;Years Ended December 31, 2024 and 202</span></a>3</p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows_487236"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;Years Ended December 31, 2024 and 202</span></a>3</p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements_9"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements for the&#160;Years Ended December 31, 2024 and 202</span></a>3</p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1e782f20_1da9_47f5_81a4_424442bfc4a9"></a><a id="REPORT_OF_INDEPENDENT_AUDITORS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Report of Independ</b><b style="font-weight:bold;">ent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">The Board of Directors and Stockholders of Armata Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Armata Pharmaceuticals, Inc. (the Company) as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders&#8217; deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Company&#8217;s Ability to Continue as a Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="margin-left:-0.25pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.89%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">Accrued clinical trial expenses and related research and development costs</span></p></td></tr><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-size:10pt;font-style:italic;">Description of the Matter</i></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.89%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;">During 2024, the Company incurred $34.5 million for research and development costs and as of December 31, 2024, the Company recorded $1.1 million for accrued clinical trial expenses. As described in Note 3 of the consolidated financial statements, the Company records accruals for estimated ongoing research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. The Company accrues for the estimated ongoing clinical trial site costs based on patient enrollment and progress of the trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;">Auditing management's accounting for accrued clinical trial expenses and related research and development costs is especially challenging as evaluating the progress or stage of completion of the activities under the Company's research and development agreements is dependent upon a high volume of data from third-party service providers and internal clinical personnel, which is tracked in spreadsheets and other end user computing programs.</span></p></td></tr><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-size:10pt;font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.89%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;">To test the completeness of the Company's accrued clinical trial expenses and related research and development costs, we obtained supporting evidence of the research and development activities performed for significant clinical trials. To assess the appropriate measurement of accrued clinical trial expenses and related research and development costs, our audit procedures included, among others, obtaining and inspecting significant agreements and agreement amendments, evaluating the Company's documentation of trial timelines and future projections of trial progress, confirming amounts incurred to-date with third-party service providers, and testing a sample of transactions and comparing the costs against related invoices and contracts. We also tested a sample of subsequent payments to evaluate the completeness of the accrued expenses and compared the results to the current year accrual.</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:AuditorName" id="Narr_P2ZzY44jZUKmWnf2SgAG9Q">Ernst &amp; Young LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company's auditor since 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="dei:AuditorLocation" id="Narr_rjKlr9xslEKQYUBoK56meQ">San Diego, California</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">March 20, 2025</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d2864551_b883_4a0c_91a4_5cf9843849e8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;"> Armata Pharmaceuticals, Inc. </b></p><a id="ConsolidatedBalanceSheets_283036"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Bala</b><b style="font-weight:bold;">nce Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_12127a33_72b6_43c7_ad5e_da119baa9625"></a><a id="Tc_2Y5bSgk37UWXdyvoddglAA_1_2"></a><a id="Tc_y62PRx-EhEqr3dZsjbRiMQ_1_5"></a><a id="Tc_C08Mdl3heE6K1H26q-q3bQ_2_0"></a><a id="Tc_SDOAZ2epCk6LlDIY06LXlQ_3_0"></a><a id="Tc_bFfrTc1_O0Sn5rv8lyFeNQ_4_0"></a><a id="Tc_XYpSRr_xQE6y7RwoX3PT9Q_4_2"></a><a id="Tc_IHH1irOOD0aCgIkaravuhg_4_5"></a><a id="Tc_8ctg3KFKv0adIHDKy7nwwQ_5_0"></a><a id="Tc_Jmle3MSn3kGsqLaBI8mWWA_6_0"></a><a id="Tc_PxxemSISwE2P1eDYs1Yyjw_7_0"></a><a id="Tc_AMVxN6PnB0CulFoZRwouOQ_8_0"></a><a id="Tc_Shkdiek_5kWHe9pMCeglTA_9_0"></a><a id="Tc_DemcrgBCfE6jUUzZVNZNuw_10_0"></a><a id="Tc_z47N9F8p_EmCAsmAobEl3g_11_0"></a><a id="Tc_YU1SUQzFG065s3Mep5Ra5A_12_0"></a><a id="Tc_xv72jfTC2UqrgDgGif_UrA_13_0"></a><a id="Tc_a3d3MRBHHke3rQB5oO8Wjw_14_0"></a><a id="Tc_souQPaS_N02FY9PWeiWvgw_14_2"></a><a id="Tc_LyMkGPIMIEOIcwBLVXuK_g_14_5"></a><a id="Tc_gKqsoxRG2Em1Zd2Il4Lo0g_16_0"></a><a id="Tc_0uOhq0zmKUW-hJ6CWY4H8w_17_0"></a><a id="Tc_7j8rGjPLskmj4rbGt1MSyg_18_0"></a><a id="Tc_Qq59GbRqIESDMQrta0kELQ_18_2"></a><a id="Tc_hRbGTPAzaEWPUIj-Lif2Eg_18_5"></a><a id="Tc_C901dOIcRkyCEObeIJuN-Q_19_0"></a><a id="Tc_8OisP5qtpkuTLf7jft22Yg_20_0"></a><a id="Tc_WIhJXgTl7EyZ5ZVJwssuqA_20_6"></a><a id="Tc_31Co0YdjEESVjcofb44Vng_21_0"></a><a id="Tc_2sp_moWsPEmVSodxBusztA_22_0"></a><a id="Tc_ymTC9WCQCEOwdF-VcDBjdQ_23_0"></a><a id="Tc_J8sR1PsL-kiRx4CC5aj4_w_24_0"></a><a id="Tc_MsFXAR6zCkqockYLIP8jmw_25_0"></a><a id="Tc_DNx1Kim2rUqtlxZ8uCxbgQ_26_0"></a><a id="Tc_QTEW1CjXH0uCJ-67roLQOw_27_0"></a><a id="Tc_Kt4sFZPDJ0KqmXvq5OGdDA_28_0"></a><a id="Tc_MAlzQiNmYk6TDIdMf-iCcg_30_0"></a><a id="Tc_RvkfnhwBKEGuBR0xi8D7rA_31_0"></a><a id="Tc_SO2TTyiAU0mcb2TiiuGCBw_32_0"></a><a id="Tc_cZ_8MhzFCU25v8J5eMeZRQ_33_0"></a><a id="Tc_lyp_TG0VoE-Vsr_soo48Pg_34_0"></a><a id="Tc_K0HDx1MWs0-tFMwlhz4wMg_35_0"></a><a id="Tc_cDJeCQwKnkGszaxULpvKvg_36_0"></a><a id="Tc_NarEV0snfESxj2LFchXuhg_36_2"></a><a id="Tc_jw0xsxvWSkev_MpXCnG4ng_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_uNE-6fZNr0a3EQtzLYKboA_4_3">9,291</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_2buloiEbxkKlm0vuKHlJ7A_4_6">13,523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_1rU6YwLdbkijnwDVDsIFdQ_5_3">1,273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_93MWJY9bs0CfdrfUfRY8AQ_5_6">2,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_DLnoBYNZFkGPUF5713aywA_6_3">744</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_c-7_Qk0oaUuKZAwGtR-LDw_6_6">3,363</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_yUHkfavdJ0mev1jqUkcQlA_7_3">11,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_GdY1JLGyYkyeXxdxfYkMjw_7_6">19,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_bxpwyAw97kS5xzakNz8WJg_8_3">5,480</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_It-45b0AF0WQ2lXv-jZSFg_8_6">5,720</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_YfNq_Q7W9Uyuvxqqo8-Rng_9_3">13,241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Ht8jbSmvAUefyi32MdnJNg_9_6">12,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_Rk918iIdfU-RUMRmXcf3mw_10_3">41,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_H5JRIOPzq0CQNmp-tBVoqg_10_6">44,717</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_0P_CpLCE302_mvIJuGAymg_11_3">10,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_kbFB47kBUUCqGPC1ZKh3Qg_11_6">10,256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="Tc_snSMwtq9VkiGfNGWO_UM5g_12_3">3,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="Tc_PcU0AMz0BEatJtpTMto1-w_12_6">3,490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_fZ69DiJ7iESDfCrmwdJqCw_13_3">975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Qg_3U6ZxSUqMyADTYZ7WSA_13_6">2,470</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_KR0KBFMmMkWDtHUXKul7MQ_14_3">86,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_POyTW_sEG0mlz748ibGWCA_14_6">98,363</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_gd8kZiqtH0mmX3dR1SSV3A_18_3">2,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_H-HqbJbqlUaEKrDY4idchA_18_6">5,689</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="3" id="Tc_L-iXJTHBwUy-lUvmrgXT7A_19_3">2,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="3" id="Tc_GhDTCFfrAk6SfcG1iFFIPw_19_6">768</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Term debt, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="armp:LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent" scale="3" id="Tc_ddOONvr7VUi1_hKZ946BCQ_20_3">38,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_s9iDHwiua020VI3C55CjJQ_21_3">4,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_Z1tu6U-mpUisZ4U5qLD3tw_21_6">9,481</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_xEZm9yZgQkCOe9pQLRZ0CA_22_3">529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_4K0U2btCoU-2YKwLgBjw4A_22_6">523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_FtVk1Gk25EuauOlJrvIDRA_23_3">48,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_T6BVYImejUOVl33crgD2pQ_23_6">16,461</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible Loan, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_E1XwfXdtdEW7xFslQVu5kg_24_3">32,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_WFi0DW_D_UGHgNI0AOsrYg_24_6">58,633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term debt, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecuredLongTermDebt" scale="3" id="Tc_26Vjq0qf2k65s0XEml7a8g_25_3">22,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecuredLongTermDebt" scale="3" id="Tc_y-vrwM_TIEiD4byLtVathA_25_6">23,674</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_rTxS1a8XgU68baZM8N5miw_26_3">27,694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_XCnAcRhoh0evYOetcF7HBQ_26_6">28,583</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_EvmLTnr6gUybCLAhGm4Xvw_27_3">3,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_eGb-xqnS2UK9nGUXZy5a4Q_27_6">3,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_tDvG7uhRT0iXHYgp_1qEag_28_3">134,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_Io6z7aWZZEilhquab2Qolg_28_6">130,428</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Commitments and contingencies (Note 12)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_GbK_OcWVfki6mBr-34sTDA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_gDOjAM7mQ02qS4WR91XBOg">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_0dn6E5qmKUSs-bCVvX50Tw"><ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_InAuXq19zUmAV3v0ppabHA">217,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_HRduUbCwC0SPPfF7REUxNQ"><ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_E_SKvkeAtUmH-OpXLYv9qA">36,183,067</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_7sWDUDoutUm6iaBDlbMCcA"><ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_fE6zOwE5uUajM3R6Pd6BSg">36,122,932</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_GZ5eyJ92aUy9F4aMZUlvtw_32_3">362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_sq1qL0QogkiVK7FElpV_qg_32_6">361</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_9iRH3SRMUki0buWWV7FVrw_33_3">279,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_JJgpPCu_K0eIz46on_dprQ_33_6">276,393</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_K5Z9_G-6yUSKSOQPYGhYYw_34_3">327,735</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_z5LlBUxp4EaagKGYEId6Uw_34_6">308,819</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_QsqDGWnNdkudKxU7WHeidA_35_3">48,019</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Fdl-saGMlEWS0MuTHnqetg_35_6">32,065</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_0POonvvd50e1GoshoXCrWw_36_3">86,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_VmJUFKtVkUSUfnqe4d7C0Q_36_6">98,363</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f19750e9_87d3_435b_b88a_11408e96ad70"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Armata Pharmaceuticals, Inc. </b></p><a id="ConsolidatedStatementsofOperations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_1339ac4c_3d94_4569_9c94_feb58bce2272"></a><a id="Tc_ACuRx6vRtEGkkfQmIhZmPg_1_3"></a><a id="Tc_EHCmo_Fii0WIWW8Rmx5I5A_2_3"></a><a id="Tc_UW_tBQqU0keEU_pmbSZc7Q_2_6"></a><a id="Tc_ubYEPWrBd0qAQuOXyRZwXw_3_0"></a><a id="Tc__hZytlWVakyQ6GsMi2uLfw_3_3"></a><a id="Tc_mIcutm4guEyCcKiDpGX1TQ_3_6"></a><a id="Tc_S9tEubdXskGGcuhF4uMeJQ_4_0"></a><a id="Tc_5UPjd5ouI0ebtWW_k6MW3w_5_0"></a><a id="Tc_mVpmHAOS20WiQoygd9ukMA_6_0"></a><a id="Tc_O3U4onZ43UyMvEdJpKRQRA_7_0"></a><a id="Tc_-_xUnRogD0-969WYrlkqxQ_8_0"></a><a id="Tc_eT7CKhaM-ECPJL0Q2geTwg_9_0"></a><a id="Tc_824iomNrVEawkYF6qORDuA_10_0"></a><a id="Tc_eOpjcpw-g0SPIuCDbi2-_A_11_0"></a><a id="Tc_r-v-upj1JEifRM-Y_DeTXA_12_0"></a><a id="Tc_d3xxxHHFE0GBbhBQ8FEjgA_13_0"></a><a id="Tc_IwtbN0whxEmjmygP-cOZUg_14_0"></a><a id="Tc_Dk8k6Abc70uZE2uIH40TCA_15_0"></a><a id="Tc_hIYyoMIkOEeiTJzdOy9pFQ_15_3"></a><a id="Tc_nHZ39-4f002r83YydzAUaQ_15_6"></a><a id="Tc_Cf3P6zbn_EuV9uDoHW5uQQ_16_0"></a><a id="Tc_n8Le5f049EG6_mX5owqmpA_17_0"></a><a id="Tc_GwGNNdCfo02mXUsKUs7Cog_17_3"></a><a id="Tc_KJssmDXx70ONpw8WKNBl2Q_17_6"></a><a id="Tc_9nOKKiIQ6UeRX6JFmnu9bw_18_0"></a><a id="Tc_Xdi3nXhSA0uJGWa8-G98IA_19_0"></a><a id="Tc_MnQbtU4sxUiiUyf3hyX40g_19_3"></a><a id="Tc_Rzb1Ju39oUShXU337i1Wyw_19_6"></a><a id="Tc_Pm_EGeHMukCzgJ6t6arbmw_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Grant revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_23SNBLt6CUeoo8axPU-rUQ_3_4">5,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_LUy9S44AX0WL5CopciqGfg_3_7">4,529</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_yFW8iOWes0Kf-yE8-qlxrQ_5_4">34,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_X0Gec4jOmkW-1WIuZlzhRg_5_7">33,770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_dpqZrKjvKk6kpcDSE-zCnA_6_4">13,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ZFZDbseJUUe7-dGBl48tXg_6_7">11,649</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_SPpVa6ZMDkSuIOLzhB89gA_7_4">47,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_hgOh7qTMf0KYNJeYV5_brQ_7_7">45,419</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_3sCSN8XmV0K0uanuS9fQ-w_8_4">42,436</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_aVZ8Twi00EaYhjYYFe6BHg_8_7">40,890</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_ialMmFXzbU62AvMLE9Q--g_10_4">697</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_ywwe4kyx10C0bQXMI-wr8A_10_7">179</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_msbOZ3trN0CoF0_F0xvYSw_11_4">10,742</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_ccTtdmpoJ0CKS3gTCd4E6Q_11_7">2,626</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of the Convertible Loan </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" id="Tc_xQSZOW5iwE-LA8QRYsi1QA_12_4">31,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" sign="-" scale="3" id="Tc_WPuf5PkR00uj08kBfcjIiQ_12_7">21,845</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain (loss) on debt and the Convertible Loan extinguishments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_t_DaX1jdu0SYni7ACDw8Ig_13_4">2,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_7fD85Kl1QkOiW__WtPcTJA_13_7">3,863</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total other income (expense), net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_hgUd76FKvki6DcT5G44Dzw_14_4">23,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_C__CIlKyp0W-8ZLva7DKYQ_14_7">28,155</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YWbwpLM8D02iBRfBpNuvtQ_15_4">18,916</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Ik0ejmwKQ0-DSuK6ysM3rw_15_7">69,045</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Net loss per share, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_YAlHXrJzN0KO-89yHdCvow_17_4">0.52</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_LPK8Jo4sbEa73PqBPZtFag_17_7">1.91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Weighted average shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_3LlDBMbClUyfnMd4JxX74Q_18_4">36,160,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_0T4zsflxYEmCAI96gfGktg_18_7">36,075,555</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Net loss per share, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_9RH1oq9z_0ayZGJelB1O2g_19_4">0.89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_ZyJpal1fh0GzopsPsuzzgw_19_7">1.91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Weighted average shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_rHXsH7fOlUqwpBYT_siuNw_20_4">59,059,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_cg85Bt8JS0aANxLhZeyVeg_20_7">36,075,555</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_69d76de5_64f4_4c73_993b_8cfabfc6e880"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Armata Pharmaceuticals, Inc. </b></p><a id="ConsolidatedStatementsofStockholdersDef"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; Deficit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_c02c31bb_de02_4d30_8738_bddb48aec784"></a><a id="Tc_c9ViZhvSrkiTo6mLRouZPw_1_2"></a><a id="Tc_60YcMeh-wUmCvy2fMT_r8w_2_2"></a><a id="Tc_0yA482HfHkedTigdRaz3ZA_3_7"></a><a id="Tc_Z6Hb2aAFd0uPm0DKCRJqDw_3_13"></a><a id="Tc_mFyB0Ak230upntKMzIEFXA_4_7"></a><a id="Tc_gNIAbho8gU6mnRqaw79KiQ_4_10"></a><a id="Tc_K8Adyr3AA0eMHvAP2m15Yw_4_13"></a><a id="Tc_4sIvd7YNs0aRnHOheNqC_w_5_2"></a><a id="Tc_Y2Jk124sA0mvWW14wC70IQ_5_4"></a><a id="Tc_2P2q1utzR0-sVLfCU5JY3g_5_7"></a><a id="Tc_FRl3cOpLcEiZ9KQCER9udg_5_10"></a><a id="Tc_anChe7fkCE2n2Dudimv75A_5_13"></a><a id="Tc_-Mxm5av6f0GzKuqP8y1l_g_6_0"></a><a id="Tc_9k-ugchpNEO_V3fsKoVVzA_6_4"></a><a id="Tc_3baTKET1_EWoXYTRmV2Oew_6_7"></a><a id="Tc_QNvEvE-3i0yyUKS_kbVXWg_6_10"></a><a id="Tc_764RGq75mEGvUB5OM8lA8g_6_13"></a><a id="Tc_AHQ187P3Ok-6aMMnKAhlxg_7_0"></a><a id="Tc_XDziB5pYj0ugxxGVWPWaCQ_7_5"></a><a id="Tc_fFBsL1ue0UO_czINEgyFhw_7_8"></a><a id="Tc_RArENeotfEqCf62nXo_a8A_7_11"></a><a id="Tc_8K6N79nst0WU3itiGPZbLQ_7_14"></a><a id="Tc_O99YP53fhECR58xqz-hbcA_8_0"></a><a id="Tc_nMzvASUb_UayBqOdgf-LXQ_8_5"></a><a id="Tc_9P4WO6-kEkW0Bp-LX0ctTQ_8_11"></a><a id="Tc_9UcgaS1jW0Gi7stgJSKzKg_9_0"></a><a id="Tc_XnjGE9EfPEGwrMjgTDUVgw_9_5"></a><a id="Tc_M7J3Qu4a7EKipiUzV2uUAg_9_11"></a><a id="Tc_tjwPZojvlUGRg0xuD70o4w_10_0"></a><a id="Tc_UFacx-esXUCvf2N1XAVigg_10_5"></a><a id="Tc_POy4h0Yk_kiSEPV5bHpBWQ_10_8"></a><a id="Tc_0qHD4nZNBkKjeY7Lg-OdUA_10_11"></a><a id="Tc_nkgdlPFmv02Tv02DeeTbKw_10_14"></a><a id="Tc_tXzcTIQJgk-JgbrY9YdqaA_11_0"></a><a id="Tc_kqp_i9wrlk2sYLYTwMqnJw_11_2"></a><a id="Tc_bgkL5yd-QkaYNxeEoVOjnA_11_5"></a><a id="Tc_Ea-CKMIBSUm00AdMi4RXug_11_11"></a><a id="Tc_F7QzyMHtqUqPW_ugoeyssA_12_0"></a><a id="Tc_g6lgFy4D1EupkDRDeBZG6A_12_2"></a><a id="Tc_0GqQptALGEOesU06xwgmyg_12_5"></a><a id="Tc_a2OruBLzmEy6aMwa9KzXtA_12_8"></a><a id="Tc_uwm1gAibdEeHaW4E3frxig_13_0"></a><a id="Tc_pgFUK1O7QEuJYD93L_ffQQ_13_4"></a><a id="Tc_Bm7u4wGxo0i-0rTU9BYX3g_13_7"></a><a id="Tc_CudkHg5MrEiOgd_Jx0w0hA_13_10"></a><a id="Tc_PiWK8MQGlE2dqbv2ex8yQQ_13_13"></a><a id="Tc_lyNaAVnsXUuc36fPJOz9MQ_16_2"></a><a id="Tc_FxX-SC5jO0WaMwafVYUoOg_17_2"></a><a id="Tc_MMYqvzYMbkKNddUuAsq41Q_18_7"></a><a id="Tc_n_7hczm1wkKGrwP7OsJx6g_18_13"></a><a id="Tc_kiHTIoHmwECLP3iiiU78lQ_19_7"></a><a id="Tc_DSE8DLQwy0C4SQZA_Unm1g_19_10"></a><a id="Tc_a4JS6AMV20umGebgBRE5_w_19_13"></a><a id="Tc_N301gtT8W0SlCBea0-zE4A_20_2"></a><a id="Tc_8nEz3nHG50OBt2ncrj6PVw_20_4"></a><a id="Tc_NgwVgGU7-UWqNlzfFO98Jw_20_7"></a><a id="Tc_80G-h2xI7EWX6bk6uSWCEA_20_10"></a><a id="Tc_cR6bVkw-8Uap-SS3e2SURA_20_13"></a><a id="Tc_hpgdC9dJ002fyXOY20Afzw_21_0"></a><a id="Tc_7kBbegug8kKuxUfqru1GEQ_21_4"></a><a id="Tc_PPRYe9Tar06O7VBtGHf14w_21_7"></a><a id="Tc_fCse0JeUXEKjML6uC_jOVA_21_10"></a><a id="Tc_4QFbEXnQLUivyikV8Uqm6g_21_13"></a><a id="Tc_qoIcL5Orbke-uoA25SDg6w_22_0"></a><a id="Tc_EvEykK77Lk6m1NHpPNNzSQ_22_11"></a><a id="Tc_Jw4wZy--EEeLDbkhI_d4sg_23_0"></a><a id="Tc_YM_VL_Sk30apph_wN3pW9w_23_5"></a><a id="Tc_Z_QlJbN-DEWYwGj7Kk_OMQ_23_8"></a><a id="Tc_A-YlcOQKGEOG5MdMcEzVMg_23_11"></a><a id="Tc_v3UV5UPXnEmXtzU2Jzdx6A_23_14"></a><a id="Tc_gCKvJt3t60e_hlc5eb_DPg_24_0"></a><a id="Tc_0unWu87dvkemd3Yb4m5nQA_24_5"></a><a id="Tc_iysAgGPFVE65pAs0lyEkqQ_25_0"></a><a id="Tc_5iHIiMZH-0-MEejRqjS90Q_25_2"></a><a id="Tc_NHVuqus_U0qB6eg3Rk4ioA_25_5"></a><a id="Tc_JrQhH6MX0ECa7XYQfp0wkA_25_11"></a><a id="Tc_7HYmFgaUB0CzTeO7Ih1tuw_26_0"></a><a id="Tc_SQFFOUqIVky7XIIm09Fzzw_26_2"></a><a id="Tc_8g9f3EXGdk621yAmWjXnUQ_26_5"></a><a id="Tc_DYOYSlA8xUGgNP5PHI6ipg_26_8"></a><a id="Tc_Pj6Y_sVX2kSqv7SlmG4bXQ_27_0"></a><a id="Tc_wqEthnn_Pk2NweRh_0g0ag_27_4"></a><a id="Tc_iq6Pr0bfkkuj9aJySMxzvw_27_7"></a><a id="Tc_qYHjwGyi6kehRwbNS1tolA_27_10"></a><a id="Tc_siFi9n9SWESkZAKfX5DVGg_27_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:60.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WYP4LOLiVE2vVMYho8f0Pw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_xfiH2Ci5kESTpyIDdcPlLg_6_2">36,144,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WYP4LOLiVE2vVMYho8f0Pw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Fnw8TZMPLUuC9PQbAtn6lA_6_5">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1Rw3csLgjECALBKYfsINwQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_x-frj5Oa4EmB0IHhOksKnw_6_8">275,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_z3NSngTeFUqo0EjEQOAFlg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_s8_X0pBZF0yXI5xxWLhs6w_6_11">239,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2022_igNvzFb5yESqV8OvL7Pg4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vopHpzELrUKGk7pCMWnLLg_6_14">36,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeiture of restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="Tc_N_UGmQ-4jEeEfzqnXYK8jg_7_2">27,341</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Withholdings for taxes related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA" decimals="INF" format="ixt:num-dot-decimal" name="armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_T_w_qEnUY0K4F3XBW79mWw_8_2">25,933</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_elsHS6ydWEONtGpKI5VfjQ" decimals="-3" format="ixt:num-dot-decimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="3" id="Tc_Sqyrr6c-XkmffjHXxoLMlg_8_8">43</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="3" id="Tc_X3jT-ve2BUqBDMO9WVDsBw_8_14">43</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Z-bcGeHDo0-b1_Vjaxg_Ow_9_2">1,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_elsHS6ydWEONtGpKI5VfjQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_mdhJV9lc50KulNV6l461Fw_9_8">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_FHUzhedVUE-OEKPw_6JBfQ_9_14">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of Common Stock upon vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_oVaGM1hobU-UGtdtS9uR0w_10_2">30,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_elsHS6ydWEONtGpKI5VfjQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ZerCulkECU23uELZasQi4Q_11_8">938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_a50PjXm-zEa5TfHm6Rww4Q_11_14">938</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b2xRzt0_BUqhKZ6JbrdY4w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qsMd3uNWn02vizrvDpJyzA_12_11">69,045</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FANVLm7Svk-J8ZYHXVSgYg_12_14">69,045</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_JulQmXm4JEuQP5Oci_0CAA_13_2">36,122,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_sJquoUbKNEGg5GmV-Xebyw_13_5">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TdUVPQRZ90GLDTkGnv6akw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ayYgZONvCEeGgcSyl6aJZQ_13_8">276,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lRVURMKV0SoOkMJkefoHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ShGmGvxDFEGsK6CGDltS1A_13_11">308,819</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_4ZAvMCoc5EK5i3Xm1CUeJg_13_14">32,065</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:60.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; Deficit</b></p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_tBG-I2r8fUGH0g0_bmOcqQ_21_2">36,122,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_SJTozgl9WEW9b_PDSbMoLg_21_5">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TdUVPQRZ90GLDTkGnv6akw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_X-dh2InPV0KDihVabrlBYw_21_8">276,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lRVURMKV0SoOkMJkefoHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_iOawaIk2EU68cuwk1gKjYg_21_11">308,819</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_PqXUH1V6Uke8CE6Bw6r5fA_21_14">32,065</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_PKEYLcvRMkquhwYjADfTTQ_22_2">37,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_M7lI9ipe70OAxCsBHMswzA_22_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tiRew-3WXUazY4UJ_rsE2g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_0aMd9TMYtE-zNC17BU--PQ_22_8">129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_wQ1NXompek6omJF1RTdRkw_22_14">130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Withholdings for taxes related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ" decimals="INF" format="ixt:num-dot-decimal" name="armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_fwwjxMSfkUqNvsHLYEl61Q_23_2">4,222</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of Common Stock upon release of restricted stock units, net of tax withholdings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="0" id="Tc_QRVa4-JEkkmwR6ahX1obEg_24_2">27,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tiRew-3WXUazY4UJ_rsE2g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_o1jKrgK9cEC1ItdyEsutJA_24_8">61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_8afPbFE7vEaGUqzYZ5DoVA_24_14">61</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tiRew-3WXUazY4UJ_rsE2g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_86WwXkpl7kCBrcfEvV2m0Q_25_8">2,893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_INzCq3pCO0ew3Zg_czjTiQ_25_14">2,893</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:37.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_12iaGKNXCkqYkhajskEVlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zhMO3VsjjECuKNACTLmFYA_26_11">18,916</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rmvSYn4V90iARR6otgudqw_26_14">18,916</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:37.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EqQhMtDQN0uq2op06-vOIg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_8mvo_f_v10mKnWzrwFxRMw_27_2">36,183,067</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EqQhMtDQN0uq2op06-vOIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bZQ2y_8wJ0yBT6o2GYc2Uw_27_5">362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K4ieWmLnSUyd7TzJckLcIw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TuEVfyIEBEKkoIHmHBvPrA_27_8">279,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_reOzmK0NOUyOz-GslMRWRg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_b3YM1yPwFEutafMhaAF3SQ_27_11">327,735</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_NdOkFbO2-UaElA0F8DQu0g_27_14">48,019</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f2c7c718_3c6e_4a43_bf56_20b9a1bea844"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Armata Pharmaceuticals, Inc. </b></p><a id="StatementsofCashFlows_487236"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><a id="_89b7a427_a54b_4827_8b6a_8a98dd47cd7d"></a><a id="Tc_vZv_6iFidEWsDA9KC6jR1A_1_2"></a><a id="Tc_mzpHnFuqTEmU1htde2Gzcw_2_2"></a><a id="Tc_a0QXiqZmR0Oar6QB_HLxsg_2_5"></a><a id="Tc_sx8w1xRuYUyeehO3cX61OA_3_0"></a><a id="Tc_9uugMfnkN0SgUAZkVSUL9g_4_0"></a><a id="Tc__-2csid7gUC1-OUlnFc8tQ_4_2"></a><a id="Tc_BYEOGq47ykO6iQ-wqgUNnQ_4_5"></a><a id="Tc_MuZ-480ZgUGMKDlQuGbDug_5_0"></a><a id="Tc_t1ey9b3vgkasSYA4hmoEuA_6_0"></a><a id="Tc_9vZPi4PmSkG6VWW9SoCVbA_7_0"></a><a id="Tc_j5oTt8Xyl0qqSf2efgJUew_8_0"></a><a id="Tc_OqawCIHm402wapf1xYSAlA_9_0"></a><a id="Tc_fJ7QRVo5cESqJaQxz1HQig_10_0"></a><a id="Tc_6q_wcnvXG0qsBVUmlkaFCw_10_3"></a><a id="Tc_W23Bamq760eJNpsTuSGHtA_11_0"></a><a id="Tc_-L0p-zFP6UWAWa9IJg4S-w_12_0"></a><a id="Tc_cmX87a0vIkikvtLQBgBsMA_13_0"></a><a id="Tc_Xl8DLInMSU6EC1McjHbElA_13_3"></a><a id="Tc_hb0ZJKSDikSjimdN4AwYgw_14_0"></a><a id="Tc_qTa_7jkCokyTqf2OnwzSAw_15_0"></a><a id="Tc_pF0EV6rv_kSPCwNYmlyaIA_16_0"></a><a id="Tc_f9GYpwy5XU2KK7CbDTTd1A_17_0"></a><a id="Tc_095eCiix-Eyxj4v3pXZsgg_18_0"></a><a id="Tc_eG8uVUb1S0m3Md1AtlfU-Q_19_0"></a><a id="Tc_qQEpT4paGUKPqNuRQTkPhQ_20_0"></a><a id="Tc_NuQ0JviXnk6Ue8teHuTK_g_21_0"></a><a id="Tc_cDJbYugE2E2I7h_BKp89EA_22_0"></a><a id="Tc_Q9QLeqUZX0u911RxH1wVRA_22_3"></a><a id="Tc_4lmtPYguHEa4OiDEVxlD-Q_23_0"></a><a id="Tc_iu_dU1BtVEiEc7GPPiSe-Q_24_0"></a><a id="Tc_MwhqnP0WFkiHaQI6GJ67aA_25_0"></a><a id="Tc_rLB-x6tYREeePxcNf9UOuQ_25_3"></a><a id="Tc_Pp_JKaNAr0yBJpQvepRiEQ_26_0"></a><a id="Tc_X55GAPPfgkOLFGqECOvNLw_27_0"></a><a id="Tc_a0ix0ilXp02Pqh70EJnO8w_28_0"></a><a id="Tc_q3zEOraxZ0WxczJOwgq-Vw_29_0"></a><a id="Tc_ePQLSg6kBku5p1vCUZS6XA_30_0"></a><a id="Tc_W26VA8jIeUCvaq6qrG9p3A_31_0"></a><a id="Tc_58U-n74nfESo2nect-q_0A_32_0"></a><a id="Tc_cdm9mERfmkWkbbvWnFMPDw_32_2"></a><a id="Tc_NPPUtCIo2EKCU1Ug0DTbrw_32_5"></a><a id="Tc_es_H7APeiU--tzCEPFRk8Q_33_0"></a><a id="Tc_p_otBu5p6UixZ3t1HqOKWQ_34_0"></a><a id="Tc_MgJDc0ggFUiQhi-JH0eBkA_34_2"></a><a id="Tc_08vcNSHGskOhism15l9oXw_34_5"></a><a id="Tc_njaVTFK2okyxQAZ52LGzaA_35_0"></a><a id="Tc_dMpllr1-E0KQS2L-as9igA_35_2"></a><a id="Tc_pdv_PS-j80qGlDXc6mOStA_35_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_uOmIQ9VHK0WZRcPz4eLztA_4_3">18,916</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_it_2XUtsi0W77t6HOyJWeQ_4_6">69,045</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_vZuY1vhlgky1UopMyYli4A_6_3">1,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_Pe17rpNuxkKnjlH5VNciNQ_6_6">972</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_RprNRKijUEK-cE4oqMYz0Q_7_3">2,893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_bseq1nlKIUaCdtJBTBP2Jg_7_6">938</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of the Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="armp:IncreaseDecreaseFairValueOfLiabilities" sign="-" scale="3" id="Tc_GlPE6RP2Fk-09PZNh0sKoA_8_3">31,399</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="armp:IncreaseDecreaseFairValueOfLiabilities" scale="3" id="Tc_dtdlB0ns2kCdA2TfscE8rw_8_6">21,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-cash interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" id="Tc_giXAatDfIk6vuvjCL2kc8Q_9_3">10,758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" id="Tc_FnzezyXUh0KUDFPlAcmCWw_9_6">2,573</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-cash interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="armp:NoncashInterestIncome" scale="3" id="Tc_iAWRsMi-x02UJESJGbbKPQ_10_6">22</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain (loss) on debt and Convertible Loan extinguishments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_5bgI7yR_UESDyhO0bV8HYQ_11_3">2,166</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_nkdT8p1rxkOnzJjRRM7EJw_11_6">3,863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="armp:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" sign="-" scale="3" id="Tc_d4bxSp6170aco9HtnRQHLQ_12_3">2,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="armp:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" sign="-" scale="3" id="Tc_-S2mcBW1PkCvdPnkaDqOUA_12_6">1,018</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss from disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" sign="-" scale="3" id="Tc_VrNWjPzBFUGLyqTOt-717A_13_6">81</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_ytcDpncspUmCzKwPz2wpeA_15_3">5,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_K5nGZGS3Gke2hh7CW_f-xg_15_6">4,826</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_tDdqcbHVzEagd9Sis4RVgw_16_3">3,755</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_PYovc8xlGkOyjTqBmawJ6g_16_6">39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredCompensation" scale="3" id="Tc_BYvLnfHyj0yjQ8GlwsWbyw_17_3">1,512</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredCompensation" sign="-" scale="3" id="Tc_SS2NVaqv-0Cbc62vYwQi5g_17_6">1,060</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_RznLkvgVUUit0B0kOOTr_Q_18_3">4,962</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_Kcz5y-njsEybB_WqNG0ECg_18_6">13,451</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_2XIjBdTNfU2AcN3m2t_iyQ_19_3">37,551</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_C4_XM2bBlEC63epmhDFlIw_19_6">47,423</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ZxavjJVL5EaJmwv-6Bh6bw_21_3">1,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_wkatwIVi50S66U3mvXqjaQ_21_6">8,144</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_Zzi3MYTKxk-nuxTl--sDwA_22_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_XOUSzK6a70quK0DyTwRGyQ_23_3">1,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Y48Qd4GQU0KodFEScxzT6Q_23_6">8,134</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of the Convertible Loan, net of issuance costs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Tc_Y_d63G3etEmREtvVdLCSzQ_25_6">29,101</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of term debt, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" id="Tc_x_JsVUliuU2eVuun2iL89g_26_3">34,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" id="Tc_7zJMj4CdCUuW2o6VkTIeEQ_26_6">24,925</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments for taxes related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_8CPv7dAoAECwaVh0RIczqg_27_3">61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_uWaTg3LWZkmzcYzuslwwCg_27_6">43</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from exercise of stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="armp:ProceedsFromExerciseOfWarrantsAndStockOptions" scale="3" id="Tc_xj20aZa89USOyahNIWKP4w_28_3">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="armp:ProceedsFromExerciseOfWarrantsAndStockOptions" scale="3" id="Tc_M5LOrAsEz0ykO4kRAcwbUA_28_6">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Ad2t3jkCxk-RlNrLtdPblA_29_3">34,958</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_OWpCCrs6UEOv_GbZmDB9lg_29_6">53,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_RbzKjE3uOU2fyEaZJvICfg_30_3">4,472</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_fHQgEuvnykeFIYRmEyFoVg_30_6">1,569</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_DoJ4FwKME028benGiDG8HA_31_3">19,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2022_igNvzFb5yESqV8OvL7Pg4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ajLyakZ3PE-xiD4yjfiT-w_31_6">20,812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_bgc5UxLFbEOgGQJhlg6PGw_32_3">14,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_3VBfkJk4NEqSXxZiZ0ce5w_32_6">19,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use asset obtained in exchange for operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_8X7yugqphU-ls_nLBqEi4A_34_3">977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_x16xnS-BZkid1MP5EXR3ZQ_34_6">2,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment included in accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContributionOfProperty" scale="3" id="Tc_1OIkMegUMkukS7XhlQT7hw_35_3">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContributionOfProperty" scale="3" id="Tc_PQuDsmDzVEG88tQAfGWIpA_35_6">217</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_77c3e9c4_5a12_4585_8f5f_9f1e80029717"></a><a id="Tc_juv0leqMhUmskB3_DqEkvw_1_2"></a><a id="Tc_V6cvAWPvYk6_wIgkc1XR0A_2_2"></a><a id="Tc_-oA7BbeChEycHCB-OuqY8A_2_5"></a><a id="Tc_tNxCXoVBbk22wOYwN9gAYw_3_0"></a><a id="Tc_CXUogQoh_k6OjSs2FUge5Q_3_2"></a><a id="Tc_ViloXP2vrEKNv0sQsDAcsA_3_5"></a><a id="Tc_QT_fWWg0-Ey-2SgcPjDffA_4_0"></a><a id="Tc_yhSIRefWxEGjqxQaS4FhhQ_5_0"></a><a id="Tc_kNsQ1HxBEUKRhuL5Cakkuw_5_2"></a><a id="Tc_trzufg4aX0qgAqqjL8S9FQ_5_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_JrhEhp58Okav-d3Pf5z86w_3_3">9,291</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_PUgw_QiDjkijTLwCzBp_Sw_3_6">13,523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_PoowoKDiq0OM7q4WTXxNeg_4_3">5,480</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_Nhs5nczoNku8CdDldSjnXw_4_6">5,720</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_UZtWWfRzYkKlXi4kukoxpA_5_3">14,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_5ffbFeJpsEiUdxq_vrYrjQ_5_6">19,243</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7c92a4cb_b682_4faa_baeb_f4e49c47f490"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Armata Pharmaceuticals, Inc. </p><a id="NotestoConsolidatedFinancialStatements_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_mWF1A-DrNkSM0zJkJrUg-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and Description of the Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Armata Pharmaceuticals,&#160;Inc. (&#8220;Armata&#8221;) together with its subsidiaries (the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on </span>the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Armata&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_KbDBEU6QS0iVowraeOUI_A">0.01</ix:nonFraction> per share (the &#8220;Common Stock&#8221;) is traded on the NYSE American exchange under the ticker symbol &#8220;ARMP&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s principal stockholder, <span style="font-family:'Times New Roman;">Innoviva Strategic Opportunities LLC (&#8220;Innoviva SO&#8221;), a wholly owned subsidiary of </span>Innoviva Inc. (&#8220;Innoviva&#8221;), owns <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_OwnershipAxis_armp_ArmataPharmaceuticalsIncMember_Gv-ymKjfckGEyekgNJZuSg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_mstPferhKES9qScFc6qXMA">69.3</ix:nonFraction>% of the Company&#8217;s outstanding equity as of December 31, 2024. The Company also received $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_D0CIVBrcHkCADcgqae2kVQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" id="Narr_hhGmNFBdOUmo6mnW1SrJeA"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_iIfGtoSfVkOyLJgO8EHWrQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" id="Narr_z9rLSyGCIES6PKqLXQ20Pw">90.0</ix:nonFraction></ix:nonFraction> million in total debt financing from <span style="font-family:'Times New Roman;">Innoviva SO</span> during 2023 and in March 2024. Innoviva designees represent <ix:nonFraction unitRef="Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA" contextRef="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_PYldRmX4ZUyocSelgjrlsg" decimals="INF" format="ixt-sec:numwordsen" name="armp:NumberOfDirectors" scale="0" id="Narr_Fmw7QvaDHki3Z7AkaVeA7A">three</ix:nonFraction> out of <ix:nonFraction unitRef="Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA" contextRef="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_PYldRmX4ZUyocSelgjrlsg" decimals="INF" format="ixt-sec:numwordsen" name="armp:NumberOfBoardDirectors" scale="0" id="Narr_WHeKZD8R2UGmlSFJekMOuA">eight</ix:nonFraction> seats of the Company&#8217;s Board of Directors (&#8220;Board of Directors&#8221;) during the year ended December 31, 2024, and cannot vote or take any action by written consent with respect to any shares of Common Stock held by Innoviva SO that represent, in the aggregate, more than <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_RangeAxis_srt_MinimumMember_1gX74jz0bEaW8OFMI4iC9A" decimals="3" format="ixt:num-dot-decimal" name="armp:CommonStockVotingPercentageHeldPercentage" scale="-2" id="Narr_U4vOUBcQgE2OjjIfsntk5A">49.5</ix:nonFraction>% of the total number of shares of the Company&#8217;s Common Stock for voting on the matters related to election or removal of the Company&#8217;s board members or amending the bylaws of the Company to reduce the maximum number of directors or setting the number of directors who may serve on the Company&#8217;s Board of Directors in accordance with the voting agreement. The voting agreement expires on the earlier of the fifth anniversary of the agreement&#8217;s effective date, January 26, 2021, or the approval by the Food and Drug Administration (the &#8220;FDA&#8221;) of any of the Company&#8217;s product candidates for marketing and commercial distribution. Innoviva SO and Innoviva are related parties of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="Tb_2C971qu-40WGXv2lX5V6gQ" continuedAt="Tb_2C971qu-40WGXv2lX5V6gQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Liquidity and Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company has incurred significant operating losses since inception and has primarily relied on equity, debt and grant financing to fund its operations. As of December 31, 2024, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_rx2nVmuea0SIXrcx0TXIQA">327.7</ix:nonFraction> million. The Company expects to continue to incur substantial losses, and its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until then, the Company will need to continue to raise additional capital. The existing cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_cVeKpQYEP0qmJh02jFUqvg">9.3</ix:nonFraction> million as of December 31, 2024 will not be sufficient to fund its operations for the next 12 months from the date of these consolidated financial statements. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recent Financing:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2025 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On March 12, 2025, the Company entered into a credit and security agreement (the &#8220;2025 Credit Agreement&#8221;) for a loan in an aggregate amount of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_lYPylZYIdk2wIBi0hqVZ8w">10.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million (the &#8220;2025 Loan&#8221;) with </span>Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA), our principal stockholder and a related party (collectively, &#8220;Innoviva&#8221;).<span style="background:#ffffff;"> The 2025 Loan bears interest at an annual rate of&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_KX7OiUvC30Ov6USjYARRmA">14.0</ix:nonFraction>%</span><span style="background:#ffffff;"> and matures on March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2025 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2C971qu-40WGXv2lX5V6gQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Concurrently with the execution of the 2025 Credit Agreement, the Company entered into amendments to (i) its existing convertible loan (the &#8220;Convertible Loan&#8221;) and secured credit and security agreement, dated January 10, 2023, with Innoviva (the &#8220;Convertible Credit Agreement&#8221;), (ii) its existing secured term loan facility (the &#8220;2023 Loan&#8221;) and credit and security agreement, dated July 10, 2023, with Innoviva (the &#8220;2023 Credit Agreement&#8221;) and (iii) its existing secured term loan facility (the &#8220;2024 Loan&#8221;) and credit and security agreement, dated March 4, 2024, with Innoviva (the &#8220;2024 Credit Agreement&#8221;), which, among other things, extended the maturity date of each loan to March 12, 2026.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2024 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;">On March 4, 2024, the Company entered into 2024 Credit Agreement for the 2024 Loan in an aggregate amount of </span><span style="font-family:'Times New Roman;">$<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_OTR9ruU8jEO4DamnlHKFLQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_D9m8yVEZAUeEYYbPfj4lvg">35.0</ix:nonFraction></span><span style="font-family:'Times New Roman;"> million. The 2024 Loan bears interest at an annual rate of </span><span style="font-family:'Times New Roman;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_OTR9ruU8jEO4DamnlHKFLQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_hxQNmul3CEW3W2TQ0lqiiw">14.0</ix:nonFraction>%</span><span style="font-family:'Times New Roman;"> and was scheduled to mature on June 4, 2025. On March 12, 2025, the Company executed an amendment to the 2024 Credit Agreement which, among other things, extended the 2024 Loan maturity date to March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2024 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets </span><span style="background:#ffffff;">of the Company and the subsidiary guarantors</span><span style="font-family:'Times New Roman;">. </span>Concurrently with the execution of the 2024 Credit Agreement, the Company amended certain provisions of the Convertible Loan and Convertible Credit Agreement and the 2023 Loan and 2023 Credit Agreement to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While the Company believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#8217;s ability to achieve the development and commercialization goals would be adversely affected.</p></ix:continuation><a id="_Hlk192849661"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_73dDRKYfj0eJ7fNKu7_Dpg" continuedAt="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_3syA4nLi7kOmuERMdUYM-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:UseOfEstimates" id="Tb__NNC4scwB0i4wYh-HRadwg" continuedAt="Tb__NNC4scwB0i4wYh-HRadwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the </p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_-ctpzPtLP0WrlMzQMTSTYA_1_2"></a><a id="Tc_h5UMB7qCLUGbj_B8-uXVpw_2_0"></a><a id="Tc_ivZoEPJTl0C4fJlBaXZ3-g_2_2"></a><a id="Tc_fHGN72Vbs0aTaJjAuUXR0Q_3_0"></a><a id="Tc_AmVrMp9080aNJuu1HxPIJA_3_2"></a><a id="Tc_-zYaNrO9zUG345t_GOxIcQ_4_0"></a><ix:continuation id="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont1" continuedAt="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont2"><ix:continuation id="Tb__NNC4scwB0i4wYh-HRadwg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the Convertible Loan, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_PpmQ_b6b-Ey8XRfTK0eZhg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;">Concentration of Credit Risks and Certain Other Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and restricted cash. As of December 31, 2024 and 2023, cash, cash equivalents and restricted cash were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions in accordance with the Company&#8217;s investment policy, to a concentration limit per issuer or sector.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Other receivables represent amounts due from the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;) (Note 13, &#8220;</span><i style="font-style:italic;background:#ffffff;">Grants and Awards&#8221;</i><span style="background:#ffffff;">) and reimbursement for tenant improvements (Note 12, &#8220;</span><i style="font-style:italic;background:#ffffff;">Commitments and Contingencies</i><span style="background:#ffffff;">&#8221;).</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_jS-no4uuCE6y0lnKBkeseQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.26;margin:8pt 0pt 4pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cash and cash equivalents consist primarily of cash deposits and marketable securities with original maturities of less than three months.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_8XmdtIqJ3E6MmRdsvC0j_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of <ix:nonFraction unitRef="Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="INF" format="ixt-sec:numwordsen" name="armp:NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" scale="0" id="Narr_VH07Zbc4eUK67CUSNJRhqw">two</ix:nonFraction> irrevocable letters of credit with financial institutions related to the Company&#8217;s operating leases (Note 12 , &#8220;<i style="font-style:italic;">Commitments and Contingencies</i>&#8221;).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_EA4KB_P64E2ucdw4PN-vjw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;white-space:pre-wrap;"> Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, Convertible Loan and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The Convertible Loan is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_V77-QbhZ7UyUssurGFK8pg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span><span style="color:#212529;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="armp:PropertyAndEquipmentUsefulLifeTableTextBlock" id="Tb_o5MnEQxmhEesk1-KMGcBEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_F1-n7zRE20q0EmkRbZO3CQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_iU2_T22x8E-diuwgoXEJeg">5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_TwxvP62zB0uMlwhQkUWi8Q" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_-PL6QDjV_UyNJX8MzTvjDQ">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_X0p3Xo14WU6gPCeyKpTmXw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_CQiNFq5bH0OSZCfb9kWPMg">3</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_aDlY3wA3nk6hKsCmJ4oMww" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_h8q9wpzjh0qz60_yuCY7JQ">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-Eh2dCRyZEObk0oB6hPNcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter of lease term or useful life</span></span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont2" continuedAt="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont3"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_meAx8huZJEaCm8oGr4yq7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="Narr_oCvar4YJvUCTOt4pmJZ7wQ"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="Narr_a3CKkILAkEmt7RtIgd6Iww">No</ix:nonFraction></ix:nonFraction> impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2024 or 2023. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="Tb_FzLFKj0VkEmbgvQeJEyqCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">In-Process Research and Development (&#8220;IPR&amp;D&#8221;) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;"> IPR&amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#8217;s IPR&amp;D assets represent capitalized in-process bacteriophage development programs for </span><i style="font-style:italic;">S. aureus</i> infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company tests IPR&amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when a quantitative analysis of IPR&amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#8217;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#8217;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, the Company performed the annual evaluation of its IPR&amp;D assets for impairment. The Company considered the development timelines for its <i style="font-style:italic;">S. aureus</i> development program and noted no qualitative factors that would indicate potential impairment of its IPR&amp;D asset. The Company also performed a quantitative analysis for impairment analysis and based on this analysis, the fair value of this bacteriophage program was greater than its carrying value as of December&#160;31, 2024. Consequently, <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="3" id="Narr_PXOuOiYgsUmYg6axx7PALQ">no</ix:nonFraction> impairment was noted for the IPR&amp;D asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company performed the annual evaluation of its IPR&amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for <i style="font-style:italic;">S. aureus</i> infections was greater than its carrying value as a result of the quantitative analysis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="3" id="Narr_DxkDzoNbZ0aXoWNPRSP78A"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="3" id="Narr_IdolUCzqv0mcYv1a3Qp1pA">No</ix:nonFraction></ix:nonFraction> impairment loss was recognized as of December 31, 2024 and 2023. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Tb_o2QaYenm6EGGuGu7IkRaeA" continuedAt="Tb_o2QaYenm6EGGuGu7IkRaeA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont3" continuedAt="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont4"><ix:continuation id="Tb_o2QaYenm6EGGuGu7IkRaeA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#8217;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="Narr_QZ4b3TjtRkecBeMFGNkj0g"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="Narr_MLjo-DE4M0KdsylMFc1DuQ">no</ix:nonFraction></ix:nonFraction> impairment as of December 31, 2024 and 2023.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_9voQTVd-40CRU6U8MWpWJg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_NAhOMa5C6UWSNcHYZbVhYQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) is determined based on the number of units granted and the closing price of the Company&#8217;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_EV9_41WHdEiLxB1shMzm7g" continuedAt="Tb_EV9_41WHdEiLxB1shMzm7g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Foreign Currency Translations and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. <span style="background:#ffffff;">Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the quarterly average exchange rate in effect during the </span>year.&#160;<span style="background:#ffffff;">Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#8217;s consolidated statement of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont4" continuedAt="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont5"><ix:continuation id="Tb_EV9_41WHdEiLxB1shMzm7g_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="armp:GrantsAndAwardsPolicyTextBlock" id="Tb_YplmNsdWtkG01FRNTKwxrQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grants Revenue and Other Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether agreements are within the scope of ASC Topic 606, <i style="font-style:italic;">Revenue from contracts with customers</i> (&#8220;ASC 606&#8221;) or other topics at the effective date of an agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;<i style="font-style:italic;">Collaborative Arrangements</i>&#160;(&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;<i style="font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</i>, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also considers the guidance in ASC Topic 730,&#160;<i style="font-style:italic;">Research and Development&#160;</i>(&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability<i style="font-style:italic;">.&#160;</i>If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company recognized as other receivables in its consolidated balance sheets $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_qx3dYJjAE0ynK7mpFACMVg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="Narr_7zqKjX0jKU2N5L_OVyXapg">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_CQpyd18Ds0qh3m21NnuflA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="Narr_Swv3vtn1OEqNsMhVHvqpGA">1.5</ix:nonFraction> million, respectively, related to invoiced grant amounts that have not been received. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_Qdp-TOMRJUKpKeiaCd0ARw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_OXNcvOE-TkKHfaqWJcdi9w" continuedAt="Tb_OXNcvOE-TkKHfaqWJcdi9w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont5" continuedAt="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont6"><ix:continuation id="Tb_OXNcvOE-TkKHfaqWJcdi9w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_Eb_a6rzslUOwDGM-XmgiQg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2024 and 2023, as such, the comprehensive income (loss) for these periods was equal to the net loss. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_Wo2J8a2qB0ql788PZa9ndw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;">Basic and Diluted Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. </span>Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.<span style="background:#ffffff;"> The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_qSIlyvhhGEWNFqz3-jUYRg" continuedAt="Tb_qSIlyvhhGEWNFqz3-jUYRg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 standard in the fourth quarter of 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. Refer to Note 15.&#160;&#8220;<i style="font-style:italic;">Segment Reporting&#8221;</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#212529;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#212529;background:#ffffff;">In August 2020, the FASB issued ASU 2020-06, Debt - </span><i style="color:#212529;font-style:italic;background:#ffffff;">Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i><span style="color:#212529;background:#ffffff;"> (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted earnings (loss) per share (&#8220;EPS&#8221;) computation. The Company adopted this ASU as of January 1, 2024, which did not have an impact on its consolidated financial statements or related disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">On October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#8217;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_73dDRKYfj0eJ7fNKu7_Dpg_cont6"><ix:continuation id="Tb_qSIlyvhhGEWNFqz3-jUYRg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): <i style="font-style:italic;">Improvements to Income Tax Disclosures</i>. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In November 2024, the FASB issued Accounting Standards Update ASU 2024-03 Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40):<i style="font-style:italic;"> Disaggregation of Income Statement Expenses</i>. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#8217;s consolidated financial statement disclosures.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6d517fda_6f7c_4000_bf11_624e23bc12d1"></a><a id="Tc_JnUgRsm0NEuvXaHUdKskzw_1_1"></a><a id="Tc_Pwqm7RAz60it2-S5W_9h1Q_2_2"></a><a id="Tc_mnPcMB-9qUeEOE-_h2Ee2w_2_5"></a><a id="Tc_HkxDrlDkikagFfcb_5JUEQ_2_8"></a><a id="Tc_Y1B0mJ9_SEGitxsmhuhQZw_2_11"></a><a id="Tc_OYTlWiAuW0aFrFrw_4OItg_3_0"></a><a id="Tc__mvHSdMgvUG8s-EUCM7fyQ_3_1"></a><a id="Tc_3RYSWsKrR0e-F_J1USsJ3A_3_4"></a><a id="Tc_RTtlupzWdkCxVlO_EFLrrg_3_7"></a><a id="Tc_3il8GxhGLk-OQ7lyGNddmQ_3_8"></a><a id="Tc_Scibf_G2JECsADjliAKVww_3_10"></a><a id="Tc_4TWEjwYOo0qeQhMCYPWA7g_3_11"></a><a id="Tc_UyMQXLO3ekenHiIUUh305Q_4_0"></a><a id="Tc_0CeoL5U43EO-F99lFvGg6A_4_5"></a><a id="Tc_xaxAZBa1HU2xUPahTQMPDw_4_8"></a><a id="_b4b33649_c803_41bf_98e6_ff2833a15a36"></a><a id="Tc_1dGAdU2Xi0yKxPDgcyPyUw_1_1"></a><a id="Tc_TrygyBG6gkmsm9bGPa4-OA_2_2"></a><a id="Tc_-oyampq4nU2Zdfc2kAXglA_2_5"></a><a id="Tc_q9clPu9WjUKfLKHkMahfCQ_2_8"></a><a id="Tc_QpRaE1LaWkyw05MN3sclBQ_2_11"></a><a id="Tc_IYXMzmkPqkmg7odXWPBnsw_3_0"></a><a id="Tc_Qj48a_HrBUCzDuBmuXceVw_3_1"></a><a id="Tc_7kBl8jivDk2ejzZ-fMSHiw_3_4"></a><a id="Tc_RnOspMvS50uJcqckBm1yNw_3_5"></a><a id="Tc_PWYVAjkDE0y4-ZtWKD6m8A_3_7"></a><a id="Tc_i_FdJTXS40OwJ2aQGCoRCQ_3_8"></a><a id="Tc_zTLF0fc08UKizDQYyANcxQ_3_10"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_FNOApKF7aUq95Id6VLOgHA" continuedAt="Tb_FNOApKF7aUq95Id6VLOgHA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.27;padding-top:12pt;margin:0pt 0pt 4pt 0pt;">4. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="Tb_6mr_Ti1z0EG99i93Mm9VCQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investments in money market fund &#8211; financial assets, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_9qcZEDh_skaFm0Zlm2Fc-A_3_2">4,955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_bAIh_tiMI0Kax823zmexkA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_8UTzcPgHPUOw5eO6Er9Ibg_3_5">4,955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan&#8211; financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="Tc_BTqaHOnVskewyfcS7vL8tw_4_2">32,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sVGisjCvnEiEB93bLojreA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="Tc_JtKidOrxIUulmyrrILL1ag_4_11">32,897</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:middle;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan&#8211; financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="Tc_8AyBA_BJAkKOkyikGAxmAg_3_2">58,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_YvPw907mK0udlp6KfJ8QZw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="Tc_1kvUidEXF0ipDCZjBwFeQg_3_11">58,633</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;">The Company&#8217;s Convertible Loan (Note 7) is measured at fair value and remeasured at each measurement period, with changes in fair value recorded as other income (expense) in the consolidated statement of operations. The Company estimates the fair value of its Convertible Loan using a weighted probability model of various debt settlement scenarios during its term discounted to the reporting date. Conversion option scenarios are valued using option pricing models with assumptions and estimates such as volatility, expected term and risk-free interest rates. </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_31a84938_2290_4988_a42e_3b4de2c48a09"></a><a id="Tc_n6kTeT-eJk2badZ7iPnItw_1_2"></a><a id="Tc_RKKHB1DmMkqHFcJDG_l7Rg_1_5"></a><a id="Tc_belbDz_CpUSncz8cs7RVRA_2_0"></a><a id="Tc_AxNIwr-rx0epB76vWF7hLg_2_1"></a><a id="Tc_Vqghqnx9B02vAqjgCJqd6w_2_4"></a><a id="Tc_dWI_Jz08Z0OTBKM6EYjwhQ_2_5"></a><a id="Tc_diuTO5abYEGczV2lQAlUYQ_3_0"></a><a id="Tc_r1ReV-lvskOtWQ-_g1zHXg_3_2"></a><a id="Tc_KLbjE3FG_kSa_5E8PjKIgw_4_0"></a><a id="Tc_6TtkxLofEkygqb6Dqt7Twg_4_2"></a><a id="Tc_LRkR8_BatkOH3O0fHwfEVQ_5_0"></a><a id="Tc_2GX5ilJFxEODkTLiYz1k2g_6_0"></a><a id="Tc_jz0c5yxSok2-hcb4xAkTIw_6_2"></a><a id="Tc_JBJU3eGkgkqxNPHWfqf3_A_8_0"></a><a id="Tc_m7SOQnYt10ekqAIniTnzIQ_8_1"></a><a id="Tc_aOvjS0ZtbUa0ohSRFjSuPg_8_4"></a><ix:continuation id="Tb_FNOApKF7aUq95Id6VLOgHA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">Level 3 fair value inputs include probability and timing of various settlement scenarios and selection of comparable companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company estimated the fair value of its Convertible Loan using the following inputs for the years ended December 31, 2024 and 2023:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_q41dpOoXzU2VY90IN7FsoQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N9_1XuuLQ0-lsYc-TWi-NA" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_wDm7rStjO0q7DqwLuzpqHA">15.67</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_T0i7nyaWzEq2E47alJJZLg" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_BOGDL5aYwkCTGuCCR3m-tw">28.28</ix:nonFraction>%</p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_p_w3bZ_ln0aJdZk7_GgZHA" decimals="4" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_vn3hnOy-kUCeOtEfREFI6A">21.01</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N0tx2XrUDkeZnYUXCzfq4w" decimals="4" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_roIYMrYlY0ejvy9YWcUQPA">45.88</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probabilities of settlement scenarios</p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_UqehtnWrBEGyotCU0pk1bg" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_e9oUwUz0AUSp_n2y2z7clw">0</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_pPPFgT2uxECtGLDgw4ehFA" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_ykbGo_NgUkq5d38RQMNLQA">75</ix:nonFraction>%</p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_uW8GX-eYnUeHey_7S13JXw" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_9lKpU6_M0EOsCW2kOfS2kQ">0</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_8HLlfMA8zkmvRWpKnH3qMg" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_psFej-ZJbkKM460d56teNA">85</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility </p></td><td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_jj6a-hSvJkuGs24AQOWWHA" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_vNzHZLiAkEWXb_zS6nInJg">83.30</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_TkXtmRTW0kmojBMn9BVCTg" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_VuBNLXg1tUifqEGw3YUc6Q">111.60</ix:nonFraction>%</p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_kRX4vihrCkaUsg38VT2Fag" decimals="3" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_OwRJvClQC0OK69lFlpv1qA">101.1</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_37d8n_o0P0-p2FnUWFQIOA" decimals="3" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_A5VZpmJB8ESWaAtTystNNA">123.6</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_pLXRlxUf9kGKDnBAIaplzQ" decimals="INF" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_Mv0c2-FbXkeOn4R7vbqrrg">0.10</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_rOsiQMIXrkabber6Gcmk5A" decimals="INF" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_mgJrcLnl-UewyyDWFJF3pg">1.20</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KZNkSs3clkaJtabzbT5F9g" decimals="INF" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_tbmPZidUzk2h0yA-H1F9mQ">0.20</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lyiDqRxypkiQAz7M1AbxDg" decimals="INF" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_Lbq1LLYAaEioaUPcBejhbg">1.50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Nx2W3bvlQUKPamjde55oCQ" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_ENc653q8902Ue241c9l9sw">4.08</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_N2i004GY7UqD_LBRSb5cDQ" decimals="2" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_Wc8I06bkPUCThz82wi2b8A">5.33</ix:nonFraction>%</p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_AyLQnVZhREiEwFcrl82R0A" decimals="4" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_qRfO6cPUiEGcZBuo2KdFcw">4.62</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_JqCSzztJk0uu3fT9ol6LJA" decimals="4" format="ixt:num-dot-decimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="-2" id="Narr_zbfAlZSY0UO1mQ8EqXD8Fw">5.39</ix:nonFraction>%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="Tb_-ZSx2VYST0qkK2jk0WEpMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents a summary of the changes in the fair value of its Convertible Loan for the years ended December 31, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_YvPw907mK0udlp6KfJ8QZw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_ohXqQoVOUkaXNaMSIzqiiw_2_2">58,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net issuance of the Convertible Loan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Tc_HxATO_niTk2SiOv0hJ4Hvg_3_5">29,226</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial recognition of modified Convertible Loan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug" decimals="-3" format="ixt:num-dot-decimal" name="armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" scale="3" id="Tc_piKLxeBxu0Cp1AqIUFFAUQ_4_5">35,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_pSgow0Qc80SpSp1cz46FaQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" sign="-" scale="3" id="Tc_4fGjKjtspk2L-gft464lCw_5_2">31,399</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="Tc_2qSU6khoGUq-LAVbZwftXQ_5_5">21,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amount exchanged <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug" decimals="-3" format="ixt:num-dot-decimal" name="armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" sign="-" scale="3" id="Tc_AtEY7jxgNE-PpsYdA8H2aQ_6_5">31,332</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_xUrXavuJzEKCYO2cJuMBNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Loss on the Convertible Loan extinguishment</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_pSgow0Qc80SpSp1cz46FaQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_WVGGA9rplkCMzWgIGuroQQ_7_2">5,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_jeLGTTprJUy_Fh3SY1R2QA_7_5">3,863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sVGisjCvnEiEB93bLojreA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_wv0genW8Ikepm7UVBl9wSQ_8_2">32,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_YvPw907mK0udlp6KfJ8QZw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_QiDJcO426EyvgzsDjawpzQ_8_5">58,633</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:justify;margin:0pt 3pt 0pt 0pt;">(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the detemination of fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7 , &#8220;<i style="font-style:italic;">Convertible Loan&#8221;</i>).</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_OJYqMPfCa0ezVFSuP1jKEw" continuedAt="Tb_OJYqMPfCa0ezVFSuP1jKEw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The computation of basic EPS is based on the weighted-average number of the Company&#8217;s Common Stock outstanding. The computation of diluted EPS is based on the weighted-average number of the Company&#8217;s Common Stock outstanding and potential dilutive Common Stock. Diluted EPS is computed using the more dilutive of the treasury stock method, which reflects the potential dilution that would occur if securities or other contracts to issue Common Stock were exercised or converted to the Company&#8217;s Common Stock. Common Stock options, warrants and unvested restricted stock units were not included in dilutive EPS as their impact would be antidilutive.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_ebs3r3GAo0SJ6-iOAhaiIg" continuedAt="Tb_ebs3r3GAo0SJ6-iOAhaiIg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the years ended December 31, 2024 and 2023 (in thousands, except share and per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_09b8c870_171a_49b4_a1f6_a76162b8bc0f"></a><a id="_73f10853_d1b5_439c_ab0a_69f51dd2b721"></a><a id="Tc_eGqfuCxz506jWHMSyun-tA_1_2"></a><a id="Tc_AgICOmECjUympf0WekecAA_2_2"></a><a id="Tc_6JFcsGI07EW23S1F0BPc3w_2_5"></a><a id="Tc_ghX-MkTiTUC68s60VORSGw_3_0"></a><a id="Tc_mJ6Oyimidk69QMuwToO7Ow_4_0"></a><a id="Tc_qh4k4Sf2G0u-rU8jxv_Rdg_4_2"></a><a id="Tc_QRz-tg4MWE-_CFNSGwrl-A_4_5"></a><a id="Tc_UNAxEGEJKU2Ahee69tN1yQ_5_0"></a><a id="Tc__kk5I9H9FkuR2IjYJFAJmQ_5_6"></a><a id="Tc_U_oL88L4CU2lGBsp4zqxOg_6_0"></a><a id="Tc_JOUzdNhPJU2mxH_uZB3vQA_6_6"></a><a id="Tc_NO5lxLmWpUytO5GPnpX9pA_7_0"></a><a id="Tc__OYyYui460KExG7AHQXvQw_7_2"></a><a id="Tc_Sn8cgLag10GRvWiIBpIKBg_7_5"></a><a id="Tc_7I4t_iM9ZUOwscegFrZWbw_9_0"></a><a id="Tc_kiGVzkEoZ0WGFZ_li2sXmg_10_0"></a><a id="Tc_aN-e0gAD1kGZA_kRELnXhg_11_0"></a><a id="Tc_BLBaQsAYfkmHRCBxoQi-4g_11_6"></a><a id="Tc_aImXcYHU00Omhkwuju8Mmg_12_0"></a><a id="Tc_rb8EmhrlskmCLvqqXPE0IQ_14_0"></a><a id="Tc_Eiq0lGzlwEmRGI10I1w4UA_14_2"></a><a id="Tc_s5iPkzmO8U-AR8aSlmWn5Q_14_5"></a><a id="Tc_5SFza9Jc90mkBqG7EAnqVg_15_0"></a><a id="Tc_nMFiuDkVv0CfaiNTUVfWPQ_15_2"></a><a id="Tc_ldS6tlpQvEez6FjwIiRBEw_15_5"></a><a id="_8cea445e_82f7_4217_8998_214b57cad0a6"></a><a id="Tc_GH06tJJXpkKkLJV5V6PtSg_1_2"></a><a id="Tc_CcB3dh0Ur0i2BNNP8I71LQ_1_4"></a><a id="Tc_9WFa6iAJ4U-bHbnz-6uXdA_2_0"></a><a id="Tc_WtYCSt6pP0iHBclbEsp0iQ_3_0"></a><a id="Tc_YoFuVUnJsUiZYeIWOcu0jw_4_0"></a><a id="Tc_ofHDi3ZILk2GiRKFfJWMHw_4_2"></a><a id="Tc_vBMR_HEtr0-p6h1282nphA_5_0"></a><a id="Tc_ACqzLCXFlkWzfTEJhNRm1g_6_0"></a><ix:continuation id="Tb_OJYqMPfCa0ezVFSuP1jKEw_cont1"><ix:continuation id="Tb_ebs3r3GAo0SJ6-iOAhaiIg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_ch1atYMGSUGR2mFIGnJFOQ_4_3">18,916</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_MJvdwVPeZkeMZLfm_3GNEw_4_6">69,045</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain from change in fair value of the Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" sign="-" scale="3" id="Tc_uN0lUy5mpk6jbA3eJxG5Rg_5_3">31,399</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on debt and the Convertible Loan extinguishments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="armp:DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt" sign="-" scale="3" id="Tc_Qq2eOkn1NUSn_uPV6D8aFw_6_3">2,166</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_3gvF9vFWC0eihqWYtEed3A_7_3">52,481</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_EGd2i2drg0eWbC_pm0yyfQ_7_6">69,045</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_6jWmx_OEe0eGkcJvnasCqQ_10_3">36,160,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_8TP8qTYdBUejYyDKK89F9Q_10_6">36,075,555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares issuable upon the conversion of the Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_hCVWa4IjqkGG5BoUMiWYig_11_3">22,899,123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_gUt6hT8ZOUenk_Is1IK_rw_12_3"><ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_gUt6hT8ZOUenk_Is1IK_rw_12_3_2">59,059,971</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_NMpk-UZ_kUimz3sxwmKaiQ_12_6"><ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_NMpk-UZ_kUimz3sxwmKaiQ_12_6_2">36,075,555</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_OK1xfUzw0EubmRCy5Z2gUw_14_3">0.52</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_NYSUo-faDk-X1PBdO2BUdg_14_6">1.91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_GxsLIA9OYEKr5fqq9aCaTQ_15_3">0.89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_fjYZ_go2RECd0WL48fcn-g_15_6">1.91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following outstanding securities as of December 31, 2024 and 2023 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_SCZ4LUrl2Ue5p7VHoA6uLg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_FRPlVpNZ5UGLs3JJR-cB7A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_qkw08y8rBEyaArOBbz9dPw_2_2">3,755,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_XkThMChsq06Wh5OxvIKHaw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_irdw26amokSNNZuxWxOTVQ_2_4">3,165,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_rohFuA_mlUuMJvakf51DjQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vcnoOYhDKUKWSbmZdGLyjw_3_2">220,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_Zs1AsV-ToEOMh54dXGkq3w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Cj5VBp5QD0KhmZdFMpAEiQ_3_4">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of the Convertible Loan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_SharesIssuableUponConversionOfConvertibleLoanMember_h0Z_P8CvIEq0cw1j1Kdi6Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_WetL4Q6uAE-3ZWHxTzot7Q_4_4">21,293,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_wEUJtdyPwUmF7kwBsHNYtg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_D3F8ArT42UiZ6oWdeedHew_5_2">19,365,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_SxAfTk9NBUeYICYKsOhlgw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_sbl7RKeoEUOL-rHscRNO9g_5_4">19,365,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_6f0L_5nlV0GXuXwSJ-l1jQ_6_2">23,341,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Yq78n-RIsEyJfZciyEfytA_6_4">44,024,924</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) The Company determined the number of shares issuable upon the conversion of the Convertible Loan as of December 2023, based on the Convertible Loan principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="6" id="Narr_FGeB_m8UKkib3aLqJqzegQ">30.0</ix:nonFraction> million, accrued and unpaid interest of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="6" id="Narr_YJOVxqZdAkqjg_TV7d7urw">2.4</ix:nonFraction> million, calculated at an annual interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_p4wDbGk_lki3eRHfTmUTSw">8</ix:nonFraction>%, converted at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_sl8a4s-ewE2wKXiVXTnv-w">1.52</ix:nonFraction> per share.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c461030e_4a8d_4a1c_bda3_93b6310da40d"></a><a id="Tc_vrxSPtI3EUC8Se_KHhpMVA_1_2"></a><a id="Tc_fn3pc6VNFkmu4cADhcJ9aw_1_5"></a><a id="Tc_kAk0HNhsPkaRlKLTJeEZpA_2_0"></a><a id="Tc_fqmYrbIFsE6ZvBbGFkOrFQ_2_2"></a><a id="Tc_u9l4VKQuL0CV1oV5ier3MA_2_5"></a><a id="Tc_iX0DyuFDoEmuAnamO3kEWg_3_0"></a><a id="Tc_G-ctLEF_EEaN-B5n5YTGYA_4_0"></a><a id="Tc_NTujUyEs60-jW8E1oKmOmA_5_0"></a><a id="Tc_T6nIqNGKoEatP2x4Rikppg_6_0"></a><a id="Tc_6mtO8px3Wki02ZAE8P-o5Q_7_0"></a><a id="Tc_7kvkARewjE-Os0NbCz27gw_8_0"></a><a id="Tc_OFcIsbHXD0qOwh13q2J9CA_8_2"></a><a id="Tc_TU6FGA1zpEOTZjpotFx8fQ_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_f8rDbtmh9EqFkCVjpbfOcQ" continuedAt="Tb_f8rDbtmh9EqFkCVjpbfOcQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Balance Sheet Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_sjmepmKrd0-Y3CDvLmsr2w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment as of December 31, 2024 and 2023 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_16WVW7L1UEKVDZzpv4Vrkw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_TWLNfMVgLkCwgHybDVbjug_2_3">21,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_5Jnw-tluDEu-Kx_JvwRpgA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_alqXaeM4BkqH4fqI066TXA_2_6">19,678</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_3TzGv1YAjkGo6HRjhuGnGQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-9ukIlvd4k6pcJY9HDahbw_3_3">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kYqBxC16p0K1mZ2qlRBw6g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_sjDPtV8J20C4fFCgj1Ax9g_3_6">817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Tfkx6Pkwf02KkxOhwrASHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Vv3h45jyWk27zrDmQ2745A_4_3">438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_p7FgB_AuUke_7o5Nlzb6Ig" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6UGqNMiDLU6cUOZlTHYSYQ_4_6">438</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_aI2oyISraU2WBXG-8aXVKQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_zFpMr9njc0agnjZFCN0mYQ_5_3">3,802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Osvcwobb1UGHl_jI9F_1uQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_B3ui9gOEckyw0-zH5WH8Dg_5_6">3,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_QXbj7ILZakChevUBfvs__g_6_3">26,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_aDdGSoAjskCO5e-7qt7xkw_6_6">24,380</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_YM_1dHChwUeJ4b7DgDgL0w_7_3">13,146</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_mJsITpjLKU-uizkjPGVEKw_7_6">11,821</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_lo7oLAfJUkyOEK1NRLiySw_8_3">13,241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_WYIE4nSZjEKweUyo_hEqbQ_8_6">12,559</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense totaled $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="Narr_LZniGlveckq9J3CIFNsejA"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="Narr_ysE4F1GxFkOKUg4uDM9fIw">1.3</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="Narr_sUJkEkIchUyBw8N2QsRkAg">1.0</ix:nonFraction> million for the&#160;years ended December 31, 2024 and 2023, respectively. Property and equipment not in use was $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-5" format="ixt:num-dot-decimal" name="armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" scale="6" id="Narr_f2P2D3kUIEKCy282KfVFTg">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-5" format="ixt:num-dot-decimal" name="armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" scale="6" id="Narr_AwkPLHCNF0yobxjDIabx4Q">8.1</ix:nonFraction> million as of December 31, 2024 and 2023, respectively, and is included in the laboratory equipment in the table above. These assets are not depreciated until they are placed in service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_05669ac6_6adc_4aed_967d_07caa7dc71d3"></a><a id="Tc_R4gy5oJM6ESDVFIYGy2yzA_1_2"></a><a id="Tc_J41X0H6A4EGUy3PSjP2-zA_1_5"></a><a id="Tc_qtaTO0UtzUiKc2PTHt0HJw_2_0"></a><a id="Tc_2Nma5-QZQUC8gnZCwlb4uw_2_2"></a><a id="Tc_DXS0NfSYAEq8qGaU_vWR-A_2_3"></a><a id="Tc_IUr6AS9C90-GxWVF0RyN7Q_2_5"></a><a id="Tc_xufMkoRgwUS5WOCuECZQfQ_3_0"></a><a id="Tc_rKHHYe9jaEKTpNFO_wm4Iw_4_2"></a><a id="Tc_Y-1EtLIpO0-ziTZ6oQqHag_4_5"></a><a id="_ee72c2ad_c890_4967_bd69_0688a3782b8b"></a><a id="Tc_jJi2FWVipE64n4se2BDhAA_1_2"></a><a id="Tc_5DFUeex55km397oYQGf8xA_1_5"></a><a id="Tc_Vz6SM_q710q3PPAfuy2tbA_2_0"></a><a id="Tc_eWUH8FrTmE-lCMlpEiDLeg_2_2"></a><a id="Tc_WLNzksG7fEOyNGh4kL-Pew_2_5"></a><a id="Tc_Lm2DSmQLz0-7rRD0_IpIbQ_3_0"></a><a id="Tc_B6N6Evg84kOvjyfr1RViIQ_4_0"></a><a id="Tc_-P7h8a_Lska9-23svFg_Ow_5_2"></a><a id="Tc_d0tzWejfQUS1PSjIsb39vg_5_5"></a><ix:continuation id="Tb_f8rDbtmh9EqFkCVjpbfOcQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Receivables</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="armp:ScheduleOfOtherReceivablesCurrentTableTextBlock" id="Tb_SNbASB4aSE23iFutTKVELQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other receivables as of December 31, 2024 and 2023 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tenant improvement allowance receivable (Note 12)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="armp:TenantImprovementReceivableCurrent" scale="3" id="Tc_w3vgq3C1Gk-hvH3gLJPgBg_2_6">1,835</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant and award receivable (Note 13)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="armp:GrantAndAwardReceivableCurrent" scale="3" id="Tc_2j87f-r0q06MRR0I_LyUfQ_3_3">744</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="armp:GrantAndAwardReceivableCurrent" scale="3" id="Tc_w31NwDm-ik2AQ_JwrT6pqw_3_6">1,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_e1v6A9brhk2Q9-2x6VCIHQ_4_3">744</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_1warD_YC10u-_fk2aXI3UA_4_6">3,363</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounts Payable and Accrued Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_MXj59ivWJkWITB1__NKKQg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_yc2QpZcvvkS9mE2XaWY0aw_2_3">766</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_f77n35VoZEm5Jl7aEuELvw_2_6">1,585</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical trial expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="armp:AccruedLiabilitiesClinicalTrial" scale="3" id="Tc_tc6BfkEudUGgKtfEoIb1hA_3_3">828</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="armp:AccruedLiabilitiesClinicalTrial" scale="3" id="Tc_0KkumMR4D0mbaOoiam3vBg_3_6">3,021</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" id="Tc_SaTVq2HwuUaVSDB0YLLUnQ_4_3">461</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" id="Tc_LlTGppiycEWaqTgyjW77Pw_4_6">1,083</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_Nhe-nNL2p0SUovo8wxtKsg_5_3">2,055</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_Wc6sAedkaU-DGKvs6AnmgQ_5_6">5,689</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="armp:ConvertibleDebtDisclosureTextBlock" id="Tb_2PKvDvLyDkW03IHeUJ_CBQ" continuedAt="Tb_2PKvDvLyDkW03IHeUJ_CBQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Convertible Loan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 10, 2023, the Company received the Convertible Loan in the aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_9sMkhMMwbUKikBvcjOTSZg">30.0</ix:nonFraction> million from Innoviva pursuant to the Convertible Credit Agreement. The Convertible Loan bears interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_qrQ_B2osZkeF5gNeU_YZOA">8.0</ix:nonFraction>% per annum and was scheduled to mature on January 10, 2024. The Convertible Credit Agreement was amended on July 10, 2023, in connection with the Company&#8217;s entry into the 2023 Credit Agreement to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. Then, on March 12, 2025, the Company executed a subsequent amendment to the Convertible Credit Agreement which, among other things, extended the Convertible Loan maturity date to March 12, 2026. The Convertible Loan principal and accrued interest are payable at maturity. Repayment of the Convertible Loan is guaranteed by the Company&#8217;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> The Convertible Credit Agreement provides that if there is a financing from new investors of at least </span>$<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_4FQlAocYb0208Y7SDKNP4Q" decimals="-5" format="ixt:num-dot-decimal" name="armp:ProceedsFromQualifiedFinancingPerAgreementBenchmark" scale="6" id="Narr_9ydW1iQ_TUS2Mqq4k09xgw">30.0</ix:nonFraction> million (a &#8220;Qualified Financing&#8221;), the outstanding principal amount of and all accrued and unpaid interest on the Convertible Loan shall be converted into shares of the Company&#8217;s Common Stock, at a price per share equal to a <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_NLLKe9dPJkWGOD2819Wd7g" decimals="3" format="ixt:num-dot-decimal" name="armp:DebtInstrumentConversionPercentOfDiscountOnSharePrice" scale="-2" id="Narr_2bjVignnP0uu_vLByXN2sw">15.0</ix:nonFraction>% discount to the lowest price per share for Common Stock paid by investors in such Qualified Financing. The Convertible Credit Agreement also required the Company to file a registration statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender&#8217;s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_ZyT7fPxm702X4S9adfhXMA">1.52</ix:nonFraction> (as may be appropriately adjusted for any stock split, combination or similar act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated authoritative guidance for accounting for the Convertible Loan and concluded that the Convertible Loan should be accounted for at fair value under ASC 480, Distinguish Liabilities from Equity, due to the fact that the Convertible Loan will predominately be settled with the Company&#8217;s Common Stock. Consequently, the Company recorded the Convertible Loan in its entirety at fair value on its consolidated balance sheet, with changes in fair value recorded as other income (expenses) in the consolidated statements of operations during each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On July 10, 2023, in connection with the 2023 Credit Agreement with Innoviva, as discussed below, the Company amended the terms of the Convertible Credit Agreement, to, among other changes, extend the maturity of the </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_2PKvDvLyDkW03IHeUJ_CBQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Convertible Loan to January 10, 2025. The Company concluded that the amendment was an extinguishment for accounting purposes. The Company recognized a $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_hHfphnzRoUq3UB_-E3jFQA" decimals="-5" format="ixt:num-dot-decimal" name="armp:IncreaseDecreaseFairValueOfLiabilities" scale="6" id="Narr_ZzErfKYnA0KwBO4EUJKEtQ">1.8</ix:nonFraction> million gain as the change in fair value of the Convertible Loan before the extinguishment date, July 10, 2023. The Company estimated fair value of the combined transaction, the Loan and the Convertible Loan, before and after modification and calculated an extinguishment loss of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_hHfphnzRoUq3UB_-E3jFQA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_5AyGRB4qKkuDHts0U_nfHQ">3.9</ix:nonFraction> million, which was recognized as other income (expense) in the consolidated statement of operations for the year ended December 31, 2023. The Company recognized losses of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_7_10_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9MsN49-EsUuh7lrZcuBNDA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" sign="-" scale="6" id="Narr_tj7iut8CSk-ugk5Q8nO1GQ">23.6</ix:nonFraction> million from July 10, 2023 to December 31, 2023 as the change in fair value of the Convertible Loan post modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 12, 2024, the Company amended the terms of the Convertible Credit Agreement and 2023 Credit Agreement, to, among other changes, extend the maturity of both loans to January 10, 2026. The Company concluded that the amendments were a combined transaction and an extinguishment for accounting purposes. The Company estimated fair value of the combined transaction, the 2023 Loan and the Convertible Loan, before and after modification and calculated an extinguishment gain of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_qzQd7EpFYkq8oeUwINwivg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_n5EqYeXb5EWM7yCGb5Y8Rg">2.2</ix:nonFraction> million, which was recognized as other income (expense) in the consolidated statement of operations for the year ended December 31, 2024. After this amendment, the Company continued to account for the Convertible Loan at fair value on its consolidated balance sheet, with changes in fair value recorded as other income (expense) in the consolidated statements of operations during each reporting period. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_qzQd7EpFYkq8oeUwINwivg" decimals="-5" format="ixt:num-dot-decimal" name="armp:IncreaseDecreaseFairValueOfLiabilities" scale="6" id="Narr_oWEEYqT870ORBju82SjJag">31.4</ix:nonFraction> million as the change in fair value of the Convertible Loan for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 12, 2025, the Company executed an amendment to the Convertible Credit Agreement which, among other things, extended the Convertible Loan maturity date to March 12, 2026.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:LongTermDebtTextBlock" id="Tb_jcfJFcae8E6K5rLovLbGJg" continuedAt="Tb_jcfJFcae8E6K5rLovLbGJg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Term Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">On July 10, 2023, the Company entered into the 2023 Credit Agreement. The 2023 Credit Agreement provides for the 2023 Loan, a secured term loan facility in an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_JJSD-xR9DEuUqzsSlzExgA">25.0</ix:nonFraction>&#160;million at an interest rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_HZ0FzPkSZ0-PWwxSIDANGw">14.0</ix:nonFraction>% per annum, and was scheduled to mature on January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the 2023 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the 2023 Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">On November 12, 2024, the Company executed an amendment to the 2023 Credit Agreement, which, among other things, extended the 2023 Loan maturity date to January 10, 2026. On March 12, 2025, the Company executed a subsequent amendment to the 2023 Credit Agreement which, among other things, extended the 2023 Loan maturity date to March 12, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The 2023 Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The 2023 Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#8220;material adverse effect&#8221; as set forth in the 2023 Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company&#8217;s operating budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The 2023 Loan was initially recognized at fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="Narr_PnEnFo7B2E2HOqAGsWkCJw">21.2</ix:nonFraction>&#160;million and subsequently recognized at the amortized cost net of debt issuance costs and debt discount of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="Narr_326xVe81RUOs3UKB6JsFBQ">3.8</ix:nonFraction> million. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_MIv8wWRsbkmUV0mdcTFmZQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="Narr_dvjTNJBX-0-11bP-wYED1Q"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_PC5IfPM4Q02DNCet-1_Lag" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="Narr_sRJxXQt9HkmuWs9CXCabLw">2.4</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_MIv8wWRsbkmUV0mdcTFmZQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_Bp0E0bBKCU2QKz42K7Z5yg"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_PC5IfPM4Q02DNCet-1_Lag" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_APsHVa_5VkS7EbDWZSCYVA">0.9</ix:nonFraction></ix:nonFraction> million debt issuance costs and debt discount for the years ended December 31, 2024 and 2023, respectively, using the effective interest method. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_lYQF9icj1kuOL4xigHQzKw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_hf1nM8V8tkuqFZ8Sy-DH8A">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_KilvybAjfU2MMseKFQN_pA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_AGd3Q0DjYEahakcWuOtW0g">2.6</ix:nonFraction> million of accrued interest expense for the years ended December 31, 2024 and 2023, respectively.<span style="font-size:12pt;"> </span>The 2023 Loan&#8217;s annual effective interest rate was&#160;<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_PC5IfPM4Q02DNCet-1_Lag" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_77ajYYb8REaEGcFfe90dMw">48.76</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_MIv8wWRsbkmUV0mdcTFmZQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_ZBFnnZDciEOK0P9lbk_ThA">27.31</ix:nonFraction>% as of December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 4, 2024, the Company entered into the 2024 Credit Agreement for the 2024 Loan in an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_1ION6vt6DE6RXRAGx714fg">35.0</ix:nonFraction> million. The 2024 Loan bears interest at an annual rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_GOQs5tFOTU2c6bS_6VdmxA">14.0</ix:nonFraction>% and was scheduled to mature on June 4, 2025. On March 12, 2025, the Company executed an amendment to the 2024 Credit Agreement which, among other </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_jcfJFcae8E6K5rLovLbGJg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">things, extended the 2024 Loan maturity date to March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2024 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the 2024 Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2024 Loan was initially recognized at cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_f9eAsRheyESHAWOFBNsXdw">35.0</ix:nonFraction> million net of debt issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="Narr_Rp_LTcKI4k24buheEuaL3A">0.1</ix:nonFraction> million, and subsequently is recognized at the amortized cost. Debt issuance costs are amortized using the effective interest method to interest expense over the term of the 2024 Loan. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_RBZa_N6QqUyQ2oiWdEiprQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_JIlBgHFzvEmBdAqS5aIrDg">4.1</ix:nonFraction> million of accrued interest expense for the year ended December 31, 2024. The 2024 Loan&#8217;s annual effective interest rate was <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_yDGzdtvVaUO97cPKrXci4g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_7JUPL6wPI0WIcF3nHYm8OA">14.25</ix:nonFraction>% as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2023 Credit Agreement and the 2024 Credit Agreement contain customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The 2023 Credit Agreement and the 2024 Credit Agreement also include customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#8220;material adverse effect&#8221; as set forth in the 2023 Credit Agreement and the 2024 Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company&#8217;s operating budget.</p></ix:continuation><a id="Tc_AojGQ1AGVkqrLUhO109AkA_1_0"></a><a id="Tc_iL6KdG2bOU6btLJbT30GcQ_1_2"></a><a id="Tc_nN-EEDqcekCCSt5inCc2uw_1_5"></a><a id="Tc_G85Hkhig9U2YIb4A3wyZOg_2_2"></a><a id="Tc_YofDUWBi5E-NGaDla52lng_3_2"></a><a id="Tc_dREr9VExUUiKGnODmdqHSA_4_2"></a><a id="Tc_9CtkOb7aC0C3W1loWKGnkw_5_2"></a><a id="Tc_VROOsaV2p0GRmbULG0M8Rg_6_2"></a><a id="Tc_msfOGTekz0Sq8XUH0LbNxg_7_2"></a><a id="Tc_4DxrbQ6xb0SFrUQ6eA7kKQ_8_2"></a><a id="Tc_xODFlKxyLEe8IvJakoKyYQ_8_5"></a><a id="Tc_b22drqmHBU2cXvioUYSl4w_1_2"></a><a id="Tc_jigKREWcfUC-JwNyJMn_1A_1_4"></a><a id="Tc_Hw6rvKnidkqpv09Q7vHQKw_2_0"></a><a id="Tc_33buzM6qO0S__aLFu7Mcuw_3_0"></a><a id="Tc_tYwyNPWJaUuakoXbbDdkxQ_4_0"></a><a id="Tc_K5iQYbwDTUe-NuwJR_QgpA_5_0"></a><a id="Tc_YO0egx0uzke9P8UJki1gBQ_6_0"></a><a id="Tc_M7y8iVw8pUGoRX-b6a87Mg_7_0"></a><a id="Tc_f5KKjLGQuEOvXFwQHGw2Gw_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_C6xpdjcXB0SHEa7Q5tomLg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Stockholders&#8217; Deficit</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 outstanding warrants to purchase shares of Common Stock were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_NLkra1S72UaqNskI2PKFRw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_HyGAt6Tz506l49Pgkj8m9Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_eJfFVYo5hUyxR3DrlCGAWA_2_0">993,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_HyGAt6Tz506l49Pgkj8m9Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_E6uiya2TvUuBD8IBJd38cg_2_3">2.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_8Mc5U6Ck2kSpYcYSeCnQCw" format="ixt:date-monthname-day-year-en" name="armp:WarrantExpirationDate" id="Tc_5jfSofCX4kyIkSyLkk5VYA_2_5">February 11, 2025</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_aSkSzFIw6E6liVy6b0eAVw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_4_hDhL-YMkChpidECZEpgQ_3_0">7,717,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_aSkSzFIw6E6liVy6b0eAVw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_QWx29fl2lkSY4LBo0hyToA_3_3">2.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_feeJaveXFUOGLBI6iniUiQ" format="ixt:date-monthname-day-year-en" name="armp:WarrantExpirationDate" id="Tc_lvu6w4C8p0aGpMBzCh45uA_3_5">March 27, 2025</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_Q2agB-03uEiWytISvo0nvQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_cPl-RJvFU0WaqQ3M8zlY9w_4_0">1,867,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_Q2agB-03uEiWytISvo0nvQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_FuOtzTvNbU2OYuIRW6w_eQ_4_3">3.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_xBgryqct0E6Zilf1u8G51w" format="ixt:date-monthname-day-year-en" name="armp:WarrantExpirationDate" id="Tc_aewpxdZtV06HDwINqUcP3A_4_5">January 26, 2026</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_8NNrUB98dU6nTV1W_TbZEA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_b49kcgosu0CV68H_G5cc1g_5_0">4,285,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_8NNrUB98dU6nTV1W_TbZEA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_Rfitt6gEZEubnTrrVfmdTg_5_3">3.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_JaLL1iLkyEWNgBPCSHnOpw" format="ixt:date-monthname-day-year-en" name="armp:WarrantExpirationDate" id="Tc_8zw8gbWAdEaNPnNAiKCo_A_5_5">March 16, 2026</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_5m5du7ROvkCWkfWMS1O-UQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_PX-t53rtOE2CXucOWhSVPw_6_0">1,807,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_5m5du7ROvkCWkfWMS1O-UQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_OSIvH6s2MEa0FVmPPsf6LA_6_3">5.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_3r_X0vA_sEGsQPwLdkNqvg" format="ixt:date-monthname-day-year-en" name="armp:WarrantExpirationDate" id="Tc_kfGYQJaT6U283IJD_VUkvg_6_5">February 8, 2027</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_8bhT2JsMPEe7lORCk6OgzQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_zbywI_3jc0WIaFKxjtKcxQ_7_0">2,692,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_8bhT2JsMPEe7lORCk6OgzQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_5OmQkFicsEaH36dYTPhRvw_7_3">5.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_zidty5XO8kGAipBpidYvpg" format="ixt:date-monthname-day-year-en" name="armp:WarrantExpirationDate" id="Tc_BnGer8CoEEmDjFjh4wVo1w_7_5">March 30, 2027</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_7LahToXqk0ys3Hj-vViLrQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_sA5SPaNn1EqXzichwaj06g_8_0">1,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_7LahToXqk0ys3Hj-vViLrQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_m7O4_lTZuESgFPEJQKFCwA_8_3">1,680.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">None</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_cCA08GkY0USMgYhKgN3wyA_9_0">19,365,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shares Reserved for Future Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024 and 2023, the Company had reserved shares of its Common Stock for future issuance as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="Tb_qT_VQ5P75k-Kb63Mnvzdjg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_d6ueP-qASUSIXQDKa4c3hQ_2_2">3,755,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_QDTO1p3mikiXT4FYVV8Euw_2_4">3,165,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GhrtbpfWc0emjiaVORy1SQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_S41RfMYTI06qa71LaGfPvg_3_2">220,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_f61X9uE-N0-LLpqFLPWZgw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_9UIBDxP7TUaMl75AvX4G6Q_3_4">200,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable under the Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" scale="0" id="Tc_IP6tYOsmmUiphG_-2QHBQA_4_2">11,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" scale="0" id="Tc_VTG3SqRHs0ugM7lLwBJGsg_4_4">9,748</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_PdC_SAUxUUK65xSOy8LXqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_UAYVR2LHNk-VHa64iC1NVw_5_2">3,405,908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_NG9OliLZLUqYSqXnApcGDA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_V5yMO9UE4k2E7CRnsWA2MQ_5_4">2,368,160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Qr8oMQHZDkCJy6pIqDlF6A_6_2">19,365,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_zPZ7oPy7skqQR5jSE3MWdg_6_4">19,365,847</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of the Convertible Loan<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="armp:SharesIssuableUponConversionOfConvertibleDebt" scale="0" id="Tc_WCj9OgfVr0OxaXTa6PRL2g_7_2">22,899,123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="armp:SharesIssuableUponConversionOfConvertibleDebt" scale="0" id="Tc_Q403LX5BpkWAJ_xWHobjhQ_7_4">21,293,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_3YYU0oyFvkeaGk2H0K1ehw_8_2">49,658,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_N9A57T2EMUy7pPfFARXKEA_8_4">46,402,832</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_aWA5hjxLdEGxM8y6hwhEmQ_1_2"></a><a id="Tc_6AdFfDCSLk-c_Vt0mBthhw_2_7"></a><a id="Tc_piEmwlQVs0aOlX1P-yXsAg_3_7"></a><a id="Tc_zsAFXu3ppUmwsGOI2vq3kw_4_4"></a><a id="Tc_BqQ-3_Cnf0OpjIVFGg_LUg_4_7"></a><a id="Tc_OXT3mDy0wEa_q0caYVx4SA_5_4"></a><a id="Tc_9pE1X9r4UEalE4rFBoKXsQ_5_7"></a><a id="Tc_8ZVq79JH6EGzKRmhcrLu7g_5_9"></a><a id="Tc_xAehQNDfCEGidnDs4Aldag_6_4"></a><a id="Tc_VvJIAemcpECdKLVXX0XuUQ_6_7"></a><a id="Tc_Vjk0h4BGnka9QxYXNFHTFw_6_9"></a><a id="Tc_m5qKrNDTukOL2_89hKJOLA_7_2"></a><a id="Tc_pHJ40NP24EGSrUaR_JJIiw_7_4"></a><a id="Tc_dDvEQBGb5keWireBnsfFqw_7_7"></a><a id="Tc_wX1UWftfjUuTD9I4ANdy0A_7_9"></a><a id="Tc_dq5qUIYRUUqKqSeRfMzbyA_8_0"></a><a id="Tc_3QxwjABvUEKmPMmW4MGf3Q_8_4"></a><a id="Tc_T4gP23ZuTEOHEhEo4p3omg_8_9"></a><a id="Tc_czmR1jucDkCIpV9jbmCGfQ_9_0"></a><a id="Tc_yES56spkJ0qkDu-eUCdRpQ_9_4"></a><a id="Tc_ihsFsXYH7EeGpd7bNCyL4g_9_9"></a><a id="Tc_cQS45BvhRUGfrQACyDhwAQ_9_10"></a><a id="Tc_2_R9oa9ovkuLf8r07oKETw_10_0"></a><a id="Tc_A8tJ0O-UmUuJMnz43JclBA_10_4"></a><a id="Tc_uVWc9pFYJ0ORHDRIrCyR-A_10_9"></a><a id="Tc_f7X61xrtyUefkvzhDOMSuA_11_0"></a><a id="Tc_pR5TPHiY00W10ndqcwqTwg_11_4"></a><a id="Tc_oX1x0lumRE-1CqavDSOd4g_11_9"></a><a id="Tc_6Ds28CpSUEeUvYAtI0VLDA_12_0"></a><a id="Tc_orasOB07OUyuzi3-TicoKw_12_4"></a><a id="Tc_dL2sG9GC4Uawii5WfqB_Fg_12_9"></a><a id="Tc_kGVyICLsv02X5okcYf_bew_13_0"></a><a id="Tc_AucfGvtcjEifaw74DDJxaw_13_4"></a><a id="Tc_qegrc4XN_06ZrLVJhjovkQ_13_9"></a><a id="Tc_C0LHjZGRjkC2WCPGxNOqZg_14_0"></a><a id="Tc_Bf73GHBXSEiIdwNC34nagg_14_4"></a><a id="Tc_tF7oBBzHBE-SpcB5Jyi98A_14_9"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_bqmixcDEukiIOHjImhIs_Q" continuedAt="Tb_bqmixcDEukiIOHjImhIs_Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Award Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#8217;s Board of Directors to its employees, directors and officers and to consultants. The term of the options granted is <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_2hEBCqxGoUqgVYfZknvwGA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_mR7V3nvpk0mbaJJpbjQ4Wg">ten years</ix:nonNumeric>, the exercise price is the Company&#8217;s closing price at the date of grant and the vesting period is usually <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_pJH1VOMu10ubY-ejaciVcg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_EJSYts7Hbk-SHSai9_7RPw">four years</ix:nonNumeric><span style="white-space:pre-wrap;">. The Company also granted RSUs under the 2016 Plan that vest over four years.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2016 Plan, the number of shares authorized for issuance is automatically increased by a number equal to <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_T8FTsTcprUy8rKzW-XC3EQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_t99IKEx2e0ieDkIKELKpUw">5</ix:nonFraction>% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Board of Directors annually beginning from January 1, 2017 until January 1, 2026. As of December 31, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_gGZqSnGwP0OUUcdXV26XfA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_F0eByqI8ikCk86AZSi3eXg">3,405,908</ix:nonFraction> shares available for issuance under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has issued restricted stock awards RSAs under certain legacy option plans that generally vested&#160;<span style="-sec-ix-hidden:Hidden_GZ0DQ00E2US7iMhH9yvSLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span>&#160;to&#160;<ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ct6tmhYJKEW98JUYWA7SAA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_XtrcRWqbd0mZ3ShsN8Xjmg">four years</ix:nonNumeric>&#160;based on service conditions. As of December 31, 2024, all RSAs were fully vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to its 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), the Company may grant or provide for the grant of rights to purchase shares of its Common Stock. The number of shares of its Common Stock reserved for issuance under the ESPP will automatically increase on January 1st of each calendar year by the lesser of <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_umBgF7ml2kCrfw0hSCQoPA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_PFxoYKykrE-6NzAIRkJecw">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s Common Stock outstanding on December 31st of the preceding calendar year and <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_umBgF7ml2kCrfw0hSCQoPA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Wak6mW8WzkW6gredLHZszA">30,000</ix:nonFraction> shares, subject to the ability of the Company&#8217;s Board of Directors to take action to reduce the size of the increase in any given year. There were <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_umBgF7ml2kCrfw0hSCQoPA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_uqmp2IRhE0-Cb10CoYvxDg">no</ix:nonFraction> awards issued under ESPP. As of December 31, 2024, the Company had reserved <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_htSBHjfgekaRHkMRgsz1MA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_L_bTNjSQWEy7kJdXGoFJ1w">11,890</ix:nonFraction> shares for future grants under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock option activities during the year ended December 31, 2024 are presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_hXjxA_r8yEyLk92wVR82ng" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ns6aM8sIPkqWQvJJjcLxvA_8_2">3,165,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_DO7dUpYh9EyU14h_LSRb3g_8_5">5.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_laK1aiNPoEWHj4VO-fQFVg_8_7"> 5.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_P5-58jxFDUCwu_s_XPmVPg_8_10">429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_CoNRiZaN306_yTHu7tQufA_9_2">1,859,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_AzJkoQ4glkeKye2ukms7_A_9_5">3.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_N6Y_azJF2UOkHuAFVwwOcw_10_2">37,282</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_CbHHUt-B4EmuRC4YAgTMXQ_10_5">3.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_wApoDjddEEybXayZEsnRgg_10_10">24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_uuecdkr4xUu-qozsUm2t3Q_11_2">1,231,023</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_POl9kGAlI0-RGHokZmJBqw_11_5">6.48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="armp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" scale="3" id="Tc_IkEvSVxmG0a6lmtfPG9Z2A_11_10">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_HH6PmZs6g0K2LPTZS2oMAw_12_2">3,755,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_7k7M2_sKZkGqKJT3FuDFzA_12_5">3.74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_8Dq0VqQbQ0iqu3Raa5UNXQ_12_7"> 7.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_wvAb8jtJHk6LgpJirqktuQ_12_10">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_UapZtwhwtEefipJazKJ14g_13_2">3,755,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_OVo3uKyOCEyWshNAnTgf9Q_13_5">3.74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_lx6OScVEUk6MzjRLIzITyQ_13_7"> 7.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="Tc_jJ5LIIlUMEGGF4DQrukMzw_13_10">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_qQL3dAO29UO_56wtRR0EDw_14_2">2,059,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_o9aetpSGrkKKLekAn_jvoA_14_5">4.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_oYN9acMUxkGZXhBacHcH-w_14_7"> 6.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_i28QqSKdLUiXKhg6VZzEgA_14_10">2</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The aggregate intrinsic value of options at December 31, 2024 is based on the Company&#8217;s closing stock price on that date of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H4YKiME1IEWZOdKMpzlX5Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_LbzwcVnV0EGNh590hHtcmw">1.85</ix:nonFraction> per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The weighted average grant date fair value of the options granted during 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Q_ubz7HACkmqcD61UyDA_g">2.54</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_0b00-Uj7kk-JO8ylsi77og">1.97</ix:nonFraction>, respectively. The fair value of vested options during the year ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_9URlzS8es0e-WsZZNeNjkg">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_gHD2Y30-dUu-TPEExeXniA">5.1</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_OeyxbUBgD0CEPs2o8t0XHA_1_4"></a><a id="Tc_AK7J_X8-Ukuq1D5pA59mIQ_2_4"></a><a id="Tc_z9ibX1R_skyHCTKWcxD83Q_3_2"></a><a id="Tc_dWCUFIB_70-w4UuOygAOBQ_3_4"></a><a id="Tc_5fcmLgukfU60FtB17F3mpw_4_0"></a><a id="Tc_25a-bvHWkE-x6w6ubkEphg_4_4"></a><a id="Tc_-r8D3J8gz0KtYm-t1nV1mw_5_0"></a><a id="Tc_9B-CwhJcy0OuZwAqGwxD_w_5_4"></a><a id="Tc_IbpLjpWG0ECdt95Z0UEY8A_6_0"></a><a id="Tc_NHCoEihtTUeuldUm6B6Srw_6_4"></a><a id="Tc_0lUvIqP_tkO1vcOT4eODPg_7_0"></a><a id="Tc_a7qcVFz2eEaYsucT5ftT9g_7_4"></a><a id="Tc_-ODSE3yUeEW7xfPZoADsFw_8_0"></a><a id="Tc__I7WDV7jgkqECF5rOfg-dA_8_4"></a><a id="Tc_4mtne1zqlEG7Rs3v5gjhsw_1_2"></a><a id="Tc_SEFK5s56I0yz3A8Ex-SZ_g_2_2"></a><a id="Tc_l8L6aMnb60WXJl_lIHmT6g_2_4"></a><a id="Tc_jsDAGGoX4k27MaFwIMBBUA_3_0"></a><a id="Tc_GOUXNaAEFkSmTxgPn8WLqQ_3_2"></a><a id="Tc_Ea_O0X-3cEWp7ZxEhTMiiQ_3_4"></a><a id="Tc_C3gYm8GkJ02tGcO_g6PH2g_4_0"></a><a id="Tc_TWH9_E0_Hkq4FwZdRBk93Q_4_2"></a><a id="Tc_qWdSwuPIiUiLDUjZOj_XXA_4_4"></a><a id="Tc_997Alwb420qARJcSx7kYOA_5_0"></a><a id="Tc_PCSrXMIsAUSn5E4E3BOQOQ_5_2"></a><a id="Tc_jrTUfDiCtU6dhbBMFmI_5w_5_4"></a><a id="Tc_hBR5pxxEVEeLTzM88R8jSA_6_0"></a><a id="_a25ffef3_4327_4072_b538_587b6e978748"></a><a id="Tc_WiyDCcOfZke7t_CbaZ7tHg_1_2"></a><a id="Tc_NAmuEeeKD0GJS9p7rR-FkA_2_2"></a><a id="Tc_WLQzE_z5cE6KaiNUKuUxOQ_2_5"></a><a id="Tc_vXuJYaKWQk2pALXqyMW9hg_3_0"></a><a id="Tc_rD6ydytrdECgpJ7dpo_-YQ_3_2"></a><a id="Tc_vhXOPW9L40WtzI5RwwhC4w_3_5"></a><a id="Tc_DiHzEIpWV0GIvgB0HbXjiw_4_0"></a><a id="Tc_3opL8LwpiEKKzfIexIw_Eg_5_0"></a><a id="Tc_mLly2pEUxEqOpf7McLrPKw_5_2"></a><a id="Tc_tA-a81O2jUWjQDe9f23a-g_5_5"></a><ix:continuation id="Tb_bqmixcDEukiIOHjImhIs_Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Restricted stock awards and restricted stock unit award activities during the year ended December 31, 2024 are presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" id="Tb_I25ARXKqtkCpTVIrYoar5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Avg</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_QarzicNc2kSX3wxOAwoMJQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_jAlY8U4_fkOQU1qsK09FEw_4_2">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_QarzicNc2kSX3wxOAwoMJQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_of4iUZUu4ESDfk06cq2hnQ_4_5">2.39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_Rs--Uwsaq0q-aQnVgUf-TQ_5_2">90,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_SsZ-MmQ0dUGwNotBmcUChA_5_5">3.38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_DvPk4JBs6EyHT-slP0qRcw_6_2">50,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_pmPKX4r8vk6rA4jCydTTvw_6_5">2.39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_lkUzZTzUSU2dFmwW6_nM0Q_7_2">20,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_ehncxShDF0GED6TPHJl0WA_7_5">3.38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_8COWQsEZn0Wg7V4VXWyPng" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_iPrvVd67-Uy0YmIdCqCIoQ_8_2">220,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_8COWQsEZn0Wg7V4VXWyPng" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_X3phwCNHOk-MUgUt-PAXMw_8_5">2.73</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024, there was $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_fPQyy0HqVEuM1qduhYrYog" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_LoZmz-gc7U2q6GSj9pOkqw">2.6</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options and restricted stock units, which the Company expects to recognize over the weighted average remaining period of approximately <span style="-sec-ix-hidden:Hidden_gW2qZueRtk-fdI8-fDXRnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.9 years</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.35pt;margin:0pt;"><span style="font-size:7.35pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The assumptions used to estimate the options fair value were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_lriccVU6_0yBsVLI-a0HzA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:45.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_BApNk3n5XkaOpKH7-XGdqA" decimals="4" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Narr_qfxXW8OyCUi2Iu3DYfIDKg">3.54</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_zHKl8i7YW0il2SCbZ7ryrg" decimals="4" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Narr_NvnPKkjIfEywtiDEIVYCag">4.25</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_-pt2ThZhNkOtRzUxqgRzhw" decimals="4" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Narr_Bs4caSxcMk6F-o0Yzn9__A">3.54</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_wDGF0KSNh0K-ZOkC4X8kag" decimals="4" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Narr_QH45xhZzU0GnYHsTia3Fwg">5.54</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_QpjN1Yhr0kCLe-x9CNhQkg" decimals="3" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Narr_3tOswYdcKUqP8op0pzQFmg">89.40</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_jVO24CHTHEOIiO_ECZ6bIw" decimals="3" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Narr_e8DwmTnF5E6Kkmb2aeKg0w">92.50</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_AE_R59dgSk29aRazyIh1uA" decimals="4" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Narr_-i9YXIG_iEuktUZS2dfDfw">75.40</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember__ONSzE2PXE2dEzLteS-O5Q" decimals="4" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Narr_N-9afHvZYEahJFBu_MzIXg">116.96</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_83vS_dwiSkeNsun5DvCQfA" decimals="1" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr__ZXqZgQOfUGvr4xCnQJQQg">5.1</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_q3iOc3hnOEKxXvfRp4uwBQ" decimals="1" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_FFg8S_ub-0291Jt9gwpLnQ">7.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Tan8oCbxTkeDxokgzAn6TQ" decimals="1" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_BfVJWrAchUGwkdKL2tyk3g">0.1</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Dse-ebonN0CTM7ve3ne8_Q" decimals="1" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_J4lHwdb9O0qmufX1kJoyRg">7.0</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ieNv8UfQuEu5yQKAxjemyA" decimals="0" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Tc_knuoNMezx0K5X6rdj5UaIQ_6_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ubx-9CKJgEWrllUJcWFg7w" decimals="0" format="ixt:num-dot-decimal" name="armp:EquitySecuritiesMeasurementInput" scale="-2" id="Tc_mio73663r06ETYpa5l34hA_6_4">0</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_7zC6flZUvkCe83zN_4zY9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The tables below summarize the total stock-based compensation expense (reversal) included in the Company&#8217;s consolidated statements of operations for the periods presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_VsjRlp7C00anCfXheLFsLQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hZUWlQV0NUG2uPPU-Be_Zg_3_3">663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Wnx7hledV0aiY-1RCUHzlg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aRg27MRtCU6BcgcALQ4MWQ_3_6">1,013</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_YbvCeB-0yEWBm5JrBGygig" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_rU6kSkHkMkOoR_qIJxldbg_4_3">2,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kBMGpinIEUqZVp0QH9Oswg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_6GRpOBhLmE2kW0pvc5y3jw_4_6">75</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hK_IpP7shUGPM8w9kYWb0w_5_3">2,893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_JR-ClKNarUWH6eo_9rc8bw_5_6">938</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 8pt 0pt 0pt;"><span style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_ac7c0bc8_d329_4b2e_bcf6_7b2aded6afe5"></a><a id="Tc_9_jahqSCakym46tFjHx4mQ_1_2"></a><a id="Tc_nAjDR9Y0m0-__mzMPqYssg_2_2"></a><a id="Tc_O3kU0z5_S0CZe3wKUEbepg_2_5"></a><a id="Tc_F0nhbSd92kKLq1RMx4j5pQ_3_0"></a><a id="Tc_A_ACNquC8UCm2Zi6_RQ_JQ_3_2"></a><a id="Tc_U-EGgf1Xhk6Zwn5y5eg2gg_3_5"></a><a id="Tc_ej7cbPYy5UqKybZE-_gjKw_4_0"></a><a id="Tc_FvR34OKFSUCD0buJHcSzYQ_5_0"></a><a id="Tc_l8IWzwyoqUmU8Tw_YwkR4A_5_2"></a><a id="Tc__enF_KyLxEWWbvnA-nHJ8A_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_6wiN-QcwkUqlxekYcdLKJQ" continuedAt="Tb_6wiN-QcwkUqlxekYcdLKJQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Income Taxes</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_lD8ThfXp006ik6qzbaB4VQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Loss before income taxes consisted of the following components (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style="height:7.25pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_dS0y-VY8SkGAlvKNxNudCg_3_3">18,020</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_Xu9dSTM0iUagzY7xGYFmPw_3_6">68,182</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_I6tf8mFtm0eTroWlXakkow_4_3">896</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_9dmKT1WPpEarDQTW8tsNmQ_4_6">863</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_x_VsB4xge0eo3Ae7HdSUBw_5_3">18,916</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_EvnstW3bvUyLtZLgk-Z2bQ_5_6">69,045</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_mIcSFOZ_GkuCSYnQjsqd3Q" continuedAt="Tb_mIcSFOZ_GkuCSYnQjsqd3Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_93feb81e_e9f7_43b4_a217_ce93452f0d22"></a><a id="Tc_Oy61bu6qxEq5W6YmG-JV2g_1_2"></a><a id="Tc_v3Bd2WNsdkam8CGd1ouCug_2_2"></a><a id="Tc_kynVh-xbMkuT4s49B9RrMA_2_5"></a><a id="Tc_Xo9RT_suZ0O1mazG8uFeLg_3_0"></a><a id="Tc_fgo7xa_xnE6U4f_yDUSEAA_4_0"></a><a id="Tc_VjDlUFMCEE68h0-KeI6Baw_4_2"></a><a id="Tc_LrzYzvRQzEGk98kcGQ34pA_4_5"></a><a id="Tc_HKIU_MAXWEyL_P67c4Ifmg_5_0"></a><a id="Tc_onWnaUPet0-Tngd84xA7Dw_6_0"></a><a id="Tc_N5MK5EuzCkSmPHfY3SmW-w_7_0"></a><a id="Tc_eWeZiov_pUuEHGukNQHjrw_8_0"></a><a id="Tc_N5KRmAO95EGJ9kKF8E7jCw_9_0"></a><a id="Tc_2JV52ZTC3Uy2ztpoZeejBw_9_6"></a><a id="Tc_lkGPBKqUkkWJLaewAeTSjQ_10_0"></a><a id="Tc_rSXBWdUNQEOHLK0nDOtLsw_11_0"></a><a id="Tc_wILcTu7ULEuwfkLDn6qaEQ_12_0"></a><a id="Tc_i0kqm99IOk22_xacEVqWwg_13_0"></a><a id="Tc_wm0qwYsXckidBEOKNjOJ3g_15_0"></a><a id="Tc_AW91tG64lU-1XGQWFWZFzw_16_0"></a><a id="Tc_Y1i6itBhI0CzGPy1RoIShw_17_0"></a><a id="Tc_tv3S7vQUN0-Bi4iAldo2Ww_18_0"></a><a id="Tc_7q1fthOvNU2t2PV9Zc-H_w_18_6"></a><a id="Tc_M6ZWWaIeckGxXlQwJAMVRw_19_0"></a><a id="Tc_HBoHzdeHIEervjc37znAaQ_20_0"></a><a id="Tc_VmuanUqij0-twjZX4NL2eA_21_0"></a><a id="Tc_BV9auBtlckqpVRUdIYyZVA_21_2"></a><a id="Tc_BDAS9pbfmkmfw9GcYgjioA_21_5"></a><ix:continuation id="Tb_6wiN-QcwkUqlxekYcdLKJQ_cont1" continuedAt="Tb_6wiN-QcwkUqlxekYcdLKJQ_cont2"><ix:continuation id="Tb_mIcSFOZ_GkuCSYnQjsqd3Q_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_NFtJzGSgzU2Grev_LYw8cQ_4_3">53,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_5RqJptfdkkeK9jT-xHXufw_4_6">46,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_8lVs5IG4fkqWd54CF_l0tQ_5_3">24,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_Ru8iHUYb30W5J8MNJdOvBA_5_6">21,431</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_gJXyPSMz102ZW1sDKdi3MQ_6_3">1,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_ZemoTKzDB028pkGMhHTmWA_6_6">2,083</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_dE1dSspDNUq00t2ofjry3g_7_3">762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_I0kFQcMeuEKpVXAAS_hFgg_7_6">856</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease accounting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="armp:DeferredTaxAssetLeaseObligation" scale="3" id="Tc_13eweLS0mUyOM920m7Fz7A_8_3">13,505</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="armp:DeferredTaxAssetLeaseObligation" scale="3" id="Tc_PWm0tNgaH0aqRvJBkKNsKg_8_6">13,899</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="armp:DeferredTaxAssetsInterestExpenseCarryForwards" scale="3" id="Tc_mMsQO5vywES7C6_0T8AkHg_9_3">1,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_XZhOhxgQVEman76yiMf1tg_10_3">2,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_g4ZVdYeC6k2Plj6P6LT9ig_10_6">1,907</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets before valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_zjUfVF4NL0m15kNHiuwrOw_11_3">97,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_nhq4D3P8T0Oo3KSOKnsoig_11_6">86,767</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_o1vlDaQBOEG1nxBSjJ6FeQ_12_3">84,217</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_RsplwbL-VUqw9B4dpwnBxQ_12_6">75,166</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_ADz6KDPNmkeQyPS3jdt2ag_13_3">12,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_m_gEAkON2ky6nhKTd3627g_13_6">11,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="armp:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_aj3BhHAh9Ey4Hh1fNZAHTQ_16_3">10,763</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="armp:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_Rr7cXwERukqiJbQMr433xg_16_6">11,510</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="Tc_pCMWMuToukWzRR3NXebF6w_17_3">3,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="Tc_QfGZbXWzQU-Euts-yy6_xg_17_6">3,077</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Debt basis differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="armp:DeferredTaxLiabilitiesDebtBasisDifferences" scale="3" id="Tc_EgtU1kHeikGbBvSYs-27oQ_18_3">1,991</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="Tc_2sqAYNU3YE6Kf8shxOatOQ_19_3">141</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="Tc_HiGFfyNCxEe-TcOVT_yPAA_19_6">91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_KlzQjaa8NUKXfgN-DOJMeQ_20_3">15,972</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_RbkaKlX2OEuDWluGuEYl_A_20_6">14,678</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_RRnmgJAp8Emg2hWMOMS9aA_21_3">3,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_snDWGr34FUWPEpMf2FCVmA_21_6">3,077</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss carryforwards at December&#160;31, 2024 are $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6Y5SYi_BTUa8vlarva5peg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_Y48q8P8Xpk2CP-x3Q4ViVQ">195.3</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_iRtQVHneb02Vlx_hfCVCVQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_VM0BmrvdTUWSaPHkD181OQ">139.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_yrOpWPoZBU2cuEPXaihZtw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_eeIVtL0s50O0UWWhCnNNdA">12.0</ix:nonFraction> for federal, state and foreign income tax purposes, respectively. Federal and state net operating loss carryforwards are available to offset future taxable income, if any, and will begin to expire in 2026 and 2029, respectively. The federal net operating loss carryforwards generated after 2017 of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-5" format="ixt:num-dot-decimal" name="armp:OperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="Narr_oiqsr0yS3EyTOAjTNihLaA">140.8</ix:nonFraction> million will carryforward indefinitely and can be used to offset up to 80% of future annual taxable income. The Company's foreign net operating loss carryforwards do not expire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss carryforwards may be subject to a substantial annual limitation as a result of ownership changes that have occurred or could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit or eliminate the amount of net operating loss carryforwards that can be utilized to offset future taxable income. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. In general, an 'ownership change' as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an &#8216;ownership change&#8217; of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not undergone an ownership change analysis pursuant to Internal Revenue Code Section 382 as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.  Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of available evidence, including the Company's history of operating losses, management has determined that it is more likely than not that the Company&#8217;s net deferred tax assets will not be realized. Accordingly, a valuation allowance has been established by the Company to fully offset these net deferred tax assets. The Company increased its valuation allowance by approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_DObK1BX9kEiszGjnp5lY6g">9.1</ix:nonFraction> million during the year ending December 31, 2024:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_duc62bnKtEeVJAFsYGwpzA" continuedAt="Tb_duc62bnKtEeVJAFsYGwpzA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_V2JCFjV5SUmd-QC4TjVVww_1_2"></a><a id="Tc_0PAQuxPsf0GSlpv_gvDDjA_2_2"></a><a id="Tc_pORZ9sKQtEapX1dbl89yiQ_2_4"></a><a id="Tc_V-L_ACA5sUGCPAuX4YiuOQ_3_0"></a><a id="Tc_on39XmoyoUuXPAqQGvOJRw_3_3"></a><a id="Tc_1rfzCnQ28U231ylKiI7P7w_3_5"></a><a id="Tc_FQYcWPy1rUam_t6I9I4vOw_4_0"></a><a id="Tc_I_j0fKl1lUiSx_R1BO6EDg_5_0"></a><a id="Tc_4KFRcmeirkmAQ7LbVGQGzA_5_3"></a><a id="Tc_dQAQM9OJJkeJF07d4FnTSg_5_5"></a><a id="Tc_MqirZJnh80mO25VHdkc0Ew_6_0"></a><a id="Tc_D3gwkyL-mUiVuco8RYA-7g_6_3"></a><a id="Tc_twqiO7NNFUKRnIJlCsWmdg_6_5"></a><a id="Tc_0AqtTJKgZE2asRhyYBlTZw_7_0"></a><a id="Tc_TK7RSKEa4kWpw9M4aOGiRA_7_3"></a><a id="Tc_Vu0ooff72EyxNxZaAYUiMQ_7_5"></a><a id="Tc_W1w5AFm790aClxncwO956A_8_0"></a><a id="Tc_AtP30EvrmEC3_PqY_-g-rw_8_3"></a><a id="Tc_e8-y6y6iwkOTRsx4pcnX3w_8_5"></a><a id="Tc_dWHUTbiqkkKZI4b005zR_w_9_0"></a><a id="Tc_TPeydXuzXkK37azG1NzMqA_9_3"></a><a id="Tc_RZpW_Mi3aES1_rd6HnU-Cw_9_5"></a><a id="Tc_mnDm9Ja12EmhW3K9IM9FoA_10_0"></a><a id="Tc_L-6kX_3rCEW4sXisMsNBiw_10_3"></a><a id="Tc_-5Mx9I6T5kC_zdRqd22-ug_10_5"></a><a id="Tc_VTJJz8egzUC3Jb_J5RTdjA_11_0"></a><a id="Tc_Jtt0gFAnaUK0ZFCy16VQww_11_3"></a><a id="Tc_xVlFlzuF4Em7g4JH_ICfmQ_11_5"></a><a id="Tc_jJbs5OLUZ0qSeU759vWhXA_12_0"></a><a id="Tc_SaGZb06XskWlYoWMr5-M6w_12_3"></a><a id="Tc_orNYIS8oQ0Gjn9l90TqqYQ_12_5"></a><ix:continuation id="Tb_6wiN-QcwkUqlxekYcdLKJQ_cont2"><ix:continuation id="Tb_duc62bnKtEeVJAFsYGwpzA_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_Y6gwwRwCeESGeg6uqS4VsQ_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_7CVmcWtXEUSvQb6nFwsZEA_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments for tax effects of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State income taxes, net of federal tax</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_YQyzZTRfR0yB4t250KR9LQ_5_2">9.6</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_o8ls7GtxZkS9-UBuWucm_A_5_4">2.9</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_aUGtvzY5cUGgCoWw-cxgBw_6_2">3.7</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_vUdZy3Qs1ki7zJnkh7EPIw_6_4">1.6</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-deductible debt items</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="3" format="ixt:num-dot-decimal" name="armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent" scale="-2" id="Tc_XRYg0x4_CE6dyzl4x8yFTA_7_2">25.3</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="3" format="ixt:num-dot-decimal" name="armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent" sign="-" scale="-2" id="Tc_cYa_TpKAq0eD5ReE53inyg_7_4">7.8</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_JMfFLCefX0aSwe4EKM5bfg_8_2">49.7</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_J2uiaFwjcUunuRrCZcNhHQ_8_4">9.3</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_rnVaioqYYUyKiTUL5J9Igw_9_2">0.5</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_U4NzhceCs0iKBYOXOWPDJg_9_4">3.3</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Return to provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="3" format="ixt:num-dot-decimal" name="armp:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" sign="-" scale="-2" id="Tc_WuW-D1rTwEyY4gLJVdNexw_10_2">1.6</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="3" format="ixt:num-dot-decimal" name="armp:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" sign="-" scale="-2" id="Tc_7oSdk0UYzU2d33UBfVZ3zg_10_4">0.7</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Permanent differences and other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_gGeHUHr1tE6Wjk5N8cqKCw_11_2">1.4</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_OU5J5ZWLu02-H8Pl8iPSVA_11_4">1.2</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_sxx6L-6QnU2va4-xf_qPug_12_2">0.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_yjSfoxdMdUyr4IL80wickA_12_4">0.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction, state of California and certain foreign jurisdictions. As of December 31, 2024, the Company is no longer subject to U.S. federal income tax examinations for tax years ended on or before December 31, 2020 or to California state income tax examinations for tax years ended on or before December 31, 2019. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses or tax credits were generated and carried forward, and make adjustments up to the amount of the net operating loss or credit carryforward.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_cDcnA2oB40qAVqOu3acTTA"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_4pZB6rpT4EmVCzDCNXMzVg">no</ix:nonFraction></ix:nonFraction>t have a liability for unrecognized tax benefits at December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s policy is to classify interest and penalties on uncertain tax positions as a component of tax expense. As of December&#160;31, 2024 and 2023, the Company has <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="6" id="Narr__-dAHyWpfUWyvMW1Pu6KIg"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="6" id="Narr_7oA2rZGRrkCHSvY3aBQiXg">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes have not been provided for undistributed earnings of the Company&#8217;s consolidated foreign subsidiary because the parent entity would not be required to include the distribution into income as the amount would be tax free.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Tax Cuts and Jobs Act subjects a U.S. stockholder to tax on GILTI earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740 No. 5. Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election either to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_oJcZ_C_y-0uEAwnfzaZ73g" continuedAt="Tb_oJcZ_C_y-0uEAwnfzaZ73g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA, with the lease term through December 31, 2031. Annual base rent is from $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_lvqDhuhNuUSizIHbky_dog" decimals="-5" format="ixt:num-dot-decimal" name="armp:OperatingLeaseBaseAnnual" scale="6" id="Narr_Bl5t4-HrmESdgQYB82DW1w">1.9</ix:nonFraction> million and increases by <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="2" format="ixt:num-dot-decimal" name="armp:AnnualIncreaseInRentPercentage" scale="-2" id="Narr_ceeVlkGGbkSg8UKKZus7kA">3</ix:nonFraction>% annually and will be $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XXu-NcK_bkaDqHPx0csY9A" decimals="-5" format="ixt:num-dot-decimal" name="armp:OperatingLeaseBaseAnnual" scale="6" id="Narr_V936j_0x_UuxNT-HYL6GgQ">2.5</ix:nonFraction> million by the end of the term. The Company also maintains an irrevocable letter of credit in connection with this lease, which had a balance of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_r5Xr-teAaUaiHHiDICZQPw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="Narr_gNIz5kR6yUSjquB6vR8jOg">0.5</ix:nonFraction> million as of December 31, 2024 and is reducing <ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_12_31_2024_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_r5Xr-teAaUaiHHiDICZQPw" decimals="2" format="ixt:num-dot-decimal" name="armp:AnnualReductionOfStandbyLetterOfCredit" scale="-2" id="Narr_WycWm04BoUau9xll5l-PBA">20</ix:nonFraction>% annually through the end of the lease term<span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the &#8220;2021 Lease&#8221;). The 2021 Lease payment start date was May 1, 2022 and the total lease term is for <ix:nonNumeric contextRef="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="Narr_8lCaBG9rHkKq7zk2sONtxw">16 years</ix:nonNumeric> and runs through 2038. Monthly rent for 2022 and 2023 was fully or partially abated while the lessor and the Company completed planned tenant improvements to the facility. Base monthly rent is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw" decimals="-5" format="ixt:num-dot-decimal" name="armp:BaseAnnualRentToBePaidYearThree" scale="6" id="Narr_f7D6abN2n0iXZWc8ca2gTg">0.3</ix:nonFraction> million in 2024. The Company was responsible for construction costs over the tenant improvements allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw" decimals="-5" format="ixt:num-dot-decimal" name="armp:AllowanceForTenantImprovementsReceivable" scale="6" id="Narr_nKyQ2BbV0kelt7Ic5pFM8Q">7.2</ix:nonFraction> million. The construction was completed as of December 31, 2024, and the Company received the </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_62072325_f91c_46c2_8c74_647672f0b308"></a><a id="Tc_lgVBRM6EK06xuku53dO_9w_1_2"></a><a id="Tc_XVycRPLyik2rHraNHEwbjg_2_2"></a><a id="Tc_R9GYu0o3nUWyMWDA-C2F1g_3_0"></a><a id="Tc_iD88mTOAHkGcPfxxRZnnHA_3_2"></a><a id="Tc_INcTsm9SgEuIlZbXNSKpCA_4_0"></a><a id="Tc_KeMou7gkS0yPtolFye7PjQ_5_0"></a><a id="Tc_IuPhp6P8QkKcLbjcuBLX0Q_6_0"></a><a id="Tc_8aEyjbCvS0W5Nb5qiOgFrA_7_0"></a><a id="Tc_GvcHQXQNPUK4qvkdd31bYg_8_0"></a><a id="Tc_PJkF4nhPa0qEIkPes1ddsw_9_0"></a><a id="Tc_Vi8duis9j0uvRlAFAEOWrw_10_0"></a><a id="Tc_mUQywf9XkEWfJx0D-Ja_PA_11_0"></a><a id="Tc_1SWiNROB-k6mlsygZ28Vrg_12_0"></a><a id="Tc_IbsWtXTE4EWt9bgdLyW3sQ_13_0"></a><a id="Tc_MDc-fcy_x02YGaJzhSXZlQ_13_2"></a><a id="Tc_XdScupYdyEWd5Y3PkUL2Jg_1_2"></a><a id="Tc_dNfCudlAfkKIARSLK0IwCQ_2_3"></a><a id="Tc_6BBmq2pC6k2Ogz57iUo37w_2_5"></a><a id="Tc_ceLHMqhabkKS5qojdjQryQ_3_0"></a><a id="Tc_dIiEEwuJ9kq4hhX59zTYqA_4_0"></a><a id="Tc_6EF1ESkvnUyLI_UqcmDeLw_4_2"></a><a id="Tc_FRtdcNG4XkSTrDXPco_s-A_4_5"></a><a id="Tc_9_219QdrxEG1Afu8q1Cc5Q_1_3"></a><a id="Tc_Rrzow05KaUi7Ndy-IhoJ-w_1_6"></a><a id="Tc_WdymO8RLJU6hdRFKETEiiQ_2_0"></a><a id="Tc_iL56NmVbYEG6ostUCncKXA_3_0"></a><ix:continuation id="Tb_oJcZ_C_y-0uEAwnfzaZ73g_cont1" continuedAt="Tb_oJcZ_C_y-0uEAwnfzaZ73g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">full allowance. Out-of-pocket expenses to be incurred by the Company were considered noncash lease payments, and included in the lease liability and right-of-use asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">In connection with the execution of the 2021 Lease, the Company delivered an irrevocable standby letter of credit in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="Narr_rEoIXen-s0qh2XTWtzjzXA">5.0</ix:nonFraction> million to the landlord in 2022.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_PUy04orVEkeamaN9Haq8-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future minimum annual lease payments under the Company&#8217;s noncancelable operating leases as of December&#160;31, 2024, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_BQYsFjYvtkim9mr4IoHfSQ_3_3">4,716</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_7iAj3jgTo0-fRbQNTMfkrA_4_3">5,293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_-KJdrYoH6kOkngJNc9Mrjg_5_3">5,452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_YVxQc7FAEkamDfunfEQR5g_6_3">5,616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_MnWnfQCJ_UqGeY_hTELI4A_7_3">5,784</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_iBCxE5dA9kSKX7JvPDIFCQ_8_3">37,996</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_yZpO9N8sWkCqw5EW9VIHZw_9_3">64,857</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: amount representing interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_J6EyhHIgS06Cj0xDrEBr2A_10_3">32,732</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of operating lease obligations </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_bgHFCEIBuEOtFt1IflqEGw_11_3">32,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_uN6v24FpWkygxzhqwbuYVw_12_3">4,431</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noncurrent operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_FvQ__iGWbkihhqm4DXRJrQ_13_3">27,694</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#222222;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Operating lease expenses were $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_Htt806vxDU-UtcdZ5sa3qQ">8.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_e-UL90Yz4EOSEcYxzxwVbA">7.4</ix:nonFraction> million for the years ended December 31, 2024 and 2023, respectively. Variable costs related to operating expenses and taxes, which are recognized as incurred, were $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:VariableLeasePayment" scale="6" id="Narr_K5asiLOq-0aFm_5PV09BKA">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:VariableLeasePayment" scale="6" id="Narr_1W2ye1-8x0mK5VlQWFir2A">1.0</ix:nonFraction> million for the years ended December 31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:LeaseCostTableTextBlock" id="Group_3_V2AQYjmUWJ6580uNCxVA" continuedAt="Group_3_V2AQYjmUWJ6580uNCxVA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes supplemental cash flow information related to the Company&#8217;s operating leases for the years ended December 31, 2024 and 2023 (in thousands):</p></ix:nonNumeric><ix:continuation id="Group_3_V2AQYjmUWJ6580uNCxVA_2" continuedAt="Group_3_V2AQYjmUWJ6580uNCxVA_3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:72.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_ppWh325-0kagClTIQ8hrUw_4_3">9,010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_j2M5b7WLsE-kcDefiofgqA_4_6">18,839</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company&#8217;s operating leases as of December 31, 2024 and 2023:</p><ix:continuation id="Group_3_V2AQYjmUWJ6580uNCxVA_3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term, years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_B7cDwQYwYEmmWnZC0SrOrg_2_3">11.74</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.8pt;text-align:right;text-indent:-0.8pt;margin:0pt 0pt 0pt -2pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_BUGsvz-EEUi0wExLUQCFFA_2_6">12.79</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate, %</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_phmgxM_ilUqz-ChYI0AajA_3_3">13.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_JhKSBNBVhkWoGenPc14Aqw_3_6">13.9</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#8217;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#8217;s reputation and business. The Company is currently not a party to any legal proceedings, </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_oJcZ_C_y-0uEAwnfzaZ73g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on its consolidated results of operations or financial position.</p></ix:continuation><a id="_e2b9e906_addc_47d1_85ab_c3f70781dbbe"></a><a id="_e2b9e906_addc_47d1_85ab_c3f70781dbbe_2"></a><a id="_e2b9e906_addc_47d1_85ab_c3f70781dbbe_3"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="armp:AwardTextBlock" id="Tb_a8CvShU-5k-jD48xA6Zvtw" continuedAt="Tb_a8CvShU-5k-jD48xA6Zvtw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Grants and Awards </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MTEC Grant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2020, the Company entered into an agreement (the &#8220;MTEC Agreement&#8221;) with MTEC, pursuant to which the Company received a $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_6_15_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_2_29PgfsbkCQszk3gpXeEQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAwardAmount" scale="6" id="Narr_f8PxUNU9qE-GUJu_I2cIcg">15.0</ix:nonFraction> million&#160;award and entered into a multi-year program administered by the DoD through MTEC and managed by the Naval Medical Research Command (&#8220;NMRC&#8221;) &#8211; Naval Advanced Medical Development (&#8220;NAMD&#8221;) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. <span style="background:#ffffff;">On September 29, 2022, the MTEC Agreement was modified to increase the total award by </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_9_29_2022_To_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_V-g9tOqDXE2fXuEN9aCnWA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAssetIncreaseCurrent" scale="6" id="Narr_TyPocBydxUmcwjwr3c1l5Q">1.3</ix:nonFraction></span><span style="background:#ffffff;">&#160;million to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_e8KlhRKgsU2__dqtJNLl0Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAwardAmount" scale="6" id="Narr_YGglFY7e40GyhV9o8JdG_Q">16.3</ix:nonFraction></span><span style="background:#ffffff;">&#160;million and extend the term into the third quarter of 2024. </span>In July 2024, the MTEC Agreement was modified to <span style="-sec-ix-hidden:Hidden_jN3anHbpa0isGOdK9gp3IA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase</span></span> the total award by $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_f3OfRucBq0qiXxxXxag-WQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAssetIncreaseCurrent" scale="6" id="Narr_svuU-YuB-EaISSjXRYoZZQ">5.3</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_XpvWEZpmi0eXkPlF_gpoDw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAwardAmount" scale="6" id="Narr_7KraMHh-m0eXEoUYyUUjEA">21.6</ix:nonFraction> million and extend the term into the third quarter of 2025. The Company is using the award to partially fund a Phase&#160;1b/2a, randomized, double-blind, placebo-controlled, dose escalation clinical study of the Company&#8217;s therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;<i style="font-style:italic;">S. aureus</i>&#160;bacteremia infections. The MTEC Agreement specifies that the award will be paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the money received is not refundable to MTEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MTEC Agreement is effective through August 15, 2025.&#160;The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue in the statement of operations when related costs are incurred. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_kA-sXj9xmUyv5HjdSnfDDQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAmount" scale="6" id="Narr_xuxzWjFEUU2_sK3mw0AVAA">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_6QVF5TJnNUu6xhAL_qid-w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAmount" scale="6" id="Narr_5e7SkLdyzEu_v1StVMNVvg">4.5</ix:nonFraction> million in grant revenue from the MTEC Agreement during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_ISHRxxWU70-yPTo0clBZbA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="6" id="Narr_Y6uSvkq-oEukouehnQszFA">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_AUoppBe8TkmxEisCXjCy5A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="6" id="Narr_YIAnl2FGcE2vVX_AbMip0Q">1.5</ix:nonFraction>&#160;million as awards receivable from MTEC, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CFF Therapeutics Development Award</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 13, 2020, the Company entered into an award agreement (the &#8220;Award Agreement&#8221;) with Cystic Fibrosis Foundation (&#8220;CFF&#8221;), pursuant to which the Company received a Therapeutics Development Award of up to $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_3_13_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_HJ-pxCwh90SIPJv_UoUV2w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAwardAmount" scale="6" id="Narr_51y6nJYqPUmDMfk3wPXQtQ">5.0</ix:nonFraction> million (the &#8220;CFF Award&#8221;). The CFF Award was used to fund a portion of the Company&#8217;s Phase 1b/2a clinical trial of the&#160;<i style="font-style:italic;">Pseudomonas aeruginosa </i>(&#8220;<i style="font-style:italic;">P. aeruginosa</i>&#8221;)<i style="font-style:italic;"> </i>phage candidate, AP-PA02, as a treatment for Pseudomonas airway infections in people with cystic fibrosis (&#8220;CF&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The first payment under the Award Agreement, in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_gXm3SotZZkifgZITvucSLg" decimals="-5" format="ixt:num-dot-decimal" name="armp:ProceedsFromGovernmentGrants" scale="6" id="Narr_hpwEA6Jt1EOfNuE2KK5vbQ">1.0</ix:nonFraction> million, became due upon signing the Award Agreement and was received in April 2020. The remainder of the CFF Award was payable to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement. The total amount of the CFF award was recognized through December 2023 and no additional payments are expected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Award Agreement), for a period of <ix:nonNumeric contextRef="Duration_3_13_2020_To_3_13_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_kfgQS3Y8DEmi378_OnwJhA" format="ixt-sec:durwordsen" name="armp:AwardAgreementInterruptionPeriod" id="Narr_nDiVxGgrF02mkVWZhDAzVA">360 days</ix:nonNumeric> (an &#8220;Interruption&#8221;) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_a8CvShU-5k-jD48xA6Zvtw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the Product for use in treating infections in CF patients (the &#8220;CF Field&#8221;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span></span>The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company&#8217;s material failure to achieve certain development milestones. The Company&#8217;s payment obligations survive the termination of the Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the CFF Award is in the scope of ASC 808. Accordingly, as discussed in Note 3, &#8220;<i style="font-style:italic;">Significant Accounting Policies&#8221;</i>, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. During year ended December 31, 2024 and 2023, the Company recognized <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_47SSxi3ckE-kheHf6e3v9A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GovernmentAssistanceAmount" scale="6" id="Narr_3VOrraB8WUuuQAR1C9mbnQ">zero</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_6TQEKKE2Ck6FoFOmzAl5OQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GovernmentAssistanceAmount" scale="6" id="Narr_QzalmkjByEKIrL8btERZ_w">0.3</ix:nonFraction> million as credits to research and development expenses related to the CFF Award, respectively. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_KR2jf0F8k0mJv0-v2n8img" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Employee Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s employees participate in an employee retirement plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986, as amended. All of the Company&#8217;s employees who meet minimum eligibility requirements are eligible to participate in the plan. The Company did match contributions of $<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_Mt6MWNR9mk-R5GmC0tgu6A"><ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_CGFSeQGNdEm18utgEW-a2A">0.2</ix:nonFraction></ix:nonFraction> million to the 401(k)&#160;plan for the&#160;years ended December 31, 2024 and 2023.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_1TQ2J93gHEG6CeMyoCOErA" continuedAt="Tb_1TQ2J93gHEG6CeMyoCOErA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Segment Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">The Company operates and manages its business as </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_segment_sNn8LuEmwE69rUms--yKEA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_1ZrkB-fawkKT2UDKjXh_4w"><ix:nonFraction unitRef="Unit_Standard_segment_sNn8LuEmwE69rUms--yKEA" contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_P_x5LLx78UiMdclKPuIZ-w">one</ix:nonFraction></ix:nonFraction></span><span style="background:#ffffff;"> reportable operating segment, which is the business of developing a pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;). The Company&#8217;s CODM is its Chief Executive Officer, who reviews financial information on an aggregate basis for </span>purposes of assessing performance, making operating decisions, <span style="background:#ffffff;">allocating resources and evaluating financial performance. The long-lived assets of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_u_Te-bqUOEC1eghs9nZXfA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="Narr_k-Nh4Q9gBEGOgn93J7C31w">14.0</ix:nonFraction></span><span style="background:#ffffff;"> million, which represents </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_u_Te-bqUOEC1eghs9nZXfA" decimals="3" format="ixt:num-dot-decimal" name="armp:PercentageOfLongLivedAssetsInGeographicalLocation" scale="-2" id="Narr_lhs1XDSyIkaeOg2llOVAHQ">99.3</ix:nonFraction>%</span><span style="background:#ffffff;"> of the Company&#8217;s total long-lived assets, are maintained in the United States.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table includes certain segment information for the years ended December 31, 2024 and 2023. </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_7KfZSSu9vkKLnETwaNGWRQ" continuedAt="Tb_7KfZSSu9vkKLnETwaNGWRQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_sGueIeoCiESsYXw20zwj8A_1_2"></a><a id="Tc_IsTP2Vx7WEGYAvf-6P_29Q_2_2"></a><a id="Tc_5rl57nmt-UaPgNxCVydFTQ_2_5"></a><a id="Tc__eJoHdP97kCBXpx_Cfjulw_3_0"></a><a id="Tc_plSitUV1h0mN-Wr-NEgrTw_3_2"></a><a id="Tc_W2PjAs9ahEqJ838r8B1fgQ_3_5"></a><a id="Tc_LGrnXGNoAkGycU6qDYDKCg_4_0"></a><a id="Tc_bpd99aNZY0OZQb26ILhsTw_5_0"></a><a id="Tc_CuL7vwSKWUyd5f0E2VEvxg_6_0"></a><a id="Tc_L38RcBHWmU270ai5sA_mQA_7_0"></a><a id="Tc_PSVr4zBBcE2CJ2-zYyzing_8_0"></a><a id="Tc_CbMm0wLUpkWb75vrbgtyXA_9_0"></a><a id="Tc_J3si1cEpKEqqnlrK2xy4rQ_10_0"></a><a id="Tc_dDmpRZ1r5UChXJOIWBLtvw_11_0"></a><a id="Tc_8vgOxVwttkuSFOBUrzgHxg_12_0"></a><a id="Tc_Vdx1wwliNEu2Keuu89H83w_13_0"></a><a id="Tc_ELDw21vm4EqWYf3IsnYgdA_14_0"></a><a id="Tc_QSewtlH080iQ2Uj-FcBHcg_15_0"></a><a id="Tc_fKLWQGI5eU2Zc-0ot50BTA_16_0"></a><a id="Tc_mJ4uNHSBpkGBS3Lxzi5VYA_17_0"></a><a id="Tc_LUIiQjlQPECGP_T1M9YFxw_18_0"></a><a id="Tc_8KVxT31Mw02kPFGH-70Fyg_19_0"></a><a id="Tc_R93Qq3ARL06lQk0X4ASWSQ_20_0"></a><a id="Tc_x_AlWCeIe0uP_v-2cMdVpw_21_0"></a><a id="Tc_tpTrX_3sCEuGkR0vwgaowQ_22_0"></a><a id="Tc_GbLPdTPJgE2gbDRp8KtqDA_22_2"></a><a id="Tc_mTGgja2iUUCe_x4aUl3S9w_22_5"></a><ix:continuation id="Tb_1TQ2J93gHEG6CeMyoCOErA_cont1"><ix:continuation id="Tb_7KfZSSu9vkKLnETwaNGWRQ_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:37.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant revenue</b></p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_EKKLA25N1kCI4reyBhRg1Q_3_3">5,174</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_eSYA_ihpNk6yPBH32QZDBA_3_6">4,529</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses:</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-PA02: Non-Cystic Fibrosis Bronchiectasis</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_NonCysticFibrosisBronchiectasisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_Na4M3PweMUi2iIIsCkq_3Q" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpense" scale="3" id="Tc_ZaxlrltZuUaWvQCiHlKR9Q_6_3">6,840</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_NonCysticFibrosisBronchiectasisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_QTrcE4TKsUW11OtCkzUlvw" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpense" scale="3" id="Tc_WCkxPY9jbUaarOQxEQjTog_6_6">4,922</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-PA02: Cystic Fibrosis</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_CysticFibrosisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_-n5s3ugSiUWuw4UgnftWDw" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpense" scale="3" id="Tc_yp3MDJXowkucxTopIVTqvQ_7_3">236</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_CysticFibrosisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_DQ9wJoe1u0-IR7_CKaA1Cw" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpense" scale="3" id="Tc_j-hdJ_DrGUSYl0JedTlCjA_7_6">1,692</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-SA02: Bacteremia</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_BacteremiaMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_nENRXrCZwUmEuUIiI0n0aA" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpense" scale="3" id="Tc_EMnA5DpR50eAGoQo4nGkhg_8_3">4,177</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_BacteremiaMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_O6wXLenwPkqANS08n0zSCw" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpense" scale="3" id="Tc_seZjxHyHvUup4P9O2PHAVg_8_6">4,789</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-SA02Prosthetic Joint Infection</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_ProstheticJointInfectionMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_cMxrWzKqB0aDivLktL7xSw" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpense" scale="3" id="Tc_ISnBdoQhiE-Yvafq2BLSgA_9_3">35</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_ProstheticJointInfectionMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_v56oVy0tEEyLTBl6m8fpVg" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpense" scale="3" id="Tc_OFLNvOyGrEyhgidsf1Iuug_9_6">202</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Expenses not allocated by projects</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="armp:UnallocatedExternalResearchAndDevelopmentExpense" scale="3" id="Tc_uTOu-ivL10CLPk0FJmI4HQ_10_3">2,408</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="armp:UnallocatedExternalResearchAndDevelopmentExpense" scale="3" id="Tc_ZOtXsLh_IEyeqieYuqu5Hw_10_6">3,042</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Total external research and development expenses</span></p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpenseTotal" scale="3" id="Tc_WIbmnIPIN0GW1WrGb5A-pw_11_3">13,696</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="armp:ExternalResearchAndDevelopmentExpenseTotal" scale="3" id="Tc_CxXkcSdzW02o3Kj6q3Vjjg_11_6">14,647</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development personnel expenses</p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="armp:ResearchAndDevelopmentPersonnelExpense" scale="3" id="Tc_J59_SAy1g0-8SlWj9NZKCA_12_3">10,764</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="armp:ResearchAndDevelopmentPersonnelExpense" scale="3" id="Tc_a488KCnsnE2WfFq4BMDH4A_12_6">9,408</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other research and development expenses</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="Tc_CndyhQrlMkS9l5G9j4AXQw_13_3">9,966</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="Tc_2v68BsniSUOy33fiOSHffQ_13_6">9,715</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Total research and development expenses</span></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_pVZFVOGlaEWIqmPeBjCe4A_14_3">34,426</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_7LOG5u26EkaIEO3oXXa4DA_14_6">33,770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses:</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative personnel expenses</p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_scC7dwJP70mNrkXpT73Mxg_16_3">4,935</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_vjSWbTCyBke8vGs-vZo3FA_16_6">2,480</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other general and administrative expenses</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_vp7_QM0EMUGyquIHe9ra-A_17_3">8,249</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_JDQlBasb-0qQA930Byc7LA_17_6">9,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Total general and administrative expenses</span></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_Ziw4X9yiRE629_m9MQd80Q_18_3">13,184</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_jxS2NMGTv0ishk2fet6X8A_18_6">11,649</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses </p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_mmpMHSqZRk2Et6j-ER0bIA_19_3">47,610</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_hziixn8VEkSp5GPC2izKnw_19_6">45,419</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_okIJjMMwXkqQeXHhvo4EdA_20_3">42,436</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_roMO3npmLEanC4K2ndApgQ_20_6">40,890</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense), net</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_fA3eyl-eCEKidO3JbR0GEA_21_3">23,520</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_44jhj4ojd0uHpFmB8W4brA_21_6">28,155</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rIiO7spHO0OuiMFVEYW8iQ_22_3">18,916</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NtSH0aWr4E-_tgSwDeZK1Q_22_6">69,045</ix:nonFraction>)</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_0BcivYBHtU2ByozzzOOn3A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On March 12, 2025, the Company entered into the 2025 Credit Agreement for the 2025 Loan in an aggregate amount of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA" contextRef="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_P3eC552nM0O0213kQ4radg">10.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million.The 2025 Loan bears interest at an annual rate of&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ" contextRef="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_ImyRZEgPoEuOvqqhpW7LVw">14.0</ix:nonFraction>%</span><span style="background:#ffffff;"> and matures on March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2025 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Concurrently with the execution of the 2025 Credit Agreement, the Company entered into amendments to (i) the Convertible Loan and Convertible Credit Agreement, (ii) the 2023 Loan and 2023 Credit Agreement, and (iii) the 2024 Loan and 2024 Credit Agreement, which, among other things, extended the maturity date of the Convertible Loan, 2023 Loan and 2024 Loan, respectively, to March 12, 2026.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_05c12939_f60c_468b_8d75_3d6ad890289d"></a><a id="Item9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_663bb35a_550e_4fe6_831d_96e00981a36b"></a><a id="Item9AControlsAndProcedures"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A.&#160;&#160;&#160;CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We have established disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Senior Vice President, Finance and Principal Financial Officer), to allow timely decisions regarding required disclosure. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our management, under the supervision and with the participation of our Chief Executive Officer and our Senior Vice President, Finance and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Based on such evaluation, our Chief Executive Officer (principal executive officer) and our Senior Vice President, Finance and Principal Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15(d)&#160;-15(f)&#160;as a process designed by, or under the supervision of, our Chief Executive Officer and Senior Vice President, Finance and Principal Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013) (the &#8220;2013 Framework&#8221;). In adopting the 2013 Framework, management assessed the applicability of the principles within each component of internal control and determined whether or not they have been adequately addressed within the current system of internal control and adequately documented. Based on this assessment, management, under the supervision and with the participation of our Chief Executive Officer and Senior Vice President, Finance and Principal Financial Officer, concluded that, as of December&#160;31, 2024, our internal control over financial reporting was effective based on those criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Attestation Report of the Registered Public Accounting Firm</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">This Annual Report on Form&#160;10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. We were not required to have, nor have we, engaged our independent registered public accounting firm to perform an audit of internal control over financial reporting as we are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">There were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(f) or 15d-15(f) of the Exchange Act during our fourth fiscal quarter ended December&#160;31, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5f6285cc_80e4_48df_b489_4bd2229fe628"></a><a id="Item9BOTHERINFORMATION_104987"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;9B.&#160;&#160;OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trading Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_hNR7mqMn_UusHGZSh2vNfQ">N</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_H5Rf9LVLdEyJQKCS6hFVhQ">o</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_5BlzwmS_8UqzufBtkaJzEg">n</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_cTE77eauWkylA9mgkHYikA">e</ix:nonNumeric> of the Company&#8217;s directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company&#8217;s fiscal quarter ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d4b0b4a6_f3f9_4986_b4b9_a5af697c9d04"></a><a id="Item9CDISCLOSUREREGARDINGFOREIGNJURISDIC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">None. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3e4829fb_0462_43c5_9058_c4fa7611657c"></a><a id="PARTIII_156407"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10.&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this item will be contained in our definitive proxy statement on Schedule 14A to be filed with the Securities and Exchange Commission in connection with our 2025 annual meeting of stockholders (the &#8220;2025 Proxy Statement&#8221;), which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated in this report by reference. To the extent that we do not file the 2025 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 10.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have adopted a written code of business conduct and ethics (the &#8220;Code of Business Conduct&#8221;) that applies to all directors, officers and employees of Armata, including any principal executive officer, principal financial officer or principal accounting officer of Armata. The Code of Business Conduct is available on our internet website at www.armatapharma.com. If we ever were to amend or waive any provision of the Code of Business Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or any person performing similar functions, we intend to satisfy our disclosure obligations with respect to any such waiver or amendment by posting such information on our internet website set forth above rather than filing a Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has an&#160;<ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_zgLawxwJWkCALjy1AosmrQ">insider trading policy</ix:nonNumeric>&#160;governing the purchase, sale and other dispositions of the Company&#8217;s securities that applies to all Company personnel, including directors, officers, employees, and other covered persons. The Company also follows procedures for the repurchase of its securities. The Company believes that its insider trading policy and repurchase procedures are reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. A copy of the Company&#8217;s insider trading policy is filed as Exhibit 19.1 to this Form 10-K.</p><a id="_d59b31c7_4132_47e9_bb07_17427e7c46e7"></a><a id="Item11EXECUTIVECOMPENSATION_44857"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11.&#160;&#160;&#160;EXECUTIVE COMPENSATION </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"> The information required by this item is incorporated by reference from the information contained in the 2025 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2025 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 11.</p><a id="_Item_12._"></a><a id="_a674205f_6e69_4e68_b62b_f555c8067fb7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:43.2pt;text-indent:-43.2pt;margin:0pt 0pt 12pt 0pt;">Item&#160;12.&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The information required by this item is incorporated by reference from the information contained in the 2025 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2025 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 12.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8a3469f2_8d27_4630_9d29_ce69a65040bd"></a><a id="Item13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:43.2pt;text-indent:-43.2pt;margin:0pt 0pt 12pt 0pt;">Item&#160;13.&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The information required by this item is incorporated by reference from the information contained in the 2025 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2025 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 13.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_07995399_0e20_42d8_8d2c_da464ddf4a02"></a><a id="Item14PRINCIPALACCOUNTANTFEESANDSERVICES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;14.&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The information required by this item is incorporated by reference from the information contained in the 2025 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Report on Form 10-K. To the extent that we do not file the 2025 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 14.</p><a id="_1b5f88f1_4bc7_4582_8350_05d428b3d392"></a><a id="PARTIV_519682"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15EXHIBITS_865142"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15.&#160;&#160;&#160;EXHIBITS<span style="font-style:italic;">,</span> FINANCIAL STATEMENT SCHEDULES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(a)(1) Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our Financial Statements are listed in the &#8220;Index to Audited Consolidated Financial Statements&#8221; of Armata Pharmaceuticals, Inc. in Part II, Item 8 of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(a)(2) Financial Statement Schedules</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">All financial statement schedules have been omitted because they are not required, not applicable, or the required information is included in the consolidated financial statements or notes thereto included in Part II, Item 8 of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/><span style="font-style:italic;font-weight:bold;">(a)(3) Exhibits</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following exhibits are filed herewith or incorporated herein by reference:<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:3.25pt;"><td style="vertical-align:bottom;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:1.81%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Document</b></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420415066161/v421749_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Articles of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on November 16, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420417021763/v464998_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-37544), filed with the SEC on April 24, 2017</span></a>).</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420418058340/tv505699_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed on November 8, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420419025292/tv521048_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on May 10, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex35124c484.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the registrant (incorporated by reference to Exhibit 3.5 to the Quarterly Report on Form 10-Q (File No. 001-37544), filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.6</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420419025292/tv521048_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Merger, dated as of May 9, 2019 (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on May 10, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Articles of Incorporation of the registrant, dated as of December 10, 2019 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on December 11, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.8</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Amended and Restated Bylaws of the registrant (December 10, 2019) (incorporated herein by reference to Exhibit 3.2 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on December 11, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.9</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465920025375/tm2010968d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Amended and Restated Bylaws of the registrant (February 24, 2020) (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on February 26, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.10</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465920040578/tm2014179d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Articles of Incorporation of the Company (effective March 26, 2020) (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on March 30, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reference is made to Exhibits 3.1 through 3.8. </p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420417023433/v465550_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-217563), filed on May 1, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420415017285/v404997_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant issued to purchasers in March 2015 private placement (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 19, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex4-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant to Purchase Shares of Common Stock issued in connection with the Company&#8217;s acquisition of certain assets of Novolytics Limited in February 2016 (incorporated by reference to Exhibit 4.13 to the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 30, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.5</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420417023490/v465628_ex4-18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant to Purchase Common Stock issued to purchasers in May 2017 (incorporated by reference to Exhibit 4.18 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217169)).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000110465920008032/tm206157d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 29, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.7</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465921007895/tm214248d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated January 26, 2021, by and between the Company and Innoviva (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 27, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.8</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465921007895/tm214248d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 27, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Company&#8217;s securities registered under Section 12 of the Exchange Act.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465921007895/tm214248d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on February 11, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Targeted Genetics Corporation 2009 Stock Incentive Plan (incorporated by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">AmpliPhi Biosciences Corporation 2012 Stock Incentive Plan (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement under AmpliPhi Biosciences Corporation 2012 Stock Incentive Plan (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420414022834/v372120_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">AmpliPhi Biosciences Corporation 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.21 to the Company&#8217;s Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Grant Notice and Stock Option Agreement under AmpliPhi Biosciences Corporation 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 30, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420419030481/tv523249_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Armata Pharmaceuticals, Inc.  2016 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 99.1 to the registrant&#8217;s Registration Statement on Form S-8, filed with the SEC on June 10, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex109f4c5b2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Armata Pharmaceuticals, Inc.  2016 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.9 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex1010ab7df.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Armata Pharmaceuticals, Inc.  2016 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.10 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420416076070/v429155_ex99-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnity Agreement with the Company&#8217;s Directors and Executive Officers (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 19, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10<b style="font-weight:bold;">+</b></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420419025292/tv521048_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Director Appointment Letter (incorporated by reference to Exhibit 10.4 to the registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 10, 2019).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11*</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex10116c3c2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Research Collaboration and Option to License Agreement, effective as of May 24, 2017, by and between Synthetic Genomics, Inc. and Merck Sharp &amp; Dohme Corp. (incorporated herein by reference to Exhibit 10.11 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12*</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex10121c63f.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement, dated as of February 14, 2018, by and between C3J Therapeutics, Inc., Synthetic Genomics, Inc. and Synthetic Genomics Vaccines, Inc., as amended by Amendment to Asset Purchase Agreement, made and entered into as of December 20, 2018 (incorporated herein by reference to Exhibit 10.12 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465920020186/tm207916d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated February&#160;12, 2020, by and between the Registrant and&#160;Innoviva,&#160;Inc.&#160;(incorporated herein by reference to Exhibit&#160;4.1 to the Current Report on&#160;Form&#160;8-K&#160;(File No.&#160;001-37544), filed with the SEC on February&#160;13, 2020).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465921007895/tm214248d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated January&#160;26, 2021, by and between the Registrant and Innoviva Strategic Opportunities LLC (incorporated herein by reference to Exhibit&#160;10.3 to the Current Report on Form&#160;8-K (File No.&#160;001-37544), filed with the SEC on January&#160;27, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15*</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000155837020006601/armp-20200331ex101b108a8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement, dated as of March 10, 2020, by and between Armata Pharmaceuticals, Inc. and the Cystic Fibrosis Foundation (incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000921114/000110465921131905/tm2131430d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Registration Rights Agreement, dated October 28, 2021, by and among the Company, Innoviva, and CFF (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on October 29, 2021)</span></a><span style="background:#ffffff;">.</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000921114/000110465921133195/tm2131735d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Lease Agreement, dated October 28, 2021, by and between the Company and 5005 McConnell Avenue, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on November 2, 2021</span></a><span style="background:#ffffff;">).</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000155837020006601/armp-20200331ex103beba44.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Assignment and First Amendment of Office Lease, dated as of April 2020, by and among Armata Pharmaceuticals, Inc., C3 Jian, Inc. and Marina Business Center, LLC (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465922020354/tm226408d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Investor Rights Agreement, dated February 9, 2022, by and among the Company and Innoviva (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on February 11, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465922020354/tm226408d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Registration Rights Agreement, dated February 9, 2022, by and among the Company and Innoviva (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on February 11, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465922038851/tm2210607d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Advisory Agreement, dated March 28, 2022, between the Company and Mr. Martin (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 25, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/tm232848d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Secured Convertible Credit and Security Agreement, dated January 10, 2023 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 10, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923019627/tm236045d1_ex4-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated as of February 9, 2023, by and between the Company and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 4.21 to the Company&#8217;s Registration Statement on Form S-3, filed with the SEC on February 13, 2023)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/tm2321012d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Credit and Security Agreement, dated as of July 10, 2023, by and between the Company and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 11, 2023)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/tm2321012d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Security Convertible Credit and Security Agreement, dated as of July 10, 2023, by and between the Company and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 11, 2023)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/tm2321012d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter of Employment, by and between the Company and Dr. Deborah Birx (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 11, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.27+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000155837024003706/armp-20231231xex10d28.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated August 30, 2023, by and between the Company and Richard Rychlik (incorporated by reference to Exhibit 10.28 to the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 21, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.28</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924030475/tm247888d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Credit and Security Agreement, dated March 4, 2024, by and among the Company and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 4, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.29</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924030475/tm247888d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Credit and Security Agreement, dated March 4, 2024, by and among the Company and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 4, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.30</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924030475/tm247888d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Secured Convertible Credit and Security Agreement, dated March 4, 2024, by and among the Company and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 4, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.31+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924082637/tm2420145d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Letter Agreement by and between Mina Pastagia, M.D. and Armata Pharmaceuticals, Inc., dated as of September 22, 2020 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 25, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.32+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924082637/tm2420145d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated as of July 22, 2024, to that certain Employment Letter Agreement by and between Mina Pastagia, M.D. and Armata Pharmaceuticals, Inc., dated as of September 22, 2020 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 25, 2024).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.33+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924090153/tm2421653d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Letter Agreement, dated July 31, 2024, by and between Armata Pharmaceuticals, Inc. and David House (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on August 15, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.34+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924105853/tm2425499d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Confidential Separation and Release Agreement by and between Armata Pharmaceuticals, Inc. and Richard Rychlik dated as of September 30, 2024 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on October 3, 2024).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.35</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924119701/tm2428608d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Credit and Security Agreement, dated as of November&#160;12, 2024, by and among the Issuer,&#160;Innoviva Sub and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on November 15, 2024).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.36</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924119701/tm2428608d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Secured Convertible Credit and Security Agreement, dated as of November&#160;12, 2024, by and among the Issuer,&#160;Innoviva Sub and the other parties thereto (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on November 15, 2024).&#160;&#160;</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.37+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924125505/tm2430081d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Separation and Release Agreement, by and between Armata Pharmaceuticals,&#160;Inc. and Mina Pastagia, M.D., dated as of December&#160;2, 2024 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on December 4, 2024).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.38+</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex10d38.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Letter Agreement, dated June 1, 2024, by and between Armata Pharmaceuticals, Inc. and Pierre Kyme.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.39</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/tm258929d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Credit and Security Agreement, dated March 12, 2025, by and among the Company and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 12, 2025).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.40</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/tm258929d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Credit and Security Agreement, dated as of March 12, 2025, by and among the Issuer, Innoviva Sub and the other parties thereto (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 12, 2025).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.41</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/tm258929d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Credit and Security Agreement, dated as of March 12, 2025, by and among the Issuer, Innoviva Sub and the other parties thereto (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 12, 2025).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.42</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/tm258929d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Secured Convertible Credit and Security Agreement, dated March 12, 2025, by and among the Company and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 12, 2025).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19.1</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Armata Pharmaceuticals, Inc. Amended and Restated Insider Trading Policy and Guidelines with Respect to Certain Transaction in Securities, Effective as of December 16, 2024 and as Amended Through December 16, 2024.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Company.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.1</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#POWEROFATTORNEY_42904"><span style="font-style:normal;font-weight:normal;">Power of Attorney (contained on the signature page).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20241231xex97.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Armata Pharmaceuticals, Inc. Policy for the Recovery of Erroneously Awarded Compensation, adopted on October 2, 2023.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-weight:bold;">+&#160;&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan or arrangement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-weight:bold;">*&#160;&#160;&#160;&#160;&#160;Indicates that certain identified information in the exhibit has been omitted because it is both (i) not material, and (ii) would likely cause competitive harm if publicly disclosed.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0a3da774_9bb6_4ca4_bbe3_6318445d9bc5"></a><a id="Item16Form10KSummary_988645"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"> Item&#160;16.&#160;&#160;&#160;Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f903bc08_3df7_4d1a_a23f_b20ef388b361"></a><a id="SIGNATURES_275590"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARMATA PHARMACEUTICALS, INC. </p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 20, 2025</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Deborah Birx </p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Deborah Birx, M.D. </p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:78.62%;border:0;margin:30pt 11.03% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:11.03%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="POWEROFATTORNEY_42904"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES AND POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Deborah Birx, and David D. House, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K and to file the same, with all exhibits thereto and all documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or his or her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:31.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:31.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Deborah Birx </p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deborah Birx, M.D. </p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:16.3pt;"><td style="vertical-align:bottom;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David D. House</p></td><td style="vertical-align:bottom;width:3.11%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Principal Financial Officer</p></td><td style="vertical-align:bottom;width:3.11%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David D. House</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"/><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jules Haimovitz</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jules Haimovitz</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Odysseas D. Kostas, M.D</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Odysseas D. Kostas, M.D.</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robin Kramer </p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair of the Board of Directors</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robin Kramer </p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joseph M. Patti, Ph.D.</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joseph M. Patti, Ph.D.</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Todd C. Peterson, Ph.D.</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Todd C. Peterson, Ph.D.</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Sarah J. Schlesinger, M.D.</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 20, 2025</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sarah J. Schlesinger, M.D.</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.24%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:11.03%;margin-top:30pt;page-break-after:avoid;width:78.62%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>2
<FILENAME>armp-20241231xex4d9.htm
<DESCRIPTION>EX-4.9
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:12 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 4.9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF COMMON STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following description of our common stock, certain provisions of our articles of incorporation and bylaws, and certain provisions of Washington law are summaries. The following description is not complete and is subject to and qualified in its entirety by our articles of incorporation and bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of March 15, 2020, our articles of incorporation authorize us to issue 217,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The holders of our common stock are entitled to the following rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Voting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our common stock is entitled to one vote for each share held on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Liquidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the event of our liquidation, dissolution or winding-up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Rights and Preferences</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Holders of our common stock have no preemptive, conversion or subscription rights, and there is no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that are outstanding or that we may designate and issue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Provisions of Our Articles of Incorporation, Our Bylaws and Washington Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Provisions in our articles of incorporation, our bylaws and under Washington law may delay or prevent an acquisition of us or a change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. These provisions include a requirement for the vote of stockholders holding at least two-thirds of all shares of our issued and outstanding capital stock to approve certain changes to our articles of incorporation or certain business combinations. These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. Additionally, because we are incorporated in Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act, which, among other things, prohibits a target corporation, with certain exceptions, from engaging</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">in certain &#8220;significant business transactions&#8221; for a period of five&#160;years after the share acquisition by an &#8220;acquiring person&#8221;, unless (a)&#160;the significant business transaction is approved by a majority of the members of the target corporation&#8217;s board of directors prior to the time of acquisition or (b)&#160;the significant business transaction was approved by both the majority of the members of the target corporation&#8217;s board of directors and approved at a stockholder meeting by at least two-thirds of the outstanding voting shares (excluding the acquiring person&#8217;s shares or shares over which the acquiring person has voting control) at or subsequent to the acquiring person&#8217;s share acquisition. An &#8220;acquiring person&#8221; is defined as a person or group of persons which beneficially owns 10% or more of the voting securities of the target corporation. Such significant business transactions may include, among other things:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any merger or consolidation with, disposition of assets to, or issuance or redemption of stock to or from, the acquiring person;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any termination of 5% or more of the employees of the target corporation as a result of the acquiring person&#8217;s acquisition of 10% or more of the shares; or</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allowing the acquiring person to receive any disproportionate benefit as a stockholder.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">After the five-year period, a significant business transaction may take place as long as it complies with certain fair price provisions of the statute or is approved by a majority of the votes entitled to be counted within each voting group entitled to vote separately on the transaction (excluding the acquiring person&#8217;s shares or shares over which the acquiring person has voting control) at an annual or special meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NYSE American Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our common stock is listed on the NYSE American exchange under the symbol &#8220;ARMP.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 250 Royall Street, Canton, MA 02021.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>3
<FILENAME>armp-20241231xex10d38.htm
<DESCRIPTION>EX-10.38
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:12 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.38</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:1.04pt 0pt 0pt 0pt;"><a name="_Hlk143871127"></a><a name="_dxtcompanion_actionscomplete"></a><img src="armp-20241231xex10d38001.jpg" alt="Graphic" style="display:inline-block;height:71.35pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:124.9pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:1.04pt 0pt 0pt 0pt;">Armata Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;background:#ffffff;margin:0pt;"><font style="color:#202124;">5005 McConnell Ave</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><font style="color:#202124;">Los Angeles, California 90066</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;">June<font style="letter-spacing:-0.15pt;"> </font>1,<font style="letter-spacing:-0.05pt;"> </font>2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Dear<font style="letter-spacing:-0.2pt;"> </font>Pierre:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This letter agreement (this<font style="letter-spacing:-0.05pt;"> </font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) is intended to confirm our mutual agreement with respect to your continued employment with Armata Pharmaceuticals, Inc. <font style="letter-spacing:-2.85pt;"> </font>(the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;) from and after the date hereof.</p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">1.</font><b style="font-weight:bold;letter-spacing:-0.05pt;">Position</b><font style="letter-spacing:-0.05pt;">.</font><font style="letter-spacing:-0.65pt;"> </font>You agree to serve as the Company&#8217;s Chief Business Officer, reporting directly to the Chief<font style="letter-spacing:0.05pt;"> </font>Executive Officer of the Company. You agree to devote your full business time and attention to<font style="letter-spacing:0.05pt;"> </font>your work for the Company. Except upon the prior written consent of the Board of the Directors<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">of</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">the</font><font style="letter-spacing:-0.65pt;"> </font><font style="letter-spacing:-0.05pt;">Company</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">(the</font><font style="letter-spacing:-0.65pt;"> </font><font style="letter-spacing:-0.05pt;">&#8220;</font><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="letter-spacing:-0.05pt;">&#8221;),</font><font style="letter-spacing:-0.7pt;"> </font>you<font style="letter-spacing:-0.65pt;"> </font>will<font style="letter-spacing:-0.7pt;"> </font>not,<font style="letter-spacing:-0.65pt;"> </font>during<font style="letter-spacing:-0.65pt;"> </font>your<font style="letter-spacing:-0.6pt;"> </font>employment<font style="letter-spacing:-0.65pt;"> </font>with<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>Company,<font style="letter-spacing:-0.6pt;"> </font>(i)<font style="letter-spacing:-0.7pt;"> </font>accept<font style="letter-spacing:-2.85pt;"> </font>or maintain any other employment, or (ii)&#160;engage, directly or indirectly, in any other business<font style="letter-spacing:0.05pt;"> </font>activity<font style="letter-spacing:-0.5pt;"> </font>(whether<font style="letter-spacing:-0.5pt;"> </font>or<font style="letter-spacing:-0.5pt;"> </font>not<font style="letter-spacing:-0.5pt;"> </font>pursued<font style="letter-spacing:-0.5pt;"> </font>for<font style="letter-spacing:-0.5pt;"> </font>pecuniary<font style="letter-spacing:-0.5pt;"> </font>advantage)<font style="letter-spacing:-0.5pt;"> </font>that<font style="letter-spacing:-0.5pt;"> </font>might<font style="letter-spacing:-0.45pt;"> </font>interfere<font style="letter-spacing:-0.5pt;"> </font>with<font style="letter-spacing:-0.5pt;"> </font>your<font style="letter-spacing:-0.5pt;"> </font>duties<font style="letter-spacing:-0.5pt;"> </font>and<font style="letter-spacing:-2.9pt;"> </font>responsibilities<font style="letter-spacing:-0.05pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font>a Company<font style="letter-spacing:-0.05pt;"> </font>employee or<font style="letter-spacing:-0.05pt;"> </font>create<font style="letter-spacing:-0.05pt;"> </font>a conflict<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>interest<font style="letter-spacing:-0.05pt;"> </font>with<font style="letter-spacing:-0.1pt;"> </font>the Company.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">2.</font><b style="font-weight:bold;letter-spacing:-0.05pt;">Salary</b><font style="letter-spacing:-0.05pt;">.</font><font style="letter-spacing:-0.65pt;"> Y</font>our<font style="letter-spacing:-0.7pt;"> </font>base<font style="letter-spacing:-0.65pt;"> </font>salary<font style="letter-spacing:-0.7pt;"> </font>will<font style="letter-spacing:-0.7pt;"> </font>be<font style="letter-spacing:-0.65pt;"> </font>paid<font style="letter-spacing:-0.65pt;"> </font>at<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.7pt;"> </font>annualized <font style="letter-spacing:-2.9pt;"> </font>rate of $400,000 per year on the Company&#8217;s regular payroll dates and subject to approved<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">deductions</font><font style="letter-spacing:-0.75pt;"> </font>and<font style="letter-spacing:-0.75pt;"> </font>required<font style="letter-spacing:-0.75pt;"> </font>withholdings.<font style="letter-spacing:-0.7pt;"> </font>Your<font style="letter-spacing:-0.75pt;"> </font>salary<font style="letter-spacing:-0.65pt;"> </font>will<font style="letter-spacing:-0.75pt;"> </font>be<font style="letter-spacing:-0.7pt;"> </font>reviewed<font style="letter-spacing:-0.75pt;"> </font>from<font style="letter-spacing:-0.75pt;"> </font>time<font style="letter-spacing:-0.75pt;"> </font>to<font style="letter-spacing:-0.7pt;"> </font>time<font style="letter-spacing:-0.75pt;"> </font>by<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Board<font style="letter-spacing:-2.85pt;"> </font>or its compensation committee (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation Committee</u>&#8221;) and may be adjusted in the sole discretion of the Board or the Compensation<font style="letter-spacing:-0.05pt;"> C</font>ommittee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">3.</font><b style="font-weight:bold;">Bonus</b>.<font style="letter-spacing:0.05pt;"> </font>You will be eligible to earn an annual performance bonus based on achievement of Company performance objectives to be established by the Board or the Compensation Committee. &#160;Your annual target performance bonus for each fiscal year commencing with the 2024 fiscal year will be equal to fifty percent (50%), although the amount of any payment will be dependent upon actual performance as determined by the Board or the Compensation Committee. Generally, you must be employed by the Company through the date on which bonuses are paid in order to be eligible to receive a bonus. Your annual performance bonus, if any, shall be paid to you at the same time as annual bonuses are paid to other senior executives of the Company and, in all events, on or before March 15 of the year following the year to which it relates. Your annual target performance bonus percentage is subject to increase, but not decrease, from time to time in the discretion of the Board or the Compensation Committee. &#160;For the avoidance of doubt, the parties hereto acknowledge and agree that the Compensation Committee did not award any annual bonuses to executive officers of the Company in respect of the 2023 fiscal year and that you have no entitlement to any bonus in respect of employment during the 2023 fiscal year.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">4.</font><b style="font-weight:bold;">Equity Award</b>. You will be eligible to receive additional grants pursuant to the Company&#8217;s 2016 Equity Incentive Plan or any successor thereto (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u>&#8221;) commencing in 2025. &#160;The actual size of your annual grant in respect of any fiscal year shall be consistent with your position as the Company&#8217;s Chief Business Officer, and the terms and conditions of any equity award granted in any fiscal year will be determined in the sole discretion of the Board and/or the Compensation Committee. &#160;The parties hereto acknowledge and agree that the current intent of the Compensation Committee is to provide you with an equity award each fiscal year (commencing in 2025) with a grant date fair value of approximately $300,000, but nothing herein shall entitle you to any specific award or any specific terms or conditions in respect of any fiscal year. &#160;The parties also acknowledge and agree that you were granted options and restricted stock units pursuant to the Plan in March 2024 and that you are not entitled to any additional grant during the 2024 calendar year. &#160;Grants shall be made annually (commencing with the Company&#8217;s 2025 fiscal year) at the same time as grants of equity are made to other senior executives of the Company. &#160;Subject to your continued employment with the Company, any equity awards granted pursuant to this paragraph in respect of any fiscal year shall vest on the same basis as equity awards granted to other senior executives vest in respect of such fiscal year.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">5.</font><b style="font-weight:bold;">Benefits</b>. You will be eligible to participate in the benefits made<font style="letter-spacing:0.05pt;"> </font>generally available by the Company to its senior executives, in accordance with the benefit plans<font style="letter-spacing:0.05pt;"> </font>established by the Company, and as may be amended from time to time in the Company&#8217;s sole<font style="letter-spacing:0.05pt;"> </font>discretion.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0.05pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">6.</font><b style="font-weight:bold;">At-Will</b><b style="font-weight:bold;letter-spacing:-0.55pt;"> </b><b style="font-weight:bold;">Employment</b>.<font style="letter-spacing:-0.55pt;"> </font>The<font style="letter-spacing:-0.5pt;"> </font>Company<font style="letter-spacing:-0.6pt;"> </font>is<font style="letter-spacing:-0.5pt;"> </font>an<font style="letter-spacing:-0.6pt;"> </font>&#8220;at-will&#8221;<font style="letter-spacing:-0.55pt;"> </font>employer.<font style="letter-spacing:-0.55pt;"> </font>Accordingly,<font style="letter-spacing:-0.55pt;"> </font>either you or the Company may terminate the employment relationship at any time, with or without<font style="letter-spacing:0.05pt;"> </font>advance<font style="letter-spacing:-0.1pt;"> </font>notice,<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>without<font style="letter-spacing:-0.05pt;"> </font>cause.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">7.</font><b style="font-weight:bold;">Termination</b>. Upon any termination of your employment, you will be deemed to<font style="letter-spacing:0.05pt;"> </font>have<font style="letter-spacing:-0.2pt;"> </font>resigned,<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>you<font style="letter-spacing:-0.15pt;"> </font>hereby<font style="letter-spacing:-0.15pt;"> </font>resign,<font style="letter-spacing:-0.2pt;"> </font>from<font style="letter-spacing:-0.15pt;"> </font>all<font style="letter-spacing:-0.15pt;"> </font>offices<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>directorships,<font style="letter-spacing:-0.2pt;"> </font>if<font style="letter-spacing:-0.15pt;"> </font>any,<font style="letter-spacing:-0.15pt;"> </font>then<font style="letter-spacing:-0.15pt;"> </font>held by you<font style="letter-spacing:-0.15pt;"> </font>with<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-2.9pt;"> </font>Company or any subsidiary. In the event of termination of your employment with the Company,<font style="letter-spacing:0.05pt;"> </font>regardless<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>reasons<font style="letter-spacing:-0.7pt;"> </font>for<font style="letter-spacing:-0.7pt;"> </font>such<font style="letter-spacing:-0.75pt;"> </font>termination,<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Company<font style="letter-spacing:-0.75pt;"> </font>shall<font style="letter-spacing:-0.7pt;"> </font>pay<font style="letter-spacing:-0.75pt;"> </font>your<font style="letter-spacing:-0.65pt;"> </font>base<font style="letter-spacing:-0.7pt;"> </font>salary<font style="letter-spacing:-0.7pt;"> </font>and<font style="letter-spacing:-0.7pt;"> </font>accrued <font style="letter-spacing:-2.85pt;"> </font>but unused vacation up to and through the date of termination, less applicable payroll and tax<font style="letter-spacing:0.05pt;"> </font>withholdings<font style="letter-spacing:-0.1pt;"> </font>(the<font style="letter-spacing:-0.05pt;"> </font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:4.5pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">8.</font><b style="font-weight:bold;letter-spacing:-0.05pt;">Severance</b><font style="letter-spacing:-0.05pt;">.</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">You</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">shall</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">be</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">eligible</font><font style="letter-spacing:-0.65pt;"> </font><font style="letter-spacing:-0.05pt;">for</font><font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.7pt;"> </font>severance<font style="letter-spacing:-0.7pt;"> </font>benefits<font style="letter-spacing:-0.7pt;"> </font>described<font style="letter-spacing:-0.7pt;"> </font>in<font style="letter-spacing:-0.75pt;"> </font>this<font style="letter-spacing:-0.75pt;"> </font>Section</div><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font>In the event (i) the Company terminates your employment without Cause (as defined below and other than due to your death or disability), or (ii) you terminate your employment for Good Reason (as defined below), and provided in either case of (i) or (ii) such termination or resignation constitutes a &#8220;separation from service&#8221; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation from Service</u>&#8221;) (such termination or resignation, an &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Involuntary Termination</u>&#8221;), then, in addition to the Accrued Obligations, subject to your obligations below, you shall be entitled to receive an amount equal to twelve (12) months of your then current base salary (ignoring any decrease in base salary that forms the basis for Good Reason), less all applicable withholdings and deductions, paid on the schedule described below (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance Pay</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:4.5pt 0pt 12pt 0pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font>The Severance Pay is conditioned upon (i)&#160;your continuing to comply with<font style="letter-spacing:0.05pt;"> </font>your<font style="letter-spacing:-0.5pt;"> </font>obligations<font style="letter-spacing:-0.45pt;"> </font>under<font style="letter-spacing:-0.45pt;"> </font>your<font style="letter-spacing:-0.45pt;"> </font>PIIAs<font style="letter-spacing:-0.5pt;"> </font>(as<font style="letter-spacing:-0.45pt;"> </font>defined<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>Section<font style="letter-spacing:-0.5pt;">&#160;</font>11)<font style="letter-spacing:-0.45pt;"> </font>during<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>period<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>time<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>which<font style="letter-spacing:-0.45pt;"> </font>you <font style="letter-spacing:-2.9pt;"> </font>are </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:4.5pt 0pt 12pt 0pt;">receiving the Severance Pay; (ii) your delivering to the Company an executed separation<font style="letter-spacing:0.05pt;"> </font>agreement and general release of claims in favor of the Company, in a form<font style="letter-spacing:0.05pt;"> </font>provided by the Company, within the time period set forth therein, which becomes effective in<font style="letter-spacing:0.05pt;"> </font>accordance with its terms, which shall be no later than sixty (60) days following your Separation<font style="letter-spacing:0.05pt;"> </font>from Service. The Severance Pay will be paid in equal installments on the Company&#8217;s regular<font style="letter-spacing:0.05pt;"> </font>payroll schedule over the period outlined above following the date of your Separation from<font style="letter-spacing:0.05pt;"> </font>Service; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that no payments will be made prior to the sixtieth (60<sup style="font-size:9pt;vertical-align:top;">th</sup>) day<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.05pt;">following</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">your</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">Separation</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">from</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">Service.</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">On</font><font style="letter-spacing:-0.7pt;"> </font><font style="letter-spacing:-0.05pt;">the</font><font style="letter-spacing:-0.65pt;"> </font><font style="letter-spacing:-0.05pt;">sixtieth</font><font style="letter-spacing:-0.65pt;"> </font>(60<sup style="font-size:9pt;vertical-align:top;">th</sup>)<font style="letter-spacing:-0.7pt;"> </font>day<font style="letter-spacing:-0.7pt;"> </font>following<font style="letter-spacing:-0.7pt;"> </font>your<font style="letter-spacing:-0.7pt;"> </font>Separation<font style="letter-spacing:-0.7pt;"> </font>from<font style="letter-spacing:0.05pt;"> </font>Service,<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Company<font style="letter-spacing:-0.5pt;"> </font>will<font style="letter-spacing:-0.5pt;"> </font>pay<font style="letter-spacing:-0.5pt;"> </font>you<font style="letter-spacing:-0.5pt;"> </font>in<font style="letter-spacing:-0.5pt;"> </font>a<font style="letter-spacing:-0.5pt;"> </font>lump<font style="letter-spacing:-0.5pt;"> </font>sum<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>amount<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Severance<font style="letter-spacing:-0.5pt;"> </font>Pay<font style="letter-spacing:-0.5pt;"> </font>that<font style="letter-spacing:-0.5pt;"> </font>you<font style="letter-spacing:-0.5pt;"> </font>would have received on or prior to such date under the original schedule but for the delay while waiting<font style="letter-spacing:0.05pt;"> </font>for the sixtieth (60<sup style="font-size:9pt;vertical-align:top;">th</sup>) day, with the balance of the Severance Pay being paid as originally<font style="letter-spacing:0.05pt;"> </font>scheduled.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:4.5pt 0pt 12pt 0pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u>&#8221;<font style="letter-spacing:0.05pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>purposes<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>your<font style="letter-spacing:0.05pt;"> </font>Severance<font style="letter-spacing:0.05pt;"> </font>Pay<font style="letter-spacing:0.05pt;"> </font>means<font style="letter-spacing:0.05pt;"> </font>(i)<font style="letter-spacing:0.05pt;"> </font>your<font style="letter-spacing:0.05pt;"> </font>gross<font style="letter-spacing:0.05pt;"> </font>negligence or willful failure substantially to perform your duties and responsibilities to the<font style="letter-spacing:0.05pt;"> </font>Company or deliberate violation of a Company policy; (ii) your commission of any act of fraud,<font style="letter-spacing:0.05pt;"> </font>embezzlement<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>dishonesty<font style="letter-spacing:-0.25pt;"> </font>against<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Company<font style="letter-spacing:-0.25pt;"> </font>or<font style="letter-spacing:-0.3pt;"> </font>any<font style="letter-spacing:-0.25pt;"> </font>other<font style="letter-spacing:-0.25pt;"> </font>willful<font style="letter-spacing:-0.25pt;"> </font>misconduct<font style="letter-spacing:-0.25pt;"> </font>that<font style="letter-spacing:-0.25pt;"> </font>has<font style="letter-spacing:-0.25pt;"> </font>caused<font style="letter-spacing:-2.9pt;"> </font>or is reasonably expected to result in material injury to the Company; (iii) your unauthorized use<font style="letter-spacing:0.05pt;"> </font>or disclosure of any proprietary information or trade secrets of the Company or any other party to<font style="letter-spacing:-2.85pt;"> </font>whom you owe an obligation of nondisclosure as a result of your relationship with the Company;<font style="letter-spacing:-2.85pt;"> </font>or (iv) your willful breach of any of your obligations under any written agreement or covenant<font style="letter-spacing:0.05pt;"> </font>with<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>Company,<font style="letter-spacing:-0.6pt;"> </font>including<font style="letter-spacing:-0.55pt;"> </font>without<font style="letter-spacing:-0.6pt;"> </font>limitation<font style="letter-spacing:-0.6pt;"> </font>this<font style="letter-spacing:-0.6pt;"> </font>Agreement<font style="letter-spacing:-0.55pt;"> </font>and<font style="letter-spacing:-0.6pt;"> </font>your<font style="letter-spacing:-0.6pt;"> </font>PIIAs<font style="letter-spacing:-0.55pt;"> </font>(as<font style="letter-spacing:-0.6pt;"> </font>defined<font style="letter-spacing:-0.6pt;"> </font>below).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:4.5pt 0pt 0pt 0pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; for purposes of your Severance Pay means the occurrence<font style="letter-spacing:0.05pt;"> </font>at any time of any of the following without your prior written consent: (i) a material reduction in<font style="letter-spacing:0.05pt;"> </font>your authority, duties or responsibilities (other than a mere change in title following any merger<font style="letter-spacing:0.05pt;"> </font>or<font style="letter-spacing:-0.35pt;"> </font>consolidation<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Company<font style="letter-spacing:-0.3pt;"> </font>with<font style="letter-spacing:-0.35pt;"> </font>another<font style="letter-spacing:-0.35pt;"> </font>entity);<font style="letter-spacing:-0.4pt;"> </font>(ii)<font style="letter-spacing:-0.35pt;"> </font>a<font style="letter-spacing:-0.4pt;"> </font>material<font style="letter-spacing:-0.4pt;"> </font>reduction<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.35pt;"> </font>your<font style="letter-spacing:-0.4pt;"> </font>base<font style="letter-spacing:-0.4pt;"> </font>salary;<font style="letter-spacing:-2.9pt;"> </font>or<font style="letter-spacing:-0.5pt;"> </font>(iii)<font style="letter-spacing:-0.5pt;"> </font>any<font style="letter-spacing:-0.45pt;"> </font>willful<font style="letter-spacing:-0.5pt;"> </font>failure<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.5pt;"> </font>willful<font style="letter-spacing:-0.45pt;"> </font>breach<font style="letter-spacing:-0.55pt;"> </font>by<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Company<font style="letter-spacing:-0.45pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>any<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>its<font style="letter-spacing:-0.45pt;"> </font>material<font style="letter-spacing:-0.5pt;"> </font>obligations<font style="letter-spacing:-0.5pt;"> </font>under<font style="letter-spacing:-2.9pt;"> </font>this Agreement. For purposes of this subsection, no act, or failure to act, on the Company&#8217;s part<font style="letter-spacing:0.05pt;"> </font>shall be deemed &#8220;willful&#8221; unless done, or omitted to be done, by the Company not in good faith<font style="letter-spacing:0.05pt;"> </font>and without reasonable belief that the Company&#8217;s act, or failure to act, was in the best interest of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Company.<font style="letter-spacing:-0.5pt;"> </font>In<font style="letter-spacing:-0.5pt;"> </font>order<font style="letter-spacing:-0.45pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>terminate<font style="letter-spacing:-0.5pt;"> </font>your<font style="letter-spacing:-0.45pt;"> </font>employment<font style="letter-spacing:-0.5pt;"> </font>under<font style="letter-spacing:-0.5pt;"> </font>this<font style="letter-spacing:-0.45pt;"> </font>Agreement<font style="letter-spacing:-0.5pt;"> </font>for<font style="letter-spacing:-0.5pt;"> </font>Good<font style="letter-spacing:-0.45pt;"> </font>Reason,<font style="letter-spacing:-0.5pt;"> </font>you must (1) provide written notice to the Company within ninety (90) days of the first occurrence of<font style="letter-spacing:0.05pt;"> </font>the events described above, (2) allow the Company at least thirty (30) days from such receipt of<font style="letter-spacing:0.05pt;"> </font>such written notice to cure such event, and (3) if such event is not reasonably cured within such<font style="letter-spacing:0.05pt;"> </font>period, resign from all position you then hold with the Company effective not later than the one-<font style="letter-spacing:0.05pt;"> </font>hundred<font style="letter-spacing:-0.1pt;"> </font>eightieth<font style="letter-spacing:-0.05pt;"> </font>(180<sup style="font-size:9pt;vertical-align:top;">th</sup>)<font style="letter-spacing:-0.05pt;"> </font>day<font style="letter-spacing:-0.05pt;"> </font>after<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>initial occurrence<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>such<font style="letter-spacing:-0.05pt;"> </font>event.</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:4.5pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">9.</font><b style="font-weight:bold;">Change in Control Acceleration</b>. If your Involuntary Termination occurs within one (1) month prior to, or twelve (12) months following a Change in Control,<font style="letter-spacing:-0.3pt;"> then </font>the<font style="letter-spacing:-0.15pt;"> </font>vesting of all of your outstanding equity awards that are subject to time-based<font style="letter-spacing:0.05pt;"> </font>vesting<font style="letter-spacing:-0.25pt;"> </font>requirements<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.2pt;"> </font>accelerate<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>full<font style="letter-spacing:-0.25pt;"> </font>such<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.25pt;"> </font>all<font style="letter-spacing:-0.2pt;"> </font>such<font style="letter-spacing:-0.25pt;"> </font>equity<font style="letter-spacing:-0.2pt;"> </font>awards<font style="letter-spacing:-0.25pt;"> </font>shall<font style="letter-spacing:-0.25pt;"> </font>be<font style="letter-spacing:-0.25pt;"> </font>deemed<font style="letter-spacing:-0.2pt;"> </font>fully vested<font style="letter-spacing:-0.1pt;"> </font>as<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>date<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>such<font style="letter-spacing:-0.05pt;"> </font>Involuntary Termination (or Change<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>Control,<font style="letter-spacing:-0.05pt;"> </font>if<font style="letter-spacing:-0.1pt;"> </font>later). &#160;For purposes of this Agreement, the term &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u>&#8221; shall have the meaning ascribed to such term in the Plan, except that Innoviva, Inc. and each of its majority-owned subsidiaries and affiliates shall be considered Legacy Investors (as defined in the Plan) for purposes of determining whether or not a Change in Control has occurred.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">10.</font><b style="font-weight:bold;">Taxes</b>.<font style="letter-spacing:-0.65pt;"> </font>All<font style="letter-spacing:-0.65pt;"> </font>amounts<font style="letter-spacing:-0.65pt;"> </font>paid<font style="letter-spacing:-0.65pt;"> </font>under<font style="letter-spacing:-0.65pt;"> </font>this<font style="letter-spacing:-0.7pt;"> </font>Agreement<font style="letter-spacing:-0.65pt;"> </font>shall<font style="letter-spacing:-0.65pt;"> </font>be<font style="letter-spacing:-0.6pt;"> </font>paid<font style="letter-spacing:-0.6pt;"> </font>less<font style="letter-spacing:-0.6pt;"> </font>all<font style="letter-spacing:-0.6pt;"> </font>applicable<font style="letter-spacing:-0.6pt;"> </font>state<font style="letter-spacing:-2.9pt;"> </font>and federal tax withholdings (if any) and any other withholdings required by any applicable<font style="letter-spacing:0.05pt;"> </font>jurisdiction<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>authorized<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>you.</div><div style="margin-top:3pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A</u>. The Severance Pay provided in this Agreement is intended<font style="letter-spacing:0.05pt;"> </font>to qualify for an exemption from application of Section 409A of the Internal Revenue Code of<font style="letter-spacing:0.05pt;"> </font>1986, as amended (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221;) and the regulations and other guidance thereunder and any state<font style="letter-spacing:0.05pt;"> </font>law<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>similar<font style="letter-spacing:-0.45pt;"> </font>effect<font style="letter-spacing:-0.45pt;"> </font>(collectively<font style="letter-spacing:-0.45pt;"> </font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><u style="letter-spacing:-0.5pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">409A</u>&#8221;)<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.45pt;"> </font>to<font style="letter-spacing:-0.45pt;"> </font>comply<font style="letter-spacing:-0.45pt;"> </font>with<font style="letter-spacing:-0.6pt;"> </font>its<font style="letter-spacing:-0.45pt;"> </font>requirements<font style="letter-spacing:-0.45pt;"> </font>to<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>extent <font style="letter-spacing:-2.9pt;"> </font>necessary<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.6pt;"> </font>avoid<font style="letter-spacing:0.6pt;"> </font>adverse<font style="letter-spacing:0.6pt;"> </font>personal<font style="letter-spacing:0.55pt;"> </font>tax<font style="letter-spacing:0.55pt;"> </font>consequences<font style="letter-spacing:0.55pt;"> </font>under<font style="letter-spacing:0.55pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>409A,<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.55pt;"> </font>any<font style="letter-spacing:0.55pt;"> </font>ambiguities herein<font style="letter-spacing:-0.65pt;"> </font>shall<font style="letter-spacing:-0.6pt;"> </font>be<font style="letter-spacing:-0.55pt;"> </font>interpreted<font style="letter-spacing:-0.6pt;"> </font>accordingly.<font style="letter-spacing:-0.6pt;"> </font>Each<font style="letter-spacing:-0.55pt;"> </font>installment<font style="letter-spacing:-0.7pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>Severance<font style="letter-spacing:-0.55pt;"> </font>Pay<font style="letter-spacing:-0.6pt;"> </font>is<font style="letter-spacing:-0.6pt;"> </font>a<font style="letter-spacing:-0.55pt;"> </font>separate<font style="letter-spacing:-0.6pt;"> </font>&#8220;payment&#8221; for<font style="letter-spacing:-0.75pt;"> </font>purposes<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>Treasury<font style="letter-spacing:-0.75pt;"> </font>Regulations<font style="letter-spacing:-0.7pt;"> </font>Section<font style="letter-spacing:-0.75pt;"> </font>1.409A-2(b)(2)(i),<font style="letter-spacing:-0.7pt;"> </font>and<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Severance<font style="letter-spacing:-0.7pt;"> </font>Pay<font style="letter-spacing:-0.75pt;"> </font>is<font style="letter-spacing:-0.7pt;"> </font>intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations<font style="letter-spacing:-2.85pt;"> </font>Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are<font style="letter-spacing:0.05pt;"> </font>not available and you are, upon Separation from Service, a &#8220;specified employee&#8221; for purposes of<font style="letter-spacing:0.05pt;"> </font>Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences<font style="letter-spacing:0.05pt;"> </font>under<font style="letter-spacing:-0.4pt;"> </font>Section<font style="letter-spacing:-0.4pt;"> </font>409A,<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>timing<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Severance<font style="letter-spacing:-0.4pt;"> </font>Pay<font style="letter-spacing:-0.4pt;"> </font>shall<font style="letter-spacing:-0.35pt;"> </font>be<font style="letter-spacing:-0.4pt;"> </font>delayed<font style="letter-spacing:-0.4pt;"> </font>until<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>earlier<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>(i)<font style="letter-spacing:-0.35pt;"> </font>six<font style="letter-spacing:-0.4pt;"> </font>(6) months<font style="letter-spacing:-0.35pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>one<font style="letter-spacing:-0.3pt;"> </font>day<font style="letter-spacing:-0.3pt;"> </font>after<font style="letter-spacing:-0.3pt;"> </font>your<font style="letter-spacing:-0.35pt;"> </font>Separation<font style="letter-spacing:-0.35pt;"> </font>from<font style="letter-spacing:-0.3pt;"> </font>Service,<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.3pt;"> </font>(ii)<font style="letter-spacing:-0.35pt;"> </font>your<font style="letter-spacing:-0.3pt;"> </font>death.<font style="letter-spacing:-0.3pt;"> </font>Except<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>minimum extent that payments must be delayed because you are a &#8220;specified employee&#8221;, all amounts of<font style="letter-spacing:0.05pt;"> </font>Severance<font style="letter-spacing:-0.35pt;"> </font>Pay<font style="letter-spacing:-0.3pt;"> </font>will<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-0.3pt;"> </font>paid<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.3pt;"> </font>soon<font style="letter-spacing:-0.3pt;"> </font>as<font style="letter-spacing:-0.35pt;"> </font>practicable<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>accordance<font style="letter-spacing:-0.3pt;"> </font>with<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>schedule<font style="letter-spacing:-0.35pt;"> </font>provided<font style="letter-spacing:-0.35pt;"> </font>herein and<font style="letter-spacing:-0.1pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>accordance<font style="letter-spacing:-0.05pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Company&#8217;s normal payroll<font style="letter-spacing:-0.05pt;"> </font>practices.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 280G</u>. If any payment or benefit you will or may receive from the<font style="letter-spacing:0.05pt;"> </font>Company<font style="letter-spacing:-0.5pt;"> </font>or<font style="letter-spacing:-0.5pt;"> </font>otherwise<font style="letter-spacing:-0.45pt;"> </font>(a<font style="letter-spacing:-0.5pt;"> </font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">280G</u><u style="letter-spacing:-0.45pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>&#8221;)<font style="letter-spacing:-0.45pt;"> </font>would<font style="letter-spacing:-0.5pt;"> </font>(i)<font style="letter-spacing:-0.4pt;"> </font>constitute<font style="letter-spacing:-0.45pt;"> </font>a<font style="letter-spacing:-0.45pt;"> </font>&#8220;parachute<font style="letter-spacing:-0.4pt;"> </font>payment&#8221;<font style="letter-spacing:-0.5pt;"> </font>within<font style="letter-spacing:-0.45pt;"> </font>the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax<font style="letter-spacing:0.05pt;"> </font>imposed by Section 4999 of the Code (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;), then any such 280G Payment pursuant<font style="letter-spacing:0.05pt;"> </font>to this Agreement or otherwise (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>&#8221;) shall be equal to the Reduced Amount. The<font style="letter-spacing:0.05pt;"> </font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduced Amount</u>&#8221; shall be either (x) the largest portion of the Payment that would result in no<font style="letter-spacing:0.05pt;"> </font>portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, <font style="letter-spacing:-2.9pt;"> </font>up to and including the total, of the Payment, whichever amount (i.e., the amount determined by<font style="letter-spacing:0.05pt;"> </font>clause (x) or by clause (y)), after taking into account all applicable federal, state and local<font style="letter-spacing:0.05pt;"> </font>employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable<font style="letter-spacing:0.05pt;"> </font>marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit<font style="letter-spacing:0.05pt;"> </font>notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a<font style="letter-spacing:0.05pt;"> </font>reduction<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>a<font style="letter-spacing:-0.35pt;"> </font>Payment<font style="letter-spacing:-0.3pt;"> </font>is<font style="letter-spacing:-0.3pt;"> </font>required<font style="letter-spacing:-0.25pt;"> </font>pursuant<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>preceding<font style="letter-spacing:-0.3pt;"> </font>sentence<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Reduced<font style="letter-spacing:-0.35pt;"> </font>Amount is determined pursuant to<font style="letter-spacing:-0.75pt;"> </font>clause<font style="letter-spacing:-0.75pt;"> </font>(x)<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>preceding<font style="letter-spacing:-0.85pt;"> </font>sentence,<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>reduction<font style="letter-spacing:-0.8pt;"> </font>shall<font style="letter-spacing:-0.75pt;"> </font>occur<font style="letter-spacing:-0.75pt;"> </font>in<font style="letter-spacing:-0.8pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>manner<font style="letter-spacing:-2.85pt;"> </font>(the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction Method</u>&#8221;) that results in the greatest economic benefit for you. If more than one<font style="letter-spacing:0.05pt;"> </font>method<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.4pt;"> </font>reduction<font style="letter-spacing:-0.4pt;"> </font>will<font style="letter-spacing:-0.4pt;"> </font>result<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>same<font style="letter-spacing:-0.4pt;"> </font>economic<font style="letter-spacing:-0.4pt;"> </font>benefit,<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>items<font style="letter-spacing:-0.4pt;"> </font>so<font style="letter-spacing:-0.4pt;"> </font>reduced<font style="letter-spacing:-0.4pt;"> </font>will<font style="letter-spacing:-0.4pt;"> </font>be<font style="letter-spacing:-0.4pt;"> </font>reduced <font style="letter-spacing:-2.9pt;"> </font>pro<font style="letter-spacing:-0.05pt;"> </font>rata (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Rata</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction</u><u style="letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Method</u>&#8221;).</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:4.5pt 0pt 0pt 0pt;">Notwithstanding<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>foregoing,<font style="letter-spacing:-0.65pt;"> </font>if<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>Reduction<font style="letter-spacing:-0.65pt;"> </font>Method<font style="letter-spacing:-0.65pt;"> </font>or<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>Pro<font style="letter-spacing:-0.6pt;"> </font>Rata<font style="letter-spacing:-0.65pt;"> </font>Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that<font style="letter-spacing:0.05pt;"> </font>would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method<font style="letter-spacing:0.05pt;"> </font>and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the<font style="letter-spacing:0.05pt;"> </font>imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification<font style="letter-spacing:0.05pt;"> </font>shall preserve to the greatest extent possible, the greatest economic benefit for you as determined<font style="letter-spacing:-2.85pt;"> </font>on<font style="letter-spacing:-0.2pt;"> </font>an<font style="letter-spacing:-0.15pt;"> </font>after-tax<font style="letter-spacing:-0.2pt;"> </font>basis;<font style="letter-spacing:-0.15pt;"> </font>(B)<font style="letter-spacing:-0.2pt;"> </font>as<font style="letter-spacing:-0.15pt;"> </font>a<font style="letter-spacing:-0.2pt;"> </font>second<font style="letter-spacing:-0.1pt;"> </font>priority,<font style="letter-spacing:-0.15pt;"> </font>Payments<font style="letter-spacing:-0.1pt;"> </font>that<font style="letter-spacing:-0.15pt;"> </font>are<font style="letter-spacing:-0.05pt;"> </font>contingent<font style="letter-spacing:-0.2pt;"> </font>on<font style="letter-spacing:-0.15pt;"> </font>future<font style="letter-spacing:-0.2pt;"> </font>events<font style="letter-spacing:-0.15pt;"> </font>(e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not<font style="letter-spacing:0.05pt;"> </font>contingent<font style="letter-spacing:-0.55pt;"> </font>on<font style="letter-spacing:-0.5pt;"> </font>future<font style="letter-spacing:-0.5pt;"> </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">events;<font style="letter-spacing:-0.5pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>(C)<font style="letter-spacing:-0.55pt;"> </font>as<font style="letter-spacing:-0.5pt;"> </font>a<font style="letter-spacing:-0.5pt;"> </font>third<font style="letter-spacing:-0.5pt;"> </font>priority,<font style="letter-spacing:-0.6pt;"> </font>Payments<font style="letter-spacing:-0.55pt;"> </font>that<font style="letter-spacing:-0.55pt;"> </font>are<font style="letter-spacing:-0.55pt;"> </font>&#8220;deferred<font style="letter-spacing:-0.55pt;"> </font>compensation&#8221; <font style="letter-spacing:-2.85pt;"> </font>within<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>meaning<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>Section<font style="letter-spacing:-0.25pt;"> </font>409A<font style="letter-spacing:-0.25pt;"> </font>shall<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-0.3pt;"> </font>reduced<font style="letter-spacing:-0.3pt;"> </font>(or<font style="letter-spacing:-0.25pt;"> </font>eliminated)<font style="letter-spacing:-0.3pt;"> </font>before<font style="letter-spacing:-0.3pt;"> </font>Payments<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.25pt;"> </font>are<font style="letter-spacing:-0.3pt;"> </font>not deferred<font style="letter-spacing:-0.1pt;"> </font>compensation<font style="letter-spacing:-0.05pt;"> </font>within the meaning of<font style="letter-spacing:-0.1pt;"> </font>Section<font style="letter-spacing:-0.05pt;"> </font>409A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless<font style="letter-spacing:-0.15pt;"> </font>you<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Company<font style="letter-spacing:-0.1pt;"> </font>agree<font style="letter-spacing:-0.1pt;"> </font>on<font style="letter-spacing:-0.15pt;"> </font>an<font style="letter-spacing:-0.05pt;"> </font>alternative<font style="letter-spacing:-0.1pt;"> </font>accounting<font style="letter-spacing:-0.05pt;"> </font>firm,<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>accounting<font style="letter-spacing:-0.05pt;"> </font>firm engaged<font style="letter-spacing:0.1pt;"> </font>by<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.15pt;"> </font>Company<font style="letter-spacing:0.1pt;"> </font>for<font style="letter-spacing:0.1pt;"> </font>general<font style="letter-spacing:0.2pt;"> </font>tax<font style="letter-spacing:0.05pt;"> </font>compliance<font style="letter-spacing:0.15pt;"> </font>purposes<font style="letter-spacing:0.15pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>day<font style="letter-spacing:0.1pt;"> </font>prior<font style="letter-spacing:0.15pt;"> </font>to<font style="letter-spacing:0.1pt;"> </font>the<font style="letter-spacing:0.15pt;"> </font>effective date of the change of control transaction triggering the Payment shall perform the foregoing<font style="letter-spacing:0.05pt;"> </font>calculations.<font style="letter-spacing:-0.65pt;"> </font>If<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>accounting<font style="letter-spacing:-0.5pt;"> </font>firm<font style="letter-spacing:-0.6pt;"> </font>so<font style="letter-spacing:-0.5pt;"> </font>engaged<font style="letter-spacing:-0.5pt;"> </font>by<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Company<font style="letter-spacing:-0.5pt;"> </font>is<font style="letter-spacing:-0.5pt;"> </font>serving<font style="letter-spacing:-0.55pt;"> </font>as<font style="letter-spacing:-0.5pt;"> </font>accountant<font style="letter-spacing:-0.55pt;"> </font>or<font style="letter-spacing:-0.55pt;"> </font>auditor <font style="letter-spacing:-2.85pt;"> </font>for the individual, entity or group effecting the change of control transaction, the Company shall<font style="letter-spacing:0.05pt;"> </font>appoint a nationally recognized accounting firm to make the determinations required hereunder.<font style="letter-spacing:0.05pt;"> </font>The Company shall bear all expenses with respect to the determinations by such accounting firm<font style="letter-spacing:0.05pt;"> </font>required to be made hereunder. The Company shall use commercially reasonable efforts to cause<font style="letter-spacing:0.05pt;"> </font>the accounting firm engaged to make the determinations hereunder to provide its calculations,<font style="letter-spacing:0.05pt;"> </font>together with detailed supporting documentation, to you and the Company within fifteen (15)<font style="letter-spacing:0.05pt;"> </font>calendar days after the date on which your right to a 280G Payment becomes reasonably likely to<font style="letter-spacing:-2.85pt;"> </font>occur (if requested at that time by you or the Company) or such other time as requested by you or <font style="letter-spacing:-2.85pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If you receive a Payment for which the Reduced Amount was determined pursuant to<font style="letter-spacing:0.05pt;"> </font>clause<font style="letter-spacing:-0.25pt;"> </font>(x)<font style="letter-spacing:-0.2pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>first<font style="letter-spacing:-0.2pt;"> </font>paragraph<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>this<font style="letter-spacing:-0.2pt;"> </font>Section<font style="letter-spacing:-0.2pt;"> </font>10(b)<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>Internal<font style="letter-spacing:-0.2pt;"> </font>Revenue<font style="letter-spacing:-0.2pt;"> </font>Service<font style="letter-spacing:-0.2pt;"> </font>determines thereafter<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.3pt;"> </font>some<font style="letter-spacing:-0.3pt;"> </font>portion<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Payment<font style="letter-spacing:-0.3pt;"> </font>is<font style="letter-spacing:-0.25pt;"> </font>subject<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Excise<font style="letter-spacing:-0.3pt;"> </font>Tax,<font style="letter-spacing:-0.3pt;"> </font>you<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.25pt;"> </font>promptly<font style="letter-spacing:-0.3pt;"> </font>return<font style="letter-spacing:-2.9pt;"> </font>to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the<font style="letter-spacing:0.05pt;"> </font>first paragraph of this this Section 10(b) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to<font style="letter-spacing:0.05pt;"> </font>clause (y) in the first paragraph of this this Section 10(b), you shall have no obligation to return<font style="letter-spacing:0.05pt;"> </font>any<font style="letter-spacing:-0.1pt;"> </font>portion<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Payment<font style="letter-spacing:-0.05pt;"> </font>pursuant to the<font style="letter-spacing:-0.05pt;"> </font>preceding<font style="letter-spacing:-0.05pt;"> </font>sentence.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">11.</font><b style="font-weight:bold;">Other</b>. As a condition of your employment hereunder, you agree and acknowledge that each of (i) your Employee Nondisclosure, Assignment and Non-Solicitation Agreement with C3 Jian, Inc., a predecessor of the Company, dated July 8, 2012, and (ii) your Employee Confidential Information and Invention Assignment Agreement with the Company, dated June 28, 2022 (each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PIIA</u>&#8221; and collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PIIAs</u>&#8221;),<font style="letter-spacing:0.05pt;"> </font>remains in full force and effect, and you shall continue to comply with each PIIA. The parties hereto acknowledge and agree that this Agreement and each PIIA shall be considered separate contracts, and the PIIAs will survive the termination of this Agreement for any reason.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">12.</font><b style="font-weight:bold;">Clawback Policy</b>. &#160;By signing below, you hereby acknowledge and agree that you are, and will continue to be, subject to the Company&#8217;s Policy for the Recovery of Erroneously Awarded Compensation (as adopted on November 9, 2023), as the same may be amended and/or restated from time to time.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">13.</font><b style="font-weight:bold;">Entire</b><b style="font-weight:bold;letter-spacing:-0.3pt;"> </b><b style="font-weight:bold;">Agreement</b>.<font style="letter-spacing:-0.25pt;"> </font>This<font style="letter-spacing:-0.25pt;"> </font>Agreement,<font style="letter-spacing:-0.25pt;"> </font>together<font style="letter-spacing:-0.25pt;"> </font>with<font style="letter-spacing:-0.1pt;"> </font>your<font style="letter-spacing:-0.25pt;"> </font>PIIAs,<font style="letter-spacing:-0.25pt;"> </font>sets<font style="letter-spacing:-0.25pt;"> </font>forth<font style="letter-spacing:-0.3pt;"> </font>our<font style="letter-spacing:-0.25pt;"> </font>entire <font style="letter-spacing:-2.85pt;"> </font>agreement and understanding regarding the terms of your employment with the Company and<font style="letter-spacing:0.05pt;"> </font>supersedes<font style="letter-spacing:-0.4pt;"> </font>any<font style="letter-spacing:-0.4pt;"> </font>prior<font style="letter-spacing:-0.4pt;"> </font>representations<font style="letter-spacing:-0.45pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>agreements,<font style="letter-spacing:-0.4pt;"> </font>whether<font style="letter-spacing:-0.4pt;"> </font>written<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.4pt;"> </font>oral.<font style="letter-spacing:2.3pt;"> </font>This<font style="letter-spacing:-0.45pt;"> </font>Agreement<font style="letter-spacing:-0.35pt;"> </font>may<font style="letter-spacing:-2.9pt;"> </font>not be modified in any way except in a writing signed by the Company&#8217;s Chief Executive Offer<font style="letter-spacing:0.05pt;"> </font>(or another duly authorized officer of the Company) upon due authorization by the Board or the<font style="letter-spacing:0.05pt;"> </font>Compensation Committee and you. It shall be governed by California law, without regard to<font style="letter-spacing:0.05pt;"> </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;">principles of<font style="letter-spacing:-0.05pt;"> </font>conflicts<font style="letter-spacing:-0.05pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>laws.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">*</b></font><b style="font-weight:bold;">*</b><font style="display:inline-block;width:30pt;"></font><b style="font-weight:bold;">*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0.05pt 0pt 0pt 0pt;">(Signatures<font style="letter-spacing:-0.2pt;"> </font>are<font style="letter-spacing:-0.15pt;"> </font>on<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>following<font style="letter-spacing:-0.15pt;"> </font>page)</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.78%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Sincerely,</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">i</p></div></div></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ Deborah Birx</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Deborah Birx, M.D.</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">ACCEPTED AND AGREED:</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ Pierre Kyme</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">8/19/2024</p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Pierre Kyme</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.52%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Date</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.3pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to P. Kyme Employment Agreement]</i></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.78%;margin-right:10.78%;margin-top:30pt;page-break-after:avoid;width:78.43%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>armp-20241231xex19d1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:13 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 19.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Armata Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10.5pt;">____________________________________</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">INSIDER TRADING POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Guidelines with Respect to</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Certain Transactions in Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:10.5pt;">____________________________________</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">Effective as of December 16, 2024<br>And As Amended Through December 16, 2024</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Page</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887557">INTRODUCTION</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887557"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887557">1</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887558">Legal prohibitions on insider trading</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887558"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887558">1</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887559">Detection and prosecution of insider trading</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887559"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887559">1</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887560">Penalties for violation of insider trading laws and this Policy</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887560"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887560">1</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887561">Compliance Officer</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887561"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887561">2</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887562">Reporting violations</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887562"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887562">2</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887563">Personal responsibility</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887563"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887563">3</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887564">PERSONS AND TRANSACTIONS COVERED BY THIS POLICY</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887564"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887564">3</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887565">Persons covered by this Policy</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887565"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887565">3</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887566">Types of transactions covered by this Policy</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887566"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887566">3</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887567">Responsibilities regarding the non-public information of other companies</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887567"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887567">4</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887568">Applicability of this Policy after your departure</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887568"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887568">4</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887569">No exceptions based on personal circumstances</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887569"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887569">4</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887570">MATERIAL NON-PUBLIC INFORMATION</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887570"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887570">4</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887571">&#8220;Material&#8221; information</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887571"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887571">4</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887572">&#8220;Non-public&#8221; information</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887572"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887572">6</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887573">POLICIES REGARDING MATERIAL NON-PUBLIC INFORMATION</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887573"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887573">6</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887574">Confidentiality of non-public information</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887574"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887574">6</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887575">No trading on material non-public information</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887575"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887575">6</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887576">No disclosing material non-public information for the benefit of others</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887576"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887576">7</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887577">Responding to outside inquiries for information</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887577"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887577">7</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887578">TRADING BLACKOUT PERIODS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887578"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887578">7</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887579">Quarterly blackout periods</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887579"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887579">7</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887580">Special blackout periods</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887580"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887580">8</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887581">No &#8220;safe harbors&#8221;</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887581"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887581">8</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887582">PRE-CLEARANCE OF TRADES</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887582"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887582">8</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887583">ADDITIONAL RESTRICTIONS AND GUIDANCE</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887583"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887583">9</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887584">Short sales</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887584"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887584">9</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887585">Derivative securities and hedging transactions</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887585"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887585">9</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887586">Using Company securities as collateral for loans</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887586"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887586">10</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887587">Holding Company securities in margin accounts</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887587"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887587">10</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887588">Placing open orders with brokers</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887588"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887588">10</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887589">LIMITED EXCEPTIONS</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887589"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887589">10</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887590">Transactions pursuant to a trading plan that complies with SEC rules</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887590"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887590">11</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887591">Receipt and vesting of stock options, restricted stock units, restricted stock and stock appreciation rights</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887591"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887591">11</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887592">Exercise of stock options for cash</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887592"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887592">12</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887593">Purchases from the employee stock purchase plan</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887593"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887593">12</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887594">Stock splits, stock dividends and similar transactions</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887594"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887594">12</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887595">Bona fide gifts and inheritance</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887595"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887595">12</a></font></font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>i</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887596">Change in form of ownership</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887596"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887596">13</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887597">Other exceptions</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887597"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887597">13</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887598">COMPLIANCE WITH SECTION 16 OF THE SECURITIES EXCHANGE ACT</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887598"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887598">13</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887599">Obligations under Section 16</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887599"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887599">13</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887600">Notification requirements to facilitate Section 16 reporting</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887600"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887600">13</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887601">Personal responsibility</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887601"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887601">13</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:12.6pt;margin-bottom:0pt;margin-left:10.95pt;margin-top:11.94pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887602">ADDITIONAL INFORMATION</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887602"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887602">13</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887603">Availability of Policy</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887603"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887603">13</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887604">Amendments</a></font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887604"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a href="#_Toc155887604">14</a></font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">SCHEDULE I (Individuals subject to pre-clearance requirements)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">SCHEDULE II (Individuals subject to Section 16 reporting and liability provisions)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">SCHEDULE III (Requirements for 10b5-1 Trading Plans)</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>ii</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887557"></a>INTRODUCTION</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Armata Pharmaceuticals, Inc. (together with its subsidiaries, collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) opposes the unauthorized disclosure of any non-public information acquired in the course of your service with the Company and the misuse of material non-public information in securities trading. Any such actions will be deemed violations of this Amended and Restated Insider Trading Policy (the &#8220;<font style="font-style:italic;font-weight:bold;">Policy</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887558"></a>Legal prohibitions on insider trading</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The antifraud provisions of U.S. federal securities laws prohibit directors, officers, employees and other individuals who possess material non-public information from trading on the basis of that information in breach of a fiduciary duty or other relationship of trust and confidence. Transactions will be considered &#8220;on the basis of&#8221; material non-public information if the person engaged in the transaction was aware of the material non-public information at the time of the transaction. It is not a defense that the person did not &#8220;use&#8221; the information for purposes of the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Disclosing material non-public information directly or indirectly to others who then trade based on that information or making recommendations or expressing opinions as to transactions in securities while aware of material non-public information (which is sometime referred to as &#8220;<font style="font-style:italic;font-weight:bold;">tipping</font>&#8221;) is also illegal. Both the person who provides the information, recommendation or opinion and the person who trades based on it may be liable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These illegal activities are commonly referred to as &#8220;<font style="font-style:italic;font-weight:bold;">insider trading</font>&#8221;. State securities laws and securities laws of other jurisdictions also impose restrictions on insider trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, a company, as well as individual directors, officers and other supervisory personnel, may be subject to liability as &#8220;controlling persons&#8221; for failure to take appropriate steps to prevent insider trading by those under their supervision, influence or control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887559"></a>Detection and prosecution of insider trading</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. Securities and Exchange Commission (the &#8220;<font style="font-style:italic;font-weight:bold;">SEC</font>&#8221;), the Financial Industry Regulatory Authority (&#8220;<font style="font-style:italic;font-weight:bold;">FINRA</font>&#8221;) and the New York Stock Exchange (the &#8220;<font style="font-style:italic;font-weight:bold;">NYSE</font>&#8221;) use sophisticated electronic surveillance techniques to investigate and detect insider trading, and the SEC and the U.S. Department of Justice pursue insider trading violations vigorously. Cases involving trading through foreign accounts, trading by family members and friends and trading involving only a small number of shares have been successfully prosecuted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887560"></a>Penalties for violation of insider trading laws and this Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Civil and criminal penalties. </i>As of the effective date of this Policy, potential penalties for insider trading violations under U.S. federal securities laws include:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">damages in a private lawsuit;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">disgorging any profits made or losses avoided;</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>1</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">imprisonment for up to 20 years;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">criminal fines of up to $5 million for individuals and $25 million for entities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">civil fines of up to three times the profit gained or loss avoided;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a bar against serving as an officer or director of a public company; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">an injunction against future violations.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Civil and criminal penalties also apply to tipping. The SEC has imposed large penalties in tipping cases even when the disclosing person did not trade or gain any benefit from another person&#8217;s trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Controlling person liability. </i>As of the effective date of this Policy, the penalty for &#8220;controlling person&#8221; liability is a civil fine of up to the greater of $1 million or three times the profit gained or loss avoided as a result of the insider trading violations, as well as potential criminal fines and imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Company disciplinary actions. </i>If the Company has a reasonable basis to conclude that you have failed to comply with this Policy, you may be subject to disciplinary action by the Company, up to and including dismissal for cause, regardless of whether or not your failure to comply with this Policy results in a violation of law. It is not necessary for the Company to wait for the filing or conclusion of any civil or criminal action against an alleged violator before taking disciplinary action. In addition, the Company may give stop transfer and other instructions to the Company&#8217;s transfer agent to enforce compliance with this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887561"></a>Compliance Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Please direct any questions, requests or reports as to any of the matters discussed in this Policy to the Chief Executive Officer or Principal Financial Officer of the Company (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Compliance Officer</font>&#8221;). The Compliance Officer(s) are generally responsible for the administration of this Policy. A Compliance Officer may select others to assist with the execution of his or her duties, including involvement of the Company&#8217;s outside corporate law firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887562"></a>Reporting violations</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is your responsibility to help enforce this Policy. You should be alert to possible violations and promptly report violations or suspected violations of this Policy to a Compliance Officer. If your situation requires that your identity be kept secret, your anonymity will be preserved to the greatest extent reasonably possible. If you wish to remain anonymous, you may (i) send a letter addressed to: Compliance Officer at Armata Pharmaceuticals, Inc., 5005 McConnell Avenue, Los Angeles, CA 90066; or (ii) leave an anonymous message on the Company&#8217;s compliance hotline (which number is published in the Company Code of Business Conduct and Ethics and will also be made available on the Company&#8217;s internal webpages). If you make an anonymous report, please provide as much detail as possible, including any evidence that you believe may be relevant to the issue.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887563"></a>Personal responsibility</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ultimate responsibility for complying with this Policy and applicable laws and regulations, and for ensuring that any covered family member or related entity likewise complies, rests with you. You should use your best judgment at all times and consult with your personal legal and financial advisors, as needed. We advise you to seek assistance if you have any questions at all. The rules relating to insider trading can be complex, and a violation of insider trading laws can carry severe consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887564"></a>PERSONS AND TRANSACTIONS COVERED BY THIS POLICY</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887565"></a>Persons covered by this Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Policy applies to all directors, officers, employees and agents (such as consultants and independent contractors) of the Company. References in this Policy to &#8220;you&#8221; (as well as general references to directors, officers, employees and agents of the Company) should also be understood to include: </p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">members of your immediate family;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">persons with whom you share a household;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">persons who are your economic dependents;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">any other individuals or entities whose transactions in securities you influence, direct or control (including, for example, a venture or other investment fund, if you influence, direct or control transactions by the fund); and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">all persons who execute trades on your behalf. </font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">You are responsible for making sure that these other individuals and entities comply with this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887566"></a>Types of transactions covered by this Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as discussed in the section entitled &#8220;<b style="font-weight:bold;">Limited Exceptions</b>&#8221; below, this Policy applies to <i style="font-style:italic;">all </i>transactions <i style="font-style:italic;">involving </i>the securities of the Company or the securities of other companies as to which you possess material non-public information obtained in the course of your service with the Company. This Policy therefore applies to purchases, sales and other transfers of common stock, options, warrants, preferred stock, debt securities (such as debentures, bonds and notes) and other securities of the Company or of such other companies. This Policy also applies to any arrangements that affect economic exposure to changes in the prices of these securities. These arrangements may include, among other things, transactions in derivative securities (such as exchange-traded put or call options), hedging transactions, short sales and certain decisions with respect to participation in benefit plans. This Policy also applies to any offers with respect to the transactions discussed above. You should note that there are no exceptions from insider trading laws or this Policy based on the size of the transaction.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887567"></a>Responsibilities regarding the non-public information of other companies</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Policy prohibits the unauthorized disclosure or other misuse of any non-public information of other companies, such as the Company&#8217;s distributors, vendors, customers, corporate partners or collaborators, suppliers and competitors. This Policy also prohibits insider trading and tipping based on the material non-public information of other companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887568"></a>Applicability of this Policy after your departure</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You are expected to comply with this Policy until such time as you are no longer affiliated with the Company <i style="font-style:italic;">and </i>you no longer possess any material non-public information subject to this Policy. In addition, if your transactions in Company securities are subject to a blackout period at the time of the termination of your service to the Company, then the blackout period will continue to apply to your transactions in the Company&#8217;s securities until the end of such blackout period. Remember, anyone scrutinizing your transactions will be doing so after the fact, with the benefit of hindsight. As a practical matter, before engaging in any transaction, you should carefully consider even the appearance of improper insider trading and how enforcement authorities and others might view the transaction in hindsight.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887569"></a>No exceptions based on personal circumstances</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There may be instances where you suffer financial harm or other hardship or are otherwise required to forego a planned transaction because of the restrictions imposed by this Policy. Personal financial emergency or other personal circumstances are not mitigating factors under securities laws and will not excuse a failure to comply with this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887570"></a>MATERIAL NON-PUBLIC INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887571"></a>&#8220;Material&#8221; information</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information should be regarded as material if there is a substantial likelihood that a reasonable investor would consider it important in deciding whether to buy, hold or sell securities or would view the information as significantly altering the total mix of information in the marketplace about the issuer of the security. In general, any information that could reasonably be expected to affect the market price of a security is likely to be material. Either positive or negative information may be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is not possible to define all categories of &#8220;material&#8221; information. However, some examples of information that could be regarded as material include information with respect to:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Financial results, financial condition, earnings pre-announcements, guidance, projections or forecasts, particularly if inconsistent with the Company&#8217;s current guidance or with the expectations of the investment community;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Restatements of financial results, or material impairments, write-offs or restructurings;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Changes in independent auditors, or notification that the Company may no longer rely on an audit report;</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Business plans or budgets;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Creation of significant financial obligations, or any significant default under or acceleration of any financial obligation;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Impending bankruptcy or financial liquidity problems;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Significant developments involving important business relationships or important corporate partnerships/collaborations, including execution, modification or termination of significant agreements or significant orders with customers, suppliers, distributors, manufacturers or other business partners;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Certain regulatory filings, regulatory approvals and denials or significant regulatory developments such as changes in regulatory guidance with respect to pre- or post- approval requirements, the contents of advisory committee meeting briefing documents, or the results of meetings between the Company and regulatory authorities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Certain important pre-clinical or clinical study results or developments;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Product introductions, modifications, defects or recalls or significant pricing changes or other product developments of a significant nature;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Significant developments in research and development or relating to intellectual property;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Significant legal developments, whether actual or threatened;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Major events involving the Company&#8217;s securities, including calls of securities for redemption, adoption of stock repurchase programs, option repricings, stock splits, changes in dividend policies, public or private securities offerings (unless pursuant to a plan or arrangement that has already been publicly announced or understood by the investment community), modification to the rights of security holders or notice of delisting;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">The existence of a special blackout period;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Significant corporate events, such as a pending or proposed merger, joint venture, tender offer or important corporate partnering / collaboration agreement, a significant investment, the acquisition or disposition of a significant business or asset (including products or product candidates) or a change in control of the company; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Major personnel changes, such as changes in executive management or lay-offs.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If you have any questions as to whether information should be considered &#8220;material&#8221;, you should consult with a Compliance Officer. In general, it is advisable to resolve any close questions as to the materiality of any information by assuming that the information is material.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887572"></a>&#8220;Non-public&#8221; information</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information is considered non-public if the information has not been broadly disseminated to the public for a sufficient period to be reflected in the price of the security. As a general rule, information should be considered non-public until at least two full trading days have elapsed after the information is broadly distributed to the public in a press release, a public filing with the SEC, a pre-announced public webcast or another broad, non-exclusionary form of public communication. However, depending upon the form of the announcement and the nature of the information, it is possible that information may not be fully absorbed by the marketplace until a later time. Any questions as to whether information is non- public should be directed to a Compliance Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;<font style="font-style:italic;font-weight:bold;">trading day</font>&#8221; means a day on which national stock exchanges are open for trading. A &#8220;<font style="font-style:italic;font-weight:bold;">full</font>&#8221; trading day has elapsed when, after the public disclosure, trading in the relevant security has opened and then closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887573"></a>POLICIES REGARDING MATERIAL NON-PUBLIC INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887574"></a>Confidentiality of non-public information</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unauthorized use or disclosure of non-public information relating to the Company or other companies is prohibited. All non-public information you acquire in the course of your service with the Company may be used only for legitimate Company business purposes. In addition, non-public information of others should be handled in accordance with the terms of any relevant nondisclosure agreements, and the use of any such non-public information should be limited to the purpose for which it was disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You must use all reasonable efforts to safeguard non-public information in the Company&#8217;s possession. You may not disclose non-public information about the Company or any other company, unless required by law, or unless (i) disclosure is required for legitimate Company business purposes, (ii) you are authorized to disclose the information and (iii) appropriate steps have been taken to prevent misuse of that information (including entering into an appropriate nondisclosure agreement that restricts the disclosure and use of the information, if applicable). This restriction also applies to internal communications within the Company and to communications with agents of the Company. In cases where disclosing non- public information to third parties is required, you should coordinate with a Compliance Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All officers, employees and agents of the Company are required to sign and comply with an agreement addressing confidential information and invention assignment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887575"></a>No trading on material non-public information</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as discussed in the section entitled &#8220;<b style="font-weight:bold;">Limited Exceptions</b>&#8221; below, you may not, directly or indirectly through others, engage in any transaction involving the Company&#8217;s securities <i style="font-style:italic;">while aware of </i>material non-public information relating to the Company. It is not an excuse that you did not &#8220;use&#8221; the information in your transaction.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similarly, you may not engage in transactions involving the securities of any other company if you are aware of material non-public information about that company (except to the extent the transactions are analogous to those presented in the section entitled &#8220;<b style="font-weight:bold;">Limited Exceptions</b>&#8221; below). For example, you may be involved in a proposed transaction involving a prospective business relationship or transaction with another company. If information about that transaction constitutes material non-public information for that other company, you would be prohibited from engaging in transactions involving the securities of that other company (as well as transactions involving Company securities, if that information is material to the Company). It is important to note that &#8220;materiality&#8221; is different for different companies. Information that is not material to the Company may be material to another company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887576"></a>No disclosing material non-public information for the benefit of others</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You may not disclose material non-public information concerning the Company or any other company to friends, family members or any other person or entity not authorized to receive such information where such person or entity may benefit by trading on the basis of such information. In addition, you may not make recommendations or express opinions on the basis of material non-public information as to trading in the securities of companies to which such information relates. You are prohibited from engaging in these actions whether or not you derive any profit or personal benefit from doing so. This prohibition against disclosure of material non-public information includes disclosure (even anonymous disclosure) via the Internet, blogs, investor forums, chat rooms, social media, or the like.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887577"></a>Responding to outside inquiries for information</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If you receive an inquiry from someone outside of the Company, such as a stock analyst, for information, you should refer the inquiry to the Chief Accounting Officer or the Investor Relations Department. The Company is required under Regulation FD (Fair Disclosure) of the U.S. federal securities laws to avoid the selective disclosure of material non-public information. In general, the regulation provides that when a public company discloses material non-public information, it must provide broad, non- exclusionary access to the information. Violations of this regulation can subject the company to SEC enforcement actions, which may result in injunctions and severe monetary penalties. The Company has established procedures for releasing material information in a manner that is designed to achieve broad public dissemination of the information immediately upon its release in compliance with applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887578"></a>TRADING BLACKOUT PERIODS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To help prevent insider trading, you may not trade securities of the Company during any &#8220;blackout period.&#8221; Blackout periods occur during each quarter around the time the Company files its SEC reports. In addition, the Company may impose other special trading blackout periods, as needed from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regardless of whether there is a blackout period in effect, you still may not trade in Company securities if you are aware of material non-public information and or in violation of any other restriction set out in this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887579"></a>Quarterly blackout periods</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as discussed in the section entitled &#8220;<b style="font-weight:bold;">Limited Exceptions</b>&#8221; below, directors, officers and all other employees must refrain from conducting transactions involving the Company&#8217;s securities during quarterly blackout periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Quarterly blackout periods start at the beginning of the 15 calendar days before the close of each fiscal quarter and end at the beginning of the third full trading day following the date of public disclosure of the financial results for that fiscal quarter. This period is a particularly sensitive time for transactions involving the Company&#8217;s securities from the perspective of compliance with applicable securities laws due to the fact that, during this period, individuals may often possess or have access to material non-public information relevant to the expected financial results for the quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887580"></a>Special blackout periods</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may also prohibit directors, officers, employees and agents from engaging in transactions involving the Company&#8217;s securities when, in the judgment of a Compliance Officer, a trading blackout is warranted. The Company will generally impose special blackout periods when there are material developments known to the Company that have not yet been disclosed to the public. For example, the Company may impose a special blackout period in anticipation of announcing interim earnings guidance or a significant transaction or business development. However, special blackout periods may be declared for any reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will notify those persons subject to a special blackout period. Each person who has been so identified and notified by the Company may not engage in any transaction involving the Company&#8217;s securities until instructed otherwise by a Compliance Officer, and should not disclose to others the fact of such suspension of trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887581"></a>No &#8220;safe harbors&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are no unconditional &#8220;safe harbors&#8221; for trades made at particular times, and all persons subject to this Policy should exercise good judgment at all times. Even when a quarterly blackout period is not in effect, you may be prohibited from engaging in transactions involving the Company&#8217;s securities because you possess material non-public information, are subject to a special blackout period or are otherwise restricted under this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887582"></a>PRE-CLEARANCE OF TRADES</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">In general, except as provided in the section entitled &#8220;<b style="font-weight:bold;">Limited Exceptions</b>&#8221; below, employees, directors and officers should refrain from engaging in any transaction involving the Company&#8217;s securities without first obtaining pre<b style="font-weight:bold;">-</b>clearance of the transaction from a Compliance Officer. However, certain employees and agents have been designated by the Company as being required to obtain pre-clearance from a Compliance Officer before engaging in a transaction involving Company securities, based on their access to material non-public information. A Compliance Officer must obtain pre-clearance from another executive officer or outside counsel before engaging in a transaction involving Company securities. Individuals subject to pre<b style="font-weight:bold;">-</b>clearance requirements as of the effective date of this policy are listed on <b style="font-weight:bold;">Schedule I</b>. From time to time, the Company may identify other persons who should be subject to the pre<b style="font-weight:bold;">-</b>clearance requirements set forth above, and a Compliance Officer may update and revise <b style="font-weight:bold;">Schedule I </b>as </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">appropriate. <b style="font-weight:bold;">Schedule I</b>, as updated from time-to-time will be maintained by the Company&#8217;s Principal Financial Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These pre-clearance procedures are intended to decrease insider trading risks associated with transactions by individuals with regular or special access to material non-public information. In addition, requiring pre<font style="font-style:italic;font-weight:bold;">-</font>clearance of transactions by directors and officers facilitates compliance with Rule 144 resale restrictions under the Securities Act of 1933, as amended, and the liability and reporting provisions of Section 16 under the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-style:italic;font-weight:bold;">Exchange Act</font>&#8221;). Pre-clearance of a trade, however, is not a defense to a claim of insider trading and does not excuse you from otherwise complying with insider trading laws or this Policy. Further, pre-clearance of a transaction does not constitute an affirmation by the Company or a Compliance Officer that you are not in possession of material non-public information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance, and may determine not to permit the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887583"></a>ADDITIONAL RESTRICTIONS AND GUIDANCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This section addresses certain types of transactions that may expose you and the Company to significant risks. You should understand that, even though a transaction may not be expressly prohibited by this section, you are responsible for ensuring that the transaction otherwise complies with other provisions in this Policy that may apply to the transaction, such as the general prohibition against insider trading as well as pre-clearance procedures and blackout periods, to the extent applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887584"></a>Short sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short sales (<i style="font-style:italic;">i.e., </i>the sale of a security that must be borrowed to make delivery) and &#8220;selling short against the box&#8221; (<i style="font-style:italic;">i.e., </i>a sale with a delayed delivery) with respect to Company securities are prohibited under this Policy. Short sales may signal to the market possible bad news about the Company or a general lack of confidence in the Company&#8217;s prospects, and an expectation that the value of the Company&#8217;s securities will decline. In addition, short sales are effectively a bet against the Company&#8217;s success and may reduce the seller&#8217;s incentive to improve the Company&#8217;s performance. Short sales may also create a suspicion that the seller is engaged in insider trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887585"></a>Derivative securities and hedging transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You may not engage in transactions in publicly traded options on the Company&#8217;s securities, such as puts, calls and other derivative securities, on an exchange or in any other organized market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">Certain forms of hedging or monetization transactions, such as zero-cost collars, forward sale contracts and many others, involve the establishment of a short position in the Company&#8217;s securities and limit or eliminate your ability to profit from an increase in the value of the Company&#8217;s securities. Such transactions are complex and involve many aspects of the federal securities laws, including filing and disclosure requirements. Entering into or altering a hedging transaction or position also may prevent you from relying on the affirmative defense for transactions conducted under Rule 10b5-1 trading plan. Therefore, the Company requires that if you wish to enter into such an arrangement, you must first pre-clear the proposed transaction with </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>9</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">a Compliance Officer. Any request for pre-clearance must be submitted at least two weeks prior to the proposed execution of documents evidencing the proposed transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887586"></a>Using Company securities as collateral for loans</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If you are required to comply with Section 16 of the Exchange Act or pre-clearance requirements under this Policy (<i style="font-style:italic;">i.e., </i>if you are listed on <b style="font-weight:bold;">Schedule I </b>or <b style="font-weight:bold;">II</b>), you may not pledge Company securities as collateral for loans without the approval of a Compliance Officer. If you default on the loan, the lender may sell the pledged securities as collateral in a foreclosure sale. The sale, even though not initiated at your request, is still considered a sale for your benefit and, if made at a time when you are aware of material non-public information or otherwise are not permitted to trade in Company securities, may result in inadvertent insider trading violations, Section 16 violations (for officers and directors), violations of this Policy and unfavorable publicity for you and the Company. For these same reasons, even if you are not prohibited from pledging Company securities as collateral for loans, you should exercise caution when doing so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887587"></a>Holding Company securities in margin accounts</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Securities held in a margin account or pledged as collateral for a loan may be sold without your consent by the broker if you fail to meet a margin call or by the lender in foreclosure if you default on the loan. A margin or foreclosure sale that occurs when you are aware of material nonpublic information may, under some circumstances, result in unlawful insider trading. Because of this danger, you should exercise extreme caution in holding Company securities in a margin account or pledging Company securities as collateral for a loan. If you wish to pledge Company securities as collateral for a loan, you must submit a request for approval to a Compliance Officer at least two weeks prior to the proposed execution of documents evidencing the proposed pledge, providing details of the material terms of the pledge arrangement. You also must ensure that you are not aware of material nonpublic information at the time you enter into the arrangement and that you comply with other applicable requirements, such as Section 16.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887588"></a>Placing open orders with brokers</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except in accordance with an approved trading plan (as discussed below), you should exercise caution when placing open orders, such as limit orders or stop orders, with brokers, particularly where the order is likely to remain outstanding for an extended period of time. Open orders may result in the execution of a trade at a time when you are aware of material non-public information or otherwise are not permitted to trade in Company securities, which may result in inadvertent insider trading violations, Section 16 violations (for officers and directors), violations of this Policy and unfavorable publicity for you and the Company. You should inform any broker with whom you place any open order at the time it is placed that you are subject to the blackout periods and provide the dates, or otherwise ensure that your open order will close before the blackout period commences. If you are subject to pre-clearance requirements, your order may remain open only for the period of time approved by a Compliance Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887589"></a>LIMITED EXCEPTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">The following are certain limited exceptions to the restrictions imposed by the Company under this Policy. <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Please be aware that even if a transaction is subject to an exception to this </i></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>10</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy, you will need</i><i style="font-style:italic;"> </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">to</i><i style="font-style:italic;"> </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">separately assess whether the transaction complies with applicable law. For example, even if a transaction</i><i style="font-style:italic;"> </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">is indicated as exempt from this Policy, you may need to comply with the &#8220;short-swing&#8221; trading restrictions</i><i style="font-style:italic;"> </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">under Section 16 of the Exchange Act, to the extent applicable. You are responsible</i><i style="font-style:italic;"> </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">for complying with</i><i style="font-style:italic;"> </i><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">applicable law at all times.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887590"></a>Transactions pursuant to a trading plan that complies with SEC rules</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The SEC has enacted rules that provide an affirmative defense against alleged violations of U.S. federal insider trading laws for transactions pursuant to trading plans that meet certain requirements. In general, these rules, as set forth in Rule 10b5-1 under the Exchange Act, provide for an affirmative defense if you enter into a contract, provide instructions or adopt a written plan for trading securities when you are not aware of material non-public information. The contract, instructions or plan must (i) specify the amount, price and date of the transaction, (ii) specify an objective method for determining the amount, price and date of the transaction and/or (iii) place any subsequent discretion for determining the amount, price and date of the transaction in another person who is not, at the time of the transaction, aware of material non-public information. In addition, a purchase or sale of a security must comply with the rule&#8217;s restriction on hedging transactions, and for plans adopted on or after February 27, 2023, the required cooling-off period, certification requirement (applicable only to officers and directors), and limitations on multiple overlapping trading arrangements and single trade arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transactions made pursuant to a written trading plan that (i) complies with Rule 10b5-1 and (ii) is approved in advance by a Compliance Officer, are not subject to the restrictions in this Policy against trades made while aware of material non-public information or to the pre-clearance procedures or blackout periods established under this Policy. In approving a trading plan, a Compliance Officer will impose criteria described un <b style="font-weight:bold;">Schedule III, </b>attached hereto, which are in addition to the requirements of Rule 10b5-1 and may be updated from time-to-time. You should confer with a Compliance Officer well in advance of the time you wish to enter into any trading plan, as establishing these plans can take several weeks or longer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The SEC rules regarding trading plans are complex and must be complied with completely to be effective. The description provided above is only a summary, and the Company strongly advises that you consult with your personal legal advisor if you intend to adopt a trading plan. While trading plans are subject to review and approval by the Company, the individual adopting the trading plan is ultimately responsible for compliance with Rule 10b5-1 and ensuring that the trading plan complies with this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trading plans must be filed with and approved in writing, in advance by a Compliance Officer. The Company may publicly disclose information regarding trading plans that you may enter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887591"></a>Receipt and vesting of stock options, restricted stock units, restricted stock and stock appreciation rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">The trading restrictions under this Policy do not apply to the grant or award of stock options, restricted stock units, restricted stock or stock appreciation rights issued or offered by the Company. The trading restrictions under this Policy also do not apply to the vesting, cancellation </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>11</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">or forfeiture of stock options, restricted stock units, restricted stock or stock appreciation rights in accordance with applicable plans and agreements. The trading restrictions under this Policy also do not apply to your election to &#8220;sell-to-cover&#8221; or &#8220;sell all&#8221; that you make at the time of receiving restricted stock unit or restricted stock awards. The trading restrictions and pre-clearance requirements do apply, however, to any subsequent sales of any such securities or the common stock underlying such securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887592"></a>Exercise of stock options for cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading restrictions and pre-clearance requirements under this Policy do not apply to:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">the exercise of stock options for cash under the Company&#8217;s equity incentive plans;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">the exercise of stock options in a stock-for-stock exercise with the Company; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">an election to have the Company withhold securities to cover tax obligations in connection with an option exercise.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">However, the trading restrictions and pre-clearance requirements under this Policy do apply to:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">the sale of any securities issued upon the exercise of a stock option;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a &#8220;cashless exercise&#8221; of a stock option through a broker, since this involves selling a portion of the underlying shares to cover the costs of exercise; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">any other market sale of Company securities for the purpose of generating the cash needed to pay the exercise price or taxes associated with the exercise of an option.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887593"></a>Purchases from the employee stock purchase plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading restrictions and pre-clearance requirements in this Policy do not apply to elections with respect to participation in the Company&#8217;s employee stock purchase plan or to purchases of securities under the plan. However, the trading restrictions and pre-clearance requirements do apply to any subsequent sales of any such securities acquired therefrom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887594"></a>Stock splits, stock dividends and similar transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading restrictions and pre-clearance requirements under this Policy do not apply to a change in the number of securities held as a result of a stock split or stock dividend applying equally to all securities of a class, or similar transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887595"></a><font style="font-style:italic;">Bona fide </font>gifts and inheritance</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading restrictions under this Policy do not apply to <i style="font-style:italic;">bona fide </i>gifts involving Company securities or transfers by will or the laws of descent and distribution; however, insider trading prohibitions may apply to gifts of Company securities, so they should not be made while you are in possession of material non-public information. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>12</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887596"></a>Change in form of ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transactions that involve merely a change in the form in which you own securities are not subject to the trading restrictions under this Policy. For example, you may transfer shares to an <i style="font-style:italic;">inter vivos </i>trust of which you are the sole beneficiary during your lifetime.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887597"></a>Other exceptions</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any other exception from this Policy must be approved by a Compliance Officer, in consultation with the Board of Directors or an independent committee of the Board of Directors, as necessary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887598"></a>COMPLIANCE WITH SECTION 16 OF THE SECURITIES EXCHANGE ACT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887599"></a>Obligations under Section 16</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Section 16 of the Exchange Act, and the related rules and regulations, set forth (i) reporting obligations, (ii) limitations on &#8220;short-swing&#8221; transactions and (iii) limitations on short sales and other transactions applicable to directors, officers, large shareholders and certain other persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors of the Company has determined that those persons listed on <b style="font-weight:bold;">Schedule II </b>are required to comply with Section 16 of the Exchange Act, and the related rules and regulations, because of their positions with the Company. A Compliance Officer may amend <b style="font-weight:bold;">Schedule II </b>from time to time as appropriate to reflect the election of new officers or directors, any change in the responsibilities of officers or other employees, any promotions, demotions, resignations or departures, and any applicable change in regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Schedule II </b>is not necessarily an exhaustive list of persons subject to Section 16 requirements at any given time. Even if you are not listed on <b style="font-weight:bold;">Schedule II</b>, you may be subject to Section 16 reporting obligations because of your shareholdings, for example.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887600"></a>Notification requirements to facilitate Section 16 reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To facilitate timely reporting of transactions pursuant to Section 16 requirements, each person subject to Section 16 reporting requirements must provide, or must ensure that his or her broker provides, the Company with detailed information (<i style="font-style:italic;">e.g., </i>trade date, number of shares, exact price, <i style="font-style:italic;">etc.</i>) regarding his or her transactions involving the Company&#8217;s securities, including gifts, transfers, pledges and transactions pursuant to a trading plan, both prior to (to confirm compliance with pre-clearance procedures, if applicable) and promptly following execution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887601"></a>Personal responsibility</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The obligation to file Section 16 reports, and to otherwise comply with Section 16, is personal. The Company is not responsible for the failure to comply with Section 16 requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887602"></a>ADDITIONAL INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887603"></a>Availability of Policy</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>13</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Policy will be made available to all directors, officers, employees and agents of the Company when they commence service with the Company. Each director, officer, employee and agent of the Company is required to acknowledge that he or she understands, and agrees to comply with, this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_Toc155887604"></a>Amendments</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are committed to continuously reviewing and updating our policies and procedures. The Company therefore reserves the right to amend, alter or terminate this Policy at any time and for any reason, subject to applicable law. A current copy of the Company&#8217;s policies regarding insider trading may be obtained by contacting a Compliance Officer and will also be available on the Company&#8217;s internal website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 12.4pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">*</font></font>*<font style="display:inline-block;width:30pt;"></font>*</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Nothing in this Amended and Restated Insider Trading Policy creates or implies an employment contract or term of employment.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The policies in this Amended and Restated Insider Trading Policy do not constitute a complete list of Company policies or a complete list of the types of conduct that can result in discipline, up to and including discharge.</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;text-align:center;margin:0pt 5.45pt 12pt 10.75pt;"><font style="font-size:0pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>14</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SCHEDULE I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDIVIDUALS SUBJECT TO PRE-CLEARANCE REQUIREMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All members of the Board of Directors of Armata Pharmaceuticals, Inc. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">OFFICERS (including officers who are also directors)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All officers at the Vice President level and above of Armata Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">OTHERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All employees of Armata Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">A full and complete list shall be maintained by the Company&#8217;s stock plan administrator under the direction of a Compliance Officer and any updates or changes shall be recorded by the Company&#8217;s stock plan administrator under the direction of a Compliance Officer.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>1</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SCHEDULE II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 36pt 0pt;"><b style="font-weight:bold;">INDIVIDUALS SUBJECT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SECTION 16 REPORTING AND LIABILITY PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All members of the Board of Directors of Armata Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">OFFICERS (including officers who are also directors)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Each person deemed to be an &#8220;officer&#8221; of Armata Pharmaceuticals, Inc. in accordance with Rule 16a-1(f) of the Securities Exchange Act of 1934.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;text-align:center;margin:0pt 5.45pt 12pt 10.8pt;"><font style="font-size:0pt;font-weight:bold;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>1</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SCHEDULE III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ARMATA PHARMACEUTICALS, INC. </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">REQUIREMENTS FOR RULE 10B5-1 TRADING PLANS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Armata Pharmaceuticals, Inc. (the &#8220;Company&#8221;) has adopted an Amended and Restated Insider Trading Policy that generally prohibits directors, officers, employees and other persons covered by the Policy from trading in Company securities while aware of material nonpublic information, and requires them to obtain pre-clearance of certain transactions relating to Company securities. However, transactions that are executed pursuant to an approved &#8220;10b5-1 plan&#8221; are not subject to these prohibitions or pre-clearance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rule 10b5-1 under the Securities Exchange Act of 1934 provides an affirmative defense from insider trading liability under the federal securities laws for transactions that are entered into pursuant to a written trading plan that meets certain requirements. In general, a 10b5-1 plan must be entered into while an individual is not aware of material non-public information. Once the plan is adopted, the individual who adopted the plan must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. Compliance with Rule 10b5-1 of the Securities and Exchange Commission will not protect an executive officer or director from liability under Section 16 of the Securities Exchange Act of 1934. Covered persons may adopt 10b5-1 plans on their own (&#8220;Voluntary Plan&#8221;) or through entering into a 10b5-1 plan in connection with the grant of an equity award under the Company&#8217;s equity plans (&#8220;Equity Award Plans&#8221;). Except as expressly provided below, these guidelines apply both to Voluntary Plans and Equity Award Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company requires that all Voluntary Plans be filed with and approved by a Compliance Officer in advance and in writing after consultation with the Company&#8217;s outside counsel. If a Compliance Officer seeks to enter into a Voluntary Plan, it must be approved in writing by another Compliance Officer in advance and in writing after consultation with the Company&#8217;s outside counsel. Once adopted, 10b5-1 plans may be amended, suspended or terminated only with the written advance approval of a Compliance Officer and in compliance with the procedure set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Directors and officers of the Company who anticipate selling any shares of the Company&#8217;s common stock are strongly encouraged to do so pursuant to a 10b5-1 plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">A 10b5-1 plan will not be approved unless (except to the extent otherwise approved by the Company&#8217;s Board of Directors) the plan provides that, or the Company&#8217;s internal procedures ensure that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A Voluntary Plan may be adopted only when the person adopting the plan is not aware of material non-public information. An Equity Award Plan may be adopted only if (A) the person adopting the plan is not then aware of material non-public information or (B) as of the date any sales are effected pursuant to the Equity Award Plan, the person will not effect such sales while aware of material non-public information of which the person was aware at the time he or she entered into the equity award agreement and adopted the Equity Award Plan.</p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>1</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The first transaction under the plan cannot take place until the later of (A) the next trading window following the date the plan was adopted or (B) the 61st day following the date of adoption. For plans adopted on or after February 27, 2023, the first transaction under the plan may not take place until the expiration of a cooling-off period. For officers and directors, the cooling-off period expires the later of (i) 90 days after the adoption of the plan, or (ii) 2 business days after disclosure of the Company&#8217;s financial statements on Form 10-K or 10-Q for the fiscal quarter in which the plan was adopted. For persons who are not officers or directors, the cooling-off period expires 30 days after the adoption of the plan.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The plan clearly specifies the amount, pricing and timing of transactions (including by formula or algorithm, which must be straightforward in design and simple to implement). The individual approving the plan as specified in the third paragraph of these requirements, and the Company&#8217;s outside counsel have sole discretion to determine if the requirements set forth in this item 3 are met.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If the specified number of shares is not sold or purchased because the trigger price has not been reached prior to the closing of the quarterly trading blackout period or the designated period to effect transactions under the plan, the unsold shares may be added to the order(s) for the following designated period(s) to effect transactions under the plan.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The plan may be terminated or suspended by a Compliance Officer, the Company&#8217;s Board of Directors or its Compensation Committee if it determines that doing so is in the best interests of the Company or that not doing so would cause a violation of applicable law. For example, but without limitation, continued trades could interfere with lock-up obligations imposed on &#8220;insiders&#8221; in connection with an underwritten public offering or cause a violation of Regulation M when the Company is engaged in a public offering of its securities.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">For plans adopted on or after February 27, 2023, an officer or director must include a representation in the plan certifying that, on the date of adoption of the plan, the individual officer or director is not aware of any material nonpublic information about the security or the Company and that the individual officer or director is adopting the plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 under the Securities Exchange Act of 1934.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The plan must provide that transactions thereunder will be consummated through a single broker that is acceptable to the Company.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;">For plans adopted on or after February 27, 2023, the person adopting the plan must not have outstanding (and may not subsequently adopt) any additional plan that would qualify for the affirmative defense in Rule 10b5-1 for purchases or sales of the Company&#8217;s securities. Certain exceptions are available, including (i) an arrangement involving a series of separate contracts with different brokers acting on behalf of the person which may be treated as a single plan, (ii) a person may maintain two separate plans at the same time, provided that trading under the later-</p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 72pt;">commencing plan is not authorized to begin until after all trades under the earlier-commencing plan are completed or expire without execution, and (iii) plans providing for the sale of securities by a broker as necessary to satisfy tax withholding obligations arising exclusively from the vesting of certain compensatory awards (an &#8220;eligible sell-to- cover transaction&#8221;), provided the person adopting such plan does not exercise control over the timing of such sales. These exceptions are complex, and you must consult with and obtain the approval of a Compliance Officer before acting on any of them. It is recommended that you consult with your personal legal advisor before acting on any of these exceptions.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">For plans adopted on or after February 27, 2023, a plan (other than one providing for an eligible sell-to-cover transaction) may be designed to effect the open-market purchase or sale of the total amount of securities in a single transaction, provided that the person adopting such a plan may only adopt one such plan in any 12-month period.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">10.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The plan must have a termination date.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">11.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Public disclosure of the plan, if any (and the level of detail of such disclosure) shall remain in the sole discretion of the Company&#8217;s outside counsel.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">12.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A Voluntary Plan may be amended or terminated by the individual only if the individual is not aware of material non-public information at the time of such amendment or termination. For plans adopted before February 27, 2023, the individual will not be allowed to trade under the amended Voluntary Plan, to start a new Voluntary Plan or to terminate an existing Voluntary Plan until the later of the end of the next quarterly trading blackout period or the 91st day following the individual&#8217;s adoption of the amendment or the new Voluntary Plan, or approval of the termination (excluding a termination that occurs automatically under the terms of the plan, including an automatic expiration of the plan following the last scheduled transaction). For Voluntary Plans adopted on or after February 27, 2023, an amendment that modifies or changes the amount, price, or timing of the purchase or sale of securities (or modifies or changes a written formula or algorithm, or computer program that affects the amount the amount pricing or timing of the purchase or sale of the securities) will start a new cooling off period, and the individual will not be allowed to trade under the amended Voluntary Plan, start a new Voluntary Plan or terminate an existing Voluntary Plan until such cooling-off period expires. In the meantime, the original Voluntary Plan will remain in effect. Equity Award Plans may not be amended or terminated by their adopters; provided, however, once per year during the First Open Window (as defined below) an adopter may elect either the minimum statutory tax rates or the maximum statutory tax rates in the applicable jurisdictions to satisfy the tax withholding due upon vesting. The term &#8220;First Open Window&#8221; shall mean the period commencing on the first Permissible Trading Day (as defined below) of the fiscal year and ending no later than February 18<sup style="font-size:9pt;vertical-align:top;">th</sup> of such fiscal year. &#8220;Permissible Trading Day&#8221; means a day that satisfies each of the following requirements:</p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:71.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The NYSE is open for trading on that day;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:71.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The adopter is not aware of material non-public information that would make it illegal for him or her to sell shares of the Company&#8217;s common stock on that day under Rule 10b-5 of the Securities and Exchange Commission; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:71.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Under the Company&#8217;s Amended and Restated Insider Trading Policy, the adopter is permitted to sell shares of the Company&#8217;s common stock on that day.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">13.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Any Voluntary Plan must provide for automatic termination in the event of death, a personal bankruptcy filing, the filing of a divorce petition, the last scheduled transaction under the plan, the public announcement of a merger, recapitalization, acquisition, tender or exchange offer, or other business combination or reorganization resulting in the exchange or conversion of the shares of the Company into shares of another company, or the conversion of the Company&#8217;s shares into rights to receive fixed amounts of cash or into debt securities and/or preferred stock (whether in whole or in part). In addition, the Voluntary Plan shall provide for automatic termination, or the Company&#8217;s internal processes shall cause the Voluntary Plan to terminate, in each case in the event of termination of employment with the Company, in which case such automatic termination will occur at the beginning of the Company&#8217;s next open trading window. </p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The plan must contain a provision requiring timely notification to the Company of all transaction pursuant to the plan to assure compliance with applicable reporting requirements.</p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:231pt;"></font>4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>armp-20241231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:13 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Subsidiaries of Armata Pharmaceuticals, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following companies are direct or indirect wholly owned subsidiaries of Armata Pharmaceuticals, Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.48%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jurisdiction</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">C3J Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="color:#231f20;">C3&#160;Jian,&#160;LLC&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States </p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Biocontrol Limited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United Kingdom</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">AmpliPhi Australia Pty Ltd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Special Phage Holdings Pty Ltd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Special Phage Services Pty Ltd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>armp-20241231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:22 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Consent of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the following Registration Statements of Armata Pharmaceuticals, Inc.: &#160; &#160; &#160; &#160; &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Hlk97981794"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-1 Nos. 333-213421, 333-217169, 333-217680, and 333-226959),</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-3 Nos. 333-237533, 333-237534, 333-256104, 333-263936, 333-264961 and 333-269726),</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-203455) pertaining to the AmpliPhi Biosciences Corporation 2012 Stock Incentive Plan and AmpliPhi Biosciences Corporation 2013 Stock Incentive Plan,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-8 Nos. 333-212183, 333-217563, 333-223987, 333-275580, and 333-276657) pertaining to the Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan and Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-8 Nos. 333-221564 and 333-232058) pertaining to the Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan, as amended, Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan, C3J Jian, Inc. Amended 2006 Stock Option Plan and C3J Therapeutics, Inc. 2016 Stock Plan, and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-250034) pertaining to the Inducement Restricted Stock Unit Award (October 2020);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">of our report dated March 20, 2025, with respect to the consolidated financial statements of Armata Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Armata Pharmaceuticals, Inc. for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 180pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">San Diego, California </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March 20, 2025</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>armp-20241231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:22 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">I, Deborah Birx, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.75pt;text-indent:-36.75pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Armata Pharmaceuticals, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.75pt;text-indent:-36.75pt;margin:0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: March 20, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Deborah Birx</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deborah Birx</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>armp-20241231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:23 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">I, David D. House, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.75pt;text-indent:-36.75pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Armata Pharmaceuticals, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.75pt;text-indent:-36.75pt;margin:0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: March 20, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David D. House</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David D. House</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Principal Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>armp-20241231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:25 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the annual report of Armata Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Deborah Birx, Chief Executive Officer and Director of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter&#160;63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:26pt;text-indent:-26pt;margin:0pt 0pt 0pt 55pt;">(1)&#160;&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:26pt;text-indent:-26pt;margin:0pt 0pt 0pt 55pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 20, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">M</p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Deborah Birx  </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deborah Birx  </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>armp-20241231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:30 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter&#160;63, Section&#160;1350 of the</p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the annual report of Armata Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, David D. House, Senior Vice President, Finance and Principal Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter&#160;63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:26pt;text-indent:-26pt;margin:0pt 0pt 0pt 55pt;">(1)&#160;&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:26pt;text-indent:-26pt;margin:0pt 0pt 0pt 55pt;">(2)&#160;&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 20, 2025</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David D. House</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David D. House</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Principal Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>11
<FILENAME>armp-20241231xex97.htm
<DESCRIPTION>EX-97
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 12:13:32 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 97</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Execution Copy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARMATA PHARMACEUTICALS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">POLICY FOR THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><b style="font-size:12pt;font-weight:bold;">Purpose</b><font style="font-size:12pt;">. The purpose of this Policy is to describe the circumstances in which Executives will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. Each current and future Executive Officer shall be required to sign and return to the Company the Acknowledgement Form attached hereto as </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-size:12pt;"> pursuant to which such Executive will agree to be bound by the terms and comply with this Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><b style="font-size:12pt;font-weight:bold;">Administration</b><font style="font-size:12pt;">. This Policy shall be administered by the Committee. Any determinations made by the Committee shall be final and binding on all affected individuals and their beneficiaries, heirs, executors, administrators, or other legal representatives. The Committee shall have full power and authority to (i) administer and interpret this Policy; (ii) correct any defect, supply any omission and reconcile any inconsistency in this Policy; and (iii) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of this Policy and to comply with applicable law (including Section 10D of the Exchange Act) and applicable stock market or exchange rules and regulations. Notwithstanding anything to the contrary contained herein, to the extent permitted by Section 10D of the Exchange Act and Section 303A.14 of the NYSE Listed Company Manual, the Board may, in its sole discretion, at any time and from time to time, administer this Policy in the same manner as the Committee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><b style="font-size:12pt;font-weight:bold;">Definitions</b><font style="font-size:12pt;">. For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Accounting Restatement</font><font style="font-size:12pt;">&#8221; shall mean an accounting restatement (i) due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a &#8220;Big R&#8221; restatement), or (ii) that corrects an error that is not material to previously issued financial statements, but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#8220;little r&#8221; restatement).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Board</font><font style="font-size:12pt;">&#8221; shall mean the Board of Directors of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Clawback Eligible Incentive Compensation</font><font style="font-size:12pt;">&#8221; shall mean, in connection with an Accounting Restatement and with respect to each individual who served as an Executive Officer at any time during the applicable performance period for any Incentive-based Compensation (whether or not such individual is serving as an Executive Officer at the time the Erroneously Awarded Compensation is required to be repaid to the Company Group), all Incentive-based Compensation Received by such Executive (i) on or after the Effective Date, (ii) after beginning service as an Executive Officer, (iii) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (iv) during the applicable Clawback Period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Clawback Period</font><font style="font-size:12pt;">&#8221; shall mean, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date and any</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">transition period (that results from a change in the Company&#8217;s fiscal year) of less than nine months within or immediately following those three completed fiscal years.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-size:12pt;">&#8221; shall mean the Compensation Committee of the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221; shall mean Armata Pharmaceuticals, Inc., a Washington corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company Group</font><font style="font-size:12pt;">&#8221; shall mean the Company, together with each of its direct and indirect subsidiaries.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(h)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-size:12pt;">&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-size:12pt;">&#8221; shall mean October 2, 2023.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(j)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Erroneously Awarded Compensation</font><font style="font-size:12pt;">&#8221; shall mean, with respect to each Executive in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(k)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Executive</font><font style="font-size:12pt;">&#8221; shall mean any current or former Executive Officer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(l)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Executive Officer</font><font style="font-size:12pt;">&#8221; shall mean each individual who is designated as an &#8220;officer&#8221; of the Company in accordance with 17 C.F.R. 240.16a-1(f). Identification of an Executive Officer for purposes of this Policy would include at a minimum executive officers identified pursuant to 17 C.F.R. 240.16a-1(b). The determination as to an individual&#8217;s status as an Executive Officer shall be made by the Committee and such determination shall be final, conclusive and binding on such individual and all other interested persons.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(m)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Financial Reporting Measures</font><font style="font-size:12pt;">&#8221; shall mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall for purposes of this Policy be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company&#8217;s financial statements or included in a filing with the SEC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(n)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Incentive-based Compensation</font><font style="font-size:12pt;">&#8221; shall mean any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(o)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">NYSE</font><font style="font-size:12pt;">&#8221; shall mean the New York Stock Exchange.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(p)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-size:12pt;">&#8221; shall mean this Armata Pharmaceuticals, Inc. Policy for the Recovery of Erroneously Awarded Compensation, as the same may be amended and/or restated from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(q)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Received</font><font style="font-size:12pt;">&#8221; shall, with respect to any Incentive-based Compensation, mean actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-based</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 6pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Compensation award is attained, even if payment or grant of the Incentive-based Compensation occurs after the end of that period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(r)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Restatement Date</font><font style="font-size:12pt;">&#8221; shall mean the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(s)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">SEC</font><font style="font-size:12pt;">&#8221; shall mean the U.S. Securities and Exchange Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 5.95pt;"><font style="display:inline-block;text-indent:0pt;width:30.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><b style="font-size:12pt;font-weight:bold;">Repayment of Erroneously Awarded Compensation</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">In the event of an Accounting Restatement, the Committee shall promptly (and in all events within ninety (90) days after the Restatement Date) determine the amount of any Erroneously Awarded Compensation for each Executive in connection with such Accounting Restatement and shall promptly thereafter provide each Executive with a written notice containing the amount of Erroneously Awarded Compensation and a demand for repayment or return, as applicable. For Incentive-based Compensation based on (or derived from) stock price or total shareholder return where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, the amount shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-based Compensation was Received (in which case, the Company shall maintain documentation of such determination of that reasonable estimate and provide such documentation to NYSE).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The Committee shall have broad discretion to determine the appropriate means of recovery of Erroneously Awarded Compensation based on all applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery. To the extent that the Committee determines that any method of recovery (other than repayment by the Executive in a lump sum in cash or property) is appropriate, the Company shall offer to enter into a repayment agreement (in a form reasonable acceptable to the Committee) with the Executive. If the Executive accepts such offer and signs the repayment agreement within thirty (30) days after such offer is extended, the Company shall countersign such repayment agreement. If the Executive fails to sign the repayment agreement within thirty (30) days after such offer is extended, the Executive will be required to repay the Erroneously Awarded Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to such Erroneously Awarded Compensation) on or prior to the date that is one hundred twenty (120) days following the Restatement Date. For the avoidance of doubt, except as set forth in Section 4(d) below, in no event may the Company Group accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive&#8217;s obligations hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">To the extent that an Executive fails to repay all Erroneously Awarded Compensation to the Company Group when due (as determined in accordance with Section 4(b) above), the Company shall, or shall cause one or more other members of the Company Group to, take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">from the applicable Executive. The applicable Executive shall be required to reimburse the Company Group for any and all expenses reasonably incurred (including legal fees) by the Company Group in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section 4(b) or 4(c) above if the following conditions are met and the Committee determines that recovery would be impracticable:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:12pt;">The direct expenses paid to a third party to assist in enforcing the Policy against an Executive would exceed the amount to be recovered, after the Company has made a reasonable attempt to recover the applicable Erroneously Awarded Compensation, documented such attempts and provided such documentation to NYSE;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:12pt;">Recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to NYSE, that recovery would result in such a violation and a copy of the opinion is provided to NYSE; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(iii)</font></font><font style="font-size:12pt;">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><b style="font-size:12pt;font-weight:bold;">Reporting and Disclosure</b><font style="font-size:12pt;">. The Company shall file all disclosures with respect to this Policy in accordance with the requirement of the federal securities laws, including the disclosure required by the applicable SEC filings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><b style="font-size:12pt;font-weight:bold;">Indemnification Prohibition</b><font style="font-size:12pt;">. No member of the Company Group shall be permitted to indemnify any Executive against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company Group&#8217;s enforcement of its rights under this Policy. Further, no member of the Company Group shall enter into any agreement that exempts any Incentive-based Compensation from the application of this Policy or that waives the Company Group&#8217;s right to recovery of any Erroneously Awarded Compensation and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">7.</font></font><b style="font-size:12pt;font-weight:bold;">Interpretation</b><font style="font-size:12pt;">. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. Notwithstanding anything to the contrary herein, this Policy is intended to comply with the requirements of Section 10D of the Exchange Act and Section 303A.14 of the NYSE Listed Company Manual (and any applicable regulations, administrative interpretations or stock market or exchange rules and regulations adopted in connection therewith). The provisions of this Policy shall be interpreted in a manner that satisfies such requirements and this Policy shall be operated accordingly. If any provision of this Policy would otherwise frustrate or conflict with this intent, the provision shall be interpreted and deemed amended so as to avoid such conflict. If any provision of this Policy is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by applicable law and shall</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.</font></font><b style="font-size:12pt;font-weight:bold;">Effective Date</b><font style="font-size:12pt;">. This Policy shall be effective as of the date it was adopted by the Committee, as set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><b style="font-size:12pt;font-weight:bold;">Amendment</b><font style="font-size:12pt;">; </font><b style="font-size:12pt;font-weight:bold;">Termination</b><font style="font-size:12pt;">. The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary, including as and when it determines that it is legally required by any federal securities laws, SEC rule or the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed. The Committee may terminate this Policy at any time. Notwithstanding anything in this Section 9 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">10.</font></font><b style="font-size:12pt;font-weight:bold;">Other Recoupment Rights</b><font style="font-size:12pt;">; </font><b style="font-size:12pt;font-weight:bold;">No Additional Payments</b><font style="font-size:12pt;">. The Committee intends that this Policy will be applied to the fullest extent of the law. The Committee may require that any employment agreement, equity award agreement, or any other agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require an Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company Group under applicable law, regulation or rule or pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company Group. Any applicable award agreement or other document setting forth the terms and conditions of any compensation covered by this Policy shall be deemed to include the restrictions imposed herein and incorporate this Policy by reference and, in the event of any inconsistency, the terms of this Policy will govern. For the avoidance of doubt, this Policy applies to all Incentive-based Compensation that is Received on or after the Effective Date, regardless of the date on which the award agreement or other document setting forth the terms and conditions of the Executive&#8217;s compensation became effective, including, without limitation, Incentive-based Compensation Received under the Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan and any successor plan thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">11.</font></font><b style="font-size:12pt;font-weight:bold;">Successors</b><font style="font-size:12pt;">. This Policy shall be binding and enforceable against all Executives and their beneficiaries, heirs, executors, administrators, or other legal representatives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">*</font></font><font style="font-size:12pt;">*</font><font style="display:inline-block;width:30pt;"></font><font style="font-size:12pt;">*</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy was adopted by the Committee as of November 9, 2023.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>armp-20241231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $= ZD# 2(  A$! Q$!_\0
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M?#ZXUK7_ (:Z5H0NX1XB>=H/[0#J"L;R?/C:3G'OZ"O2O^&D?'=OX=\.?:O
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M6&"/UKYZLOV8O&MAHMOX/A^*-Q!X"MIQ)%:6]CY5^(PVX1?:5<';GT'^% '
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M_P#BJ/+U'_GO;?\ ?EO_ (J@"[15+R]1_P">]M_WY;_XJCR]1_Y[VW_?EO\
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M;OA;_H=_#/\ X%I_\<H^KUOY']S#ZS0_G7WH[VBN"_X6[X6_Z'?PS_X%I_\
M'*/^%N^%O^AW\,_^!:?_ !RCZO6_D?W,/K-#^=?>CO:*X+_A;OA;_H=_#/\
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M%O\ H=_#/_@6G_QRCZO6_D?W,/K-#^=?>CO:*X+_ (6[X6_Z'?PS_P"!:?\
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M-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&:
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M0O\ P6P__$U\T_\ #:WB/_H7-*_[_P M'_#:WB/_ *%S2O\ O_+1_9.9]_\
MR;_@A_;.4]E_X#_P#Z*U;X5^"XK)F3PEH:MN3D:="/XA_LU<_P"%3^"?^A0T
M+_P70_\ Q-?,ES^V=XANHC&WAW2L$@_Z^7L<U+_PVMXC_P"A<TK_ +_RT?V3
MF??_ ,F_X(?VSE/9?^ _\ ^EO^%3^"?^A0T+_P %L/\ \31_PJ?P3_T*&A?^
M"V'_ .)KYI_X;6\1_P#0N:5_W_EH_P"&UO$?_0N:5_W_ ):/[)S/O_Y-_P $
M/[9RGLO_  '_ (!]+?\ "I_!/_0H:%_X+8?_ (FC_A4_@G_H4-"_\%L/_P 3
M7S3_ ,-K>(_^A<TK_O\ RT?\-K>(_P#H7-*_[_RT?V3F??\ \F_X(?VSE/9?
M^ _\ ^EO^%3^"?\ H4-"_P#!;#_\31_PJ?P3_P!"AH7_ (+8?_B:^:?^&UO$
M?_0N:5_W_EH_X;6\1_\ 0N:5_P!_Y:/[)S/O_P"3?\$/[9RGLO\ P'_@'TM_
MPJ?P3_T*&A?^"V'_ .)H_P"%3^"?^A0T+_P6P_\ Q-?-/_#:WB/_ *%S2O\
MO_+1_P -K>(_^A<TK_O_ "T?V3F??_R;_@A_;.4]E_X#_P  ^EO^%3^"?^A0
MT+_P6P__ !-'_"I_!/\ T*&A?^"V'_XFOFG_ (;6\1_]"YI7_?\ EH_X;6\1
M_P#0N:5_W_EH_LG,^_\ Y-_P0_MG*>R_\!_X!]+?\*G\$_\ 0H:%_P""V'_X
MFC_A4_@G_H4-"_\ !;#_ /$U\T_\-K>(_P#H7-*_[_RT?\-K>(_^A<TK_O\
MRT?V3F??_P F_P""']LY3V7_ (#_ , ^EO\ A4_@G_H4-"_\%L/_ ,31_P *
MG\$_]"AH7_@MA_\ B:^:?^&UO$?_ $+FE?\ ?^6C_AM;Q'_T+FE?]_Y:/[)S
M/O\ ^3?\$/[9RGLO_ ?^ ?2W_"I_!/\ T*&A?^"V'_XFC_A4_@G_ *%#0O\
MP6P__$U\T_\ #:WB/_H7-*_[_P M'_#:WB/_ *%S2O\ O_+1_9.9]_\ R;_@
MA_;.4]E_X#_P#Z6_X5/X)_Z%#0O_  6P_P#Q-4IOA7X+&J6R#PEH84JV5_LZ
M+!_\=KYV_P"&UO$?_0N:5_W_ ):B?]LWQ"]Q',?#NE;D! _?R]Z/[)S/O_Y-
M_P $/[9RGLO_  '_ (!]-_\ "I_!/_0H:%_X+8?_ (FC_A4_@G_H4-"_\%L/
M_P 37S3_ ,-K>(_^A<TK_O\ RT?\-K>(_P#H7-*_[_RT?V3F??\ \F_X(?VS
ME/9?^ _\ ^EO^%3^"?\ H4-"_P#!;#_\31_PJ?P3_P!"AH7_ (+8?_B:^:?^
M&UO$?_0N:5_W_EH_X;6\1_\ 0N:5_P!_Y:/[)S/O_P"3?\$/[9RGLO\ P'_@
M'TM_PJ?P3_T*&A?^"V'_ .)H_P"%3^"?^A0T+_P6P_\ Q-?-/_#:WB/_ *%S
M2O\ O_+1_P -K>(_^A<TK_O_ "T?V3F??_R;_@A_;.4]E_X#_P  ^EO^%3^"
M?^A0T+_P6P__ !-'_"I_!/\ T*&A?^"V'_XFOFG_ (;6\1_]"YI7_?\ EH_X
M;6\1_P#0N:5_W_EH_LG,^_\ Y-_P0_MG*>R_\!_X!]+?\*G\$_\ 0H:%_P""
MV'_XFC_A4_@G_H4-"_\ !;#_ /$U\T_\-K>(_P#H7-*_[_RT?\-K>(_^A<TK
M_O\ RT?V3F??_P F_P""']LY3V7_ (#_ , ^EO\ A4_@G_H4-"_\%L/_ ,31
M_P *G\$_]"AH7_@MA_\ B:^:?^&UO$?_ $+FE?\ ?^6@?MJ^)"<#PYI1/_7:
M6C^R<S[_ /DW_!#^V<I[+_P'_@'TM_PJCP3_ -"AH7_@NA_^)H_X5/X)_P"A
M0T+_ ,%T/_Q-?/UE^U?XSO5#KX7TF)#T:6YE7].M;<'[2?B(H&GLM$B_O!6F
M.W\R,]_R]ZQEE^81WE_Y-_P3>.99;/:/_DO_  #V;_A4_@G_ *%#0O\ P70_
M_$T?\*G\$_\ 0H:%_P""Z'_XFO')_P!HGQ88&FL].T"Y0#(+S3(#USSR!T[D
M9/3-<WJW[7/C+0Y?+OO">FP$\!C/*4;C. PR"?8&B&7YA-VC+_R;_@BGF>6T
MU>4=/\/_  #Z%?X>^%]#:*\T[PYI-A=QNNR>VLHXW7)YPP4$5U@Z5\J>$_VL
M-=\8^*=(T6XT+38(;VZ2)I8YI"RC.<@'CM7U6.E>=C,+B,+-+$;M=[GJ8#%X
M;%P<L+LGVL+1117GGIB44M% "8HI:* "DI:* "BBB@ HHHH *X'XC74UOXO^
M'*1321I+K4J2*CE0Z_8K@X8#J,@'![@5WU<QXL\)S>(==\*7\5Q'"FCZ@]Y(
MCJ29%-O+%M7'0YD!Y]#71AY1C.\MK/\ )G)BHRG3M#>\?PDK_@>>Q?&OQ&NC
MW7B&;P]IZ^';+5&T^XD6^<W+*)O*\Q$V8XR,@L.^*S[.XFL_C#XY\1>(K/3;
MBV\/V\3I/YDDDUK%Y+,H@!& 6S\W3GH3722?!Z^?X8ZOX8&HVXN+W4Y+Y;CR
MFV*K7 EVD9SG Q6U)\,DU#6O'$U_<++I_B2"&W\J(%9(@D11CGH3SD5Z_ML+
M!3Y-+W6E]KQ_3F/$]AC*CASW=K/6UKVGVZ)\OWG->'_CE/-J>EIK-II5M8ZK
M#+-;?V?J0N9[<I&9=DZ;1@E >5) (Q5_1_B!XUUJRTW5(O"EH-(U=<VCI>,\
MUNK*3%+<+L "'C.PD@-T-5_"7P=O=(GM[?43X<DTZVMY+?S[#1EAO;D,A0&2
M7)VG!R2@&3[$UH^%O ?BW11HVE7/B>!O#ND86%+2U,=U<QJ-L<<SEBNT#&=H
M!.T=*FJ\&K^SM\^;SV\]M_\ ,THK'/E]JY?+EOTW\M]O\CC_  _XWUW6O"&F
M:AXGMK/47;Q1!96S6T\D#(WVHQ[F"!0P3C .0P^]71WWQ8UV2#6]:TG0+6]\
M,:-<207$LMX4NIO*_P!:\2;"N%YQN89P:9IOPBU>RTE-*DU2RDLK7Q!#K-JZ
MP.LFP3^:Z/\ ,03T (P/6G7WPIU^*WUS1-)UVSL_#&LW$D\Z2VC/=P"7_6I$
M^X+AN<;@<9-7*6$G-[6OYVMIVZV_7R,H0QL(+>]O[M[Z[M]+_IYD=W\6?$6I
M:OKT/AW1-.O-/TJT@O3<7MX\+2I)%Y@4*J-\V/7CU-1ZG\<+FYFT"#1K'3H9
M-4TT:DKZW?&UC;)QY,;!3NDSGT&/K6]H_P ,7T6_\5/!=1BTU6SM[2VC*G="
M(HC&-Q[]NE83?";Q#:>&](TFWU31]1M+;3ULKBPUC3S/;;US^^C 8,K8.,$D
M=*B+P3:5EI;O_+K?T?H:26/2;N];_P NGO:6]5ZL]+\.:G<ZSH=G>WEA+I=U
M-&&DLYF#-$W<9'!^OI6E6#X$\+_\(7X1TO1#=->FRA\LSN,;N2>!V S@#L *
MWJ\:IR\\N3:^A[U+F]G'GWLK^OR"BBBLS4**** "BBB@ HHHH **** *6J_Z
MJ'_KLG\ZNU2U7_50_P#79/YU=H **** "BBB@ HHHH **** "BBB@#AOCA_R
M2;Q/_P!>;?S%?GSHND76OZI::;8QB6\NG$42%@H9CT&3P*_0;XX?\DF\3_\
M7FW\Q7PW\(?^2F^&/^OU/Y&ONLADX82K-;I_H?G7$<%4QM&#V:2_$SHO ^M2
M^*V\-_8RFLJ[1FVD<+AE!)^8\=!UJ?0?AYKOB.&YGM+>&*TMI/*EN[RZCMH
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M#J9/FM5WJ0;]9)_J?,U%?3/_  Q'J'_0V6W_ ( M_P#%T?\ #$>H?]#9;?\
M@"W_ ,76O]M8#_GY^#_R,O["S'_GU^,?\SYFHKZ9_P"&(]0_Z&RV_P# %O\
MXNC_ (8CU#_H;+;_ , 6_P#BZ/[:P'_/S\'_ )!_868_\^OQC_F?,U%?3/\
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MYGS-17TS_P ,1ZA_T-EM_P" +?\ Q='_  Q'J'_0V6W_ ( M_P#%T?VU@/\
MGY^#_P @_L+,?^?7XQ_S/F:BOI2Z_8LOK6$R-XKMR 0,"Q;N<?W_ 'J7_AB.
M_P#^ALMO_ %O_BZ/[:P'_/S\'_D']A9C_P ^OQC_ )GS-17TS_PQ'J'_ $-E
MM_X M_\ %T?\,1ZA_P!#9;?^ +?_ !=']M8#_GY^#_R#^PLQ_P"?7XQ_S/F:
MBOIG_AB/4/\ H;+;_P  6_\ BZ/^&(]0_P"ALMO_  !;_P"+H_MK ?\ /S\'
M_D']A9C_ ,^OQC_F?,U%?3/_  Q'J'_0V6W_ ( M_P#%T?\ #$>H?]#9;?\
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MO^Q9?)<QPGQ7;[G!(/V%NW_ Z/[:P'_/S\'_ )!_868_\^OQC_F?-E%?3/\
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MRF=YC7P,J:HM:WZ'Z=P?D&!SJG6EBTVXM6L[;W/M+_AM7P5_T"M>_P"_$/\
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M7O\ OQ#_ /':/^&U?!7_ $"M>_[\0_\ QVOBVBC_ %@QW=?<'^HN3?RR_P#
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M*U[_ +\0_P#QVC_AM7P5_P! K7O^_$/_ ,=KXMHH_P!8,=W7W!_J+DW\LO\
MP(^TO^&U?!7_ $"M>_[\0_\ QVC_ (;5\%?] K7O^_$/_P =KXMHH_U@QW=?
M<'^HN3?RR_\  C[2_P"&U?!7_0*U[_OQ#_\ ':/^&U?!7_0*U[_OQ#_\=KXM
MHH_U@QW=?<'^HN3?RR_\"/M+_AM7P5_T"M>_[\0__':/^&U?!7_0*U[_ +\0
M_P#QVOBVBC_6#'=U]P?ZBY-_++_P(^TO^&U?!7_0*U[_ +\0_P#QVC_AM7P5
M_P! K7O^_$/_ ,=KXMHH_P!8,=W7W!_J+DW\LO\ P(^TO^&U?!7_ $"M>_[\
M0_\ QVJTO[9G@Q[Z&8:7KNU P(\B'//_ &UKXVHH_P!8,=W7W!_J+DW\LO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGL.]<&8Y5#,91<I6Y3V\@XEJY!"I"G24^=IZMK:_^9^:G_"M/&'_ $*>N_\
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M^(BXG_H'C][_ ,C\TO\ A6GC#_H4]=_\%D__ ,31_P *T\8?]"GKO_@LG_\
MB:_2W<OJ/SHW+ZC\Z/\ 5FE_S]?W(/\ B(N)_P"@>/WO_(_-+_A6GC#_ *%/
M7?\ P63_ /Q-'_"M/&'_ $*>N_\ @LG_ /B:_2W<OJ/SHW+ZC\Z/]6:7_/U_
M<@_XB+B?^@>/WO\ R/S2_P"%:>,/^A3UW_P63_\ Q-'_  K3QA_T*>N_^"R?
M_P")K]+=R^H_.C<OJ/SH_P!6:7_/U_<@_P"(BXG_ *!X_>_\C\TO^%:>,/\
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M='^K-+_GZ_N0?\1%Q/\ T#Q^]_Y'YI?\*T\8?]"GKO\ X+)__B:/^%:>,/\
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MQE_]!-?FMIEG_:&HVEIO\OSYDBWXSMW,!G'XU\/Q'5JTZE)4Y-7OLVNQ^S<
MX;#5Z&)EB*<96<=TG;1]T=I_POGXB?\ 0XZI_P!])_\ $T?\+Y^(G_0XZI_W
MTG_Q-;5U\)_"D/BZ3PLGC.^76Q+]G07&C;;=I<<*9!*2 >F<5QOAOP5+K?CB
M+PW<S_8IC+)"\JIOVE%8GC(S]W]:^7D\="2BZCNW;25]>VC/T>G')ZL)5(T8
MV4>;6G;W>ZO%76G2YL?\+Y^(G_0XZI_WTG_Q-'_"^?B)_P!#CJG_ 'TG_P 3
M69K'@D:3X&TCQ$+TRF_NY[7[-Y6 GE_Q;L\Y],<5RU83Q&+INTJDNC^)]?F=
ME+ Y973E3H0:3:^!;IV?3N=Y_P +Y^(G_0XZI_WTG_Q-'_"^?B)_T..J?]])
M_P#$UP=%9_6\3_S\E][_ ,S?^R\!_P! \/\ P"/^1WG_  OGXB?]#CJG_?2?
M_$T?\+Y^(G_0XZI_WTG_ ,37!T4?6\3_ ,_)?>_\P_LO ?\ 0/#_ , C_D=Y
M_P +Y^(G_0XZI_WTG_Q-'_"^?B)_T..J?]])_P#$UP=%'UO$_P#/R7WO_,/[
M+P'_ $#P_P# (_Y'>?\ "^?B)_T..J?]])_\31_POGXB?]#CJG_?2?\ Q-<'
M11];Q/\ S\E][_S#^R\!_P! \/\ P"/^1WG_  OGXB?]#CJG_?2?_$T?\+Y^
M(G_0XZI_WTG_ ,37!T4?6\3_ ,_)?>_\P_LO ?\ 0/#_ , C_D=Y_P +Y^(G
M_0XZI_WTG_Q-!^/'Q$((/C'5/^^D_P#B:X.BCZWB?^?DOO?^8?V7@/\ H'A_
MX!'_ ".[7X[_ !#10J^,-3"@8 W)_P#$TO\ POGXB?\ 0XZI_P!])_\ $UP=
M%'UO$_\ /R7WO_,/[+P'_0/#_P  C_D=Y_POGXB?]#CJG_?2?_$T?\+Y^(G_
M $..J?\ ?2?_ !-<'11];Q/_ #\E][_S#^R\!_T#P_\  (_Y'>?\+Y^(G_0X
MZI_WTG_Q-'_"^?B)_P!#CJG_ 'TG_P 37!T4?6\3_P _)?>_\P_LO ?] \/_
M  "/^1WG_"^?B)_T..J?]])_\31_POGXB?\ 0XZI_P!])_\ $UP=%'UO$_\
M/R7WO_,/[+P'_0/#_P  C_D=Y_POGXB?]#CJG_?2?_$T?\+Y^(G_ $..J?\
M?2?_ !-<'11];Q/_ #\E][_S#^R\!_T#P_\  (_Y'>?\+Y^(G_0XZI_WTG_Q
M-'_"^?B)_P!#CJG_ 'TG_P 37!T4?6\3_P _)?>_\P_LO ?] \/_  "/^1WG
M_"^?B)_T..J?]])_\31_POGXB?\ 0XZI_P!])_\ $UP=%'UO$_\ /R7WO_,/
M[+P'_0/#_P  C_D=Y_POGXB?]#CJG_?2?_$T?\+Y^(G_ $..J?\ ?2?_ !-<
M'11];Q/_ #\E][_S#^R\!_T#P_\  (_Y'=O\=OB%(N&\8:F1UQN3_P")I?\
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M_P!5#_UV3^=7: "BBB@ HHHH **** "BBB@ HHHH YWXB?\ (B:__P!>,O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-Q_\=H_X9*\ _P#0.?\ \";C_P".U[511_9^#_Y\Q_\  5_D']O9M_T%U/\
MP.7^9XK_ ,,E> ?^@<__ ($W'_QVC_ADKP#_ - Y_P#P)N/_ ([7M5%']GX/
M_GS'_P !7^0?V]FW_074_P# Y?YGBC?LD^ 2,"PD4^HN9_\ XY2_\,E> /\
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M ,"KC_X[4^F_LM>"=)U*UOK6R>.XMI!+&3<3L P.0<&3FO8J*:P&$3NJ4?\
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M33MIK*QE&W:3&),(A^;D<' H_P"%@_%F'3+NZN?#EK'*)$\N"WTJXE(7S"K
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MSYGDX7&<T )H_CKXM7VE-=WNCFP >V@5%T1Y93DS%Y3&9U."5A0KQL#EB3C
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MU+10 F!Z48'I2T4 )@>E1S6L-QL\V))-C!UWJ#M/J,]#4M% "8'H*,#TI:*
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>armp-20241231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %E T(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"%I:]_T3GQ#^<'_P 77H]%'LJG_/Q_<O\ (/K.'_Z!U]\O\SSC_A:>O?\
M1.?$/YP?_%UN>#_B'9^++JXL'M+O2-7MU#RZ=?H$E"]-PP2&'N#75UYOXQ18
M/C/\/98QLDF2_BD8<%T$&X*?4 C-1+VE&TG.ZNEJEU=NAK3^KXKFIJERM1DT
MTW]E-ZW;WM8](HHHKN/'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A /%'_0_7W_ (!Q4>UJ?\^W]Z_S#ZM1_P"?\?NE_P#(GH%%>?\ _" >*/\
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MCUYQ\&?];X]_[&F]_E'7H]<F%_@KY_F>GF7^]2^7Y(****ZSS HHHH ****
M//? _P#R4_Q]_OVG_HLUZ%7GO@C_ )*?X^_W[3_T6:]"KEPWP/UE^;/1Q_\
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MF^%DEQ?B]?5MMTS-))+%;A#N..%(/"X"Y4Y'%>@45A]5HK:)VO,<4]Y_@O\
M(\Z'P:LDNIY%N<I*(0-\9+KL1$P#NQ@B/ICN>:FT_P"%*V6L:;>R:I+<)9.L
MBQ.IY8!L]\ %F+=,Y[UW]%"PU%.ZB)YABFK.?2W3M8*\X\;?\EA^&WUU'_TG
MKT>O./&W_)8?AM]=1_\ 2>EB?@7^*/\ Z4AY?_&E_@J?^D2/1Z***ZSS0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /./@S_K?'O_8TWO\ *.LWPS^T-IGB+XFW7@PZ?-:7,,TT
M"W,DBE)&C)X Z\X.*TO@S_K?'O\ V--[_*.OF*YM)M/\<>-?%EHK-<>'?$"7
M+A>IA>617_DOZU\[5Q-3#TZ3ALV[^BU?X'WF%R^AC\1B8UMU&/+Y2=DOQL?0
M_P 1?VBM+^'WC>W\-/IT]_<R+&9)8I%58RYX4Y]L'\:IZK^T<]KXLUK0M/\
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MJ\7>([E2+S7;P7!8]=@D 4?J:Q?%VF^,X/@[X6O=<O+6]\%J\)6SM/DG"G.
M25ZXSSS7@3QV*BN:_P!GFV75Z7ZVL?;T<GRV;]FXKX^2[DTVU%7Y>E^:]D]#
MWCQ=^T-%X?\ &*^'M.\.7VO73P)<1M9LIWHPSD#KTKJ_AY\0-0\:R7:WWA?4
M?#P@ *M?  29]/I7SGKL5SJ_QZTS_A'-83PR9-)A:WN[A0PBC\H84@GKCBOH
M_P"&5GJVGZ7<P:UXIM_%-YYN]9X%5?+3'W2 3WS7HX3$5JU:7,_=3:Z6_P S
MP<SP6$PF$IN$5SRBGJY<VN[M\/XG95YKX-_Y+7\1/^N6G_\ HDUZ57FO@W_D
MM?Q$_P"N6G_^B37I5_CI?XO_ &V1\_@_X6(_P?\ M\#TJBBBNL\P\\^$'^L\
M8?\ 8=N/Z5Z$>AKSGX47$=HGC2:9UCBCUNY=W8X"@ $DUWUOJ-M=VD=S#*LL
M$B>8C*<[EQG(KDPS7LHK^MST\PBWB).W;\D?(WPO^&=]X^\<>/$@\1ZAX=2+
M490XM%_UP,K]>170_'?X8:5\,?@E!IFDB:<OJ4<L]Q,=TDK;6Y.!^E?2UE]D
M\OS[>..'S5$C?)L;GGYAU!Y[TD\MC=R&VF:"9PHD,4F&P.@.#7G1RRE&C*%_
M>=]?7RN>]/B'$3Q<*UGR1<7RZ:\JMJ[7?SO8^7/B%XM@^-A\&^&_"]K=74MK
M+')<W#PE4B  !R3]#46E_#.W^(?[0GC?3KV_U+38H(?,6;3I!&S$&-<$E3D<
MYQ[5]0V-QID>IW-C:I#%=0QI)*D<87"MG;R!S]TU;2*UCE:=$A65^#(H 9OQ
M[T?V<JLN>K*[NKZ::)JVX+/I8:FZ.&IN"Y6E=W:<FI-[:[:*Q\_?LN23^'?$
M?C3PC+M>&QN!)%.\8663YBIW$?>[=>GXU]$U3M#82G[5;"W8R9_?1@9;GGD=
M:BU?Q!IVA6\<]_=QVT4C^6C.?O-@G _ $_A7H8:DL-15-RNE^5SP\PQ+S'%.
MM&%I2M=;ZI6;^=KG%^ _^2G>/_\ KK:_^BS7HM><^ 6#_$SQ\RG*F2U(([_N
MS7HU5AOX;]9?FR,P_C+_  P_](B%%<WXW\:P>#+*W8VTNH:A>2B"SL+?'F3R
M>@ST [D]*P!XA^)#@,/".F1@\A7U/YA['"XJI5X0ERZM^2;_ ",J>#JU(*IH
MD]KM*_I=GH=%>>?V_P#$C_H5-)_\&7_V-']O_$C_ *%32?\ P9?_ &-3]8C_
M "R_\!?^1I]1G_/#_P #C_F>AUYYX\L-1T/QEH_C#3[*35(;:VDL;ZT@&9?*
M8AE=!W((.1WS1_;_ ,2/^A4TG_P9?_8T?V_\2/\ H5-)_P#!E_\ 8UE4JQJ1
MM:2_[=?3Y'3A\/4H3YN:#5FFN>.J:L^H[_A=6C]].UD'T.GR<?I1_P +JT;_
M *!^L?\ @OD_PIO]O?$C_H5-)_\ !E_]C1_;WQ(_Z%32?_!E_P#8UG[6IW?_
M ( SH^K8?^5?^#8_Y#O^%U:-_P! _6/_  7R?X4?\+JT;_H'ZQ_X+Y/\*L^'
M?']]+X@CT'Q)HIT35)D,EL\<PF@N .H5AT(]#4.NZE=0_&/PQ9)<2)9S:==O
M) &.QV#1X)'<C)_.G[2IR\RGU2^'N[=R5AZ"FZ<J37NN7QW323>C2MT&?\+J
MT;_H'ZQ_X+Y/\*/^%U:-_P! _6/_  7R?X5Z!BC%=')6_G7W?\$X/:X3_GT_
M_ O_ +4\_P#^%U:-_P! _6/_  7R?X52TDWWQ#^(FD^(3I]SIFBZ)#.+9KM-
MDMS+*NPG:>BA<_C7IN*6DZ4YM>TE=+7:VVPUBJ5-2]C3M)IJ[=]&K/HNF@44
M45UGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ><?!G_6^/?\ L:;W^4=:]K\*/#5I_P )!Y=A
MQKN3?AG)$N23^'+&LCX,_P"M\>_]C3>_RCKT>N'#TX3I1YE>U_U/9QU:I2Q4
MU3DU?EO;R2:^YZG%WOP?\+7^B:/I,VGYL=)?S+2,.1L;U]ZTM$\ :+X>\1:I
MK=C:F+4=3.;F7<3O.<].U=%170J%)-245?\ I?D<,L7B)1<)5&T[WU?5W?WO
M7U.1L/A5X9TZ[UJ>+3E8ZS_Q^I(2R2\D\@_4_G7/V7[.'@*QU%+Q-&WLC;UB
MDE9HU/\ NDXKTZBH>&H2M>"T\C6.88R%^6K)7WU>MM/RT.;\/?#[1/"^MZEJ
MVGVGE7^H$?:)2Q);G./:ETOX?Z)HWBG4/$-G:F'5+_\ X^)%<X?ISCIVKHZ*
MT5*FK)16FOS,'B:\G)N;U5GKNET]-#SWP1_R4_Q]_OVG_HLUZ%7GO@C_ )*?
MX^_W[3_T6:]"K+#? _67YLZ,?_&7^&'_ *1$****ZCS@HHHH **** "O._A-
M_P A/QQ_V')?_05KT2O._A-_R$_''_8<E_\ 05KEJ?Q:?S_(]'#_ .[5_2/_
M *4CT2N=\;> =$^(6FQ6.N6@N[>*02H-Q4JV".H^M=%171*$9Q<9*Z9Q4ZDZ
M,U4IMIK9K<YR^^'VAZCX07PQ-9YT946,0!B.%.1S46I_#70-8\'V_ABZL_,T
M> ((X-YRNWISUKJ**S=&F]XK:WR[>ALL57C:TWH^;?KW]?,\XU;]GWP5K<\,
MUYIKRRPPK C><P(11@#KZ5N>"/AAX?\ AX]RVB6C6QN0!)ND+9QTZUU=%3'#
M482YXP2?>QK/'XNK3]E.K)Q[7=ON"O-?!O\ R6OXB?\ 7+3_ /T2:]*KS7P;
M_P EK^(G_7+3_P#T2:BO\=+_ !?^VR-,'_"Q'^#_ -O@>E4445UGF'CO@_0;
MOQ-#XJT^*Z-E9/K]P]S(@!=PNTJ@# C!/7/88[U?A^'.O16DMK(UG<-Y7E0W
MS3NLD*X*[50+CG.<Y_"KGPHE$">-9#T36KEOR K(@\3>)M$TR/7+C<UK<1D^
M3?7"'>22P:-<C " _+G)_"O%C&FH1E-/K]USZV<Z\JTX4VDE;?JVO^ 6+[X7
M:Q+:R-!<Q)<R2.\NV=D\U#*"L>[:<#RU4=#SFF_\*MU.U?S((;.<[8U*7%V_
MS* ^4+"/H&8$<<X XJ<_%C4GO'5-+B6T1X(&N))54!W,>6VEMX7YSU4=.M5?
M$'Q0N[ZUO([+R(H4E"HRN?-G3S&&8\=>(V)/O0_JV^H1_M!VBTK/];=G_P %
M#D^&OB*UN;J:"6R-SL1(KQYW\QT6!8A&R[, $AVSD\MTIVB_#/6M/9EN5LKR
M.0LR^;=.?LAW$Y0!!N)&WGY<8/!J6;XHZHD=RD,%C<20P?:/-C=FC \LN8\C
MJP^4?\"%22?$_5+>>>VGM;**> &0EI&VR >7^[3U?,F/PIVPR=[LEO'R7+:.
MOWZ?/^O0SYOA/K+?9TBEA@BCLUBC2*[95@ERY<X\OY@Q8'.5Z8K8\;?#[4M0
MM-)MM$^RK#8+NB6XF9 DO WL K;P5W*5X^]U]*T_Q5O[2%9I[2!4N(&F@0$[
ME_>[%#9('(#'J/NFKG@OXDWOB?6+"UFM;>WCN;4SG8^]@0 2#@G;]X<'KG@F
MJBL,_P!VF];$3>/5JTDK0O\ EKUUZ_B5OAK%+#\0?'$<S;YE-H'8=SY7->F5
MYUX#_P"2G>/_ /KK:_\ HLUZ+79A=*?S?YL\K,7>NG_=A_Z1$\Y\6 /\8_!:
MMRJVUVP!['"C->C5YSXJ_P"2S>#?^O2[_DM>C4Z/QU/7]$+%_P *A_A_]ND%
M%>7?%/XWK\-O$6F:-'H=WK5W?Q^9%':'+$YQM"X))JKX1_:&L=?UNYT35-$U
M#P[K,<+3QVM^A4R *6QR 0<#N*AXR@JGLG+7;YFD<JQDZ"Q$:=XM7W6VU[7O
M;Y'K=%?/UG^UBMS:2ZA_PANKMI$$GES7\*[XHS[MC&?;-=3XX_:$TOPMX?\
M#NKZ?8S:W;:V66!8#A@5QP1ZY;&*A8_#2BY*>B]?0VEDF80J1INEK)V6JW2O
M:][)VUU/6**\C\(?M"VFM^++;PYK6@:EX7U.[XMTU",H)#V'(!&<<>IKURNF
ME7IUUS4W<\_%8.O@Y*%>-FU=>:\FM#SWXE #Q=\/W'##5'&>^#"_%1>(O^2Y
M>$O^P9>_^A1U-\2_^1K\ ?\ 85;_ -$O4/B+_DN7A+_L&7O_ *%'7%4^*7^*
M/_MIZ]#X*?\ U[J?^WGH]%%%>H?.!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YO
M\&2/.\>C/(\4WIQ^$=>D5P&L?#_5;#Q+>:]X3U6+2[F_VF]M+F'S()W P),
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Y]\.?^1T^(7_ &$XO_1"5Z#7GWPY_P"1T^(7_83B_P#1"5Z#7-AOX?S?
MYL]''_Q_^W8?^D1"BBBND\X**** "BBB@ HHHH **** "BBB@ HHHH *\]\"
M?\E'\=_]=X/_ $6*]"KSWP)_R4?QW_UW@_\ 18KEK?'3]?T9Z.%_@U_\*_\
M2HGH5%%%=1YP4444 %%%% !1110 4444 ><?#;_DHGQ,_P"PC;?^DR5Z/7G'
MPV_Y*)\3/^PC;?\ I,E>CURX;^'\Y?\ I3/2S'^.O\,/_2(A11174>:%%%%
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MQ*WXI_H='16'_P )''_>%'_"1Q_WA6OM8=SF]C/L;E%8?_"1Q_WA1_PD<?\
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M:WM];37,%H\;%F6/=G)' !"GFJ<6A>7HT5S?:W:V%]<6[W5M92@[I(USR6Z
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M']X>))0P\WIU&[I[5]$?\,<>"O\ GZU+_O\ +_A1_P ,<>"O^?K4_P#O\/\
M"NE9;F*::MIZ=-NGD<#S[(FFFI--MVUMK>_72]V?.^A?&:?0[O0GCL@;?3K.
M6S>-92K2B0Y9@P^Z>GY4R_\ BZTUUJCV]K<".[L38Q_:[QIWB!.6;)'4],#
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MD""X,?EOC&TX'S#&/RKW?_ACCP5_S]:G_P!_A_A1_P ,<>"O^?K4_P#O\/\
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M+:1Z=HHL;!;\:C=0/<&1KB0'."Q'"]0![U]$?\,<>"O^?K4_^_P_PIC?L?\
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MM,_Z!6M_^"]Z/^%Q:9_T"M;_ /!>]=Y@>@HP/04:!J<'_P +BTS_ *!6M_\
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M_P#A<6F?] K6_P#P7O1_PN+3/^@5K?\ X+WKO,#T%&!Z"C0-3@_^%Q:9_P!
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M ,4KJPTG<O\ B7Q+!X7LDN;BWNKE'?8%M(3*P..I [<5S/\ PN+3/^@5K?\
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M\Q^5'_"&#_GF/RI+"U%M<IYG2ENEO?Y]SS+228?$,>L:G%+?W,(5HOFV_.H
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MFB_]>4/_ *+6M:LGPC_R*FB_]>4/_HM:UJB?Q,TA\"] HHHJ"PHHHH ****
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MI8S,ISHN\4DK][(*\X^+/_(P?#S_ +#R_P#HF6O1Z\X^+/\ R,'P\_[#R_\
MHF6N[%?PGZK\T>/EW^\+TE_Z2ST>BBBNH\T**** "BBB@ HHHH **** "BBB
M@ HHHH **** "O/?BY_Q^^ _^QDMO_0)*]"KSWXSJ]IIGA[5]A>VTC6K:]N=
MHR5B&Y"WX%P?IFNK#?Q4OZV.7%?PF_ZW/0JX=OA1ISZI]N>XF:7S;B;;QM+2
M @9'?;DD>]=G;W,5W!'-!(LL,@#*Z'(8'N*EK&-2=._*[&TZ<*EN97/.5^#-
MJNH6ER=3G=+80;$>-208UVC#=@1R0.]6KSX26%W:Z1']LGCGTNT2WM;A5&]&
M4@B3Z\=.G)KO**U^LUFT^8Q6&HJZY3SV/X/V<4^J,EYMCOO-8C[.A>-Y.6(?
MKC.3CWIP^$-DVN3:E+=><]U'$MTKP*?,9(_+#*3RF5 Z>E>@44?6:O\ ,'U:
MC_*<EX/\!?\ "*7GGMJ4M]LLX[&))(U0)$C$J..IYZFG_%/_ ))QXD_Z\9?_
M $$UU5<3\8=4@L/ &JV[MNN;Z(VEO"OWY)'^4 #OUS3IRE5KQ;U=T*K&-*A)
M1T5F=!X1_P"14T7_ *\H?_1:UK50T&R?3=#TZTEQYL%M'$V.F54 _P JOUA-
MWDV=$%:*04445!84444 ,F8I#(PZA217"_!.WC7P+%<A1]HN[JYFGD_BD?SG
M&2>_  _"NYN/^/>7_=/\JXKX*_\ ).M/_P"NMQ_Z/>GT%U.YJ"_4O8W"J"28
MV  [\5/12&>$?![QY;:!;R:#%IU]<R/(7CC1 I$@4>:F&(Y#9./0YI/BIXZA
M\3W>GZ+_ &?>P&"Y#O')&&+3G B3"D\\LQ],#-'[2_V.QATY[#3BWB6=]\-W
M;2^3+'M("MD?>.Y@!]:O?LWQV-WIE_+<Z:(?$EK+LNKF>3SI6W\Y#=LG.0*U
M_O&6M^4]H081?I3J**R-3@/C)&L>AZ7>J-MS:ZG;-%(.JDN%/Y@FN_K@OC/_
M ,BI;?\ 81M?_1JUWM/H2MV%%%%(H**** "BBB@ HHHH *BNKF.RMI;B9@D4
M2%V8]  ,FI:XGXQWDEMX!OH(6*S7SQ62$>LKA/Y$UI3A[2:AW9G5G[.$I]D4
M?A=:2^(;B_\ &E^A^T:FQ2R1O^6-JIP@'IN^\?K7=ZC!]IT^ZA!(,D3)E6VD
M9!'![4:98QZ9IUK9PKMBMXEB1?0* !_*K-55J<\^9;=/3H32I\D%%[]?7J?-
M?P[^+1\ _!FXNF0:G>V^K/:+#-<'+;CD<GVKF==N=53X@^)O VG6YMIO$M[#
M-*<A3"A7>X!'4\GZ\^M3_$?P</"WQCT#0[>X-[I.M:K%J,UA*@*(QEPP ],9
M_"NC\ JVK_M5^*+O_61VD4B9_N\(H_7-?5+V<%*O%7YHN7XJWW.Y\H_:3<,/
M)VY9*/X._P!ZL=MI>J7WASXM:-X(TN1(= L]'666$P\L^YANW>^!^.:](T_Q
M+I6JV,]Y9ZC;7-I;LRRS1R JA7[V3VQ7RYKE_K?BSX_^*K3PI+MFN52SEOXI
M"OD1HJ+(P/J"I''X=:Z)=-.H72?#/P0SPV-N5;7]9C.UG;'S8.?FW=#BO/K8
M.,E%R=G9-_FV_OLNK/0HXR47)1C=7:7Y)+\WT1]$:5J]EKEC'>Z?=17EI)G9
M-"P96P<'D5P,RK\/?B9;2(/*T3Q,QB=1]V*] RI]MXR/J*[/PKX<T[PGH-KI
M>EQ)#9P+A53H3G)/U)R:YWXT:9_:'P[U.=#MN=.VZC XZJ\+!^/0D C\:\NB
MX^U<%\,M/\G\MSU:RE[)5'\4=?\ -?/8[BBJFDWO]I:79W?'[^%)..G(!JW7
M(U9V9UIW5T%4==_Y FH_]>\G_H)J]5'7?^0)J/\ U[R?^@FG'XD*7PLX'P'X
MEMO!_P !]*UF[5FM[/3Q(RH.3R0 /Q(KY)\8?$.;XH^-4O\ Q%=2VVEA]JPP
M#=Y$7HH]3ZU];?#6/1]7^$WAK0M6,$RZA8X%G*^#,JG+8&<G''2IK/X'_#B_
MMUGMO#EC-"V=KHSD'!P?XO6OH</BJ.#JU)5(MR;=FNB^9\[B,+6QE*E&G)**
M2NGU?R..\"_M _#_ $>WTSP[HMI>6T)98(E,(Y8G&6.>23U->4_M%:+=^"_C
M%%K_ )+-:74D=W#(1\K,N-RY]00./<5])V?P.\"6%U#<V_ANUBGA<.C@OE6!
MR#]ZM/QTWA6ZL(]/\4M9/;3DLD-WCDCJP[C&>O;-9T<91HXA3HQDTTT[ZMFM
M;!UJV'=.O**:::MHEZGS!^T%\:='^)VBZ+8:.DY>*0S3>:FW#%<!1ZU[K\&?
MA[;V/PLT6QUS38+B;#7!BN8PVPN<]#T.,59\*_"3X>Z;K$D^EZ1;37MHRMND
MS((RP#*1NXZ$$$9KTBLL5BZ?L8X?#II)WUW-<+A*GMI8C$23;5M-OZT/D/XD
M?#N\/Q^L#I_ANY;1/MEGO:WLF-OMW+OR0NW&,YKZHTOPQI&AS-+I^F6ME*PV
ML\$*H2/3(%:E%<F(QD\1"$'IRJWJ=>'P<,/.<UKS._H>=?"3_D*^/O\ L89_
M_0$KT6O.OA)_R%?'W_8PS_\ H"5Z+66)_BOY?DC7"_PE\_S84445RG4%%%%
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M\!:K#;C=<Q(+B+'7?&0XQ[\5T8=I58M]SGQ";I22['6T5E^%]:A\1^'=-U.
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M$.-A(7G.XMC/.*N5+$2C)2T3U]=5_G<B-7#QE!QU:T]-'_E8]JHKRZR^-?\
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M%^]<?],8C_Z$U=)X3^&^D>$I&N8UDO\ 5)/]=J5ZWF3R'_>[#V&!74JH50%
M '0"EJHT4GSS?-+\O1=/S\R*F+DX>RHKDAV6[]7N_P NR"BBBND\\**** "B
MBB@ HHHH **** "BBB@ HHHH **** .=\7:9I7B>P.EZAJ @@\Q6FA294,@!
MSL;/.#W%9FH?"C1]0.HE)+BVCO9(KCRX& 6*:/[LJ#'#8Z]CZ5QNDZ--JWQ0
M\;D:'IVJP)?VRO->2[7B'V=,[1M.?7M45IXV\8Z[K=Z++?%IR7T]@\/D1>7!
M$@($@8G>7R <'C!KUHT:D5:G.UDG]]F>3*M3D[U(7NVONNOZL>AVG@&"&;29
M[G4+R^N-.G>XCEF* LS+M((50,8],52L?A-HFGRM(7N)D-M<VS)*PVE)I [Y
MX]1Q7">#]8\2IH/@C3K?7_GU26X\ZXEMDD=$09"#/?(/)]?:K@^(>OK/8ZJU
M_"]K=ZT^DG13 FZ-/G ??][<-H)SQ@TW1KIM*?\ 5WY>HE6H-)N';\EY^AT]
MC\---O\ PQ>Z8-:OM1TV[B$,;%XSY*JV1L*J,D$#KGI537OA'HVN7=Q%?:S?
M>=?111SQB2,&8QD%7/RYSQT''M7(W'Q*UK_A%]+6POC:ZA]DN;V:.TL8FRJ2
M,JEMV%5<CG R:ZW0]%U#Q<FC>(I#:J+VU@GE8J=\3;03LYXYZ?AZ<MJM2O.4
M[:O[_N\OP%&5&K:$87T7W??Y_B>ASW4-E&AGE6-68(I<XW,>@^M<IK?@MM2\
M1:A+@G3]8L#8WI1L/'@':RY]F(_*JOB:Y:?XF:%9RH9;6VL+F_2,?Q2J54?7
M 8X^M<G9?$+Q#;>#_P#A*9M8LK\W-G<7*:-Y*HT3(3M"$?,P7'S;CV-<]*C4
M24H/5_K>WY7.BK6@VXS6B_2U_P ['73?#?3-'N5U*'5KO2HXH(H[G8\>R98A
MA2^Y3@XXR,57;P!X=\3IK/V35)9);^\AU*62WE1C%($ 0@$$8(4'!!S7GGB#
M6?%VO> M574KF3[#)#;7"7<EO"I+-(H:,*A.4Y!!//&*V+KQCK.@ZKXATBWN
MK:*2"?3+**_^RQKY?FQ O(P P?8'@5U^QK6NI^]_DX^7F<GMJ-]86C_FI>?D
M=?I/PPT2'4TGBU"YN[NRU'[=)ND4D3&+9A@!P"#G%7X?AEI4,&G0^9<,EE?3
M7\89A\SR!PP/'3YS7E,GBG7/".I:Y9V=ZU[?:CXABLY-12",N!]F5LJA^3<<
M8YXZUTMKXK\976I^%M,N;I=-N+J.]ENB;:-WF2%D*< D*64D''3-3.E7T?/I
M;]&^WJ5"M0U7L];_ *I=_0Z/2_@_INES6974-0GALHIX+6"612D,<JE6487/
M /&<FE7X.:,MO+#Y]WMD@M;<_.N=MNQ9.W4D\URFB_$CQ 9]!U&XO8;ZWUIK
MM3I20*K6GE1NZX8?,2-N&W>O%-/C_P 1:5X/?7I=<L=0DN].^UQV#PJC6KEU
M&1MY9%#<[N<BDZ>)O\>O_!?EW3&JF%M\&G_ 7GV:.E\>^![>_:ZQ/]GBUR6V
MMKZ::0!4BC;(5!_>8_+^-=]:W4%Y%YEO(DL8)7<AR,@X(_ UX9XTUO54NK;0
M]0U--;2+4=+NDO%A2-E+3C*$)QVR.^*]#\&,;;QOXSL8^+1)K>=4'1'DC._\
M]H-8U:4E23E*]M?R7^7W&U*K'VK45:^GYO\ S^\[:BBBO-/2"BBB@ JIJFDV
M>MV4EG?VT=W;2##12KN!JW10!YT/ &O^$W)\'ZS$EF?^89JX:2%/]QQ\R_3F
ME_X5WK/BJ4/XRUA+JU!R-*TP-%;'_?)^9_T%>B44[LFR*VGZ;:Z39QVME;QV
MMM&,)%$H50/H*LT44B@HHHH **** "BBB@ HHHH **** "BBB@ JKJ6F6FL6
M<EI?6\=U;2##Q2J&4_@:M44TVG=":35F>?GX52:,S-X8U^^T)<Y%J2)[<?\
M &Z#Z$4&R^)EI\L6H^'+]1_RTN(9H6/X+N%>@45T?6)OXK/U2_/<Y_J\%\-U
MZ-_EL>?C1_B-J'RW6O:-I:'J;&U>5OP+D8_*I['X2Z<UW'>:Y>7?B2\0[E;4
M'S&I]1&,*/RKN:*'B)[1T]%;_@@L/#>5WZN__ &HBQH%10JJ,  8 %.HHKF.
MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYFFF88SV50/0# K8HH=2;33>X*G!--+8****S- HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>armp-20241231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N UX# 2(  A$! Q$!_\0
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M@J"2..>>U 'IU%>0:I^TYX1TW5]*3SY9-%O(;J5M4%O-M7R?+.5&SYT(<DR
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M9%F9 <Q-QDO@')Y/-5/B)\#KGQ7XJT"XTZ^ALM#BMH[;5K)E.;I;9O-LPN.
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MKS;XX?$!?!GPWUF32]1BC\0RHMEIT<9$DINI"$C 0<DY8=N.M=#\,=-U[2/
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M1110 4444 %%%(3@4 +15>]O4LK4SN1Y8*@G/'+ 9_6G+=1-;>>7"0X+;V.
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M^=RH&YN3R>>:U***1 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)HH(X(%1VD8M@["K@AL56O\ ]J'P:NB7=U83S7-[#!=S?99873RC;PI,_G,
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MCN1@WSG:L,FX[% .<KN(R3C&?;G%2@HINZO_ %^IZ$Z-5SG%6?LVUTZ7VO\
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M\]K%#:OM;S=OR*VT9.6 W'&,$X/%?:?[.R:K87%SIFI2R2V]I;G[#YO+B E
MH)[@%6P3R1BOES]EOQ)#X$\2M8WVE311W\[I]HDB!\K:HX]5QDGW&:^Q/AW,
M]S\1-?D*ML6W6-6QP<,O?\ZK#8;V<74O\CR<VQGM&J"6BZ]_/UWZ^5D>I4V1
MMJ$TZH;G_4M]*V/FF?'?[66MG4/'>D::97\N" RM'_#DDX/^?:N5T>^2SA7
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M418D5$4(BC"JHP /04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***BNKJ*RMI;B=Q'#&I=V/0 4;@1
M:EJ5MI-G)=7<JPP1C+,Q_P \UY5JGCZ[\:W[Z?IU_;Z+IZD*\T\RI(^3@=\\
M^@KS#XR?'_18];2TU:XO8+3:S006,(E=!T#L"0,FO%)=>^&>H74LTGBKQ##*
M6WL\]@3\W7.03S7TF$P,(KFK.TO1NQ\UC,QDI<M)777WDC[5\/\ ASP9H:F6
M;4K'4+I07>:YN$8+CJ0N<  ]S^==8GBG08HCLU;3TC4A?EN$ !P3CKZ _D:_
M/V+5OAK)^]C\=ZSE!G(TV4D#.>WOS^M*FI_#6(LX\;:VQ!Y,>G2 D^H]:UGE
M]*H[RK-_]NLYHYK5IJT:"7_;Z/OR?QUX=M@QEUS3T 3S23<I]W.,]>F0156Z
M^)WA2R;;-K]BC^9Y13S06#8S@CJ.!7P4=1^%T:)GQ#X@N$(&%2Q X[=359O%
MOPICFD4)XHORF2S[(D'OU.:7]EX9;U)?^ _YA_;.(>U*/_@?^2/M[6/C/\.I
M$$-YK>GW:2(S[>'! ./S/8=Z\G\6?$KP!ID\EWX>U>>TNH\-Y4(+(6)Z*<]N
M_45\['XB_#BW:5;3P?K.H-'C)GOP@/O\HIDOQ@T2W*#3_AGIY+GY/MMU),Q'
MKC-=-+"8>B_=<W]UOS.:IF.(J[J"_P# F_R1]E?#OXV6VMP1)=7$<R,=JW,9
MX)]&'8UZY;W$=S&'C8,#Z5^:J_'W7D\J.U\/:#IEHLF^>.QM=K$#^'<#U(./
MQKZL^"_QDMM7TJVE:Y'V)QC=*P!A(ZH_IC^5>7C,''6I25O(]G X]U+4ZCN^
MY]!T5X9X^_:[\&>$A);Z7*WB/4%XV69_<J?>3H?^ YKYO\>_M4^.?&ID@MKW
M^P+%^/(TXE7(]#)][\L5\;B,SP]#2]WY'ZCEO">9YBE/D]G!]9:?<M_T\S[3
M\;?%SPE\/4;^V]:MK:<#(M4;?,?^ #G\Z^?_ !M^W$B>9!X5T/S#T%WJ3$+]
M1&O)_$BO$_ W[/WCOXD.+JUTJ6VLY3N;4-2)B1L]QN^9_J ?K7T)X)_8DT/3
MO+F\3:I/JTPY-O:_N8OIG[Q_2O.^L8_%_P &/+'O_P %_HCZAY7PWDG^_5O;
M5%T7^2V_[>9XA+\1=:^*5V%UR;^T)RX>)8H%_<D?W% X]*Y&T\GPSJ^N/>,!
M?&U:T$4ZNDF3(&! X&,!N<=&XK[VU'PIX7^%?@G5;W2M$MK"TLK9[B5;6("2
M0*I."QY8\=S7B-S\.X?C%X*TOQ'>Z'/HEW>Q-(L,B[)HUW,%SD9 (PV#SS7V
M.52G1H^PQ$^;6_I\S\FXAE3Q->6-RZE[.#7(U?=-?RKT\SYB-E!J-[:R7JM>
M:>C"9M-5C&LDBXVG<I!'3K74Z3>V.EP7,FG6!LI[R?SKF0R%VQC9M4'(4;>.
M!SWS6]?_ +/.N:5(ZV5Y'-'V$RE2.>>E5[?X.^*B/+<VT8S]X.3CU[?2OI7[
M.3YM+GY]&5>G#V*DU'L<MHW@G1- GGNOMLER;B5I<+"HE0'^ L<YZ Y]CZTM
M]:6 >U6T@2VBLX/(@. 7 [Y/?.!FN_M/@/JDI+3WJ(V !Y:DX..>M7X/V=W9
M'$]]/)D #:@&#ZTHNG!W7]7-:U2OB(\LVVM/PV^X\K81RE264%DP?FSD <9'
M3K37A5U5M@\SY3DMP>,$_C7JLG[.<F1LOYU R "F?UJ&]_9^NU#&VO&0XP!(
MA].>E:>VCW.)X>78\QFB#0X"D*W.6/W>.G^&::;6*&!'.]4$0!9L#(ST]ORK
MKKWX)>);2'$;VUR!D["2O;MD5@7?@CQ79$A]"EEQU9&#<=R,9_*M%4OLS)X>
MVYP&N^-?L&LPVEI M]=,P9()B0LF<@9/I][\JK'Q'>6'BNV7Q ]O86\\8\];
M>T53&2#@D@;L#@<^]:VO^#[F\\117MUI]PIAB9(XI8254XY)]AG^=<?=^$S;
MZ;>2-%,LY.<R$E4C &21[\X_"O/FZKJ<]]$^G]=7^!]?AE@XX;ZO&$92FE=R
M=K._?2UEZW>G8V/$OQ3T,6EY8Z6\\^K"7RH[YQL@5,=0.N<@ 9]3FO,/$^O3
M:B\[RR/?WR/YBN@R&SC@^W6NKT?P+#-<I-=6MRNFE%::3R3Y@&[D@'J>>E)_
MPBB:A=3PZ=#=3 R[('6T=2^#CD8XR.Q]JN5.=2\Y/X?+K;_._P CGHXJC@^7
M#THV]M:\I-:1D]GT3LD[[Q9XCKVMS>(K*>]FL5L_L4JB*- 20ZMD@_7)_,5U
M7AWQ)!XCMUO+HN8X]R!<;-I![@>Y^M=2_@'5-$\27BWNG7""YV3I;FV/F @;
M22,9';KW(]:71_AQXJU,:M<_\(K<V6BR.T\=S/%L!91M8 ]CE>^ 3QUI3C&T
M6GM>_P D_P#@?@/#UZ_M*JG\52S5]4^9JZL]&U=Z[7N5)=1U[QQ>V=E?ZW/-
M&\J11B>7$<9)49QT P.N.U>B:U\-+?0XDMM(M+B^(DS--(@=^$.2I ^[N&:M
M_#SX*Z_K7B5[6S@2Q6&WBO1<3Q\C>-R-MP<Y8$>G!KZA@^$GC>/PQ.=+\1SW
M'B%6!A:X0)"\8&3&P4 DLQ;GTQ[U%2I&=.3W3_X'ZHG#8=X3&4J<])1NFW:U
MG>S;C=NZ:OII:Q@_LT_!Z^TQK?5=1\N261 (8=I_= \DY]3D5]MZ#8BSLD7&
M,"O(_@AXH\/^(-'M!'(\&JQJ8[NQDB;?;2H0LB/@8!#>]>W( $ 7IVQ7CXFO
M[6UMCUL-A94&W45F.JO>V$&H0F*XB61#V/4?0]JL45PGH'S1\<_V7O\ A(;*
M]OO#Z^>TJG[1IKM@3#N5]&_+/UKX>U+0M(T#4V6#6(;*Y0_9Y4N[TK)&P;H&
MSE3G@CVK[S^-O[75M\*_&2>'=&\+7_C6ZM45]6;3I J6!<9CC9B,>8PRVS.<
M8/>OSN^)VJS>-_!FM^.5\)3V2W>H3)'=/&2#"7QO+8V[@Q*GZ5Z4.:45SQOM
M;:_D>Q0PF,48NFM)-):K=[:7NKVT^\^W?@)^R'<Z7%#K?B?4II;J<^>J;P[+
MNYR#TR1CGFOJG1=!L/#UFMK86ZP1#KC)9CZDGDGZU\[_ ++7[8.B?&C49/"-
MQI,_AK6K&UC-I#=2JXO(U0!BI'&X<';UP<]C7TQ7'4YH^[+0X<33JTZEJV_R
MM\K:?<%,E7=&13Z2L3E/DS]K+P4VH:6-4@A,EU9'<-O783\W^-?+5E<QW2JN
M_''\3=,'/]"*_2?QSX936;)U*;C@]J^*OB7\";W1=6N+W2%8Q2-N-JN!MY_A
MZ<>U?0X*O'EY),^6S#"RY_:0/.<3)=((3@LH*R+D#..W^-30VSEVN59VP0-P
M.6SP3P?<?K4,=U/:,8+VWFMB@)(=6&1T/7\JNVVH6BQG 4G)Q@#C\^]>J]4>
M-%M?$5UADGWM(J;(WR70%>3U^G>G+;RP2J@9L%B^T+D9'IGVQD]:NK=FY=42
MW,A/S' )/7':I(K?4;ML0:9<,2"03&1P/>IND7J]D9+63/&,,Q\S)('!4DG'
MR_I38[5X8',?RG;AVSR.><#MG^5:IM-7B"!M,N,DY)$)/N,G%-DM;R!%>:PD
MCW+N)>,Y /X<4[KN&O8J("MO\P5Q@D-GELDGK5>UCNF@ ^<H9CE@H8X[<'K@
MU,-0A5&#1A"&)#8X!/';^52P30R;.4=\DJ2>A]J9G=$4D]P&51DRD!EP@PS9
MSD8'\JC@,L#R!D0*1N0Y R?Y]_UJXH(,;^:P=2=NQB#].*62T)@W%R0YP=IY
M/XXZTM2E;H5IIIY&,:DQ8&&R-HQT']3FJEM<FVB+(0 &89D.<+D <^O^-:?V
M5"IV%NQ.UL9P3QZD<]/I2M:1Q(,,&#GYNHQ_CUIW#IN4C<W$QDD$<3L5P%*[
M-HXP?;Z]Z>D>#'N Y +&+!^7^(^@Z<&K,T0DF0D(3NX8#.X^^/\ /-((HE0*
M'7!/0.0?H!_2@5S.N07)4$DEMP9^2WMSQQ[5(SJTRLJ\+RVXYVGMG/7_ .M2
MO=PQL2)F; *[6SGT./ZU/IFA:KXHN([?3;)]I^3S&R%0>I/O^?%#LM07-+W8
ME.)Y-0GCL4)9W<?,#GCU]AWKVOP'\?[GX16]MIITV'5-.A&SAC'*/4@\@_B/
MQKLO@Q\$H](S-=PI=74P ED= 01_=&>U>C>*_P!E+P;XOMC(D,VC7Q'^MLFP
MA/NAX_+%?(YS5Q%9)865K?B?H_"M++L-5<LU@VI=NGW-/[B]X'_:F\">,C'#
M)J!T2\; \G41L!/H'^[^M>NPS1W,22Q2++$XW*Z$%6'J"*^%_'7['/C'PX))
M]%:'Q':+D[(3Y<^/]QN#^!_"O/?#'Q&\<_!_4'M+&^O]':-OWFFWB-Y>?>)^
MGU&#7R4<RKX=\N+I_-?U;\3]2J<*9?F<'5R;$I_W7K_P5\TS]+:*^5_ '[;E
MG<>7;>+]+:T;H;VP!=/J4/(_#->H>)_BC:>*;6SLO#6I0FVOD#/J+/Y2*A[9
M;&..O?MUKZ#!U:>.=J,O7R/SS-<KQF3?[Y3:3T3W3?DS<\3?$9TO3I/A^#^T
M=38[2ZC*(?ZX_*O#?CC\-_$7B#[.;C5+^ZU*.W:1[.REVF7S72,Q9Z F+SR,
M8PR@U[UX1@\+^$K-88-5T][N109)S<IO?TQSTZXJ5(+;4O&GVH3Q2+#AN'!^
MXI5!U]993^%>NJJHNU)?/J_\CRL(^6JJU1W:Z=/^"?%7B+XGC7=0C\->5OM(
MH;6:TOO*\O[48TF#N1V=DF@+#LZN.U5/A)\<-?\ "ND_V+I!#Z?I]U]NO8D;
M]\RK=Q;T0=S)YT2#ZM69^U;X>T_X9?M#Z=K-G/&EGJ=Z\MU;03;FM]\6':2+
M.54LQ96 QDR9ZBL#]C'P8/BOXW\1:A=M&++1]1&IK9R-B>=_F2W(7KY<98N>
M,%RGI5^SBY.L]K?B?:1P=!?[79>SY$_G>UO73^D???PA77["7Q!8^);Y[[4I
M;B/4LM]V%9XP3 @_N1LC*.Y')Y->@7%G!=H4GACF0]5=00:H"R\OQ$E\HQYU
MKY3G'=6RO\VK5KS92N[H^1JR527-;<X;7OA-I>H$SZ<6TJ['(:$G83].WX8K
M"M?%6N^ [M+/7XVN+0G$=XO.1]>_\Z]6JKJ>F6NL64EI>0K/!(,,K#]1Z&NF
M.(;7+5]Y?BO1G!*@D^:GH_P(]+U>VU:V2:WD61&&00:O5XY=VU_\*]:0H[SZ
M)<-\K'G8?0^_\Z]3T;5H=6M$EB<,&&<@U%6CR6E%WB]F72J<]XRT:-"BBBN8
MW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKR+
M]H3QWJ?PIM= \7VLLTVF6TT]C>Z:GW+AIXB+8GON%PD2#VF:@#UVBOD^#XM>
M-?!MKJ?@^YF&M:EI6D7][JVM7EZRS%[6UL3)]G"IA2\EV<9R%"YYZ5IZC^U9
MK>F3:H8-%TVZ@A.I6MK9O=.+V*6R S-= #"PS'.T@9&Z,_-O^4 ^G:*^;/B%
M\3/&NO?!CQ-#&VGZ-XFTSQ;I_AN\N;"680R0S75F"T1X="T5VJGG(^<@]"*/
M_#37BBVT[38;#2]!O+G59+2#3X/M<SM8>9J,-CMO3R=W[W?QCE'7!QN(!]0T
M5\M^)/VE/B%X;T^]U>32/#5QI=I;ZI>O$K7"SM#IURD,Z@Y(#2A\H>B%<'?G
MBS+^U!XGGUG5[:'1](LK'^T&TRWOM0D9$TZ1;H0;[H"3+JRY<;1'@@*2=P:@
M#Z;KQSX_^.CHVF2:? =VR/S9E!Y<_P "?GS^5:/[//B74/$7PVN=3UB_AO[D
M:OJ:M<VTA>$HEW*J^63SL"@;?;%>(^.O$UGXJ\3WEG-*PU"1A>! ,[8LD#KU
MQ@#VR*]+ TU*ISRZ?F>;CZKITFH[L\(N],O=<O%O+P_:)[G<\KL<!>H&/;M^
M J@O@>.9WBC"I&6W[>IXP#^=>B:_>6'A.QC-_?P(99&BMK:&,R3SYSE5C49/
M8\#BKN@^*O#]U;S6[FVANI4556[4P21@=>' ).?2OHW)V[GRL<+6G'VJ@^5]
M;.QYT/A[>I9374-A(]M -CSJ  Q[<CH>:IV_@N&Y)6)0)R3'M7)X(X_*O;]/
M:\LM(N+"*Y6?39&W21HG)/&/F]^];G@;PQ$]Q>7CVRW=U;0>9!:H=OFN,X&2
M/\:RE5<(N4N@J5%5JD:<-V>!S?"S5=/C9IK&5I-XRP567 /!P.151_A^5@>2
M/_CY5>5C4\YSG/ZUV=MXYOM(\<7FH7D4B2K(-EE.-\:@GE2&P<CC!'O7JOQ!
M\+FVUE+A(XH89USY@4YW9]NN>#^-<&%QZQ#<;6L?09KD;RV$:BES)_\  _S/
MG^#X8W*:$VH-'&T?F;'C4X;)/!SZ5<M/",D=NP6-70@^86SQ[@GGMT]37J;Z
M$]O8W ,B_/M9D9B ISZ=C4,VH:#I]J([K5]-M2YY22X1<Y'0 G/!Q7HQDT?/
M*E*II"+9YJO@NW\D1I#O,9&X-\I?=C\C_A7:>#--3PX[1*&DL+D!)HV48YX!
M(^GZ5U/_  CY7;'!#)YK-N9NJR#'4'_/6H-=%KH%E'++"Y$BE;> $;F8@@_0
M ]S4RJ1BFY;!3A-S2AN8?@?]EJ;Q9XKO4DU>'3="67,0C'F3LIYV@=%QG&2?
MPKZH\!?L]^"?A\(Y++24O+U<'[9??O9,^HSP/P%>-_![Q<)X[2Y6=)65S;S&
M+A0Z]OR(KZDT^X%U:1R YR*^,J9=A:%3VE*/Q:KYGZM/B/-,=16'KUG:.EEI
M>W>V]_,L]*0]#CK2T59XYX;\>/!_CCQII\,.D7<!\/?:8SJ5G<OY;7$",&8*
M I^4D $'D@>_/K^FQB_TFV:>!89?+"O$O(1AP0.!P"#6A+&LT;(XRK#!%."A
M<X&,G-/S+E+FBHO9&%=^%;:X).P<^U4O^$)MLYV#\JZNBM%5DNIRNA3>K1SL
M/A&VC_@'Y597PU;+_ /RK9HI>TD^HU1@NAD'PY;$?<%1/X7MF_@7\JW**.>7
M<?LH=CE[CP5:R _NQ^5<_P"(/".G:-IEWJ-X1#:6L;2RR;2<*!D\#K7I%,FA
MCN(GBE19(W!5D<9!'H15JM-;,S^K4F_>1\S:%\,M4\5ZM+XHM)?L.A7@,<-E
M,2))8_\ GHP(.W)SA>H_&NZ/PJA$95X$8'[VX9!KK_BAJESX9\(M=:9'&UVC
MI%;VI3(FD8@)& ".K8_#-:GAJ\U+6-,CFU2Q2PNF0![=<LBMW.3@GFM(XF<>
MHJN"I5/>M9;(^<OB3H:3ZCH7A/PWJ5O;^(=2O0K>6H<P6Z*7E<CMT4?5A7J$
M7PR5""$PP[@5T5W\&O#5SXFM_$HLROB&WC,:7PD8,02&P0#@\@=J[@(,#Y1F
MG]9G=NXIX2BZ<816U_O?G\E_3/G'4/ACJ=Q\<-+N'T<W.D'2)DEU)N1%+O4J
M#D=3C [\GM76^)_#6D> O".IZUJ<3MIMA"T\ZQ1[V9<\X'?)/?CUKV+:!VJ&
M^B@FLYTN8UEMVC821NH(9<<@COQ6?MYZV9JZ%&4H<T=(V6G77\SQ#P=\.5\3
M>.-.\?Z/J,$OAC4=&6W^S;/GD(<LC @8P-S=_P#&O7/[!2VLIQ;@),8V",.S
M8X/YUXO\%+KQKH.K:UHPTM[;P/97LC:;/.@=DC<[C%U#81BPR 0  .U?0$;%
MT5CC)&>#D5FYR>YTUJ<%.T4K)67ITOY]SS[X?_!KP]X'GU2[LK,QZE>7/F2W
MF\[VV\+].#^->A 8 !.3ZT4M1>Y+;D[L*S]=@O[K3)H--F2UNI1L6Y<9\D'J
MX'<@=!TSC-:%%+8$[.Y\Q?M+_#_2O ?P233=%M,237YGFN) KRW-PR/F65V(
MRQ/<Y] !7R[K/AVSM/AC;Z)Y!-LML;=CNM#GCDY63=G/.<5]E?M?,J_#S3\]
M3?K@!@I^XW?:3^0KY0\52#_A%XP%D!P>MX6'Y& ?SI2F[[G2J]3>^M[_ #.U
M_86^&UAXT\%>++?4?/M]0L+^SFL=2AC:.6TG6-P)(I"Q!/J H!'#;@>/N/2%
MODTZ%-1>*6\0;9)81M60C^(#MGKCM7R3_P $Z_+_ +(\?E2ID^W6VX!8@1\C
MXR5.\_\  _P[U]A57,VM3.I5E/1][_>%%%%(Q&21+*I!&:Y?7O!MOJBMNC4D
M^U=5FEJE)QV)<5+<\2UGX.6UV6WVT<JGLZ UB1_ JP23<-.MP?7RAZY_G7T,
M8U;J!3?(3^Z*Z%B)KJ<SPT&[V/%[+X10P@!8$3_=4"M./X51 <I7JXC4=A2[
M1Z5+KS92H070\I/PIAQ]RJL_PFC(.$'Y5[!@>@H*@]A2]M,?L(=CP'4_@K:W
M(;S+.*7/7=&#FN.U+]G33'D+KIX1O6,E:^K&A1NJBHGL(7ZH*UCBIQZF,L)3
MENCXVO?V<+8H5B^TPCMM?..<]ZS)OV='R-EW=1C)]#7VJ^C6[]4%0MX>MF_Y
M9C\JW6-FNISO+Z3Z'Q5'^SM.&)>^N'.>,*!BI$_9SE92&O;HY().!ZU]H?\
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M>"=6&IZ3$V<G KHZ^3DK.Q]FG=7"BBBI&%%%% !1110 4444 %%%% !1110
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MKGQ%?V-.52/1&V"P:Q->%&3^)G,6<%GJ=M)HWABUBU1Y;/;<7\S,B(K XP.
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M['$K"!$4=B<TN(TC"'D"JU^;BPG>"YB>"93AHY%*D50DOO>NQ1N::(UFN4
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M@6.F(<!8F*F;&"<D<]#TZ5]<5\>?M@> ]5M+U?$*Z:UYI;29DN8N?*/0!QU
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MGQ1'@%?#_A7PZ/$5Y<>&+>]^T31,'"A#+*55@T9RK+R""#UQX_\ $+X,Z_\
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MV\N2,<FM>T@N)L>7!*_^ZA-=VGQB2#BS\,Z9;>F5S_("G-\9];D_U5MI]O\
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M[G1'5WZ'C/[-ESI&M1>,?$6A?9-.L-6N8IK;0[1ES91)%L1Y47Y4DEP6*CH
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M\<_%>+P]J>H:%I]K)%?PR&$S3%56)P0"6!Z@@Y'M@USN@>%_$'BMM5G.E_\
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M9[XS[4_XFZ%/8WMOX@L%_?6Y'F =U]:D\/:A_:MC:7%I%%*(U*'/RX8]0_\
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MUU4(>QBHIWU..M-U9.35C&DMJJR6Q]*Z'6[S3YQIL%A9O;2I'MN9'.0S>O\
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MNDT:PL-0T2_O;B_6TG@0-% P&93_ )X_&G6]MI;^&[N\FO#%J*.!#; <./\
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M]6<WUBG]G7T1Z;17F1\5>/+?YI=!211U"H?Z-3H/B]/92;-8T2XL_5X\G]&
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M00>8OP_O&."<3:D_0=3Q4;?&;PO!=B"S^&-DS=FNKV1LGTY_"E]0P2^S-_\
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M.P'W[M_*OG!8/B1873/9>)-)TE"^[RHM211Z $?Q8]ZH7/\ PFJJ1=_$S2(
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MC;6/]G9P<XZ_6HU_:!ULJ"OA+PM%@@,6T\#\1D^E:?5,'_SZ?_@1S?VAC?\
MG['_ ,!?^9])7/[:NDJQ$&A3R#<P!:4#( ^4].Y_*L^3]M"XF<_9/"S./*&%
M,C,?,SSR!]T#/;)]J^?V_:*\7I$SVNDZ! FTE&CTY>QQZU2/[1_Q*,;O_:=I
M;,C;6B@L(U['D9!]*KZKA%_RY^^3_P B7CL9+_E]]T%^K/HF7]J/QOJ<LO\
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MQ/5OT5_Q2\CDM6\.VM]K5U<V&E"SM6^['( 6#=_;W]LU6M/ "ZCJ6^"'<TC
M2>8ORQIQN+'H!P>37<:58MK$TMG<I(FI(NYPZ;5=,*2X SW../:N@TC46\,V
M\]J+>TG>60 PM&99$*G.XJ,D_P JWCBJ;I<Z=EY_UN<D\!6CB/92C=[^[K=>
M7DS#\-^#HK*ZFAFNC=74JPI:":VD200M,F^2/>H&T1ECN[8JEXOFN==OEM8D
M\NS@E/E(SM(2I'+LY)/0#CM7:OJFM2VMZ\=ZT@F5I_)D+8;;RR=,KD*1^(X.
M,58TOQI9ZV(18-IMA>%<?V?J$(FC# $95DVMD$ E22#ZK4?6*<9*+>KU6O\
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MZVHKX;U[]M;QQJ)9=.L]+TB,]"L33./Q8X_\=KSW5_C?\0O%TABF\1ZC-O\
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M1*I)0I&[;AQA3WXH \"TG6_'?PVN-*673M:UNP,NN:SIDACDD*R%;A!9R\9
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MF2QKZC R:X3Q=9?"GPYIE]J5YI<-U8W5D(+DZ>'EAEBC:& !MK;-Z[H@"?F
M48/RUI?&/X8:MXWUWPAK.AOID>H:'+>8;4D+!!/;/$)$PK99'*-M( .#R*\F
MTS]D_P 4+8:XESJVF6[ZBTLBP)/-.L3.NG@DNR+G+64K'"@#S0 .#0![$_PG
M^&-_IT4;Z-H]S9:4\B9:0,L+/+YKASNY)D._YL_,<]:M0^&?AU/I&MV*)I$U
MEJ>+S41]I#F7!&V1FW9 4J-IR I'&*X%?@!KES\-OB#X3>ZT^QL->O4FTZS6
M5[A;5-Z/+OF,:.P=E8A2&V9P&(Z9VL_LRZK:++<>&;C2-.NGO]1GD14,7GVM
MS<12"WWA&V?)&RAMK;"P90<4 =[JMA\,OA[I%K<-8:;%;W\EI;0I;[7>XS=[
MH2!NRP6>8OGG!8FN@\(^!?!6@Z[J6I^'=-TZWU1R\-W-9D%UW/O9#@G:"_S;
M>!G)QR:\%TK]E/Q1IDUBKW.@7T!DT]WDNGGDFTT6NHRW>RV9D.X2)*$);80T
M8/S X7T?]GOX(W7P?BU1=0E6]O9HXK7^TDOY9FO8XWE99)(70+$_[TYVL^23
MS@ 4 >OSP)<1E'&0:\X\7_#..\9KBU'ER]<K7I=(0",'D5K3J2I/FBS.=.-1
M6DCYQO[?6=&/E2&0HIX;K6?-K=VS*<\@$'G!S7T=?Z%:7ZD21*<^U<IJ?PML
M;LED0*?:O1CBX2_B1//EA9+X&>&R:MJ'E%1'N;GD.,'T!]JK2W>JSA29%1@,
M<OP*];G^#PR=CD?C3(O@X"?G<G\:V]O070Q^KU3RE'E5\S7'F@?=0#I5^RTN
M^U60)!"P!_B(KV+3?A/96S NH-=;IWAFRTY0(XER/:LY8U1TIJQK#"-ZS9YU
MX-^%HA=9[H;FZ\UZG96,5C"L<:@ 5850@P!@4M>7.I*;NST84XP5D%%%%9F@
M4444 %%%% '/>/M(.M>%;ZW49D">8G^\O(_EC\:\>N?"7_"?>$K26U?9K&GN
M/)8OLPRLI(S[J./>OH!T#H5(R",5Y"(QX&\;36\V4TR_.4?LC'U^AX^A%=M)
M*M2E1?JOU.6<I4*T*\>A@^%? 6M:MK0UCQ8Q66V:,V]E#(K1(P4AFX]R2/7V
MXK4313XKUS4]\,MCI<<JV\T7D1*UWL92L;,&9BH(!YQPW Y->DFWR!@XX_"L
MJ]TMI+B9D@,F^,!&5MHC?NQ_3GVK&G'V;3B_OL[_ ->1M6KNLGSQW5DE=)+M
M9?K<Y;QEX#EUQ!>Z=)%!KL4J36]S/R!M/W2<' YZX..U8%[X]N+2;^SY+S28
M+R-1')'>1S/)=3<@HWRJL:GLV6SD< &O2_$&M0^%M$N;^ZB:=H(&D2(,%,S
M<*">Y.!^-<YJ5S+?*UMK?@T7MY=1+Y!LF\R-P2#L>4@&,J1DGIQD>E7R56_:
M4[=K/;\R(U:-O95T^]UNNF]OZL<=<>'K+Q+XDB^Q:9=:-83I#"0+6,$RD$R
M*W1452&8?>+ @UZ9IWA"RTK1WT^TC12Z.'G:) TA;/+ #!Z].E7O#^@V'AZP
M2WL[6.R4@%XHY&D4-C& QY('3H/I6!XGU_5=-\4VEOI,#ZD)+1FN;0SK$D.&
M'ER!F!P2=ZD=P,]JF,5)VLE_7?\ S*J59)?$VEW_  TU2MY'G-O\ %M-)N#:
M:[>:9KEW%NFBBP(W?: J_+C'W?U)Q65\%YM+^&$VKVGB2%M,U+;$$DFM@NY
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M6-8QPH  VH. *ZVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME)R=V=T8J.B+=%9NK^(;#0Y].AO9Q#)J%R+2V7!.^4JS!?R5ORK2J2@HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>armp-20241231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !' #H# 2(  A$! Q$!_\0
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)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>armp-20241231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ #H# 2(  A$! Q$!_\0
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M;MJ[]-]D<YXEL=(\6RW7Q%^$>H"+7]*;??V$2%!<IU),9ZY&?8X/>O;?A/\
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,-:=GHT%%%%69'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>armp-20241231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !& #@# 2(  A$! Q$!_\0
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F)=J*J+UPHP***@L=1110 4444 -2-8]VU0NXY.!C)]:*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>armp-20241231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !. #H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**\5^/
MGQ#\9:)XR^'7@CP1-INF:KXNNKQ'UC5+9[F.TBMX#,P6)67<S< 98 <F@#VJ
MBO"_^$&_: _Z*IX5_P#"4;_Y(H_X0;]H'_HJGA7_ ,)1O_DB@#W2BO"_^$&_
M:!_Z*IX5_P#"4;_Y(KD/B1XQ^-7P%M- \1Z_XK\->,-$N-;L=)N],M]#>RF*
M7,RQ;XY1,P#*6!P1@XQ0!]1T444 %?"_PT^!OA'XP:/\1_B%XVG\2:SKOA_Q
M7KJ64T'B&[MC;PQ.P$<(20+&"@V\#I7W17QE=?#+XP_"*]UWP?H'BOP,OASQ
MOK.K:A'<:S8W'GVHG!=D8K(%8@' ]ZF4E!7D:TZ<ZLN6"N]7]RN_P,'4O OP
MRT[]EJS^-7]G^.Y;2YT^VOQHH\<:@)%$TB($\SS<<;\YQVKJ/B9\"_AM\-=5
M^'UC+'XYU!O%^M1Z-&Z>-=006I:)Y/,;,OS ;,8'K7-WO[/?QBU']GNU^#S?
M$CX9CP[;V4%@MVMG<?:2D3JZD_O=N24&>/6NB\??"[XY?$/4O!=]J'Q ^%T$
MGA354U>S$%C=;9)5C>,*^9?NX<].^*7/'N'LI]F6=4^ /PVTSXW:%\."OCF2
MXU71[G5UU$>--0"1+#)&AC*>;DD^9G.>,57TG]F3X3?$+XH>,O &H:=XNNE\
M*+IUZ;B]\7W\T4[SJ[H50R_*R&/KZG(Q4EY\-?CIJ_Q<T;QY_P )_P#"YM;T
MW3)](@MH[*Z,3QS.CL2/-W;@8QC'O574? _[0?PI\9>)/B!_PDOP\O+_ ,4R
MZ;I]U;'3+Q8X_++11LA\S/\ RT).?04G.,4Y-Z(J-"I.:IQ6KV/3?V-Q/:>"
M_&NE2:A?ZA:Z1XRU;3K-]2NWNIH[>.;$:&1R68 >IKWVO*_V=?A9KWPI\):U
M;>)M4L-6US6-<O=;NIM+@>&W5[B3>417).![FO5*T, KS'XF:99ZQ\2?AY:7
M]K#>VKRWI:&= Z$B#C(/%>G5YUX[_P"2J_#G_KK??^B*Y<2KTTGWC_Z4CT\N
M;C7;6_+/_P!(D4_'UAX2\%Z?YZ^&-*>5F5$46D8RS' &<8')'-<7+*^DW%Y)
M?^%M%DBLPCW=LEM&'MD..23PW)'3KVKU+XC^"7\7:9Y4#(MPK!T,J[ER#D9'
M<<5XKHVJ:M\0M?U#PV)(8[O(_M"[9"8[Q8F 'ECVQS[U[F'P]&5.ZC'3XKKI
MY'SN)QN(C5Y95):KW;/KY_TCV'3_  'X-\3Z,6?PWI@CF3DQVRHP^C 9!]Q7
MG-W?7-]\"O#INIY+F2'7+>W665MSE$NRBY/<[0!FO;=!TA=&TM+<?PKBO##_
M ,D*T7_L8T_]+FKYO&1A"3]FK+EE^A]KE-6K5C'VLFVIPW=[74KGT..E+2#I
M2UZ1\R%>=>._^2J_#G_KK??^B*]%KRKXMZI)H7CWX>W\=A<:B5N+N(06NW>S
M-#P!N('8\9[5R8EVIW?>/_I2/4RV+GB.5;N,_P#TB1UGC_X@:=X"TKS[S,UQ
M*"(;5#AI#]>P]37E5MXA\,>#+/PEXGCLA*UT;Q+?R9/F*M+SC)P<*3]:ZBXU
MN6^UK^T[SP!XCO+@ +&DRP%(QCH%\SUR>?6ECUBWB;<GPLU93A@ (+?"YZ[1
MYGRY]L5Z5+&X:G'E]Y]]]='IMYGDU<JQM67,N56VUB[:IWW\CT71M;L_$>D0
MZA82B:VF3<K=QZ@CL17@Y_Y(5HO_ &,:?^ES5VVE>)-2T1+N/2? 6OAK@[DM
M[B2!(5?U+;SM!XSUZ5S_ (J\-7/A#X1>&M(OI(Y-2DUNU=TA.097N?,94[G&
M3^6:\;%RC4<I4[V2>Z[V/J,KISH<D*UN9SAHFGLI7>C=EJMSW$=*6D%+7I'S
M(5D^)_"NF>,-+;3]5MA<6Y82*0Q5XW'W71ARK#L16M12<5)6:T+A.5.2G!V:
MZG"K\+)(U"IXR\4J@X -^IP/J4S2_P#"KYO^AS\4?^!R_P#Q%=S16'L*?;\S
ML^O8C^;\%_D<-_PJ^;_H<_%'_@<O_P 15G1OAAINFZS!JUY>ZEKNHVX(MYM5
FN3-]GSU*+@*I/KC/O7844U0IIWL)XW$23CS;]K+\@HHHK<X3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>armp-20241231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %A ;\# 2(  A$! Q$!_\0
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M$WC/]GKP'K6M> M&U'5;W3(YKF[GA8O*Y+98G=UXKU7_ (8P^"7_ $3;0?\
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MWDW)-+O,B2M(%D5XR5"(5(!-'MJG\S^\/9P['H__  QA\$O^B;:#_P!^&_\
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ML#IH;QQ\3(+B"Q4AOWB%BY'7E5'S8'(Q7V#_ ,*I\%_]"EH7_@L@_P#B*/\
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MO?\ 8UWG_I"U?4D?W%^@H =1110 4444 %%%% !1110 4444 %%%% !1110
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M]E?ZW<ZC;Z9\2-)MK(7]Z9C;P&?29/+0L?E0.\A"]!SZ5]]1$,F0<@Y(([T
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M?LO?]C7>?^D+5]21_<7Z"@!U%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 45@^.?&-EX!\*:CKVH!WMK./>4B&6<D@*H]R2!7F_P]_:"F^+,=S:>
M'-!>'583F5K^=1;PQG@.2OS,<Y^55[=1UH Z3Q[\=O"/PXURVTG6;V5+R51(
MRP0M((4/1GQTSCH,GVJ>UT^]^)(BO-7C:R\--B2WTDGY[L=5>X(_A/41#C^_
MG[HX?QK^RY:?$#78=:UCQ'>/J+X%XT-NBI*HP L:_P   &,G<?6O:]/L(=+L
M+:SMUV6]O&L4:YSA5  'Y"@#)\->!/#W@Z2ZDT31[33'N3NF:WC"E_;Z>W2M
MZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-#'<1/%*BR1NI5D<9
M# \$$=Q6-I?@;PYH>@SZ)IV@:7I^C3[_ #=.M;***WDW##;HU4*<CKD<UN44
M 9-AX2T/2]%ET>RT?3[329599+""UC2!PPPP,8&T@CKD<UF-\+/!CZ;IVGMX
M1T)K#3I#+96ITR'RK5R<EHDVX0D@'*@'BNIHH YL?#7PB(M2C'A;11'J<RW%
M\G]GPXNY0VX/*-OSL&Y#-DYYJ2\^'WA?4+VYN[KPWI%S=W)B:>>:PB>24Q8\
MHLQ7+%,#;G[N!C%=!10!R5Q\)/ UW'?1S>#/#TR7TJSW:R:5 PN)!DAY 4^=
MAN;!.2-Q]:ZFWMXK2WB@@B2&")0D<<:A510,  #H .U244 %?,W_  4=_P"3
M1/&7_7:P_P#2R&OIFOF;_@H[_P FB>,O^NUA_P"ED-=&'_C0]495?X<O0Z_]
MC#_DUSX;?]@>/_T)J]JKQ7]C#_DUSX;?]@>/_P!":O:JBM_$EZLJ'P+T.9^)
M.O\ AOPOX'U?5/%P@;P[;P[KQ+BV-PCKD +Y05C(22 % ))( &:\V^#%Q\'[
M4>&]3\$^"=+\'S^*8+B6RE@\/QZ=-,8B1+$^U RR *S;&P2JL?X3C:_:?-M_
MPI+Q"DUOK=S=2>1'81^&YA#J/VTS(+8V[GA7$NPY/& <@CBOFSX&_ Z3X2_'
M_P"'%]\2/B=XE\9>+=7L-2N/#VAZG)&L>ESO%YMV)421M\A228>8N$)!'4K6
M19]T44G05\SZ;^V=9WWC+3T?1UB\(ZEXZN/A[9ZAYQ-Q)?Q1%O/* ;?):56B
M'.X8#'@X !],T5S/Q&\?Z;\,O!6K>)=4$LEMI]M)<?9[==TTY1"WEQK_ !,0
MIP/J3@ FN4^#_P <M/\ '_P-\'_$37WL?"\.OV45UY-S>*L43/DB,2/MW' /
MIG!XH \J_:O_ .3B/V7O^QKO/_2%J^I(_N+]!7R!^T=XW\/>+/VC/V9(]%UW
M3=6DA\57;2)8WD<S(#9, 2%8X'%?7\?W%^@H =1110 4444 %%%% !1110 4
M444 %%%% !1110 445B>)/&6C^%('?4K^"WE$9D2W,@\Z4#LB9RQ)X '4F@#
M!^)D,7BNUC\%K&L\NKKFZ9AD6UJK O+_ +Q.%3_:.?X34_PX^$OAWX66UW%H
M=M(CW3!IIYY-\C@9VKGL!D\#UJWX(T2ZM8;G5]60#6]482W"YR+=!_JX%/H@
M//JQ<]ZZ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^9O^"CO_)HGC+_KM8?^ED-?3-?,W_!1W_DT3QE_
MUVL/_2R&NC#_ ,:'JC*K_#EZ'7_L8?\ )KGPV_[ \?\ Z$U>U5XK^QA_R:Y\
M-O\ L#Q_^A-7M516_B2]65#X%Z'D_P"U1JV@Z/\  3Q;)XE\+WGC71YX([.3
M0=/SY]Z\TR11(A!!5O,="&'*D9'(%?%O[$O@&V\"_M":??']GOXA>&+[4XKB
MW;Q7XUU)KR/3T$+N4C_<( TA54W,2<' /)!^POVQK+0+_P#9R\81^*/$^H^#
M] 6*&2[U;24+W<:K/&P2(#DN[!4'^]7Q1^Q;XI^'>O?M(^%K?PY\6/BYXOU-
M(KV9=.\5PL=.8+;NK&0E^&&XE3@C<H'!(K(L_3[J*^,]$_8V\0V/BS0]%EEM
M%\(:)\3;GXB6VII/^]>)XV,=F8L9\P3.07R%V+D?,<#[,I: /F[XH?"?XJ_&
MKP7JDEUKEKX%UJ"WU;3[32=-$.HVM_#,FR&226:,-#(R;D)7.U9&YYP+'P1_
M9=M(?V7? _PU^+FFZ;XQET6&-VM+N%)(+>50ZHJ%<;MBNRASR0QS7T310!\,
M_&/X ?#KX-_M)_LUW7@KP=I/AFYO?%%U%<2Z=!Y;2HMFY"MSR 3FON2/[B_0
M5\M_M7_\G$?LO?\ 8UWG_I"U?4D?W%^@H =1110 4444 %%%% !1110 4444
M %%%% !1110 AZ5\H_$OX(>(?BM\7=3UC0[Z-M+CN(K9[V>3;]G=%4.L8'+!
M#Z?Q$CJ#7T/XVUNZMX[71M)<+K>J%HX'QD6\8_UDY'H@(QZLRCO6SH6BVOAW
M2+73;)"EM;($0$Y8^I8]V)R2>Y)- %NWC,,$:,YD*J 6;J<#K4E%% !1110
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M S_+/%=W7&_$0_VS_9?AA.3J\W^E8[6D>'F_[Z^2/_MI0!YO^R]XTU;XB_\
M"1:WKT7GZBC0VL=^$V*8@"?*4#@8;YCCKN&>@KWJJ]C86VF6ZP6EO%:P+TB@
M0(H^@'%6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *^9O^"CO_)HGC+_ *[6'_I9#7TS7S-_P4=_
MY-$\9?\ 7:P_]+(:Z,/_ !H>J,JO\.7H=?\ L8?\FN?#;_L#Q_\ H35[57BO
M[&'_ ":Y\-O^P/'_ .A-7M516_B2]65#X%Z'C?[7WA_3_%7[/?BO2=4FUZ.S
MNHX8V@\+IOU*[;SDVVUNIX+RMB/GC#'/&:^-OV)_A7JG@[X\:#/XJT+XN^#Y
M+=;E='A\6ZB+[2;S_1Y%,+;8T$<HC+.@Y!$;8Z#/VS^T]+ID7P4U_P#M8WR6
MSFWCCGTS48M/N8)FGC6*:*YE98XF1RKAF('RX.<X/R%^Q;XQT_Q;\=Y_M/CS
MXG?%*QTZ>YL-'U_6(57P^EWY#-*JLKMYDPB$@5R I4L0!N6LBS]$*6DZ"O'K
M']J;P7J'C:/P_$]V()?$4WA*'5VB M)=6BA\Z2U5MV[( 9=VW:75E!SU /8J
M*\O^/'[06B? #P]%JNK:1KNO&022FT\/Z>UW-'!& 99Y,85(TW+EF(^\,9YQ
MU7PX^(FB?%7P%H?C#P_<-<Z+K-JEW:RR1E&*MV93R""""/4&@#Y__:O_ .3B
M/V7O^QKO/_2%J^I(_N+]!7RU^U:P;]H?]E['/_%5WG_I"U?4L?W%^@H =111
M0 4444 %%%% !1110 4444 %%%% "&N.\(#_ (2#Q-KGB-OF@#_V78GMY43'
MS7'^]+N'TC6KWC[7)M%\.SBR8?VK=LMG9(>IGD.U#CT7)8^RFM3P_HMOX=T2
MQTRUSY%I"L*D]6P,9/N>I]S0!H4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\S?\ !1W_ )-$
M\9?]=K#_ -+(:^F:^9O^"CO_ ":)XR_Z[6'_ *60UT8?^-#U1E5_AR]#K_V,
M/^37/AM_V!X__0FKVJO%?V,/^37/AM_V!X__ $)J]JJ*W\27JRH? O0\F_:7
M\9V'AKX1>)HGT#2_&M_-;QV\7AG4KB&.*\::5(D$OF' C#.&9CT"D]LU\]?L
MQWOBG1OB;X3TGQ[\'O GAA([>YM/#^J>"]2AE&G/Y3RRQ- LK%1(@DS*O?:&
MSN!'HG[2G['_ ,"OBEXAN/B#\5E\B6"SCM7O[K5VLK>&&/<5'! ZLQR:^??V
M6Y/V8/#'[4N@:3\#-%UW5=:FAN[:\\1I=7!TR"(6[2&,F3_6EB@ P,9P<G&*
MR+/T;/2OS\T#]G/QO#XC\*>$)M(O4.A?&F[\;2ZO)&3:RZ48VFCF$OW2[LXB
M\O.X.&R,#-?H'1B@#YH^-WQYUR]^%5]9Z5\+_B$][K-[=Z%-%::,)+JVM5&R
M2\1=^TJRL1%N(RW)&%.=GP_\'/#_ ,9/V</!_AB31_%OPQT.P$9LM(M[]].U
M.VCA\R*-9FC)/S*=Y4DY+*3R*]^Q2T ?G]\1/V:] ^!G[3'[.%YH^O\ BO6)
M+_Q-<PR)XAUN6_1 MF[ HKCY3SR1VK[_ (_N+]!7RW^U?_R<1^R]_P!C7>?^
MD+5]21_<7Z"@!U%%% !1110 4444 %%%% !1110 4UV"(68A5 R23TK*\5>+
M-)\%:--JNLWD=C8Q$ R29Y)Z  <DGT%<7:^(K;XU#R-(N&?P?'@7]VN4:\?
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M)!I!UO[!I^F33-+:B18RT;!=KD,P&T'/;J0*\ML_V@8M3^-VFZOHNMZEXC\
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M\?8TNF6<]I):R6L,EM(2SPM&I1B3DDKC!YY^M60,#% 'YO?M!>"/V@[+XR_
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MX'_\)J7_ .+H_P"%;?M6_P#16O __A-2_P#Q=?4]% 'RQ_PK;]JW_HK7@?\
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M9$4<G,3E<QLV&RN, $9KW>WMX[2".&%%CBC4(B*,!0!@ ?A0!)1110 4444
M>,?M7_&'5/A!\&/%^K>&HXKCQ19:-=:A;";F.W2-.9G'< D!5_B8@=,D=O\
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MP9?:%I5U+>R:EJMUK5]<O&L2R7,[ OLC7B- %5509P%ZDYH ]-HHHH ****
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M7S-_P4=_Y-$\9?\ 7:P_]+(:Z,/_ !H>J,JO\.7H=?\ L8?\FN?#;_L#Q_\
MH35[57BO[&'_ ":Y\-O^P/'_ .A-7M516_B2]65#X%Z!1116184444 %%%%
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M "BBB@ KYF_X*._\FB>,O^NUA_Z60U],U\S?\%'?^31/&7_7:P_]+(:Z,/\
MQH>J,JO\.7H=?^QA_P FN?#;_L#Q_P#H35[57BO[&'_)KGPV_P"P/'_Z$U>U
M5%;^)+U94/@7H%%%%9%A1110 4444 %%0"]MR<">,G.,!A4] !1110 4444
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MGC+_ *[6'_I9#7TS7S-_P4=_Y-$\9?\ 7:P_]+(:Z,/_ !H>J,JO\.7H=?\
ML8?\FN?#;_L#Q_\ H35[57BO[&'_ ":Y\-O^P/'_ .A-7M516_B2]65#X%Z!
M1116184444 %(PRI^E+2$9!'2@#\[/'MGX:T(?'3PQ:^"U@UK7O&W]B>'/$J
M!+.TT>^FTVS: F[5A);A96,@"@!F8*,ER*^G_%_Q.\0?#:'P7X!MI?[?\:W&
MA27EUJ<FGW5U')]F$$4DK16R,_[R65>> H)/)PIM:3^S+82Z=\1]*\4:U/XJ
MT;QU.UWJ=E<VD4 28Q11!XF3E=J01;>I#+N!S5"^_9?U'4M+\,2S?$[Q*GB[
MPSYL.E^*XHK87OV61462WN%9#'<*WEHQ+KG<JMUR2 9'A7X^_$3QMXW\+>%C
MX.LO!VI:UX0N-?EAUR69I[*YANHH'A>(*N4)DRIR"5() ^Z<SPW^T_XT\?ZQ
MX$T31/#^BZ?JOB"RU^&Z.H7<SI::EI5REO-'\B?-"S/E7'S8/*C&#!X@\ ^)
MH?VI?!W]E7OBF"TT[PA>Z7/XKDTX744MU-=03[9F*A/F5';*@*K*J\#Y:]"T
M?]F73_#7C7P+KNCZ]?6D'A2WOH(K.2&*7[8][*LMY--(0&,DCHK$C !S@8.*
M .?T']H[Q-XJ\::0^A>$KO6/!]YK]SH-Q/;V%V)+1(9983?-.4\AHO-A960-
MN4,#DD,HR_#O[8<<_A3QCXBU*+3@OARPN+K4- CDDAU73;A9$CBM9X)%R=Q8
M_OE&TXX!!!/=^&_V=(_!WCG4]5T7QGXAL/#6HW\NK3^$4>$V'VR1MTCJQ3S4
M1GRYC5PI8D]"15>X_99\/^(+J]E\5ZE?>*C-H%QX92:]6*.X^Q3F,RB2:-0T
MK[HD*LWW""0,DD@'GWCC]I_XB> /!7CO6+KP.ES%H=K97UEJ=U;7NG6ERLTX
MAEMR)X@_FQEE8$?*ZMG*D$4_X[_'/QSX8T+XW^'+8Z7INN^'/!:^*M-U2W62
M55AD^TQM$RDK^]5K8E7'RG<I*C!!Z;7/V4;WQ1\*]8\$:W\4?%6N6U^D-LE[
MJ*6KS6]M$ZR+&NV-0[ED3=+)N8X[9-7?$/[+R^,_$7B_4_$'BV_OT\4^%O\
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M?C'Q]^T=X>^R7UG:^$-3^'MGXECT>:%S(C7$X!#2!L%P0H#;<!<X&236U/\
MLLW$NH>+;I?'.HHWB3PW;^&+I?L%N=EM"DBHR<??Q/-R<CYQQ\HK;\#?LZP^
M!M<\*:Q;^)=0N-0T+PTOA9WDAB"W=I'*)("Z@?*Z$8)7&X$\"@#YZT3Q5=?$
M+QQ^SGXAL/#7A_PQKK>(?%]A]GLD)MHC%#=QNP*HK-N9#(1A=S,22,YKUBU_
M:,\3W.DZCIUSIVBZ5K^B>*I?#.L:A<7+-9QXMEN89X(N)9C,LD*B)?F5G;)(
M7)TO#W[)UMX:\/\ A6WM/%NJ#7/#&L:AK&F:N;>#<KWID^TQR1;=CHWFR8Z$
M9&#Q6S+^S/HT>K^&=<LM7U"T\1Z1K5UKLVID)*U_<7,/D7!E1AM&8@J(5 ,:
MHH'&00#D?AQ^TQKWQB\.>![/0-*T[3/%VOZ-J&L7":C)(UK;1VEV+1@  KL9
M)67 (!5=Q.2,'/3XL_$&T^/>EGQ*++PWH-G\/9_$>K>'L&XDMY$N8UG F1]L
MC#;\C8P%)XRQQM67['&G:%H'A&WT#QKXAT+7O"LU]_9FOV@MS<BVNYC+-;2H
MT9CE0L0?F7(*@C!KMO\ A0.DKXUT;Q$-3U"::TT.X\/7L%T4E74K:659F\TE
M>',BDDK@$.PP., 'E+_M2>.QX3UGQ+;^!S=:*?"%UXGLKV>UO;2WM)88A,+6
M>62+$F^(Y62+@LC# !#5M^(/BMXDA\-_";6O$'AKPUJEOXJ\4:1!:J7>1]-2
MYM?,$RAT(,R2>:H92,*0>I(%[3?V3WTKX>Z]X'C^(_BFY\,7FF3:/INGWIMY
M5TJUE4HZ(WEAY2(R40RLVP=!D"M[7?V?&U[P=\-M!E\4WL0\$ZC9ZE!<QVL.
MZ[>V4I$L@(P!M)!VX)//% '*^)?VC]>\,?&'2/#EWINE_P!F:CXHC\-K:P7#
M37D<<ENTD=Y(Z9CC#,I @?#E?FSVJW^S+8VVG?$K]H.*UMXK:(^.!(4B4*"S
M:;9LS8'<L23[DU=G_95TUM9>[M_$NJVMLOC0>.8+18X6$=\RLLREF4L\;;VP
M"<ID $@ #L_AI\)Q\.O$OCK6!K-SJC^*]5&K30SPQHMO((DA"H5&2OEQQCGG
M*D]S0!L_$SQ-J'@WP%KFMZ586^I:A8VS30VUU=I:PN1W>5_E10,DD]@:\(\/
M?M:7L[>(]&NK.PO];M?$>E>'=*OK7S8+.]DOX5ECE99 75$'F$D;MX0;3\W'
MMOQ>^&6G_&/X=:QX0U.YN+.TU%8_](M=OF1O'*DL; ,"K /&I*L"&&0>":\X
MU[]DO1_%;^-9]8\2:S/?>)YM-U![VW\J"6PO[*-4@NK9E7Y2-BG:=PZCD&@#
MEOB]XY^+FD'P!82?V1X>NKOQ];:*]W"'GAU2T>WDFBE50X>)=R,CQMDDIP=I
MYV=2^)/BM/'7QLTSPSX4\/R>*O#6B:7J%E='?YNL;X[AQ#,RJ&!!B=4&6 +Y
MSR:Z?4/V>3K?AS0H-8\9:UK'B+2-<MM?BU^ZCMQ,\\"LB(8D18Q'Y<CKM"CE
MBV<UN^$OA$/"WQ8\7>./[<N[Z;Q%:65G+8S0QK'"ML&$15E 8G]Y)G/7=VP*
M ..\._&#7O'/A+3M;TJ'0]6TR?P4NO7<4OFQJ]U*C&*'/S;4.R4,"I8;.ASQ
MYA\,?B?\0?'?CKX:P>&6\.>&]$U3X7C7[?P^+206EM,TUJFS,;+\J[@JX7"K
MNX)/'O'A#X$Z1\/_  -XI\->'KRZLH-<N;VY6:0+*;+[06(CB4C CCW'8AX&
M3ZFN9\*?L]V?PDC\'ZYI^K:QJEWX,\+S>'EMX8(FDU*R#1RQQ%, "0-"@!4C
M=D@XSD %;X3_ !H\6_$?1/! DM=*L_$,^H:A;>)]/"2G^SA9R&*:-#G[XD,2
M@MPPD##C@^]=!7D?P1\%VZ^(O&'Q$;P]?>%[[QC-;S-I>I!5GB2*%4WO&I*Q
M22,"6 .3M0MR,#UV@#Y^\>?M!^(-)T+XA>+_  [I6GZGX7^']Y-:ZO:SRNEY
M=BWB26[: CY%,:N=JMG>4/*@@GEIM&D^+W[5^M:;KB:-K_@F?P+IMY'IM_9R
M.1!/>79!4%L+*6BC)?'1$ P1FO2]9_9QTO4=8\7M;:S?Z?X?\9.)?$.@PA#!
M>2&-8I'5B-T1EC1$DVGY@,C:Q)K0TKX,2Z3\;+SX@Q>(K@+<Z7#HIT86D2VZ
M6L+R21*K#YLJ\TASW!QCB@#TU5$:!0, # %?.U[^TKK-IX8T7XCQZ9877PUU
M'7$T5UCD?^T((Y+W[%%=XQL93-M)C'S!6!R2"M?16,BO'=)_9KT?1?,TN+5;
MZ7P5_;']O0^%Y$C:WAN_/^T85\;_ "1/^]$9Z-WV_+0!YY>_M0>--+\!_$/Q
MO>:#HHT;P'XINM'U2QM[F:2>XLX6A$DT+E5 =5E+;67#;2,KP3SOBSXL>-?#
MWAW]IG6=;MO#WC31O"NI0VUMH>H02) T!LK*8*P;>K +.Q(*_,^3E1@"]\&/
M@_J/C^Z^+>F^*HO$6B^%-:\;7>KOH>H:=]GAU2T<Q-$1(Z[PCF+$B Y(&#M#
M<^F>._V8+'QGI?Q2TV/Q+J6EV/Q!D@GU&*&*&3R9$AB@9HRRY&Z.",8.<')'
M7@ Y+QO^TCXP\.2?&YK+0]$%I\-M*L=:02W,Q:^@DMY9WB.$ C?;$0#\P!(S
MD<CHKCXU>(E\5ZSX>O=$TF]6[\$R^+-,0SNJ (XC>UN"5;(/F(0ZKC&X%>A-
M?6_V4I-?'Q.%UXWU CX@:7;Z1J@2QMP(X8HFA'E<<,8Y) 2<\L",8%:,G[.%
M_-XG@UQ_'-^;N+PM+X4"BPMPA@?:3*1C_6;T1O[O&,<T <7+\;O%FD_ /P!X
MM\.:5X;TT:_HFFQZ+X5A@D9[K4;B(LMI"$*+'$HV_-@A45V( 6KWB_\ :,\;
MZ#?:UI6C>$SXJU[PHMA'K.GZ18WDXO;B:*.::.VE5"D>R.167S3\Y."%')U_
M#G[+5YX2N?!L^F^.KYW\)Z$N@:4E[IT$R6\7 >55XQ,Z(B,_]U<#&YLZMY^S
M;*_C%/$VG>/_ !)HFIW]G;V?B'[!]G$>MB%2J22*\;>5+M)7?%M.T*.P- 'C
M7[8?CS4/BG^SU\:5TO3],E\,>&)O[)G>_#&YFNXFA::2(8VIY1E"C.2S*_*C
M!/V7!_J4_P!T?RKP[QW^RCI7C#3OB!I%KXCU;0_#_CC$VK:7:+$Z"ZVQJUQ"
MSJ2C.(DWCD,1G@DD^UZ99MIVG6UJ]U->O#&L9N;G;YDI QN;: ,GJ< #VH M
M4444 %?,W_!1W_DT3QE_UVL/_2R&OIFOF;_@H[_R:)XR_P"NUA_Z60UT8?\
MC0]495?X<O0Z_P#8P_Y-<^&W_8'C_P#0FKVJO%?V,/\ DUSX;?\ 8'C_ /0F
MKVJHK?Q)>K*A\"] HHHK(L**** "BBD9MJDGL,T >6_'/X[6?P17PM->:=+?
MVFJZQ;:?>W$;[5TVVED6+[7)Q]Q99(4Q_P!-,]C4?Q\^*GB'X66_A&;1-)TW
M54US7[/0)!?W<D!ADN9!''(-D;[E!SD<'TKSSQG\/S^TQX7^),M]JVN^'M&O
MK:70TT^XT3RW-O"I99E6:'S27D9I 8^H6/'S"O-O%/CKQ)\3_P!G?X.0>(/#
M7BZQ\7Z=XIT237D@T*\6>$6LP^T7:_NC\A4"0-S][&,@B@#Z+^%/QHN?&7Q#
M\<> M?TB+2?%7A/[)-.UG.9[6ZMKE&:&6-RJL#\C*R,H((XR#FJ7Q ^*WC+0
M?C7X=\!Z'HVAW<>O:5>ZE;7NH7\T1C-JT"NCJD+_ 'C<+@@GA3D=*D3X#?V'
MHNN7G@3Q'<^'/%WB*Y@N]2\4:I:C4[NZ6-2J1NDC( JJ=JJ,!>>.37EOC?PO
MKEY^T5\)--UC5/$NI3:9X?U:PU+Q5HNDRVD1N+B2T,(9T1XXPRQOQNP-F21Q
M0!Z3X%_:3A\<_!7Q!XTM] N8M:T2[O=(N?#XE#N^I6\AB^S1R 8</)L"OCHX
M) P16KH?[0_A[4OV<;?XPW.^UT+^Q#K-Q I#21%4)D@[9=7#1XXRPKDK7X?Z
M9H?B'0?A?X,36/">D:&LNN3:DFG/<QW=Y(3@-<SHR229DDE8EBP;R\=./&;3
MX6Z]=^ ?V@_V?K>UUFXM+Z6YU3POK=UIDD%G.]PHN)[7S0BQ+MNE?&,#;*,9
MP: /H#1/CMK3ZU>>&]7\*^5XNDT&+Q%IFEV%WYJW4$DODF)I&50DD<C1B0X*
M@.&!(SBW\(OC%XC\5>._%/@?QKX5@\,^)]#M;345.G7_ -NL[NTN#(L<D<I1
M&#!X9%960?=R,@UP%IJ>H7?Q<?XO7?ACQ!#I'AKP(VC?V<NFRF^N;^>ZCFE@
MA@V[I"@@C7<,J2_!(4D=3^SWXNM_&'B'Q)JL_ASQ/I_B'4TBN-0OM<T*XTZ&
M.-/D@LX3,JF18P9#E1RS.QQO H ]SKB_&_CJ?1]?T/PQH\,5UXBUD331+.2(
MK:VA"^=<28Y*J9(T"CEFD49 R1VE>(:MI]SI'[8_A_6;IRNEZMX+N])M"<[1
M=Q7D4[IZ!GB;('<1-_=H ;HW[0EYXR^/.J>!/#<7AJZL=#F\C5C>:R\.IH0H
M,CPVGDD21@LJ;MX&X-TP,^OZ_P"(]*\*Z9)J.LZC:Z581D![F\F6*-23@ LQ
M Y->1>+-!L/B_P"/O!NK:;H^H:3XB\'^(#--JE_IDEJZVJQRQS1)(ZCS8I@P
M "EE/#?PUY3^UOX!\8Z'^S+\5;OQ=XWB\;6#VL$ECIQT*&T-JXNXB"KAV+MM
M.T9 ]: /;?C)\:X/"WP>^(GB?P;J&BZ[K/A+3+B_GM)+G>D;11M)LD$>64D*
M< XR>XZUUW@WXAZ/XJL(UCU;3YM5@LH+N_L[>X5GM?,0,"ZYRH/."?2OE?\
M:$\/7_CP?$WQ3X9\.:S#82?"_4O"SVRZ3-%/J.H3R*;2%(=F]_) D&\#:OGX
M!^]BOXE-_+\0;6ZT/P'JVM1?\*=O]%73I])NK6VN[PO#+'8RR;%"%E248)!&
M2!@L,@'UQH7Q$\+^)[6_N=(\0Z9J=O8#-W+:7<<BP#!/SD'Y> 3SZ4NC?$+P
MQXBLIKO2_$&F:C:PHTDDUK=QR(BK]XD@\ 9&:^'?$'@K4)K+XJRW^E^)Y]+U
MCX;Z-:P7%KHC6H-Q#<3YMH(&4<1[XAY#DNREE^;-:6HZ1=?$33OBMJ^CZ3K
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M .UC:Q>%=:U"XU;7["7281HT\C7FRVLXO,@&SYPKP2C<N<;<YP03#\2=(DU
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MK?6=9U34_$TL4VH'4YXI$+1)LCV!8UVA4&T#.,=LDFNL\-: /#6D+8"_O=2
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MJVF^'-636K)Y+L-*;A'D=2[;<,-TKMT!W8;.X9J+_A)OC;_T(_@__P *:?\
M^1*/^$F^-O\ T(_@_P#\*:?_ .1*/9ONOO0<Z['<^'?A]I/AGQ%XEUNU6:34
M/$$T$M[)/)OXAA6&.->.$"J3CGEV/>N6\*?L[^%/"=SH!B-_?V/AQWDT'3+^
MX$EKI18,N84"C)5795:0NR*2%(S6?_PDWQM_Z$?P?_X4T_\ \B4?\)-\;?\
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=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>armp-20241231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $/ WT# 2(  A$! Q$!_\0
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M^=6JI7/_ "%;+_<D_P#9: +M%%% !115&77=.@G:"2_M8YE.TQM,H8'TQG-
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MM:XSQ)\*M(\4?$'PQXQNY[Q-3\/+.MI%$ZB%Q*NUMX*DGCI@B@#Y1LM0\;_
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M/'3GZ0KSW3?@AH.E>)O!NN0W.H-=^%=*;2+)'E0H\+(%)D&S); Z@@>U>A4
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M3_"<YYS4-Q^R-X7OM-\5VE]XA\3ZBWB>*UCU*ZO+^.6:0V[;HW#&+@]L=,<
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M51@*HY/0#/?- 'S1^T#\(_#R^(Y=&T1K[Q-\7_%>J)?V5]<2_O=%ME<%I R
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M/_C0!=HJE_9,']^?_P "'_QH_LF#^_/_ .!#_P"- %VBJ7]DP?WY_P#P(?\
MQH_LF#^_/_X$/_C0!=HJE_9,']^?_P "'_QH_LF#^_/_ .!#_P"- %VBJ7]D
MP?WY_P#P(?\ QH_LF#^_/_X$/_C0!=HJE_9,']^?_P "'_QH_LF#^_/_ .!#
M_P"- %VJ6H?ZZP_Z^/\ V1J/[)@_OS_^!#_XU4O],A66R :;YI\',[G^!O>@
M#8HJE_9,']^?_P "'_QH_LF#^_/_ .!#_P"- %VBJ7]DP?WY_P#P(?\ QH_L
MF#^_/_X$/_C0!=HJE_9,']^?_P "'_QH_LF#^_/_ .!#_P"- %VBJ7]DP?WY
M_P#P(?\ QH_LF#^_/_X$/_C0!=HJE_9,']^?_P "'_QH_LF#^_/_ .!#_P"-
M %P]*I:9]^]_Z^&_D*4Z5!@_//\ ^!#_ .->#>+_ -I30O GB[6M"N=$U>ZF
ML[DHTT%VH5LJIR,N#W[UU8?#5L5)QHQNT<F)Q='"14Z\K)Z'T-17S'_PV'X;
M_P"A=UW_ ,#$_P#BZ/\ AL/PW_T+NN_^!B?_ !==W]D8[_GV_P /\SSO[;R_
M_GZON?\ D?3E%?,?_#8?AO\ Z%W7?_ Q/_BZ/^&P_#?_ $+NN_\ @8G_ ,71
M_9&._P"?;_#_ ##^V\O_ .?J^Y_Y'TY17S'_ ,-A^&_^A=UW_P #$_\ BZ/^
M&P_#?_0NZ[_X&)_\71_9&._Y]O\ #_,/[;R__GZON?\ D?3E%?,?_#8?AO\
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M>)GG'^W[4?V1CO\ GV_P_P P_MO+_P#GZON?^1]0T5\Q_P##8?AO_H7==_\
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M-A^&_P#H7==_\#$_^+H_LC'?\^W^'^8?VWE__/U?<_\ (^G**^8_^&P_#?\
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MO+_^?J^Y_P"1].T5\Q_\-A^&_P#H7=<_\#$_^+H_X;#\-_\ 0NZ[_P"!B?\
MQ=']D8[_ )]_E_F']MY?_P _5]S_ ,CZ<JCK7_(+N/\ =_K7SC_PV'X;_P"A
M=UW_ ,#$_P#BZO\ A_\ :=T'QEKEAH=OH>L6T^H3"W2::[5D0GN0')(XJ)95
MC(1<I4]%Z?YEPSC SDH1J:O39_Y'T;15(:5 ?XY__ A_\:/[)@_OS_\ @0_^
M->4>R7:*I?V3!_?G_P# A_\ &C^R8/[\_P#X$/\ XT 7:*I?V3!_?G_\"'_Q
MH_LJ#^_/_P"!#_XT 7:*I?V5 ?XY_P#O^_\ C7/>,=>T[PA:QM+]HGN9<^7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M].KMM??R/=J3.*\@U_Q[JUK\3UNX+IE\(Z7=0:-?Q@#8UQ.I/FENWEL85/\
MOMZ5-KMUK7BGQ3XTAM/$%[HD'AVVA%K'9"/;+,T32EY=RDL.%&T$< ^M)8.>
MCDTE:_IJE;UU7WC>/AJHQ;:=NFMDW??;1_-'K.<4M>107^L^,_"EAXIU+Q-)
MX7\/C18KLMIK(LAN"I,KR;T(V#@*HZY.>U=Q\-]1U75_ FAWNN)LU6>U22<%
M-A)(X)7L2,$CL3657#NE'F;6CL_7^M^QM1Q2K3Y5%I-73[K3_/3N=(>AK\]/
MC[_R6;Q?_P!?O_M)*_0L]#7RC\2/V8O%?COXA>(M;T^\TJ.TN[O<BW$TBN $
M0<@1D=O6O9R+$4L/7E*K*RM^J/"XAPU;%8>$:,7)J73T9X9H'Q0\5>%]-6PT
MO6I[6S1B\<6R.3RF/4QEU)0GK\I'/-9,OB75)M&FTF2]DDT^:[^WR0O@[[C;
MM\PL1N)QQUKV;_AC/QO_ -!#0_\ P(E_^-4?\,9^-_\ H(:'_P"!$O\ \:K[
M!8_+DW)3C=GQ#R[,VE%PE9'@U%>\_P##&?C?_H(:'_X$2_\ QJC_ (8S\;_]
M!#0__ B7_P"-5K_:F"_Y^HQ_LG'?\^F>#45[S_PQGXW_ .@AH?\ X$2__&J/
M^&,_&_\ T$-#_P# B7_XU1_:F"_Y^H/[)QW_ #Z9X-17O/\ PQGXW_Z"&A_^
M!$O_ ,:H_P"&,_&__00T/_P(E_\ C5']J8+_ )^H/[)QW_/IG@U%>\_\,9^-
M_P#H(:'_ .!$O_QJC_AC/QO_ -!#0_\ P(E_^-4?VI@O^?J#^R<=_P ^F>#4
M5[S_ ,,9^-_^@AH?_@1+_P#&J/\ AC/QO_T$-#_\")?_ (U1_:F"_P"?J#^R
M<=_SZ9X-17O/_#&?C?\ Z"&A_P#@1+_\:H_X8S\;_P#00T/_ ,")?_C5']J8
M+_GZ@_LG'?\ /IG@U%>\_P##&?C?_H(:'_X$2_\ QJHG_8[\:I/%$;_1-T@8
MC_2)<<8S_P LO>C^U,%_S]0?V1C_ /GTSPNBO>?^&,_&_P#T$-#_ / B7_XU
M1_PQGXW_ .@AH?\ X$2__&J/[4P7_/U!_9.._P"?3/!J*]Y_X8S\;_\ 00T/
M_P ")?\ XU1_PQGXW_Z"&A_^!$O_ ,:H_M3!?\_4']DX[_GTSP:BO>?^&,_&
M_P#T$-#_ / B7_XU1_PQGXW_ .@AH?\ X$2__&J/[4P7_/U!_9.._P"?3/!J
M*]Y_X8S\;_\ 00T/_P ")?\ XU1_PQGXW_Z"&A_^!$O_ ,:H_M3!?\_4']DX
M[_GTSP:BO>?^&,_&_P#T$-#_ / B7_XU1_PQGXW_ .@AH?\ X$2__&J/[4P7
M_/U!_9.._P"?3/!J*]Y_X8S\;_\ 00T/_P ")?\ XU1_PQGXW_Z"&A_^!$O_
M ,:H_M3!?\_4']DX[_GTSP:BO>?^&,_&_P#T$-#_ / B7_XU1_PQGXW_ .@A
MH?\ X$2__&J/[4P7_/U!_9.._P"?3/!J*]Y_X8S\;_\ 00T/_P ")?\ XU43
M_L=^-8YXXC?Z)ND#$?Z1+CC&?^67O1_:F"_Y^H/[(Q__ #Z9X717O/\ PQGX
MW_Z"&A_^!$O_ ,:H_P"&,_&__00T/_P(E_\ C5']J8+_ )^H/[)QW_/IG@U%
M>\_\,9^-_P#H(:'_ .!$O_QJC_AC/QO_ -!#0_\ P(E_^-4?VI@O^?J#^R<=
M_P ^F>#45[S_ ,,9^-_^@AH?_@1+_P#&J/\ AC/QO_T$-#_\")?_ (U1_:F"
M_P"?J#^R<=_SZ9X-17O/_#&?C?\ Z"&A_P#@1+_\:H_X8S\;_P#00T/_ ,")
M?_C5']J8+_GZ@_LG'?\ /IG@U%>\_P##&?C?_H(:'_X$2_\ QJC_ (8S\;_]
M!#0__ B7_P"-4?VI@O\ GZ@_LG'?\^F>#45[S_PQGXW_ .@AH?\ X$2__&J/
M^&,_&_\ T$-#_P# B7_XU1_:F"_Y^H/[)QW_ #Z9X-17O/\ PQGXW_Z"&A_^
M!$O_ ,:H_P"&,_&__00T/_P(E_\ C5']J8+_ )^H/[)QW_/IG@U%>\_\,9^-
M_P#H(:'_ .!$O_QJC_AC/QO_ -!#0_\ P(E_^-4?VI@O^?J#^R<=_P ^F>#4
M5[S_ ,,9^-_^@AH?_@1+_P#&JB'['?C4W+0?;]$WA Y/VB7&"2/^>7M1_:F"
M_P"?J#^R,?\ \^F>%T5[S_PQGXW_ .@AH?\ X$2__&J/^&,_&_\ T$-#_P#
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M+:X5W4 X)P#TS1]9Q4+^[:V^GE9?AL_Q$\)@ZEO>O?1:[N]W^.K6W=&+\)/
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M!_\ H;]#_P#!A%_\57YP@@C(((I-P]1^='^K='_GX_P#_6FO_P ^U][/T?\
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MWZ'_ .#"+_XJOSAHH_U;H_\ /Q_@'^M-?_GVOO9^CW_"W/ __0WZ'_X,(O\
MXJC_ (6YX'_Z&_0__!A%_P#%5^<-%'^K='_GX_P#_6FO_P ^U][/T>_X6YX'
M_P"AOT/_ ,&$7_Q5'_"W/ __ $-^A_\ @PB_^*K\X:*/]6Z/_/Q_@'^M-?\
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MK='_ )^/\!?ZTU_^?:^]GZ/?\+<\#_\ 0WZ'_P"#"+_XJC_A;G@?_H;]#_\
M!A%_\57YPT4?ZMT?^?C_  #_ %IK_P#/M?>S]'O^%N>!_P#H;]#_ /!A%_\
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M .2_I:%?V=%5%-2V:?W**M_Y+Y^6MF+1117F'KA1110 4444 %%%% !1110
M52U'_76'_7Q_[(U7:I:C_KK#_KX_]D:@"[1110 4444 %%%% !1110 4444
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M445ZYXP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >M_!Z;2[_P .>+4U#PUH^I2:-I$VHP7%U S2/(&
M <AAE1GH /K6O8_"KPIJ.O\ AC2]:OK[3M?\31)?I;Z7;I]CM8Y,E(AN);)
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M'4%MK:%&MH(S\ZQR$\DLJD$CI7%:C?VVI_&U[FSBC@LY-?3R8XD"HJ"X4*
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MSZW7_?DT?VH/^?6Z_P"_)JYBC% %/^U!_P ^MU_WY-']J#_GUNO^_)JYBC%
M%(ZH,'_1;K_OT:^.?BS\$?&_BWXF>)=6TO09;FPN;O?%+YL:Y'EH.A8$<@]:
M^TR.*X'5?C!X-\&ZSJ&EZUX@L]/OTEWM;S,0RJR@J>G<<UV8;,GE<G532OI[
MVW?NNQR8C)WG25",92:UM%7?;L]-3X^_X9N^(_\ T+,W_?\ A_\ BZ/^&;OB
M/_T+,W_?^'_XNOKC_AHGX;_]#=IO_?;?X4?\-$_#?_H;M-_[[;_"O1_UO?\
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MLS?]_P"'_P"+KZX_X:)^&_\ T-VF_P#?;?X4?\-$_#?_ *&[3?\ OMO\*/\
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MW_Z&[3?^^V_PH_UO?\]/[_\ [8/]0:O_ #YJ_P#@/_VI\C_\,W?$?_H69O\
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M]M_A1_PT3\-_^ANTW_OMO\*/];W_ #T_O_\ M@_U!J_\^:O_ (#_ /:GR/\
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M_P# ?_M3Y'_X9N^(_P#T+,W_ '_A_P#BZ/\ AF[XC_\ 0LS?]_X?_BZ^N/\
MAHGX;_\ 0W:;_P!]M_A1_P -$_#?_H;M-_[[;_"C_6]_ST_O_P#M@_U!J_\
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ML;[2=0M-*O$M(H!I-^(;J..W0HD<DC*1(I#$D8ZUR7_"G_'?_0FZ[_X+Y?\
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M.>,YZ58_X4_X[_Z$W7?_  7R_P"%'_"G_'?_ $)NN_\ @OE_PJ92Q<U9Q?\
MX#WMY>2-*<,JI.\:D;Z?;[-M=?[S.Z'[0\,7B"34X]"D;?K\VL&.2=<JDEJM
MN44@<.,%@W0''%<SXA^(FCWO@:^\.:;IFJ(UUJ$6H/J&J7XN9I&167:V% Q@
M\8]\UE_\*?\ '?\ T)NN_P#@OE_PH_X4_P"._P#H3==_\%\O^%7*KC9IJ47K
M?[/??H84L-D]&494YQ7+;[?\KNK^]K9]SD:*Z[_A3_CO_H3==_\ !?+_ (4?
M\*?\=_\ 0FZ[_P""^7_"N'ZO6_D?W,]KZ_A/^?T?_ E_F<C177?\*?\ '?\
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M_N8?7\)_S^C_ .!+_,Y&BNN_X4_X[_Z$W7?_  7R_P"%'_"G_'?_ $)NN_\
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M/J];^1_<P^OX3_G]'_P)?YG(T5UW_"G_ !W_ -";KO\ X+Y?\*/^%/\ CO\
MZ$W7?_!?+_A1]7K?R/[F'U_"?\_H_P#@2_S.1HKKO^%/^._^A-UW_P %\O\
MA1_PI_QW_P!";KO_ (+Y?\*/J];^1_<P^OX3_G]'_P "7^9R-%==_P *?\=_
M]";KO_@OE_PH_P"%/^._^A-UW_P7R_X4?5ZW\C^YA]?PG_/Z/_@2_P SD:*Z
M[_A3_CO_ *$W7?\ P7R_X4?\*?\ '?\ T)NN_P#@OE_PH^KUOY']S#Z_A/\
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MK*T"LJ,<+E5/ P.E<6_@SXIO:ZI;-X>\1_9]4E$U[']@DVSOG.YOEZYJ"U\
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MIGQ)_P"$7/\ :%K>>'9-.TM2;***,![>Z#-_I$<C9)QM(&.>U>??#_\ 9?\
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M_3/(HR*_,S_A87BK_H9]:_\ !C-_\51_PL+Q5_T,^M?^#&;_ .*H_P!9Z?\
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MD(EMA:L]M,RY7S-[%U)(;C("\#I76Z7K$>J:ZMXC?:G^V->-=6\02^MK>%,
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M !X_XT?ZKK_G]_Y+_P $/^(CR_Z!/_)__M3\P/L-U_SZS_\ ?IO\*3[#<_\
M/M/_ -^F_P *_4#^Q[/_ )X_^/'_ !H_L:SR#Y R.AW'_&C_ %77_/[_ ,E_
MX(?\1'E_T"?^3_\ VI^8'V&Z_P"?6?\ []-_A1]ANO\ GUG_ ._3?X5^G_\
M8]G_ ,\?_'C_ (T?V/9_\\?_ !X_XT?ZKK_G]_Y+_P $/^(CR_Z!/_)__M3\
MP/L-U_SZS_\ ?IO\*/L-U_SZS_\ ?IO\*_3_ /L>S_YX_P#CQ_QH_L>S_P">
M/_CQ_P :/]5U_P _O_)?^"'_ !$>7_0)_P"3_P#VI^8'V&Z_Y]9_^_3?X4?8
M;K_GUG_[]-_A7Z?_ -CV?_/'_P >/^-']CV?_/'_ ,>/^-'^JZ_Y_?\ DO\
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MJWS2*!\N,<# QFOT?_L>S_YX_P#CQ_QH_L>S_P">/_CQ_P :UI\..D[PK?\
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MF>3.%+ \#).<\5WM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5]0O
MH=,L+F\N"RP6\;2R%5+$*H). ,D\#H.:XI?C/X?GM?#EY;"\NM.URW6[AO8[
M9A'%$SQQJ\N<,H+RH.AZDG !-=CK&IVFBZ3>ZA?R"&QM('GGD89"QJI9B1[
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M*V )HX6).<##RH.N>> : *-K\"O!5FZ21:,@F">7),97,DZ?N\+*Y.9 /*3
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MTFD4F5[3[&S#!P"8/EX^O7FNTHH X#1?@=X2T&"6.UL[C]ZBQR/)=RLSA1<
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M>A[8&,"H-,_9Z\':38BRM[.=;,LYD@$Q"RJTD4@1\ %@I@C SR ",D&O2Z*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
.4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>armp-20241231xex10d38001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20241231xex10d38001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "/ /H# 2(  A$! Q$!_\0
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M(%O=(!,QD^>9MI EC)RV#D_,N15*QUEH;:'P\^I2V5K9LFH:Q<63;99<DDO
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MK(D5XG9'#(ZG!5@01^%?0QX<PTE?G?X?Y'S$N*<7%M>SC^/^9^B'_"^?A_\
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M1HW1A@@@X-:8+%X3$Q<,*](]+6W,LPP6,PLE4Q:UEUO?;SU/T=^%WBZ+QSX
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*+-\ONWO?;YG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>armp-20241231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 12:13:38 AM-->
<!--Modified on: 3/21/2025 12:13:38 AM-->
<xsd:schema targetNamespace="http://www.armatapharma.com/20241231" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:armp="http://www.armatapharma.com/20241231" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails" id="DisclosureNetLossPerShareBasicAndDilutedEpsDetails">
        <link:definition>99940501 - Disclosure - Net Loss per Share (Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" id="DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails">
        <link:definition>99940602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" id="DisclosureBalanceSheetDetailsOtherReceivablesDetails">
        <link:definition>99940603 - Disclosure - Balance Sheet Details (Other receivables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" id="DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>99940604 - Disclosure - Balance Sheet Details (Accounts payable and accrued liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" id="DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails">
        <link:definition>99940902 - Disclosure - Stockholders' Deficit (Shares Reserved for Future Issuance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails">
        <link:definition>99941102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
        <link:definition>99941103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails">
        <link:definition>99941104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails">
        <link:definition>99941202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" id="DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2">
        <link:definition>41202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails" id="DisclosureSegmentReportingSegmentInformationDetails">
        <link:definition>99941502 - Disclosure - Segment Reporting - Segment information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" id="StatementConsolidatedStatementsOfStockholdersDeficit">
        <link:definition>995200300 - Statement - Consolidated Statements of Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlans" id="DisclosureEquityIncentivePlans">
        <link:definition>995211001 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" id="DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails">
        <link:definition>99940101 - Disclosure - Organization and Description of the Business (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" id="DisclosureLiquidityAndGoingConcernNarrativeDetails">
        <link:definition>99940201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>99940301 - Disclosure - Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" id="DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>99940302 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails" id="DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails">
        <link:definition>99940401 - Disclosure - Fair Value Measurements (Assets and liabilities at fair value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" id="DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails">
        <link:definition>99940402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails" id="DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails">
        <link:definition>99940403 - Disclosure - Fair Value Measurements (Changes in Fair Value of Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" id="DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails">
        <link:definition>99940502 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails" id="DisclosureBalanceSheetDetailsNarrativeDetails">
        <link:definition>99940601 - Disclosure - Balance Sheet Details (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails" id="DisclosureConvertibleLoanNarrativeDetails">
        <link:definition>99940701 - Disclosure - Convertible Loan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureTermDebtDetails" id="DisclosureTermDebtDetails">
        <link:definition>99940801 - Disclosure - Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails" id="DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails">
        <link:definition>99940901 - Disclosure - Stockholders' Deficit (Summary of Warrants Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" id="DisclosureEquityIncentivePlansNarrativeDetails">
        <link:definition>99941001 - Disclosure - Equity Incentive Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails" id="DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails">
        <link:definition>99941003 - Disclosure - Equity Incentive Plans (Restricted stock award and restricted stock unit award activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" id="DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails">
        <link:definition>99941004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" id="DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails">
        <link:definition>99941005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" id="DisclosureIncomeTaxesNarrativeDetail">
        <link:definition>99941101 - Disclosure - Income Taxes (Narrative) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>99941201 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" id="DisclosureGrantAndAwardsNarrativeDetails">
        <link:definition>99941301 - Disclosure - Grant and Awards (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails" id="DisclosureSegmentReportingNarrativeDetails">
        <link:definition>99941501 - Disclosure - Segment Reporting (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" id="DisclosureSubsequentEventsNarrativeDetails">
        <link:definition>99941601 - Disclosure - Subsequent Events (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>995210101 - Disclosure - Organization and Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern" id="DisclosureLiquidityAndGoingConcern">
        <link:definition>995210201 - Disclosure - Liquidity and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>995210301 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995210401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995210501 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetails" id="DisclosureBalanceSheetDetails">
        <link:definition>995210601 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureConvertibleLoan" id="DisclosureConvertibleLoan">
        <link:definition>995210701 - Disclosure - Convertible Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureTermDebt" id="DisclosureTermDebt">
        <link:definition>995210801 - Disclosure - Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficit" id="DisclosureStockholdersDeficit">
        <link:definition>995210901 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995211101 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211201 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwards" id="DisclosureGrantAndAwards">
        <link:definition>995211301 - Disclosure - Grant and Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan" id="DisclosureEmployeeRetirementPlan">
        <link:definition>995211401 - Disclosure - Employee Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995211501 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211601 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>99920302 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>99930303 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>99930403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99930503 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables" id="DisclosureBalanceSheetDetailsTables">
        <link:definition>99930603 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficitTables" id="DisclosureStockholdersDeficitTables">
        <link:definition>99930903 - Disclosure - Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables" id="DisclosureEquityIncentivePlansTables">
        <link:definition>99931003 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99931103 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>99931203 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>99931503 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" id="DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails">
        <link:definition>99941002 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeasesDetails">
        <link:definition>99941203 - Disclosure - Commitments and Contingencies (Operating leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails" id="DisclosureEmployeeRetirementPlanNarrativeDetails">
        <link:definition>99941401 - Disclosure - Employee Retirement Plan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd" />
  <xsd:element name="ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantExpirationDate" id="armp_WarrantExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquityIncentivePlan2016Member" id="armp_EquityIncentivePlan2016Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="C3jStockPlan2016Member" id="armp_C3jStockPlan2016Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" id="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockOptionsMember" id="armp_CommonStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PropertyAndEquipmentUsefulLifeTableTextBlock" id="armp_PropertyAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LaboratoryEquipmentMember" id="armp_LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OfficeAndComputerEquipmentMember" id="armp_OfficeAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AnnualIncreaseInRentPercentage" id="armp_AnnualIncreaseInRentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceFourMember" id="armp_ExercisePriceFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceFiveMember" id="armp_ExercisePriceFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" id="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetLeaseObligation" id="armp_DeferredTaxAssetLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxLiabilitiesRightOfUseAsset" id="armp_DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="GrantsAndAwardsPolicyTextBlock" id="armp_GrantsAndAwardsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceSixMember" id="armp_ExercisePriceSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AwardAgreementInterruptionPeriod" id="armp_AwardAgreementInterruptionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AwardTextBlock" id="armp_AwardTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AwardAbstract" id="armp_AwardAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" id="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" id="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MedicalTechnologyEnterpriseConsortiumMember" id="armp_MedicalTechnologyEnterpriseConsortiumMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquitySecuritiesMeasurementInput" id="armp_EquitySecuritiesMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedLiabilitiesClinicalTrial" id="armp_AccruedLiabilitiesClinicalTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ProceedsFromExerciseOfWarrantsAndStockOptions" id="armp_ProceedsFromExerciseOfWarrantsAndStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsAndRestrictedStockAwardsMember" id="armp_StockOptionsAndRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceSevenMember" id="armp_ExercisePriceSevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceEightMember" id="armp_ExercisePriceEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InnovivaStrategicOpportunitiesLlcMember" id="armp_InnovivaStrategicOpportunitiesLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BaseAnnualRentToBePaidYearThree" id="armp_BaseAnnualRentToBePaidYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ExercisePriceNineMember" id="armp_ExercisePriceNineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceTenMember" id="armp_ExercisePriceTenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AnnualReductionOfStandbyLetterOfCredit" id="armp_AnnualReductionOfStandbyLetterOfCredit" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="UnvestedRestrictedStockMember" id="armp_UnvestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SecuredTermLoanMember" id="armp_SecuredTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConversionPercentOfDiscountOnSharePrice" id="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromQualifiedFinancingPerAgreementBenchmark" id="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseFairValueOfLiabilities" id="armp_IncreaseDecreaseFairValueOfLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfOtherReceivablesCurrentTableTextBlock" id="armp_ScheduleOfOtherReceivablesCurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TenantImprovementReceivableCurrent" id="armp_TenantImprovementReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ConvertibleDebtDisclosureTextBlock" id="armp_ConvertibleDebtDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LiquidityAndGoingConcernAbstract" id="armp_LiquidityAndGoingConcernAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" id="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProbabilitiesOfSettlementScenariosMember" id="armp_ProbabilitiesOfSettlementScenariosMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" id="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" id="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentMeasurementInputForPeriod" id="armp_DebtInstrumentMeasurementInputForPeriod" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CreditAndSecurityAgreementMember" id="armp_CreditAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfLongLivedAssetsInGeographicalLocation" id="armp_PercentageOfLongLivedAssetsInGeographicalLocation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SharesIssuableUponConversionOfConvertibleLoanMember" id="armp_SharesIssuableUponConversionOfConvertibleLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NoncashInterestIncome" id="armp_NoncashInterestIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ArmataPharmaceuticalsInc.Member" id="armp_ArmataPharmaceuticalsInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfDirectors" id="armp_NumberOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfBoardDirectors" id="armp_NumberOfBoardDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockVotingPercentageHeldPercentage" id="armp_CommonStockVotingPercentageHeldPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" id="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" id="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GrantAndAwardReceivableCurrent" id="armp_GrantAndAwardReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SharesIssuableUponConversionOfConvertibleDebt" id="armp_SharesIssuableUponConversionOfConvertibleDebt" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent" id="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CreditAgreement2023Member" id="armp_CreditAgreement2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CreditAgreement2024Member" id="armp_CreditAgreement2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AwardAgreementWithCysticFibrosisFoundationMember" id="armp_AwardAgreementWithCysticFibrosisFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromGovernmentGrants" id="armp_ProceedsFromGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AllowanceForTenantImprovementsReceivable" id="armp_AllowanceForTenantImprovementsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryforwardsNotSubjectToExpiration" id="armp_OperatingLossCarryforwardsNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EmployeeStockPurchasePlan2016Member" id="armp_EmployeeStockPurchasePlan2016Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SingleReportableSegmentMember" id="armp_SingleReportableSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OperatingLeaseBaseAnnual" id="armp_OperatingLeaseBaseAnnual" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt" id="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CreditAgreement2025Member" id="armp_CreditAgreement2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonCysticFibrosisBronchiectasisMember" id="armp_NonCysticFibrosisBronchiectasisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExternalResearchAndDevelopmentExpense" id="armp_ExternalResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CysticFibrosisMember" id="armp_CysticFibrosisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BacteremiaMember" id="armp_BacteremiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProstheticJointInfectionMember" id="armp_ProstheticJointInfectionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnallocatedExternalResearchAndDevelopmentExpense" id="armp_UnallocatedExternalResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExternalResearchAndDevelopmentExpenseTotal" id="armp_ExternalResearchAndDevelopmentExpenseTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentPersonnelExpense" id="armp_ResearchAndDevelopmentPersonnelExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxAssetsInterestExpenseCarryForwards" id="armp_DeferredTaxAssetsInterestExpenseCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxLiabilitiesDebtBasisDifferences" id="armp_DeferredTaxLiabilitiesDebtBasisDifferences" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent" id="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" id="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>armp-20241231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 12:13:38 AM-->
<!--Modified on: 3/21/2025 12:13:38 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureNetLossPerShareBasicAndDilutedEpsDetails" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetailsOtherReceivablesDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSegmentReportingSegmentInformationDetails" roleURI="http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638781128152619137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638781128152619137" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128152619137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638781128152619137" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128152619137" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638781128152619137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638781128152619137" xlink:to="us-gaap_OtherAssetsCurrent_638781128152619137" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638781128152619137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638781128152619137" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638781128152619137" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638781128152619137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_Goodwill_638781128152619137" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638781128152619137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638781128152619137" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638781128152629136" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638781128152629136" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638781128152629136" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638781128152629136" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638781128152629136" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638781128152629136" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638781128152629136" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638781128152629136" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638781128152629136" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638781128152629136" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638781128152639135" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638781128152629136" xlink:to="us-gaap_CommonStockValue_638781128152639135" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638781128152639135" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638781128152629136" xlink:to="us-gaap_AdditionalPaidInCapital_638781128152639135" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638781128152639135" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638781128152629136" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638781128152639135" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638781128152639135" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638781128152639135" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt_638781128152639135" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638781128152639135" xlink:to="us-gaap_SecuredLongTermDebt_638781128152639135" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638781128152649168" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638781128152639135" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638781128152649168" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638781128152649168" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638781128152639135" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638781128152649168" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638781128152649168" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638781128152639135" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638781128152649168" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638781128152649168" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638781128152639135" xlink:to="us-gaap_LiabilitiesCurrent_638781128152649168" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638781128152649168" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638781128152649168" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638781128152649168" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_638781128152649168" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638781128152649168" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_638781128152649168" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent" xlink:label="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent_638781128152659170" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638781128152649168" xlink:to="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent_638781128152659170" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638781128152659170" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638781128152649168" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638781128152659170" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638781128152659170" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638781128152649168" xlink:to="us-gaap_OtherLiabilitiesCurrent_638781128152659170" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638781128152669167" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638781128152669167" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638781128152669167" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638781128152669167" xlink:to="us-gaap_OtherNonoperatingIncome_638781128152669167" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_638781128152669167" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638781128152669167" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_638781128152669167" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128152669167" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638781128152669167" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128152669167" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638781128152669167" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638781128152669167" xlink:to="us-gaap_OtherNonoperatingExpense_638781128152669167" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638781128152669167" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638781128152669167" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638781128152669167" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638781128152669167" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638781128152669167" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638781128152679140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638781128152669167" xlink:to="us-gaap_OperatingExpenses_638781128152679140" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638781128152679140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638781128152679140" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638781128152679140" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638781128152679140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638781128152679140" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638781128152679140" order="2" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638781128152679140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_ProfitLoss_638781128152679140" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638781128152689142" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638781128152689142" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_638781128152689142" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_OtherNoncashExpense_638781128152689142" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638781128152689142" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638781128152689142" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NoncashInterestIncome" xlink:label="armp_NoncashInterestIncome_638781128152689142" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="armp_NoncashInterestIncome_638781128152689142" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128152689142" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128152689142" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638781128152689142" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638781128152689142" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638781128152699144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638781128152699144" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_638781128152699144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities_638781128152699144" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638781128152699144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_ShareBasedCompensation_638781128152699144" order="10" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_638781128152699144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_638781128152699144" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638781128152699144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638781128152699144" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638781128152699144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128152679140" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638781128152699144" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638781128152709140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638781128152709140" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638781128152709140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638781128152709140" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638781128152709140" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638781128152709140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638781128152709140" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638781128152709140" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781128152709140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781128152709140" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638781128152709140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781128152709140" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638781128152709140" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_638781128152709140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781128152709140" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_638781128152709140" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638781128152719147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781128152709140" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638781128152719147" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_638781128152719147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781128152709140" xlink:to="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_638781128152719147" order="4" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128152719147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128152719147" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638781128152719147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_638781128152719147" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Net Loss per Share (Basic and Diluted EPS) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt" xlink:label="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt_638781128152729147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt_638781128152729147" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_638781128152729147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_638781128152729147" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638781128152729147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638781128152729147" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638781128152729147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638781128152729147" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781128152739149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781128152739149" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638781128152739149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638781128152739149" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638781128152739149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638781128152739149" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - Balance Sheet Details (Other receivables) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="OtherReceivablesNetCurrent" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_TenantImprovementReceivableCurrent" xlink:label="armp_TenantImprovementReceivableCurrent_638781128152739149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OtherReceivablesNetCurrent" xlink:to="armp_TenantImprovementReceivableCurrent_638781128152739149" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_GrantAndAwardReceivableCurrent" xlink:label="armp_GrantAndAwardReceivableCurrent_638781128152739149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OtherReceivablesNetCurrent" xlink:to="armp_GrantAndAwardReceivableCurrent_638781128152739149" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - Balance Sheet Details (Accounts payable and accrued liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638781128152749149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent_638781128152749149" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_638781128152749149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_638781128152749149" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AccruedLiabilitiesClinicalTrial" xlink:label="armp_AccruedLiabilitiesClinicalTrial_638781128152749149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="armp_AccruedLiabilitiesClinicalTrial_638781128152749149" order="3" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Stockholders' Deficit (Shares Reserved for Future Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638781128152749149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638781128152749149" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638781128152759147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638781128152759147" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_638781128152759147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_638781128152759147" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638781128152759147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638781128152759147" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638781128152759147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638781128152759147" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_638781128152759147" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="armp_SharesIssuableUponConversionOfConvertibleDebt_638781128152759147" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638781128152769234" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638781128152769234" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638781128152769234" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638781128152769234" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="DeferredTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638781128152769234" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638781128152769234" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_638781128152769234" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638781128152769234" xlink:to="armp_DeferredTaxLiabilitiesRightOfUseAsset_638781128152769234" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638781128152769234" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638781128152769234" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638781128152769234" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638781128152769234" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638781128152769234" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638781128152769234" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxLiabilitiesDebtBasisDifferences" xlink:label="armp_DeferredTaxLiabilitiesDebtBasisDifferences_638781128152769234" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638781128152769234" xlink:to="armp_DeferredTaxLiabilitiesDebtBasisDifferences_638781128152769234" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638781128152799497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638781128152799497" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638781128152799497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_638781128152799497" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638781128152799497" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638781128152799497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_638781128152799497" xlink:to="us-gaap_DeferredTaxAssetsGross_638781128152799497" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638781128152799497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781128152799497" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638781128152799497" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638781128152799497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781128152799497" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638781128152799497" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxAssetLeaseObligation" xlink:label="armp_DeferredTaxAssetLeaseObligation_638781128152799497" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781128152799497" xlink:to="armp_DeferredTaxAssetLeaseObligation_638781128152799497" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638781128152809196" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781128152799497" xlink:to="us-gaap_DeferredTaxAssetsOther_638781128152809196" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638781128152809196" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781128152799497" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638781128152809196" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638781128152809196" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781128152799497" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638781128152809196" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxAssetsInterestExpenseCarryForwards" xlink:label="armp_DeferredTaxAssetsInterestExpenseCarryForwards_638781128152809196" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781128152799497" xlink:to="armp_DeferredTaxAssetsInterestExpenseCarryForwards_638781128152809196" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638781128152819149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638781128152819149" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638781128152819149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638781128152819149" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638781128152819149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638781128152819149" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638781128152819149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638781128152819149" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638781128152819149" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638781128152819149" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent_638781128152829155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent_638781128152829155" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_638781128152829155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_638781128152829155" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638781128152829155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638781128152829155" order="8" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638781128152839150" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638781128152839150" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638781128152839150" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638781128152839150" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638781128152839150" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638781128152839150" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638781128152839150" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638781128152839150" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638781128152849138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638781128152849138" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638781128152849138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638781128152849138" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" xlink:type="extended" xlink:title="41202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638781128152849138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638781128152849138" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638781128152849138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638781128152849138" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638781128152859139" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638781128152849138" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638781128152859139" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638781128152859139" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638781128152849138" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638781128152859139" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails" xlink:type="extended" xlink:title="99941502 - Disclosure - Segment Reporting - Segment information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_638781128152859139" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_638781128152859139" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638781128152859139" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_LaborAndRelatedExpense_638781128152859139" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_638781128152869165" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_638781128152869165" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ResearchAndDevelopmentPersonnelExpense" xlink:label="armp_ResearchAndDevelopmentPersonnelExpense_638781128152869165" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="armp_ResearchAndDevelopmentPersonnelExpense_638781128152869165" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExternalResearchAndDevelopmentExpenseTotal" xlink:label="armp_ExternalResearchAndDevelopmentExpenseTotal_638781128152869165" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="armp_ExternalResearchAndDevelopmentExpenseTotal_638781128152869165" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_UnallocatedExternalResearchAndDevelopmentExpense" xlink:label="armp_UnallocatedExternalResearchAndDevelopmentExpense_638781128152869165" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="armp_ExternalResearchAndDevelopmentExpenseTotal_638781128152869165" xlink:to="armp_UnallocatedExternalResearchAndDevelopmentExpense_638781128152869165" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExternalResearchAndDevelopmentExpense" xlink:label="armp_ExternalResearchAndDevelopmentExpense_638781128152879139" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="armp_ExternalResearchAndDevelopmentExpenseTotal_638781128152869165" xlink:to="armp_ExternalResearchAndDevelopmentExpense_638781128152879139" order="2" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>armp-20241231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 12:13:38 AM-->
<!--Modified on: 3/21/2025 12:13:38 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedStatementsOfStockholdersDeficit" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureLiquidityAndGoingConcernNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureConvertibleLoanNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureTermDebtDetails" roleURI="http://www.armatapharma.com/role/DisclosureTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxesNarrativeDetail" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureGrantAndAwardsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSegmentReportingNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSegmentReportingSegmentInformationDetails" roleURI="http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.armatapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_1" xlink:title="us-gaap_RevenueNotFromContractWithCustomer_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_RevenueNotFromContractWithCustomer_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_GainsLossesOnExtinguishmentOfDebt_2" order="11" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.armatapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:title="ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:title="SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:title="definition: ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis to SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: IndefiniteLivedIntangibleAssetsByMajorClassAxis to IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityNameAxis" xlink:to="IncomeTaxAuthorityNameDomain" xlink:title="definition: IncomeTaxAuthorityNameAxis to IncomeTaxAuthorityNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShortTermDebtTypeAxis" xlink:to="ShortTermDebtTypeDomain" xlink:title="definition: ShortTermDebtTypeAxis to ShortTermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:title="EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="EmployeeStockOwnershipPlanESOPPlanDomain" xlink:title="EmployeeStockOwnershipPlanESOPPlanDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="EmployeeStockOwnershipPlanESOPPlanDomain" xlink:title="definition: EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis to EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:title="RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:title="RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:title="definition: RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis to RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:label="AcceleratedShareRepurchasesDateAxis" xlink:title="AcceleratedShareRepurchasesDateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:label="AcceleratedShareRepurchasesDateDomain" xlink:title="AcceleratedShareRepurchasesDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AcceleratedShareRepurchasesDateAxis" xlink:to="AcceleratedShareRepurchasesDateDomain" xlink:title="definition: AcceleratedShareRepurchasesDateAxis to AcceleratedShareRepurchasesDateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_1" xlink:title="us-gaap_GovernmentAssistanceTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_1" xlink:title="us-gaap_GovernmentAssistanceTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GovernmentAssistanceTypeAxis_1" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GovernmentAssistanceTypeAxis_1 To us-gaap_GovernmentAssistanceTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:title="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_1" xlink:title="us-gaap_ProjectMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:to="us-gaap_ProjectMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1 To us-gaap_ProjectMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Stockholders' Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:to="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Organization and Description of the Business (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ArmataPharmaceuticalsInc.Member" xlink:label="armp_ArmataPharmaceuticalsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="armp_ArmataPharmaceuticalsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NumberOfDirectors" xlink:label="armp_NumberOfDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_NumberOfDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NumberOfBoardDirectors" xlink:label="armp_NumberOfBoardDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_NumberOfBoardDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CommonStockVotingPercentageHeldPercentage" xlink:label="armp_CommonStockVotingPercentageHeldPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_CommonStockVotingPercentageHeldPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2025Member" xlink:label="armp_CreditAgreement2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="armp_CreditAgreement2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAndSecurityAgreementMember" xlink:label="armp_CreditAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_CreditAndSecurityAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Significant Accounting Policies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_LaboratoryEquipmentMember" xlink:label="armp_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="armp_LaboratoryEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_OfficeAndComputerEquipmentMember" xlink:label="armp_OfficeAndComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="armp_OfficeAndComputerEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Fair Value Measurements (Assets and liabilities at fair value) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" xlink:type="extended" xlink:title="99940402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProbabilitiesOfSettlementScenariosMember" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="armp_ProbabilitiesOfSettlementScenariosMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DebtInstrumentMeasurementInputForPeriod" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="armp_DebtInstrumentMeasurementInputForPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails" xlink:type="extended" xlink:title="99940403 - Disclosure - Fair Value Measurements (Changes in Fair Value of Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_UnvestedRestrictedStockMember" xlink:label="armp_UnvestedRestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="armp_UnvestedRestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SharesIssuableUponConversionOfConvertibleLoanMember" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="armp_SharesIssuableUponConversionOfConvertibleLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandAndBuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Convertible Loan (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureTermDebtDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Term Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2023Member" xlink:label="armp_CreditAgreement2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="armp_CreditAgreement2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2024Member" xlink:label="armp_CreditAgreement2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="armp_CreditAgreement2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Stockholders' Deficit (Summary of Warrants Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceFourMember" xlink:label="armp_ExercisePriceFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceFiveMember" xlink:label="armp_ExercisePriceFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceFiveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceSixMember" xlink:label="armp_ExercisePriceSixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceSixMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceSevenMember" xlink:label="armp_ExercisePriceSevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceSevenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceEightMember" xlink:label="armp_ExercisePriceEightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceEightMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceNineMember" xlink:label="armp_ExercisePriceNineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceNineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceTenMember" xlink:label="armp_ExercisePriceTenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceTenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_WarrantExpirationDate" xlink:label="armp_WarrantExpirationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="armp_WarrantExpirationDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Stockholders' Deficit (Shares Reserved for Future Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="armp_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="armp_SharesIssuableUponConversionOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Equity Incentive Plans (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_StockOptionsAndRestrictedStockAwardsMember" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="armp_StockOptionsAndRestrictedStockAwardsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="armp_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EmployeeStockPurchasePlan2016Member" xlink:label="armp_EmployeeStockPurchasePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="armp_EmployeeStockPurchasePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="armp_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - Equity Incentive Plans (Restricted stock award and restricted stock unit award activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_C3jStockPlan2016Member" xlink:label="armp_C3jStockPlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="armp_C3jStockPlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xlink:type="extended" xlink:title="99941004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CommonStockOptionsMember" xlink:label="armp_CommonStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="armp_CommonStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EquitySecuritiesMeasurementInput" xlink:label="armp_EquitySecuritiesMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_EquitySecuritiesMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" xlink:type="extended" xlink:title="99941101 - Disclosure - Income Taxes (Narrative) (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_OperatingLossCarryforwardsNotSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Commitments and Contingencies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_OperatingLeaseBaseAnnual" xlink:label="armp_OperatingLeaseBaseAnnual" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_OperatingLeaseBaseAnnual" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AnnualIncreaseInRentPercentage" xlink:label="armp_AnnualIncreaseInRentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_AnnualIncreaseInRentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AnnualReductionOfStandbyLetterOfCredit" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_AnnualReductionOfStandbyLetterOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_BaseAnnualRentToBePaidYearThree" xlink:label="armp_BaseAnnualRentToBePaidYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_BaseAnnualRentToBePaidYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AllowanceForTenantImprovementsReceivable" xlink:label="armp_AllowanceForTenantImprovementsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_AllowanceForTenantImprovementsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeasePayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Grant and Awards (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="us-gaap_GovernmentAssistanceTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_GovernmentAssistanceTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_GovernmentAssistanceTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="armp_MedicalTechnologyEnterpriseConsortiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardAgreementWithCysticFibrosisFoundationMember" xlink:label="armp_AwardAgreementWithCysticFibrosisFoundationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="armp_AwardAgreementWithCysticFibrosisFoundationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="us-gaap_GovernmentAssistanceLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount" xlink:label="us-gaap_GovernmentAssistanceAwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceAwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAssetIncreaseCurrent" xlink:label="us-gaap_GovernmentAssistanceAssetIncreaseCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceAssetIncreaseCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GovernmentAssistanceAssetIncreaseCurrent" xlink:to="us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GovernmentAssistanceAmount" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GrantsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProceedsFromGovernmentGrants" xlink:label="armp_ProceedsFromGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="armp_ProceedsFromGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardAgreementInterruptionPeriod" xlink:label="armp_AwardAgreementInterruptionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="armp_AwardAgreementInterruptionPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Segment Reporting (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SingleReportableSegmentMember" xlink:label="armp_SingleReportableSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="armp_SingleReportableSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_PercentageOfLongLivedAssetsInGeographicalLocation" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="armp_PercentageOfLongLivedAssetsInGeographicalLocation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails" xlink:type="extended" xlink:title="99941502 - Disclosure - Segment Reporting - Segment information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NonCysticFibrosisBronchiectasisMember" xlink:label="armp_NonCysticFibrosisBronchiectasisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProjectMember" xlink:to="armp_NonCysticFibrosisBronchiectasisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CysticFibrosisMember" xlink:label="armp_CysticFibrosisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProjectMember" xlink:to="armp_CysticFibrosisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_BacteremiaMember" xlink:label="armp_BacteremiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ProjectMember" xlink:to="armp_BacteremiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProstheticJointInfectionMember" xlink:label="armp_ProstheticJointInfectionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ProjectMember" xlink:to="armp_ProstheticJointInfectionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SingleReportableSegmentMember" xlink:label="armp_SingleReportableSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="armp_SingleReportableSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExternalResearchAndDevelopmentExpense" xlink:label="armp_ExternalResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="armp_ExternalResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_UnallocatedExternalResearchAndDevelopmentExpense" xlink:label="armp_UnallocatedExternalResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="armp_UnallocatedExternalResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExternalResearchAndDevelopmentExpenseTotal" xlink:label="armp_ExternalResearchAndDevelopmentExpenseTotal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="armp_ExternalResearchAndDevelopmentExpenseTotal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ResearchAndDevelopmentPersonnelExpense" xlink:label="armp_ResearchAndDevelopmentPersonnelExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="armp_ResearchAndDevelopmentPersonnelExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Subsequent Events (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2025Member" xlink:label="armp_CreditAgreement2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="armp_CreditAgreement2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>armp-20241231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 12:13:38 AM-->
<!--Modified on: 3/21/2025 12:13:38 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current, Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent" xlink:label="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent" xlink:to="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation and current convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Current Maturities Other Than Convertible Debt Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term debt, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Long-Term Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term debt, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 12)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, $0.01 par value; 217,000,000 shares authorized; 36,183,067 and 36,122,932 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Description of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Not from Contract with Customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total general and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value, gain (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of the Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on debt and Convertible Loan extinguishments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on convertible loan extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on debt and the Convertible Loan extinguishments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeiture of restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeiture of restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:to="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock returned value shares issued net of tax withholdings .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholdings for taxes related to net share settlement of equity awards</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:to="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock returned shares issued net of tax withholdings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Returned Shares Issued Net Of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholdings for taxes related to net share settlement of equity awards, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon release of restricted stock units, net of tax withholdings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon release of restricted stock units, net of tax withholdings (In shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_IncreaseDecreaseFairValueOfLiabilities" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) fair value of liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Fair Value of Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of the Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest expense</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NoncashInterestIncome" xlink:label="armp_NoncashInterestIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NoncashInterestIncome" xlink:to="armp_NoncashInterestIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NoncashInterestIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of interest income included in net income that result in no cash inflow</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NoncashInterestIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Interest Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_NoncashInterestIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest income</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of the Convertible Loan, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Secured Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of term debt, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment, Tax Withholding, Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for taxes related to net share settlement of equity awards</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:to="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants and stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Exercise Of Warrants And Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset obtained in exchange for operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContributionOfProperty" xlink:to="us-gaap_ContributionOfProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContributionOfProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contribution of Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContributionOfProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment included in accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Description of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Description of the Business</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_LiquidityAndGoingConcernAbstract" xlink:label="armp_LiquidityAndGoingConcernAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_LiquidityAndGoingConcernAbstract" xlink:to="armp_LiquidityAndGoingConcernAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_LiquidityAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity And Going Concern [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_LiquidityAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity and Going Concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Substantial Doubt about Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity and Going Concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Details</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Details</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ConvertibleDebtDisclosureTextBlock" xlink:label="armp_ConvertibleDebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ConvertibleDebtDisclosureTextBlock" xlink:to="armp_ConvertibleDebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardAbstract" xlink:label="armp_AwardAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardAbstract" xlink:to="armp_AwardAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about award abstract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant and Awards</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardTextBlock" xlink:label="armp_AwardTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardTextBlock" xlink:to="armp_AwardTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">represents about award text block.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant and Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risks and Certain Other Risks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-Process Research and Development ("IPR&amp;D")</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translations and Transactions</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_GrantsAndAwardsPolicyTextBlock" xlink:label="armp_GrantsAndAwardsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_GrantsAndAwardsPolicyTextBlock" xlink:to="armp_GrantsAndAwardsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about the grants and awards policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants And Awards Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Revenue and Other Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Adopted Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:to="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of estimated useful lives of property and equipment including, but not limited to, laboratory equipment, office and computer equipment, and leasehold improvements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of useful lives of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assets and liabilities measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated the fair value of its Convertible Loan using inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in the fair value of its Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Computation of Basic and Diluted Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ScheduleOfOtherReceivablesCurrentTableTextBlock" xlink:label="armp_ScheduleOfOtherReceivablesCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScheduleOfOtherReceivablesCurrentTableTextBlock" xlink:to="armp_ScheduleOfOtherReceivablesCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScheduleOfOtherReceivablesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of other current receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScheduleOfOtherReceivablesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other Receivables, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScheduleOfOtherReceivablesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Warrant Information</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of components of common shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Shares Reserved for Future Issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:to="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares under options that were assumed in merger during the reporting period pertaining to the stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share Based Compensation Restricted Stock Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Assumptions Used in the Black-Scholes Model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock-Based Compensation Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of (Loss) Income from Continuing Operations Before Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Reconciliation of Statutory to Effective Tax Rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of certain segment information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ArmataPharmaceuticalsInc.Member" xlink:label="armp_ArmataPharmaceuticalsInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ArmataPharmaceuticalsInc.Member" xlink:to="armp_ArmataPharmaceuticalsInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ArmataPharmaceuticalsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Armata Pharmaceuticals, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ArmataPharmaceuticalsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Armata Pharmaceuticals, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ArmataPharmaceuticalsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Armata Pharmaceuticals, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Entities [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_InnovivaStrategicOpportunitiesLlcMember" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innoviva Strategic Opportunities LLC [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innoviva Strategic Opportunities LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innoviva Strategic Opportunities LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Ownership Percentage, Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding equity (in percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total debt financing</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NumberOfDirectors" xlink:label="armp_NumberOfDirectors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NumberOfDirectors" xlink:to="armp_NumberOfDirectors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NumberOfDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of directors during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NumberOfDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Directors</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NumberOfBoardDirectors" xlink:label="armp_NumberOfBoardDirectors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NumberOfBoardDirectors" xlink:to="armp_NumberOfBoardDirectors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NumberOfBoardDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Board directors during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NumberOfBoardDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Board Directors</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CommonStockVotingPercentageHeldPercentage" xlink:label="armp_CommonStockVotingPercentageHeldPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CommonStockVotingPercentageHeldPercentage" xlink:to="armp_CommonStockVotingPercentageHeldPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CommonStockVotingPercentageHeldPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of voting rights of the total number of shares of the common stock of company on matters related to election or removal of board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CommonStockVotingPercentageHeldPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Voting Percentage Held Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_CommonStockVotingPercentageHeldPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares (in percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2025Member" xlink:label="armp_CreditAgreement2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CreditAgreement2025Member" xlink:to="armp_CreditAgreement2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CreditAgreement2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents 2025 credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CreditAgreement2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Agreement 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_CreditAgreement2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAndSecurityAgreementMember" xlink:label="armp_CreditAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CreditAndSecurityAgreementMember" xlink:to="armp_CreditAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CreditAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to credit and security agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CreditAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit And Security Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_CreditAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit And Security Agreement</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SecuredTermLoanMember" xlink:to="armp_SecuredTermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SecuredTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to secured term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SecuredTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_SecuredTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xlink:to="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of irrevocable letters of credit with financial institutions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Standby Letters of Credit included in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Letters of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Long-Lived Asset, Held-for-Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of in-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, Impairment Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_LaboratoryEquipmentMember" xlink:label="armp_LaboratoryEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_LaboratoryEquipmentMember" xlink:to="armp_LaboratoryEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_OfficeAndComputerEquipmentMember" xlink:label="armp_OfficeAndComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OfficeAndComputerEquipmentMember" xlink:to="armp_OfficeAndComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OfficeAndComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OfficeAndComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_OfficeAndComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in money market fund - financial assets, included in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan- financial liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProbabilitiesOfSettlementScenariosMember" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProbabilitiesOfSettlementScenariosMember" xlink:to="armp_ProbabilitiesOfSettlementScenariosMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input used to determine value of probability of settlement scenarios.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probabilities of Settlement Scenarios [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probabilities of settlement scenarios</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Option Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DebtInstrumentMeasurementInputForPeriod" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DebtInstrumentMeasurementInputForPeriod" xlink:to="armp_DebtInstrumentMeasurementInputForPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of input used to measure debt instruments, including, but not limited to, convertible and non-convertible debt for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Measurement Input For The Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument, measurement input, for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net issuance of the Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of initial recognition of modified convertible loan of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Initial Recognition of modified Convertible Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial recognition of modified Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount exchanged in financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Amount Exchanged</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount exchanged</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on the Convertible Loan extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain from change in fair value of the Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt" xlink:label="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt" xlink:to="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from gain on debt and extinguishment of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilutive Securities, Effect on Basic Earnings Per Share, Gain on Debt And (Extinguishment of Debt)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on debt and the Convertible Loan extinguishments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon the conversion of the Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding stock options</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_UnvestedRestrictedStockMember" xlink:label="armp_UnvestedRestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_UnvestedRestrictedStockMember" xlink:to="armp_UnvestedRestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_UnvestedRestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_UnvestedRestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_UnvestedRestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SharesIssuableUponConversionOfConvertibleLoanMember" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SharesIssuableUponConversionOfConvertibleLoanMember" xlink:to="armp_SharesIssuableUponConversionOfConvertibleLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon the conversion of Convertible Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon the conversion of Convertible Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon the conversion of the Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of diluted weighted shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible loan principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and unpaid interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" xlink:to="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of property and equipment not in use included in laboratory equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment Not in Use Included in Laboratory Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment not in use</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Machinery and Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Other Types [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LandAndBuildingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAndBuildingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land and Building [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_TenantImprovementReceivableCurrent" xlink:label="armp_TenantImprovementReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_TenantImprovementReceivableCurrent" xlink:to="armp_TenantImprovementReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_TenantImprovementReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount of current tenant improvement receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_TenantImprovementReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant Improvement Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_TenantImprovementReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant improvement allowance receivable (Note 12)</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_GrantAndAwardReceivableCurrent" xlink:label="armp_GrantAndAwardReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_GrantAndAwardReceivableCurrent" xlink:to="armp_GrantAndAwardReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_GrantAndAwardReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount of awards receivable current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_GrantAndAwardReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant and Award Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_GrantAndAwardReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant and award receivable (Note 13)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AccruedLiabilitiesClinicalTrial" xlink:label="armp_AccruedLiabilitiesClinicalTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AccruedLiabilitiesClinicalTrial" xlink:to="armp_AccruedLiabilitiesClinicalTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AccruedLiabilitiesClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AccruedLiabilitiesClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AccruedLiabilitiesClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical trial expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued expenses</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xlink:to="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from qualified financing per agreement benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Qualified Financing Per Agreement Benchmark</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from qualified financing per agreement benchmark</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xlink:to="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent  of discount on share price for conversion of debt into shares of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Conversion, Percent of Discount on Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount on share price for conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2023Member" xlink:label="armp_CreditAgreement2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CreditAgreement2023Member" xlink:to="armp_CreditAgreement2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CreditAgreement2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents 2023 credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CreditAgreement2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Agreement 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_CreditAgreement2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2024Member" xlink:label="armp_CreditAgreement2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CreditAgreement2024Member" xlink:to="armp_CreditAgreement2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CreditAgreement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents 2024 credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CreditAgreement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Agreement 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_CreditAgreement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance cost and debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceFourMember" xlink:label="armp_ExercisePriceFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceFourMember" xlink:to="armp_ExercisePriceFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Four [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.87, February 11, 2025</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceFiveMember" xlink:label="armp_ExercisePriceFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceFiveMember" xlink:to="armp_ExercisePriceFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Five [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.87, March 27, 2025</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceSixMember" xlink:label="armp_ExercisePriceSixMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceSixMember" xlink:to="armp_ExercisePriceSixMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceSixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Exercise Price Five Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceSixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.25, January 26, 2026</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceSevenMember" xlink:label="armp_ExercisePriceSevenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceSevenMember" xlink:to="armp_ExercisePriceSevenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceSevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Seven [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceSevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.25, March 16, 2026</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceEightMember" xlink:label="armp_ExercisePriceEightMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceEightMember" xlink:to="armp_ExercisePriceEightMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceEightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Eight [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceEightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $5.00, February 8, 2027</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceNineMember" xlink:label="armp_ExercisePriceNineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceNineMember" xlink:to="armp_ExercisePriceNineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceNineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price nine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceNineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $5.00, March 30, 2027</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceTenMember" xlink:label="armp_ExercisePriceTenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceTenMember" xlink:to="armp_ExercisePriceTenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceTenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price ten.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceTenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price 1680.00</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_WarrantExpirationDate" xlink:label="armp_WarrantExpirationDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_WarrantExpirationDate" xlink:to="armp_WarrantExpirationDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_WarrantExpirationDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the terms related with expiration of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_WarrantExpirationDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_WarrantExpirationDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Expiration Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP) Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP), Plan [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EquityIncentivePlan2016Member" xlink:to="armp_EquityIncentivePlan2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EquityIncentivePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EquityIncentivePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EquityIncentivePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2016</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Balance Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Balance Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable under the Employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future grants under the 2016 Plan</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:to="armp_SharesIssuableUponConversionOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable upon conversion of convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issuable Upon Conversion Of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon the conversion of the Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shares reserved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shares reserved</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_StockOptionsAndRestrictedStockAwardsMember" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_StockOptionsAndRestrictedStockAwardsMember" xlink:to="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options And Restricted Stock Awards [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options And Restricted Stock Awards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options And Restricted Stock Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EmployeeStockPurchasePlan2016Member" xlink:label="armp_EmployeeStockPurchasePlan2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EmployeeStockPurchasePlan2016Member" xlink:to="armp_EmployeeStockPurchasePlan2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan 2016</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period of share-based payment award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of annual increase in number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period of share-based compensation award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock closing price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of vested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost related to unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining period for recognition of compensation costs related to unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Forfeited/Cancelled/Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Outstanding Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Outstanding Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Forfeited/Cancelled/Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Exercisable at December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (Years), Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Outstanding Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Outstanding Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Exercised</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:to="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation arrangement by share based payment award options forfeited in period intrinsic value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Forfeited/Cancelled/Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Exercisable at December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_C3jStockPlan2016Member" xlink:label="armp_C3jStockPlan2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_C3jStockPlan2016Member" xlink:to="armp_C3jStockPlan2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_C3jStockPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to C3J 2016 stock plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_C3jStockPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">C3J Stock Plan 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_C3jStockPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">C3J Stock Plan 2016</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Avg Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CommonStockOptionsMember" xlink:label="armp_CommonStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CommonStockOptionsMember" xlink:to="armp_CommonStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CommonStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CommonStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_CommonStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EquitySecuritiesMeasurementInput" xlink:label="armp_EquitySecuritiesMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EquitySecuritiesMeasurementInput" xlink:to="armp_EquitySecuritiesMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EquitySecuritiesMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of input used to measure investment in equity security measured at fair value for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EquitySecuritiesMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EquitySecuritiesMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value input, equity securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Jurisdiction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State Tax Jurisdiction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Tax Jurisdiction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="armp_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards that are not subject to expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Not Subject to Expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxAssetLeaseObligation" xlink:label="armp_DeferredTaxAssetLeaseObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DeferredTaxAssetLeaseObligation" xlink:to="armp_DeferredTaxAssetLeaseObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DeferredTaxAssetLeaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax asset lease obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DeferredTaxAssetLeaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset Lease Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_DeferredTaxAssetLeaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease accounting</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxAssetsInterestExpenseCarryForwards" xlink:label="armp_DeferredTaxAssetsInterestExpenseCarryForwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DeferredTaxAssetsInterestExpenseCarryForwards" xlink:to="armp_DeferredTaxAssetsInterestExpenseCarryForwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DeferredTaxAssetsInterestExpenseCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible interest expense carry forwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DeferredTaxAssetsInterestExpenseCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Interest Expense Carry-forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_DeferredTaxAssetsInterestExpenseCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets before valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets after valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="armp_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Right of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research and development</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxLiabilitiesDebtBasisDifferences" xlink:label="armp_DeferredTaxLiabilitiesDebtBasisDifferences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DeferredTaxLiabilitiesDebtBasisDifferences" xlink:to="armp_DeferredTaxLiabilitiesDebtBasisDifferences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DeferredTaxLiabilitiesDebtBasisDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from debt basis differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DeferredTaxLiabilitiesDebtBasisDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Debt Basis Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_DeferredTaxLiabilitiesDebtBasisDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt basis differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for tax effects of:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income taxes, net of federal tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent" xlink:to="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for debt items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible debt items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in rate</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:to="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a return to provision.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Return To Provision, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return to provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_OperatingLeaseBaseAnnual" xlink:label="armp_OperatingLeaseBaseAnnual" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OperatingLeaseBaseAnnual" xlink:to="armp_OperatingLeaseBaseAnnual_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OperatingLeaseBaseAnnual_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of annual base rent for operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OperatingLeaseBaseAnnual_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Base Annual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_OperatingLeaseBaseAnnual_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual base rent for operating lease</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AnnualIncreaseInRentPercentage" xlink:label="armp_AnnualIncreaseInRentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AnnualIncreaseInRentPercentage" xlink:to="armp_AnnualIncreaseInRentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AnnualIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in rent percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AnnualIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Increase in Rent Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AnnualIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in rent percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Letters of Credit Outstanding, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby letter of credit</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AnnualReductionOfStandbyLetterOfCredit" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AnnualReductionOfStandbyLetterOfCredit" xlink:to="armp_AnnualReductionOfStandbyLetterOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual reduction of standby letter of credit..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Reduction Of Standby Letter Of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual reduction of standby letter of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_BaseAnnualRentToBePaidYearThree" xlink:label="armp_BaseAnnualRentToBePaidYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_BaseAnnualRentToBePaidYearThree" xlink:to="armp_BaseAnnualRentToBePaidYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_BaseAnnualRentToBePaidYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount for base rent to be paid in year three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_BaseAnnualRentToBePaidYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Base Annual Rent To Be Paid Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_BaseAnnualRentToBePaidYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Base annual rent for 2024</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AllowanceForTenantImprovementsReceivable" xlink:label="armp_AllowanceForTenantImprovementsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AllowanceForTenantImprovementsReceivable" xlink:to="armp_AllowanceForTenantImprovementsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AllowanceForTenantImprovementsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of allowance for tenant improvements receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AllowanceForTenantImprovementsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance For Tenant Improvements Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AllowanceForTenantImprovementsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for tenant improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense under operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeasePayment" xlink:to="us-gaap_VariableLeasePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeasePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeasePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2029</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: amount representing interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows from operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term, years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate, %</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="us-gaap_GovernmentAssistanceTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTable" xlink:to="us-gaap_GovernmentAssistanceTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:to="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medical Technology Enterprise Consortium [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medical Technology Enterprise Consortium [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MTEC Grant</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardAgreementWithCysticFibrosisFoundationMember" xlink:label="armp_AwardAgreementWithCysticFibrosisFoundationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardAgreementWithCysticFibrosisFoundationMember" xlink:to="armp_AwardAgreementWithCysticFibrosisFoundationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardAgreementWithCysticFibrosisFoundationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to award agreement (the "Award Agreement") with CFF.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardAgreementWithCysticFibrosisFoundationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Agreement with Cystic Fibrosis Foundation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AwardAgreementWithCysticFibrosisFoundationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CFF Therapeutics Development Award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="us-gaap_GovernmentAssistanceLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceLineItems" xlink:to="us-gaap_GovernmentAssistanceLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount" xlink:label="us-gaap_GovernmentAssistanceAwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAwardAmount" xlink:to="us-gaap_GovernmentAssistanceAwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceAwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Award Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistanceAwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAssetIncreaseCurrent" xlink:label="us-gaap_GovernmentAssistanceAssetIncreaseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAssetIncreaseCurrent" xlink:to="us-gaap_GovernmentAssistanceAssetIncreaseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceAssetIncreaseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Asset, Increase, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistanceAssetIncreaseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in expected revenue from grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Asset, Increase, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAmount" xlink:to="us-gaap_GovernmentAssistanceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Income, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistanceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant revenue from the MTEC Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants receivable</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProceedsFromGovernmentGrants" xlink:label="armp_ProceedsFromGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProceedsFromGovernmentGrants" xlink:to="armp_ProceedsFromGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProceedsFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash inflow associated with government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProceedsFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Government Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProceedsFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from governments grants</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardAgreementInterruptionPeriod" xlink:label="armp_AwardAgreementInterruptionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardAgreementInterruptionPeriod" xlink:to="armp_AwardAgreementInterruptionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardAgreementInterruptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardAgreementInterruptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Agreement, Interruption Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AwardAgreementInterruptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award agreement interruption period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contribution to 401(k) plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SingleReportableSegmentMember" xlink:label="armp_SingleReportableSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SingleReportableSegmentMember" xlink:to="armp_SingleReportableSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to single reportable segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single Reportable Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single Reportable Segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segments</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_PercentageOfLongLivedAssetsInGeographicalLocation" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_PercentageOfLongLivedAssetsInGeographicalLocation" xlink:to="armp_PercentageOfLongLivedAssetsInGeographicalLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of long lived assets In geographical location.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Long Lived Assets In Geographical Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Project [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Project [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NonCysticFibrosisBronchiectasisMember" xlink:label="armp_NonCysticFibrosisBronchiectasisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NonCysticFibrosisBronchiectasisMember" xlink:to="armp_NonCysticFibrosisBronchiectasisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NonCysticFibrosisBronchiectasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Non-cystic fibrosis bronchiectasis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NonCysticFibrosisBronchiectasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Cystic Fibrosis Bronchiectasis [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_NonCysticFibrosisBronchiectasisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AP-PA02: Non-Cystic Fibrosis Bronchiectasis</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CysticFibrosisMember" xlink:label="armp_CysticFibrosisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CysticFibrosisMember" xlink:to="armp_CysticFibrosisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CysticFibrosisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Cystic fibrosis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CysticFibrosisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cystic Fibrosis [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_CysticFibrosisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AP-PA02: Cystic Fibrosis</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_BacteremiaMember" xlink:label="armp_BacteremiaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_BacteremiaMember" xlink:to="armp_BacteremiaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_BacteremiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Bacteremia.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_BacteremiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bacteremia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_BacteremiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AP-SA02: Bacteremia</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProstheticJointInfectionMember" xlink:label="armp_ProstheticJointInfectionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProstheticJointInfectionMember" xlink:to="armp_ProstheticJointInfectionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProstheticJointInfectionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Prosthetic joint infection.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProstheticJointInfectionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prosthetic Joint Infection [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProstheticJointInfectionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AP-SA02Prosthetic Joint Infection</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExternalResearchAndDevelopmentExpense" xlink:label="armp_ExternalResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExternalResearchAndDevelopmentExpense" xlink:to="armp_ExternalResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExternalResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of external research and development expenses incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExternalResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">External Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ExternalResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">External research and development expenses</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_UnallocatedExternalResearchAndDevelopmentExpense" xlink:label="armp_UnallocatedExternalResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_UnallocatedExternalResearchAndDevelopmentExpense" xlink:to="armp_UnallocatedExternalResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_UnallocatedExternalResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of external research and development expense not allocated by projects.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_UnallocatedExternalResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unallocated External Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_UnallocatedExternalResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses not allocated by projects</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExternalResearchAndDevelopmentExpenseTotal" xlink:label="armp_ExternalResearchAndDevelopmentExpenseTotal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExternalResearchAndDevelopmentExpenseTotal" xlink:to="armp_ExternalResearchAndDevelopmentExpenseTotal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExternalResearchAndDevelopmentExpenseTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of total external research and development expenses incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExternalResearchAndDevelopmentExpenseTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">External Research and Development Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="armp_ExternalResearchAndDevelopmentExpenseTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total external research and development expenses</label>
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ResearchAndDevelopmentPersonnelExpense" xlink:label="armp_ResearchAndDevelopmentPersonnelExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ResearchAndDevelopmentPersonnelExpense" xlink:to="armp_ResearchAndDevelopmentPersonnelExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ResearchAndDevelopmentPersonnelExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel expenses incurred in connection with research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ResearchAndDevelopmentPersonnelExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Personnel Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ResearchAndDevelopmentPersonnelExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development personnel expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative personnel expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other general and administrative expenses</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>armp-20241231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 12:13:38 AM-->
<!--Modified on: 3/21/2025 12:13:38 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedStatementsOfStockholdersDeficit" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureOrganizationAndDescriptionOfBusiness" roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureLiquidityAndGoingConcern" roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureNetLossPerShare" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureConvertibleLoan" roleURI="http://www.armatapharma.com/role/DisclosureConvertibleLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureTermDebt" roleURI="http://www.armatapharma.com/role/DisclosureTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureStockholdersDeficit" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlans" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxes" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureGrantAndAwards" roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEmployeeRetirementPlan" roleURI="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSegmentReporting" roleURI="http://www.armatapharma.com/role/DisclosureSegmentReporting" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSubsequentEvents" roleURI="http://www.armatapharma.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetailsTables" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureStockholdersDeficitTables" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficitTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansTables" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSegmentReportingTables" roleURI="http://www.armatapharma.com/role/DisclosureSegmentReportingTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureLiquidityAndGoingConcernNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureNetLossPerShareBasicAndDilutedEpsDetails" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetailsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetailsOtherReceivablesDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureConvertibleLoanNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureTermDebtDetails" roleURI="http://www.armatapharma.com/role/DisclosureTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxesNarrativeDetail" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureGrantAndAwardsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureEmployeeRetirementPlanNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSegmentReportingNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSegmentReportingSegmentInformationDetails" roleURI="http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20241231.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <presentationLink xlink:role="http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document And Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638781128153949191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638781128153949191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638781128153949191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638781128153949191" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638781128153949191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638781128153949191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638781128153949191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638781128153949191" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638781128153949191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638781128153949191" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638781128153949191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638781128153949191" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638781128153949191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638781128153949191" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638781128153949191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638781128153949191" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638781128153959179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638781128153959179" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638781128153959179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638781128153959179" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638781128153959179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638781128153959179" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638781128153959179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638781128153959179" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638781128153959179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638781128153959179" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638781128153959179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638781128153959179" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638781128153959179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638781128153959179" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638781128153969184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638781128153969184" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638781128153969184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638781128153969184" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638781128153969184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638781128153969184" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638781128153969184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638781128153969184" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638781128153969184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638781128153969184" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638781128153969184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638781128153969184" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638781128153969184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638781128153969184" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638781128153979169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638781128153979169" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638781128153979169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638781128153979169" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638781128153979169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638781128153979169" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638781128153979169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638781128153979169" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638781128153979169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638781128153979169" order="27" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638781128153979169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638781128153979169" order="28" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638781128153989168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638781128153989168" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_638781128153989168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_638781128153989168" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638781128153989168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638781128153989168" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638781128153989168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638781128153989168" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638781128153989168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638781128153989168" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638781128153999168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638781128153999168" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638781128153999168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638781128153999168" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638781128153999168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638781128153999168" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638781128153999168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638781128153999168" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638781128153999168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638781128153999168" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638781128154009177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638781128154009177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638781128154009177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781128154009177" xlink:to="us-gaap_AssetsCurrentAbstract_638781128154009177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128154009177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638781128154009177" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128154009177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638781128154009177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638781128154009177" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638781128154009177" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638781128154009177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638781128154009177" xlink:to="us-gaap_OtherAssetsCurrent_638781128154009177" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638781128154009177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638781128154009177" xlink:to="us-gaap_AssetsCurrent_638781128154009177" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638781128154019176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781128154009177" xlink:to="us-gaap_RestrictedCashNoncurrent_638781128154019176" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638781128154019176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781128154009177" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638781128154019176" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638781128154019176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781128154009177" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638781128154019176" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638781128154019176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781128154009177" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638781128154019176" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638781128154019176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781128154009177" xlink:to="us-gaap_Goodwill_638781128154019176" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638781128154019176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781128154009177" xlink:to="us-gaap_OtherAssetsNoncurrent_638781128154019176" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638781128154019176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781128154009177" xlink:to="us-gaap_Assets_638781128154019176" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638781128154029170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638781128154029170" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638781128154029170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638781128154029170" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638781128154029170" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_638781128154029170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638781128154029170" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_638781128154029170" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent" xlink:label="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent_638781128154029170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638781128154029170" xlink:to="armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent_638781128154029170" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638781128154029170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638781128154029170" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638781128154029170" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638781128154029170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638781128154029170" xlink:to="us-gaap_OtherLiabilitiesCurrent_638781128154029170" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638781128154029170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638781128154029170" xlink:to="us-gaap_LiabilitiesCurrent_638781128154029170" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638781128154029170" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638781128154029170" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt_638781128154039165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" xlink:to="us-gaap_SecuredLongTermDebt_638781128154039165" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638781128154039165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638781128154039165" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638781128154039165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638781128154039165" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638781128154039165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" xlink:to="us-gaap_Liabilities_638781128154039165" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638781128154039165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" xlink:to="us-gaap_CommitmentsAndContingencies_638781128154039165" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638781128154039165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" xlink:to="us-gaap_StockholdersEquityAbstract_638781128154039165" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638781128154049174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781128154039165" xlink:to="us-gaap_CommonStockValue_638781128154049174" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638781128154049174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781128154039165" xlink:to="us-gaap_AdditionalPaidInCapital_638781128154049174" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638781128154049174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781128154039165" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638781128154049174" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638781128154049174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781128154039165" xlink:to="us-gaap_StockholdersEquity_638781128154049174" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638781128154049174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781128154019176" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638781128154049174" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638781128154059173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638781128154059173" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638781128154059173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638781128154059173" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638781128154059173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638781128154059173" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638781128154059173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638781128154059173" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638781128154059173" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638781128154059173" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638781128154069179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638781128154069179" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638781128154069179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638781128154069179" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638781128154069179" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638781128154069179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638781128154069179" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638781128154069179" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638781128154069179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638781128154069179" xlink:to="us-gaap_OperatingExpenses_638781128154069179" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638781128154069179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638781128154069179" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract_638781128154069179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherExpensesAbstract_638781128154069179" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638781128154069179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638781128154069179" xlink:to="us-gaap_OtherNonoperatingIncome_638781128154069179" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638781128154069179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638781128154069179" xlink:to="us-gaap_OtherNonoperatingExpense_638781128154069179" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_638781128154101120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638781128154069179" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_638781128154101120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128154101120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638781128154069179" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128154101120" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638781128154101120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638781128154069179" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638781128154101120" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781128154101120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638781128154101120" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638781128154101120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638781128154101120" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638781128154109186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638781128154101120" xlink:to="us-gaap_EarningsPerShareBasic_638781128154109186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781128154109186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638781128154101120" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781128154109186" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638781128154109186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638781128154101120" xlink:to="us-gaap_EarningsPerShareDiluted_638781128154109186" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638781128154109186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638781128154101120" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638781128154109186" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Stockholders' Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154119229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638781128154119229" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638781128154119229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154119229" xlink:to="us-gaap_StatementEquityComponentsAxis_638781128154119229" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638781128154119229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638781128154119229" xlink:to="us-gaap_CommonStockMember_638781128154119229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638781128154119229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638781128154119229" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638781128154119229" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638781128154119229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638781128154119229" xlink:to="us-gaap_RetainedEarningsMember_638781128154119229" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638781128154119229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638781128154119229" xlink:to="us-gaap_EquityComponentDomain_638781128154119229" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154129186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154119229" xlink:to="us-gaap_StatementLineItems_638781128154129186" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638781128154129186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_StockholdersEquity_638781128154129186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638781128154129186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_SharesOutstanding_638781128154129186" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_638781128154129186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_638781128154129186" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_638781128154129186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_638781128154129186" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_638781128154129186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638781128154129186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638781128154129186" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638781128154139184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638781128154129186" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638781128154139184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_638781128154139184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_638781128154139184" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_638781128154139184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_638781128154139184" xlink:to="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_638781128154139184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638781128154139184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638781128154139184" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_638781128154139184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638781128154139184" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_638781128154139184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638781128154149192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638781128154149192" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638781128154149192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638781128154149192" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638781128154149192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638781128154149192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638781128154149192" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781128154149192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_NetIncomeLoss_638781128154149192" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638781128154149192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_StockholdersEquity_638781128154149192" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638781128154159188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154129186" xlink:to="us-gaap_SharesOutstanding_638781128154159188" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638781128154159188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638781128154159188" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638781128154159188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638781128154159188" xlink:to="us-gaap_ProfitLoss_638781128154159188" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638781128154159188" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638781128154169187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638781128154169187" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638781128154169187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="us-gaap_ShareBasedCompensation_638781128154169187" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_638781128154169187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities_638781128154169187" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_638781128154169187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="us-gaap_OtherNoncashExpense_638781128154169187" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NoncashInterestIncome" xlink:label="armp_NoncashInterestIncome_638781128154169187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="armp_NoncashInterestIncome_638781128154169187" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128154169187" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128154169187" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638781128154179184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638781128154179184" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638781128154179184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638781128154179184" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781128154179184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781128154179184" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638781128154179184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781128154179184" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638781128154179184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638781128154179184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781128154179184" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638781128154179184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_638781128154179184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781128154179184" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_638781128154179184" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638781128154189183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781128154179184" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638781128154189183" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128154189183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781128154159188" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781128154189183" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638781128154189183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638781128154189183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638781128154189183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638781128154189183" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638781128154189183" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638781128154189183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638781128154189183" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638781128154189183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638781128154189183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638781128154189183" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638781128154189183" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638781128154199184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638781128154199184" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638781128154199184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638781128154199184" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638781128154199184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_638781128154199184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638781128154199184" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_638781128154199184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638781128154199184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638781128154199184" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638781128154199184" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_638781128154209186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638781128154199184" xlink:to="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_638781128154209186" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781128154209186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638781128154199184" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781128154209186" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638781128154209186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638781128154209186" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638781128154209186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638781128154209186" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387811281542091861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387811281542091861" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638781128154219183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638781128154219183" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638781128154219183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638781128154219183" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638781128154219183" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty_638781128154219183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638781128154219183" xlink:to="us-gaap_ContributionOfProperty_638781128154219183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638781128154229182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638781128154229182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128154229182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638781128154229182" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128154229182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638781128154229182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638781128154229182" xlink:to="us-gaap_RestrictedCashNoncurrent_638781128154229182" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638781128154229182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638781128154229182" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638781128154229182" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="extended" xlink:title="995210101 - Disclosure - Organization and Description of the Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638781128154239201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638781128154239201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern" xlink:type="extended" xlink:title="995210201 - Disclosure - Liquidity and Going Concern" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_LiquidityAndGoingConcernAbstract" xlink:label="armp_LiquidityAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_638781128154239201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_LiquidityAndGoingConcernAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_638781128154239201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210301 - Disclosure - Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638781128154249190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638781128154249190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="995210401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638781128154249190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638781128154249190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995210501 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638781128154259188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638781128154259188" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetails" xlink:type="extended" xlink:title="995210601 - Disclosure - Balance Sheet Details" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638781128154259188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638781128154259188" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureConvertibleLoan" xlink:type="extended" xlink:title="995210701 - Disclosure - Convertible Loan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ConvertibleDebtDisclosureTextBlock" xlink:label="armp_ConvertibleDebtDisclosureTextBlock_638781128154269204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="armp_ConvertibleDebtDisclosureTextBlock_638781128154269204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureTermDebt" xlink:type="extended" xlink:title="995210801 - Disclosure - Term Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_638781128154269204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_638781128154269204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersDeficit" xlink:type="extended" xlink:title="995210901 - Disclosure - Stockholders' Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638781128154269204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638781128154269204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlans" xlink:type="extended" xlink:title="995211001 - Disclosure - Equity Incentive Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638781128154279317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638781128154279317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995211101 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638781128154279317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638781128154279317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211201 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638781128154289195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638781128154289195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureGrantAndAwards" xlink:type="extended" xlink:title="995211301 - Disclosure - Grant and Awards" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardAbstract" xlink:label="AwardAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardTextBlock" xlink:label="armp_AwardTextBlock_638781128154299218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardAbstract" xlink:to="armp_AwardTextBlock_638781128154299218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan" xlink:type="extended" xlink:title="995211401 - Disclosure - Employee Retirement Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638781128154299218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638781128154299218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSegmentReporting" xlink:type="extended" xlink:title="995211501 - Disclosure - Segment Reporting" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638781128154299218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638781128154299218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211601 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638781128154309201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638781128154309201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920302 - Disclosure - Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638781128154309201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638781128154309201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638781128154309201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638781128154309201" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638781128154309201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638781128154309201" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638781128154309201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638781128154309201" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638781128154319191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638781128154319191" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638781128154319191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638781128154319191" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638781128154319191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638781128154319191" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638781128154319191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638781128154319191" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_638781128154319191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_638781128154319191" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638781128154319191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638781128154319191" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638781128154319191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638781128154319191" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638781128154319191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638781128154319191" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638781128154329184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638781128154329184" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_GrantsAndAwardsPolicyTextBlock" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_638781128154329184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="armp_GrantsAndAwardsPolicyTextBlock_638781128154329184" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638781128154329184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638781128154329184" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638781128154329184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638781128154329184" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638781128154329184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638781128154329184" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638781128154329184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638781128154329184" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638781128154329184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638781128154329184" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_638781128154339185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_638781128154339185" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638781128154339185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638781128154339185" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638781128154339185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638781128154339185" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_638781128154349194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_638781128154349194" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638781128154349194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638781128154349194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638781128154349194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638781128154349194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Balance Sheet Details (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638781128154349194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638781128154349194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ScheduleOfOtherReceivablesCurrentTableTextBlock" xlink:label="armp_ScheduleOfOtherReceivablesCurrentTableTextBlock_638781128154359188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="armp_ScheduleOfOtherReceivablesCurrentTableTextBlock_638781128154359188" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638781128154359188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638781128154359188" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersDeficitTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Stockholders' Deficit (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638781128154359188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638781128154359188" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_638781128154359188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_638781128154359188" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables" xlink:type="extended" xlink:title="99931003 - Disclosure - Equity Incentive Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638781128154369191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638781128154369191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_638781128154369191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_638781128154369191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638781128154369191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638781128154369191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638781128154369191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638781128154369191" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638781128154369191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638781128154369191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638781128154369191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638781128154369191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638781128154379207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638781128154379207" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638781128154379207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638781128154379207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638781128154379207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638781128154379207" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSegmentReportingTables" xlink:type="extended" xlink:title="99931503 - Disclosure - Segment Reporting (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638781128154389211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638781128154389211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Organization and Description of the Business (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154389211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable_638781128154389211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638781128154389211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154389211" xlink:to="srt_OwnershipAxis_638781128154389211" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638781128154399209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638781128154389211" xlink:to="srt_OwnershipDomain_638781128154399209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ArmataPharmaceuticalsInc.Member" xlink:label="armp_ArmataPharmaceuticalsInc.Member_638781128154399209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638781128154399209" xlink:to="armp_ArmataPharmaceuticalsInc.Member_638781128154399209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638781128154399209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154389211" xlink:to="dei_LegalEntityAxis_638781128154399209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638781128154399209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638781128154399209" xlink:to="dei_EntityDomain_638781128154399209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154399209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638781128154399209" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154399209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638781128154399209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154389211" xlink:to="srt_RangeAxis_638781128154399209" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638781128154399209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638781128154399209" xlink:to="srt_RangeMember_638781128154399209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638781128154399209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154399209" xlink:to="srt_MinimumMember_638781128154399209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154409201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154389211" xlink:to="us-gaap_StatementLineItems_638781128154409201" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638781128154409201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154409201" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638781128154409201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638781128154409201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154409201" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638781128154409201" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_638781128154409201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154409201" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_638781128154409201" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NumberOfDirectors" xlink:label="armp_NumberOfDirectors_638781128154409201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154409201" xlink:to="armp_NumberOfDirectors_638781128154409201" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NumberOfBoardDirectors" xlink:label="armp_NumberOfBoardDirectors_638781128154409201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154409201" xlink:to="armp_NumberOfBoardDirectors_638781128154409201" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CommonStockVotingPercentageHeldPercentage" xlink:label="armp_CommonStockVotingPercentageHeldPercentage_638781128154409201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154409201" xlink:to="armp_CommonStockVotingPercentageHeldPercentage_638781128154409201" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_LiquidityAndGoingConcernAbstract" xlink:label="armp_LiquidityAndGoingConcernAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154419203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_LiquidityAndGoingConcernAbstract_2" xlink:to="us-gaap_StatementTable_638781128154419203" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638781128154419203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154419203" xlink:to="us-gaap_TypeOfArrangementAxis_638781128154419203" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128154419203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638781128154419203" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128154419203" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2025Member" xlink:label="armp_CreditAgreement2025Member_638781128154419203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128154419203" xlink:to="armp_CreditAgreement2025Member_638781128154419203" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638781128154419203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154419203" xlink:to="srt_CounterpartyNameAxis_638781128154419203" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154419203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638781128154419203" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154419203" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154419203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154419203" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154419203" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638781128154419203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154419203" xlink:to="us-gaap_DebtInstrumentAxis_638781128154419203" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638781128154429193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638781128154419203" xlink:to="us-gaap_DebtInstrumentNameDomain_638781128154429193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAndSecurityAgreementMember" xlink:label="armp_CreditAndSecurityAgreementMember_638781128154429193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638781128154429193" xlink:to="armp_CreditAndSecurityAgreementMember_638781128154429193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember_638781128154429193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638781128154429193" xlink:to="armp_SecuredTermLoanMember_638781128154429193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638781128154429193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154419203" xlink:to="us-gaap_SubsequentEventTypeAxis_638781128154429193" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638781128154429193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638781128154429193" xlink:to="us-gaap_SubsequentEventTypeDomain_638781128154429193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638781128154429193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638781128154429193" xlink:to="us-gaap_SubsequentEventMember_638781128154429193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154429193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154419203" xlink:to="us-gaap_StatementLineItems_638781128154429193" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638781128154429193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154429193" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638781128154429193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128154439189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154429193" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781128154439189" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638781128154439189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154429193" xlink:to="us-gaap_DebtInstrumentFaceAmount_638781128154439189" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128154439189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154429193" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128154439189" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Significant Accounting Policies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154439189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638781128154439189" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638781128154439189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154439189" xlink:to="srt_ProductOrServiceAxis_638781128154439189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638781128154449207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638781128154439189" xlink:to="srt_ProductsAndServicesDomain_638781128154449207" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638781128154449207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638781128154449207" xlink:to="us-gaap_GrantMember_638781128154449207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154449207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154439189" xlink:to="us-gaap_StatementLineItems_638781128154449207" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_638781128154449207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154449207" xlink:to="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_638781128154449207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638781128154449207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154449207" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638781128154449207" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_638781128154449207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154449207" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_638781128154449207" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_638781128154449207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154449207" xlink:to="us-gaap_GoodwillImpairmentLoss_638781128154449207" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638781128154449207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154449207" xlink:to="us-gaap_OtherAssetsCurrent_638781128154449207" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638781128154459194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638781128154459194" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638781128154459194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638781128154459194" xlink:to="srt_RangeAxis_638781128154459194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638781128154459194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638781128154459194" xlink:to="srt_RangeMember_638781128154459194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638781128154459194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154459194" xlink:to="srt_MinimumMember_638781128154459194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638781128154459194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154459194" xlink:to="srt_MaximumMember_638781128154459194" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638781128154459194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638781128154459194" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638781128154459194" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638781128154459194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638781128154459194" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638781128154459194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_LaboratoryEquipmentMember" xlink:label="armp_LaboratoryEquipmentMember_638781128154459194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638781128154459194" xlink:to="armp_LaboratoryEquipmentMember_638781128154459194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_OfficeAndComputerEquipmentMember" xlink:label="armp_OfficeAndComputerEquipmentMember_638781128154469194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638781128154459194" xlink:to="armp_OfficeAndComputerEquipmentMember_638781128154469194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638781128154469194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638781128154459194" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638781128154469194" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638781128154469194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638781128154469194" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638781128154469194" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_638781128154469194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638781128154469194" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_638781128154469194" order="2" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Fair Value Measurements (Assets and liabilities at fair value) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_638781128154469194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_638781128154469194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781128154479205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638781128154469194" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781128154479205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154479205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781128154479205" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154479205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638781128154479205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154479205" xlink:to="us-gaap_FairValueInputsLevel1Member_638781128154479205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638781128154479205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154479205" xlink:to="us-gaap_FairValueInputsLevel3Member_638781128154479205" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638781128154479205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638781128154469194" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638781128154479205" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638781128154479205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638781128154479205" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638781128154479205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638781128154479205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638781128154479205" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638781128154479205" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" xlink:type="extended" xlink:title="99940402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781128154489200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781128154489200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781128154489200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781128154489200" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781128154489200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154489200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781128154489200" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154489200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638781128154489200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154489200" xlink:to="us-gaap_FairValueInputsLevel3Member_638781128154489200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638781128154489200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781128154489200" xlink:to="us-gaap_MeasurementInputTypeAxis_638781128154489200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638781128154489200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638781128154489200" xlink:to="us-gaap_MeasurementInputTypeDomain_638781128154489200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_638781128154489200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781128154489200" xlink:to="us-gaap_MeasurementInputDiscountRateMember_638781128154489200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProbabilitiesOfSettlementScenariosMember" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember_638781128154489200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781128154489200" xlink:to="armp_ProbabilitiesOfSettlementScenariosMember_638781128154489200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_638781128154489200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781128154489200" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_638781128154489200" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638781128154499192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781128154489200" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638781128154499192" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638781128154499192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781128154489200" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638781128154499192" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638781128154499192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781128154489200" xlink:to="srt_RangeAxis_638781128154499192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638781128154499192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638781128154499192" xlink:to="srt_RangeMember_638781128154499192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638781128154499192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154499192" xlink:to="srt_MinimumMember_638781128154499192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638781128154499192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154499192" xlink:to="srt_MaximumMember_638781128154499192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781128154499192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781128154489200" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781128154499192" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DebtInstrumentMeasurementInputForPeriod" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod_638781128154509207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781128154499192" xlink:to="armp_DebtInstrumentMeasurementInputForPeriod_638781128154509207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails" xlink:type="extended" xlink:title="99940403 - Disclosure - Fair Value Measurements (Changes in Fair Value of Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638781128154509207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638781128154509207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781128154509207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638781128154509207" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781128154509207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154509207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781128154509207" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154509207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638781128154509207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781128154509207" xlink:to="us-gaap_FairValueInputsLevel3Member_638781128154509207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638781128154519207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638781128154509207" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638781128154519207" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638781128154519207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638781128154519207" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638781128154519207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638781128154519207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638781128154519207" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638781128154519207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638781128154519207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638781128154519207" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638781128154519207" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_638781128154519207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638781128154519207" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_638781128154519207" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_638781128154519207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638781128154519207" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_638781128154519207" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_638781128154519207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638781128154519207" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_638781128154519207" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638781128154519207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638781128154519207" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638781128154519207" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638781128154519207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638781128154519207" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638781128154519207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638781128154529197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638781128154519207" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638781128154529197" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Net Loss per Share (Basic and Diluted EPS) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781128154529197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781128154529197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638781128154529197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781128154529197" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638781128154529197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_638781128154529197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781128154529197" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_638781128154529197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt" xlink:label="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt_638781128154529197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781128154529197" xlink:to="armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt_638781128154529197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638781128154529197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781128154529197" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638781128154529197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638781128154529197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638781128154529197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781128154539200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638781128154529197" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781128154539200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638781128154539200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638781128154529197" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638781128154539200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638781128154539200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638781128154529197" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638781128154539200" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638781128154539200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638781128154529197" xlink:to="us-gaap_EarningsPerShareBasic_638781128154539200" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638781128154539200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638781128154529197" xlink:to="us-gaap_EarningsPerShareDiluted_638781128154539200" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781128154549219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781128154549219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638781128154549219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781128154549219" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638781128154549219" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638781128154549219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638781128154549219" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638781128154549219" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_638781128154549219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638781128154549219" xlink:to="us-gaap_StockOptionMember_638781128154549219" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_UnvestedRestrictedStockMember" xlink:label="armp_UnvestedRestrictedStockMember_638781128154549219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638781128154549219" xlink:to="armp_UnvestedRestrictedStockMember_638781128154549219" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SharesIssuableUponConversionOfConvertibleLoanMember" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember_638781128154549219" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638781128154549219" xlink:to="armp_SharesIssuableUponConversionOfConvertibleLoanMember_638781128154549219" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638781128154559207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638781128154549219" xlink:to="us-gaap_WarrantMember_638781128154559207" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638781128154559207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781128154549219" xlink:to="srt_CounterpartyNameAxis_638781128154559207" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154559207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638781128154559207" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154559207" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154559207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154559207" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154559207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638781128154559207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781128154549219" xlink:to="us-gaap_DebtInstrumentAxis_638781128154559207" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638781128154559207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638781128154559207" xlink:to="us-gaap_DebtInstrumentNameDomain_638781128154559207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember_638781128154559207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638781128154559207" xlink:to="armp_SecuredTermLoanMember_638781128154559207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781128154559207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781128154549219" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781128154559207" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638781128154559207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781128154559207" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638781128154559207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt_638781128154569199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781128154559207" xlink:to="us-gaap_ConvertibleDebt_638781128154569199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638781128154569199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781128154559207" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638781128154569199" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128154569199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781128154559207" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128154569199" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_638781128154569199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781128154559207" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_638781128154569199" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Balance Sheet Details (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638781128154569199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation_638781128154569199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_638781128154579199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_638781128154579199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638781128154579199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638781128154579199" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638781128154579199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638781128154579199" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638781128154579199" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638781128154579199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638781128154579199" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638781128154579199" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638781128154579199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638781128154579199" xlink:to="us-gaap_MachineryAndEquipmentMember_638781128154579199" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember_638781128154579199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MachineryAndEquipmentMember_638781128154579199" xlink:to="us-gaap_TechnologyEquipmentMember_638781128154579199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638781128154579199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MachineryAndEquipmentMember_638781128154579199" xlink:to="us-gaap_OfficeEquipmentMember_638781128154579199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_638781128154589201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638781128154579199" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_638781128154589201" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638781128154589201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_638781128154589201" xlink:to="us-gaap_FurnitureAndFixturesMember_638781128154589201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember_638781128154589201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638781128154579199" xlink:to="us-gaap_LandAndBuildingMember_638781128154589201" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638781128154589201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LandAndBuildingMember_638781128154589201" xlink:to="us-gaap_LeaseholdImprovementsMember_638781128154589201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638781128154589201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638781128154579199" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638781128154589201" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638781128154589201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638781128154589201" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638781128154589201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638781128154589201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638781128154589201" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638781128154589201" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638781128154589201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638781128154589201" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638781128154589201" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - Balance Sheet Details (Other receivables) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_TenantImprovementReceivableCurrent" xlink:label="armp_TenantImprovementReceivableCurrent_638781128154599197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="armp_TenantImprovementReceivableCurrent_638781128154599197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_GrantAndAwardReceivableCurrent" xlink:label="armp_GrantAndAwardReceivableCurrent_638781128154599197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="armp_GrantAndAwardReceivableCurrent_638781128154599197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638781128154599197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_638781128154599197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - Balance Sheet Details (Accounts payable and accrued liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638781128154599197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccountsPayableCurrent_638781128154599197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AccruedLiabilitiesClinicalTrial" xlink:label="armp_AccruedLiabilitiesClinicalTrial_638781128154599197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="armp_AccruedLiabilitiesClinicalTrial_638781128154599197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_638781128154599197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_638781128154599197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638781128154599197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638781128154599197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Convertible Loan (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154609203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_1" xlink:to="us-gaap_StatementTable_638781128154609203" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638781128154609203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154609203" xlink:to="srt_CounterpartyNameAxis_638781128154609203" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154609203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638781128154609203" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154609203" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154609203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154609203" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154609203" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638781128154609203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154609203" xlink:to="us-gaap_DebtInstrumentAxis_638781128154609203" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638781128154609203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638781128154609203" xlink:to="us-gaap_DebtInstrumentNameDomain_638781128154609203" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember_638781128154619214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638781128154609203" xlink:to="armp_SecuredTermLoanMember_638781128154619214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154619214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154609203" xlink:to="us-gaap_StatementLineItems_638781128154619214" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638781128154619214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154619214" xlink:to="us-gaap_DebtInstrumentFaceAmount_638781128154619214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128154619214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154619214" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128154619214" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_638781128154619214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154619214" xlink:to="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_638781128154619214" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_638781128154669224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154619214" xlink:to="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_638781128154669224" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_638781128154669224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154619214" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_638781128154669224" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_638781128154669224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154619214" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities_638781128154669224" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128154669224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154619214" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638781128154669224" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_638781128154679241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154619214" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_638781128154679241" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureTermDebtDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Term Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638781128154679241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638781128154679241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638781128154679241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638781128154679241" xlink:to="us-gaap_DebtInstrumentAxis_638781128154679241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638781128154679241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638781128154679241" xlink:to="us-gaap_DebtInstrumentNameDomain_638781128154679241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember_638781128154679241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638781128154679241" xlink:to="armp_SecuredTermLoanMember_638781128154679241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638781128154679241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638781128154679241" xlink:to="us-gaap_TypeOfArrangementAxis_638781128154679241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128154689212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638781128154679241" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128154689212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2023Member" xlink:label="armp_CreditAgreement2023Member_638781128154689212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128154689212" xlink:to="armp_CreditAgreement2023Member_638781128154689212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2024Member" xlink:label="armp_CreditAgreement2024Member_638781128154689212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128154689212" xlink:to="armp_CreditAgreement2024Member_638781128154689212" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638781128154689212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638781128154679241" xlink:to="srt_CounterpartyNameAxis_638781128154689212" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154689212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638781128154689212" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154689212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154689212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638781128154689212" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638781128154689212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638781128154689212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638781128154679241" xlink:to="us-gaap_DebtInstrumentLineItems_638781128154689212" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638781128154689212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638781128154689212" xlink:to="us-gaap_DebtInstrumentFaceAmount_638781128154689212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128154689212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638781128154689212" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128154689212" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue_638781128154699203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638781128154689212" xlink:to="us-gaap_LongTermDebtFairValue_638781128154699203" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638781128154699203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638781128154689212" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638781128154699203" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638781128154699203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638781128154689212" xlink:to="us-gaap_DeferredFinanceCostsNet_638781128154699203" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_638781128154699203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638781128154689212" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_638781128154699203" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638781128154699203" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638781128154689212" xlink:to="us-gaap_InterestExpenseDebt_638781128154699203" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Stockholders' Deficit (Summary of Warrants Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781128154709206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781128154709206" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638781128154709206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781128154709206" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638781128154709206" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638781128154709206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638781128154709206" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638781128154709206" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceFourMember" xlink:label="armp_ExercisePriceFourMember_638781128154709206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781128154709206" xlink:to="armp_ExercisePriceFourMember_638781128154709206" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceFiveMember" xlink:label="armp_ExercisePriceFiveMember_638781128154709206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781128154709206" xlink:to="armp_ExercisePriceFiveMember_638781128154709206" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceSixMember" xlink:label="armp_ExercisePriceSixMember_638781128154709206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781128154709206" xlink:to="armp_ExercisePriceSixMember_638781128154709206" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceSevenMember" xlink:label="armp_ExercisePriceSevenMember_638781128154709206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781128154709206" xlink:to="armp_ExercisePriceSevenMember_638781128154709206" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceEightMember" xlink:label="armp_ExercisePriceEightMember_638781128154709206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781128154709206" xlink:to="armp_ExercisePriceEightMember_638781128154709206" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceNineMember" xlink:label="armp_ExercisePriceNineMember_638781128154719216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781128154709206" xlink:to="armp_ExercisePriceNineMember_638781128154719216" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExercisePriceTenMember" xlink:label="armp_ExercisePriceTenMember_638781128154719216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781128154709206" xlink:to="armp_ExercisePriceTenMember_638781128154719216" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154719216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781128154709206" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154719216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638781128154719216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154719216" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638781128154719216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781128154719216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154719216" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781128154719216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_WarrantExpirationDate" xlink:label="armp_WarrantExpirationDate_638781128154719216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154719216" xlink:to="armp_WarrantExpirationDate_638781128154719216" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Stockholders' Deficit (Shares Reserved for Future Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781128154729215" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781128154729215" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638781128154729215" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638781128154729215" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638781128154729215" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638781128154729215" xlink:to="armp_EquityIncentivePlan2016Member_638781128154729215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781128154729215" xlink:to="us-gaap_AwardTypeAxis_638781128154729215" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638781128154729215" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154729215" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154729215" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638781128154729215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781128154729215" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154729215" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154729215" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638781128154729215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638781128154729215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154729215" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638781128154729215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_638781128154739204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154729215" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_638781128154739204" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638781128154739204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154729215" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638781128154739204" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638781128154739204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154729215" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638781128154739204" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_638781128154739204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154729215" xlink:to="armp_SharesIssuableUponConversionOfConvertibleDebt_638781128154739204" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638781128154739204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781128154729215" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638781128154739204" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Equity Incentive Plans (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638781128154749209" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154749209" xlink:to="us-gaap_AwardTypeAxis_638781128154749209" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638781128154749209" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154749209" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154749209" xlink:to="us-gaap_EmployeeStockOptionMember_638781128154749209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_StockOptionsAndRestrictedStockAwardsMember" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154749209" xlink:to="armp_StockOptionsAndRestrictedStockAwardsMember_638781128154749209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154749209" xlink:to="us-gaap_RestrictedStockMember_638781128154749209" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154749209" xlink:to="us-gaap_PlanNameAxis_638781128154749209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638781128154749209" xlink:to="us-gaap_PlanNameDomain_638781128154749209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638781128154749209" xlink:to="armp_EquityIncentivePlan2016Member_638781128154749209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EmployeeStockPurchasePlan2016Member" xlink:label="armp_EmployeeStockPurchasePlan2016Member_638781128154749209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638781128154749209" xlink:to="armp_EmployeeStockPurchasePlan2016Member_638781128154749209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638781128154759207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154749209" xlink:to="srt_RangeAxis_638781128154759207" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638781128154759207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638781128154759207" xlink:to="srt_RangeMember_638781128154759207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638781128154759207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154759207" xlink:to="srt_MinimumMember_638781128154759207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638781128154759207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154759207" xlink:to="srt_MaximumMember_638781128154759207" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638781128154759207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154749209" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638781128154759207" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638781128154759207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638781128154759207" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638781128154759207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member_638781128154759207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638781128154759207" xlink:to="armp_EquityIncentivePlan2016Member_638781128154759207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154759207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154749209" xlink:to="us-gaap_StatementLineItems_638781128154759207" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638781128154769204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638781128154769204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638781128154769204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638781128154769204" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638781128154769204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638781128154769204" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638781128154769204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638781128154769204" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638781128154769204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638781128154769204" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638781128154769204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638781128154769204" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638781128154779207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638781128154779207" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638781128154779207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_SharePrice_638781128154779207" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638781128154779207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638781128154779207" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638781128154779207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638781128154779207" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638781128154779207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638781128154779207" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638781128154779207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154759207" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638781128154779207" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638781128154789204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638781128154789204" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638781128154789204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638781128154789204" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638781128154789204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638781128154789204" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638781128154789204" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638781128154789204" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387811281547892041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387811281547892041" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638781128154799215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638781128154799215" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638781128154799215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638781128154799215" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638781128154799215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638781128154799215" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638781128154799215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638781128154799215" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638781128154799215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638781128154799215" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638781128154799215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638781128154799215" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387811281547992151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387811281547992151" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638781128154799215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638781128154799215" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638781128154809206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638781128154809206" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638781128154809206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638781128154809206" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638781128154809206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638781128154809206" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638781128154809206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638781128154809206" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638781128154809206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638781128154809206" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638781128154809206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638781128154809206" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_638781128154819220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_638781128154819220" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638781128154819220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638781128154819220" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638781128154819220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638781128154819220" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638781128154819220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638781128154819220" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - Equity Incentive Plans (Restricted stock award and restricted stock unit award activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154829386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638781128154829386" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638781128154829386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154829386" xlink:to="us-gaap_AwardTypeAxis_638781128154829386" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154829386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638781128154829386" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154829386" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638781128154829386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781128154829386" xlink:to="us-gaap_RestrictedStockMember_638781128154829386" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638781128154829386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154829386" xlink:to="us-gaap_PlanNameAxis_638781128154829386" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638781128154829386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638781128154829386" xlink:to="us-gaap_PlanNameDomain_638781128154829386" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_C3jStockPlan2016Member" xlink:label="armp_C3jStockPlan2016Member_638781128154829386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638781128154829386" xlink:to="armp_C3jStockPlan2016Member_638781128154829386" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154829386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154829386" xlink:to="us-gaap_StatementLineItems_638781128154829386" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638781128154829386" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154829386" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638781128154829386" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638781128154839215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638781128154829386" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638781128154839215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638781128154839215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638781128154829386" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638781128154839215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638781128154839215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638781128154829386" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638781128154839215" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638781128154839215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638781128154829386" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638781128154839215" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387811281548392151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638781128154829386" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387811281548392151" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638781128154839215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154829386" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638781128154839215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638781128154839215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638781128154839215" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638781128154839215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638781128154839215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638781128154839215" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638781128154839215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638781128154849209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638781128154839215" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638781128154849209" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638781128154849209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638781128154839215" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638781128154849209" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638781128154849209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638781128154839215" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638781128154849209" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xlink:type="extended" xlink:title="99941004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154849209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638781128154849209" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638781128154849209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154849209" xlink:to="srt_RangeAxis_638781128154849209" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638781128154859225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638781128154849209" xlink:to="srt_RangeMember_638781128154859225" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638781128154859225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154859225" xlink:to="srt_MinimumMember_638781128154859225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638781128154859225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154859225" xlink:to="srt_MaximumMember_638781128154859225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638781128154859225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154849209" xlink:to="us-gaap_StatementClassOfStockAxis_638781128154859225" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638781128154859225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638781128154859225" xlink:to="us-gaap_ClassOfStockDomain_638781128154859225" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CommonStockOptionsMember" xlink:label="armp_CommonStockOptionsMember_638781128154859225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638781128154859225" xlink:to="armp_CommonStockOptionsMember_638781128154859225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638781128154859225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154849209" xlink:to="us-gaap_MeasurementInputTypeAxis_638781128154859225" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638781128154859225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638781128154859225" xlink:to="us-gaap_MeasurementInputTypeDomain_638781128154859225" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638781128154859225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781128154859225" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638781128154859225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638781128154869210" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781128154859225" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638781128154869210" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638781128154869210" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781128154859225" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638781128154869210" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638781128154869210" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781128154859225" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638781128154869210" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154869210" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154849209" xlink:to="us-gaap_StatementLineItems_638781128154869210" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EquitySecuritiesMeasurementInput" xlink:label="armp_EquitySecuritiesMeasurementInput_638781128154869210" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154869210" xlink:to="armp_EquitySecuritiesMeasurementInput_638781128154869210" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99941005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154879225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638781128154879225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638781128154879225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154879225" xlink:to="us-gaap_IncomeStatementLocationAxis_638781128154879225" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638781128154879225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638781128154879225" xlink:to="us-gaap_IncomeStatementLocationDomain_638781128154879225" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638781128154879225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638781128154879225" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638781128154879225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638781128154879225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638781128154879225" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638781128154879225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638781128154879225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154879225" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638781128154879225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638781128154879225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638781128154879225" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638781128154879225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" xlink:type="extended" xlink:title="99941101 - Disclosure - Income Taxes (Narrative) (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154889237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_638781128154889237" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638781128154889237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154889237" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638781128154889237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638781128154889237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638781128154889237" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638781128154889237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638781128154889237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638781128154889237" xlink:to="us-gaap_DomesticCountryMember_638781128154889237" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638781128154889237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638781128154889237" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638781128154889237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638781128154889237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638781128154889237" xlink:to="us-gaap_ForeignCountryMember_638781128154889237" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154899223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154889237" xlink:to="us-gaap_StatementLineItems_638781128154899223" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638781128154899223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154899223" xlink:to="us-gaap_OperatingLossCarryforwards_638781128154899223" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration_638781128154899223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154899223" xlink:to="armp_OperatingLossCarryforwardsNotSubjectToExpiration_638781128154899223" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638781128154899223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154899223" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638781128154899223" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638781128154899223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154899223" xlink:to="us-gaap_UnrecognizedTaxBenefits_638781128154899223" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638781128154899223" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154899223" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638781128154899223" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638781128154909216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638781128154909216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638781128154909216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638781128154909216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638781128154909216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638781128154909216" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638781128154909216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638781128154909216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638781128154909216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638781128154909216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638781128154909216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638781128154909216" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638781128154909216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638781128154909216" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxAssetLeaseObligation" xlink:label="armp_DeferredTaxAssetLeaseObligation_638781128154919217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="armp_DeferredTaxAssetLeaseObligation_638781128154919217" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxAssetsInterestExpenseCarryForwards" xlink:label="armp_DeferredTaxAssetsInterestExpenseCarryForwards_638781128154919217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="armp_DeferredTaxAssetsInterestExpenseCarryForwards_638781128154919217" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638781128154919217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="us-gaap_DeferredTaxAssetsOther_638781128154919217" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638781128154919217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="us-gaap_DeferredTaxAssetsGross_638781128154919217" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638781128154919217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638781128154919217" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638781128154919217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638781128154909216" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638781128154919217" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_638781128154919217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_638781128154919217" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_638781128154919217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638781128154919217" xlink:to="armp_DeferredTaxLiabilitiesRightOfUseAsset_638781128154919217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638781128154929226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638781128154919217" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638781128154929226" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_DeferredTaxLiabilitiesDebtBasisDifferences" xlink:label="armp_DeferredTaxLiabilitiesDebtBasisDifferences_638781128154929226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638781128154919217" xlink:to="armp_DeferredTaxLiabilitiesDebtBasisDifferences_638781128154929226" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638781128154929226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638781128154919217" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638781128154929226" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638781128154929226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638781128154919217" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638781128154929226" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638781128154929226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638781128154919217" xlink:to="us-gaap_DeferredTaxLiabilities_638781128154929226" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638781128154939224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638781128154939224" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781128154939224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781128154939224" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638781128154939224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781128154939224" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638781128154939224" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638781128154939224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781128154939224" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638781128154939224" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent_638781128154939224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781128154939224" xlink:to="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent_638781128154939224" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638781128154939224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781128154939224" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638781128154939224" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638781128154939224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781128154939224" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638781128154939224" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_638781128154939224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781128154939224" xlink:to="armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_638781128154939224" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638781128154939224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781128154939224" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638781128154939224" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638781128154949215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638781128154949215" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Commitments and Contingencies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128154949215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable_638781128154949215" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638781128154949215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154949215" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638781128154949215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638781128154949215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638781128154949215" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638781128154949215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember_638781128154949215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638781128154949215" xlink:to="us-gaap_CashMember_638781128154949215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638781128154949215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154949215" xlink:to="srt_RangeAxis_638781128154949215" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638781128154949215" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638781128154949215" xlink:to="srt_RangeMember_638781128154949215" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638781128154959218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154949215" xlink:to="srt_MinimumMember_638781128154959218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638781128154959218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154949215" xlink:to="srt_MaximumMember_638781128154959218" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128154959218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128154949215" xlink:to="us-gaap_StatementLineItems_638781128154959218" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_OperatingLeaseBaseAnnual" xlink:label="armp_OperatingLeaseBaseAnnual_638781128154959218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154959218" xlink:to="armp_OperatingLeaseBaseAnnual_638781128154959218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AnnualIncreaseInRentPercentage" xlink:label="armp_AnnualIncreaseInRentPercentage_638781128154959218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154959218" xlink:to="armp_AnnualIncreaseInRentPercentage_638781128154959218" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_638781128154959218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154959218" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_638781128154959218" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AnnualReductionOfStandbyLetterOfCredit" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit_638781128154959218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154959218" xlink:to="armp_AnnualReductionOfStandbyLetterOfCredit_638781128154959218" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_638781128154959218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154959218" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_638781128154959218" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_BaseAnnualRentToBePaidYearThree" xlink:label="armp_BaseAnnualRentToBePaidYearThree_638781128154969214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154959218" xlink:to="armp_BaseAnnualRentToBePaidYearThree_638781128154969214" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AllowanceForTenantImprovementsReceivable" xlink:label="armp_AllowanceForTenantImprovementsReceivable_638781128154969214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154959218" xlink:to="armp_AllowanceForTenantImprovementsReceivable_638781128154969214" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638781128154969214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154959218" xlink:to="us-gaap_OperatingLeaseExpense_638781128154969214" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment_638781128154969214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128154959218" xlink:to="us-gaap_VariableLeasePayment_638781128154969214" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638781128154969214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638781128154969214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638781128154969214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638781128154969214" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638781128154979216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638781128154979216" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638781128154979216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638781128154979216" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638781128154979216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638781128154979216" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638781128154979216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638781128154979216" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638781128154979216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638781128154979216" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638781128154979216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638781128154979216" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638781128154979216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638781128154979216" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638781128154979216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638781128154979216" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638781128154979216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638781128154979216" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - Commitments and Contingencies (Operating leases) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638781128154989216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments_638781128154989216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638781128154989216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638781128154989216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638781128154989216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638781128154989216" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Grant and Awards (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardAbstract" xlink:label="AwardAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTable" xlink:label="us-gaap_GovernmentAssistanceTable_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardAbstract" xlink:to="us-gaap_GovernmentAssistanceTable_638781128154999226" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTable_638781128154999226" xlink:to="us-gaap_GovernmentAssistanceTypeAxis_638781128154999226" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis_638781128154999226" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_638781128154999226" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_638781128154999226" xlink:to="armp_MedicalTechnologyEnterpriseConsortiumMember_638781128154999226" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardAgreementWithCysticFibrosisFoundationMember" xlink:label="armp_AwardAgreementWithCysticFibrosisFoundationMember_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_638781128154999226" xlink:to="armp_AwardAgreementWithCysticFibrosisFoundationMember_638781128154999226" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTable_638781128154999226" xlink:to="srt_RangeAxis_638781128154999226" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638781128154999226" xlink:to="srt_RangeMember_638781128154999226" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781128154999226" xlink:to="srt_MaximumMember_638781128154999226" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLineItems" xlink:label="us-gaap_GovernmentAssistanceLineItems_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTable_638781128154999226" xlink:to="us-gaap_GovernmentAssistanceLineItems_638781128154999226" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount" xlink:label="us-gaap_GovernmentAssistanceAwardAmount_638781128154999226" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638781128154999226" xlink:to="us-gaap_GovernmentAssistanceAwardAmount_638781128154999226" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAssetIncreaseCurrent" xlink:label="us-gaap_GovernmentAssistanceAssetIncreaseCurrent_638781128155009220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638781128154999226" xlink:to="us-gaap_GovernmentAssistanceAssetIncreaseCurrent_638781128155009220" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration_638781128155009220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceAssetIncreaseCurrent_638781128155009220" xlink:to="us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration_638781128155009220" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount_638781128155009220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638781128154999226" xlink:to="us-gaap_GovernmentAssistanceAmount_638781128155009220" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638781128155009220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceAmount_638781128155009220" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638781128155009220" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_638781128155009220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638781128154999226" xlink:to="us-gaap_GrantsReceivableCurrent_638781128155009220" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProceedsFromGovernmentGrants" xlink:label="armp_ProceedsFromGovernmentGrants_638781128155009220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638781128154999226" xlink:to="armp_ProceedsFromGovernmentGrants_638781128155009220" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_AwardAgreementInterruptionPeriod" xlink:label="armp_AwardAgreementInterruptionPeriod_638781128155009220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceLineItems_638781128154999226" xlink:to="armp_AwardAgreementInterruptionPeriod_638781128155009220" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Employee Retirement Plan (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638781128155019217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638781128155019217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - Segment Reporting (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155019217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_3" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155019217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638781128155019217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155019217" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638781128155019217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638781128155029235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638781128155019217" xlink:to="us-gaap_SegmentDomain_638781128155029235" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SingleReportableSegmentMember" xlink:label="armp_SingleReportableSegmentMember_638781128155029235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638781128155029235" xlink:to="armp_SingleReportableSegmentMember_638781128155029235" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638781128155029235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155019217" xlink:to="srt_StatementGeographicalAxis_638781128155029235" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638781128155029235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638781128155029235" xlink:to="srt_SegmentGeographicalDomain_638781128155029235" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US_638781128155029235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638781128155029235" xlink:to="country_US_638781128155029235" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638781128155029235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155019217" xlink:to="us-gaap_SegmentReportingInformationLineItems_638781128155029235" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638781128155029235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155029235" xlink:to="us-gaap_NumberOfOperatingSegments_638781128155029235" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638781128155029235" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155029235" xlink:to="us-gaap_NumberOfReportableSegments_638781128155029235" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638781128155039229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155029235" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638781128155039229" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_PercentageOfLongLivedAssetsInGeographicalLocation" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation_638781128155039229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155029235" xlink:to="armp_PercentageOfLongLivedAssetsInGeographicalLocation_638781128155039229" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails" xlink:type="extended" xlink:title="99941502 - Disclosure - Segment Reporting - Segment information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155039229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155039229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638781128155039229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155039229" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638781128155039229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638781128155039229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638781128155039229" xlink:to="us-gaap_SegmentDomain_638781128155039229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SingleReportableSegmentMember" xlink:label="armp_SingleReportableSegmentMember_638781128155039229" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638781128155039229" xlink:to="armp_SingleReportableSegmentMember_638781128155039229" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638781128155049225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155039229" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638781128155049225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_638781128155049225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638781128155049225" xlink:to="us-gaap_ProjectMember_638781128155049225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_NonCysticFibrosisBronchiectasisMember" xlink:label="armp_NonCysticFibrosisBronchiectasisMember_638781128155049225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638781128155049225" xlink:to="armp_NonCysticFibrosisBronchiectasisMember_638781128155049225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CysticFibrosisMember" xlink:label="armp_CysticFibrosisMember_638781128155049225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638781128155049225" xlink:to="armp_CysticFibrosisMember_638781128155049225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_BacteremiaMember" xlink:label="armp_BacteremiaMember_638781128155049225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638781128155049225" xlink:to="armp_BacteremiaMember_638781128155049225" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ProstheticJointInfectionMember" xlink:label="armp_ProstheticJointInfectionMember_638781128155049225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638781128155049225" xlink:to="armp_ProstheticJointInfectionMember_638781128155049225" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638781128155049225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781128155039229" xlink:to="us-gaap_SegmentReportingInformationLineItems_638781128155049225" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638781128155049225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638781128155049225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExternalResearchAndDevelopmentExpense" xlink:label="armp_ExternalResearchAndDevelopmentExpense_638781128155049225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="armp_ExternalResearchAndDevelopmentExpense_638781128155049225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_UnallocatedExternalResearchAndDevelopmentExpense" xlink:label="armp_UnallocatedExternalResearchAndDevelopmentExpense_638781128155059218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="armp_UnallocatedExternalResearchAndDevelopmentExpense_638781128155059218" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ExternalResearchAndDevelopmentExpenseTotal" xlink:label="armp_ExternalResearchAndDevelopmentExpenseTotal_638781128155059218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="armp_ExternalResearchAndDevelopmentExpenseTotal_638781128155059218" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_ResearchAndDevelopmentPersonnelExpense" xlink:label="armp_ResearchAndDevelopmentPersonnelExpense_638781128155059218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="armp_ResearchAndDevelopmentPersonnelExpense_638781128155059218" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_638781128155059218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_638781128155059218" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638781128155059218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638781128155059218" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638781128155059218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_LaborAndRelatedExpense_638781128155059218" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_638781128155059218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_638781128155059218" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638781128155059218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638781128155059218" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638781128155069218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_OperatingExpenses_638781128155069218" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638781128155069218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_OperatingIncomeLoss_638781128155069218" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638781128155069218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638781128155069218" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781128155069218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781128155049225" xlink:to="us-gaap_NetIncomeLoss_638781128155069218" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Subsequent Events (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781128155079222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_StatementTable_638781128155079222" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638781128155079222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128155079222" xlink:to="us-gaap_SubsequentEventTypeAxis_638781128155079222" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638781128155079222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638781128155079222" xlink:to="us-gaap_SubsequentEventTypeDomain_638781128155079222" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638781128155079222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638781128155079222" xlink:to="us-gaap_SubsequentEventMember_638781128155079222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638781128155079222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128155079222" xlink:to="srt_CounterpartyNameAxis_638781128155079222" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638781128155079222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638781128155079222" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638781128155079222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638781128155079222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638781128155079222" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638781128155079222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638781128155079222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128155079222" xlink:to="us-gaap_DebtInstrumentAxis_638781128155079222" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638781128155079222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638781128155079222" xlink:to="us-gaap_DebtInstrumentNameDomain_638781128155079222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember_638781128155089225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638781128155079222" xlink:to="armp_SecuredTermLoanMember_638781128155089225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638781128155089225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128155079222" xlink:to="us-gaap_TypeOfArrangementAxis_638781128155089225" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128155089225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638781128155089225" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128155089225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20241231.xsd#armp_CreditAgreement2025Member" xlink:label="armp_CreditAgreement2025Member_638781128155089225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638781128155089225" xlink:to="armp_CreditAgreement2025Member_638781128155089225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781128155089225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781128155079222" xlink:to="us-gaap_StatementLineItems_638781128155089225" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638781128155089225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128155089225" xlink:to="us-gaap_DebtInstrumentFaceAmount_638781128155089225" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128155089225" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781128155089225" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638781128155089225" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-37544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARMATA PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1549568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5005 McConnell Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">665-2928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARMP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,183,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the registrant&#8217;s fiscal&#160;year ended December&#160;31, 2024, are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,291<span></span>
</td>
<td class="nump">$ 13,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">2,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">11,308<span></span>
</td>
<td class="nump">19,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">5,480<span></span>
</td>
<td class="nump">5,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">13,241<span></span>
</td>
<td class="nump">12,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">41,687<span></span>
</td>
<td class="nump">44,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research and development</a></td>
<td class="nump">10,256<span></span>
</td>
<td class="nump">10,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,490<span></span>
</td>
<td class="nump">3,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">2,470<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">86,437<span></span>
</td>
<td class="nump">98,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">5,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">2,280<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent', window );">Term debt, current</a></td>
<td class="nump">38,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">4,431<span></span>
</td>
<td class="nump">9,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,249<span></span>
</td>
<td class="nump">16,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible Loan, non-current</a></td>
<td class="nump">32,897<span></span>
</td>
<td class="nump">58,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Term debt, non-current</a></td>
<td class="nump">22,539<span></span>
</td>
<td class="nump">23,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">27,694<span></span>
</td>
<td class="nump">28,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,077<span></span>
</td>
<td class="nump">3,077<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">134,456<span></span>
</td>
<td class="nump">130,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.01 par value; 217,000,000 shares authorized; 36,183,067 and 36,122,932 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">279,354<span></span>
</td>
<td class="nump">276,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(327,735)<span></span>
</td>
<td class="num">(308,819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(48,019)<span></span>
</td>
<td class="num">(32,065)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 86,437<span></span>
</td>
<td class="nump">$ 98,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation and current convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">217,000,000<span></span>
</td>
<td class="nump">217,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">36,183,067<span></span>
</td>
<td class="nump">36,122,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">36,183,067<span></span>
</td>
<td class="nump">36,122,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">$ 5,174<span></span>
</td>
<td class="nump">$ 4,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">34,426<span></span>
</td>
<td class="nump">33,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,184<span></span>
</td>
<td class="nump">11,649<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">47,610<span></span>
</td>
<td class="nump">45,419<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(42,436)<span></span>
</td>
<td class="num">(40,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Interest expense</a></td>
<td class="num">(10,742)<span></span>
</td>
<td class="num">(2,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of the Convertible Loan</a></td>
<td class="nump">31,399<span></span>
</td>
<td class="num">(21,845)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on debt and the Convertible Loan extinguishments</a></td>
<td class="nump">2,166<span></span>
</td>
<td class="num">(3,863)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">23,520<span></span>
</td>
<td class="num">(28,155)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,916)<span></span>
</td>
<td class="num">$ (69,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (1.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">36,160,848<span></span>
</td>
<td class="nump">36,075,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (1.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">59,059,971<span></span>
</td>
<td class="nump">36,075,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">$ 275,493<span></span>
</td>
<td class="num">$ (239,774)<span></span>
</td>
<td class="nump">$ 36,080<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2022</a></td>
<td class="nump">36,144,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted stock awards (in shares)</a></td>
<td class="num">(27,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings', window );">Withholdings for taxes related to net share settlement of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings', window );">Withholdings for taxes related to net share settlement of equity awards, shares</a></td>
<td class="num">(25,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon vesting of restricted stock units, shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,045)<span></span>
</td>
<td class="num">(69,045)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">276,393<span></span>
</td>
<td class="num">(308,819)<span></span>
</td>
<td class="num">(32,065)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2023</a></td>
<td class="nump">36,122,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">37,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings', window );">Withholdings for taxes related to net share settlement of equity awards, shares</a></td>
<td class="num">(4,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Issuance of common stock upon release of restricted stock units, net of tax withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of common stock upon release of restricted stock units, net of tax withholdings (In shares)</a></td>
<td class="nump">27,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,916)<span></span>
</td>
<td class="num">(18,916)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 279,354<span></span>
</td>
<td class="num">$ (327,735)<span></span>
</td>
<td class="num">$ (48,019)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2024</a></td>
<td class="nump">36,183,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock returned shares issued net of tax withholdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock returned value shares issued net of tax withholdings .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (18,916)<span></span>
</td>
<td class="num">$ (69,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,893<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncreaseDecreaseFairValueOfLiabilities', window );">Change in fair value of the Convertible Loan</a></td>
<td class="num">(31,399)<span></span>
</td>
<td class="nump">21,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">10,758<span></span>
</td>
<td class="nump">2,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_NoncashInterestIncome', window );">Non-cash interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on debt and Convertible Loan extinguishments</a></td>
<td class="num">(2,166)<span></span>
</td>
<td class="nump">3,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Change in right-of-use asset</a></td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss from disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">5,106<span></span>
</td>
<td class="nump">4,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(3,755)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Accrued compensation</a></td>
<td class="nump">1,512<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(4,962)<span></span>
</td>
<td class="num">(13,451)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(37,551)<span></span>
</td>
<td class="num">(47,423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,879)<span></span>
</td>
<td class="num">(8,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,879)<span></span>
</td>
<td class="num">(8,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of the Convertible Loan, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of term debt, net of issuance costs</a></td>
<td class="nump">34,889<span></span>
</td>
<td class="nump">24,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for taxes related to net share settlement of equity awards</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ProceedsFromExerciseOfWarrantsAndStockOptions', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">34,958<span></span>
</td>
<td class="nump">53,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(4,472)<span></span>
</td>
<td class="num">(1,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">19,243<span></span>
</td>
<td class="nump">20,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">14,771<span></span>
</td>
<td class="nump">19,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">977<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContributionOfProperty', window );">Property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncreaseDecreaseFairValueOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncreaseDecreaseFairValueOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NoncashInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income included in net income that result in no cash inflow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NoncashInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromExerciseOfWarrantsAndStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromExerciseOfWarrantsAndStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContributionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of property contributed in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContributionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,291<span></span>
</td>
<td class="nump">$ 13,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">5,480<span></span>
</td>
<td class="nump">5,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 14,771<span></span>
</td>
<td class="nump">$ 19,243<span></span>
</td>
<td class="nump">$ 20,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and Description of the Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Armata Pharmaceuticals,&#160;Inc. (&#8220;Armata&#8221;) together with its subsidiaries (the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on </span>the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Armata&#8217;s common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;) is traded on the NYSE American exchange under the ticker symbol &#8220;ARMP&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s principal stockholder, <span style="font-family:'Times New Roman;">Innoviva Strategic Opportunities LLC (&#8220;Innoviva SO&#8221;), a wholly owned subsidiary of </span>Innoviva Inc. (&#8220;Innoviva&#8221;), owns 69.3% of the Company&#8217;s outstanding equity as of December 31, 2024. The Company also received $90.0 million in total debt financing from <span style="font-family:'Times New Roman;">Innoviva SO</span> during 2023 and in March 2024. Innoviva designees represent three out of eight seats of the Company&#8217;s Board of Directors (&#8220;Board of Directors&#8221;) during the year ended December 31, 2024, and cannot vote or take any action by written consent with respect to any shares of Common Stock held by Innoviva SO that represent, in the aggregate, more than 49.5% of the total number of shares of the Company&#8217;s Common Stock for voting on the matters related to election or removal of the Company&#8217;s board members or amending the bylaws of the Company to reduce the maximum number of directors or setting the number of directors who may serve on the Company&#8217;s Board of Directors in accordance with the voting agreement. The voting agreement expires on the earlier of the fifth anniversary of the agreement&#8217;s effective date, January 26, 2021, or the approval by the Food and Drug Administration (the &#8220;FDA&#8221;) of any of the Company&#8217;s product candidates for marketing and commercial distribution. Innoviva SO and Innoviva are related parties of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_LiquidityAndGoingConcernAbstract', window );"><strong>Liquidity and Going Concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Liquidity and Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company has incurred significant operating losses since inception and has primarily relied on equity, debt and grant financing to fund its operations. As of December 31, 2024, the Company had an accumulated deficit of $327.7 million. The Company expects to continue to incur substantial losses, and its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until then, the Company will need to continue to raise additional capital. The existing cash and cash equivalents of $9.3 million as of December 31, 2024 will not be sufficient to fund its operations for the next 12 months from the date of these consolidated financial statements. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recent Financing:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2025 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On March 12, 2025, the Company entered into a credit and security agreement (the &#8220;2025 Credit Agreement&#8221;) for a loan in an aggregate amount of </span><span style="background:#ffffff;">$10.0</span><span style="background:#ffffff;">&#160;million (the &#8220;2025 Loan&#8221;) with </span>Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA), our principal stockholder and a related party (collectively, &#8220;Innoviva&#8221;).<span style="background:#ffffff;"> The 2025 Loan bears interest at an annual rate of&#160;</span><span style="background:#ffffff;">14.0%</span><span style="background:#ffffff;"> and matures on March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2025 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Concurrently with the execution of the 2025 Credit Agreement, the Company entered into amendments to (i) its existing convertible loan (the &#8220;Convertible Loan&#8221;) and secured credit and security agreement, dated January 10, 2023, with Innoviva (the &#8220;Convertible Credit Agreement&#8221;), (ii) its existing secured term loan facility (the &#8220;2023 Loan&#8221;) and credit and security agreement, dated July 10, 2023, with Innoviva (the &#8220;2023 Credit Agreement&#8221;) and (iii) its existing secured term loan facility (the &#8220;2024 Loan&#8221;) and credit and security agreement, dated March 4, 2024, with Innoviva (the &#8220;2024 Credit Agreement&#8221;), which, among other things, extended the maturity date of each loan to March 12, 2026.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2024 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;">On March 4, 2024, the Company entered into 2024 Credit Agreement for the 2024 Loan in an aggregate amount of </span><span style="font-family:'Times New Roman;">$35.0</span><span style="font-family:'Times New Roman;"> million. The 2024 Loan bears interest at an annual rate of </span><span style="font-family:'Times New Roman;">14.0%</span><span style="font-family:'Times New Roman;"> and was scheduled to mature on June 4, 2025. On March 12, 2025, the Company executed an amendment to the 2024 Credit Agreement which, among other things, extended the 2024 Loan maturity date to March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2024 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets </span><span style="background:#ffffff;">of the Company and the subsidiary guarantors</span><span style="font-family:'Times New Roman;">. </span>Concurrently with the execution of the 2024 Credit Agreement, the Company amended certain provisions of the Convertible Loan and Convertible Credit Agreement and the 2023 Loan and 2023 Credit Agreement to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While the Company believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#8217;s ability to achieve the development and commercialization goals would be adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_LiquidityAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity And Going Concern [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_LiquidityAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the Convertible Loan, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;">Concentration of Credit Risks and Certain Other Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and restricted cash. As of December 31, 2024 and 2023, cash, cash equivalents and restricted cash were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions in accordance with the Company&#8217;s investment policy, to a concentration limit per issuer or sector.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Other receivables represent amounts due from the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;) (Note 13, &#8220;</span><i style="font-style:italic;background:#ffffff;">Grants and Awards&#8221;</i><span style="background:#ffffff;">) and reimbursement for tenant improvements (Note 12, &#8220;</span><i style="font-style:italic;background:#ffffff;">Commitments and Contingencies</i><span style="background:#ffffff;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.26;margin:8pt 0pt 4pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cash and cash equivalents consist primarily of cash deposits and marketable securities with original maturities of less than three months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of two irrevocable letters of credit with financial institutions related to the Company&#8217;s operating leases (Note 12 , &#8220;<i style="font-style:italic;">Commitments and Contingencies</i>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;white-space:pre-wrap;"> Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, Convertible Loan and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The Convertible Loan is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5 &#8211; 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3 &#8211; 5 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-Eh2dCRyZEObk0oB6hPNcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter of lease term or useful life</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. No impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2024 or 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">In-Process Research and Development (&#8220;IPR&amp;D&#8221;) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;"> IPR&amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#8217;s IPR&amp;D assets represent capitalized in-process bacteriophage development programs for </span><i style="font-style:italic;">S. aureus</i> infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company tests IPR&amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when a quantitative analysis of IPR&amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#8217;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#8217;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, the Company performed the annual evaluation of its IPR&amp;D assets for impairment. The Company considered the development timelines for its <i style="font-style:italic;">S. aureus</i> development program and noted no qualitative factors that would indicate potential impairment of its IPR&amp;D asset. The Company also performed a quantitative analysis for impairment analysis and based on this analysis, the fair value of this bacteriophage program was greater than its carrying value as of December&#160;31, 2024. Consequently, no impairment was noted for the IPR&amp;D asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company performed the annual evaluation of its IPR&amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for <i style="font-style:italic;">S. aureus</i> infections was greater than its carrying value as a result of the quantitative analysis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No impairment loss was recognized as of December 31, 2024 and 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#8217;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted no impairment as of December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) is determined based on the number of units granted and the closing price of the Company&#8217;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Foreign Currency Translations and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. <span style="background:#ffffff;">Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the quarterly average exchange rate in effect during the </span>year.&#160;<span style="background:#ffffff;">Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#8217;s consolidated statement of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grants Revenue and Other Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether agreements are within the scope of ASC Topic 606, <i style="font-style:italic;">Revenue from contracts with customers</i> (&#8220;ASC 606&#8221;) or other topics at the effective date of an agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;<i style="font-style:italic;">Collaborative Arrangements</i>&#160;(&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;<i style="font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</i>, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also considers the guidance in ASC Topic 730,&#160;<i style="font-style:italic;">Research and Development&#160;</i>(&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability<i style="font-style:italic;">.&#160;</i>If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company recognized as other receivables in its consolidated balance sheets $0.7 million and $1.5 million, respectively, related to invoiced grant amounts that have not been received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2024 and 2023, as such, the comprehensive income (loss) for these periods was equal to the net loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;">Basic and Diluted Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. </span>Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.<span style="background:#ffffff;"> The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 standard in the fourth quarter of 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. Refer to Note 15.&#160;&#8220;<i style="font-style:italic;">Segment Reporting&#8221;</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#212529;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#212529;background:#ffffff;">In August 2020, the FASB issued ASU 2020-06, Debt - </span><i style="color:#212529;font-style:italic;background:#ffffff;">Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i><span style="color:#212529;background:#ffffff;"> (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted earnings (loss) per share (&#8220;EPS&#8221;) computation. The Company adopted this ASU as of January 1, 2024, which did not have an impact on its consolidated financial statements or related disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">On October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#8217;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): <i style="font-style:italic;">Improvements to Income Tax Disclosures</i>. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In November 2024, the FASB issued Accounting Standards Update ASU 2024-03 Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40):<i style="font-style:italic;"> Disaggregation of Income Statement Expenses</i>. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#8217;s consolidated financial statement disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.27;padding-top:12pt;margin:0pt 0pt 4pt 0pt;">4. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investments in money market fund &#8211; financial assets, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan&#8211; financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,897</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:middle;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan&#8211; financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,633</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;">The Company&#8217;s Convertible Loan (Note 7) is measured at fair value and remeasured at each measurement period, with changes in fair value recorded as other income (expense) in the consolidated statement of operations. The Company estimates the fair value of its Convertible Loan using a weighted probability model of various debt settlement scenarios during its term discounted to the reporting date. Conversion option scenarios are valued using option pricing models with assumptions and estimates such as volatility, expected term and risk-free interest rates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">Level 3 fair value inputs include probability and timing of various settlement scenarios and selection of comparable companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company estimated the fair value of its Convertible Loan using the following inputs for the years ended December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15.67%-28.28%</p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.01%-45.88%</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probabilities of settlement scenarios</p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%-75%</p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%-85%</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility </p></td><td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">83.30%-111.60%</p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.1%-123.6%</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.10-1.20</p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.20-1.50</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.08%-5.33%</p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.62%-5.39%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents a summary of the changes in the fair value of its Convertible Loan for the years ended December 31, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net issuance of the Convertible Loan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,226</p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial recognition of modified Convertible Loan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,031</p></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,399)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,845</p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amount exchanged <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,332)</p></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_xUrXavuJzEKCYO2cJuMBNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Loss on the Convertible Loan extinguishment</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,863</p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,633</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:justify;margin:0pt 3pt 0pt 0pt;">(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the detemination of fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7 , &#8220;<i style="font-style:italic;">Convertible Loan&#8221;</i>).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The computation of basic EPS is based on the weighted-average number of the Company&#8217;s Common Stock outstanding. The computation of diluted EPS is based on the weighted-average number of the Company&#8217;s Common Stock outstanding and potential dilutive Common Stock. Diluted EPS is computed using the more dilutive of the treasury stock method, which reflects the potential dilution that would occur if securities or other contracts to issue Common Stock were exercised or converted to the Company&#8217;s Common Stock. Common Stock options, warrants and unvested restricted stock units were not included in dilutive EPS as their impact would be antidilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the years ended December 31, 2024 and 2023 (in thousands, except share and per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,916)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain from change in fair value of the Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,399)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on debt and the Convertible Loan extinguishments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,166)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52,481)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,160,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,075,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares issuable upon the conversion of the Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22,899,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 59,059,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,075,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.52)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following outstanding securities as of December 31, 2024 and 2023 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,755,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of the Convertible Loan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,293,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,341,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,024,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) The Company determined the number of shares issuable upon the conversion of the Convertible Loan as of December 2023, based on the Convertible Loan principal amount of $30.0 million, accrued and unpaid interest of $2.4 million, calculated at an annual interest rate of 8%, converted at $1.52 per share.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Balance Sheet Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment as of December 31, 2024 and 2023 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,678</p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 438</p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,447</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,380</p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,821)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,559</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense totaled $1.3 million and $1.0 million for the&#160;years ended December 31, 2024 and 2023, respectively. Property and equipment not in use was $8.3 million and $8.1 million as of December 31, 2024 and 2023, respectively, and is included in the laboratory equipment in the table above. These assets are not depreciated until they are placed in service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Receivables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other receivables as of December 31, 2024 and 2023 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tenant improvement allowance receivable (Note 12)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,835</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant and award receivable (Note 13)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 744</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,528</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 744</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,363</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounts Payable and Accrued Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 766</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,585</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical trial expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 828</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,021</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 461</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,083</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,055</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,689</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ConvertibleDebtDisclosureTextBlock', window );">Convertible Loan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Convertible Loan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 10, 2023, the Company received the Convertible Loan in the aggregate amount of $30.0 million from Innoviva pursuant to the Convertible Credit Agreement. The Convertible Loan bears interest at a rate of 8.0% per annum and was scheduled to mature on January 10, 2024. The Convertible Credit Agreement was amended on July 10, 2023, in connection with the Company&#8217;s entry into the 2023 Credit Agreement to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. Then, on March 12, 2025, the Company executed a subsequent amendment to the Convertible Credit Agreement which, among other things, extended the Convertible Loan maturity date to March 12, 2026. The Convertible Loan principal and accrued interest are payable at maturity. Repayment of the Convertible Loan is guaranteed by the Company&#8217;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> The Convertible Credit Agreement provides that if there is a financing from new investors of at least </span>$30.0 million (a &#8220;Qualified Financing&#8221;), the outstanding principal amount of and all accrued and unpaid interest on the Convertible Loan shall be converted into shares of the Company&#8217;s Common Stock, at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in such Qualified Financing. The Convertible Credit Agreement also required the Company to file a registration statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender&#8217;s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52 (as may be appropriately adjusted for any stock split, combination or similar act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated authoritative guidance for accounting for the Convertible Loan and concluded that the Convertible Loan should be accounted for at fair value under ASC 480, Distinguish Liabilities from Equity, due to the fact that the Convertible Loan will predominately be settled with the Company&#8217;s Common Stock. Consequently, the Company recorded the Convertible Loan in its entirety at fair value on its consolidated balance sheet, with changes in fair value recorded as other income (expenses) in the consolidated statements of operations during each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On July 10, 2023, in connection with the 2023 Credit Agreement with Innoviva, as discussed below, the Company amended the terms of the Convertible Credit Agreement, to, among other changes, extend the maturity of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Convertible Loan to January 10, 2025. The Company concluded that the amendment was an extinguishment for accounting purposes. The Company recognized a $1.8 million gain as the change in fair value of the Convertible Loan before the extinguishment date, July 10, 2023. The Company estimated fair value of the combined transaction, the Loan and the Convertible Loan, before and after modification and calculated an extinguishment loss of $3.9 million, which was recognized as other income (expense) in the consolidated statement of operations for the year ended December 31, 2023. The Company recognized losses of $23.6 million from July 10, 2023 to December 31, 2023 as the change in fair value of the Convertible Loan post modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 12, 2024, the Company amended the terms of the Convertible Credit Agreement and 2023 Credit Agreement, to, among other changes, extend the maturity of both loans to January 10, 2026. The Company concluded that the amendments were a combined transaction and an extinguishment for accounting purposes. The Company estimated fair value of the combined transaction, the 2023 Loan and the Convertible Loan, before and after modification and calculated an extinguishment gain of $2.2 million, which was recognized as other income (expense) in the consolidated statement of operations for the year ended December 31, 2024. After this amendment, the Company continued to account for the Convertible Loan at fair value on its consolidated balance sheet, with changes in fair value recorded as other income (expense) in the consolidated statements of operations during each reporting period. The Company recognized $31.4 million as the change in fair value of the Convertible Loan for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 12, 2025, the Company executed an amendment to the Convertible Credit Agreement which, among other things, extended the Convertible Loan maturity date to March 12, 2026.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ConvertibleDebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ConvertibleDebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Term Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Term Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">On July 10, 2023, the Company entered into the 2023 Credit Agreement. The 2023 Credit Agreement provides for the 2023 Loan, a secured term loan facility in an aggregate amount of $25.0&#160;million at an interest rate of&#160;14.0% per annum, and was scheduled to mature on January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the 2023 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the 2023 Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">On November 12, 2024, the Company executed an amendment to the 2023 Credit Agreement, which, among other things, extended the 2023 Loan maturity date to January 10, 2026. On March 12, 2025, the Company executed a subsequent amendment to the 2023 Credit Agreement which, among other things, extended the 2023 Loan maturity date to March 12, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The 2023 Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The 2023 Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#8220;material adverse effect&#8221; as set forth in the 2023 Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company&#8217;s operating budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The 2023 Loan was initially recognized at fair value of $21.2&#160;million and subsequently recognized at the amortized cost net of debt issuance costs and debt discount of $3.8 million. The Company recognized $2.4 million and $0.9 million debt issuance costs and debt discount for the years ended December 31, 2024 and 2023, respectively, using the effective interest method. The Company recognized $6.7 million and $2.6 million of accrued interest expense for the years ended December 31, 2024 and 2023, respectively.<span style="font-size:12pt;"> </span>The 2023 Loan&#8217;s annual effective interest rate was&#160;48.76% and 27.31% as of December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 4, 2024, the Company entered into the 2024 Credit Agreement for the 2024 Loan in an aggregate amount of $35.0 million. The 2024 Loan bears interest at an annual rate of&#160;14.0% and was scheduled to mature on June 4, 2025. On March 12, 2025, the Company executed an amendment to the 2024 Credit Agreement which, among other </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">things, extended the 2024 Loan maturity date to March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2024 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the 2024 Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2024 Loan was initially recognized at cash proceeds of $35.0 million net of debt issuance costs of $0.1 million, and subsequently is recognized at the amortized cost. Debt issuance costs are amortized using the effective interest method to interest expense over the term of the 2024 Loan. The Company recognized $4.1 million of accrued interest expense for the year ended December 31, 2024. The 2024 Loan&#8217;s annual effective interest rate was 14.25% as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2023 Credit Agreement and the 2024 Credit Agreement contain customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The 2023 Credit Agreement and the 2024 Credit Agreement also include customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#8220;material adverse effect&#8221; as set forth in the 2023 Credit Agreement and the 2024 Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company&#8217;s operating budget.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Stockholders&#8217; Deficit</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 outstanding warrants to purchase shares of Common Stock were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 993,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February 11, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,717,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 27, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,867,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">January 26, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,285,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,807,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February 8, 2027</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,692,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 30, 2027</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 1,680.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">None</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shares Reserved for Future Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024 and 2023, the Company had reserved shares of its Common Stock for future issuance as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,755,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,165,216</p></td></tr><tr><td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,000</p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable under the Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,748</p></td></tr><tr><td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,405,908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,368,160</p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,365,847</p></td></tr><tr><td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of the Convertible Loan<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,899,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,293,861</p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,658,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,402,832</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Award Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#8217;s Board of Directors to its employees, directors and officers and to consultants. The term of the options granted is ten years, the exercise price is the Company&#8217;s closing price at the date of grant and the vesting period is usually four years<span style="white-space:pre-wrap;">. The Company also granted RSUs under the 2016 Plan that vest over four years.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2016 Plan, the number of shares authorized for issuance is automatically increased by a number equal to 5% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Board of Directors annually beginning from January 1, 2017 until January 1, 2026. As of December 31, 2024, there were 3,405,908 shares available for issuance under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has issued restricted stock awards RSAs under certain legacy option plans that generally vested&#160;<span style="-sec-ix-hidden:Hidden_GZ0DQ00E2US7iMhH9yvSLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span>&#160;to&#160;four years&#160;based on service conditions. As of December 31, 2024, all RSAs were fully vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to its 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), the Company may grant or provide for the grant of rights to purchase shares of its Common Stock. The number of shares of its Common Stock reserved for issuance under the ESPP will automatically increase on January 1st of each calendar year by the lesser of 1% of the total number of shares of the Company&#8217;s Common Stock outstanding on December 31st of the preceding calendar year and 30,000 shares, subject to the ability of the Company&#8217;s Board of Directors to take action to reduce the size of the increase in any given year. There were no awards issued under ESPP. As of December 31, 2024, the Company had reserved 11,890 shares for future grants under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock option activities during the year ended December 31, 2024 are presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 429</p></td></tr><tr><td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,859,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,282)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,231,023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,755,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,755,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,059,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The aggregate intrinsic value of options at December 31, 2024 is based on the Company&#8217;s closing stock price on that date of $1.85 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The weighted average grant date fair value of the options granted during 2024 and 2023 was $2.54 and $1.97, respectively. The fair value of vested options during the year ended December 31, 2024 and 2023 was $2.8 million and $5.1 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Restricted stock awards and restricted stock unit award activities during the year ended December 31, 2024 are presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Avg</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td></tr><tr><td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 90,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.38</p></td></tr><tr><td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td></tr><tr><td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.38</p></td></tr><tr><td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.73</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024, there was $2.6 million of total unrecognized compensation expense related to unvested stock options and restricted stock units, which the Company expects to recognize over the weighted average remaining period of approximately <span style="-sec-ix-hidden:Hidden_gW2qZueRtk-fdI8-fDXRnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.9 years</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.35pt;margin:0pt;"><span style="font-size:7.35pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The assumptions used to estimate the options fair value were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:45.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.54%-4.25%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.54%-5.54%</p></td></tr><tr><td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">89.40%-92.50%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">75.40%-116.96%</p></td></tr><tr><td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.1-7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.1-7.0</p></td></tr><tr><td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The tables below summarize the total stock-based compensation expense (reversal) included in the Company&#8217;s consolidated statements of operations for the periods presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,013</p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75)</p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 938</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Loss before income taxes consisted of the following components (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style="height:7.25pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68,182)</p></td></tr><tr><td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (896)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (863)</p></td></tr><tr><td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,916)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 53,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,591</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,431</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,083</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 856</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease accounting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,899</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,907</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets before valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 97,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 86,767</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (84,217)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,166)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,601</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,763)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,510)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Debt basis differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,991)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (141)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (91)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,972)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,678)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss carryforwards at December&#160;31, 2024 are $195.3 million, $139.2 million and $12.0 for federal, state and foreign income tax purposes, respectively. Federal and state net operating loss carryforwards are available to offset future taxable income, if any, and will begin to expire in 2026 and 2029, respectively. The federal net operating loss carryforwards generated after 2017 of $140.8 million will carryforward indefinitely and can be used to offset up to 80% of future annual taxable income. The Company's foreign net operating loss carryforwards do not expire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss carryforwards may be subject to a substantial annual limitation as a result of ownership changes that have occurred or could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit or eliminate the amount of net operating loss carryforwards that can be utilized to offset future taxable income. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. In general, an 'ownership change' as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an &#8216;ownership change&#8217; of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not undergone an ownership change analysis pursuant to Internal Revenue Code Section 382 as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.  Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of available evidence, including the Company's history of operating losses, management has determined that it is more likely than not that the Company&#8217;s net deferred tax assets will not be realized. Accordingly, a valuation allowance has been established by the Company to fully offset these net deferred tax assets. The Company increased its valuation allowance by approximately </span>$9.1 million during the year ending December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments for tax effects of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State income taxes, net of federal tax</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.6</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.9</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.7)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-deductible debt items</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 25.3</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7.8)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49.7)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.3)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(3.3)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Return to provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.7)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Permanent differences and other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1.4)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1.2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction, state of California and certain foreign jurisdictions. As of December 31, 2024, the Company is no longer subject to U.S. federal income tax examinations for tax years ended on or before December 31, 2020 or to California state income tax examinations for tax years ended on or before December 31, 2019. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses or tax credits were generated and carried forward, and make adjustments up to the amount of the net operating loss or credit carryforward.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not have a liability for unrecognized tax benefits at December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s policy is to classify interest and penalties on uncertain tax positions as a component of tax expense. As of December&#160;31, 2024 and 2023, the Company has no accrued interest or penalties related to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes have not been provided for undistributed earnings of the Company&#8217;s consolidated foreign subsidiary because the parent entity would not be required to include the distribution into income as the amount would be tax free.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Tax Cuts and Jobs Act subjects a U.S. stockholder to tax on GILTI earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740 No. 5. Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election either to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA, with the lease term through December 31, 2031. Annual base rent is from $1.9 million and increases by 3% annually and will be $2.5 million by the end of the term. The Company also maintains an irrevocable letter of credit in connection with this lease, which had a balance of $0.5 million as of December 31, 2024 and is reducing 20% annually through the end of the lease term<span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the &#8220;2021 Lease&#8221;). The 2021 Lease payment start date was May 1, 2022 and the total lease term is for 16 years and runs through 2038. Monthly rent for 2022 and 2023 was fully or partially abated while the lessor and the Company completed planned tenant improvements to the facility. Base monthly rent is approximately $0.3 million in 2024. The Company was responsible for construction costs over the tenant improvements allowance of $7.2 million. The construction was completed as of December 31, 2024, and the Company received the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">full allowance. Out-of-pocket expenses to be incurred by the Company were considered noncash lease payments, and included in the lease liability and right-of-use asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">In connection with the execution of the 2021 Lease, the Company delivered an irrevocable standby letter of credit in the amount of $5.0 million to the landlord in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future minimum annual lease payments under the Company&#8217;s noncancelable operating leases as of December&#160;31, 2024, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,716</p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,293</p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,452</p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,616</p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,784</p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,996</p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 64,857</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: amount representing interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,732)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of operating lease obligations </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 32,125</p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,431)</p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noncurrent operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,694</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#222222;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Operating lease expenses were $8.4 million and $7.4 million for the years ended December 31, 2024 and 2023, respectively. Variable costs related to operating expenses and taxes, which are recognized as incurred, were $1.7 million and $1.0 million for the years ended December 31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes supplemental cash flow information related to the Company&#8217;s operating leases for the years ended December 31, 2024 and 2023 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:72.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,839</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company&#8217;s operating leases as of December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term, years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">11.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.8pt;text-align:right;text-indent:-0.8pt;margin:0pt 0pt 0pt -2pt;">12.79</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate, %</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">13.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">13.9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#8217;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#8217;s reputation and business. The Company is currently not a party to any legal proceedings, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on its consolidated results of operations or financial position.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant and Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardAbstract', window );"><strong>Grant and Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardTextBlock', window );">Grant and Awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Grants and Awards </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MTEC Grant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2020, the Company entered into an agreement (the &#8220;MTEC Agreement&#8221;) with MTEC, pursuant to which the Company received a $15.0 million&#160;award and entered into a multi-year program administered by the DoD through MTEC and managed by the Naval Medical Research Command (&#8220;NMRC&#8221;) &#8211; Naval Advanced Medical Development (&#8220;NAMD&#8221;) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. <span style="background:#ffffff;">On September 29, 2022, the MTEC Agreement was modified to increase the total award by </span><span style="background:#ffffff;">$1.3</span><span style="background:#ffffff;">&#160;million to </span><span style="background:#ffffff;">$16.3</span><span style="background:#ffffff;">&#160;million and extend the term into the third quarter of 2024. </span>In July 2024, the MTEC Agreement was modified to <span style="-sec-ix-hidden:Hidden_jN3anHbpa0isGOdK9gp3IA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase</span></span> the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025. The Company is using the award to partially fund a Phase&#160;1b/2a, randomized, double-blind, placebo-controlled, dose escalation clinical study of the Company&#8217;s therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;<i style="font-style:italic;">S. aureus</i>&#160;bacteremia infections. The MTEC Agreement specifies that the award will be paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the money received is not refundable to MTEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MTEC Agreement is effective through August 15, 2025.&#160;The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue in the statement of operations when related costs are incurred. The Company recognized $5.2 million and $4.5 million in grant revenue from the MTEC Agreement during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the Company had $0.7&#160;million and $1.5&#160;million as awards receivable from MTEC, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CFF Therapeutics Development Award</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 13, 2020, the Company entered into an award agreement (the &#8220;Award Agreement&#8221;) with Cystic Fibrosis Foundation (&#8220;CFF&#8221;), pursuant to which the Company received a Therapeutics Development Award of up to $5.0 million (the &#8220;CFF Award&#8221;). The CFF Award was used to fund a portion of the Company&#8217;s Phase 1b/2a clinical trial of the&#160;<i style="font-style:italic;">Pseudomonas aeruginosa </i>(&#8220;<i style="font-style:italic;">P. aeruginosa</i>&#8221;)<i style="font-style:italic;"> </i>phage candidate, AP-PA02, as a treatment for Pseudomonas airway infections in people with cystic fibrosis (&#8220;CF&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The first payment under the Award Agreement, in the amount of $1.0 million, became due upon signing the Award Agreement and was received in April 2020. The remainder of the CFF Award was payable to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement. The total amount of the CFF award was recognized through December 2023 and no additional payments are expected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Award Agreement), for a period of 360 days (an &#8220;Interruption&#8221;) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the Product for use in treating infections in CF patients (the &#8220;CF Field&#8221;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span></span>The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company&#8217;s material failure to achieve certain development milestones. The Company&#8217;s payment obligations survive the termination of the Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the CFF Award is in the scope of ASC 808. Accordingly, as discussed in Note 3, &#8220;<i style="font-style:italic;">Significant Accounting Policies&#8221;</i>, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. During year ended December 31, 2024 and 2023, the Company recognized zero and $0.3 million as credits to research and development expenses related to the CFF Award, respectively. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about award abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>represents about award text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Retirement Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Retirement Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Employee Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s employees participate in an employee retirement plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986, as amended. All of the Company&#8217;s employees who meet minimum eligibility requirements are eligible to participate in the plan. The Company did match contributions of $0.2 million to the 401(k)&#160;plan for the&#160;years ended December 31, 2024 and 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Segment Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">The Company operates and manages its business as </span><span style="background:#ffffff;">one</span><span style="background:#ffffff;"> reportable operating segment, which is the business of developing a pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;). The Company&#8217;s CODM is its Chief Executive Officer, who reviews financial information on an aggregate basis for </span>purposes of assessing performance, making operating decisions, <span style="background:#ffffff;">allocating resources and evaluating financial performance. The long-lived assets of </span><span style="background:#ffffff;">$14.0</span><span style="background:#ffffff;"> million, which represents </span><span style="background:#ffffff;">99.3%</span><span style="background:#ffffff;"> of the Company&#8217;s total long-lived assets, are maintained in the United States.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table includes certain segment information for the years ended December 31, 2024 and 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:37.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant revenue</b></p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,174</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,529</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses:</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-PA02: Non-Cystic Fibrosis Bronchiectasis</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,840</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,922</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-PA02: Cystic Fibrosis</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 236</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,692</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-SA02: Bacteremia</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,177</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,789</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-SA02Prosthetic Joint Infection</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Expenses not allocated by projects</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,408</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,042</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Total external research and development expenses</span></p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,696</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,647</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development personnel expenses</p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,764</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,408</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other research and development expenses</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,966</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,715</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Total research and development expenses</span></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 34,426</p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,770</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses:</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative personnel expenses</p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,935</p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,480</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other general and administrative expenses</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,249</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,169</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Total general and administrative expenses</span></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,184</p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,649</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses </p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 47,610</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 45,419</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,436)</p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,890)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense), net</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,520</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,155)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,916)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On March 12, 2025, the Company entered into the 2025 Credit Agreement for the 2025 Loan in an aggregate amount of </span><span style="background:#ffffff;">$10.0</span><span style="background:#ffffff;">&#160;million.The 2025 Loan bears interest at an annual rate of&#160;</span><span style="background:#ffffff;">14.0%</span><span style="background:#ffffff;"> and matures on March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2025 Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Concurrently with the execution of the 2025 Credit Agreement, the Company entered into amendments to (i) the Convertible Loan and Convertible Credit Agreement, (ii) the 2023 Loan and 2023 Credit Agreement, and (iii) the 2024 Loan and 2024 Credit Agreement, which, among other things, extended the maturity date of the Convertible Loan, 2023 Loan and 2024 Loan, respectively, to March 12, 2026.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (18,916)<span></span>
</td>
<td class="num">$ (69,045)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cybersecurity Risk Management and Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include operational risks, intellectual property or trade secret theft, improper disclosure of confidential information, fraud, extortion, harm to employees or customers, and violation of data privacy or security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cybersecurity risks related to our business, technical operations, privacy, and compliance issues are identified and addressed through a multi-faceted approach including third-party assessments, internal information technology (&#8220;IT&#8221;) audits, and IT security reviews. To defend, detect, and respond to cybersecurity incidents, we perform cybersecurity reviews of systems and applications; audits of applicable data policies; vulnerability assessments and penetration testing using external third-party tools to test security control; security incident and event management; continuous monitoring, and threat intelligence gathering; conduct employee training; and implement appropriate changes. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We leverage third-party expertise to audit and test our cybersecurity program and perform employee awareness training. These include periodic reviews of cybersecurity threats and related controls, including review of periodic penetration testing conducted by independent third parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We maintain a cyber liability insurance plan underwritten by multiple insurance companies, which provides protection against certain potential losses arising from cybersecurity incidents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Our business strategy, results of operations and financial condition have not been materially affected by risks from cybersecurity threats, including as a result of previously identified cybersecurity incidents, but we cannot provide assurance that they will not be materially affected in the future by such risks or any future material incidents. For more information on our cybersecurity related risks, see Item 1A Risk Factors of this Annual Report on Form 10-K.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include operational risks, intellectual property or trade secret theft, improper disclosure of confidential information, fraud, extortion, harm to employees or customers, and violation of data privacy or security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cybersecurity risks related to our business, technical operations, privacy, and compliance issues are identified and addressed through a multi-faceted approach including third-party assessments, internal information technology (&#8220;IT&#8221;) audits, and IT security reviews. To defend, detect, and respond to cybersecurity incidents, we perform cybersecurity reviews of systems and applications; audits of applicable data policies; vulnerability assessments and penetration testing using external third-party tools to test security control; security incident and event management; continuous monitoring, and threat intelligence gathering; conduct employee training; and implement appropriate changes. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We leverage third-party expertise to audit and test our cybersecurity program and perform employee awareness training. These include periodic reviews of cybersecurity threats and related controls, including review of periodic penetration testing conducted by independent third parties. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cybersecurity Governance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cybersecurity is an important part of our risk management processes and an area of focus for our Board of Directors (&#8220;Board of Directors&#8221;) and management. Our Board of Directors delegated oversight of Cybersecurity to the Audit Committee. Members of our Board of Directors receive reports and presentations on data privacy and security, which address relevant cybersecurity issues, and which can span a wide range of topics, including but not limited to, recent developments, evolving standards, vulnerability assessments, review of risks from third parties such as service providers and suppliers, and the current threat environment. These updates are presented by IT third-party experts, finance, and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">legal departments. Members of our Board of Directors also engage in ad hoc conversations with management on cybersecurity-related news events and updates to our cybersecurity risk management and strategy programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Audit Committee&#8217;s cybersecurity-related oversight includes the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Receiving notice of, and providing guidance with respect to, material cybersecurity incidents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing our risks and cybersecurity programs and policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Overseeing our management and mitigation of cybersecurity risks and potential breach incidents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing reports and key metrics on the Company&#8217;s cybersecurity and related risk management programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing the progress of major technology-related proposals, plans, projects and architecture decisions to ensure that these projects and decisions support our overall business strategy.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Audit Committee<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board of Directors delegated oversight of Cybersecurity to the Audit Committee. Members of our Board of Directors receive reports and presentations on data privacy and security, which address relevant cybersecurity issues, and which can span a wide range of topics, including but not limited to, recent developments, evolving standards, vulnerability assessments, review of risks from third parties such as service providers and suppliers, and the current threat environment. These updates are presented by IT third-party experts, finance, and legal departments. Members of our Board of Directors also engage in ad hoc conversations with management on cybersecurity-related news events and updates to our cybersecurity risk management and strategy programs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Audit Committee&#8217;s cybersecurity-related oversight includes the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Receiving notice of, and providing guidance with respect to, material cybersecurity incidents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing our risks and cybersecurity programs and policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Overseeing our management and mitigation of cybersecurity risks and potential breach incidents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing reports and key metrics on the Company&#8217;s cybersecurity and related risk management programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing the progress of major technology-related proposals, plans, projects and architecture decisions to ensure that these projects and decisions support our overall business strategy.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">management<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our management engages with third-party experts who have significant IT expertise and broad cybersecurity experience, including in cybersecurity threat management, cybersecurity training and education, incident response, cyber forensics, insider threats, business continuity and disaster recovery, and regulatory compliance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">individuals have significant prior work experience in various roles involving IT security, auditing, compliance, systems, and programming. These individuals are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents and design.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the Convertible Loan, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risks and Certain Other Risks</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;">Concentration of Credit Risks and Certain Other Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and restricted cash. As of December 31, 2024 and 2023, cash, cash equivalents and restricted cash were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions in accordance with the Company&#8217;s investment policy, to a concentration limit per issuer or sector.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Other receivables represent amounts due from the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;) (Note 13, &#8220;</span><i style="font-style:italic;background:#ffffff;">Grants and Awards&#8221;</i><span style="background:#ffffff;">) and reimbursement for tenant improvements (Note 12, &#8220;</span><i style="font-style:italic;background:#ffffff;">Commitments and Contingencies</i><span style="background:#ffffff;">&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.26;margin:8pt 0pt 4pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cash and cash equivalents consist primarily of cash deposits and marketable securities with original maturities of less than three months.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of two irrevocable letters of credit with financial institutions related to the Company&#8217;s operating leases (Note 12 , &#8220;<i style="font-style:italic;">Commitments and Contingencies</i>&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;white-space:pre-wrap;"> Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, Convertible Loan and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The Convertible Loan is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5 &#8211; 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3 &#8211; 5 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-Eh2dCRyZEObk0oB6hPNcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter of lease term or useful life</span></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. No impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2024 or 2023. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development ("IPR&amp;D")</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">In-Process Research and Development (&#8220;IPR&amp;D&#8221;) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;"> IPR&amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#8217;s IPR&amp;D assets represent capitalized in-process bacteriophage development programs for </span><i style="font-style:italic;">S. aureus</i> infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company tests IPR&amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when a quantitative analysis of IPR&amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#8217;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#8217;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, the Company performed the annual evaluation of its IPR&amp;D assets for impairment. The Company considered the development timelines for its <i style="font-style:italic;">S. aureus</i> development program and noted no qualitative factors that would indicate potential impairment of its IPR&amp;D asset. The Company also performed a quantitative analysis for impairment analysis and based on this analysis, the fair value of this bacteriophage program was greater than its carrying value as of December&#160;31, 2024. Consequently, no impairment was noted for the IPR&amp;D asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company performed the annual evaluation of its IPR&amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for <i style="font-style:italic;">S. aureus</i> infections was greater than its carrying value as a result of the quantitative analysis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No impairment loss was recognized as of December 31, 2024 and 2023. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#8217;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted no impairment as of December 31, 2024 and 2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) is determined based on the number of units granted and the closing price of the Company&#8217;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translations and Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Foreign Currency Translations and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. <span style="background:#ffffff;">Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the quarterly average exchange rate in effect during the </span>year.&#160;<span style="background:#ffffff;">Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#8217;s consolidated statement of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_GrantsAndAwardsPolicyTextBlock', window );">Grants Revenue and Other Awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grants Revenue and Other Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether agreements are within the scope of ASC Topic 606, <i style="font-style:italic;">Revenue from contracts with customers</i> (&#8220;ASC 606&#8221;) or other topics at the effective date of an agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;<i style="font-style:italic;">Collaborative Arrangements</i>&#160;(&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;<i style="font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</i>, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also considers the guidance in ASC Topic 730,&#160;<i style="font-style:italic;">Research and Development&#160;</i>(&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability<i style="font-style:italic;">.&#160;</i>If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024 and 2023, the Company recognized as other receivables in its consolidated balance sheets $0.7 million and $1.5 million, respectively, related to invoiced grant amounts that have not been received. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2024 and 2023, as such, the comprehensive income (loss) for these periods was equal to the net loss. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;">Basic and Diluted Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. </span>Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.<span style="background:#ffffff;"> The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 standard in the fourth quarter of 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. Refer to Note 15.&#160;&#8220;<i style="font-style:italic;">Segment Reporting&#8221;</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#212529;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"><span style="color:#212529;background:#ffffff;">In August 2020, the FASB issued ASU 2020-06, Debt - </span><i style="color:#212529;font-style:italic;background:#ffffff;">Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</i><span style="color:#212529;background:#ffffff;"> (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted earnings (loss) per share (&#8220;EPS&#8221;) computation. The Company adopted this ASU as of January 1, 2024, which did not have an impact on its consolidated financial statements or related disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">On October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#8217;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): <i style="font-style:italic;">Improvements to Income Tax Disclosures</i>. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In November 2024, the FASB issued Accounting Standards Update ASU 2024-03 Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40):<i style="font-style:italic;"> Disaggregation of Income Statement Expenses</i>. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#8217;s consolidated financial statement disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_GrantsAndAwardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about the grants and awards policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_GrantsAndAwardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_PropertyAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of useful lives of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5 &#8211; 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3 &#8211; 5 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-Eh2dCRyZEObk0oB6hPNcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter of lease term or useful life</span></span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_PropertyAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of property and equipment including, but not limited to, laboratory equipment, office and computer equipment, and leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_PropertyAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of assets and liabilities measured at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investments in money market fund &#8211; financial assets, included in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan&#8211; financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,897</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:middle;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan&#8211; financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,633</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of estimated the fair value of its Convertible Loan using inputs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15.67%-28.28%</p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.01%-45.88%</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probabilities of settlement scenarios</p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%-75%</p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%-85%</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility </p></td><td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">83.30%-111.60%</p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.1%-123.6%</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.10-1.20</p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.20-1.50</p></td></tr><tr><td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.08%-5.33%</p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.62%-5.39%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of changes in the fair value of its Convertible Loan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents a summary of the changes in the fair value of its Convertible Loan for the years ended December 31, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net issuance of the Convertible Loan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,226</p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial recognition of modified Convertible Loan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,031</p></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,399)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,845</p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amount exchanged <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,332)</p></td></tr><tr><td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_xUrXavuJzEKCYO2cJuMBNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Loss on the Convertible Loan extinguishment</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,863</p></td></tr><tr><td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible Loan at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,633</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:justify;margin:0pt 3pt 0pt 0pt;">(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the detemination of fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7 , &#8220;<i style="font-style:italic;">Convertible Loan&#8221;</i>).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the years ended December 31, 2024 and 2023 (in thousands, except share and per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,916)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain from change in fair value of the Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,399)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on debt and the Convertible Loan extinguishments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,166)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52,481)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,160,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,075,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares issuable upon the conversion of the Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22,899,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 59,059,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,075,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.52)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,755,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of the Convertible Loan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,293,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,341,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,024,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) The Company determined the number of shares issuable upon the conversion of the Convertible Loan as of December 2023, based on the Convertible Loan principal amount of $30.0 million, accrued and unpaid interest of $2.4 million, calculated at an annual interest rate of 8%, converted at $1.52 per share.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment as of December 31, 2024 and 2023 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,678</p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 438</p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,447</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,380</p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,821)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,559</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ScheduleOfOtherReceivablesCurrentTableTextBlock', window );">Schedule of Other receivables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other receivables as of December 31, 2024 and 2023 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tenant improvement allowance receivable (Note 12)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,835</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant and award receivable (Note 13)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 744</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,528</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 744</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,363</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 766</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,585</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical trial expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 828</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,021</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 461</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,083</p></td></tr><tr><td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,055</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,689</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ScheduleOfOtherReceivablesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ScheduleOfOtherReceivablesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 993,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February 11, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,717,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 27, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,867,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">January 26, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,285,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,807,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February 8, 2027</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,692,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 30, 2027</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 1,680.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">None</p></td></tr><tr><td style="vertical-align:bottom;width:36.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Shares Reserved for Future Issuance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,755,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,165,216</p></td></tr><tr><td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 200,000</p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable under the Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,748</p></td></tr><tr><td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,405,908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,368,160</p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,365,847</p></td></tr><tr><td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of the Convertible Loan<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,899,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,293,861</p></td></tr><tr><td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,658,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,402,832</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 429</p></td></tr><tr><td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,859,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,282)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,231,023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,755,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,755,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,059,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock', window );">Schedule of restricted stock awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Avg</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td></tr><tr><td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 90,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.38</p></td></tr><tr><td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td></tr><tr><td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.38</p></td></tr><tr><td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 220,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.73</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in the Black-Scholes Model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:45.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.54%-4.25%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.54%-5.54%</p></td></tr><tr><td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">89.40%-92.50%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">75.40%-116.96%</p></td></tr><tr><td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.1-7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.1-7.0</p></td></tr><tr><td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The tables below summarize the total stock-based compensation expense (reversal) included in the Company&#8217;s consolidated statements of operations for the periods presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,013</p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75)</p></td></tr><tr><td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 938</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were assumed in merger during the reporting period pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of (Loss) Income from Continuing Operations Before Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Loss before income taxes consisted of the following components (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style="height:7.25pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68,182)</p></td></tr><tr><td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (896)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (863)</p></td></tr><tr><td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,916)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 53,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,591</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,431</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,083</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 856</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease accounting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,899</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,907</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets before valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 97,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 86,767</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (84,217)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,166)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,601</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,763)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,510)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Debt basis differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,991)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (141)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (91)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,972)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,678)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td></tr><tr><td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Statutory to Effective Tax Rates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments for tax effects of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State income taxes, net of federal tax</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.6</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.9</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.7)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-deductible debt items</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 25.3</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7.8)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49.7)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.3)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(3.3)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Return to provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.7)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Permanent differences and other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1.4)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1.2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future minimum annual lease payments under the Company&#8217;s noncancelable operating leases as of December&#160;31, 2024, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,716</p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,293</p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,452</p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,616</p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,784</p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,996</p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 64,857</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: amount representing interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,732)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of operating lease obligations </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 32,125</p></td></tr><tr><td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,431)</p></td></tr><tr><td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noncurrent operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,694</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes supplemental cash flow information related to the Company&#8217;s operating leases for the years ended December 31, 2024 and 2023 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:72.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18,839</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term, years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">11.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.8pt;text-align:right;text-indent:-0.8pt;margin:0pt 0pt 0pt -2pt;">12.79</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate, %</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">13.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">13.9</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of certain segment information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:37.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant revenue</b></p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,174</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,529</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses:</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-PA02: Non-Cystic Fibrosis Bronchiectasis</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,840</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,922</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-PA02: Cystic Fibrosis</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 236</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,692</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-SA02: Bacteremia</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,177</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,789</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">AP-SA02Prosthetic Joint Infection</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> Expenses not allocated by projects</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,408</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,042</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Total external research and development expenses</span></p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,696</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,647</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development personnel expenses</p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,764</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,408</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other research and development expenses</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,966</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,715</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Total research and development expenses</span></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 34,426</p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,770</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses:</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative personnel expenses</p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,935</p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,480</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other general and administrative expenses</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,249</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9,169</p></td></tr><tr><td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">  Total general and administrative expenses</span></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,184</p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,649</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses </p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 47,610</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 45,419</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,436)</p></td><td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40,890)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense), net</p></td><td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23,520</p></td><td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,155)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,916)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>item </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Total debt financing | $</a></td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_NumberOfDirectors', window );">Number of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_NumberOfBoardDirectors', window );">Number of Board Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_CommonStockVotingPercentageHeldPercentage', window );">Total number of shares (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=armp_ArmataPharmaceuticalsInc.Member', window );">Armata Pharmaceuticals, Inc. | Innoviva Strategic Opportunities LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Outstanding equity (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_CommonStockVotingPercentageHeldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting rights of the total number of shares of the common stock of company on matters related to election or removal of board members.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_CommonStockVotingPercentageHeldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NumberOfBoardDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Board directors during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NumberOfBoardDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of directors during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=armp_ArmataPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=armp_ArmataPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity and Going Concern (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (327,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (308,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC | Credit And Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC | Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_CreditAgreement2025Member', window );">2025 Credit Agreement | Innoviva Strategic Opportunities LLC | Secured term loan | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_CreditAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_CreditAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_CreditAgreement2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_CreditAgreement2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash', window );">Letters of credit | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of irrevocable letters of credit with financial institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_OfficeAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_OfficeAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Assets and liabilities at fair value) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Investments in money market fund - financial assets, included in cash and cash equivalents</a></td>
<td class="nump">$ 4,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Loan- financial liabilities</a></td>
<td class="nump">32,897<span></span>
</td>
<td class="nump">$ 58,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Investments in money market fund - financial assets, included in cash and cash equivalents</a></td>
<td class="nump">4,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Loan- financial liabilities</a></td>
<td class="nump">$ 32,897<span></span>
</td>
<td class="nump">$ 58,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details) - Fair Value, Inputs, Level 3<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Discount rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">15.67<span></span>
</td>
<td class="nump">0.2101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Discount rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">28.28<span></span>
</td>
<td class="nump">0.4588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Probabilities of settlement scenarios | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Probabilities of settlement scenarios | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="nump">0.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Volatility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">83.3<span></span>
</td>
<td class="nump">1.011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Volatility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">111.6<span></span>
</td>
<td class="nump">1.236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Expected term (in years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Expected term (in years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Risk-free rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">4.08<span></span>
</td>
<td class="nump">0.0462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Risk-free rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">5.33<span></span>
</td>
<td class="nump">0.0539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DebtInstrumentMeasurementInputForPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instruments, including, but not limited to, convertible and non-convertible debt for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DebtInstrumentMeasurementInputForPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=armp_ProbabilitiesOfSettlementScenariosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=armp_ProbabilitiesOfSettlementScenariosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Changes in Fair Value of Liabilities) (Details) - Fair Value, Inputs, Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Convertible Loan at the beginning of the period</a></td>
<td class="nump">$ 58,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Net issuance of the Convertible Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan', window );">Initial recognition of modified Convertible Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(31,399)<span></span>
</td>
<td class="nump">21,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged', window );">Amount exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,332)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss on the Convertible Loan extinguishment</a></td>
<td class="nump">5,663<span></span>
</td>
<td class="nump">3,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Gain (Loss) on Extinguishment of Debt<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Convertible Loan at the end of the period</a></td>
<td class="nump">$ 32,897<span></span>
</td>
<td class="nump">$ 58,633<span></span>
</td>
<td class="nump">$ 32,897<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount exchanged in financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of initial recognition of modified convertible loan of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Basic and Diluted EPS) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">$ (18,916)<span></span>
</td>
<td class="num">$ (69,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Gain from change in fair value of the Convertible Loan</a></td>
<td class="num">(31,399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt', window );">Gain on debt and the Convertible Loan extinguishments</a></td>
<td class="num">(2,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (52,481)<span></span>
</td>
<td class="num">$ (69,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">36,160,848<span></span>
</td>
<td class="nump">36,075,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Shares issuable upon the conversion of the Convertible Loan</a></td>
<td class="nump">22,899,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">59,059,971<span></span>
</td>
<td class="nump">36,075,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (1.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (1.91)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from gain on debt and extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">23,341,812<span></span>
</td>
<td class="nump">44,024,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC | Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible loan principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued and unpaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">3,755,965<span></span>
</td>
<td class="nump">3,165,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_UnvestedRestrictedStockMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_SharesIssuableUponConversionOfConvertibleLoanMember', window );">Shares issuable upon the conversion of the Convertible Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,293,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">19,365,847<span></span>
</td>
<td class="nump">19,365,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_SharesIssuableUponConversionOfConvertibleLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_SharesIssuableUponConversionOfConvertibleLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment', window );">Property and equipment not in use</a></td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of property and equipment not in use included in laboratory equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 26,387<span></span>
</td>
<td class="nump">$ 24,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(13,146)<span></span>
</td>
<td class="num">(11,821)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">13,241<span></span>
</td>
<td class="nump">12,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">21,316<span></span>
</td>
<td class="nump">19,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 3,802<span></span>
</td>
<td class="nump">$ 3,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Other receivables) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_TenantImprovementReceivableCurrent', window );">Tenant improvement allowance receivable (Note 12)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_GrantAndAwardReceivableCurrent', window );">Grant and award receivable (Note 13)</a></td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">$ 3,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_GrantAndAwardReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of awards receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_GrantAndAwardReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_TenantImprovementReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of current tenant improvement receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_TenantImprovementReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Accounts payable and accrued liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 1,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AccruedLiabilitiesClinicalTrial', window );">Accrued clinical trial expenses</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">3,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts Payable and Accrued Liabilities, Current, Total</a></td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="nump">$ 5,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AccruedLiabilitiesClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AccruedLiabilitiesClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loan (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncreaseDecreaseFairValueOfLiabilities', window );">Change in fair value of the Convertible Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31,399)<span></span>
</td>
<td class="nump">$ 21,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible loan extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,166<span></span>
</td>
<td class="num">(3,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value, gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,399<span></span>
</td>
<td class="num">$ (21,845)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark', window );">Proceeds from qualified financing per agreement benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC | Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice', window );">Discount on share price for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncreaseDecreaseFairValueOfLiabilities', window );">Change in fair value of the Convertible Loan</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible loan extinguishment</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value, gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent  of discount on share price for conversion of debt into shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncreaseDecreaseFairValueOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncreaseDecreaseFairValueOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from qualified financing per agreement benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Debt (Details) - Secured term loan - Innoviva Strategic Opportunities LLC - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Jul. 10, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember', window );">2023 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">48.76%<span></span>
</td>
<td class="nump">27.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Recognized at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt issuance cost and debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember', window );">2024 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">14.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_CreditAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_CreditAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_CreditAgreement2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_CreditAgreement2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Summary of Warrants Outstanding) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">19,365,847<span></span>
</td>
<td class="nump">19,365,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFourMember', window );">Exercise Price $2.87, February 11, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">993,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Feb. 11,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFiveMember', window );">Exercise Price $2.87, March 27, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">7,717,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Mar. 27,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSixMember', window );">Exercise Price $3.25, January 26, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">1,867,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Jan. 26,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSevenMember', window );">Exercise Price $3.25, March 16, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">4,285,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Mar. 16,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceEightMember', window );">Exercise Price $5.00, February 8, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">1,807,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Feb.  08,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceNineMember', window );">Exercise Price $5.00, March 30, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">2,692,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Mar. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceTenMember', window );">Exercise Price 1680.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 1,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the terms related with expiration of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Deficit (Shares Reserved for Future Issuance) (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">3,755,965<span></span>
</td>
<td class="nump">3,165,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares', window );">Shares issuable under the Employee stock purchase plan</a></td>
<td class="nump">11,890<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">19,365,847<span></span>
</td>
<td class="nump">19,365,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_SharesIssuableUponConversionOfConvertibleDebt', window );">Shares issuable upon the conversion of the Convertible Loan</a></td>
<td class="nump">22,899,123<span></span>
</td>
<td class="nump">21,293,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">49,658,733<span></span>
</td>
<td class="nump">46,402,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock units</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants under the 2016 Plan</a></td>
<td class="nump">3,405,908<span></span>
</td>
<td class="nump">2,368,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_SharesIssuableUponConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable upon conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_SharesIssuableUponConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares that, although not legally released, will be released by a future scheduled and committed debt service payment and will be allocated to employees for service rendered in the current accounting period. The ESOP documents typically define the period of service to which the shares relate. ESOP shares are released to compensate employees directly, to settle employer liabilities for other employee benefits, and to replace dividends on allocated shares that are used for debt service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">49,658,733<span></span>
</td>
<td class="nump">46,402,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested options</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of share-based payment award</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants under the 2016 Plan</a></td>
<td class="nump">3,405,908<span></span>
</td>
<td class="nump">2,368,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Equity Incentive Plan 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of share-based payment award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of annual increase in number of shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants under the 2016 Plan</a></td>
<td class="nump">3,405,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=armp_EmployeeStockPurchasePlan2016Member', window );">Employee Stock Purchase Plan 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of annual increase in number of shares</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Additional awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">11,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock closing price</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember', window );">Stock Options And Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested options</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining period for recognition of compensation costs related to unvested options</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of share-based compensation award</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of share-based compensation award</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=armp_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=armp_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=armp_EmployeeStockPurchasePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=armp_EmployeeStockPurchasePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Summary of Stock Option Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Balance Beginning</a></td>
<td class="nump">3,165,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">1,859,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(37,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited/Cancelled/Expired</a></td>
<td class="num">(1,231,023)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Balance Ending</a></td>
<td class="nump">3,755,965<span></span>
</td>
<td class="nump">3,165,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at December 31, 2024</a></td>
<td class="nump">3,755,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2024</a></td>
<td class="nump">2,059,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning</a></td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled/Expired</a></td>
<td class="nump">6.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending</a></td>
<td class="nump">3.74<span></span>
</td>
<td class="nump">$ 5.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest at December 31, 2024</a></td>
<td class="nump">3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2024</a></td>
<td class="nump">$ 4.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Outstanding</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at December 31, 2024</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2024</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Beginning</a></td>
<td class="nump">$ 429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue', window );">Aggregate Intrinsic Value, Forfeited/Cancelled/Expired</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Ending</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2024</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2024</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeited in period intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Restricted stock award and restricted stock unit award activity) (Details) - Restricted stock awards - C3J Stock Plan 2016<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Avg Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">3.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per shares) | $ / shares</a></td>
<td class="nump">2.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">3.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=armp_C3jStockPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=armp_C3jStockPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details) - Common Stock Options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=armp_CommonStockOptionsMember', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">0.0354<span></span>
</td>
<td class="nump">0.0354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">0.894<span></span>
</td>
<td class="nump">0.754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">0.0425<span></span>
</td>
<td class="nump">0.0554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">0.925<span></span>
</td>
<td class="nump">1.1696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_EquitySecuritiesMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_EquitySecuritiesMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=armp_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=armp_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,893<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,230<span></span>
</td>
<td class="num">$ (75)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating Loss Carryforwards, Not Subject to Expiration</a></td>
<td class="nump">$ 140.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Accrued interest or penalties</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">195.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">139.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (18,020)<span></span>
</td>
<td class="num">$ (68,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(896)<span></span>
</td>
<td class="num">(863)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (18,916)<span></span>
</td>
<td class="num">$ (69,045)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Components of Deferred Tax Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 53,618<span></span>
</td>
<td class="nump">$ 46,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Capitalized research and development</a></td>
<td class="nump">24,045<span></span>
</td>
<td class="nump">21,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DeferredTaxAssetLeaseObligation', window );">Lease accounting</a></td>
<td class="nump">13,505<span></span>
</td>
<td class="nump">13,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DeferredTaxAssetsInterestExpenseCarryForwards', window );">Interest expense carryforward</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,086<span></span>
</td>
<td class="nump">1,907<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">97,112<span></span>
</td>
<td class="nump">86,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(84,217)<span></span>
</td>
<td class="num">(75,166)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets after valuation allowance</a></td>
<td class="nump">12,895<span></span>
</td>
<td class="nump">11,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(10,763)<span></span>
</td>
<td class="num">(11,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">In-process research and development</a></td>
<td class="num">(3,077)<span></span>
</td>
<td class="num">(3,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DeferredTaxLiabilitiesDebtBasisDifferences', window );">Debt basis differences</a></td>
<td class="num">(1,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(15,972)<span></span>
</td>
<td class="num">(14,678)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (3,077)<span></span>
</td>
<td class="num">$ (3,077)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DeferredTaxAssetLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DeferredTaxAssetLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DeferredTaxAssetsInterestExpenseCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible interest expense carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DeferredTaxAssetsInterestExpenseCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DeferredTaxLiabilitiesDebtBasisDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from debt basis differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DeferredTaxLiabilitiesDebtBasisDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Adjustments for tax effects of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent', window );">Non-deductible debt items</a></td>
<td class="nump">25.30%<span></span>
</td>
<td class="num">(7.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(49.70%)<span></span>
</td>
<td class="num">(9.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent', window );">Return to provision</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Permanent differences and other</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for debt items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a return to provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AnnualIncreaseInRentPercentage', window );">Annual increase in rent percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Standby letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_BaseAnnualRentToBePaidYearThree', window );">Base annual rent for 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AllowanceForTenantImprovementsReceivable', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense under operating leases</a></td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable lease payment</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_OperatingLeaseBaseAnnual', window );">Annual base rent for operating lease</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_OperatingLeaseBaseAnnual', window );">Annual base rent for operating lease</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Standby letter of credit</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AnnualReductionOfStandbyLetterOfCredit', window );">Annual reduction of standby letter of credit</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AllowanceForTenantImprovementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for tenant improvements receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AllowanceForTenantImprovementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AnnualIncreaseInRentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in rent percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AnnualIncreaseInRentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AnnualReductionOfStandbyLetterOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual reduction of standby letter of credit..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AnnualReductionOfStandbyLetterOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_BaseAnnualRentToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for base rent to be paid in year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_BaseAnnualRentToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_OperatingLeaseBaseAnnual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual base rent for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_OperatingLeaseBaseAnnual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Future Minimum Lease Payments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 4,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">5,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">5,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">5,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">5,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">37,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">64,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(32,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease obligations</a></td>
<td class="nump">32,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(4,431)<span></span>
</td>
<td class="num">$ (9,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease obligations</a></td>
<td class="nump">$ 27,694<span></span>
</td>
<td class="nump">$ 28,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Operating leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 9,010<span></span>
</td>
<td class="nump">$ 18,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, years</a></td>
<td class="text">11 years 8 months 26 days<span></span>
</td>
<td class="text">12 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, %</a></td>
<td class="nump">13.90%<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant and Awards (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2022</div></th>
<th class="th"><div>Mar. 13, 2020</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=armp_MedicalTechnologyEnterpriseConsortiumMember', window );">MTEC Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAwardAmount', window );">Revenue from grants</a></td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAssetIncreaseCurrent', window );">Increase in expected revenue from grants</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Government Assistance, Asset, Increase, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Assets, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Grant revenue from the MTEC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Revenue Not from Contract with Customer<span></span>
</td>
<td class="text">Revenue Not from Contract with Customer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=armp_AwardAgreementWithCysticFibrosisFoundationMember', window );">CFF Therapeutics Development Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Grant revenue from the MTEC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ProceedsFromGovernmentGrants', window );">Proceeds from governments grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardAgreementInterruptionPeriod', window );">Award agreement interruption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=armp_AwardAgreementWithCysticFibrosisFoundationMember', window );">CFF Therapeutics Development Award | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLineItems', window );"><strong>Government Assistance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAwardAmount', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardAgreementInterruptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardAgreementInterruptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow associated with government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAssetIncreaseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset from government assistance, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAssetIncreaseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes increase in asset from government assistance, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=armp_MedicalTechnologyEnterpriseConsortiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=armp_MedicalTechnologyEnterpriseConsortiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=armp_AwardAgreementWithCysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=armp_AwardAgreementWithCysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plan (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Retirement Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution to 401(k) plan</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets | $</a></td>
<td class="nump">$ 13,241<span></span>
</td>
<td class="nump">$ 12,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember', window );">Single Reportable Segment | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets | $</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_PercentageOfLongLivedAssetsInGeographicalLocation', window );">Percentage of long-lived assets</a></td>
<td class="nump">99.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_PercentageOfLongLivedAssetsInGeographicalLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of long lived assets In geographical location.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_PercentageOfLongLivedAssetsInGeographicalLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Segment information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">$ 5,174<span></span>
</td>
<td class="nump">$ 4,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Total research and development expenses</a></td>
<td class="nump">34,426<span></span>
</td>
<td class="nump">33,770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">13,184<span></span>
</td>
<td class="nump">11,649<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">47,610<span></span>
</td>
<td class="nump">45,419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(42,436)<span></span>
</td>
<td class="num">(40,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">23,520<span></span>
</td>
<td class="num">(28,155)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,916)<span></span>
</td>
<td class="num">(69,045)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember', window );">Single Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">5,174<span></span>
</td>
<td class="nump">4,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_UnallocatedExternalResearchAndDevelopmentExpense', window );">Expenses not allocated by projects</a></td>
<td class="nump">2,408<span></span>
</td>
<td class="nump">3,042<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ExternalResearchAndDevelopmentExpenseTotal', window );">Total external research and development expenses</a></td>
<td class="nump">13,696<span></span>
</td>
<td class="nump">14,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ResearchAndDevelopmentPersonnelExpense', window );">Research and development personnel expenses</a></td>
<td class="nump">10,764<span></span>
</td>
<td class="nump">9,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development expenses</a></td>
<td class="nump">9,966<span></span>
</td>
<td class="nump">9,715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Total research and development expenses</a></td>
<td class="nump">34,426<span></span>
</td>
<td class="nump">33,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">General and administrative personnel expenses</a></td>
<td class="nump">4,935<span></span>
</td>
<td class="nump">2,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative expenses</a></td>
<td class="nump">8,249<span></span>
</td>
<td class="nump">9,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">13,184<span></span>
</td>
<td class="nump">11,649<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">47,610<span></span>
</td>
<td class="nump">45,419<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(42,436)<span></span>
</td>
<td class="num">(40,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">23,520<span></span>
</td>
<td class="num">(28,155)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,916)<span></span>
</td>
<td class="num">(69,045)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember', window );">Single Reportable Segment | AP-PA02: Non-Cystic Fibrosis Bronchiectasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ExternalResearchAndDevelopmentExpense', window );">External research and development expenses</a></td>
<td class="nump">6,840<span></span>
</td>
<td class="nump">4,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember', window );">Single Reportable Segment | AP-PA02: Cystic Fibrosis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ExternalResearchAndDevelopmentExpense', window );">External research and development expenses</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember', window );">Single Reportable Segment | AP-SA02: Bacteremia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ExternalResearchAndDevelopmentExpense', window );">External research and development expenses</a></td>
<td class="nump">4,177<span></span>
</td>
<td class="nump">4,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember', window );">Single Reportable Segment | AP-SA02Prosthetic Joint Infection</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ExternalResearchAndDevelopmentExpense', window );">External research and development expenses</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ExternalResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of external research and development expenses incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ExternalResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ExternalResearchAndDevelopmentExpenseTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total external research and development expenses incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ExternalResearchAndDevelopmentExpenseTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ResearchAndDevelopmentPersonnelExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred in connection with research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ResearchAndDevelopmentPersonnelExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_UnallocatedExternalResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of external research and development expense not allocated by projects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_UnallocatedExternalResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=armp_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=armp_NonCysticFibrosisBronchiectasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=armp_NonCysticFibrosisBronchiectasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=armp_CysticFibrosisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=armp_CysticFibrosisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=armp_BacteremiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=armp_BacteremiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=armp_ProstheticJointInfectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=armp_ProstheticJointInfectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Narrative) (Details) - Innoviva Strategic Opportunities LLC - Secured term loan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | 2025 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_CreditAgreement2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_CreditAgreement2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  ZD=%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  ZD=%HM64:C\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    (  ZD=%K".<7*AP@  +@T   8
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULM9MO;^*X%L:_BL6N1KM2*?D#M)UI
M*S%0=KG;=E'I[*AW=5^8Q!1K$IOK.*5\^WN<0$)Z'4-69EY,DY#S)/[%=LYC
M.]=K+GXD2T(D>H\CEMRTEE*N/G<Z2; D,4[.^8HP^&7!18PE[(K73K(2!(=9
M4!QU/,?I=V),6>OV.CLV%;?7/)41960J4)+&,1:;KR3BZYN6V]H=>**O2ZD.
M=&ZO5_B5S(C\MIH*V.L4*B&-"4LH9TB0Q4UKX'X>=;. [(R_*%DG>]M(%67.
M^0^U,PEO6HZZ(Q*10"H)#'_>R)!$D5*"^_CO5K157%,%[F_OU,=9X:$P<YR0
M(8^^TU N;UJ7+122!4XC^<37OY-M@7I*+^!1DOV/UOFYO7X+!6DB>;P-ACN(
M*<O_XO<MB+V 2Z<FP-L&>!\"W&Y-@+\-\(\-Z&X#NAF9O"@9AQ&6^/9:\#42
MZFQ04QL9S"P:BD^9>NXS*>!7"G'R=L2#%!ZC1 ,6HCLFJ=R@"<OKDWHN;?1M
M-D*__/PK^AE1AAYH%,'AY+HCX>)*HA-L+_0UOY!7<R'70P^<R64"5PE)6!7H
MP%T7M^[M;OVK9U0<D> <^>X9\AROJ[FAH3E\3.;GR+O,PGN:\)$Y_%\I*\*[
MAM+XQ8/P,SW_'SZ(OP?S1 IH)O_1L<^UNWIMU7=\3E8X(#<MZ!P2(MY(Z_;3
M3V[?^:+C9E-L9$FLPK1;,.V:U$NFSYL5T6$SA[M.^P\='V-44SZ6Q"I\>@6?
MWG%\!HRE.$)/9,6%U($RZTB1ZO .C5%-05D2JX#J%Z#ZQX&:$D&Y:I\A@NY6
M6Z<.*.TZK=I>RQC?%)HEL0JTBP+:Q9&M3V#($[)>K+Z&F;46.$JT5<P8UI26
M);$*K<N"UJ6QA#,2I (@D00- HG&-"+H,8WG1.AHF;4<QVW[%[VNMGX90YL2
MLR16(795$+LREG+[DGPBKU2]&:&B/>)8VR3-.H.GA\'S $U_5QO#NV_/D^'@
M?G:&)H_#<QU HUI3@);$*@!=ITS^G&,03EC !33,+-,X0S,)71OB @UYRJ38
MP-]0R_6 ^O>!#I\YJ"D_6VI5@'O9LWL,P&?\CB8A]'5T08,\7ZMONP<DK]RV
MV^M>]?J76GK&X,;T+*E5Z7DE/>\8>H,P!/7D;+>![N$\]"?3USFS9,]Q>N@A
M&'+&P$NBP1MA^MS$K-,8I"6U*LC2.[C&-/K_0 [5'C3@9[YF6HAFN7L.+R'V
M"N9<9_2&YNC&Z$[A$-S2(KCF)/\CNJ+SFPK^1EF@KX1FS:&^X[/J&VRI5;&5
MSL$UI_P?L4UY(L%!_)NNZM\69L4KQ^GWM=RLV@A;:E5NI9%PS?E_UC('@N!Z
M3&8!WW6TD*S:!EMJ54BE<7#-V?X]#Z N39><F7+@ R+]?J_M77GZMZA5VV!+
MK4JK- ZN.=M_IA*\ E\@U_ME_BO:&HF-%IE9:<CC&%*7F>3!#RTVJ][!EEH5
M6^D>7'/:#ZXTI.P5S3;QG$=:6@=]PU1+R:I!L*56'6(M'8)GSN%WM0G=O0=+
M##E!K<DZ(/3X,KL;/-P]:0=JK5H"6VI58J4E\(ZR!-\A_6S_8)" 08O$"71E
M(9HD2:KORPYH/G(M-JM>P)9:%5OI!;RCO,!?/ +/B<%TJA$0H9UH.*!4 \MJ
MOF]+K0JKS/>]H_+]82J$&F#+1]6RS@RRUU0/S:SXHD_US5&-J9TBU??*5-\[
M*M6?,$E$/M^H!G'Q#J.6FEFQCIK53-^66I5:F>E[1V7Z67-$0S!'KUQHDXL#
M.H^<M7$0@*D4(!+F@EIZ5O-]6VI5>F6^[YG3]2V]68RC"'U-$_@YT;=/LT[=
M%(LYK#&L4^3]7IGW>^:4?0OK+B;B5?5FOX&"7()3BE>8Z>O</YPV,,<UQG8*
M ^"5!L SI^V3X?@)#=*02B[00$H"5CP;@QQ'^%5+S:Q73\UJ_F]+K4JMS/\]
M<_I>3$^-*<,LH. XL[&?[-B=$-GX-[P8\O4I?RN6VJGW Y>IAVG5)MA2JZY=
M*&V"?]1$PFRI!ET-[?6 3"TL<USC-0FG< A^Z1#\HQS"-)U'-(!&RK$V]S"K
M-%[48=4L;-5ZF9I:6_9VZSOG_G7G34>F- '^429@?QSB#"H5ACM"?Z82^C6F
M/+N6ELW\?KA5Z^^7K^]>^D[_HBCCEL0IG("_MVK(G+?O>K%D;Q(/DJNYFA==
M$$AK]0/8!U2GRDYPEJA1);DD2!1SK)]^NO3<BR\)&I$%931+HJ>"OV_V.D]!
M(IRY$<FS:+7 :K?$Y(&0["<0SA[ODD<AV+PSM%[28(G6%/J/.4$+2 Y#V(.W
MOU+8FQS':GG4;BQ"512:9&L0U;F4(==S4(@W<-X"LOPLF$!$?3D6-%&#C1N"
MA3H3KCHB 5%CCL7:LC,$%1#1#WS%CB_\ @6=8B'19#+)+T63ZIH:I-[&7,1(
MK2G2SBJ;GTCC]GD*I^673LLW^Z)=,C*F4.3)2%L#S0I=3PO)JK&RI5:%5!HK
MWVR(=I#J!M0.A-\)EDCT"<>K+^B%I]"F[N^UXY%FG<;03N&G_-)/^68?M(.F
MI@A4%Z4%9Y:8889&%&SL&=C9B"ZX8!1KP5GU5K;4JN!*;^4?Y:V&T$$+Z)8F
MT-6]HS^(/DLS2SGP[\IS75>[OL@<W)C:*:R57UHK_\",R':$;9R_)5[46\*T
M^.^ 7+OM>FW?U6*SZJULJ56QE=[*/]I;E=S&<% []'% K&ZAI#FL,;%3&*AN
M::"Z9N?SD=AVH6DMLP-RXQ<=,7-0XY7+IW!1W=)%=<TN:@"XPAQ9S3#' 8%:
MLVF.:XS)ZKQ*9^]3#S5,EGTRDZ! K=3+O_HHCA:?Y0RRCU$ZY>GY-ST/6(VR
M)2@B"PAUSB_@S2[RSV3R'<E7V8<C<RXEC[/-)<&0KJL3X/<%YW*WHRY0?*QT
M^S]02P,$%     @ #J1T6F]CWK0T!@  _QD  !@   !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6RUF6UOVS80Q[\*X15;"]BQ2.JQ=0RD#K85V$/0M-MK6J)C
MHI+HDI2=[-./E!W+%BDZV[H7;23[COH?Q;O?D9[MN/@BUY0J\%B5M;P>K97:
MO)U.9;ZF%9%7?$-K_<V*BXHH?2L>IG(C*"E:IZJ<HB"(IQ5A]6@^:S^[$_,9
M;U3):GHG@&RJBHBG][3DN^L1'#U_\)$]K)7Y8#J?;<@#O:?J\^9.Z+OI<92"
M5;26C-= T-7UZ :^76!D'%J+/QC=R9-K8$)9<O[%W'PHKD>!441+FBLS!-%_
MMG1!R]*,I'5\/0PZ.C[3.)Y>/X_^8QN\#F9))%WP\D]6J/7U*!V!@JY(4ZJ/
M?/<S/004F?%R7LKV?[ [V 8CD#=2\>K@K!54K-[_)8^'B3AQ@.&  SHXH)<Z
MX(,#;@/=*VO#NB6*S&>"[X PUGHT<]'.3>NMHV&U>8WW2NAOF?93\P6O)2]9
M010MP'M2DCJGX-X,)\$$?+Z_!:]?O0&O *O!IS5O)*D+.9LJ_63C/\T/3WF_
M?PH:>,HMS:\ AF.  A0ZW!<O=\?G[E,=[S%H= P:M>/AH: ;(6BM )%2Q^D*
M9^\?NOU-:KV5&Y+3ZY'.'4G%EH[FWW\'X^"=*[AO--A9J/@8*O:-/E\0N0;Z
MI8'<7-"O#=N24L?NC'H_5-(.9?)_.\]0!F?3[6DTMA'$D7DM6X?,\"@S],J\
M$W1#6 'HHZY/DLI6,E=K*G027'I9^Z'C4T4HP3W9MA%"<>16'1U51U[5O[<"
M!<VIGM5E29WJ(NO!21CVQ-DV&,<#4QH?Q<5><9^X(N4+9B^V9P_B(.TI=%AE
M,()NB<E18N*5^)%*)5AN2H]9GBYUB?7<*$R#GCB'48("M[;TJ"V]L"(U*H5Z
M:E>BR9N-AI<:@YHJE\[4GA^,PG[N.*Q0%&5NI=E1:>9?A5HG4:Q^ "750 /"
MD&O"5Y-&W[3OW24XLZ2$,$Z3GF"'59C Q"T8!AUT J_D#_5D(WA.I02FY!&1
M[XM40;>ZL6AGV@F9P)Z_ $5Q3_1%LW/5)ZB$7M4_<5[L6%DZI4$[A<.LOU O
M69T+ZW &O0@YU*'A%#^XGSXV2Z*^-ML(A<F0MHX_T ^@?1GR:,/68],XQ/V%
MZ##+TL$:"3ONP/!%K4#)R)*53#%W$8=>?/W3AN!;C78><T<MZ,?639[S1K<
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M:B_7E&C5QD!_O^*Z\A]NS&\ Q]]\YG\#4$L#!!0    (  ZD=%K5?L'R>0(
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M-71S=5O$YT05%[L)?;9"M3!SD$Q[6"UBT _"H97<<C-\A9R/*5RMP/L<;.(
M=I%;Y((H0 .<@%JV1IXS!WU4)":.J;#16:GZ7-H.K6XY';DY_;[BZ0KK+',2
MIR +?<,XZM9_-K$8!L& KUK^1F[^ON<L)21K:%$Q(CD1OE/]R2ZT\?Z B2WK
M(S?K]Q82M<2GU;8^05M=8Q&+50H8P-U2.7)3^0=:8K6?/6(9G96SSZ7MT.J6
ML]%KG+T?D%2(2DW"X([JPNSOU<N=8,J$G=?=WSUYEOK\CQ)5HPXXO2T D+L
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MK;5NBPWIR56?HO842!Y"Z1T"^#IA*626ROD!JR\>H_D\%*WY/ B\QI-E28O
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M6!A>!9T]\0"!0,#D>' @<R?T\9Y"A7IA.=0%.FL.?G@?&;"O,%EUC)D!",.
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M7 &[(1->7F!\:;KJ&'173\X&>$U86(0E:I\L)%+C /:-<,V<;J#8>BWVDT@
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M*_1$I N4CR;GH@,]._D/?T  :J$94%]S1:%D7<RM24CN3J_Q>S$WVAN_1Y]
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M*9!3=OW0:!_.D7I16<-#'N +V--Y:$YF4^08M4G #%VG%.Q@"V6+E_#8LYY
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MD=@8"MK"G8J' M)!0PSU[UA7!4EL2J$!JJE$5#>V&@K?=33/##UI5$T9=](
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M&@FJSF%RDM22\"51#!VN.5-$P%1(2I IM:062("<JC?)PU%@QNZ93+AUGY6
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M\/?-VW.]O'G!?Z;REB.<<[:$J#<ZCAPBFU=Q,]"BLB_1A=!XU]INQBBJHEF
M[TN!BW,[, KZ?TW,_P%02P,$%     @ #J1T6CTN[0%"!   30P  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&ULU5?;;N,V$/T50ALL$D"P[K(VL0TD
M>VD+9+M!DK;/M#2VB:5$+4G%<;^^0TI6Y)7CWE[:%XL<SAR>(6>&X]E6R*]J
M Z#)<\DK-7<V6M>7GJ?R#914340-%:ZLA"RIQJE<>ZJ60 MK5'(O]/W4*RFK
MG,7,RN[D8B8:S5D%=Y*HIBRIW-T %]NY$SA[P3U;;[01>(M93=?P /J7^D[B
MS.M1"E9"I9BHB(35W+D.+F]BHV\5?F6P58,Q,9XLA?AJ)C\5<\<WA(!#K@T"
MQ<\3O ?.#1#2^-9A.OV6QG XWJ-_LKZC+TNJX+W@O[%";^9.YI "5K3A^EYL
M?X3.G\3@Y8(K^TNVK6X8.B1OE!9E9XP,2E:U7_K<G</ (/-?,0@[@]#R;C>R
M+#]031<S*;9$&FU$,P/KJK5&<JPRE_*@):XRM-.+&\IIE0-YL!'P 31E7,T\
MC=!&P<L[F)L6)GP%)@C)9U'IC2(?JP**0P /.?7$PCVQF_ DX@?()R0*7!+Z
M87P"+^H=C2Q>]&\=;6'BXS F1RY537.8.Y@$"N03.(NW;X+4OSI!,NY)QJ?0
M_SK)TS#IA!Q%(G<2LUGJ':%503Y^:UB-^:5=4J'.P1KLUPA51*P0((=R";*_
M$:N%@XCD C-4:2B,GMX 60F.J<ZJ-3EG%4I$HU!975R2MV^RT(^N_O%WS.)[
M241NZ5)(JH7<#9S8 YR1,'"C(!T(@G=N.LW(IT963#<2K&,K]FS&:L0@BX*Q
M+)B2+ZL5RUO;7)1UHY'2>/LXR@[&MX#U9"-X05A92_$$1OMET\C-_' PB^,I
M>12:\A&%,'6C;#H6QRCV<1NE+K'^Y4W9<&INJ@ ,WIQ16QCWVN=!Y 9Q>C$0
M!&X6!A>OA$8;-H.3C-PP#H:"T$V2=X/;&VQJD&@II&:_MP)XQG=& ='&0:1X
M%DPB+'B<[[51X/<"?(ULK.V 2D7 U)P3,>KB\Z%JL \ WTU>"_5*:((1VR"+
M+8;]6?8]@VP2O C^)"\.]W2MG"G$SWECV-K4 ,*/A6NWINF28TPM,3 FY'&#
MU09W58 10C%.#=O^'A&PJ33CQFYGEVN.1<IN8XH4!N>DOX@OJ"3)/5)G3V8+
MU4GD0/)?2ON_D_Z/4%%S@B_Y1*CA98OABX/D_&>A 2/T8A"O9A2$5\,(=K,H
M(3]( VDC=DME<00FNAB1G<;Q2!:X29B-I&<'NF>8Z%$:]?/K/!>-J0IW=-?&
M _) H6SPZ&\973+.-,,;ZQ7K@2+M%/E \?]ZM2,'!P>8'I1T-\F2_HQR?!U9
MCD532X:_79TY4MJ/7$WD^F'09<?^*%\%B-/QVQ"X?A8=N?'0]9-D,$_<-.LK
MY;%&PANT>"7(M6UD%;$GTG9[O;3OE:_;%O%%O6VT/U.Y9I4B'%9HZD^FB4-D
MV[RV$RUJVS NA<;VTPXWV.^#- JXOA(8]-W$;-#_@UC\ 5!+ P04    "  .
MI'1:C)U%'O\%  "J$P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6S-
M6&MOVS84_2N$VQ4;8/C=)$N3 $G:81W:M6BZ[3,M75M$)5(E*3O>K]_AI:3X
MF699.Q0('#W(<\]]G$N*9TMC/[F,R(O;(M?NO)-Y7Y[V^R[)J)"N9TK2>#,S
MMI >MW;>=Z4EF?*D(N^/!H.C?B&5[ER<\;/W]N+,5#Y7FMY;X:JBD'9U1;E9
MGG>&G>;!!S7/?'C0OS@KY9QNR/]1OK>XZ[<HJ2I(.V6TL#0[[UP.3Z\F83P/
M^%/1TJU=B^#)U)A/X>9U>MX9!$*44^(#@L2_!5U3G@<@T/A<8W9:DV'B^G6#
M_@O[#E^FTM&UR?]2J<_..R<=D=),5KG_8):_4NW/\X"7F-SQKUC&L</CCD@J
MYTU13P:#0NGX7][6<5B;<#(X,&%43Q@Q[VB(6;Z47EZ<6;,4-HP&6KA@5WDV
MR"D=DG+C+=XJS/,7UT8OR'HUS4F\,5*?]3U0P[M^4B-<1831 83A2+PUVF=.
MO-(II9L ?=!I.8T:3E>C>Q%?4M(3XV%7C :CR3UXX];',>.-_X./$6&R'R$H
MX]25,J'S#DK?D5U0Y^+9D^'1X,4]_"8MO\E]Z _B=S_"<4]L@XAW6OPF=06E
MB>& 8SGN"I\11A:EU"M(*B$H(JT?;DU7FI_+^=S27'I<%:;27IB9>#H>] 8H
MQCP/NII94XC76IN%6DA15M95$N.\V<&]MI0J+RZ!2-"U[XF/^RQ/25H'^YX0
M:B\D_H0-#&#ZI#?X091DA=2Z*O";BJ5T(O2JM,J#+P;J\)7%Z!W_)[L&MRDQ
MFL05*ID1JGP]? A*8K2N.\I2^6P]HL^>G(R&QR^< !"LPH,8@S!WUY(WW1!3
M/1<&@ZQ(,JGGY+J";CWL\TQV1?E5<'UOEF!AR\GG[*3N!O9OI4TR,1S%%YO9
MIUM**@\O)1KRU-'G*I!BUVMZ7\R?6&8JR3:]\)G2\]:)0\75^I6&O,+4!M.C
M X516J435<J<\RZ3Q%8P<%<H2'HI5S*,1]$T-GKB ^$Q$SX41N7$'$%$W1(0
MIZN]64U- 3,JX7BI5$FKR#$5K(WH_NP6605^ZR.Z/.2068<LV&@S3/*@   4
M'7X:NM(Y\NZ.?$Q@@]K:6C4^&.L>4.FEA6)3>. S1$LQ."((3E+,E)8(-;+*
MZM987!6@7( ./# A)XF8?UROJ(7,*\DE5?G,(/8RK+A@I5*@40A3R%IH(PQM
M[/ZP!,\@LR2O8@'!VMYQ+C-5CM!1@TIIM.'%3"HK A\2%<K0BLN;:S$Y@41>
M*A>L5\IEXHV24Y4K'_+(CK[Z7*%BNB*MJ!' #/N&>S@LT0412D)Q(&:>D#GP
M0;Y\Z$8'.P3N(1IQXTWRB7MW+<!\M=.CC3TH([0CY;G=*$M0TZ;C)KY%))W)
M5<J9F<J<4\$;AF[D5S>>@+8VN[6,AABE#?%! >)'NL6.T)'[J5DC-BR@A#T7
M&!<*-H]HW6B6D _4B*R3A- ME<9R$>"],FF/5ZL']=K]S91?-XM0-W!.E</V
MR06?P\YS,ZQ-AP_/(-G"[>L,VT:ZW[9EM^3VE/Y=6^;U20>#=1'STRUE81$N
M#3*TB1LR.M?J;^[Y3X>]DW8)GV/S'F+&R62?MHKAD"]3"JV/WVTQ"L70W4SI
M)IO02@NNF%T[J+,I=C@( -J9DUP!,8%M?]A'I]OPX>5AAL2*PJ1JIA(9OP!"
M7Y%Y4N6Q2^V$,3?.Q0U.[^<F.-VXRG'@UR-X0!5?$,66)IH6N,*61\22Q.:7
MBBF ZPWP^& 2 UN*?#'J:'-#MA'Y4',[N(]*.,K*;P25E?N[643L>@&?? 6U
M<;;VBOW?ZW"*80@7:FF/^HX>KCXGEF&)E'L+-%;=XZ3Y.#%P=+ZM(K@S<(7U
M1M^+(K"-OV17L-=T=\G9K#D8@R-5_"*HXW_/CN/_7#B_ZKIYH#<\'0][D[8C
M/$;I#TO$NX=^9.COY=-BW_=Z?^W\I" [YU.B4  HFGB4TCYM#Z(NX_G+W?!X
MB@5K<X6LY33#U$'O^'E'V'@R%&^\*?DT!CW)FX(O,Y+8HH8!>#\SQC<WP4![
M/'?Q#U!+ P04    "  .I'1:#TMMA3$&   M%0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6SM6%ESVS80_BL8Y9AV1D-)E'PTMC43.^VTF:;U)#V>
M07!%8@(""@!*5G]]=P&2HJTC3NOV*2^Q"&)WO[V^W?!R;>Q'5P)X=E<I[:X&
MI??+5Z.1$R54W"5F"1K?+(RMN,='6XS<T@+/@U"E1NEX?#JJN-2#^64XN[7S
M2U-[)37<6N;JJN)V<PW*K*\&DT%[\%X6I:>#T?QRR0OX /[WY:W%IU&G)9<5
M:">-9A865X/7DU?7,[H?+OPA8>UZOQEYDAGSD1Y^RJ\&8P($"H0G#1S_K. &
ME")%".-3HW/0F23!_N]6^P_!=_0EXPYNC/I3YKZ\&IP/6 X+7BO_WJQ_A,:?
M$](GC'+A7[:.=R?3 1.U\Z9JA!%!)77\R^^:./0$SL<'!-)&( VXHZ& \@WW
M?'YIS9I9NHW:Z$=P-4@C.*DI*1^\Q;<2Y?S\-[ 5>P.9OQQY5$>'(]&(7D?1
M](#H)&7OC/:E8]_K'/+["D:(HP.3MF"NTZ,:WX!(V'0R9.DXG1W1-^V<FP9]
MTW_B7!2=[1>E7GCEEES U0"+W8%=P6#^\MGD='QQ!-BL S8[IOTXL..BYPGK
MI-FOFKVMU89-QB%FTR'S); ;4RVYWC#0'BSD3&IOP@NZPF[P2'KVNK  V%T>
M]1UZQ9;6K&0.CF'W;S7\;+@>,LX<B)KT>\*C\) MN)!*^@V:9/C("]14< ^,
M5Z9&?6;!GJ<GR1@K6:G0E)[NR0#4>6;I+EZ:S)+Q"[8$BV]U7:$QG;,U=XQ(
M*:\5&378!A[M,U3SENL:*:6-PTG";JW40BZY"J)<"%O'2$1#'.66?,,S!80A
M:$+<"7L/>!Q\1QCW/&;2L0*M<-2!JK)-/]8OGYVGD[,+QW)3H7XID.4R)W/)
MK007\>]H:^.'JNBV1\V2*TPG_M.:Y\Z!=^U3F]E676=DTT(SUB54%K^8%509
M!G"2QG9Z4!IW:-NC;<H2NIL'EX^5R9"M2RG*(:52%\S@12H)J0MT#^X\$ <\
M\+$-*\LIKZC]09Y. ]1WW(JRQ7ER"&?P%3[5A/-QB)\"\#ULI\=:12 5X@QT
M#6F3EWRQD#0X<.R$C&GJ!7H0F!R-R7+AV$)@&!2G.>6:6K>4S5 [6,BJSA$W
M6TB4$E@C)&.LIS.3*5GT) 58PL&4K&2KT5"+Y4@8D&MPJ%))'*ND>87%2O#Q
M(9?.6YG54>2;K=5<$@?HW'T[1.1*86@L5P^D*[ %6#2%+2L^U=+)+:1%K7-*
MF4?@PEA$3M$5)=<%N&,QY<J9QGWH!Q969)2:HIF__2"U_=N\0FP9;BO(&T$@
M,)H+T! 51%8+W)4;43?.=#$TV'W!)XGEB+EL>&$;A2:!])3'?H[L%VG&Q6(V
M L\M:!&XK57>..%+3L53*]+#G='(21N6 9;H$C>7R'0EIQ)BQ#+I^*(BVU0%
M/%]AS/'J8H%7P]O)!2.:Q&T.*=N71,1'6KK%DG']T=9++S;!6>V,0G2BC73D
M+\XZPSFL9*@MMK"FVDN$N#9BFBDA69T7T!\SH=6(S:66#>-9$*;0\B_J=(2.
ML68KKFJ($V.2I-N)@4BV5+ C&CBSHMZ@ V&0ZS7X6"HX,*5S-:=$T)M8G>$<
MBU]T$VJ:G+?F(NJ6C7JFGJ?)[!ZFY^/DN^[@<;;:H;H!CIT3^0A7H,C;[1H4
MY.)LQY*BDD &49LAJQT%E^1C^HE8NOE6@2]-?AC]:7)V'WV:G'8'&(.=@4G5
MJ+'4_@WF)!3P>'JQ9?W9WN&T9V^9[;)#;R>9-3/U\-8Q[6T=72DV8EGP9;L;
MA)V$%@\BVGL;R>?6D%I#X]+)%XRV_2-XC\=?,-!FCQQH3[DGS9YT3YK]]WO2
M_3(XQDB"NY)FAT"7W$Y!':,8NCM.)NW5X2Z!H8>?X[ DKOL/&<7V[SV"#Z@
M=CH:=Y'81V&-?YC-PQ0RVSKU:,8X1!@/4M%52=.$>QP*?4D9P\9,3U[0T$,0
MAQ7OVR[ZM79HG_NZSCWA.G<TX/UE[^NN]]2[WO'@_[^;X+X/**/>)ZQ0?/2A
MSK&P*,6O6=UI]RWP=?P$MKT>/R3BB"OH/V(*%B@Z3LY.!LS&CW/QP9ME^""6
M&8]%%GZ6P+% Z *^7QCCVP<RT'TAG?\-4$L#!!0    (  ZD=%I *\!.[P,
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ML9!3>N#;1!6@N=.RYID4+"=BA#U2JT32O:"7]KCK/9:CQ_^#;:_C_.N,/T3
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M1Q+>A*%L NF18@6 LNYS#VX'O9UKUE7Q:G/KF@G7XBK?;]8][H<HF(VQIW4
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MM;.]7$&H6LZC"GE=;(#32<Z' F),I@?J?E\<KBY:V58GQ=L'!6%7YSJL&(H
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MSZV2"$I:@/G$F+)YH0W:3\-7_P502P,$%     @ #J1T6@MUOXU:"   TQ8
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M,*DFJ9"3*>6QTQBQ4B*MR'U>/A(_=]*4%W#70 XKB'2T[EA^)TJ).(E,/\$
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MQ=>0XQ?L$/C5WZD-P9;\<:$DRI0&X/G,@E&D+[1 \S+XR1]02P,$%     @
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M0,+@TN.#,L7+$+F%M'?N>\'2,P&=_K)'2;!9 3H"F")\1SH,E%%3++/WH.D
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M%6A*_ #>;QIP3N4'+N OSW_Y+U!+ P04    "  .I'1:C\&-\WD"  ":!0
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M+L#YN41#5A]60?MOPO1O4$L#!!0    (  ZD=%IIXF)JS00  #8.   9
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M,[J$G!/U+:6>*%Z:F\&2*[AGF,<,+G9$Z WP?L6Y:B=:0'=5G/\#4$L#!!0
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MLIT#VXT6M9V]UD+C)&>7.QR=01H'_'\CL-8.&W- -XPO_@902P,$%     @
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M&/R2P;=R%P=9*3]23<<G4FR(--2(9CZLJI8;A6.Y<<J5EOB7(9\>G_U8,_U
MSO,$<F,?<L%IKDC[FLXXJ,.3GL9##&DO*0&G!:#_#*#GDR\BUTM%SO(4TL<
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M#F +&VSA(>O36RRU;)4#DW/6?R^U'K :[ES)@EUB9D6Y$N4=^[0$Q8G.FET
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M]<[CH4-T,Y(U@E5E/0;-E<6AJEZN<8H%71W _:52=B]4%QSFXLF_4$L#!!0
M   (  ZD=%I%O=(2V@,  +4/   9    >&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;*V7;6_;-A#'OPJA%4,"!-&#'3]DMH'8VK  31,T3?>:EFB+"$6J)&6W
M0S_\CI*L2I[,QIOR(A8IW?]X/QX?;K87\E4EA&CT-65<S9U$Z^S6=564D!2K
M:Y$1#F\V0J980U-N795)@N/"*&5NX'DC-\64.XM9T?<D%S.1:T8Y>9)(Y6F*
MY;<E86(_=WSGT/&1;A-M.MS%+,-;\DST2_8DH>76*C%-"5=4<"3)9N[<^;>A
M7Q@47WRF9*\:S\B$LA;BU33NX[GCF1$11B)M)##\[,B*,&:48!Q?*E&G]FD,
MF\\']3^*X"&8-59D)=A?--;)W)DX*"8;G#/]4>S_)%5 -T8O$DP5_]&^^M9S
M4)0K+=+*&$:04E[^XJ\5B(9!$)PP""J#X,A@<,K#H#(8'!L,3A@,*X-A0:8,
MI> 08HT7,RGV2)JO0<T\%# +:PB?<C/OSUK"6PIV>O$HMYC3OW$Y"3Q&(5&1
MI%G1%AND$X*6N0(KI=#%!RPE-A-UB2Y"HC%EZA*]0RY2"99$(<K1"Z=:74$G
M/#]0QD!'S5P-0S4.W:@:UK(<5G!B6#YZ$%PG"OW.8Q)WV*]^8A]8!%Q@5(,*
M#J"6@57Q <MK-/"O4. %0_3R'**+=Y== [/+A"1JR%!-T@:_#KGP[7*#PZA.
M*K8"']09,BA<#$^X6(DTA5R 3(Q>KU"&)=IAEA-T 1,<"\:P5"@CLG1XB;[;
MXUE:G9E=[E9E.")S![8Q1>2..(M??_%'WF]=K$NQ22%F=KC=PKOV_)F[:Q+\
MR4<M*,,:RM *Y9YSL:,[C* 3:[*E$7K,,B%U#NE/826\?[_JBMZJ>F[T?8J%
M/8FU:-[4-&^L-#\)C1GLUFN--I1C'E&^-8G41;!4&C=F<^JU)WQE=78N%ZN_
M5K2C.MJ1-=H/>;J&]0*;:T@E'']"=BX4J\BYJ5**C1I1#(Y624_N6D3&-9'Q
M&XDL!9:QG8M5ZEPNXW]QF1QQZ<E=B\NDYC+YW[L,K),'RFF:IUVPK/KGPNI3
M+.Q)K,5U6G.=OF&_X7765;<7<Z+!2181KN'*VW6X+ZVZY_(LQ::M@VDXO3E*
MP)Y<MD#YWH_KH6=%=6?NUA@] :$4O.2:1IC!_>Z>P\7C._JOYZ#=Z[D@>U4+
M^U)K$V]<R'TK\<=<*PTW<7,&DB\YU=^:B=F9E7;%LVGZ'7DYF@;3YM]1DO8U
M@I*9VZAG4B*W15VH4"1RKLL;>]U;UIXK4WN:>NBH'VK2NZ(2<W_(E 4M7.>W
ME"O$R 8DO>LQG/.RK!'+AA99436MA88:K'A,H*XFTGP [S="Z$/#.*@K]<4_
M4$L#!!0    (  ZD=%JXG6*\"@0  "X8   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;*V9_W.;-AB'_Q4=Z^V2N]4(\-?,]EUJ3-==NN6:=?M9P:]M
M74&BDK#;N_[QE3"A)L;$K/HE!LSG>8$'O09ENN?BD]P"*/0E39B<.5NELAO7
ME?$64B)[/ .FOUESD1*E5\7&E9D LBI":>+Z& _=E%#FS*?%MGLQG_)<)93!
MO4 R3U,BOKZ!A.]GCN<\;?A -UME-KCS:48V\ #J8W8O])I;458T!28I9TC
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M=0S-6Y<5_F^:.G'OJ-HRH0F'#5(&@VM4I.H4JR=&EBX('J7!6''#'(,?E"W
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M=HJX-9YW!&]3^AF:*VED7P'TWYT*1^\EY.)_4ZD-MF_&UGOR4I0D@9FE-IT
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MN=P(%.0QC76 K3K9]-1][^F=:R3Z-!J@(?X)N8[K=31H>;GYL,/<-YL_$CY
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M3K76T,KP>#_(O7C2'N)P[_L1OC@C7T-5?Y["/:RX%X^/8$4[K.BE.7I 95Z
M%1UB=41K5_7#SO+]+&M?$Z_XI'CM"G]X4N4_3./7L/9;;MPH?H;J[S4O.>I%
MV:(92%4A;=7'-*M-&WA9-3^[XU4/^95I2A<# N<D&O1&5/YUU995$ZM692OT
MJ"PU5N5P2:TL:G> ]N=*V>W$&6B:X^1?4$L#!!0    (  ZD=%JGA  3I ,
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;,5676_;.!#\*X2N."1
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MYOFUC3'W'TWS&-Q2N6$8&P6LD=([O\#MDDW -ATM*IM13T)CXMEFCF\22%.
M\VLA]+YC%NA>N>0O4$L#!!0    (  ZD=%JI)#CU500  'L0   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;*V8;6_;-A#'OPJA%4,*5)&H9V6V@=;&
ML !;%S3I]IJ6SS$12=1(VD[ZZ4?*BFQ+E.(6?1-+UMWY=\?C_:E,]HP_B0V
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MA#67^1E6WM!B:T]UED)KD=G;#250B9H.\'XEA#XUS #%2>+L?U!+ P04
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M[M-&]^E>W;>N 6!V0M9&YA)-R[)-L9$+&B4[AD<DLE/Y?GH85IDP!%9]^=$
M,O+8A9J]@HIJU&B+"OL=J)TB#)HB#/ZN"!E5J5AQ#6;G\!C>=SFOD*/6=@2]
ML+4=E:G7HBJ]?JNS,91+U_ 5. U5-VA6JS-E:LX4UWN?K9NSYI-KL?X3ICJH
M+HA<4J[,KBX,,NB=F7++JOE7$RU*US_OA#;=V US<UZBM 'F^4((O9W8%S0G
M</(;4$L#!!0    (  ZD=%HK64V?ZP4  #HM   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8W+GAM;+6:6V_;-A3'OPKA%4,#9-;%UV:) <>Z=5BZH&FWAV(/
MC$3;PB11(VD[!?;A1TJR;-DR8Q<G+XDD\_P.+W\<DH>\W5#V#U\2(M!+FF3\
MKK,4(K\Q#!XN28IYE^8DD[_,*4NQD*]L8?"<$1P51FEBV*8Y-%(<9YW);?'M
MD4UNZ4HD<48>&>*K-,7L^SU)Z.:N8W6V'S['BZ50'XS);8X7Y(F(K_DCDV]&
M38GBE&0\IAEB9'[7F5HW@356!D6)/V.RX7O/2#7EF=)_U,O'Z*YCJAJ1A(1"
M(;#\MR8SDB2*).OQ;P7MU#Z5X?[SENX5C9>-><:<S&CR5QR)Y5UGW$$1F>-5
M(C[334"J!@T4+Z0)+_ZB3576[*!PQ05-*V-9@S3.RO_XI>J(/0.K?\+ K@SL
M<PUZE4'OP,"V3QCT*X/^N1X&E<'@P*!_JM'#RF!XKL&H,AB=6Z5Q95#(Q2B'
MHQA+!PL\N65T@Y@J+6GJH1!$82V',,Z4=I\$D[_&TDY,?(8S@7 6H>D&LXBC
M]Y\P8U@)Z@J]=XC <<*OT"_HZY.#WK^[0N]0G*&'.$FD\OBM(60=%,D(*W].
MZ<\^X<]"#S032X[<+")1B[WWBKVM 1BR\74/V-L>N+>UQ">2=Y']X1K9IFVW
M5&BF-W_ K(NL7F%NMO6'WORW5=)%/:LP[[>8NWKS:2Z]]\R3WCV]N4-"K7?_
M?/->BWGP6MLSV76#MLHW1K)7:[E7\/JGAN*+.T.%H%OJ<J^U55/$#<]Q2.XZ
M<@[@A*U)9_+S3];0_+5-$Y P!Q+F0L(\2)@/"0N 8 V=]6N=]0MZ[U3,I&O"
M,CF!"S3E/.8"9R%!WWZ7Q=!'05+^=YO^^I#Z@X0YD# 7$N9!PGQ(6  $:^AO
M4.MOH(USG\F:9"N"YHRF:*'B7=M$?%]"!@5$+6'7$VO8E6%ZO2\DK:=+A73L
MT;:ZPZ9'%]*C!PGS(6%!"1OM]_Z@[HG&L _K81]JA_UC%LK="2=J 49><KGX
M)Y'</IREA>&Q%HZDH/5^J12.'0X.';J0#CU(F \)"X!@#<V,:LV,M)IIG:JN
MU3,1UVBKJ&LT6S$F"UVC)X'E#*;*TSGRXDR6CW&"'BF/B[WF-_=%J)WK<T+D
M"GR5$K57H%GKC*>MVJ4S'B3,T7?:'V))6-E'O.Z:MKD.LDX>),R'A 5 L(:
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M/U:X7D&[ +Q?*67WADO0+^S\-U!+ P04    "  .I'1:<./4=P4#  #D"@
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MEY<<*TNJLB-HKJN2%16RQM'-6):AP-0$^7U-J=AUE(.ZL/7_ %!+ P04
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M*'8K/)95GE_#OH<21E[9;BGW;AGZY3]02P,$%     @ #J1T6K % +TV @
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MCGH[@=Z.>CN!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WC'YV81
M[T"]@T#O0+V#0.] O8- [P;U;@CT;E#OYB?U+N/7(9=KS_<:K_^35(_G<_/U
M\I?E]\[)3;C@7-]6E*>_4$L#!!0    (  ZD=%KART;(_0$  #TI   3
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MLAH460V*K',46>?_*>N]<YL_CA^?96>;_BV?C?^:/'\!4$L! A0#%     @
M#J1T6D;'34B5    S0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    "  .I'1:+5E&H_(    K @  $0
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M965T-"YX;6Q02P$"% ,4    "  .I'1:;6^!ZH,%  #N(   &
M    @('='@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M#J1T6EZ<O^;T!@  L1X  !@              ("!EB0  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    (  ZD=%IZHT'1K0(  # (   8
M          " @< K  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    "  .I'1:4)M]B (#  #Q!@  &               @(&C+@  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ #J1T6AC?#:/2"   &AD
M !@              ("!VS$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    (  ZD=%KT8-5/.AL  ,Y4   9              " @>,Z  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ #J1T6N>>#%IQ
M!P  PQ8  !D              ("!5%8  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    "  .I'1:%C9!N88%  "F$   &0
M@('\70  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  ZD
M=%H]+NT!0@0  $T,   9              " @;EC  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ #J1T6HR=11[_!0  JA,  !D
M         ("!,F@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    "  .I'1:#TMMA3$&   M%0  &0              @(%H;@  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  ZD=%I *\!.[P,  ,H)
M   9              " @=!T  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ #J1T6I9.NV:U"   AQH  !D              ("!]G@
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  .I'1:N5[!
MQ\@*   F'@  &0              @('B@0  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    (  ZD=%H+=;^-6@@  -,6   9
M  " @>&,  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M#J1T6O9=HX6@"   "A8  !D              ("!<I4  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    "  .I'1:1&(0>;$"   R!@  &0
M            @(%)G@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    (  ZD=%HZ1_GG?@4  /,.   9              " @3&A  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ #J1T6JP0\6M1 P
M^ <  !D              ("!YJ8  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    "  .I'1:/53GVT\"  "D!0  &0              @(%N
MJ@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  ZD=%HL
M=6B^0P(  (H&   9              " @?2L  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ #J1T6CRE,S@1 @  W00  !D
M     ("!;J\  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ZD=%IIXF)JS00  #8.   9              "
M@9;A  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ #J1T
M6K&T4$#0 P  F L  !D              ("!FN8  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    "  .I'1:AO0+0,8#  !C"0  &0
M        @(&AZ@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   (  ZD=%H H?T% P4  +8/   9              " @9[N  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ #J1T6I/M/'1=!0  R@\
M !D              ("!V/,  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    "  .I'1:F(Z[EP,$   7"P  &0              @(%L^0
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  ZD=%HD)=F@
MSP,  ",+   9              " @:;]  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ #J1T6D6]TA+: P  M0\  !D
M ("!K $! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  .
MI'1:N)UBO H$   N&   &0              @(&]!0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  ZD=%J1/#_!! ,   \)   9
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M970T-"YX;6Q02P$"% ,4    "  .I'1:7." \^ #  !$#0  &0
M    @(&D'0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M  ZD=%I_]#OF- 4  /X>   9              " @;LA 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ #J1T6JGG?=9U @  5@8  !D
M             ("!)B<! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    "  .I'1:,Z^E>)\#  #&$   &0              @('2*0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (  ZD=%JRG$@D:P(
M )X&   9              " @:@M 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ #J1T6J).H%V: @  , <  !D              ("!
M2C ! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  .I'1:
M^C].VLX$  "C&P  &0              @($;,P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    (  ZD=%J;,0%C"P4  -,C   9
M      " @2 X 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ #J1T6M@L<[)'!0  :"4  !D              ("!8CT! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  .I'1:9((M%=$#   "#@
M&0              @('@0@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    (  ZD=%J4+Y<LG@4  &8;   9              " @>A& 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ #J1T6O$F#0<(
M!0  ,AH  !D              ("!O4P! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    "  .I'1:<&K-=D,#   H"P  &0
M@('\40$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (  ZD
M=%JGA  3I ,  !,0   9              " @795 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ #J1T6L:_[=$Z P  K L  !D
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M=#8S+GAM;%!+ 0(4 Q0    (  ZD=%H5U$<[( 0  %44   9
M  " @8IK 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @
M#J1T6ISCVZ=9 P  W P  !D              ("!X6\! 'AL+W=O<FMS:&5E
M=',O<VAE970V-2YX;6Q02P$"% ,4    "  .I'1:T^%/>,4"  "-!P  &0
M            @(%Q<P$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4
M Q0    (  ZD=%HK64V?ZP4  #HM   9              " @6UV 0!X;"]W
M;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ #J1T6KI%RF=4 @
MO 4  !D              ("!CWP! 'AL+W=O<FMS:&5E=',O<VAE970V."YX
M;6Q02P$"% ,4    "  .I'1:<./4=P4#  #D"@  &0              @($:
M?P$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (  ZD=%J
MWAR.U@4  +D?   9              " @5:" 0!X;"]W;W)K<VAE971S+W-H
M965T-S N>&UL4$L! A0#%     @ #J1T6MX5!!O- @  H0D  !D
M     ("!8X@! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4
M"  .I'1:^-/EQE$#  ".%0  #0              @ %GBP$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    (  ZD=%J7BKL<P    !,"   +              "
M >.. 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (  ZD=%J#$3,MI04   HO   /
M              "  <R/ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  .
MI'1:L 4 O38"   <*@  &@              @ &>E0$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  .I'1:X<M&R/T!   ]*0  $P
M            @ $,F $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3P!/
+ * 5   ZF@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>173</ContextCount>
  <ElementCount>364</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - Consolidated Statements of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Organization and Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Convertible Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureConvertibleLoan</Role>
      <ShortName>Convertible Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureTermDebt</Role>
      <ShortName>Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Grant and Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureGrantAndAwards</Role>
      <ShortName>Grant and Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - Employee Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan</Role>
      <ShortName>Employee Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995211501 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995211601 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99920302 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetails</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersDeficitTables</Role>
      <ShortName>Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureStockholdersDeficit</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlans</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99931503 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSegmentReporting</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Organization and Description of the Business (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails</Role>
      <ShortName>Organization and Description of the Business (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails</Role>
      <ShortName>Liquidity and Going Concern (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940302 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Fair Value Measurements (Assets and liabilities at fair value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements (Assets and liabilities at fair value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails</Role>
      <ShortName>Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940403 - Disclosure - Fair Value Measurements (Changes in Fair Value of Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements (Changes in Fair Value of Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Net Loss per Share (Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails</Role>
      <ShortName>Net Loss per Share (Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940502 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails</Role>
      <ShortName>Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Balance Sheet Details (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails</Role>
      <ShortName>Balance Sheet Details (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Details (Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940603 - Disclosure - Balance Sheet Details (Other receivables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails</Role>
      <ShortName>Balance Sheet Details (Other receivables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940604 - Disclosure - Balance Sheet Details (Accounts payable and accrued liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details (Accounts payable and accrued liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Convertible Loan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails</Role>
      <ShortName>Convertible Loan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureConvertibleLoan</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureTermDebtDetails</Role>
      <ShortName>Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureTermDebt</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Stockholders' Deficit (Summary of Warrants Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Deficit (Summary of Warrants Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureStockholdersDeficitTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Stockholders' Deficit (Shares Reserved for Future Issuance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Deficit (Shares Reserved for Future Issuance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureStockholdersDeficitTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Equity Incentive Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99941002 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99941003 - Disclosure - Equity Incentive Plans (Restricted stock award and restricted stock unit award activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails</Role>
      <ShortName>Equity Incentive Plans (Restricted stock award and restricted stock unit award activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99941004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails</Role>
      <ShortName>Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99941005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Income Taxes (Narrative) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail</Role>
      <ShortName>Income Taxes (Narrative) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>99941103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes (Components of Deferred Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>99941104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>99941202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies (Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>99941203 - Disclosure - Commitments and Contingencies (Operating leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies (Operating leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Grant and Awards (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails</Role>
      <ShortName>Grant and Awards (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureGrantAndAwards</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - Employee Retirement Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails</Role>
      <ShortName>Employee Retirement Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>99941501 - Disclosure - Segment Reporting (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSegmentReportingTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>99941502 - Disclosure - Segment Reporting - Segment information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails</Role>
      <ShortName>Segment Reporting - Segment information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="armp-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>99941601 - Disclosure - Subsequent Events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>armp-20241231.xsd</File>
    <File>armp-20241231_cal.xml</File>
    <File>armp-20241231_def.xml</File>
    <File>armp-20241231_lab.xml</File>
    <File>armp-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="armp-20241231x10k.htm">armp-20241231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>armp-20241231x10k003.jpg</File>
    <File>armp-20241231x10k004.jpg</File>
    <File>armp-20241231x10k005.jpg</File>
    <File>armp-20241231x10k006.jpg</File>
    <File>armp-20241231x10k007.jpg</File>
    <File>armp-20241231x10k008.jpg</File>
    <File>armp-20241231x10k009.jpg</File>
    <File>armp-20241231x10k010.jpg</File>
    <File>armp-20241231x10k011.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="548">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "armp-20241231x10k.htm": {
   "nsprefix": "armp",
   "nsuri": "http://www.armatapharma.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "armp-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "armp-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "armp-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "armp-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "armp-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "armp-20241231x10k.htm"
     ]
    }
   },
   "keyStandard": 313,
   "keyCustom": 51,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 31,
   "hidden": {
    "total": 12,
    "http://fasb.org/us-gaap/2024": 9,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 173,
   "entityCount": 1,
   "segmentCount": 64,
   "elementCount": 649,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 548,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:OtherNonoperatingIncome",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit",
     "longName": "995200300 - Statement - Consolidated Statements of Stockholders' Deficit",
     "shortName": "Consolidated Statements of Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WYP4LOLiVE2vVMYho8f0Pw",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WYP4LOLiVE2vVMYho8f0Pw",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical",
     "longName": "995200405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "longName": "995210101 - Disclosure - Organization and Description of the Business",
     "shortName": "Organization and Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern",
     "longName": "995210201 - Disclosure - Liquidity and Going Concern",
     "shortName": "Liquidity and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "995210301 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurements",
     "longName": "995210401 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShare",
     "longName": "995210501 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetails",
     "longName": "995210601 - Disclosure - Balance Sheet Details",
     "shortName": "Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.armatapharma.com/role/DisclosureConvertibleLoan",
     "longName": "995210701 - Disclosure - Convertible Loan",
     "shortName": "Convertible Loan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:ConvertibleDebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:ConvertibleDebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.armatapharma.com/role/DisclosureTermDebt",
     "longName": "995210801 - Disclosure - Term Debt",
     "shortName": "Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersDeficit",
     "longName": "995210901 - Disclosure - Stockholders' Deficit",
     "shortName": "Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlans",
     "longName": "995211001 - Disclosure - Equity Incentive Plans",
     "shortName": "Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxes",
     "longName": "995211101 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211201 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.armatapharma.com/role/DisclosureGrantAndAwards",
     "longName": "995211301 - Disclosure - Grant and Awards",
     "shortName": "Grant and Awards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:AwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:AwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan",
     "longName": "995211401 - Disclosure - Employee Retirement Plan",
     "shortName": "Employee Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.armatapharma.com/role/DisclosureSegmentReporting",
     "longName": "995211501 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.armatapharma.com/role/DisclosureSubsequentEvents",
     "longName": "995211601 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "99920302 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables",
     "longName": "99930303 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:PropertyAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:PropertyAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "99930403 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShareTables",
     "longName": "99930503 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables",
     "longName": "99930603 - Disclosure - Balance Sheet Details (Tables)",
     "shortName": "Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersDeficitTables",
     "longName": "99930903 - Disclosure - Stockholders' Deficit (Tables)",
     "shortName": "Stockholders' Deficit (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables",
     "longName": "99931003 - Disclosure - Equity Incentive Plans (Tables)",
     "shortName": "Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesTables",
     "longName": "99931103 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "99931203 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.armatapharma.com/role/DisclosureSegmentReportingTables",
     "longName": "99931503 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
     "longName": "99940101 - Disclosure - Organization and Description of the Business (Narrative) (Details)",
     "shortName": "Organization and Description of the Business (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_D0CIVBrcHkCADcgqae2kVQ",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
     "longName": "99940201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)",
     "shortName": "Liquidity and Going Concern (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_OTR9ruU8jEO4DamnlHKFLQ",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
     "longName": "99940301 - Disclosure - Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:NumberOfStandbyLettersOfCreditIncludedInRestrictedCash",
      "unitRef": "Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:NumberOfStandbyLettersOfCreditIncludedInRestrictedCash",
      "unitRef": "Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "99940302 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)",
     "shortName": "Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_F1-n7zRE20q0EmkRbZO3CQ",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:PropertyAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_F1-n7zRE20q0EmkRbZO3CQ",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:PropertyAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails",
     "longName": "99940401 - Disclosure - Fair Value Measurements (Assets and liabilities at fair value) (Details)",
     "shortName": "Fair Value Measurements (Assets and liabilities at fair value) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
     "longName": "99940402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)",
     "shortName": "Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N9_1XuuLQ0-lsYc-TWi-NA",
      "name": "armp:DebtInstrumentMeasurementInputForPeriod",
      "unitRef": "Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N9_1XuuLQ0-lsYc-TWi-NA",
      "name": "armp:DebtInstrumentMeasurementInputForPeriod",
      "unitRef": "Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails",
     "longName": "99940403 - Disclosure - Fair Value Measurements (Changes in Fair Value of Liabilities) (Details)",
     "shortName": "Fair Value Measurements (Changes in Fair Value of Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_YvPw907mK0udlp6KfJ8QZw",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails",
     "longName": "99940501 - Disclosure - Net Loss per Share (Basic and Diluted EPS) (Details)",
     "shortName": "Net Loss per Share (Basic and Diluted EPS) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
     "longName": "99940502 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)",
     "shortName": "Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails",
     "longName": "99940601 - Disclosure - Balance Sheet Details (Narrative) (Details)",
     "shortName": "Balance Sheet Details (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:Depreciation",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:Depreciation",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
     "longName": "99940602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)",
     "shortName": "Balance Sheet Details (Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails",
     "longName": "99940603 - Disclosure - Balance Sheet Details (Other receivables) (Details)",
     "shortName": "Balance Sheet Details (Other receivables) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg",
      "name": "armp:TenantImprovementReceivableCurrent",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfOtherReceivablesCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg",
      "name": "armp:TenantImprovementReceivableCurrent",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfOtherReceivablesCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails",
     "longName": "99940604 - Disclosure - Balance Sheet Details (Accounts payable and accrued liabilities) (Details)",
     "shortName": "Balance Sheet Details (Accounts payable and accrued liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
     "longName": "99940701 - Disclosure - Convertible Loan (Narrative) (Details)",
     "shortName": "Convertible Loan (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:IncreaseDecreaseFairValueOfLiabilities",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_4FQlAocYb0208Y7SDKNP4Q",
      "name": "armp:ProceedsFromQualifiedFinancingPerAgreementBenchmark",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "armp:ConvertibleDebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.armatapharma.com/role/DisclosureTermDebtDetails",
     "longName": "99940801 - Disclosure - Term Debt (Details)",
     "shortName": "Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "armp:ConvertibleDebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails",
     "longName": "99940901 - Disclosure - Stockholders' Deficit (Summary of Warrants Outstanding) (Details)",
     "shortName": "Stockholders' Deficit (Summary of Warrants Outstanding) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_HyGAt6Tz506l49Pgkj8m9Q",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails",
     "longName": "99940902 - Disclosure - Stockholders' Deficit (Shares Reserved for Future Issuance) (Details)",
     "shortName": "Stockholders' Deficit (Shares Reserved for Future Issuance) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
     "longName": "99941001 - Disclosure - Equity Incentive Plans (Narrative) (Details)",
     "shortName": "Equity Incentive Plans (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails",
     "longName": "99941002 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)",
     "shortName": "Equity Incentive Plans (Summary of Stock Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails",
     "longName": "99941003 - Disclosure - Equity Incentive Plans (Restricted stock award and restricted stock unit award activity) (Details)",
     "shortName": "Equity Incentive Plans (Restricted stock award and restricted stock unit award activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_QarzicNc2kSX3wxOAwoMJQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_QarzicNc2kSX3wxOAwoMJQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
     "longName": "99941004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)",
     "shortName": "Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ieNv8UfQuEu5yQKAxjemyA",
      "name": "armp:EquitySecuritiesMeasurementInput",
      "unitRef": "Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ieNv8UfQuEu5yQKAxjemyA",
      "name": "armp:EquitySecuritiesMeasurementInput",
      "unitRef": "Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails",
     "longName": "99941005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)",
     "shortName": "Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail",
     "longName": "99941101 - Disclosure - Income Taxes (Narrative) (Detail)",
     "shortName": "Income Taxes (Narrative) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "armp:OperatingLossCarryforwardsNotSubjectToExpiration",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "armp:OperatingLossCarryforwardsNotSubjectToExpiration",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails",
     "longName": "99941102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)",
     "shortName": "Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails",
     "longName": "99941103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)",
     "shortName": "Income Taxes (Components of Deferred Tax Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails",
     "longName": "99941104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)",
     "shortName": "Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "longName": "99941201 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:AnnualIncreaseInRentPercentage",
      "unitRef": "Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "armp:AnnualIncreaseInRentPercentage",
      "unitRef": "Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
     "longName": "99941202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)",
     "shortName": "Commitments and Contingencies (Future Minimum Lease Payments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
     "longName": "99941203 - Disclosure - Commitments and Contingencies (Operating leases) (Details)",
     "shortName": "Commitments and Contingencies (Operating leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
     "longName": "99941301 - Disclosure - Grant and Awards (Narrative) (Details)",
     "shortName": "Grant and Awards (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_e8KlhRKgsU2__dqtJNLl0Q",
      "name": "us-gaap:GovernmentAssistanceAwardAmount",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "armp:AwardTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_e8KlhRKgsU2__dqtJNLl0Q",
      "name": "us-gaap:GovernmentAssistanceAwardAmount",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "armp:AwardTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails",
     "longName": "99941401 - Disclosure - Employee Retirement Plan (Narrative) (Details)",
     "shortName": "Employee Retirement Plan (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails",
     "longName": "99941501 - Disclosure - Segment Reporting (Narrative) (Details)",
     "shortName": "Segment Reporting (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_sNn8LuEmwE69rUms--yKEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_sNn8LuEmwE69rUms--yKEA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails",
     "longName": "99941502 - Disclosure - Segment Reporting - Segment information (Details)",
     "shortName": "Segment Reporting - Segment information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
     "longName": "99941601 - Disclosure - Subsequent Events (Narrative) (Details)",
     "shortName": "Subsequent Events (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "armp:ConvertibleDebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Accounts Payable and Accrued Liabilities, Current, Total",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Other Accrued Liabilities",
        "verboseLabel": "Other accrued expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r730"
     ]
    },
    "armp_AccruedLiabilitiesClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "AccruedLiabilitiesClinicalTrial",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities clinical trial.",
        "label": "Accrued Liabilities Clinical Trial",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r123",
      "r537"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r730",
      "r1016"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r886",
      "r887",
      "r888",
      "r889",
      "r956",
      "r1018"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r327"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r799",
      "r832"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r792",
      "r802",
      "r835"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r827",
      "r836",
      "r840",
      "r848"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r368"
     ]
    },
    "armp_AllowanceForTenantImprovementsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "AllowanceForTenantImprovementsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for tenant improvements receivable.",
        "label": "Allowance For Tenant Improvements Receivable",
        "terseLabel": "Allowance for tenant improvements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "armp_AnnualIncreaseInRentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "AnnualIncreaseInRentPercentage",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in rent percentage.",
        "label": "Annual Increase in Rent Percentage",
        "terseLabel": "Annual increase in rent percentage"
       }
      }
     },
     "auth_ref": []
    },
    "armp_AnnualReductionOfStandbyLetterOfCredit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "AnnualReductionOfStandbyLetterOfCredit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual reduction of standby letter of credit..",
        "label": "Annual Reduction Of Standby Letter Of Credit",
        "terseLabel": "Annual reduction of standby letter of credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities excluded from computation of diluted weighted shares outstanding",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "armp_ArmataPharmaceuticalsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ArmataPharmaceuticalsInc.Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Armata Pharmaceuticals, Inc.",
        "label": "Armata Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Armata Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r105",
      "r126",
      "r148",
      "r190",
      "r198",
      "r216",
      "r220",
      "r229",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r416",
      "r420",
      "r453",
      "r530",
      "r621",
      "r695",
      "r696",
      "r730",
      "r756",
      "r915",
      "r916",
      "r974"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r131",
      "r148",
      "r229",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r416",
      "r420",
      "r453",
      "r730",
      "r915",
      "r916",
      "r974"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r785"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r785"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r785"
     ]
    },
    "armp_AwardAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "AwardAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about award abstract.",
        "label": "Grant and Awards"
       }
      }
     },
     "auth_ref": []
    },
    "armp_AwardAgreementInterruptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "AwardAgreementInterruptionPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product.",
        "label": "Award Agreement, Interruption Period",
        "terseLabel": "Award agreement interruption period"
       }
      }
     },
     "auth_ref": []
    },
    "armp_AwardAgreementWithCysticFibrosisFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "AwardAgreementWithCysticFibrosisFoundationMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to award agreement (the \"Award Agreement\") with CFF.",
        "label": "Award Agreement with Cystic Fibrosis Foundation [Member]",
        "terseLabel": "CFF Therapeutics Development Award"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "armp_AwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "AwardTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "represents about award text block.",
        "label": "Award Text Block",
        "terseLabel": "Grant and Awards"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "armp_BacteremiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "BacteremiaMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Bacteremia.",
        "label": "Bacteremia [Member]",
        "terseLabel": "AP-SA02: Bacteremia"
       }
      }
     },
     "auth_ref": []
    },
    "armp_BaseAnnualRentToBePaidYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "BaseAnnualRentToBePaidYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for base rent to be paid in year three.",
        "label": "Base Annual Rent To Be Paid Year Three",
        "terseLabel": "Base annual rent for 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "armp_C3jStockPlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "C3jStockPlan2016Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to C3J 2016 stock plan.",
        "label": "C3J Stock Plan 2016 [Member]",
        "terseLabel": "C3J Stock Plan 2016"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Axis]",
        "documentation": "Information by project."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r523",
      "r982"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r121",
      "r684"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Investments in money market fund - financial assets, included in cash and cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r957",
      "r958"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r92"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r71",
      "r145"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r71"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "terseLabel": "Cash",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r127",
      "r128",
      "r129",
      "r148",
      "r172",
      "r173",
      "r182",
      "r184",
      "r192",
      "r193",
      "r229",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r290",
      "r291",
      "r294",
      "r297",
      "r303",
      "r453",
      "r576",
      "r577",
      "r578",
      "r579",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r609",
      "r630",
      "r648",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r870",
      "r881",
      "r890"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "verboseLabel": "Warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r98",
      "r532",
      "r608"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r255",
      "r256",
      "r669",
      "r907",
      "r912"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total shares reserved",
        "totalLabel": "Total shares reserved",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r747",
      "r748",
      "r750",
      "r751",
      "r752",
      "r753",
      "r886",
      "r887",
      "r889",
      "r956",
      "r1015",
      "r1018"
     ]
    },
    "armp_CommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "CommonStockOptionsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time.",
        "label": "Common Stock Options [Member]",
        "verboseLabel": "Common Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r609"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r58",
      "r609",
      "r627",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, $0.01 par value; 217,000,000 shares authorized; 36,183,067 and 36,122,932 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r533",
      "r730"
     ]
    },
    "armp_CommonStockVotingPercentageHeldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "CommonStockVotingPercentageHeldPercentage",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting rights of the total number of shares of the common stock of company on matters related to election or removal of board members.",
        "label": "Common Stock, Voting Percentage Held Percentage",
        "terseLabel": "Total number of shares (in percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Retirement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "verboseLabel": "Comprehensive Income (Loss)",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risks and Certain Other Risks",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r109"
     ]
    },
    "us-gaap_ContributionOfProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContributionOfProperty",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of Property",
        "terseLabel": "Property and equipment included in accounts payable and accrued liabilities",
        "documentation": "Value of property contributed in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r14"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt.",
        "terseLabel": "Convertible loan principal amount",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r97",
      "r984"
     ]
    },
    "armp_ConvertibleDebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ConvertibleDebtDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for convertible debt.",
        "label": "Convertible Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible Loan- financial liabilities",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r958",
      "r959",
      "r960",
      "r961",
      "r963"
     ]
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible Loan, non-current",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r273",
      "r292",
      "r480",
      "r489",
      "r529",
      "r685",
      "r687"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "armp_CreditAgreement2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "CreditAgreement2023Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents 2023 credit agreement.",
        "label": "Credit Agreement 2023 [Member]",
        "terseLabel": "2023 Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "armp_CreditAgreement2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "CreditAgreement2024Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents 2024 credit agreement.",
        "label": "Credit Agreement 2024 [Member]",
        "terseLabel": "2024 Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "armp_CreditAgreement2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "CreditAgreement2025Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents 2025 credit agreement.",
        "label": "Credit Agreement 2025 [Member]",
        "terseLabel": "2025 Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "armp_CreditAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "CreditAndSecurityAgreementMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to credit and security agreement.",
        "label": "Credit And Security Agreement [Member]",
        "terseLabel": "Credit And Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r859"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r859"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r861"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r861"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r863"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r861"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r854"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r855"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r855"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r853"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r853"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r853"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r856"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r858"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r858"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r859"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r862"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r860"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r857"
     ]
    },
    "armp_CysticFibrosisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "CysticFibrosisMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Cystic fibrosis.",
        "label": "Cystic Fibrosis [Member]",
        "terseLabel": "AP-PA02: Cystic Fibrosis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r48",
      "r94",
      "r97",
      "r153",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r728",
      "r882",
      "r908",
      "r909",
      "r910",
      "r968",
      "r969"
     ]
    },
    "armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "DebtInstrumentConversionPercentOfDiscountOnSharePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent  of discount on share price for conversion of debt into shares of common stock.",
        "label": "Debt Instrument, Conversion, Percent of Discount on Share Price",
        "terseLabel": "Discount on share price for conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Price per share",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r272"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r464",
      "r465",
      "r703",
      "r704",
      "r728"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r271"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Term Loan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r728",
      "r882",
      "r968",
      "r969"
     ]
    },
    "armp_DebtInstrumentMeasurementInputForPeriod": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "DebtInstrumentMeasurementInputForPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instruments, including, but not limited to, convertible and non-convertible debt for the period.",
        "label": "Debt Instrument, Measurement Input For The Period",
        "terseLabel": "Debt instrument, measurement input, for the period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r153",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r728",
      "r882",
      "r908",
      "r909",
      "r910",
      "r968",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r29",
      "r41",
      "r84",
      "r85",
      "r153",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r728",
      "r882",
      "r968",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r967",
      "r968",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance cost and debt discount",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r287",
      "r463",
      "r464",
      "r465",
      "r703",
      "r704",
      "r728"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Liability, Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r87"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r967",
      "r968",
      "r969"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r95",
      "r392"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r531"
     ]
    },
    "armp_DeferredTaxAssetLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "DeferredTaxAssetLeaseObligation",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset lease obligation.",
        "label": "Deferred Tax Asset Lease Obligation",
        "terseLabel": "Lease accounting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "armp_DeferredTaxAssetsInterestExpenseCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "DeferredTaxAssetsInterestExpenseCarryForwards",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible interest expense carry forwards.",
        "label": "Deferred Tax Assets, Interest Expense Carry-forwards",
        "terseLabel": "Interest expense carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total deferred tax assets after valuation allowance",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Capitalized research and development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "armp_DeferredTaxLiabilitiesDebtBasisDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "DeferredTaxLiabilitiesDebtBasisDifferences",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from debt basis differences.",
        "label": "Deferred Tax Liabilities, Debt Basis Differences",
        "negatedLabel": "Debt basis differences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "In-process research and development",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "armp_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "Deferred Tax Liabilities Right of Use Asset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "verboseLabel": "Employer contribution to 401(k) plan",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r24"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r190",
      "r203",
      "r220",
      "r695",
      "r696"
     ]
    },
    "armp_DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from gain on debt and extinguishment of debt.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Gain on Debt And (Extinguishment of Debt)",
        "terseLabel": "Gain on debt and the Convertible Loan extinguishments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Gain from change in fair value of the Convertible Loan",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Equity Incentive Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r329",
      "r360",
      "r361",
      "r363",
      "r714"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plans"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r785"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r785",
      "r828"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Domestic Tax Jurisdiction",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share",
        "terseLabel": "Per share information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r169",
      "r172",
      "r182",
      "r183",
      "r184",
      "r189",
      "r410",
      "r413",
      "r430",
      "r431",
      "r526",
      "r543",
      "r688"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r172",
      "r182",
      "r183",
      "r184",
      "r189",
      "r410",
      "r413",
      "r430",
      "r431",
      "r526",
      "r543",
      "r688"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r186"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r185",
      "r187",
      "r188"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r717"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Adjustments for tax effects of:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "U.S. federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r378",
      "r402",
      "r717"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r717",
      "r885",
      "r949"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r717",
      "r885",
      "r949"
     ]
    },
    "armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for debt items.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Items, Percent",
        "terseLabel": "Non-deductible debt items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r885",
      "r949",
      "r951"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "verboseLabel": "Permanent differences and other",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "armp_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a return to provision.",
        "label": "Effective Income Tax Rate Reconciliation, Return To Provision, Percent",
        "terseLabel": "Return to provision"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State income taxes, net of federal tax",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r717",
      "r885",
      "r949"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted-average remaining period for recognition of compensation costs related to unvested options",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost related to unvested options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "documentation": "Information by name of employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares",
        "verboseLabel": "Shares issuable under the Employee stock purchase plan",
        "documentation": "The shares that, although not legally released, will be released by a future scheduled and committed debt service payment and will be allocated to employees for service rendered in the current accounting period. The ESOP documents typically define the period of service to which the shares relate. ESOP shares are released to compensate employees directly, to settle employer liabilities for other employee benefits, and to replace dividends on allocated shares that are used for debt service."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]",
        "documentation": "Entities identify multiple employee stock ownership plans by unique name."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "armp_EmployeeStockPurchasePlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "EmployeeStockPurchasePlan2016Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2016 [Member]",
        "label": "Employee Stock Purchase Plan 2016 [Member]",
        "terseLabel": "Employee Stock Purchase Plan 2016"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r116",
      "r135",
      "r136",
      "r137",
      "r154",
      "r155",
      "r156",
      "r158",
      "r163",
      "r165",
      "r167",
      "r191",
      "r230",
      "r231",
      "r248",
      "r305",
      "r400",
      "r401",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r466",
      "r467",
      "r479",
      "r542",
      "r566",
      "r567",
      "r568",
      "r583",
      "r648"
     ]
    },
    "armp_EquityIncentivePlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "EquityIncentivePlan2016Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2016 [Member]",
        "label": "Equity Incentive Plan 2016 [Member]",
        "terseLabel": "Equity Incentive Plan 2016"
       }
      }
     },
     "auth_ref": []
    },
    "armp_EquitySecuritiesMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "EquitySecuritiesMeasurementInput",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value for the period.",
        "label": "Equity Securities Measurement Input",
        "terseLabel": "Fair value input, equity securities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r799",
      "r832"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r796",
      "r829"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "armp_ExercisePriceEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ExercisePriceEightMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eight [Member].",
        "label": "Exercise Price $5.00, February 8, 2027"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five [Member].",
        "label": "Exercise Price $2.87, March 27, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four [Member].",
        "label": "Exercise Price $2.87, February 11, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ExercisePriceNineMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price nine.",
        "label": "Exercise Price $5.00, March 30, 2027"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ExercisePriceSevenMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seven [Member].",
        "label": "Exercise Price $3.25, March 16, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ExercisePriceSixMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Exercise Price Five Member.",
        "label": "Exercise Price $3.25, January 26, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ExercisePriceTenMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price ten.",
        "label": "Exercise Price 1680.00"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExternalResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ExternalResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails": {
       "parentTag": "armp_ExternalResearchAndDevelopmentExpenseTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of external research and development expenses incurred during the period.",
        "label": "External Research and Development Expense",
        "terseLabel": "External research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExternalResearchAndDevelopmentExpenseTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ExternalResearchAndDevelopmentExpenseTotal",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total external research and development expenses incurred during the period.",
        "label": "External Research and Development Expense, Total",
        "totalLabel": "Total external research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r724"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r724"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r445",
      "r446",
      "r448",
      "r484",
      "r485",
      "r486",
      "r703",
      "r704",
      "r710",
      "r711",
      "r712",
      "r720",
      "r724"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r524",
      "r720",
      "r725"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r309",
      "r314",
      "r433",
      "r446",
      "r484",
      "r710",
      "r711",
      "r712",
      "r720"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "verboseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r433",
      "r434",
      "r435",
      "r436",
      "r446",
      "r486",
      "r703",
      "r704",
      "r710",
      "r711",
      "r712",
      "r720",
      "r724"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of changes in the fair value of its Convertible Loan",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r957",
      "r958"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r447"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of estimated the fair value of its Convertible Loan using inputs",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r442",
      "r447"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount exchanged in financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Amount Exchanged",
        "terseLabel": "Amount exchanged"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Loss on the Convertible Loan extinguishment",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r447"
     ]
    },
    "armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of initial recognition of modified convertible loan of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Initial Recognition of modified Convertible Loan",
        "terseLabel": "Initial recognition of modified Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Net issuance of the Convertible Loan",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r447"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r964"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Convertible Loan at the end of the period",
        "periodStartLabel": "Convertible Loan at the beginning of the period",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r447"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r445",
      "r446",
      "r448",
      "r484",
      "r485",
      "r486",
      "r703",
      "r704",
      "r710",
      "r711",
      "r712",
      "r720",
      "r724"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r447"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "terseLabel": "Foreign Tax Jurisdiction",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Foreign Currency Translations and Transactions",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r836"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r836"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r836"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r836"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r836"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss from disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r905",
      "r906"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain (loss) on debt and Convertible Loan extinguishments",
        "terseLabel": "Loss on convertible loan extinguishment",
        "verboseLabel": "Gain (loss) on debt and the Convertible Loan extinguishments",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r26",
      "r27"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "totalLabel": "Total general and administrative expenses",
        "verboseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r632"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r233",
      "r525",
      "r696",
      "r701",
      "r722",
      "r730",
      "r899",
      "r900"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r244",
      "r701"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r234",
      "r240",
      "r244",
      "r701",
      "r722"
     ]
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Income, Increase (Decrease)",
        "terseLabel": "Grant revenue from the MTEC Agreement",
        "documentation": "Amount of increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_GovernmentAssistanceAssetIncreaseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceAssetIncreaseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Asset, Increase, Current",
        "terseLabel": "Increase in expected revenue from grants",
        "documentation": "Amount of increase in asset from government assistance, classified as current."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Asset, Increase, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes increase in asset from government assistance, classified as current."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_GovernmentAssistanceAwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceAwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Award Amount",
        "terseLabel": "Revenue from grants",
        "documentation": "Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_GovernmentAssistanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_GovernmentAssistanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Table]",
        "documentation": "Disclosure of information about government assistance."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Axis]",
        "documentation": "Information by type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Domain]",
        "documentation": "Type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "armp_GrantAndAwardReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "GrantAndAwardReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of awards receivable current.",
        "label": "Grant and Award Receivable, Current",
        "verboseLabel": "Grant and award receivable (Note 13)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrantMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant [Member]",
        "terseLabel": "Grant",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "armp_GrantsAndAwardsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "GrantsAndAwardsPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about the grants and awards policy.",
        "label": "Grants And Awards Policy Text Block",
        "terseLabel": "Grants Revenue and Other Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrantsReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable, Current",
        "terseLabel": "Grants receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r785"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "verboseLabel": "Impairment of in-process research and development",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r879",
      "r902",
      "r903"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "verboseLabel": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r23",
      "r78",
      "r721"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r79"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "verboseLabel": "In-Process Research and Development (\"IPR&amp;D\")",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r377"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r100",
      "r104",
      "r527",
      "r539",
      "r690",
      "r695",
      "r892",
      "r894",
      "r895",
      "r896",
      "r897"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "verboseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r377"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r251",
      "r252",
      "r438",
      "r442",
      "r447",
      "r563",
      "r565",
      "r633",
      "r681",
      "r723",
      "r986"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r438",
      "r442",
      "r447",
      "r563",
      "r565",
      "r633",
      "r681",
      "r723",
      "r986"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r378",
      "r379",
      "r387",
      "r397",
      "r717",
      "r954"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r378",
      "r379",
      "r387",
      "r397",
      "r717",
      "r954"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r371",
      "r378",
      "r384",
      "r385",
      "r386",
      "r389",
      "r396",
      "r403",
      "r404",
      "r405",
      "r406",
      "r581",
      "r717"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Accrued interest or penalties",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r373",
      "r374",
      "r389",
      "r390",
      "r395",
      "r399",
      "r575"
     ]
    },
    "armp_IncreaseDecreaseFairValueOfLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "IncreaseDecreaseFairValueOfLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) fair value of liabilities.",
        "label": "Increase Decrease Fair Value of Liabilities",
        "terseLabel": "Change in fair value of the Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Compensation",
        "terseLabel": "Accrued compensation",
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r878"
     ]
    },
    "armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in operating lease right of use asset.",
        "label": "Increase (Decrease) in Operating Lease Right Of Use Asset",
        "negatedLabel": "Change in right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Shares issuable upon the conversion of the Convertible Loan",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r184"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r827",
      "r836",
      "r840",
      "r848"
     ]
    },
    "armp_InnovivaStrategicOpportunitiesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "InnovivaStrategicOpportunitiesLlcMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva Strategic Opportunities LLC [Member].",
        "label": "Innoviva Strategic Opportunities LLC [Member]",
        "terseLabel": "Innoviva Strategic Opportunities LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r852"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r852"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r852"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "In-process research and development",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r901",
      "r902"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r283",
      "r288",
      "r705",
      "r706"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable",
        "terseLabel": "Accrued and unpaid interest",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r983"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "General and administrative personnel expenses",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "armp_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandAndBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandAndBuildingMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land and Building [Member]",
        "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Operating leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r478"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Standby letter of credit",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r48",
      "r49",
      "r51",
      "r52",
      "r53",
      "r56",
      "r148",
      "r229",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r417",
      "r420",
      "r421",
      "r453",
      "r607",
      "r689",
      "r756",
      "r915",
      "r974",
      "r975"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r99",
      "r535",
      "r730",
      "r883",
      "r898",
      "r965"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r120",
      "r148",
      "r229",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r417",
      "r420",
      "r421",
      "r453",
      "r730",
      "r915",
      "r974",
      "r975"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Change in fair value, gain (loss)",
        "verboseLabel": "Change in fair value of the Convertible Loan",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "armp_LiquidityAndGoingConcernAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "LiquidityAndGoingConcernAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity And Going Concern [Abstract]",
        "label": "Liquidity and Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "armp_LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation and current convertible debt.",
        "label": "Long-Term Debt, Current Maturities Other Than Convertible Debt Current",
        "terseLabel": "Term debt, current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Recognized at fair value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": [
      "r957",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Term Debt",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermConvertibleDebtCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r324",
      "r369",
      "r436",
      "r490",
      "r562",
      "r564",
      "r571",
      "r598",
      "r599",
      "r653",
      "r655",
      "r657",
      "r658",
      "r660",
      "r679",
      "r680",
      "r700",
      "r707",
      "r713",
      "r724",
      "r725",
      "r726",
      "r727",
      "r740",
      "r917",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected dividend yield",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term (in years)",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Volatility",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate",
        "verboseLabel": "Risk-free interest rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r724"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r724"
     ]
    },
    "armp_MedicalTechnologyEnterpriseConsortiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "MedicalTechnologyEnterpriseConsortiumMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Technology Enterprise Consortium [Member].",
        "label": "Medical Technology Enterprise Consortium [Member]",
        "terseLabel": "MTEC Grant"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r324",
      "r369",
      "r436",
      "r490",
      "r562",
      "r564",
      "r571",
      "r598",
      "r599",
      "r653",
      "r655",
      "r657",
      "r658",
      "r660",
      "r679",
      "r680",
      "r700",
      "r707",
      "r713",
      "r724",
      "r725",
      "r726",
      "r740",
      "r917",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Parent",
        "terseLabel": "Outstanding equity (in percent)",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r73",
      "r101",
      "r118",
      "r132",
      "r133",
      "r137",
      "r148",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r166",
      "r167",
      "r180",
      "r229",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r410",
      "r413",
      "r431",
      "r453",
      "r541",
      "r629",
      "r646",
      "r647",
      "r754",
      "r915"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders, basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r159",
      "r160",
      "r161",
      "r162",
      "r169",
      "r170",
      "r181",
      "r184",
      "r413"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common stockholders, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r171",
      "r174",
      "r175",
      "r176",
      "r177",
      "r181",
      "r184"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "armp_NonCysticFibrosisBronchiectasisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "NonCysticFibrosisBronchiectasisMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Non-cystic fibrosis bronchiectasis.",
        "label": "Non-Cystic Fibrosis Bronchiectasis [Member]",
        "terseLabel": "AP-PA02: Non-Cystic Fibrosis Bronchiectasis"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r827",
      "r836"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "armp_NoncashInterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "NoncashInterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income included in net income that result in no cash inflow",
        "label": "Noncash Interest Income",
        "negatedLabel": "Non-cash interest income"
       }
      }
     },
     "auth_ref": []
    },
    "armp_NumberOfBoardDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "NumberOfBoardDirectors",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Board directors during the period",
        "label": "Number of Board Directors"
       }
      }
     },
     "auth_ref": []
    },
    "armp_NumberOfDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "NumberOfDirectors",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors during the period",
        "label": "Number of Directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r893"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r699",
      "r893"
     ]
    },
    "armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "NumberOfStandbyLettersOfCreditIncludedInRestrictedCash",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of irrevocable letters of credit with financial institutions.",
        "label": "Number of Standby Letters of Credit included in Restricted Cash",
        "verboseLabel": "Letters of credit"
       }
      }
     },
     "auth_ref": []
    },
    "armp_OfficeAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "OfficeAndComputerEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Computer Equipment [Member]",
        "label": "Office and Computer Equipment [Member]",
        "terseLabel": "Office and computer equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "terseLabel": "Office and computer equipment",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r690",
      "r892",
      "r894",
      "r895",
      "r896",
      "r897"
     ]
    },
    "armp_OperatingLeaseBaseAnnual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "OperatingLeaseBaseAnnual",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of annual base rent for operating lease.",
        "label": "Operating Lease Base Annual",
        "terseLabel": "Annual base rent for operating lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "verboseLabel": "Rent expense under operating leases",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of operating lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Noncurrent operating lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r473"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate, %",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r729"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term, years",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r729"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "armp_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards that are not subject to expiration dates.",
        "label": "Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating Loss Carryforwards, Not Subject to Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of the Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Organization and Description of the Business",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r91",
      "r572",
      "r573"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other receivables",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r730"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_OtherExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpensesAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses [Abstract]",
        "verboseLabel": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other general and administrative expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r1017"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r730"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "Interest income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Total other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current",
        "totalLabel": "Other receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r791",
      "r801",
      "r834"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r794",
      "r804",
      "r837"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r794",
      "r804",
      "r837"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payments for taxes related to net share settlement of equity awards",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "Employee Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r712"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "armp_PercentageOfLongLivedAssetsInGeographicalLocation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "PercentageOfLongLivedAssetsInGeographicalLocation",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of long lived assets In geographical location.",
        "label": "Percentage of Long Lived Assets In Geographical Location",
        "terseLabel": "Percentage of long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "armp_ProbabilitiesOfSettlementScenariosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ProbabilitiesOfSettlementScenariosMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of probability of settlement scenarios.",
        "label": "Probabilities of Settlement Scenarios [Member]",
        "terseLabel": "Probabilities of settlement scenarios"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of the Convertible Loan, net of issuance costs",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "armp_ProceedsFromExerciseOfWarrantsAndStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ProceedsFromExerciseOfWarrantsAndStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of warrants and stock options.",
        "label": "Proceeds From Exercise Of Warrants And Stock Options",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ProceedsFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ProceedsFromGovernmentGrants",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow associated with government grants.",
        "label": "Proceeds from Government Grants",
        "terseLabel": "Proceeds from governments grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from issuance of term debt, net of issuance costs",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ProceedsFromQualifiedFinancingPerAgreementBenchmark",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from qualified financing per agreement benchmark.",
        "label": "Proceeds from Qualified Financing Per Agreement Benchmark",
        "terseLabel": "Proceeds from qualified financing per agreement benchmark"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Related Party Debt",
        "verboseLabel": "Total debt financing",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r491",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r682",
      "r708",
      "r739",
      "r740",
      "r741",
      "r744",
      "r745",
      "r913",
      "r914",
      "r919",
      "r985",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r491",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r682",
      "r708",
      "r739",
      "r740",
      "r741",
      "r744",
      "r745",
      "r913",
      "r914",
      "r919",
      "r985",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r132",
      "r133",
      "r142",
      "r148",
      "r157",
      "r163",
      "r166",
      "r167",
      "r229",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r410",
      "r413",
      "r415",
      "r418",
      "r419",
      "r431",
      "r453",
      "r527",
      "r540",
      "r582",
      "r629",
      "r646",
      "r647",
      "r718",
      "r719",
      "r755",
      "r876",
      "r915"
     ]
    },
    "us-gaap_ProjectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProjectMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Domain]",
        "documentation": "Planned program of work."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r523",
      "r982"
     ]
    },
    "armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of property and equipment not in use included in laboratory equipment.",
        "label": "Property and Equipment Not in Use Included in Laboratory Equipment",
        "terseLabel": "Property and equipment not in use"
       }
      }
     },
     "auth_ref": []
    },
    "armp_PropertyAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "PropertyAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of property and equipment including, but not limited to, laboratory equipment, office and computer equipment, and leasehold improvements.",
        "label": "Property and Equipment, Useful Life [Table Text Block]",
        "verboseLabel": "Schedule of useful lives of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Details"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r478"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Balance Sheet Details",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r110",
      "r113",
      "r114"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r122",
      "r538"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Long-lived assets",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r478",
      "r528",
      "r538",
      "r730"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r110",
      "r113",
      "r536"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r478"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "armp_ProstheticJointInfectionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ProstheticJointInfectionMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Prosthetic joint infection.",
        "label": "Prosthetic Joint Infection [Member]",
        "terseLabel": "AP-SA02Prosthetic Joint Infection"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r307",
      "r324",
      "r355",
      "r356",
      "r357",
      "r369",
      "r436",
      "r487",
      "r488",
      "r490",
      "r562",
      "r564",
      "r571",
      "r598",
      "r599",
      "r653",
      "r655",
      "r657",
      "r658",
      "r660",
      "r679",
      "r680",
      "r700",
      "r707",
      "r713",
      "r724",
      "r725",
      "r726",
      "r727",
      "r740",
      "r748",
      "r911",
      "r917",
      "r960",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r307",
      "r324",
      "r355",
      "r356",
      "r357",
      "r369",
      "r436",
      "r487",
      "r488",
      "r490",
      "r562",
      "r564",
      "r571",
      "r598",
      "r599",
      "r653",
      "r655",
      "r657",
      "r658",
      "r660",
      "r679",
      "r680",
      "r700",
      "r707",
      "r713",
      "r724",
      "r725",
      "r726",
      "r727",
      "r740",
      "r748",
      "r911",
      "r917",
      "r960",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r796",
      "r829"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r273",
      "r292",
      "r480",
      "r489",
      "r529",
      "r686",
      "r687"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development expenses",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "armp_ResearchAndDevelopmentPersonnelExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ResearchAndDevelopmentPersonnelExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel expenses incurred in connection with research and development.",
        "label": "Research and Development, Personnel Expense",
        "terseLabel": "Research and development personnel expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r797",
      "r830"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r798",
      "r831"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r795",
      "r805",
      "r838"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r873",
      "r880"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock returned shares issued net of tax withholdings.",
        "label": "Restricted Stock Returned Shares Issued Net Of Tax Withholdings",
        "negatedLabel": "Withholdings for taxes related to net share settlement of equity awards, shares"
       }
      }
     },
     "auth_ref": []
    },
    "armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock returned value shares issued net of tax withholdings .",
        "label": "Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings",
        "negatedLabel": "Withholdings for taxes related to net share settlement of equity awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Issuance of common stock upon release of restricted stock units, net of tax withholdings (In shares)",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock unit",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Issuance of common stock upon release of restricted stock units, net of tax withholdings",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r86",
      "r534",
      "r569",
      "r570",
      "r580",
      "r610",
      "r730"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r154",
      "r155",
      "r156",
      "r158",
      "r163",
      "r165",
      "r167",
      "r230",
      "r231",
      "r248",
      "r400",
      "r401",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r422",
      "r424",
      "r425",
      "r427",
      "r429",
      "r466",
      "r467",
      "r566",
      "r568",
      "r583",
      "r1018"
     ]
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueNotFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Not from Contract with Customer",
        "verboseLabel": "Grant revenue",
        "documentation": "Amount of revenue that is not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r729"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of common shares reserved for future issuance.",
        "label": "Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]",
        "verboseLabel": "Schedule of Shares Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Components of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of Reconciliation of Statutory to Effective Tax Rates",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r717",
      "r949"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Stock-Based Compensation Expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "verboseLabel": "Schedule of (Loss) Income from Continuing Operations Before Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "armp_ScheduleOfOtherReceivablesCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ScheduleOfOtherReceivablesCurrentTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current receivables.",
        "label": "Schedule of Other Receivables, Current [Table Text Block]",
        "terseLabel": "Schedule of Other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r478"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of certain segment information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were assumed in merger during the reporting period pertaining to the stock option plan.",
        "label": "Schedule of Share Based Compensation Restricted Stock Award Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r88"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in the Black-Scholes Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "verboseLabel": "Schedule of Warrant Information",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Long-Term Debt, Noncurrent",
        "terseLabel": "Term debt, non-current",
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "armp_SecuredTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "SecuredTermLoanMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to secured term loan.",
        "label": "Secured Term Loan [Member]",
        "terseLabel": "Secured term loan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r190",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r227",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r253",
      "r254",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r692",
      "r695",
      "r696",
      "r701",
      "r743",
      "r985",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r595",
      "r596",
      "r597",
      "r654",
      "r656",
      "r659",
      "r661",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r683",
      "r709",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r742",
      "r748",
      "r919",
      "r985",
      "r987",
      "r988",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r190",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r210",
      "r212",
      "r213",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r691",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period of share-based compensation award",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "verboseLabel": "Unvested restricted stock units",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Avg Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per shares)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants under the 2016 Plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at December 31, 2024",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercisable at December 31, 2024",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options forfeited in period intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Forfeited/Cancelled/Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited/Cancelled/Expired",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding Ending",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Beginning",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Balance Ending",
        "periodStartLabel": "Shares, Balance Beginning",
        "verboseLabel": "Stock options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2024",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Vested and expected to vest at December 31, 2024",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Vested and expected to vest at December 31, 2024",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of annual increase in number of shares",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Additional awards",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Cancelled/Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r333",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "verboseLabel": "Common stock closing price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "verboseLabel": "Expiration period of share-based payment award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2024",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2024",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at December 31, 2024",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of vested options",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "armp_SharesIssuableUponConversionOfConvertibleDebt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "SharesIssuableUponConversionOfConvertibleDebt",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issuable upon conversion of convertible debt.",
        "label": "Shares Issuable Upon Conversion Of Convertible Debt",
        "terseLabel": "Shares issuable upon the conversion of the Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "armp_SharesIssuableUponConversionOfConvertibleLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "SharesIssuableUponConversionOfConvertibleLoanMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issuable upon the conversion of Convertible Loan",
        "label": "Shares issuable upon the conversion of Convertible Loan",
        "verboseLabel": "Shares issuable upon the conversion of the Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balances (in shares)",
        "periodStartLabel": "Balances (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r146"
     ]
    },
    "armp_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to single reportable segment.",
        "label": "Single Reportable Segment [Member]",
        "terseLabel": "Single Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State Tax Jurisdiction",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r117",
      "r190",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r227",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r250",
      "r253",
      "r254",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r692",
      "r695",
      "r696",
      "r701",
      "r743",
      "r985",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r127",
      "r128",
      "r129",
      "r148",
      "r172",
      "r173",
      "r182",
      "r184",
      "r192",
      "r193",
      "r229",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r290",
      "r291",
      "r294",
      "r297",
      "r303",
      "r453",
      "r576",
      "r577",
      "r578",
      "r579",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r609",
      "r630",
      "r648",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r870",
      "r881",
      "r890"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r58",
      "r61",
      "r62",
      "r116",
      "r135",
      "r136",
      "r137",
      "r154",
      "r155",
      "r156",
      "r158",
      "r163",
      "r165",
      "r167",
      "r191",
      "r230",
      "r231",
      "r248",
      "r305",
      "r400",
      "r401",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r466",
      "r467",
      "r479",
      "r542",
      "r566",
      "r567",
      "r568",
      "r583",
      "r648"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r595",
      "r596",
      "r597",
      "r654",
      "r656",
      "r659",
      "r661",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r683",
      "r709",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r742",
      "r748",
      "r919",
      "r985",
      "r987",
      "r988",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails",
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "Organization and Description of the Business",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r191",
      "r467",
      "r491",
      "r574",
      "r594",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r631",
      "r632",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r749"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureConvertibleLoanNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardAndRestrictedStockUnitAwardActivityDetails",
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r191",
      "r228",
      "r467",
      "r491",
      "r574",
      "r594",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r631",
      "r632",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r749"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r790",
      "r800",
      "r833"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r58",
      "r61",
      "r86",
      "r280"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Forfeiture of restricted stock awards (in shares)",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r57",
      "r58",
      "r86"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised",
        "verboseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r57",
      "r58",
      "r86",
      "r339"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r58",
      "r61",
      "r62",
      "r86"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedLabel": "Forfeiture of restricted stock awards",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r57",
      "r58",
      "r86"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r58",
      "r61",
      "r62",
      "r86"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "terseLabel": "Outstanding stock options",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "armp_StockOptionsAndRestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "StockOptionsAndRestrictedStockAwardsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Awards [Member].",
        "label": "Stock Options And Restricted Stock Awards [Member]",
        "terseLabel": "Stock Options And Restricted Stock Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders' deficit",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r75",
      "r611",
      "r627",
      "r649",
      "r650",
      "r730",
      "r756",
      "r883",
      "r898",
      "r965",
      "r1018"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "verboseLabel": "Stockholders' Deficit",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r147",
      "r289",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r428",
      "r651",
      "r652",
      "r667"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events",
        "verboseLabel": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r482"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r483"
     ]
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "verboseLabel": "Liquidity and Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_TechnologyEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TechnologyEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Equipment [Member]",
        "terseLabel": "Laboratory equipment",
        "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals."
       }
      }
     },
     "auth_ref": []
    },
    "armp_TenantImprovementReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "TenantImprovementReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of current tenant improvement receivable.",
        "label": "Tenant Improvement Receivable, Current",
        "terseLabel": "Tenant improvement allowance receivable (Note 12)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "armp_UnallocatedExternalResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "UnallocatedExternalResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails": {
       "parentTag": "armp_ExternalResearchAndDevelopmentExpenseTotal",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSegmentReportingSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of external research and development expense not allocated by projects.",
        "label": "Unallocated External Research and Development Expense",
        "terseLabel": "Expenses not allocated by projects"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r388",
      "r716"
     ]
    },
    "armp_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Unvested Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r107",
      "r108",
      "r111",
      "r112"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_VariableLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeasePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Payment",
        "terseLabel": "Variable lease payment",
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "armp_WarrantExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.armatapharma.com/20241231",
     "localname": "WarrantExpirationDate",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the terms related with expiration of warrants.",
        "label": "Warrant Expiration Date",
        "terseLabel": "Warrant Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Outstanding warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r747",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted",
        "totalLabel": "Weighted average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r184"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareBasicAndDilutedEpsDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r184"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-9"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii)(B)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1B"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001558370-25-003406-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-003406-xbrl.zip
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MG_:OAV,'9.H0[:W?CV079Q TIGX'8#QV'7 EG/JW<J[(B*JA%A6K#C9(N0R
M+-.8TEDR]L"_KL34&P^E O>J!#[9L0Y*1K7TI_1&-_S:PP/I W*YK..%LBSI
MCSUJ@!Y4Q<.=O2_P[M/^92V_GY+C'_MI[=!1W6;GE!OVTCJPP*S6L!*?#YY
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M?,J!\UW'YYGI;(PMTKDN+2^IE?-^Y]/I/AG ;O#K-U 33"-R@LLR,^TY\R5
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M6\B 3L=!D2>SQ1ONU,:1[?Y&WB8GH-N(PI*U)%[RB$Z*B5E6?^T6H<+^RHY
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MVP")Q',VUA ]9ID>LTS-M0FW+ID105'J?,SOHU*(RZKEP>2A6E$#QU?%)KC
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MA,$Y?ROI,P4/;!J.%DRPIZH27+!>L XO^4U)47[:GZL.H%8M(<]4K<RMJ#N
MZ;I%MW)K,L_@O^2>&<K=M9=1LD)$W';<7MBV_0.(8O2F$K8\&-/'=^4&1*0$
M?D$N_SLM3A8^2$;4-' ?@U#4[TWB K2Q9^_[W;PAWIDC>G/*(SO?I6,+_UVX
M'=UQ8V?.FSSQ)@?@SRN8=;XY=YF*>.A^B5#\F>!D'40+G2_/KNFP%J6$4_'Q
MGP'38.(M-U/TA$+-@=2V,1B/8!/AE6V"+:&C+@[2&;^+KO9PVK /&,?49CHL
ME:L=N3#$>QVQ4P45=)UIDZFT+0 <<ELIK%1\,@+!">M#8V%] '02[D58'V )
M2[8F7 41^RYPPR+4>^&F[Z&:CLC[=SO: ;HKCBC64,W:>WA':WE=SG9/76R.
M%6K2H#TD,]"A9C3@ )RC>.F--%X\(L%691>L6@(X/O<B:AO:P1V;N2/7C3;W
MTA^_4L:.=#5+5[86I^B=_!CE*3I#Y=^I$D3@XPB$G ].BM(AG:ME/HJ,0'\6
MW?&K*?C;A>D]:R3_\]RE >7MA>OE 7G+*/@K0=3J/-[+D,=S_ #G^!Z5Y7C^
M/Y[_H9__#^1(.>3Y'\:1LD21P,V0V:,&!Y/.,[3)5;,$G&"U%E77 (;Y-.FJ
M22H@K&,=,;Z;YEGEO(1?:R1M&@*PE6:]TXE)1E0/:4"W!#\6-F$VOT=QG'IL
M[CT4N>Q4)[]UNV%; %X0.VDTI O4_)D)/'[%(;/7#/=-HSFD:@S J;'?/%(1
M!DITE\]KQ$MG>6)"([')&@*H4-Q/9#*B0(GK+J!_7A&$RI?.-!*;K@, I8K[
MB4]'W/%14EL/;L][]F/1U+%HZE@T=2R:.KCHP$ZL:I@(P112B+]GCDK]=;VL
M1U N ZK>)5C?T%QA<HO8L<^OJ5RSI@#.P$,J4#/FP(L?+[F5I==1\>ML7F)6
MBX#Q!_N <3JV$T1E&#QW2@@<4GA8KV1"J[Y&^)$B\L3-0GJ(0,P*>*Q5JFLV
M(>'.ACF&@0<( W>L%,?0[S'T>PS]'D._8Z]4UL>33H<:_TC2 ^>DNM/9LG%X
M6<L=\N#"#3W^@@3[>(?#D&W$O[FD?KP9<%Q(9Z/#T605-^%D7,O6C-^">+E#
M&*U21JM\R%FU^57S>$A/8T%:>?N>^*;-5@?L/'S=5-!W36FBK!_H::R793;[
MUTT#._N^<J=KM+G(W9##+E+IS^9?L!_, ^27BC;X<Y RQ^68V #(*AE4<4=G
M^(LUNZD#^3KR".L.?4+I_\.88=78 !)P7H)95K'WP,QT^I[8Y;,GO/K2&%+?
M(P)(*3IX<[O#U!=K4C\SJ?)+Y[=O>^0O3PYC5G7C [@__B685AV+ >IU0^]+
MC<BBW)F_@^'A%=I>_34-J.KU@J$&A^1?&,I^2#6[9SZ/F6%P@\0K'FQ#<\]@
MT"2* S\($_X2H_B"I@^P(/^*R26]@M1--_2?.!CR4Z@9DP!_A8GQJ''^P0^[
M!>L,*X>CY:P1<<0(SG=EU-+OJ),CYW"M<4KH\92$#,$<MH3B 60H;*\/K8B$
M*Z(PZTJQY J=2]3N.8AN!AG6!N^)\_E&WH$FI:'7$<'D0?2C>F7#VBL?1]T7
MR!&[<5?ZLDYS,Q@)$@-,.;.>E-DR\MN8V/LS+>+2ID](X !LK6Q5M?IBY@XE
M/7@YOD9/B+*5>_MNHQA77>UI:  @%M&$V38D]<#U=)O$ P[<;']=LS.@<-52
M,95K;ENU+%IU \#IWEA"K0@=U5[]QM]8-SR97(,!X"]N8Z=J5 Q>M7/!'7*(
MK%T2;SBFBBH_.1B82SKZVPBJB1^^V@^M$^(MV0%OLB HO7NNAIGR:?<&;<>O
M%-3I9%$T:$]0#RO0=13AI^#)O8^)&Z-%X,W6:TSB)!+:-@T]]:ICW73L2L.F
MVE8L-]84CKK$5*MJ-$=I&2"82N?^3\ R\@$)SGA@58/#.*BJ]5 MA9ZMFU"?
M].8(PPY:#@C@R&A2DNW>6$X"0->,]52>&K+GN^M^M(SYKCDD?PZK&Y-Z>#GR
M>]*=!OG[4;Z\;[".DFYTL",NP8E"U^Z_5BC'#A18;TLW8MZA%X[ \GN';MT-
M-V,7"2%(/ MV@R,O_4,A1*N68+TUW0C6B@=PA%W=+96OG!(9 3ZCV6,_N M5
M>+9)!P#RZ/H4?1-60-6 DEW:>HIO2>"A,RL%T+8'D'TVG/RUG!@SFZ;\MD66
M89(_ %E^^[%QBLS?=E-DLJ$<,9:3]>A\EP\G7D8L!CRHA!>[!]Z5J2RFYD#>
M6-U]]-SV]=1R2X!)(W;BLWHCM4PIS)=RC1=V6[6$X3-KH*I6TH-SF[?K+=GB
M0BHV6'\IJJX% $=<PX?DK<@:543BQBX<XL7&3D :> #BL5"XLE@TQ(PJE-E\
MSK94=@)1P +P*#44AH(0F,O/+%XBPN>\_"K\%NT!"*RE<6M Y+BE(PD[]\0)
MS[7WKX)G_DDO/5T# ,:NL7)62BPTM(TJI2D[/S&<SI,@Y!4#6@$I8 &X65M.
M)05!XPJ$5]@N<>A?K]8$/Z5W?.G%HFL!8.)H5:PB#ATA,!<F4[34IN%H<5![
MJN013M,)^/!BETJ*/A-,&\LX:P1YJZ&5M(DP. [HB><E*U[&B_Q/:$V0EY8H
MLL\A$@QG%FB%21S\2WRO)$P5=NZL>\AKI587NF,!'*U1(GF#5)J@;P(@+MGQ
M3!=DC1EIJ-47W/"$=QYX:1Q:^/N[LWIHH=2WPSMWOBNZ/X1 0EYNK0T7U(".
M)0&6;GXI<X\I_<>4_F-*_S&E'T)*OZJ626FX=.@#8OPQ)?^8DF_DZH&EY!>3
MTN0ND@&.YAY28UTME:\:G,-S^E15Z\KU]#GH:G  CAX[F:E)@',X?[%9I:I:
MO!:2&R@_5/UNN8>03WG&X_]/W%!<>WL51&[D!=&"85+L$\]1Y"U7+OE3MN:T
MZ@: IT4OL/:D]2TV68JIR"M-58=?>)8^>S^+1+ZJR#>5":YE1P RN"U$UY(X
MJ/;SI>=DM[&>^V57[^TPJ-ZI+'_C4.XOL&LYI%3^WGJ>V5(#9V+QZRXIO[01
MT5ET^1PS2YX$=)E>?*DI3[-H-Z3(?MQG(EG0 D=@)3W:OK[J_Y'06!/R,S4:
M4E0?]Q&5B9 Q@SO\D,ZUI7$PY\?=8 [OR^&=P8_<5)<A7?A&"GETBS:/YVA8
M?O2-'GVC1]_H>!41K._9?,+OL5L@@XE1P(()OEA:&049XV90;;&A::6YN_WF
M@7VBKL<QTZ>B-NX%AEG2ZF E"ZHI?3T8K LV@X.X\!PQ /FCQB9@ (:KI=(5
M]DQ#W2",_[X)X[\?@_&JVV<Z9_SW_2TF+ROA2.'^-RP=QZRC8];1,>OHQ6<=
M[7ARM.>[*8 D 0/^ZF/=,5T P#Z@M?2..0,0<@9:B^]0+I::XFB1.XD+[[7*
M8R^'!9 IT$!,"B+@2*1*R]?(38M^D)_'PV\)6@7)BITJ!"A_-B+RT 6F,567
MU>S=*X"D@M:3L06YD/1AC@C)LUK,<E9  T@A:"0_!1F0Y&)0L;8S$41B09=S
M#9+4\G7Y\GG-CJFZRVZED #R!QI(1DK"F.%H\?(4OW\ $<JF>. %\7VR6KED
M,YMG+^WL]0#HQ]VH=7G(?W>R09WOLF'YZY[YP ?[KF?Z(AY#P.?78C))NZEB
M;CV0YYLMS*V[$0YX_@JSW3V(>_<_\%W6H4MIH4\S<A<LEKJ8EP8>3'2]<V%7
MKKE6,V#<2\EE>&FC\]H6,")A1NTT2J9'=^?E,U/,@*:YME<X(6KWIA(40-3+
M0G$*)Z:2CK[S4ZL#!T_(EM<E4  .KO:\+M$Q**_O@V=+5I<@ ?BB6G.Z1,:P
MC$9/2)/NHX8%X%%JS^PR(8.R^Y*C:,GN"BP UTYK=E<(&93=-^SD9<GM,B@
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M;CNV0_G@CLM'=MS(=TC])_[B>?Y[AMJQ<.Y8.'<LG&MW[#H6SAU4X=R!%>/
MNG\01(+0L1CG6(P#OACGXL,?:96$L39$!0G RAC*0528'],'C^F#7;O2[6_E
MN\-AR(Z0O%'7GO262!Q6(N* C('C<1KPMLBQ5'*,&S^[OB-Y+ROPZF\'[8_H
M:@!M<!VO#P_!X+Y@%:^S^S5H>#5H-[B&UX>'D(S^@C6\SN[7H.&,T7,4C*GD
M$@P@I,:_8#V7</PUJ'K!>&.J#XC#9#,L(2P-4$Z;S3AW5/T^TQ [1>UU'&+;
MF"=H,^QU3*N14WR[Q^]U'*'A3K!#3TD>X%@&;Y8UQ@_"7NTUS[+& GL-LRP[
M%/*K<^!-L6;(O0[W =SYU4Q:T/)\)Y0FJY20KY2;B?/0]?Z\]Y:L*?V"?12V
M2.G]WC:EMS2ZPX=W@LAA['4$$B<9%HY XYB^^^+N#FV<IGN\._1X=^AP3I#C
MW:&O[^[0PO9DC\VEQ2_J)%P-_ %EY&JH@/!&HD!'FZ(K X21IFM4*,D+AQ4R
M^LC;W5X*D>UA-9F[2E@ [FFU?FSS=Y7XPSGF?D$NWR=S+;F.UDEL**]2@Q_
M]>]F(L")0FMY= U@6""3=IFD J*BJ8[874#_O"((74<QXL6?=TS?M&5.33H
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M?9L.(&1NMY"<GJ@6H9*?3U-.9B&$?_PO4$L#!!0    (  ZD=%I/Z1D?=W\
M -Q;"  5    87)M<"TR,#(T,3(S,5]L86(N>&UL[+U[<^0XDB?X_YK==\#5
MC>UDF86R*C/[536/-3US-:M*Z21EU?:EK;51)$+B%(.,)AE*J3_]P0$^0 9!
M@B1(."/GC^Y21@#^"O<?7@['O_Z/ETU GFF<^%'X;]^]>_OC=X2&;N3YX>._
M?;=+UT=_^>Y__/O_]=_^]?\^.OK?)[=7Q(O<W8:&*7%CZJ34(U_]](G<1]NM
M$Y)?:!S[04!.8M][I(2\^_'M3V]_?/N!'!W].R=QXB2L2Q023NO]VW?Y%Z<9
MM2C\F7SXX?V['][_^/Z/Y-W[G]]]^/G#7\CQ+WG#7YAH:[^S9>"'O_\,__?
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M<.[O>Z^SHQO!+5L$3_CO/3G?:))>5M0FN42PZ&>O;@S1H[<T:.FIU02(4TI
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MX^H %CD?'3^\BI+D,JNZ?1F>.S$<P,UT5-7*'^=H:^V7F'#!HV;^S2QZ-$R
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MF[MJ/45[Q9U'VNODM9G \8NOFM-,RQ%WQ,]@;3G\)V2'%POF4-HD,$!QUB]
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MD2P].C^B/N+,R3:S(%^=+BHCCED(:@PXC_1Z+:6%BS6\\^)O=INVGV<ZE@L
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MV6)+[<C*[7<+-KEL=(=,>Q2KOFMX\5?[P")KC!-:]71L/VJ#E@M:I57E-7N
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MKQ1'7.KWF*#D 225O\,P=9O$A&H@!7:$\R,20SR3N(G,T?3KXYG-:>9.-/3
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MJ3KA&40*\SQHG$+#IT? =T5J6RZK;.>%<2>O-"4%_Q4!"?AL*I/!TMS)EKG
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MPZU*Y1T-!=I+/7@+]T/=+8@$OP8> A"I9"LU6M1G'@U=%(C=@4]KO7RY>ML
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MQ9MJCZ*\FRA*J,_+.ZGKO5NH[1;RRN[EC7O+.R#5VO 1KK:'TZ[PG]@OZ-?
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MC?!+(5DF0#M9Q^0853-^[8 XV 2VD7_PQDFJ'*,.;3R7%,LX5]>-(5;CV-0
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MGURUJ<=&&G$AC;(T[7Y$:CKFC(T@3<0=ESUJOH2[>ML /P(,"]2:E..B@ZB
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M93U[J(>=YV$0UN^LQ3..GC."(G=@YF$&1R[A*W2![TI/5/0"CH8S@J*/S*!
ME7,C_<1H=[+#%HL!>M/-!^5D(+VA?01.@HJ%(#ID:]T) 2^/L4BQE7YP4M!(
MRDY=\^2VNCK,!3Q"*E3R8EEOKX&'-3\"#:P&/@A;#>P:805+BS3C)](.J]@0
M*VO)N^' J T'/FG;PO9K./!)Z7Y5B[L[U)&#-=B/PEDG9AQ#,G*8P@()[*J
MR\IGR'D5I=G,(TAF'M/ E,5%&%F&N(9@^X"4C13U,O?=2_ *O&"#VY_-I3R'
MW[R< \&9@5(5Z:9BC^!2Z0OP06A[2/*YNX8^Q#,;7JB)L$4H[QCYTEQP1>>-
M.AESM=YXP1: 1Q"^0@=03+X+FXP'X 0K'_Z%%E#$?)JLJGB'!HIK,8V%C98:
M?>ADR"[M,]&!R]S64@@GEMDT'O5!B2H16^BJX\NZGIYAI)/(D_T&HCL[3 ?_
M](1"_+1D<C(Y/"U)B[5(N=:/NY)WQQ_&GG[L]+$7AW*TP4PYL'.+S[/IZ2<M
MW5] WZ*'$ID0O5G0-V'5/(E?2".XYPR'B4T!3 ()VD942+3AGRT5Q10XC:@F
M-PUR"?1$H&<(.63PD5@@BJ%S$21^'+*-7&K3F@\[ [DJ\.(RFOG<0W8>1GMI
MO!7W_D\2PLB%#A:"20).KI'1H8FT@W])<AV$ *Y\D2&A+NG(*" LXN!-E)19
MELS0GO-T>.L]0;&H_;M?M!8;@+>I_NHVB*(+M&?=+E.?$334Z!F,18\-1!5!
M21&-B@)%L2ZBBW07Q(_)\S^!$S\%5V\;&!*(ZJR-9,L8/!_423TN0V7LJ&5W
M-/G=]AUPF4F!I\<H O'%"WY7>^//UWB^HXPDLL4,GD]*!1^7Q[IO?K@[VD9*
M. <^6,*8-@=14H^&(#+RC<LL>;?*OGJSU] G:-T#) \V_$0[J/Q1$?LV2+*4
MT?!&A=R*?&VQ^=3?!0^>M=./UTC'%X&/IO($S>;9M![XT3E $WHQB[3E[.1D
MRKX+^A&WXM_R+S'8UKXEUKXI5MJ64NX!6,\.\OXH;0H&1IP8V:D><]1I5&*I
M)\Y.9M.)GJ"\DC=3JB4>@456 Y5D1T/J6)45>#RD8@D\ INM!AJY>D/Z1:*C
M14"X)4N(NP#]ZL=(&-2T5;X24$<ZT1J/AY6M-*)J>Q?$ME<D;7\K+VQ3%/CX
MQ<5B>;B_;;+&.F6OL?;5X3=)>87X5RNM\GTAU='=[R&V=R"FM%HDRT#'!VF1
M!G_Q6Y%8^BI!H@136-$8;@'&2$K?DRVF/CZA/R[09QB7=)&_]A#E%+N48^!5
M PUTLF@VC%OY=]EA6,GDVG?S,]=Z&VEL=RU!P+95'0E+.U&3HH6TN52^#P,T
M<<1;_#8_1GK"C_;)"SA1@E(+. ;:R0G?Z66+; 0XRE7_H8BW /65Q;,'5]2;
M?4Z6LBHF2!5Z3;%:\*"QN+U<BRA&/CJX[R'S_W7]FER^@+&S0E[XC",?C>!(
M!_L['-1'>"N'$X^((@T$S>CP:;0KCR\AVJB*$H(D/@9"T 7-"/%9X9GNG@Z?
MM-.A:M8DRHUJSF,@BJ#4&6MF35DS2UGC@Q5^\VL@;VZA_8P]O4* M2K*F7*N
M8^"+@,3YF>#)Z(:8LO#B]POU^4RA2_-+!@FY=+\DXN]6"L(\X/B0B^6W"!#2
M<W8I](RF(-P..OH615+RMI<%G$GDU(R1X4L0N-^AYZ6FCK:_@L\>V&WF2I^E
M1@Z)<LO:G\ZF4V/.S!KQKEO%M!V:.+2<=3E278+G^-R.8'0)E^AW@-9OO$,5
M3NZQ<4>%^&V/[SD,T7FJ4E"'X-'*88ZQ$::IR&V/Y4TER6YY6- "AR5U6<9.
M$V&9VQ[BEWGR5+M)DKW%Z6A$D1I,QDX0<6HT/KL7H4:NU/YL,+&_.-]!<N<>
MXU'I":+@]BFX0O.N@_V3[9+C^!<-[#(KL>;+=IGE)A!_\7DCK#BP=LTH9+-P
M2][--3MR %J+>QFE>7P-7.PC=0=5*3%E;%%0<KEKGJ*N>3:$<YFN)!_!>YAZ
MU=39S]=KC7W0IZCT4=%.C?3C\E@@TD%+3IH*<VB+T8Y6I"E\ZX-(S49+*<V-
M+82DB(+N KPB2U"R9R_W7"YMJZJ^HG=F]Z#/CJVS%5FC-54&/AHDK^7N0>A4
MS5B5EGV<=.U>A>-R3B.BJMQC3W.K&,6U'">U^U2F(F/P02T[<IU=^38)M]OZ
M0*"^P'?R*M3;$$S7141^ '$2^D_!?1B\P@ABUT:M%@BT\HZ3?-VH;5PF\2+J
M(;>4NZ_\%6,IJZK8XR1LI]KKV';?$.;60=+ZI+6LS[/9=*(GR%)GAZFU G;@
MKZ5WMWD7P7H-XS1(KN^FHJ\ ZC*5.$D2%X33:J"D0CV6[;M6J::ZR$GF7@$R
M5,:]%)3,.ZSP2AH[?B-,! ,N'71WHP(N/0 D$L2[@0L[PM%0\3_X/?.K[6%E
MU'_+",K4O$!3J""!:)4&BL4?<GR?9JK@!2MN7*1I]%+,%%549"AKR&3$4C*I
MM4\P#J(P9*E2A2.\F6['HC N((\^[5%''WY_P&==-1-5Z3?3L)::<_B2&!?:
M5P2SVFYZ\*LIN/$AJ(%K2$,L!["OT(?K9$V%K/1[6>(/2.+/>D$3&B/%Q!CD
M$/G5?F.C5_Q]P.AQQ=#]VE7=SONV7?PTC;BVVG8)BD4]<%,;+@N[AL*6.7/?
M3VSO  EF6F/!8.OUX$9(2KHA1$)+FW_C.R$6Z,9_0!K);@+LU>%!ET".<<#<
M0,9.+81[/SR[!3%NR6*9NDI=)'$4V[Z+B,^,8<;+-GAVM!+4*#,PYGCPD)JY
M96^D?/=YFPJ<RTL?%W@Y!\^ MK*.*T#9+8@B ,JS(OG/71#_-XCQW0-^S.X^
M@7"-U(*C/=A./*$.'XU*&SRGNI"_4S,G1;Y9]^LG/,$^!>?@WH;N?P,[?$+Y
M:E<?G"QE57Q$JM!K^]%L>&DBI%&F1;3))3<@O0[")^#;?GRSWH3!*]$0?IT+
MX&O-_:I4WG$PH)6TBJQU#)EBRL,A.])E;=K!,T)>.D6N-6GV6KU[OOO5#B&F
M.Q'\WMXR_+G7)1T- X2%:^LETX2PI0S#E>LD1@FRL^NB,N0C:4VKT4HY!EEI
MY596NT6JM_+ZWXVT]!EIU2Z?,T<GVQU!$G"'^/#T'7BOX"L2X(5VH-RT.%-&
MF]:&7TH5, +G#:+Z( OU[T%+6F6E'!V;6'*/('JIE!IJ=L&-RRDK]).V\#7]
M$HDJ>2>!D,RETG60T.S#9(LY2B)1!>_DV:O!/(*O*D8D7,QQ\H@FN%'/4GNC
MU'R)&JR(5Z6RCHY<?.F-.B'NC6$M275T/&)1I_6)\F'X=3/8\LUWD0KQM3T.
MMNF@I!PCAP9E'0>/I*1O>TC-<5/=N^=ABDZ$KBIVJ4?#$QGY5)U6F^&!FB+Y
M11*&]&L+=J:QLX(E9NL@3@,9)^X"WVE"D7V^L;.$(VE.E*X<7YYIO_8JZZ7)
M7=>IY%W7KD;+(U6._'JK81DZQX]\Z2XT:.2)R_WGL_90YHI'#*:88W./6Q;]
M-X##GP%WCMIGK\ #6-O0SW_$=H,TVTO98D9.H88*,,P7;;?DNLSV>M@S$-NE
MEVPQQT4N405T<F75NUG/E]#V8Z3%.8D<W]R3TFG5DQ(IFBQCTL)[=9Y$LWG%
M+:$L-PY^Z[=K?PD0$7S,Z7D40?Q\Q0$L[T;4]&6NSK2%2ZK5=+$3RDD@X-.H
M]SB?M1*@^AA>BUA93$&N&4"" +-D-<XI@0(N7 9XJ2+)AC33(/C PE.<$@R!
M-9*",H=\!2YT;.\)."]^X 6K[94?@Q"-0Q'VR!@%80PIO@YDLP^% 0SX]AQ0
M(KQN]Q?,9<4J!,2._#<8OUQLHQ@ZU_ Y#)"FKM&"TB5(T7DA6\;XR*%$ V:Z
MV%#O0\I0P 76!WRA&!BJ7>QUXR9*'S1\U=; T&2X-=IGD 'Z9S2KC !?#-U3
M7B=+XUN.^R!F'E/0[G*CQ!:6<?:DS4E)G13IC,XRW^'D&@+4;*C$X.:);)3S
MHFZH@J,;Y3Y^V-89HMF+FOQP<H(T>3).\HC*/JZXJ:*JV+WO72ROH8]20=N[
M1_L)+/P5/M*.2 0Y/UEG011:TDZZOB'P5)ACS2FK1F]JSXM,H[?T5%J94DPE
MF)*!D"ZM4=Z^.N%&H?ND46(6(0[8&H(7W'/RT#%M![P6M0R!A0P&B5%0M7[&
M,YSAV^""KQS.$J\^]1 H)#V028AJE+LZREGX?1@X +C1-=+47C^IE'7GWJST
M8\*[F;!&/404NOVXP3<Z84(:>@]076X=ZKP\HT.^D<"]/!+LV,+H:KWQ@BT
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MP%T0XQ4K>=R#1D7B,#&)XF!-7:GS,QI'GZ8@5_G24'C#(E10IA;L42!$S7I
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M?JT3.@5%4:=H"IHF?A\.D%C5-%4WR8;""!HE6728GF4SA=NT+EZ/,JFL.)@
MR(]N?2?J9._9)\-TDBT'CO.4\VOA@^?7\*.GF-1]ND?NNT&!"OV\J3;[MZ/J
MHG0SJ":$ZXX>@.)@4(0/GW0-GW32%2M)R1+-JN[L]+AA"O(Z6+EXDWE8NK]Y
M3 GL0BG&QUHNE2G?^D[WD[3NKB&M%;UG3&<7H[V*89FZMI"X1-9@)\/PF.<J
MBM67?1>"^8%AI_*_UID4>]?>%IBG+'.HZJ[*W=B' SL>)54$\HVE(T-"HF>#
M!M0PZ[?7"NRQ_*T\[P[[F=N,_TRPR[#=@UTS](71GIE4'LSDG*I#-% R]K$U
M#F<7>E7KU-2'=)L7+:%V!]#PP?3MC,=+G-TUQ*_*SBR^:9A(W.1G[#[:O$?=
M=*L-$E,9Z%,0U:#OK.2A_-PY1K\S]-#B[G=M/<CQ".2+E;O,:'(_&H)'8R3<
MRKZ56]]L/?CIA8>''A[R+G#T^'EC:;+=='LR+#[$;GJZ=!\)P'%^ =*[PV3B
ML*_6]:Y?3]%CXVKTV#@16B;96M[ RMAY*S\-+<;%Q[XXR@L+.!I4;AZLIN^,
MR.F"ZX."A@VR.A_>1]?+,[-<\2['[M).!$[4%D-=P_*PV%QG="@H5QX,[)D%
MW%G=(J/V'"9!SBJ!$CF>I:0"-P9)EHU*)!D2C+8UC,OZ@VBE*_[;5X8@8Q>%
M/@J9*\]IB[9.#W82]Y1:-![BV _5HH<L*/DL$*\FKA<:K/8])[]X5NOAMY"9
M&NB0WB!==EYNI!] MQ*K3]J+.J^BCB0@S7\YSR\F 0=_;R=+W;6#^WCZI7W;
MLQ>\]5E;]5P2B8_<R*J6(G,TN*XOB[[SIP/!.T3PPM] \/SDMKU+\(I(GBYZ
MJ<=^FR^7#5C,U2M=+?#Y L'S:\"^F@<[ZH%NA>9U8S[OM.-L:%%KJ:PHIQ]Z
MOA.#U7S9,V-WT/&*P?L]9MY;\G1<"*3:JJ:E8:(U&L\%9&3N'C.+: "!]T#@
MR+.NIS[5\4Z;=H0';8Q8>#>JR;GN0%.SOG-"SPH!$9*=.!X"DET^N7F^Q7$1
M !-%>=@H#HPVW^U*$_.F4I)9W\7_9X4 /L0F0WSR6 B(=;DH00![(@3P&&&U
M0=_HC3)U8SD*#[0[Z-\C%<X" 6R(C86XZ+$0$.YR81L!ARZ ?ADA]A'0KBM-
M3W!?D%GQ'.KI*GXEAV,/"7C/4[D):?/,;)ADFX7:S;3;5MNWO.],Q>D71!\
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M7E3,GH5S>MSYE3.1QR!M\V6$<D_:IC6Z,\>-5H<=C=7'=%E)IF\SK;,PD(%
M!FF;<Q7&'6D;O6J@>KEPIX] #_^.Y<7Q*'H6$6,@B$':YAR%<$?:IL6BN+(
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MS>"?A@:4C4_2OZ\451\#V6YV!NGXG$L__K1 3X:,VF<R1"MB=^_O7Z053$*
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MF8[8-K6\4PZOF'8+X/Y]X>ZDF3'B27ZNAU0\:N+V(<,DJ>9GE.2I)\7]"M[
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M 80"".U)LZO*ZJRZOHS(Q1XT9Q J3'NDXW#*COL;EF$@X-0B4M551I*$82,
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MB!U(D@UA\$MV<I?,,^S\Q%H%>(2!7)!PG$FW]B#:;K7)JK=^E":WL+I I.[
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MNN_:P]MD6[BXE4O=KWI31$.NZN*T* 5WH9C(K>N(" 8'<O/*1>\@R<;Y:,(
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MYGB3GIU,C/^**R) 4T][D;&RXX819R^OL/P,J8!IZ59]U7N5]^<Y>_-?S+V
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MZK0FDG/+PVMY[CAJ>%CNW@=B@5Y03=#5+<4!J//B:C=#YCAG=A,PC^B6!H@
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M,JF  .-02L:+AF;5%#&&T9I6!WTU?8CU !8 2'D!A F_QHK UJ=-O?)@RB;
MH9R<[.B\M?CK(1@B/X6!Y@\6:+X_@V(9#MI%OP7J'LE7YAO:"=P4_YDB8C\+
MO>0E!&;.,B&5ZJF'GN[O/7W1@Y2<]H57#Y2@K*O6/2KR"BHM<14O$?$F;\<5
MK*=&_,%WU_(GXV^'@1;OLDH623MAN&T."0KZ[\&AKL3AWE_39%PS^XX537#
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M 6JE\MQEEN6S<#M'-17]I[=(3ZUQGJ.\4RM$KVB.RW<P::T]-*A,2470XU&
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M8.=K(=K9+*=K;YPO_?X\&W%,FRTR;CW$WQM4FZ2@5:Q&$Y_8K\8N529-1HL
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M#BG?YQDC9*[SDGDQHE82)9M!T412O,A!8>XC>L6K$NZ;%?7"..P!R']BDGJ
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MHTT$CDL81CZZ: C^KJB$)P8;"VM#RND,RQ)$BHN,XUIV6YC13 >F>\Y%U^N
M(EA34VT A02LW43WY$@;_X"#+$^)7&$%_,Z,R!:],5BUJ^9&Q/!P;&$8HI9C
M'D==1;JHF%=D6CBZIE5M)IYZ8'3PP/R(2!N\*H95!*8=2 _/N(!,#B!*.D$
MH<IA//'4L;W0"MA.ZTS-D%)N*E 1C5@1BT&0@:.>7S=(0] KC,[<R(&*'HUY
M,=..0N)_"&FVHHCYO,<Q,#[PWP&K]3S'NONI"%'0BX+BL3CA3SF?_38MEQ@K
M:O&AS1*))PDK@I>V+LA/E7X=F*\"6''YA:!ODC03X2-;D:4SEHH#MAZSX-"R
M">M]VX"88_3M&Y"&%][*T74'S)D"197!AUWZZ,$D5=Z ?QSE!W3(=F%&P1%
MP@TH,G9LT?AYTGHA7<TQ;O W9(LJL$+UD7AF\L7?SE^>VU=9_J0"+WPAC#[R
M-_R"I3C8NU74V9;<<3LW0M@5^0;DITQ)'DDMKJD&6J'MBC-2?WOY_*<?SQ=/
M"HTV[#TR<BV+/))(\4@SH#4B)=Q'?:MR& C-Y2/WF-TD*-PIN-OC%KK678<!
M8.+/6Q(%5*HI'=>Q;4/B@6$8#[_\XI.,2:[%$Y7V@F])GN_LY_PUB;9>&/D!
MOZDC?U2-B5P'W+H;ZMOM=RPN<5WX19=W\:UIZ=<_=44K?FV^HX#TTYJUGH-C
M/D\#Z7VKW%O^VGZ4DH%E)GO)46REUA?7I_QZ61P:\&=+0!BF\Y/)G;0;"!]$
M3&*XD/2V'QF0E&P33ETJ+%_EU286=I?%_J80>M,(+';* <]^>.*Z#&/SH/O*
M#ZS%"]K[7=5WTU>_[;=VD_>XE/?)7,J;2WES*>^N?IL_Z3A4\'#('VNQ6*ES
M($6D/'+1,DYLV 3'H <Y\J()BZ>@\]@K;8?:1;J#79F2/?,HV.;BB,\8:U>3
M=^W =E9X4+6>&,6+5S%"1=6'(P<UNN'-I-]3GNLE.1X*-OE'.$F[=:F)R.@N
M,B<?'O:_\[ Q,DG=!>^NN02_S>03FA-HR']$?LS'%N=!3JSA.2I4E!!'$\#D
M,-+S6!IY!J^K@%3DNQ"E_,7ZA*;=L6?!O;A./+!'#QY\^=4B_$ZX#SOY7I@E
MSE_AH?6ZE*1!%'N_.9I?]I@FRD=O]+BF-<7#@*?".BR7+4K'OI7#]V_M;YJ8
M\1. (5RE<J68PMB\!0_L$3Y)IKL<3/>PYZ SL5>FE> .A> 55=?%&3E[HM[K
M"%$=UFY_Y<3X9%F/<E,9FPF0M:X\E>DEL9\J'V?NALXXX73@ X8,Z80MUE]'
MVMG2D[6-R,+:PI4DM9<&4F;#:NQ=GEXQ":8,)<RC+JO:E:\7K'Q%S&ONZ5R1
MV &J&^76"1]?A3,0 &#^ 3A*1C-(:$:RZ"@P0L6LK%&6V<@7.X_Z!098.!2A
M]5L;W>A0-B+G=FKW2]<CZR_OW><)A'0L'0]'7G+49 PC:4DTYF\B[:9U2UW4
MHZ7AYC.?FF=/'X1,%96)'/_7>'PTK4V_CXE0U^>-LCGO[146%6\=9KRTG.:1
M)[]'[4<W,:;3IMQ9$SKL;E+=+U,"/X2!'SS\D$-#.DH/^T0"6W$''D<_L0O&
MRWUR\KY>?/#([E5NW7T^<&FAYC52AQ]^C67TP<?RBRF,O1/42A#\QU=CF8+U
M73+5XY8I&= 5 TK6B5T0@3$3D(/!2Z*IG)Q'1M4.KMVQ=\-[:TN=N+1?RH[=
MDY6Y=@/ M0Q<TWI4E<B.4:5F2K7*Y)PJ;ZB;WM6*K0Z&!X%*7P1%,"Q>,S10
M-;.Z]-'W<%_]-U.$"Q-+VC%)1YH@*L@3077?)NDADZ/AI$-]<L7<A',B/6_9
MWQ^<P;<=^B--Y('"A9QQEM,*2SZ.68;,B"B^<00P6A6$L%Y+L: 3EU9KK$!\
M2?E-*@2_"]YOY/]]&A_F_CS5.!P_MSC_5'LI%A(3,OO3"DXQ\?H7ZFIY?I6W
MVWR%ADNEAGY\55;KL"J999L7:^H]'G&"3@RJM@7AQN<(&R/T:FBY::WH@!@-
M1+\05K>;EG9>';E]-6M)N=0/Z#_$J_Y9OOB"OZCD!X;J&_P]ZC(IE&=B6'71
MU+$J(0*!'ABAOX7RLE1."R,OEC'SX=F,R6^'VL8\,#T/&Y=\ !;(F8:$I;PK
M=CG.O,$CRO5)6T(!OOGQ:8@B>9'H+3PA5A.:O&#?S#,:/LH[L+^?,*]/6.=O
MM^-&.DF*[:YJ#E)?1@8ZCH=F\JJH=H2&(T(A^!VK%95H0#P ?/'FD'9RHV76
M59PC848'Y<)@G!O"47'=@4HV$^3*DC^JI8,[XJT=7MU24$?:V13F#6VN*# '
MGCQKD!;$M_S]'$'W>!ZH7C;QM,'KIHNC<A@Y7Q)AJV0J]JZ)W!S+\77]I1;,
M1M\R^!>]R2SPP;VGU!5O?9=HC962-D4+5N(7;.YM(X%K64,?Q%NS-[Q.1!U$
M9F$N)R8L1@Q?N"J+ZT)[5=>I=FL$HQY[+0SX8C0+ EFE#R!@/*+$!(N5+41_
MS70O5!8&^6BV-@D-A60\1ZM.2'!HT: !@5X+MQ8KGB&>)M+.P#LHG$U@0,(O
M')FEZL+FDQM1GB=VK3VG AH0']:Y=^&9,BUY#!0ZG@YAH76'+CY]^."#5Q*?
M[.QJP:+&AD<K\'W#[%Y0YSWVPC63<FKXE#OI.H%&1(F6$7?/F)0C>]^K7Y_.
MU:^Y^C57O]Z@D>VH%8E2V7)H:T[5>9ULW<[4\)$)+@A@E@?7&(T#YE X>\9&
MW1F?4Z/0,#9\MI/SIW2I"\?"-&$QWY+;>60QB^?I%_.RJ=8DQ8PS" @:+B$@
MR_A=+I6ZQQ&O[/O$%[;@[R,>=<DK.F$9JW)+8\8N"2Y=/4*Z(M.F,%6AD'[S
MA2K"% !H+_9A:'SE39OWLA:7M(QD05S%J50L*Y9:)Q> -PH.K^"@;$F%19D*
MB70B@WL;KE?6BNVV5O2\;2G1$M6[>+N&Q[XJ=YV=]X9CXTG(@O=852FFOO"G
M;8=Z1EX?,G>TWRA<SFNS^\3AY-P9%59;7A,$UK7%!]\,@0"\<)E:UZEAN!I.
M#W@XGH3DR<2(1X87,FB%I*\IO2%EE':@!M$@^"LL6U"&VW&,LY..XBK?=<57
M^A]?_ZHU341/>M@]/'_TV<!/H27]M3LAL0UH5&=5?FCZ_5>;\G6Q]G98CWC>
M[/LV_/^U/H)\C;;.GS[R?_A5CP#,:]@QXO9@EX:Q?AW>S+XX"T9@14?E33!W
M7[L!R/DB _W?__'E9Y]_^?5_?K1?^W&E7QJ;KE\ZY#L>XGX1DC;%V?\M5Z_(
M+4-ZJB=Z"<LW795+U@F>V*O4CA;^J^+,$AT2)-1T6'0-4,6 .!JY8D;=F46K
M>.G\P-A[VB7;GJ4RPCYQ!0;ZVRL96 BC*:4A%<YE6-$?9@*_KPY<Q=1_9>CU
ME8]7\M\,T<B[*V%&>E52@(3D4-A<IOW9%B$^1KXYTV#)\L.M=85%I&ZVB-'?
MBJ23L@4:0NES2O!AM(BGJ/M*6WG"<UTV3;B_YNM)%;'8+CC2Q8$;+5&8*%@(
ML3;;? UP+H7CE?(\48B:&?6]OEEGB7=*@:_M*C3F[Q$^2K\1_Z-<&[O,__Z/
M+[[\Y&N*?XNV8P0*]U?';)1*3S&^8[4GZ#(MB:I87YI;<7*=X9&C!L9>(N7K
MLJE@M/9V>9I$3N_G\F?N!AX6<YQ-A5$,$5BK[0>,&790%9KUSDU[)_D$/MZ0
MS[![W>UY" 7$5<\.=&L5LV+AK.PKPRTSQ(@S!MWPRM_@5X\9WWS!_93Z-X;8
MAZU8'"*V7HE?^)69?T(FYR,RE!_!LLYF_]_=[*>+*.G3X)4JF/I*7>"XVO;4
MRAX7''TC-2;'%J^>)-3Q0G?0&\;+QZO"E^SW5TT;GDS^>D.-\U6QI"8@V-/@
MB0<G=!MIS!3=$JUR9\9*>@^G3J^OW.DEG!A\2!'G7]])8].RT#\6?%Y,^V^9
M3AV#SMEB6\_3A!D0Z[H%N74PW=:#F]R:C#W*"AV8_>1"1O"JQTN[CFVQJ,<<
MMSO4R+2L*"LG$408+,ZPX%IW!+QGT\(-3<'RLQ,Y_=#R#.&[<2:#_5N%8T>>
M)O4/D/<,UZ1_7C?,*L<T8ZV0!U";V6AT/*);1C$;O=GH'?=UJ6'NC#T][)M@
MON[HX:+WQ[FME\P3#AJ>Z+6:D1/RX,QP39&[E1L+L<\VW$HT]CXVV+(%;UUJ
MWF&9Y)R0':4*'BT(D%<L/D!21]M[BM<$L2.#^&'&-L"\NW =<^ZX6!.BZ?;@
M $CLX-%FY>%PRHG^34GL6)\IZTVX,R5$@(R)U[*NE [D-9$:-99.E%=B^L';
MHMPN^[9C$,7!.;%-*]F'N.,C;_"\[>=M?RQ/33UF#!Y\5BN;UG-JNI7<"(1@
M64]"/[*&MB\_,XV&;Y\]O[A0G()U!P);O$:WOSE51E6B+(PJ?@+[<C16+EX7
MJ]Y<#U&I$1> _X96;))]VQ8,H-/,V\&'>%J'E:W!)_V>*] 'T48)#S?E&@0/
MA_#U3"0B[HY2HDAK<XF_TBV5CVCD)U"+)$%\,P9"*+YEU7?[9BW!.%.=-9OL
MEM'30"[S=ET)-P^W71S"-3XHSB_/,VE<YON7UY0.P+0>FV1Z:N8GSP8N"A($
MW)L)PP,;71)S>JO);T<Z0NP37%)_I1D*_9O<Q;EGW;&R_KJH2J'WR1;.882G
M.IZ4+INTF+'[WOUDFZ-[6URS <[SEI3/KP[UN[L&]03N1'[D9'0_>W:SB3]E
MXF&:@7+0IA !0)C=CYP*/Q6KJYJPF=SQ\31LRV#4F%#CL0)RY'>^W20> S\]
M??QM/ <D7U^VREE;,K"#N628.-#X=P<Q<,++0 W#1LAV#>WV-&\'R'NG=@&:
M[])*XKZ'TE^X:_#<NB(1(A@-TFHK>=<U*];T8!9"OGO7+Y4VJFGU$!/JN,11
M#5?>2A\%<QEA[GM.?E*MA1A8F.,N<\%Y1%*5V+_R7 DKHC=N7*E!/85*.:L(
M49:8U21,W^0>M]F6]Q-W\=F,NYAQ%W\<W,5\P/]['_#>9X6Q)['/>I7R5[I0
MXX+4--=8-(_I5*2#W*//+QZ[2"[EM['N8[BBH).:8#1Y?G7H*.-!ZJL'OOO+
MGN '=>%SW09<'+%)"X.+ #8SUU8*:+[@.257TDU4 :GSP+"6_.2:Z,EBFD>*
MDMI!8.F9<4 <]9>8O#B,H^8#5(Y>P&.>$'C=Q+#D*C3B;WNB;WFI;H%GL7(\
MK3N=K,;TMB4-ADGA?!9RW?1EG>-N\8$V;3H0OR.D#.=[!Z;)7=BJ18C:\*]=
MPQT;G8!$5E<E=8ZQ.Q/>.P\@];$V1<?T0^&>IN-M[SHX2B5(M_B"=0_F++HB
MK%>!R\(A(?9@6E%73;<CW%&7>5<,'$*$51'(]W71J197.%Y!P'M55.;%NHF(
MB/Y\V5P7SOLLMUMTJ%"1@?9B6$/;9;C+'#;-5O66*J"KE.]:QELK?3F7]Q)C
M)DT1=/(# "@ +-@,5GE[C<N@/9HVXZH3C6-MH>!5*QI#P<QP^)^,(D4>U.MW
M>1$_F-?P_:]AH]TD G:G?]C7*)BL'*>$7].0N'/<H%)9";'UJO!$G4Q>8/_D
M6%CI#L/O"5AI8Z#VJF/+=3H\@1VTT.CM-]DFVN+2.N30C,+AZP2&R!1 =W(?
MR?*31GT<J( /#(ZLI+KF..Q$N9NQ3:H\2.UR*^60 8IGM^.W-942/E]\3WE8
M."H"G^0LY;H!Z02&\V:9T'1T?'??*R]0,&MA(C_-3<"HK,6I*1HEBREER*E2
MD]"@K$7/DY#I2':;*)?A1 X03QBH?^@= 9[6#AEJ/,@I"%C WDZETZ'$+\)=
M*VZ6>?3@P<>+'XG2%1/RC)F?P^/^E:GD/$I:G<F_]N4:']"TI)VM]*I27NR/
MQ%<=?.^%TOT#FS9THR^VQ,V2FU_[N%FCHQN4-P(,X<=QP.[GWL\[#TXK%$%T
M]D#"+ DZ=A$CACI%6+=WFE/PQCH8=BN';,R+&:DT1@!$KU""Y-ME>=F+"<+7
M;DQU?5I\9@]\-6_8E-P?KN8&M)XA;!B)UM2>%LE@WOX:&6.0I0DAH08W+O=O
M2C$BD=9D;#RP)GFYQZB+<=+ F&MJ+[S?J9S@5HI/O">9'(5!>FR&\,[(<C@M
MQQN0<1*=[H;::9EN!?4N*K+QKI0L\OZJ[X2B?,6Y1\=77E!@>6]R$'\I"!5D
M519*R:WW:G@55J\ \CIO6PHTHI'DJ@QQ7$60P$*U<^D(6X(O6J/*3 @'3(P!
M9L1SCL8,<CP:IQ;(ZBHLBH*4LCE0'8@9(M "Z?O]3.O_IW4FKHL.NAFL5X$0
M8'U==E>*3? 0MH],Y<"T)Q+KK5O$A!H( U5VC8'^/P*[&3KTN?#F=""PN,=M
M&&-8;V=(O&E(+WH?5+^!+ZLI?E,=LE@_'DB#LR8>11%G9]PGKN-@B7)J'AM2
ME@681F4Y#F[BTC='\:\NAG;?'B$6:4TE1OV>%M9WP8 F,A8,:=RKA*LT.'.=
M>M.L>F'ZX=],M=:P[PI3?LO>Y+3$JK"U:YMP'>=.KGB^>,IV#5 #.!A\072I
M]VVKC2G2-1[WO6_$D=7CA!EYI(FE,.+9C%O)C@BG#9W(H8XE?JO5IE0W$TP*
MSR9F)W&P_*N0@4A>R1[<QIQ.)9T;?M0Z/TV441/<1Y:6_D3CY%*=(H \^0TX
M(0!/3CAX^98TNV5V0*(!'Q/&0!G:L>",B4O!LKV\I9O"3L7P,VJ )NJQ<(RN
M@Y_+9&<-.; 54582/@5X>J4R0"X?*#ERF_26B5Z+/XZY[0LZS&ZBAZE8.&&E
M@LA@7;,4-SP@W796=IUOPWQWJ2Q-%A',$U8XB^LE&F+82$:OE3NAPJNG,JU1
M,N1XUP6X]-G<]B!LEC&VQ:[?JY(#N9(T;#S9%2N,$/;#;\""*?KEU845N ]G
MMF9E:4JYV4O6G7>7^)4(ZW]U6Z]8>LC+7G:R9/$VTVQ:W(TOTG9C @L9V1$>
MBZ;?=RP[/.3,P8:%GRZ01/4U.#5U)$B="DZW3#(W&9PF_NKY>]R$__E<#)Z+
MP7^<8O#;;[4V2S6HQDP=R ;425I/X"G<7)%\!>MN<V"T;KPO17F2GD7NEX60
M79T2 F=G<$^J'N,.9#TGLRB^-C@M)P,5._E$<<#YYYL>T*K)8RUF[V"6)\\7
M:UE^!\BG8L9S\<(<I_LCEQLT\R.J"8?/90.<JLN@B&N!LXNSH'AI]779-@X2
M[S/@5_F_PM= FL1^,NK-J:?UXVK5[]0!>1DEG"(.CH_T%Z(!3^:&<IMY+3F;
M%X7H5%XX$MJ?B!=T\=+N"B-%L%]<;VIE"#U *@4G:Q#?!*CL*OR]4KVNX-\%
M@\%I6&4LB,2XI!Q7;)&4@Y.<K\M&&'GC;*"K:E$*(_Q-WI&/P8'*7H',B4\%
M!SO]R$DJD8N7T][SS:+N%<$PO$9^T4?00,!.O2J?=:M*I2U7[Q%C3D(;N+:0
M@"9"CN*Z2!C!P@ -Q'S"MJ1+RB66<A:3+.N^6/L+(.''9HZ\,[)>MPLUIB\_
MBE;O6G*KPR(QHFFB8E4)/N:7\*D9MY;$0W8OZQTP-TAU?"/NY..F;?OPP^<6
M5H;]<+\4[+>/+^/DLS!1N/I0%ANG2"ALU^B&$ T[6]^<H:TO\TLT7$>TJZ^K
M-4JV@>0Z_LM3@"2M1X92OVG:5W)-ZAM4Y>=5'H),"$)Q-B L2Q;- @Y%2 A<
MYV-L.)6*D@94X?!'%UB$J$!LXF !@CLD]>Z9_S!LY<U& !D499(:)PA8H#1/
M%0'[R.(?K9ES&\A=9B8JQ?V".7I7-HDKT[P@=<[M_6V,"TIT0KF;F):-YPC#
MG."V83*WJBMN4/H@_CE65JOI97$:]:^.Y\7G J/<**7/SGA=< U0K"@O ZWW
M\#&*7!<EHM'[QY4*RGI>&BZ(PMF>%[%5(+7!Q/?D*=[,Y*[!?5>\AAPZ2":^
MIQJ<5@(?/F!WX.+Q!?B1"V*YI\9D-A!7>>=S<M0,#,N=^(["YJ.GN#;"*#M.
MFJR#7,*@_GE/RB<E;2LR=GAHSAMQL0LO:DGD_/FB[FFOPWA$13-Z##9!S*MM
M>UXSLUR#5;.( JME+L)<#]X*Z6'TEU0Z?OA9%@*N1X_XK3P+NY]]CQ>%\H%;
M)\.C1XL/GKVX^!#O36C RSK<UG7"3K6_LN@"/?45JU?2"R[7BDWTAEX84 !_
MT_*=P@QM@88'I-7CX!:1MXDZ&Q;@O0[C_909CL*8.;0H*L0U*L?WIW53]WO2
MXB[^Y&H"5OYX'A;YXHGUPBV+\%YK,81T=5IP+C,9UBKX!=0Q]FVR(0HNM_V6
M\E)GS>9LUZRH!Q>;G!D4"BX7YN@&](A/U'JQ$64<TPEJVU+*L1:C.5/%)CKH
M\'9:K5_[Q9-0N^HM^AH1/QPHY(/=#Y!")?7M& VY'=K"_E+#(!>I.>?.F5M=
MD?<>+O&2_TN_O@SOPL47O-H?/C1+^)<2]BX$O?KM^*U/%Y6@>R\O*:I"[5RV
M#C:@+2<#L$),UR)]96U_]+_HO VVK0O[VO&WLP-.\\<*@/2JQ O61?_HP<>/
MPLL"J,6]C_1EBXQ 2>QKKXKZ?/%]@Q=%.<!8=2?["SO$V2V0O2?VM%NUU&AZ
M #^2T,0!AF=L8RE>N2L$&6C]/M:#[G3(H_F_+B0<8G9 K<7Q. >/5-8$,-!3
MD'I(&Z!DPF0E2@737?E<8D0A.<&%\^M!1EFPB"J^)=B=R!=GDBH*6F2LD=N]
MD<Q-TQTB $';8PQ;'!RUVR(<]&L$I#)_1VCX[E&HQ&I\B=P$+%1XCAX5;#!Y
M\1&%S5$D!3DX/Z\A;[J'M<A7;=-U?GH<G]=^\>VW+XVFG?_C,?+8/$.VW_YW
M..N^CD46PY=K-][C[U\JD#\2 :*ZQ7KSEE&0O4S!HJPQ?J)#%'97^CS5BXJ;
MD,3N<2CO#Z8 _7MDL][(!)I&<&0*'%=*V'FD<W-)[&.#DK-D0L ;UN' #NY)
MV551B?98(V.B(:+^Z/2ZCALP ;-Q 52W5KIE5JP+4P*WI&<GZF0IP:6Z2J9^
MA+JE;& %7.& =DV(UC"HMD(/N(RYLLE@T4Q1;1;=!?%!P]?#JX?[PK+=4968
MS5*44::[+/OJE?.&SM]G(N<OYAK27$.::TB_V%[_',L^( .+AXLDD;+3 *])
M9WP9L<V)[S]9\T>2P"4%Y,0;WS4>V7*;G:@CII4?5H=AP&8K76S^?C$AKM1$
M278BM?C\"7D5E O8JD2>0P90>Q<R6D)WS20I<1K5>R/6$DS1NY#2<OF>6&9:
M_"C !L7!^1/[G:E!^<-^RK5 76(B4LU1A2D8OCNX"!^2B5YLQ %/._A#C11I
MG70+,&$X,-!)YEWXE//YI'K*^4)!MK&(5"E:GPI(-U;/Z(9M$GU=_K,O!O4?
M4KS@*FV)\I66:M67D1 )'H=Z#^>+GT470Z2)(@DU)#T46,-J:*.'8$YJ2@S)
MCSCD"7%6,(IQBB0E[Z5O74ZRK"V]';T:4P;9JR9-+=!& F@-7Y5'SJ>Z%KRB
M0 ,9G_G9<7#Z2<'>%.8^1<<]O;0$ N9PMM1D&^ZW#F^9"XI^;G36,GN($,^&
MQ4&7*,I_,;^%MU9<@1IV#21DF^';'4B??ELEY]^2&_^YBXI?>)M]K^SW%Q6Q
MZEU>A=U1%R<P9)8*\?@SDXX].&TN<+\#2Y&W\93!%VT59^XRBI(\<7-8QW5!
M07'FR)EW0LTO0'L&W6%_Q-S_(%O/($24 R1/*,>V!P=HAASR/(A\1[4$[9UV
M4?DDG.,DBCP"P'UZ5[IXR.R&(S[$ ;@B<=2@L$NE " HBZD:![L9G$^;J%1X
M-^!\\:W6A+D(/'&Y$;9:<YZNW60EZCNOR53KYX@5$PDF2.@-JB.)TS/LPW(H
M5Y\V*%YS'[KU^J1/"<@P;E87-]4AKK\)GPOS"21R8?$WEA[R+QV L!R)-X6R
M&ZE*G>?;2C5HCSU\.O<_3J]TI[Y)L3ME1>'O^0MJ0IH:?Z554NU*'/@&'+?H
M.2R*5U/;8/RZSU.[Y <3&1+04(&JIVIP05->[Q66GW]0J/G%IM%KW6 $Q.7N
MC["RJ$K6MW2D9-&UM309YYV/[>C6IHW33[2MP3@7)N=\\?2:M!6)HN^Z:45,
MZZCK+$N'^"#VM-C$:/D>&WNL1-9"9GATPF7,-CIQ\^3ACCW0TM%?#0.3\\6H
MU91^(H(VT\(S>_ A\,(0G,J1MH0I;^[GZ*3ZECEQC$Y,JR2ZR<!@ "K;*(R"
M.;W5*&]YXD+RC)AM-693@]=NXJG'N)]#=A"S<G%!FR6  %*M/E?O',>3G&\5
MB),MC2&-*WL9)AJ'6JE%K)=M<\.-;I[JK '-1XID@\V!'X:V8S2Y,=G*NU"K
M4D]_Y%EGZAUS]4.G@QU\!#SPYY?.,UE21@ DBK+KJOR&.2ZU,L.5TX0B)W9=
M2A3%][FF^N9-,-O4A\1=832P Y\N^,]!\9F&^[0GQL_@3_ZM%MT\EJ1MI+40
MA>%])\ 7S5,CMF2'F ]"V#\]9M4M'MHKCI]J:Y(8%I:[0P=FS&DG(J^31+6Y
M -V)^UZ!T2;8G&"TDD?01O2VX;X6);ADIT+U_4979661O8APAM'F:\[>T#4P
M>@2WT"[Q.B9Q3XC?J,>0<QQ5L^M 'M=*]\)H"*DHE#8:D\@G\,8L!BYH/CF0
M;"'0!^1-\U/&,;6#J8X\UR>+7=K#08=P/&G&;\V*<K[33+WWH7MR/SO\V^#9
M-2TG"K+X@%4>_+^K> (.=LNZ@9.R:3 %/*MA5_0K+I]-Y888ZJD-= L"9(@!
MGD PO*5X<IG<( T=GT)BMY"!,T/4XQQ\2(O__&CY]B1_+S"?WQ3+MB=#]^@+
MP&4^A?]Q%;;A9P\69#G/X)H6.NK@[?)+F/YSMOCT4;@ =6,1J)%?=.O9"L2M
MX;6<<HE\$:\SN@8CHR @=$G>&!NB5J#7G8D%Z;7>XZK2EW-5::XJS56ENUI;
ML?V28V%(Z<\"/*S)O:DJY?8-U\@YKY%?$LE%[-"F$],9L1O[/2<0@C<*?!^=
MKP0:#H_4[&AK=8QGDEYA;2W@AM#8ECV\ 7(QI''V6YY'^FH\B]SI$X#R%@,[
M&F+ ?_!L65Z,*:0MV9R91KG@AU9M;UIV>YY>Q!_TI>OR7US$ %)X7UQ*\A>S
M0<D?3790SE<IF-U9\Q/[I#4ER:I$$8RNH#>1E!IFE9(8>S03ZW@X =?L.3O'
M$APD"1+?-O(N%2@,,^K'*+M&\G;L;#+1<Y3+#D]1:_X^+(35J[,E!-F1&JD[
M 8K<Y.U:,MMY=R5?$:IHN)/\C<'T8NVJO\[9EK:XDD20,MXO=N$0H, :[/;5
MSJTLW@42&7! D*$6=+8L\"KD(!6\5E5N"NLIIMIH6-P^>AR&%$PL*9&L4(*Z
M/^)R[M_Y:E7*#]9%+JR8Z[+CR$$H.[N>O]Q=->W^C%30>6A-6,SX5_B!.O;N
MVCO"/G6D11!,)+J4%TJ("4=<JUJT-NAA;9+XG9DFH7YAL:G"D@31STYZ^_-5
M E#E*<-]KW/11>?<5'AGT@-A[=29Z-<KD4!5X07HVBT2-Y!?%W9^^3MD-MCS
M($*ML&V_CA[$5_^QP?^E9N'-RR&/DX4?GN<OLE!_IW+(FST/F^C?TZ^^;00_
M<W-0E'$@V-0_>TF;[@"_T[8B"N/BXF"K0173ADPO@0&D,!./I<Q;%=G6S2J^
MC LBB<HU(=[A?KC[0="?G-FE_T?DMIK&G6B5X_(I.H2XJE&BC4.5EWQJ>#5<
M$@,)D\[2?O%A?1Y>C+BD#G&7?X;!A7B.K6A'PB&IZC 3<'97R;UQEJL]E:=.
M_^Z29WQ,:;@?]47$"G8YD9$(Y\0Q8]&)94)<%.8J4^I9M5)U/'N,.W<5ZTQ<
M&")PHG0*'C5J1Q (11U6%1I@PRYAX@Z;84WWL,ISO@"CJ?5C!A/4Y54>H7I-
M#;T$E1F(V@I(W^Y75Z8;FXTN%A_2#_SWMFU^:W[\V1VV9F+L)*#Z-(13GS[X
MFHXW/G:^NBK7X9*P)5\\>O#QU[^]74L'=3R!@ =<DZHAEN\@!AS^E4A:OT(#
M"/W7Z,]LUTF.F*SXA=6%G#3(;YR2.#[W;W6V;\F,4-TU_*Y9BP2*5B:8T->W
MIFW*"B;!-Q/[DDKX>Q$9Q%XRB9_NKZ>OI<[UF X&%NI0#/?+IX^GR-A!2<-F
M6MB%PV^^(1#<PP=G_S<C&]GNH2&I8W5__W^ST9/H7[^@'Z.$$SNSL.U9D86_
M3 ^S9DJG5FEX" E/9=V7TES_\-,/UA^J"7#/:\]J*F(??^+%:3)&&-@29)V_
M#54"V\LBUI1D7L!K>5,L@=WYX.;FYKPK5N>7S?6'S.[.SCK-UC,0B8</7\2
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M9P%W'$LT,QL\27I8)4HWWKRTYZ5]AZ7]HX>@.LE WV_C4J=>G$+0 3'P1N<
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M\%1);JO?7S5MJ>(@JL!QO/-81:<<7R;S[! )C$[^- ^$KR>WL4!L1=ZTN@L
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M]O]0QZ1SAK\/M,#B73MMYNTS;Y_?8OM,3*[?/%2[;YP03CA[2OAK/M[Q\!M
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M[ZANB\Q7O>O9'YP>>E_6>8<:\O1UMR=JCZ"%H2=B.89^DNP6-9.Z=:*R'BH
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M061--_IZUH4)/;LX?3PZF==99DLWJ68=%<':=AI>C_;4O$[KZ3>)-L* \-O
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M"BAOP"QAFFM+]F^63TAPR7+BM7?O=L(QIVQL+EDY954/#Q'JQ/<):PUPQD.
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M/ZW90_4FN:\?\4S[UG>WBL= _D)EMV^9/?Q671P#)!)K>/L+S@(>W&<![[.
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MX3M@YX@W(D!N9VTQH^]S3Q/[S&KLUK;;P?(CL0-]5+C<IR]B_GC OQ=1.6>
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M$CZ)N/Q$]-$9M3MG<&M:7KP%5L?]O,RR:6  (<O<"1M4.\.-J5NV;;QY;8<
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MR/([_%S8#C-DA%5 M[P\Z!YZVJKP>_DJV/0(B/D$.B%UZRN8-4D2_0)HR5-
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MT:_"9Y7<R,FYW")]0X5$%! DAFJKI.A7L3&&_Q/S9(C_CYNO6T&Y)=/74:Q
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M-:5CVHRJ=A%[9+[.'H6OU2*,<0?>?!6J5F'8)'L\7+O.)!]"6@=RB_$ACY$
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M/H<A$)DXY7S\<LK;C0@_^7!P_.C(AEI1#IZ_ "I),6F"C+!)'J]I6)8GQ]T
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MFL%@X0NZ74 !3#R0L"Q,0#/N6*H7G&T\_M:AO65(V9HF9D.:!T9G!:).,*M
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M.NV.TRG(3-*E?%;)9,1:/9^7:XHJ:+4"9"9EM$8AK\AYI8#RB4TWFIU.$06
MT*DN4((LF;,<JW(V-Z=J4 9M%8E32YK63Q)89?LN%IQ!9_F A ;:,2X,!PO^
M N/1KPW/9 Q5)OC3OI$E%N8'2J*44V6YEI/JV9HB:[F:JF=035=%L5!7U4)6
MR@SE!]YK->DY4[]KMN5<]?%)[[_;NMXTBT60,$:O[&>EZ]N/5*55>7-D_<5]
MK=\:%S?XRK%GEH3\A6[*+53)GHG'4O8M]2;7;VI231B]\JY\57R14+?4SIZ;
MY9-G(7O^9-[4Y/$KZX<-YUX3:U?"G95QWO-F_Q!=WM24\2N?GKMWMT[MXZ:2
M[>=N>_:3?'U?@"O'9G1R?"P:SM5565!+S9.VZJCO?JN)KQR;45[SFO+9X=F[
MH.HGQ^6S?L[J]6YJF?&WGW9,)%_<67+[R'T[5P].\IW'QV(M.W[E]<<'ZMR=
MW/4JTK6(RL^N^-Q_[=5RXU<6+QX^+K/7UH%0\LU#^P5/RK^ZJ>4GK&>KK1NH
M7<NT'X]1H7M10DWSOE@KC%]91AW-:1Z4&I7L:[7Z^?)P^7+I]VJB,'[IIY*[
M+!SFN[5*IU1T.T6[7C'E9DT4QR]]KHIWU9O/PR,AFW'E"]3-W*J9(DBI8Y=^
MO.>DU\9]2:J^.<UR\\AHU*H.OG3"WJNR+E_<'AP?MY'LW!QD[*O\(UXI<<+F
MN[9_<ZW>U2X%Z?"Y</V(C,?W)KET;/?/^Q?MH^N3BY/*U8G6.SA_>/+/:DVX
M=&S[FV=OKOUQ>R15.N*++IV8RKDMX$LG[*K@7[7>A,_.6?4QU3K-EAZ?E>,\
M'L"$;<V]YIVCU^MSM]UY59SZD2=>W/7Q4R?LZ\U;IG!4OWT[J=R5+VX<3Q7:
ME?,;N'1L6JW;^M']=?%3K3Q>5T]>4^=&0ZJ0IX[S:4$0=3SYVW:_5+FJHY-3
M_S*%GSJ!7/)7AGN=>?.Z;?_^O)%[;7B2]-S$BL?XI8\GK=.GYKV9J_1?,B\/
MISW7]=^*<&EV]%)9+-G"L_Y:J=P]O&IVHZXH#Q9^Z@3*DMQNK6,_NM>5SL.=
MK7\<^.ZGAY\Z@;+ZG?M2X;%T@^?4TP]3#UKYX%7'\#.!LD[S[JUX[9ZGVL;M
MAU(J9=17I=:K21,HZ\(]?"K>9C]+[3=;:S^?GUSG7SOXT@D84+[\$,^,CN14
MWSSSXR7OES[J33R ">1R<U]Y%$NO3\>"7SI-97..?7YSA9\Z@5S./,4]?+DN
MGPIG;YVG][?,U9%>QBLP@5PNBN;GC7'9>6YG[\LG^D4C992T9DV>L%NW[^V&
MU>H=G%6._(-;X</(EW.8#>4)6W!W)=W?]XUB5>AH=>G>,/RCTD&O)D_8 NVE
MEK]H?1Z6JE+F/7^:01?HY1;C^H0M,/O=VOV1\&!74@^N@QG85O+7>*P3MN!,
M."Y_B!>/KI#R#B]Z9NM3Z5W@2R=L@58^1:6;WIF%8?A3_:B>=]_/WO&E$[8
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M4\1T+K.BK1IA&'FP,?^K<BT'8/2_[Z]*D^J>D<\8IS!:FO_$%:?@*\QS@%/
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M8\9UT//RN#,)X5HKY\[UB3>+<:?Z\)*_[QF"4%&?6Z_/SX<H>W#<Q-P)DH[
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M!2"?O6I.D>##__D5#/WZXA9$J:=H^*H-NN)'H9$?AW%^!'SJL<##LT#XJQQ
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M47\2K8Z;&IUM"RB"E? C\Q0EI5NC%RI3K"PHK:YEDIR&6</]]GJK/WQY$:@
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M9S48C[?&U,Y@]& ML<O#B<$;5,0;'++>OX+#<2R'WS(:?IZ&=-U^W+$AV!S
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M7Y&)<XJF8]93\3.QGK>_&W#[ROA[JOW<_869JS=D"0(BYH^Z*,$\Y'U*)1N
MK4G^<%]55H1&(CQ/=@XO&XLI_'C)G ;"6AYA/>ZME.+[)/3/I7DY29SKH.*L
MWF-JU'Q:&%'T.-N>+X1?_QQSM&W]"6]XT:Q3P=;) #D)Y;A,VH999+Q/6(IB
M,T+61YKIE" A'%9'G\'=P G#0%'%7 YLQ8&S@="#D\\ V89E)UR41S4;F\><
MA,5"-$H@-PQGWC#?I(:\=\-@JPRK28BW&.^=+0*>/EB';\!J(I8ZRY'(C: !
MCP%S)S:?B]]4!'(#D7>15CTFCVKX/+7AFGSL*)1O&XHF%@*_SU U<IX#*^)I
MLN0> .O]%? *(3"K<K]I^?)C0]/-/Q-S82@12Q<_?(9EJ@@(C*$!LLC2H+>J
M.-;OH<:4?>)$'DAX9>2JML6CM5);M9Z:70+<8PE/.-=/-A$$'E;^#4G?$3:F
M/+QFF[:Q=,$' 1>5OK9/Q39B[HHV_UL\ HX!V2MR).D2C%L;?R +O[%X.3OX
M[VU=7OR0A_/8Q+%DB_C2F,>P%I2T;;+OG?QI0^1HT/ZR(,N/3?7HQ*JV?SA(
MDULCLG^Q$V@+Z<@!GBH?9^X[$3,(:TR$3;>6M=-T/7I,6V,6[AH6JU@$UTET
M7-M]97&T(R3X_AHNHR"$0$6 91 _5!IFA50P@M<5?-E_WK=E*0=]B"[D95#(
M8$MVSVG"AB*^A=1I"6_,P;? LL1Z$?X&@]4\O;6>F5-XX^\'WX;AU6%25<&W
MMO]:\XRV1P0+MK[\7)OWE%HO.6'68://;Y;-!IU;_H%:M+_R+,NA)#GLHYJ0
MU*NMI==>GI_0RWQ*I$;SSFM\^>N?X/%8RP=)Q43)V(J3BV!AX[=$2AQ+AW'I
M$]'O=R+<]B,L1-M?E60SDZS_]N4KG21$M+']<31,;W:^V7/#K'U_075NT_LD
M837]C3CYT_L;0B[][=JQIL@2!YL9*/:Q.F%.63;PG%13 ;1+.WUPQR\3I/>8
M\UWF_!Q&8'_A-E*@@3?-!..\YPTO=F-5L;U(AZCJ(MINCGO)1F.:A 2I(^SZ
MKP]3#R%^O ;#\MCNW571)U]MRS'._E [^L5*YK:!E&X^"-]93[X&UM/7MA&M
M[[& J/D$@P4_#MBSELOV4//CL<*(35=N#T)GFLLP7+(>I)ED T]QV#P28!JV
M;GE;H=UWM-M/<L@0:U:*"CD-5]0COJ[R'+IC[S,_(/2-^0'QIRC]5H(  ?)[
M"0)>@L ?)@A@IK2L5]/(/AF8L (.MV*^I+?U"Z3U+A*(5ECN.E'=1ZV14Y8.
M1$*W+HR_Q'\3;\K.7:G()-<3:(6(^GU Z>Z/>_KDUFJ"*@*G#"F_S_2XV '%
M($6NNY#?7.%6%WWKK6^977Z\DL.EV!/"BY^::QFRG.G5.-".0^[5?&P5AO2Q
M)9!WO&DRPDOP]+\^__ 7YV^J'&$[0'-R_N$3>T]<>GZP;R& 3X#X^@C"('Z\
M&MT$F5A!?7,FML,5L?C]9&F8%@\4H*LJ I_TW>S?Y>"I^F@>X>V[I-P'?SV7
MU,GYW_@A? +\N/5<A8_%3O?$^=$#V@8\MK+AD[ZH=^9W*:]4V Q:?8_=:QF@
M,M^TY.-V^ZP'5%N-A&JTXV.F&LZP4UEZ+F9+?P+*_923*).8QM<=YC791DRO
M-Z@-QV$)PF6AR >=1.^<X7X,>4<H'W"3?(5D+N4KN3>2^5[7Q6A5KTP-*91F
M7D(O=*M.27-17'[&=?$>%8&"L60U_/81X@W)#).;7@UP:A0,&5E2+/+D>\\C
M3W1;9")#;#75;B=Y7-!]5//8T?>^#N)6.\[J=PE?U>_R85?49QPT7R"2)WLF
M'S=IW$>]3RJ$/,#8,..9@.V N]Z*C9HC]VT5LJI3IL1VV5N#@'QR5'7'='.<
MZ+"( O;>S@MT=PO$:F&F9O@30$T#20&V"O&R#4'9_4D2D7S6\AY?5$5N17\Z
M!4Z82:RLG0+DX,/!!"^,[,PL93A$JGE<^UDJ&H&UF@=J?U=3#"QB-;^% X!#
MG"G@/A$)TD"2V(%BP4S\^-BP--9L5!-YCB;BS6!5+#:V/G#MR?<R$B6T1] #
M -XM2"P?,SFLZ>B2 -VBF1@)S.]H(1(A9G;;-0=9:(!+H5'\%DC&W'40A@"2
M@/W 1&XR-29["R.BJXKD3"48F*))@]1C_.@!(MNI*@/;-:5P(!_PIWM8KF-3
M?/.P 08![^$!Y Q3$O$S2'E#+#%W1[?$H@P1](,@X?=+/NAXK$Q-Z*R]D[9$
M4$U$ 2]JJC&S-EDQ1?-" =8FLQ+QYNR0)"8^>8M- 34'SX%<V^:#\0PD?BGR
MQW!KUE[!K@#DC8C\/3+8HC!!K_?IF*\D^*HL ]Q;A9MWR"XP89(G@ S"!#PD
MRIPD/?FRA@K$"=D4Y',G(8J:!D@[BU<LWX&(CG,8(4?_@=MB%]_3R&H EXCO
M,H">\J)$)/WN6I.Q>'"_"[XV8A=XY\'7A]\P4Q%F6D2 5D14JN("LY  H%9\
MC&#N@)J@:.@M&/G1^3WY\ONK)RO4W!QGBY ]CK<9GJ0MJ"<8'G;()DP9 7@2
M[E2"())$&:]>&Y$T=W)<YI()<A,R^+<4:X$G34@1N58(H]LLZ#AO90_%?KA$
M+%X,V1YHGJC-.\L1D@G6$2# A(I872?JX6)'1ECI4@Q(WD&@R7*FQL?C&V[M
MMQ,H\'?QPJ:82'43PP49/43-(F4,' 43\*($E9UJN_US0HGSSL0 /$^ @<(&
M@)3POR?$;-CG88V&X^A40<'J^6YE._'!$B 7XI^V81ZG1WE;@^99F@03=#R<
MB$:#5GF6BR/R=U#O),>!\0.)/HH$6$C-C<:/A?A,H]@;CBE4B TK12/6ST"M
MN4,T_O%QMX+&#SWY'.OV[1;NLU?^+35F4H!EK X/]GUM_NO>^Y"V3H;EDAB;
M5*<&TRCS[5XYL+SD;N[Y\3ZQOV1AP''.2CE73')X'Z=I66F'M?7(]3% 2'8@
M5]W)5>R.?BR$BH2_*R!\CYI&%0>Y$N9WW=<XWB:K<,8V^;+]U'SRY9+)VIXW
MGIW-\#F8XMV0D%UY68 , :?10K[=W-V#,(RQ*W) QAR^G4%:@7]OMQEX?8H*
M:[@B5/C]<[*!M+H%Q37DX]  N"^.8XWPCCSYDI)D&N-V59[MLXA* :D,K%4'
M9T<"V]N(]QDS17;,%CQ@U]FU)*@;ME9CTQ<HGV!"\!_84+CC=G0E&*))UYA]
MIX@U'2?D^62@@94C3%0D2.K;$BEHX4/%D+?T[9"GMD\.4C7Y'4YY6X&IF=XC
M\:/?;,^(EV7WG;8SZ8\D#&Y7=O0!9HJD_?ULLIG: <"ND077UE!UR&!%<@H"
M8"O?^Y5*.JQQRQ0EAI>]4>"YP?++(W?K\7&7OUN_>ANT37UZN^#OO BH/?EB
M"O$M5/XCXL9VQIAI3%C8[\A>!9-#)8:&S JV2P?_-L%*IKU84W)#GL+,85B;
M^J!E%H+<!5MVNI5FCFP%!T+?5%;Y;6TY:PE [$0E/?HEGY49X<A.>7_=?H?1
MZIX=F&+$0>$H!' <OO00<*:P!V?RX$P/!&=B[;+< 4Z?;6IZJ4:]J%)Y4R^W
MFJU>$BXVR_;<CAQ%VN54;)XNM7.#<3\5#QC=SFS9I_O4X4AQ\:HPM4)+HM+A
M84%*L=W74$# (UW/'#[G*C&Z,] HML46QDFCW6U0]7[(_<SDM*.69PDJ3K&5
M@F$$GU>U?"&)1[J>&=CTV(I:36S:N5 XHO=SU56>J_?#VV>^ >4Z;:U^PK:E
MWX:+G;RU+\0LCDMXJ]Y#@$!4>!)'P_RBR*9GULJKVXND$6\2W&%OWF9.C_;
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M6X^9(XY&, P#;#^\&;K#MOD.14)N*9XD;=G.OMD67K.PG:FB:M?.AL]VOE8
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MY'BE3V";#^178C/WR<?BJ\<@N1[X)00)O"VAL%<VCB/EG/AM(C.[;?T,=_
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MX+G.V$[H@,4Z$JJ_W+M/H%\#.35$_2@-P 5Z["K'W-==WF-7',G1G>U@TCZ
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M:9U.H?N>NZ]V]'9>;VL)NJE#>6QMR^2]O3V 1:G*IBW];<<M.!0$6)D)D^O
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M2X46\MV>!_W.\+U%KMNMT6V/]S[)RQ[UAP>= _->@44&_^QG/;A[@OYC=0R
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MJ:$,M%RQO%6-?)]82.3HLS1>CUP1,FI_W=\1V7YWP2C4EMJE.!FHO$1HUIP
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MB>DX73_# IDP&/.E@S&0U$N TBM6>UMWFNJ&&M"CE=SNUUKL?,8+B82:;U_
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M/7,+$FHFU,N]WD*K]K=,:4IWAV2':F>!A(+ZWUWZ10EU@QZ:8T4#@L)_7KF
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MM1KFUPZWFW2(W8J^6FF4WG4F510.S]=F92MW JTVZTK4A%D5MIS!>>[[?/F
M4VJ:?QRP\<IL*97+B9S:?Q '0Q%-78*9[M1=.I.Y(ZF7)FN'HBH45=<!MYMT
M*H8UBM_'7V@GT >X#4^=1O_=9<%55!5]H(/>]RA-O!7]["0> RNGU><X"-#&
M)GTC.>VEGYM]L"FFHI.5&J.MT9I__+E& +U7@3TKB. TQT3FC@#_RZ3\106W
MZVD)A>WU"MO;+-7\LN[9=TB2QL-"BO:?&:DOSG>TOEG/:ZS8AFM.?H:P?3^
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M<T <1D!L8BFMB?0VK>6*6S:K-7.C789OK1D*E6_=I1*)NTSR+#W(OB C7NV
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M;J=14S;]/&\TLEY.SNI,<^QF75TSF#Q\FZ M6,W8-@ ;[MVF%4515^**[1I
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M\H!FC%W&Y,U\0^\/N-)XOAT66L+B4^4!6^#+734[TZ5\,R%$4TLCM9'60!X
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MCQ*IL@#IVC9"$JCHD+Y#]85Y=0ZH96OU.A-XZTOONNV1CNQDH@D3UA#@I&'
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M8!3UR 0 $0@3 3QQM W$*J^" PNHT@A>(B^R&BI[!TL!G *.1[0M :7AN*_
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MRC %*?YR.O/=._.9$[%(ZU0IL7N;[N.YL/M,5\_3;B#%]4VGA;OT?XS^SW>
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M'4!6E[N_X,_N:9(.V O4#R?;*?>J'IQZJQTBR+\NHM =]S3$B&=E;JO00>_
M_&CM_W6X^&=]-2Z9NFG]WBFE![N:!&H"YNNG8R4^M!11BXLC,/%O4??$M;W=
M)44G2&SGJ/Z]5VSA.<10-('@_XH%KY$$GO3/(W28,W$5/SBRK3X<UY41@&KP
ML]UGOB[[.WCNWW,@U$,"^&TIN@B1'C[]Z+D^9!QS_AM#H<[[]PR\W>Z,0!-4
M\D*P.M"U?7W[P/PFQB86Y%[_W:ZE7U?8#,B5]".%;?L1$#!]KRFX^Z"U"Y:R
MV*.O^,\!V-]$5O]HX^!LGU>[/=KG#X]A$CKJX$O N*2_X(C8_X(+%?[RWR^
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M=)&+/BR4SAT52G_A:_Y2P9^((JY0\N7UJBY?=RH&0M8#(W@0*G&68CZ!G//
M9W'AVD];\>.!#RBHA?.GQ7ZVS.[6KNBF:FOQD:7X'805Z(V(67[AMO-PMMNZ
MI]^M;WB=FFY;MGA_1_$QE^/<M12A,1MFJ\7&C-:P2FN-+'1"VJ0^&>IH6X[0
MA-YMW_4(WU540YVYLQ<N^8HBVF!.:'LL&'/7"7GT7PZ 2)P%.%S8HG 38/"+
M9X+=./X/TKIHV[51X-I\]OF;LYEI'!HYM[]/L?.JAAO)GB;6YJ4\%>_EY 5[
MZ/ D/N3O]+NZ!)[[EB*YEM^$YN4^]G[*.';@J%R,5KTN75NG>14KN'BF/RID
M2F,8SWBB]^Z_XG< 57%UYU#=Y$LZK5+]+J+J6"L]'%#6VAI?%:K5I5$O:=/"
MB%M[CIKA"IU^6@10)1)8N%_XO\XGD-P?%[H^0]Z*'O=W%!<FW9<-?Q^1(<?G
M#M:>#"95K>8T-_QJ,6YN)MY523=E$Y+86DD5C<S&3:2_,1A!8&_&D#\ U;MG
MR%XFET5*K>H$*<4'-2U-]&A-O"Y#;N2)Y&HRV/!(SNCG[;8JXEEO#/M'GX+J
MEX3^JTKXG!\WI,BQI0GML)"W/H#=XDYOCO?<2-_BFKB:W%ZW5$GI[-'R3+RD
M,9]6T?[$0K1T68FOF'1UTM".> E^:5Z".S7;Z\M2B5_4:7..S#>-[ SP$II)
M$.%X_F\DLU\&HM-.#2/2^7:>JQ74FL"E!^2PX%T5H@J=\69M(YODR)(V&V*B
M4AHCWJ]_&"R1/ '1L\GKMV8UMQ+.;[WOV\ML]\QB64YH)AEYW-(P1FR*FW5A
M@KK7M8K$5:;?*^0$E7,UAQ^T,'F4&0&"I)*W8;%7D\(O U&A5FUM.*S>XS"9
MVY0=I16O)1O7M8C$&7&47P[ZG#@I9E.N4-D4>N#21%$RP81C\K\F@M_:[KZ7
MR@'KF<7^4HT@NOT<50\BP_LW,;SWA?*DP6DT,5AJZCSK*JAI%..#3Q8LN=C5
MLD/A-L#@,W$A&E^V!-E36YI2M5TCF5FF&Z.C>P6] !="#IB0,.@M!N-&;<3G
MEA:Q2AN-8J/A6P'0$ ?ZZ)UR,3B>YT*Y !P7N%J3\(E1XTJKWG+4G!.NEVI<
M$X[9[)AN">XPCF ,6G28L3<O&PT@'B0NDD\=&=>_BW']SXCU:O+\!8BU+1JT
MF1ZNVIJ269G:>,,:9/NJQ)H:=8I=BY4F?,[3Y%(9<]8:#I@N<G6F>S4I_@)P
MS-A*7!F:1A5)MRO44L$-A1:N"L<BH><]><C4D,7,'?50K6BNF^/WF.[#&-!E
MOUJ!(<?6JJ*?HY)@9$2_^^O@;";7+W.*S!;[SNAU4Y7JDN9'#9=SD^M&B5U-
ME=GZ2-Q&+JCTMR5!,URS6E$V*Z24[)&6/$WR8J$1E$6.K*J15?6+-KA[I#EW
MN(HSZ5)QS'4M7>>+4C<[IKPKTMQ,-2F<)'$+(;EV?RXF=9R8L(#FB'=H[@KE
M7;Y,)==+D_Y0X1)6UTW)?U4;/9<F"<JDPJ(E=CACFMJDR9$^X)=:6J'Q354@
M-GWF-AG3,('=![<=&RJZZ<5L=P8&P+HC,'4]*(1B'Q1M.%D'Y2]+ <S*%O5_
MQU1#TEV8/:(:AZ5-(!Q1ZF\;PLN/_A:#<BA; O.+YYAS)8 ?S(L/2IX$=4WL
MV-Q2;,AL9-^,ZDQ,UP:,Q/[W[Q]0&R1*>=]5Y$02Y)OE9*-LQJLE^.(1'.X
M#E@"B0CB'@"!)A-1QOL] "+B3/<!AX@SW0D@4#R!O=D[((+$14M O"NT?LN$
M]S>9\'5W',KJ_=.:$,D_K0F!DPDD*@H1T<A5:21L*#A+(8 ]-6!_2@THE2!N
MVW7JKBI(_%0L2":PGU<:XA37NW64:E.Q 7>7)GYY6%E9*KHYAR;9<V'WK?=W
M T><K_O<>M]G:4#AFS4>N__$I\OJ?]3+7S D<Z;L?83EK1?H95\*G[A80\X\
MDQ87N$VVWL*./6WJ<RJ-(**1'O4F2CEKEX]B>N(?2WW:.;"V'BE%/NVPVLZ^
M]QOB>[?A9,!W]48'J?(YS*W7^7A*$09C 1?P7_^0Y%MM(2(6\6-91&!?^.$\
MXK6HA'/QB*ZQHB:Z(G<04>W'T6::SV_T\2UXA-@<8U2EZ:1Y,B6-);;<("K=
M!N 1Y*]_T"<$?;=YS'VKA3G%4"Q1]X4A49ZIAFH[EF_7>@!I_XXXVXU["I\H
MAW@^<>A^^R4_E&RT)37 ]M@C0COF?/WA,JVDXLB:ZZ9FR:*5RJW'ZDTXG\63
M6DO+:Q6M9C:%1:&XTN7A6""@=(0]8?B%DDXBEO'0+&,K'MTOS_C[$SW6;R$>
M?8Q-:*E*;JX:!8Y?##ISI)%G:K9W%38!SA0\_ 2_('/->2TU*<\X3.LB\Z64
M7.-3#_ +$F:PO]4,_3$-2>TW8P4C7?'LNN+->Q-?S]YT\ZW>L]#U6ECS#0Q(
M):$PKU/VA,_5*[3':/WN$/&$9" BT4QD0HK8PEEM3#??ZSWQA9=2%NJ-TFS/
M[F':PK#RS;(LME;F30S+Q68\K9>JHL5W\Z1B"HPET4/(%X HQ.#T1_L-7SV>
M_L\BAEZDS<#W$&RJ$734N]^\@ LTWDQ@U"%)T$<$\<99![\Y2"2XUY2+D\O>
MZ7G8'2W</W>XHO</_X-+%GWR%D2)DI"A1 LRCC$",<0482B-2($:8J*LR*0X
M4I)@NO^(NU\ AL (4W&R:*5%;3TC2"<[S:^(60.RL9<C#7:::3)]9(;$!6&V
MJ=07?=L>"UAX9 W7>&23%%I(>J#@7HGGALH<C@S-GD6,R; E,YA6*B_09F5%
M3)-S:,-&7HYD!39=7;AIFD_/L(%*"LV&4(0C0[/S<2XW'J&]B48./".Y3BIC
M; Q]9Z'9E2DE#>O]=9)?E-;# 1<7QM,2U M#LV>739RHE;(M/IU!AFXQ+[4V
M_09@FZ&1.EWH;KRUN>!G/-WVA+ZG-0D6C RM4U",K%!:EU=<MSM<&FS<R!=I
M.'*WSDNGUP4Z?UM<951;TDV8RQC.D",]M1IO2)[&+_25HO4EN5PJ;C-# 1]5
M9-9Y8YP AZ$7RJ<+A8*\3F(HFH@%VXV!_2KVE=,7@ZE3"KCAE>=3!__80/AB
M#3D+/@>"RVMM73-T>S+JS1&$5#5RL1F**:+3N'Z2XLM#+9LVS%6$FX+)AO!P
M'7BX?F:AZK=@AQW<87-DO[DN;&X,#1&FX><9GLH??)Q\N.<J&22:H&X9UQT.
MY@9K.['%<ZL4@?@ =)\S7F3G3'N@?VBP_7W#!4W0/[1)[YW#A4@P$6#N$#!X
M@HK@<H=PB1C9G<(%3R!8!)B+ >:S+M'WI..;'<+5$HS>$T5O>@)WD)273!#D
M72>@G#C0"^3HO6!*5 )+OJ.#1H1V94([80_Y.%I<,Z>+3-#8=R*ILR;ZO2U/
M_QPD(1+T?3<0_SR2?*%%])9_WC1\(;QAZ(\&]X@?F&>?C47>V2:O'[(1*&]W
M=@QG"= (S#AWE@04VNK%XUPO'ID5N'&@"R1KF;-TX T#AUK;ETY\X>Y1[)W#
MYZU05;F%K..=/MW2<JR^+%5755=.;Q/_4/H)P<*Q[>?I8D/='SU$;.%\;"$P
MBOQXMG#QP*P+L86>R\BM=@51>7&\Z5.K7#\[JWM!KA])/Z$T]K4H]D]X,R^/
M\%MO^",HA/?+P^XFAR=\)N=+Z=D*._>;TA-)/CZ+VU+T6QRN0#HC>I9U9HC2
MMLRNWA,US?2"G#[Z1$/"\TD]$7OXKNQA*_1$[.'.): /L =&GI7::+<^YT0K
MTVAW:<>NSAI!"A]]HB#*UZ2?.], _'R^R/AS<2WOYCDLM[,.W7SK]\4E[U&(
MXE:.)0(PJ89HK0N.,K.KI@$W89FZ#GY:@-9SH$F^Q4970L=.$:NQ@B@FSBI4
M7F[QJ6U:($H_,>@E!:V(\?Q<QO.J_>GF6[\OQG./XMDY& ^W-&RGBP^7_+KL
M#,IC+3[ AHT@[Y!DGA#B_3(,EVV&=9CW<$P1+UG%GV>672_A)*.,%,M29  _
MUK85QV8-N:R*_AI5Q7XET616D%K9VD#(:6ZZU3<:4WLAXR=R?4Z/NVBNSR?2
M4EH "=418$Z&<YANLDU%>=D%2]Z>%$Q=B8G^6?DEQ_3GTXIY +W!=]LTEM.9
M*Z=R38_>'\31'40+2KHB6I!]3EYD+.)P,Y<(%WS5X8X1SRFAVZ-DJ)<Q@/]U
M%.JX9^<P2<>T?N]X]L&NMM%,F,^^QTH\B*041V#BWZ+NB6M[NTN*3I![;?WW
MGN_C/G116+<]%KQ&$GC2/X_08<(,H(,C.TH"VO[L. \H>.Z[(9U;R,"T&@R%
MJ>1_S\#;[<X(H#(F+P2K%TB./T/F_\38Q(*<X[_;M?3)R"OX&F @N!CTHR"_
M[4= J_1SK0!9I(.D*7O/JL3#T,\WD=4_VC@XV^?5;H_V^<-CF(2..O@2W!?2
M7W!$[']CF/_+?[],<SJ&YK,XL(.E_]$KC]^!99LHR^ C94BCBJ P(TH@\"$A
MB( =")+"X$02&R$R%DYJ79/HT"47*VZ1[)+]62Y>[&#C4XFR2SPE8]VJ+6OB
MC$[G9-1TT^[)1%EM;70F\=6PHKEMPB:8%-.T*NRI1-F>R33;@NT.D!HZ$S<Y
MVLTJY?&I1-G1V*16HK R.)(G1L(ZP[<XECV5U-J99G0^6TES'$E/D'A)*9 I
M$9I<0^LL6YO^9MEL;+B<QM":E&O@Q!P^,[3.?*G "Q6VU^769:%.4A)1&,W&
MIQ)E3:-KB'Q=<9!XVQC+-+%BJ8PGD.&1U62EE.3<35IKS>KY41]OS;IQ3Z#"
M(Y6N,E#-I3#G72Z?<[5J(S^U/($^]<Q2<\;6F"27*S):*4MSU#3M"4QX)%;L
M)+%!.XWS:VSCS,V!HDQ3<"092OW5<O54:<%K6K=8%A6/5=JM:4- D?!#K58O
MU97Y:H.KY<LEQ,C4G++M"2@:'NH5RE+;I?@RYWHCK9PQR(7(-:!P$!JJ(MIB
MQC"%FH9APDJ4N,ZBZP$4/8$EW@Q9>'V[)VFJG.)JI>JT5L3!T!. 8KL,ZN1(
M0N?C:"_7Z&:[@^P&K/4$I/JH2JI.:E) TIM<?8TVS4)K H:> )6SQ%O4LL%7
MD7A*)516ETVL"X:>@!6U0$?.I+:L\IB#U3O,0(KG!7]H" 05<M#MB@5%TG*K
MGM[PBFRETP1#3\ UGS+S&UG)%SC%6DXEG-H8K-@ XM8)0IFYHL$OU"D2=[SI
MH$=4RY@"R/0$M%(=1G13CBYIBWFGR<N%_GK0\8>&B"J585O,?#B::;.1Q^2D
M_GBJFO[0@P3PPW(5;Z=D[\2O3R1FPR6],L>;(M[Y\G0/KQ'1=<SC.\3_Y)JI
MO!26B#)Y[RVA!TM@/[2CWWW#!?VIC1;O'"Q@95'F^QT")N)C]PD7-$I\OT^X
M1(SLGA)YWY.-?T)ZX=L,_(?G\6+)!'G;I@QGSB>[1(/-B(HN3D4/DW\)%*@H
M23="DO>0A(F2=%\8Z.XLD"@3=B'_/AL-W-E>;Q$T=>>G<(,[=*L:W7LZWZV/
MZ?XIZ!:X<ZL$\;L^E!]%4)^_<6^#&Z0_155Q8F80G6B,8SHL.BR)EK4>F98G
M6O)YJF+<E69_O7OUX>.*W[,17JVWR%&4\)F#A%E;J(T.PT&]/FVLAH5Y3Q-5
M:B&J56[)NE])1PC%B]9V! <CA=.'Y'8BN+>:=8J;7&N\X;&<I2R%<M^CI4:0
MNYG$GTCTK;XB$=&>T5<14>W=4BTN.!O&E=UTU>:[4G8T6_<S=65^.ZI--A?%
MN3.2-4TI,=-V?)7ON:-M5T2"?$HRZ)<:2-^MTAY(%6EQKCI@I1N@MUO;OM]^
MX+?\W/D[]B-TD!^KQ9\OT?PNM8?O*9B %VGP7G6.V%MS2\$GV!RM=^QD(4>,
MM$573A+IK* C3F/;"9$XF7D4D?VW-C9$=/^ HLVGZ;[ITFJ>[P]QI)LLTI5J
M4:XM4VR0<8BA3P1^7O'FEK),ZW*=GG^FDG7C+9^;0?TL;G0E*63WV;;7ZF'[
M5=:04XJAC%3'/MV?-6WZV=(O6=:XV%O76Y4-BF"#+FIG2K**5QH"Z5=G>*(1
M(C*C?!<S2D3B#R!P7(#$!\K,;)<VF12"T7,M5YGDV[,N"T@<2B5/"/U67_:'
MM[EDE+D%3C](-(.V%G%F@O5O@@\BK>L[&UMN< J1=G8U>:AN00^MLZ[KHN$
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MRVB,<H-AK[MI\''.=>SX>DT*4*;RJW>^RS(>RZB3489.;"C:JAV3U1$X2\4
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M;QHM$TQ159S3$M$ZJD%Z9=,3#GB!;+I#7;D+#OD_5U0!;[#UN^*#5S,GG>*
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MU/OD^-<_3"(<)[J7L62@T6TQU6?C2L!L0PPL*(<9/*7JS@!?DLYR9,?GT)(
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M'Y/GYR#&[6MN\:]T@O9X+;EPXX]UX_=LJNUOXU^7WGUXA$Z.U&QC;0?H8=R
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M6YWRPTE*/+T31AA.72Y"Q@$YZ?3\K$&1E\5V'_3[\45^Q.W7BZU.WIM/WJ@
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M!Z-<)G'I"+EBN^#FQ*NK^+!9WMQ]/L(UB0KOI%XJZABPM8[A(^B%S6-%/96
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MW*^-JG8K)9+7Q?.X*R9R/26?*TKF_;TBGU(I@:ED4B29W%3A]+LV?3@G!K$
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M4^9^AMAJ4?+E#=7LDVM@79!]L(SPI!5"T.SE+Y]N;D;WO><RN;_H#DTYU\K
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M\9" /2H.HJBW25$JT:=1F/ZR31A A0"T;5<Q*-Z;<\BU?Z%>]/QQ^&&9\CB
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MHEM+[\&(D7^&D>57;!RW?_B#AM=L^L:-A$11)?#+Y]"Y?^;%,W; 7!E9F(F
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MYN%18V3U#)Z')+3\+NV;R,Z*KWB6%\J=14BY$HUHJL2E+7_L")<WU!B^IZ2
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M8'!DT1)GZHX#0J ^W:=_Y]GGI/*LL5W2/?V0_8/;MNL[\^_G<A?AB3U\*6Q
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MJ*O#9FZEK@Y'TM5![Y#T.6KE>(^XACEP!MPJ[0AF+XI@J>8%V2[=,(IS";@
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M;(HFFO 0?G4C$!A@KMTE [ 46<^V0>S$:#I>NN&$M#_:;HJ1I#CS&18!^,$
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M(^DM?^*T3ENOYR*^^%6X%]NPR]XA8B""1OS%-+L@DOYKN#%[U#!-^HQPC+!
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M8%1DK+[ H-&.,:$G^V>>9)/&?20^I?&>4>#!.UP6N7P1;K<T))0^,Q=B2C$
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M2E%I]LB5><M2K(U&)IWQ\S>;>_E!?#.<'KV^F:$DX/DWT29R''E;P]*GVH-
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MSQA$PKKQR4:I3> Y(<#VR-_N.Z&X=A0N*V7.-)D<NE Y4";&E2<9D/#S\<]
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MW!:Z6G57)3/OQY7"SF(I+405A3-L]62M&G7>W!3-%?)^<".\2Y;[M,'D*EP
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MX<FA:P^?*7SG> 9<5K"^M_1!6NQ/0<9K81* FS[_<K2GS-+VC*%,8$L/!\Q
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M;RQ[>SO0!9:?NF$8-,8(:]HUI/.;/1'% :\M4/U?4,43@"E6ZD^[?V)Q 0>
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M<U2!Q W5\LTL_RB!IMW>:6P8D"G8GE,E@ST'S'GM4,IURZ#Z8ZAS+TC,.=^
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MN\R^*^P_$V38P7NQQ<.>%OCZZ1-+:([<4=UV_J;%9EWI/NBNI107\MJV8OE
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M5QZ2)<]K#OFA-&:9=I2UB/2 '79N\R.>YF:<AO)$RS&;,ITJSC_>F<ZE3D7
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M]W0M&9S)E2I-!'_4&TY2<$XOI=4A_9I=-RE4SJS)E;!JFT]/N73SIL&T+O6
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MXLO,*;UA0L-&0S[$1.OM4V&+XZ&18(C]5\F>,(X$J'!YQF%!>.%BDO0>C>%
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M7L#_SF/ _XD8P7F???0X,IYU-T\'-:QOKT.L\5%7.<&W!")9 &3/GE99POG
M1WIML#L/4B1;H8.5*F7E:JMC)*J3J].>XK2Z::0EE>C>2CV3A@ 7)>]"^'F_
MK&>+D#X%KYQJZ=;6C1-E+7>\$G#"'K30,=\^YYK]I$S-^88@>TO].[W^*,J$
M>6.5E^CYV"/04EL_M9Q!.9TZ3;,DW-N.9]X_ P1?:YK7U.ES< ,N5-^EY=;4
MZ1Q8SMC79R([3\GF55AI?(")+>;8RPXYX#=>;&]*%^$MJFND%"Z#4:;M-B(O
M7Q[&[*E$_S)%?_EY8FU/F)AVA^<E=RO/@!DP@&O'XVK'=<\^TC^>B(*^[OR9
M6W)7578EK)AX/;*P#U%'LIDA@GPU;O>WE,'C_3M[FB6IV8Y7!;K$'?S0#NB?
M2TFB%$CCA+<7G C?+LAVJ_+94<[ZY*_JM%];AD00$[7!PX#P2R4& # PE\VA
M/71O!A-YE63>=X33:\ABW'XOGJ=LQM+KM!6D45C?W2<(/&I=2"R7:E8O-F"T
MF*)<"RG4 [JUD*THJ?#"Q27=CU;NNX7^RG#>7OAH/_=;%XD^\#F3YK1R"P!!
M51PDG[U@\W:2<ZEG1L[7^O@RR,WF6/[LVZ@U0T$[E0!>:>FMHK'DR^//'L<I
M'A'%(E>(8M]R/OL-AO.@Z^Z^L8I/#](C][Z5WDMX'IY\:8=/Q(#NDUV8(=HU
MMXISAB+N43>[H7M-XGD^:M_3D^B %PATOY@T3.7H<L'B$Z8@U;8=L!I7P=?#
M!)X+D>FSN9;5Q17RUOV';+G?7,,0XBL-5NE;R [&#3AWF*2F25<4HM%(O!4I
MV]9#7"F[C7X^H/[D=T%\:!9Y\NU2_[K,FCVL3":Z\X>Q%66\)7H8F<Y"LN&1
MO)W'+_\['O-)%_LV^9C.Z45OM%H32Z<W&]6V N^;<^ZV(YX?QLZ@DQCU2CPH
M//+RH$6O;.O,%Q<+%C>CN[5.:O,TMT#@;W?+-%3<LA[N:HZ3PC#=CK#Z(?/?
M[T/',&OR=RSPSCAU<L(G!I-5!@.ZYC_)AUW:Y5;!Q?Z*3K ;,Q-Z,PK.DD#T
M+<:5YSGNUX;XO%>XI'9UQG1Y![F#GZT/YZBOG:PJ3WVF>=3N5.<@W?DQU(ZU
M;RBOW1 Y1O?1+LS81BC9_HM%&'/&[JD*WC8.K4\C]/OGKD;%IACW1O(PS1.G
MSM.]AFL&O\"<"\A5/_/KI(W@E3/ 2RC?]"_N"+G-$X,6F/Q2&#P_X=7H\$F#
M\.DSNU]7#SKIZLX#?;IA(U#T9'P&%V>I(_&B-[DUS20&%WX(2S.Q:Q5XP;B,
ML@RV5[UYH[KXM("L7[K@-OK!S<K$]]'5 >"2KB!TEKK_(YZG"?#-/V8]"HH4
MOBQ-QP/I_%D%],&IF$W5>\;KZC.(Y[C#_:OU@R,"U,GCVU0& MTL3ZSGF9>4
MS=6+$&XMT\JRY4N1KJ(L[C4]&(5*Y4%DIK,S$D/C%19%[W0E))<)UGFWY-)?
MOH#A$'7*>,:;_>VZW=7@ATQI-44'8'H0ALN6OSKP'*R'%X$W*SSD,6U6$O0>
M+6TC2=XW:Z<*&A.Q(VM9V7*JW4-B8)S.S>3BIZJ\?4\W-&D1)V64L>SK$_>M
M6BE77[@/>-!D(#@>#+FZFU+)W/Z;'>#==/7$+&&T[]1FTVUZ2;VFYH7^ZKS8
M\(GL<+NQ+T,\LX;_D^_S:E?7H^[V <?^P,@./]':E*>^4$&6X!D:P@J)/<':
M<_M_-N!7<MYF34$B/K=AIB/1<QJ21OGWF="_.#ESJ47<[$*Y%%*XU-.%<T'0
MXNG"SI]%^5&L;.><3(L#/&#Z6_(NK1@;X"WO&[NP/SMYS^,>_W[++9>F5XNG
M7+(UZ:IV@L#\UD<JQ\T(#RL(U:48FBL7[K[Z4*C#)7SM8_XN&P.5_KDYMY]L
M=KQ3: /J?\JMJP&X05>D)5LNSZW\%:6'Y DN4=(O&57_Q_YWR+\C $XD%(S]
MH\G^+]?GA)9+4OOW93!=O1@;U97Z:&\&O! K.\[IDCSS1G93Z;\/7!=C,Z#2
M^#\2G3@K"'5#03',8YH#9.XGUEO1 V>K45D(%*3A*RFU:TS$@5>B09 "@U@N
M!N$2,.#RY\(_ #O\@=?8.>;.6.&K6@$*B),O%7JN,3RW1B6E^0_"YUE0.R#_
MV80L]2?M6Q_ .(WD_/1'43U.27G%?_2E$866'OY6 \&>[-TX[(VGA088>1[.
M"*:V1__Q8:IGK%4[38QN.T4'^])9*C>G^V\;)_MM>:R=E[6 #?T?'__-?]'_
M;\)T-OLO4$L#!!0    (  ZD=%H/R 3QZX\  %RF   8    87)M<"TR,#(T
M,3(S,7@Q,&LP,#0N:G!GW+L'7%/;GC^Z%0&E"H)(#0I2I"E=6A2D"TB7&I$.
M(@+22P0%I L(* A([T1Z)U01D%ZBE-"[0.B!A.0?S[ES[SG>F?/FS9MW9][;
M9/'AL_9:O_4KWU_+WN"_X6>!BVI*JDK F;, <(;P ^ G 06 Z.S9GQ_"=8[P
M(3Y/3'SN'#$9*2G)>0HR"@IR,G)R2BK:BY14-%3DY!<O7Z2Y1$=/3T]!S7#E
M,MT56CIZNI]$SA 1]IPCOD!,?(&.DIR2[O_VA6\!:,Z?L2:2)SIS#3A+<X:(
MY@R^ P 1^"0^\]L%_.TZ<Y; (PGI^0MDY(0%51>!LV>(B,Z>(_K)->&N/^$^
M<(Z&F/;JK;LDE[0M2*^YT D'QF:<YY O:Z77&4)QBCQV#;I =IGA"B/3=2YN
M'MX;HF+B$I*WI13N*2HIJZBJZ>KI&Q@^-#*VM+*VL;6S=W![[N[AZ>7M\_)5
M<$CHZ[#PN/BW"8E)[]XG9V9EY^3FY1<4EE=45E77U-;5M[5W='[N^M+=,SPR
M.C:.^/9]8FY^87%I>65U;7UG=V__X/ (?7SR4ZXS -&9?[O^7;EH"'*=/7>.
MZ!SI3[G.G/7\N8#F'/'56R2T=[5)+5PN71,./$\G'YM1UGJ!0T0'1?_8=8CL
M,J?HW/6=GZ+])ME_3K"@_Y)D?Q?L'W)- !1$9PC&(Z(!P,"I;F8X#_"_?91"
M/[.)CS32VU(@FI^,3(&3G.R?I"RGXH'ZHE,?LE6^?K%[)K 8'V$UF8Z:P>7D
MZT_E;[_EM=@.#%\IN2W/E^0QC.F?NLZCGW^:.Z1Q\OT)T7QN?3O''.+U,Q_;
M;A!&%H2JK-H^X9:[BIW% _,;0ZL%A_K@E05,TC&SORTU'KBSL9UTG.:"!\C5
MS?% IML\J)\:)QB#-C8^.KV4?A'W#+KCOKJO\V^;2,>?X8%]JN9CZ/N5/Y->
MQ0/!.3#HT.T=ZA52/,!@'J/(UI.'Q4)=\0#[23\(%XB8$=J36<!=3FO" _=6
M.L ?0%BSIU[@>=;T",%2?K;A;96QS5&9>O>3<V^%--K/A;#-(@S-G1?H'LJ)
M8&43;Y6KQN%XKSPS.\<<E/[@?-^]IAQFU?[U-8<DPZ<AE3A8^')N@6L5H^@(
MU%JB9!(Y+GLMG*=TH8N,)_/%_V?'7M' L="$YVG$+G1UQSS"W-T;#US':.*!
ML@"M4S:^))I*:$>,.E&3%DI]5_9RXW;7#&NC&&K!-$)U3.=TF_.U6I&C\_+9
M/+F%X2;:9F/T9 &28*5*S]"G^Z>\50VUFW1=CT-)=/=<!L>OG.RU#^N$;.94
M'>U*"YNR\GMPZ6WPY3#*;A;N^7!\PU[?F6P+$'GYP)&\8'C^,T-M\O#R)99)
M.JLWU*1YEJ:;,9L6L]+=EI1<68[DU3.56C;W'/R_<-7Z4I.@\SIPPCNDT>ZI
M9_SX;*EB7,B,%IW?'M\7=CG8V"\>"!E/]ILIKPECV^5A3,CC&3[SYAOS,W\W
M<PCBED9.YK"6WH':M)"[VRJ\W/5;GH!U,8<UY[$IS/UY<D*QKV=TLR3:<@YC
M__*!;U'":*:(B6RDO+[[PH=%GW#/%SA)+]UYKARNU%PS+:K,<,B/I$_OLJVW
ME+S :8Y++FZ%N1$H5Q-I:_CH&S/_9.3BG%5G+[&._RVSE6"N46>HO:SXPN=D
M5R\W PSXA+4D\E'GK58B-RO,R?ZFKI9PB521!G-X54,V3G"YJISB.K_,UN0'
M2XD ZZ+(9+2 K[3#=L:!F7=7%'SQ$U;\9!U\HF4>8^ZRX'S,#Z9LKH_!Q2/J
MPM ,Z"P\D,.Q((P'%M2Q].#],+8813I#H^5@.NT[Q/^*0;^L4>P5,<\0=I#"
M2JUM1GYO:$NN4V#UM:I89PM0GR]#;!J8=N")NTA-!QT\]<<#+UP,;Y0N%;-/
M;.>M#ZC.+FCVE.@S6&UNB\,*F^*5/VJ;0_' >=)P\&I ,QYHD<S' Z^(.D'[
M8 ATED7OM$3K^!!W@'M\4@4ZQ@.@>@@V;)7.,!T/M)V9CSD!P> HJAO@.6!'
M^90:,8,FI6<;S\-BH#YXX.9?[5!&,430J"LN;%2P+]U+U*;GGIF(<=3%^<.;
MH._\C6.P>"!F6@AW;Y^)+QKM/E^B8**A>W\\*US64:46(]M^%U?Z0&DQ]N[J
M^<V-Y!^.QF[ZU[*CU4:MY;/R9!%8*:@HG;:BW6/"+^#W8>[H7N05T17 -U;9
M1*VM0:XZS/JHMHGF@G7R8R+Z!U[ 66%_QQL)]-+V'H?*^F14#?'U:C<VFY(T
MDWP/96^$[^$!]!T9;3R@<'"$.].IC&5GX\$#&2<8/ #,%_^;@FSP@ $!&>"%
M(W4\$"M[]J^W94V,XH%TYVW(,NB_9=<RBCJ"7C6F"V%SMR>T_'6I__I,>SJ#
M U/?YXJ,C=@NMH;,K[&F,N#U%66SH2_-[UF5GSPH\NT1B3"<=!XJMWUEWJ_/
MJZ>CC41H", *C<U[-5><")A6;:$S3.XK0$=T(;G&BI^;:3\7 *DE_1B>SKYF
ME/>.XA. HK-R,X#_P?BNA5N0<\QF^Z=&:S(L%M8&A1%(Y%X5YKNH#S']"AY
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M\V;%[<M=7R6L+-%1)BES5DD,\P<'3C7W^SCC.I]>W)*<4Y$1/+NDJ4R_2F<
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MGU^=#O&E[M2\>*[UVOB)@=32QX::\+LW*#O5JL^ORU41-$G[RI:!D2_71;=
M2D2?MSKY>TF_*V;N,#0??=?OEEC:<VO%R#M7HND6W;0=H)3/*2U;#W%7ZBOV
M1+W.GI]%NC;XN(W7A_-)**4@^1S]&GR8^?6])D9\Y)Q.C@[V9!8,3M/]Z$L&
M*!#)CKW\-XO/(]W.TB@!&VLF:>?1%H14'AKC.G$]RX3YS;F4;($/SS?,S.AO
MM6N_JELXE^[+- "**-+ZKEG\P==L<NL_U0KGPW:&\0 #;I+C_J^=L-?VRWUF
M^"6%^1(YOBQKJY/3]JDO+QB>-:A]I#C?*NOVS;()$CK7WT2?75TNEMKN;:XG
MT2==_*:4;%.//-KMPPJJ*)WL^D7N*"O92\9USE_(OKSL0'(-B7XYZ(WJ<W1A
ME-,X:&-=C&O-,HT$7F#KNK%\G9'V^4JZ6K!IMPU;J=T225W[ZTXGU?#9RT+-
M#(ZT$U\&33N2A%6V!;]_EQD5#BK;FG@F4Z4]N)?LC+TQK3F&_7*UXL-FE)JI
M&?SK1[D'GV(^VIQSZ0?F\\"7Q;@;W34$KU<J!Y'4QND_8/WJ[913$WP\H,\J
M-0:YZ/>@H;FJ,;KW2SC=VQO"=7NV6K="++O,.1YK-5&O3Z[3X 8](M0&#FIL
M"=&'2BND^5I577WRA2=1_1TJ,#;//=;+Q*^5>BL 6M:*^-[G>79PBH,2V?=/
M#7IV;Y,+']=H!GSQO/3V#,F\$C+ ]!'*P:B99SV,M4>!.*KC3>MAC+B$320U
M?UT,1Q'U6VA+L"IWQZD.TGLSKZH\W.O,F\38ZB^D29C* [_NF+;43]W('XD[
MNZ;5T?" =/#&X$#*G%SYC*U*3LCYK(J'62JEWPTNN"[UR\#?W7KDEK 6_FVG
MIGU3_4'EL%.E5GFQ.'G]]=KW;S@;*7^<K489NB8L;+OOEX [33 J!O:;['JU
M@;F!9Z23CAKHQ%587G3E8W)+O83F-;;##B+(C4J<-A?JJD128YH" 5JJ"Y-'
MH:2E7ER%?(20Y9$RWJ&Q,%:DRB>/!Q*;W#?0"<U,G?S@BWXN+'W-UN*!WSSE
M#,76$E;,B0A^F[J !TXV' GU7I^/@(?%\[P]:(I,<2>R'CH=BHN]U._WD(B0
M6XQK;E0CGISY\2Q+;'5L1>X&86/?[,S)?@-.W3Q*,Z9+%[$OWXD'R$+1T,,U
M8OJE&3J<!*S=F<8^6=2'%5GE"06]I_,(Y==TJ12\P%6(5CX,*4,<-!!RV9 8
M-=7&K;:1+L> X/LO>)^XGB$EJLWWZB'+*W=%.+_/=BVV6N6_9X\4@+A7(ZJV
MG6,WGAL.C$.KPJ<FU/.A;<Q%U;'GTDP1J%)TEMQFI.VDV"AZX?#5,%: X)A4
MZR?^D1/3U=5&CQY27:'O.N>S5!8>'-.N)JCF(P11L+=Z_^J&4DI.<6IBT7.8
M([)[TDSK869C3!NH4B"W9K[7F<K1F"1GSE]S.^+Y* </IVPH.\T'EW5'!%]N
M@H\[0DS";:#ST<;L8H:YN).9-XRK4N9H_@%1YPSUU+-V/9<T]$TX/<-K^&*=
MESJN-0E^0N<NT0$_9L*>(53(!GA@2.@!.@*GGO0*_H/1EU!V*)OJR_%"P\$8
M^XU!-"\>0-2G8[Q7][45?4+[_R6/B/XPV)Q15C'275DR,73(#P$TB&S#,\5^
MX+$G,NK>,"\M_0CU.OB$LY.@Q1Y[:DM+/!!4$GE6V=CV6P 7=-"0@+D60SPP
M7Q3T-D=)KJ^U >+H>2!;K"CE59\V0?^X-#%Z+<\J76$P'R:+H>X8."%;A:#)
M\ !6'V2!?D^(_F:$$N,,! ^$E_@WX)31T/=]!X3><F#5?QL;(Y_9V*#5M(,K
M\(8Z.I6L"@]8LH?/$6>G<]!3D$+D":#\,PL%_(H'#Z"AQPG\U'R5A9U^,\=L
MP8K>V[\L8KZ/3A)^BYL88I_N>E?]I-._14!K$KY(V!?_]Y-?MG1Y=LR /BW=
M2RQ4.=@=H%]U[T.#6F.]1#22.=P$,Z">O+6-S>G; [SKFE)4+1[TP_H/(EX)
M"!Q ?>O2A+-O&#RE6N.$(;OYL#\(!<ASEKM_Z)X_!!:AUZBIZA=?P5S>ZO -
M\04A_(@+)[WB%LQ1I25L2=Y>A36)-;>\/YG27S'\?-> *#)\J3@[A['3?*90
MEH7_XYQ.Y%+OUX24B;6\DNC#\+V93]C[A$JT-)A08<+P0*?V(2@L?9]^$(ZB
MQP/H0MG?M/K.7Q.\=P(B (_CGRWQH+QYYS K'V)DLN%#D21^OTCF\1!.7DD9
MJJ9%X\0"FL-9\U,+.^E'ISEC8[0S&X]^@"^!5_DRH+-\>&!'SS]TWO:4^+D0
MEAB*NY%> _V"!ZCWN-==\$#Z(.:G"0AM9CGS@F&'SNVSLC*TTB#.'=WJE!U!
M?=[3BDR%AIA;3E<2CH"JIUZ76E!HP9X-]Z_)(7G^MVJ;X2G; URW1CX1O9#6
MD[@Q$EH_'-'<'!60.Z2'JG3(TU;MXXR#[W%[/F\P67Y.\!N/M+LKT/,M(EX]
MXJT<IK53>5-DVSD50?/7PQ]RQ%UO/;]*%OE\OM;?ML6G,^EU:16<;'W(?@09
M>-@KG>_WA>O1399'027;R*P_J^:9[ML"Y>\]E)-5\*^'16U7DG]B&N;$.J+9
M[2%=(+JAFBQ_^*GN#;'KT,M:JA<GPU";"5)E#+]TUA6EW<]ZOBZ=SV9^@7G6
MG[2GGU>%!_*<MR#+%@?.)U!0$QZ(G>9*=60),#:1+QCH*7MQ>Z.3[YN)-)]8
MX_V>R=&WYUZNRV[TB9XJ=-679N1_-]Y(IJB1\HN@[R%7/IT4#B&"9=!G_!D
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MV1)H"G3T644/S.&H4PWND RR&PW&$D]3A<8/UZ80?SQC85^+HGU^VE>[9N1
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MCG22!-W\#+YQ!$5;QA!#!\;S\  T])^!E).TK(K<(/QUC<W[C>3N;N]6@'F
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MHU(GTL4&@G4[$O_F#\2IUP1[F4_LLHD#; S>&M_E!F2(KX;O1<_?J>P+=/2
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M],?5S2+.9O]&6K<;"U!* \^XU@PVJ++0S&R+P^2D@CN[=+(XF3@+3:D52BS
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M#$9,0IYGP-*V< Y2]D?SEL@6NOR9SXX,@T]8LJ;[:MY9$JH1?!06:>FO$IZ
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MR@2 *?$>77]0DTU"AM;2&V>-2TF_(5Z_/@ B)5I6818!,!D//.>W-2SWY2
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M^AYSYR&9;9;\?'[:W45'0I%'BP>EC?F=*N83UET/_;IHYS=2<C,J+&EG@\;
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MDW39S9M*0B][$NQS+&ZU["@DF[,EYQM.M=:_182^E3\B [#WEHSK%@[)6B)
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M2GY^[<+UWK\P.@;YV]D#YE&6QT-M.U? 1OK7<XMG^,LYGMQ2Z/AFD5'3.D$
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MN:G@P2..\I*(N20,N7MQ5\;2=SK.UI)2.*JAR6YR-$=,'HS$9D]'CT51L"<
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MODOWAU,@YB)F)3(T![M99SN)ML9./71R?M76)XRQ(7()E6]*B>+3TRUJENJ
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M"\T&C\N!3>^/'618_=_._E?" OY?T#20E<XTPZR DB K[H$&@0((:+1C8'S
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MZI8M>Z#5>T>F)P#Z_6C6&LK8(97("H\:3)=2N:D>/"!&?:LYI((U0-.$$66
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M*N>//LJ\D]VY4([*("]?ZZJ YUUL*#8Y(+H,TL5?L@X=5M2>9$C3J%3$*?Q
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M!" 2T^UQO==%;'@O_;@XC\[J6($NW<O-ZIC<R?4JO>+OLCG;C=ET<9 E.KN
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M3YT1?&[:]"70W8^W)+1*3:_XS3Y!GMYMY$ZN_PO8^DPLW>2:?UJ7[:7% K6
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M:%S6D*K'&FMK3R7##0C\/@ LX%QL;G@AH-JG^=V?-0ZLIY:FJ?31NC!UA[V
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M^OW0.HQ,R2S)KM.L:HI=-93!E?Y7 ,5R)F\=,-[ ^RH^SUJ Q3:_HG'R+^Z
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MR:.1+P7E&(H=L$PE/7.N8"#$;*]Y-=(G;9TNDNZ%DR_>NPI*+#A!E=Q6_Q)
M^#F8\9>\#0_+:J]P\A=D;0 R0@XX/%XN4PNE-DXII3Y>\?X<<$-G=9$528L_
M[L.!4C8@4F<>__+\2G!@2.H=3]SK6UIO*9AA?L*2^UKB3)G%Y.&C>;(R3W@R
MXV+UQ&UAHV]LAW56=6TE(J2;" 59>X1>\<><-"):\UY[*B8>:"KL'V?*&2\T
MJF#>RTX\,BXIY:WH**W#*'3+#\M>W/],1H=VJ]QVG\8N5/I@WTO-G.2UH3PW
M2;E10UU[S]6YGP Q0=GK[]3OM<D'#B/-TV?:(IR&J7H*L?@/ORPMM-XIHK3[
M'*TV\^3HMWT3/T?)WIA##3S^\:]1&,@?%!QVL?\$>/:($:6NG*82XU]$DG;5
M3$VY,&D+I\)QAL_L4)ZD71O/O(80=8MZYW)/^4Y^NO]PJ-$LDX?#O?OQD/$+
M3VD(/<38@.^/P=FH(V5,U4YTCV:#>I^N;PI5.=9&1= */J]:P?IE>=&7;77^
M!?(MI18,I9VE/I.KF*4!FIK?/)]*/]:*RYC*N2@ '%2^&V0&K:5!H;9U5G'E
M\45^<>>((W&_?=0LO^%GJW/!P@+5!:SLQMH""0AI&/C%8+ J/7-@OTJ!LZ#6
MK0^D8+_K:]1Q>>^7=HDOF:N/?T;KD2MI.;(SK32U%+V45]^3; M]1^$.UY0)
MJ4%=*HX,2JS.+L+\[9OO6\A8[G4./T)8KC/F]U*? !$;E=&]DXJ9A"3=GN$?
M?)SW.RX>O;2<N\__K7V9"3[U-8%9L;7K\G="8Y\9U4.H_44U4?QZA3/&4[9S
MJPD,[U_?#8IJ64%8QO9WS U(]H1VRGK<3_5'$HN[8&[1QKQR^?/]BLR,8'W\
MS$2)-*_K8?LK9\O-7QD3LOE1V0^G!6;K2W#6#'U0YJ4-:X7G+*>M#R,@(%;G
M4636ML;V&2K^ZR3Q0/&"91WO(C/%.\VP%$R);"V>H(@O%T(G\CTZX6NT*/ZS
MV0YQJ8NL4!^*ZDGGPP>K/CV$@]5M=G-;W+[,:LI+A=XK"1WOLRCH+Q=\H7PX
MJA+)H#WM9 :?OK 6I3'N$0D)S@NJN7*MC280*KVKBQJ]BQ.( =+/BLK0:??9
MR8FW6'4J4Y5Y26T0+)!U+YBVE+>P"?"B0N00L^'SY8#8[TG65&ENT\W9=W8/
M\O2Q<]&.)ZLX]\X;):WO4 &=M$Q-%5.9>)1]>K6-E;5<6-VG+&*,I*+^OSOP
M9I_O5%J8UZ']@^$"ZDO3MW@S.5#<4>2[*-*F_"7=+TU),@Q[GI1G$%PKWKU4
MJ,5"9)#NZINE.D# GO>=#_^Q@8Q=V\OF5XU;:#L$R\L]@T*GQP:_/6)!1>)9
M:R,B%XO7ZXULY;FE9#O4%SV@:3#?@P&[25/HEY]%9'9HW3]D@$!TF/I,\P(!
M\;)EY,PLLB)6R#A:R3"DEWM)SG]QEGR)=Y1ZYCQ[8T1[]@ORV+-'@FH&7(/S
M!"!RDQF_[&>8QKVU*1'BTC7($G#]^2U8'4Q!;Z<AP!V@@G(G"V@&(05F%1JD
MP*2PW+=769;6OLS6PH$1PMC)0C\J4W#HO\[]#*B?]<S=,R0?_]:@2 66Z&7]
M$"?]_%?_Y,OR\.Q*1@R0\PLAJA$@?T[>G)NU=%65?Y=B376 2HHI7'L2#2C?
M7, Z2OY1?1)($E)IUKI,VV;+*(#HPC7ABM(D8V("? /]]1&@Q88;V():)OA%
M%;Y/.U/]=E:4SW8O+\\S<?T@$E-(/PCK>DX_6_H$Z/Q.$4;UM_TX^K+3P$VE
M*SF9[-%[^+C;<91_<'%(\"0[3HU2*_)9QP^L@9%G],Z%>Q6:<3Q'[,UT'"W9
M2J;0 UKGF3*:?)"J%&4/?[=#P<8P3S2%KD*W%=>+FP(I6,ZE)</4Q6*:]Z-.
M(@4VL&BFU35Y_0G@[SK$-*>0JI?"R;[4JCOAFLC(\T'EMKJ1;W^,F8:UOA[9
M5?$CBQ=?ZC@+ 0W"%C0)R["8V[\\)8+@ZBZMB.K)N/.Q4LI@+803TZ7O'AJ"
M$'F:%:B\/TJN1?H/Y526D0[<ATV2GGL> 2O57M;KQZ"-PD3?0EV#EI:>P6,B
M_&=/ ),G0)4')0(2W$H_^P0P/Z5+,:V+6SF8OH^XP\9_7I(IEW,)W+,.X>IC
M@_=FP"ALG@#EJV&7[OA2#RVRI>NBFL&5D.2L\A4#5TE%IR'^JNIH?O)VJ'/4
MVA. =+]5"+$=#<\?8:IJBA3)//"$XG?38I6E#BLH.3(U;"NGERA,IE;K\L\Q
MYX:;_/__RD"++JK9P'1-!<=*Y"1[KK8ZM%_C/[_/"XB#G21EBH*,L'AL@8@#
ME%_YQ7'3VYW15P]E/GS_GC%=#L&+?5["T@-YI>YB][J G'\EAJ#4$0'<G>"H
M#"'D=OUOCD"(=H@(?OKF8%@(F3I^P,/T@;<RL,Q])\V\[-X;]>>5''NQU>P[
M!7V'6J1KWQU+,T%GFXS8^W5OR0X?FLIQI_I/I +V6)N&NS3:F5N9"I?\YT)N
M8D.OD"026$=ML):L,C/GO,X&?8<EWH<'&7?^R;8;3M:688JRO%1.]@1P+W?X
MN2V%%Y]BK6>$U/;0K-],BTC,KZ[G9JVU&0IJKA&2-!E"4UJQY^]*"@Y$/-T=
M@5]3.M#?-)1]%I?5*R[\$%=J9==4H2!FOACYZ'QI5K"^**X@'_??9^%4?^Z9
MX/5LXWCYMZ B7 -A+_NI\X*@=(.UT;3M^NF-P$]L.\XCF[^$A =V^7$$&AQ<
MWZ;'5E #O_&X'2B+LRYS2!#J8XHR_M1XCPC>APPS_&@4;T%/63\4'Z6MF' F
M;"@_8:B3GA'Z7<E @\U?5[1?=M9GB3.X+%C'?]CHVC$7ZY>V<SMKGN]&V?4%
MG? ]PT)5I@ ABK"4R\&72*RMTPBWJ"6%J1DX^QQ4N7?+1BG3F&^!"=1MH7Z/
M]IV8F39AP+3'W9EE$#IUL:[,-^,_(("AGNIA,FG>HI[TTRRT^^T;2#C?-)(L
MQ-G@_0[7VX?\F2AFJG#LE^5'KKV.X>=@O?7HYBR\"TD,BU;VNDF^)G9*\5=G
MBADT-OF-4=^UF[O__F$ _W%[W3<\MM'RSO(@H=J\Q:F7C,M1R,!U73PX9]T(
M;8]T=E)GWNWS$T"YI9:MU7BP-JR2X8?\71>%[41#%NKK3*7"O\VQZ$A$$,6$
M_$UG3CW (I+FVW(M]UOYL=D)II'JI?G>[))_K*3PV\XH.^*T/<(63_=MH[7:
M"%GGF9NQHU[0#:T.XWGKM>I.;-UBF<O*R['9SDS2L7M)W)TCRQD[[?R_35_2
M"+]R4PB-B)C!"Z,=BX8]*N/!V"].]U2> *5:LDVPA66].2E3B[&17S>3YJ>I
M*R]!-:J!.\<NUDOZ7>O'X&_3N3QO */4<BY2U"#1AS8G&UL]%7>V]=]5++L9
M@0@\#:[F9':QB9KR99T1)5;YDFNW\N*)1["RI88M^!\IY?S >3U 6[-Q2+GF
M1();1WNIII?E<?!5>*E4-VX#JN!\JLE8?_TG3O]N!ND7G^+RCT!-:V$267;5
MBU\07UIH\/',%!Q/-3-W5VHU)K7,\ MJQ04F-TB3-[1)^WJ2K)FHU+\&?I\\
M )[3)1J[9:TG'A=43CFQ!LWRY0H" P/>$-B)/,AMZQ,G2UQZ2B'_8:@G/$NI
MR4U/K&^:;@XFK3^*N7GZU>7,T[==U-*,0^+8 .33AO@2QI$N+!W3OA8P1;GO
M]3Y;\8]R:1>6,.-%CX=R6L[^?R?E1O7F9.M;Z%:5KWOCFOY(/B PVCW5TS)Z
M8:YG6ZE@3ZT5$(;[;>?[GL=W;SF?#-XLB7(6+N57$W)-RM-OBFA4=RF'I,L7
MX*&N<$2SE[Y\5.7E.QIC->&7T<?WYGZ]"@8L-_"F?G;V-]IL&VA"&Z'?5>4
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M109%%8?4A4J923PL/0'8K"1AZP9B='@U3X 02K6#VX>"T5!.N?>FYH1N,4\
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M67P=V.A-(%<UD7D<H#P3$\A#F&Y.$ZQ"(\Q?:9V[__6&BN_.Y(R#]H3M$^9
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M&9)&*-V)T_28A\%F"(4-T/9C,Y7?U=XM578T3NQ0B0GYB@.(Z0 7EZ)MJP\
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M7U,B$RD*><U/?&LB'V^65'=XJDX8USV4(!@]%$,U2S& ;J>LG^9+:G2.='L
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M<F(T7^-4HKLR'<+3.\;M^M/KVGZ[F6J_2&$LJFR!A\&-TQ(/5H90,Y_$[JD
MO)DIPYGZ5D7A\\\1#>1-4N6%P4;I.CA>>'K A\FHZ:XAM98M#$33X;2N8\O=
M>S.]^N&."#S/\GC9[)G2^R#&Z GQO[#?X_5JQ-VEV(NZCF5^^)] KL\=;EWT
MOH0A"B)6A#QIG.QV?HULD+"9EU?WD'U*X,W+,3[2$U;I5"#3_O5?OZZV'@$O
M[1DT8%/0@90W%#BL=+7]%PS1OB'6H-L/AJ-I4A5_J9CE"G3/.?PX(C0LJ*?O
M"VC5WPS+EO23=FYC)GF]60OYO((%^7?%/GM6+<8/]KK"B-K!!$B'7+L$7OW!
M.R:^&T6_0)DQH5UF'F9NOFP%CQGUS,JIW&XU=BXO/FY!J-5'IF&K(,M/0X25
M?&@A4(F1H$C]D*"8!%.6/#EV[):A9TJH=20X6;X(]><4U@?QB<A/((3_<752
M=* L:<D?X@G$\N;HPW'DH3>BS+H2K%EVZ-C\I>OH[+L!P:#L=?#VTS41GU*=
MLD>+N3B1#^,+1>$X5TAF=7,!B809,H6E[8_Z#?<EY=?QF;IO/\/@Q_9U=VRI
M[(WM5C%"7T4QW)QQF G[_IP?$]LV+'.VM9BH_]5YGU?3<'JDV2 6M2@*H&\1
MKI=I%IA*#U?,DK*@4X^ ENO69"Z\3^E;P7/7H#/LIR_& '9II+CA8L;S\W43
M!8#B8-=/5FT.!-OX3[V^>]/E'.*[T.I1F%=S5GF>%HO>O!7M%UH:H0_>,,(U
M:E* 02QW39??I;9R4EJXKAZR3C0Q59/3I^3-VYPM&E,531_3,OI<+9CD1V,1
MD\8 !L7VE9FG+IV3:Q;/RC[OCCK\Q5GQ]"G^\2\W;4S=#88G\)=<2JJ_0FM_
M#+&F82\O]M;P]I#36A_M2*ZWF!'X T]"(\O4 JQ_RX-\41P8C$<]%I0O"-YN
MXLU^XMH?,##:)NS$;G.CYT!)2M/6N&#4F@ZT,"TO1,2:F;,5AZF5]%(IX8?D
MD@\]L]IT92"#!I4@;:UP_F/%T++1DMV>0KYGAE<'/KAGY-?#C)J-OP:^2^D1
MGQSNS.:=7UQ,\$N_956O,Y)X%ZW("RPF%TPHI@\SI>9JT+S@TE0@W\X._S\,
MS'GR;*O,U*A5/3<I]+G0!@*6 3XYUO,;(K<5O-$X?GV ?7-L.J%]P25,I[*4
MGR3_E&^@*ETHB[6J]"C&MRY)83M6<DI2P;KB5[,R><$+Q?Z["=08?3&\0JE$
M ?!5T9:*P@[;_I ^&-%T3.8OT31918U48^%UJ]/CXPD7HC&9&'VA?+_.]PA
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M9^+;@WN ;O%\[;F-="TAU&,_5C7OC[L9C2WU-8-5B^(_I<ZYL/7YFGH)DW=
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MCJ)1HLKH6J9H3'Y+23'U?=7OS$PGM/M3[LOBEPO[6;%QO1ME.NF76LK<^X^
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M]]7-O>1]2!AA^-$!">07SK^H%&_&#3#G6\ "B2/DTI#(<W,-.A5RS_:7^8D
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M=4I3ZR52I.HH4>1\_3]_^TT'W*I*+$6Y0^;MY0JMP[NZ4O92$%U!!_V6Z*(
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M*>T^<XV9/)J#.8,8+<QY?']\< ZG".&L,#4_6=CI -E1PV"R0C%^"_H<!.
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MH?CC,!:X'WKG3@\=!8^K-3.S .&B.-W<?M].B^S-/W<LIX'KUH>''!%O??F
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M^=../@+@.^AZ?<7553M,.S9'(^:3P?.H0C*R!<>0<_;(B-NO7RC%I9U8O@.
MC5-J3\1QVJ$ET"WT0KZHM[F%L>F0TY.V-K"QO@'UE,>)VK86"4<R4'ES0,)3
M"2PV,_/1SFZ7='EQT^+^2. F.^?77DJ4L&0_)3"<4[O9#TZ/4?_),NZ?)1T(
M-8]YVQ)YIEB*+FN?/ZGC/3EE;TNF2T#8ML8ET^K6&$4QH+&$I_6H=.W1_?TX
MFG0#?AV*Z@U?'P<;M*J; .-:+AVLU1S_);B,_S\,YW\#U(%(//&K200'/P7X
MOIN'!0B_RF&3\Y*,W_/13H(_/6= %.'FU0]X"__M-S55)ETH]XM7>U?U0; N
M=43!1U);>&U.J]_Y !R0OFW$/8L,J:S'\<C-CA*F>]VB:IZIC>-MJ?[ML7<*
MHLV2YDX=;1AY:54!NBDS$+5?,V\#<P#)7\;'L7F4Z_@_$APD)O)7H-'EFG[O
M.4V +PDA>=HQ9^<_$6''"K4(:S:]93". TH>)'K?!QMV*4$P'/JY9V+"&N*[
ML/GG&@4ZC3;MOH0-15[4I,O[=0%^) 0!A3OO$]0Z6N'9&AT@NJ'8@Y$"N9=T
M:[A,!3ZAON%<XO<5MX4T3B5KC75^5TG)J\=E,_=T1Q*EU?D4"LN$ANVK&#_$
M6E(#;UBFH<6Y0=S6H<^/9KJHYE!YXQ<M6 14/M%J7SQ(5%'>#P"LNLJD_,RT
M.OZTY+IA]/! GN8+B@(LSR,@+)X\ZM'7?TI-U4%M6TVG,;DXHU!,FHL@U&#J
MZ.ILBJZJO .V<A6KT^?82EB_O<I,!IS.R"]86:>N^I'@8^ &1=$1$8=*T*T,
M"CI3L<RN>&A=JS?AW&7V<,U6O_IOFN3_V_C5\V]'!Q4EP DP3:HS=?]$Z/L.
MV*J[<V+-[#<[R3?6 "G&,L/\@*-5%$D*G.V'GM,-;O?V*8Y-,ET.<=D,/DNX
M-"^E*JI]N?Q-;.UC?\EH&K^E&9]W>*.6N&&T(:KHA>F!=9F_76_*G')ELBM-
MJ7,OZZU5XD5,1_9Q#YP,72A>LO6?K#:Y<?:0A3T*&!BTX#E_>?B-%I%4;7D4
M[C"W.IHR\JO.*LZ-8/=U[>=<5CIZ;)86L<>A[DJ D*10-"OJY<RBU+-CHI_1
M[I5S=:R+T'RU O9E;0^6'&P\!Z+=U>=WZOZ,%9V'4B0[D/#MI8$" ITBO3DW
MGVM>5]]1H0(U"&, JKDM>4-;4)2H1<U@'4VLO$6B8/'GW_4QD! 93&<Y1NN/
M1E,XF;.WY>&5/\ME\XH):DZ/<BXNGM23\=E8RXKFABY856&D2DH-_0MUUN2!
MS(3 6YF23N=T?!8X%L@/1]A@*RXMZ, HFU0R0P\ER3BV;ZQ,5C-RC,%H4:5%
MF"R.$.TZHE)HVI<M=:CVM=35.;VUX*G01"]]JO'H 0, *O__I(N+;CDW6'S'
MLNO'V.LC)<U_@?:YWK)/BD;+T*P>OQZOWSP$KU0TMF9S-0R[XD3-:SQF$7K[
M-<OS3^/$Z[9\ZV_-?)%,Y,R%4RA0ISDOS^N!UTZ-(,HEMFEF"9^T^\N/@N*F
M$8G\'@"BB(7+/7(L]-+G,%),#$H_JS.PQ.GBL) DW3B-1VC9[:(F1AN6<BH"
M]?A,E,Z&\07$V-N)CT*]SW\._*31V"DP^:,P=^(;;&[:G^9(Y%N]CO-LK'%L
MDBV6/ ?+^$TO0I4U_@_7*^R])."5V3E5!!3&H_"F.\+IY%),N93P(M-<>>JQ
M99/J&OW;Y#JL^Y-Z?"F;8HP>6@%11 ()42*Z@KC6M,;YO'YY5_-8F<@,EKCG
MEU) -QV>?_&8TU)!1XZ)>2UL<H,=W0S)'YF3AN=]56@$$42]'O)EJ(O8UA#,
M,=-D?2VR2#?N/4)!&7<KA1DPF(41R0^\;4;/:SC0:5@O39SRC,[R\10>)@NR
M!?):$VI/^($'TRS_98V)>^..]+S,!"]6Z I]E0)Q1F:5@:>A&U/IX]*?[(!N
M<8*"Q9^Y:B*>AN1]7$-\>_'WBY23-2\[2(.@LW8$%B=,$[)<\'.RNRMUG+#0
MFL*#>HB9^VE+7R^SX3+L'=[X/<7?PCN5TH 'P$!'U&FB2=&56[5[,%.L^R6)
MX!F=4,.%S#",]XDQ@2BU7E>^/?SK?WD2/*S\+U!+ P04    "  .I'1:(53L
M8UT'  #R!P  &    &%R;7 M,C R-#$R,S%X,3!K,# V+FIP9YV1>SS4^1K'
M?W,SPR#,C-N:$$*BD%N)C=S2A*&L<9F#9(4CMYH5BJR8J*U1PF$ELBL:8MR*
M7$+N.\B8D<O,4 @9UR',CGV=/?O/_G'.>7^?[U_/\WU>G_?K*Q@13 )29VP=
M; $0& ! P@,(1@%K  (&[Y40J+!@"!@,"H6)P>$B"'$Q<7&D&!(I(2DC)2$I
M+8E$2LE*2:/0& Q&?)^<O"Q:7@:-0>\M 4&$;Z P41A,%"V!E$#_SPB: &D$
M8 <<AX . &!I$$0:)'@+* MSPD!_ /P;$%B8402.$!5#"@=H4@ 8!(& H9"]
MU,)NG+ /0*5A,JKZIT10+K[P ^%H@X3[3Q!J5A7-&#Q]2=W0+R)15$Q63EY!
M4>.@II;VH6-&QB:F9L>M3]O8VMD[G'%U.W_!_3L/@O_%@$N!WP==CHR*OGJ-
M]$/,K:0?DV^GI)(?4#(>/LI\G)5=\+2PZ%GQ+[^6O*RLHE77U-;5M[2^;6OO
M>-?9-3 X]'Z8,<)DL3G<J>F/GV9FYWC+*ZMKZQO\S:T]+Q   ?W)WWI)"[W
M4"@$"M_S H&O[0U(0V&J^B(RIUS@ON&H P8)"+35_2<5S:)JAO@EC%\$74Q6
M_1A;@[>G]H?9?R>6^'^9_4?L+R\6( X!"3\/(@U8 CNN!60M<%Y%Z0CIQMFZ
MH>@3(\=V+)CB%&]O>[6[1EA'_4FQS<KV-]7ITXUE;/JD9?)61WH4UAVO&$7X
M0#GX,VPJ![O.3+UIR/LF=L3-M,D_>^7&W6S)V[S^]=ER/HZ[X^1%:4EG/U[#
MZ3@.KHE45YMTZL@9'-I9=HDP' S%\\<F)Q#;RKS8;-R7EBI>0#[-,U<-_W[M
M.;/X<8DO-Z52Z4Q9DUMKJ&_","W-W544MVI1PP_@5;8( (S%8.@S+Z?BS]5>
M1/Z-"TFL.6/<K+INGR5+P74D^TOP2O=Z)E^9'9:L7!EBJ:#GQU-.LM ,8D7!
MG>XX,1;_Q1SO<4/8/>YI0U,RS'UQ<?2E;GS]<+P2B;"[Y1]Y/;J(U6O>^WZL
M -\37TAQ57_T2VUG@\( W08CDF"#=H9_8BRX<G4UFV[00K:XJ8OFWD6$F9B\
M.\]8G@ZZO=O:1BU$.WGGR!1LZI88A2-+>Q)/M]#.[%#TH7+OO-DW0; )+;8)
MFGS5_;B,+NG5/M<$-Y!@ D=5Q'G$H%@;OB/;DLRZ[,'/L4L6 %TG\NOQ?G75
M_^Q%O[-NCQLB;]_C,WGC^YB?.53R:]VEVYPW=U V0WH^'43/= NS'ZO(5SMU
M2^N\5\0Q>F#*6.K'>I7-Z@_3V=/OYZ\7+ZA^M>83.W:_H9MKE,UEMWJ0[' -
M<6%N[U<]%M1JAV%9Y"XX5.KEB1.-HI,)Q+AMK+M34B/2 _T\7;''H+P9WGF.
MME(\[[OD.BD R/$*,_N-?EM<.[(?'22K0T7I2=!:*F2D@W?+U/LU^CZ>O*;$
M8)RRN@D D@"VY.#PNX'L&RA9LE9I>B)9*U\RD.-34T(*8V^D1)]$.=8.TW*"
M%2Z^'%QPCZ+T5LT[GQS%;-Y:.C*IG!8](1Z+KZC_+7 XK JGXT*K:5C&O-[Q
MH/KG<JQB:O6YO UJ3;Q&/&N_Q))=NCGLZ6S-(PO5"L9:W6KHF=V^F:,#^\U5
M@[[MT]<IR!UICW2WO'C%%<<O+*ZY%WUO1YY6Y9EVU6PJ8^IA_WX!D'AEE/3T
M= X'2DC^.<K<Z,7<-<6VW.Z#:K1ZU&L3V0YZX^F0N."%+GXD.W-!NW@;PK_&
MQAIPFN9,? [Q=I_[\>,*^H8FWKWT-NL8NT#J,(76$+[*->^>6-IXBT3F?)'X
M;!PSG4L;>H3_\%V7>OJE-/;@%:[*4-]&711KVGZ\@*QCZ$S-%@#!_6D^JDM5
M1_G$9L+ S/&>XZ&,E+5TCW\XC#H-AO[$10@ O<VB4<5/.T]9C1G4O%4J\\6G
M]BWBVU?4%),#NF'MC!D*UL![XM+ PI3R)9I=P,QY1TNE+,42XW/SJ6//U29)
MC8C8,P_6EX_L(SDZ\"Q>/2,9C!G5KEXIQ\7MY!,B,H.TN[WT(/"41(1UHBFU
MT-+7\IZB<BOQUM:++%Z@)Q%!XN B%A<WG(;9#\;9-2&M"P&;E54['QBCZP2C
MY-S(\/#@0%A#;].I8_1VS#3BE6LX1!.2D)=85#NX$(;UN?Y]8,#7,G7?E*U+
M5=%F#[,-TRW<H_K;^;$PWAU.?"[/)U2G>2NI$189IYM7&:W(*AQVB-KP<;,-
M,>Y4EFR3BPP]#W6OW5;E3:3%P_C5GWV2-^RKES!M+RB<7+N6<>7RY7G7LPUI
MGMW12..+$I .E&D?XG XL?"!M1+]&/[ Z[-%'O(7I6(23^KT&[VYN2O/,/</
MHSI ODW-]R)=]C8 ?@T^F5%:ZO+3/K8*5[Z=Z\0BVJ:NXRYGS3@[87OT>U&E
M]^V?T(>FCJJIW)K%N^?$]S>*\31;PV[+CJ-XV"E"YOKA96903:?J#YKE%P2
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M%P"E!.P";" @?0", D%0(%D'@)7GA(&^ _P!""S/J*"HI Q'R ?X2  ,@D#
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MO/EE5X&UQ6OC VL'ML(G_8JGID]-4Q "/K/$K4!_U/332$!0;+Y;_:V\R4_
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M]=9@-^9*6 V[0N=VF_7>W/VSG1JCPTH"DTX0$?CU9+0%;4Q!!.C4\=>SR(G
M:$$.;*D"1. +5&+ ##:3M4P&4#EQLV,*V\ @$!7N"UZ_S#'5,AJ5$]A 9JCQ
ML]P^/K0O:4KR'NN>F214";U>@C;M,6',XFAF=,@42UG6PC] H]HAW8CUF4'9
M.3(BX/4%X/EXD8T_]DI PGE)_(*V/+MLPD*@NGH>"2)$(%1_J>6$L4H<SWR>
M%SMU*7I:JGAZ0&&+["WV\UIMW#*X'/2V#F:ZT%DH+U\FS'NMJ>IK4_6LP"/7
M"-WH87<9,D'C)%^7%_XKR#T4"=JYK9ERK,HY+H;[8DMC=8UJ?5-B9XW";CEH
M2&HHPJ-N]>8&%Z+I!E04_9P,1/GK.??B;#P,PYCU5Y.0$FAUPGD0=!!=J#O.
MH9E,)R)\60:;A1=,;G&UF7MOO;K!T?B3<#K8/8*<M_ATJG#NCCH=6>>QR-%H
M"L?KXZR8XU8R[D^?].P$2%=E.D!#(-C^0@?RX-U>ZVCKS.JCK#_I/@YGH$1%
M!'*T[A.!-AL>O"H G2^'FN$L,1P]"]>RNL[-U7@QD\M<K@K%<2J\_&+N[J!8
MHN3/+H9NBE2-K>$+N;'Y,X%0X>8HY,Q.'49F:9 (,"K166ZFMEO.X9P\,30_
MFD)8G/I?I'_\_>,Q/OMWE.Q*L&4NSY\%!R.?XL0)H6+GK)#_H1F2@YX=."81
MV=.^&&C!?.[Z2M?Q,E534@J"$ZDNXMV&GCVR!JU)SSY<?_R&KEL^%1EP?0%Z
M^]RF;!B*-@+]67:5)8M3IMA7>0<W3NBCH&4J)MX62&C4^YDDO8/GKR0LG_\3
M_C $HU12@A@A83M=.3A#T+O%R_F8[N!\E0)$)]33$<NV%BNM^JE@KL[HZC?S
M$$ST02I&!T%U#P=;B2.!WFE$"W?!+SA:TBN*?^DJ[GA=BM<QC=+29 Q+,C!.
MO_4^Z-N/]_MYM4S'1. _MH?]2A8=3M0"4QNAZ)F/-\09VY;C5EKWD&*>CQ.[
M:YJU0_MZ8W>OW1OL+1XLN)Q'6ZS,.2T3AS<MQ-FW@J\H<>"E<6EH%0NT3NA+
ME] 37$NW1\=9F3<-=8#-+8DS1&^SZ_CJ;28RJUN+K_X)I7"A15<L0E>&2+7&
M]P)X<?Q=2HK.=G63-QJ%2]N\Z>_L?(U@BOH8+UEDQ_9+1ZC)]>LAC!3BVS$#
M<QH_Y+K]N ZA/UQ5$2F,>!/3G[WRMLM5ET25\1^3Y6U8FSIL=4S1E@B8EX(/
M*]A/[/Y>Z0DG2-W52[)$#HQN$X$_5QF,Y8\.@K8GLO;L[<JYGE.;BG-K,8);
M_>&M31<B14JC+N]'B<^FM6*YI2WINAS=V:1GH3K<'^V&TM^4?OTM:7'=6LGJ
M$:;!P>X&H\30FR9&DI4L], "%\L)=\E9RW*$HFK.%LM)V*?R>:?/Z[NC%B*F
M4=Z2)=<"BP"U_OM+=,%#/C!* B/.<ZDP\'#Q$N3)T$Z5Z95UJ63#9'7?5_L*
M#:\&!P<UCU=(+S1<%B%=RT*T$![S8"V(P+?R R*@8=*<'[<K/FHT *N&X=/5
M=YK.Q3/?(,17^VOR_+3,SJ;04V4$_BO(:' 1K;?X6TJ'#3;C##J[$=;\"?ZI
M92FO9=\A4Y((E$_SG!A?\;(B C&@I[9&N%>'\D3@SVIN-,+>(@*)9C@7(O <
M0@0.A>!.17^4_(H<M/B]_*'7(!0%' =71P\=#2<NG[$@4\)+Q8:Z"U>X[$8M
MJK\/,SVOO5%D*CO0ZY&L6]R9#IU%^ZXP%Y;CB(#..)3A])DCC-F[H6(WDVFF
M\5:\ND]1Z*)+UW?#P!!#WIKO9* /AZ512ONY)8ZUD@N.V(F1EUA/3?:&N5YE
MAX^Q3]^W7<6\[S+./G> ;% RS(D(_):-F_4C=#>,G/$ZG22 O[<H6XH1IHC
MO@=/Q?%9C&_6R?VI(P&81T!0(->_Y[)_GZ+;E(6SL\F+CQ&AY2E.QS(I="9S
MA0O)OI>BCH3?6G!E$Z9-#%M6'+TX_$EU/W&KA8T[L)EHA9-AOBZ)R"XEKS1?
M4Y*'*F(6NQ:IY]1=G&T_JSO+I->;FN\E>T;;_B1AY4^G?M_WNXATWF4WI[$V
M%B*HB7SO*_#^JZW5UJ4MT>$79SF*7#)Q+4AZT[Z6*D4B4!&!A_]DJW_M=S"C
MZ-7M-ZW>1@3>[N.L6['UOA%N>Z[E*HUA_8NZG\2RJ5_1DMF2'0D<]H%-\L$V
MBU0]*_IP9?\BDP>"IP\,W67U&.MZ;5]1MBH&^AWS1P+8$]&>@&O0^QB=-LO+
MS3GR"$CJ@J8A8F%+]WFJS//.U[W!SM'7UGP\8^6&+'$4F$_--W$!6Z8##B^K
M3>6@=2]"]\OS;<V5Y4B+[K[F<B"=_)4_) 8PZJG^A9@.9/",O@1MAF[+(T0'
M$=#BA7]V7G?#B>SA4X6C6[:KPPG)*N:LL!65*38# F<33<M?71'.]">$6BP*
MH[<H+3J'H^B].8O;XCMC*TS:5(\QG%TNT#0N"]O(D:'3IPH"GSZ&[J^\5+AP
M[WH(-R4\ VR7(;XL6-L#IM)<U@&@-*->7X\5X'@ZK,>7//]4\]R[%<G7=:X$
M!CSQ[';>!,W='-"8A-E;,IHZ9S(T889"RARRT'&.QT((TUF3+<$(Q;%^\8^Z
ME32![+\9L.HX,>^E101/N\F7LV17 I. $,JR$[[\NIH\1+JTY&MG9W!C?-U=
M25&^D7&K\>3$;'ADE<X<5>=QL^BH]&\32D71<JA>'<[W8APGU6F#34RRZ(@,
M!WY%TM6V3SLF,"=L"S@UB43#$5'8L#J<."A$BHL&P0%GA;2?:-T%HVYI>US)
MO]6S;F[>1WVU[WKG1R63Y]^L>MFD[4:PD6A0QTB0"4\<5!\C.6.&GOXB&[;8
MV3YA8T3?O,__+.>^$;=9L/.%#BOJ5R*DH6<E1&!U&6R[=\J^!SX,+=G2("R?
MD4/I,#+8;)PUYAB;?):VTTB^W "CG7<D"->GKHL\3[W-+IU6G+C.%YP@T>6_
M]Y]-=D(.)(ZBPET!_#7HFE#?HI]:]*_UOL4(^C>__*B@ZRL8"Y *I_Y.7!KI
MVHL TS7Z>^>:;5U ( Q\OZ?M7-8.U&N]YQ&D07FPNYW.J4M1CO?$;8+:!ERD
M&;3E,XY^>W+:68HQL7!$O.39HP:NZU! XI[B9I';YB9LEAV9W%FOJNZ,[S9F
M?$"&?PKD>Q2D9/DQ]E5U7AF4"IT2\1*:8=?O8K+ZU6?RYJYY^;,X;!LKSTX1
M%<H\-CSG&<19LV9":L"F\EN-]GL5'E6>F1GA,L"CF1T'6FJAA!2>PAZ-0]/0
MH)1Z0Z]W[X/T-&4%[+,\+8+_N]@D6L9C+Q55/H\4;OG$+QH_OM-']HOMF?<O
M9PH"DUOH\H383IF7GQ]935]M<B>K4&B<H3%C&,5,IM]Z?;T(Z:H;NSK&\P%N
MB-/$"T$HL'*[GB;'Y-LA]KV-%QL8LG)U@T(6"_\B!6)P7!"J=CP\?7\KID:+
MX9JFE>LV'Z>DS#=@^K/H8( \3EAO!LI39 FQ$ [ONL;ZX'M5?(?BUXV-.'=^
MWX%TTL7/5X W[G*<3V9&+"N*,.+AN5-2.DS5:Q\2R>HF2JNO#O#J/GO8UU#C
M8^/3*[LA_,L$&,8PGA341+P6BG)T\R]^-S);MKMQJW,7PO%3E$EO,CY_R9VR
MG&)I)+;1<=E%I0LA$RMU!?QHLHKC5]G*I)=IA-#7EE@-0UUKR>OU]:Z(+74*
M5F'I.4C+>7T-L>^H34W!6N2577IJ-_ P?+@NGOFRCY":.XW&L#N-) 1.C;-"
MLV]WO(%W]N$Y8*5X!?1>Q% TEGGU1J7)0HZGKR?G[?!GG:V=H<]L/MBU_G8@
MG6U4P=QNSV280HY[PV@W$0$E=ZM2WC_3<<]=UM#?J^_)&,R3[67:4.+%[2=G
M,1(X.CX[FW =!RKJY&_5PHL>/(JUJ:9EE.B'5WTY>,9TV51TIHB3)?;&$4]X
M2Q6LE;?$TFE!OB58 Z.;IG?*"';V=OLJF<AY/3NT5^>#??SKU1D9]![R.$*1
M!&.*K,F#(;5M'!==, &54CXU+R!57I/VL::FOB(:1J(<R93QI:OVZ?&@S]X\
MT82+XXT*GYUK+43'7XQ+RYJL]^^A'CY9%C0?X:-];<!9Z66!^W)$!*(LJ-'5
M3:'=9<LQ0NT+)R3>;E(S#OP)I+7';95QXNN6Z?B66QOO+;GPU]#@N+( ;IQX
M1^T"Y8R4PXMOF$=&\J%-'QR_W)AACS(S1;PNAWFX2;G&#C>9"-P?"$[/$.W@
MYD?/A"H*Y\B$0,U2JT?:M7@H<(&.)U+RV<$7'^P/JGGMVYI/W!*K$Z"_:;0J
M!YPZF^&JEUJNF)B8.V5>&W]9=K,5XBK8H,S!ZYYV;$_B2]L0T:W!-N0=& 8$
MQ_M%XK(ANMK%\PU0,*8EFL &:>A@EF>J3@I9M*G_ZBR=N>#,<>J;S%=\VG=P
MNTH">MZ<V$#>M'DU46A7:,$J!)NJ=,M:4FWWV[-)?#--6;MUS.P"I43_7&HL
M'\W\&3#5GQ><[O!BR1*\W!LNV,XY5!*J0\\16C'GC;"VQ92%Z)_W99X:$@2:
MC'5Q+#G[6:A%C%:[\Q+'7EA]3=1*"X/YMH3*W2EXX WJ&4/TC;8/C9TOW\E%
ME]-HLOWV.$_A/\);6Z[H=,>P&%7H1"^P8+03S)HR/V'8/&VAU-0)EWZJ,=;G
M)<_%_WCB?D_VD&>N1Y]=/4+,!NU:@K$;Z7DR*XQ -;.;*F*' +M]"S0G7[-O
MZ-6]Z[?4[KQ_>TJ]=2S?$H=2[[QKN2(X$L4?:3?NTLQK<K<FV=**7HI#TRC]
M@66X'-4Z$Y=&;^7>CH>ES&;6M\Q/A;CI[K7J.(5V$UB,,.8L,V%Z8SCJ23+?
M9[",CV*HC^-]U/SWMQEY6?D.V: LJ.:I#*ZPRV0DJ-&T&+<^HX_9"#IJ4M$=
MJZ;T\F JJJC7$2M="Y,C>:G&0A]V)8F3VW,62H*CS,-?Q"GG06@0R.H&/Y;4
M9=.&WJ=L&\E&R>J4O7IUO8 ]0)+P2J=([QZ/2,#D&]N"<!3#Z2T.YV=B Y!R
M- /CPY#S+DLF&UYB?1IUR+2_B+(D L)TI^*P'S.OB4"^F.43]6.67R(DDW\'
M?_R5C"VNSR2V+[!/24?P^H5\K4E8RXW;DU45)MW?OL=>?2".DL:P=)W WNW<
M4.3W\^9*JB?Q%?H8.NNJQ:FV0]*&(*'*6E[U*K&\'*  "5X):_%$]O&%=V N
MF:QK#8$]M=<N&DA\>1EBW7!F;Y4.:/#_$N-X\ U-R&**S7B97//M[,?$Y+ZF
M<(+F:F*"CE"@[%Y8)G-=W5A5%BWDLQQ<T4BLOC'.+\A%"U3'#C K2:139[[2
M]O68ZZ)JR'>(WKC9G\VL5#B=GQMX6>2O) '51T;!&'X(/-' UKK+IHYC.2E=
M"KBX='XI(]]>13L/;YSE2NE<VGZ/<^XJGT[=D;SD*ERMC6T,-'RT<9V5UN=]
MTBKW11VX42SD&/L"O1?7Z$D$*+FFUN8K'^G.([IB*I, :H;^58#FKH(NQ=<P
MFIRWY!J]=[\H,ZU:5H.CCL3#%@%%K;)?%3^?54>:WCCVT=M+'1\JY]/ZE,<*
MEG*7B@:YU*$L5#!4W?5&0564U6!2O&KSM")7&22E XOHZJHI$G\^>L,NOD<Q
M?M[5[IWV:=-:VNH!5?G\;#8HSWLD-( =(QQ;!69=G!V2>>>EL1JETV#:%V^:
M__& 4:V<-AS14$&#*LD,RL9%84RU</9%D/LS3RJ;OW,+3EN-HNRJ8DQD706I
M]8<$WQKP<L2#'OX.7K:,\]X+">#'$#Y]WJ[_B+._6(*T;Y[B1JV[7*0:B,B;
M3. (N]$?)%OV,TCSG5DRA[*9(6[/VS;?8>%R2FN J Y'."ZKP'SSCDG89Z'*
MZG2$3I3&;AAV?Z (2C^G."K+F@VJ\A9[T:->&^LW]P[U(L$!-58@.R\02T?[
MIO(V0/'*.6.RF0EGKX]1)/ ZL[E4IWW,"UK?ZMX][](?#'=]4-L2F$L@>:Y!
M 2PW&V'R R[A8M!IR/!WJ+5)H<R-99IX:4BU^4,/3RNHJXE"VFO]P4X01V7/
M-W>6F,;G4SJ1//3B+P-X88X0^T[Y:)\3]<XAT@XC%I:3+S&&<@%#G-A;)M<0
MZ-=/I&*D%F\K?#,+H0:4/N!",8F/<#)+*'W3:47I4E.'5,,\E\^B<RI4$2$H
M3D=)$J$'%C;%(34<5_'?UYND."-QH.6]=ZYPI4L!XUBCD_GA/+?/4(UQE]+0
ML\V/<ZWVXS;[H]]^ZRKTWC_D/#%:U*/MBW]%H\'?!"C]G;6!PR'H$!$@YSI'
M_P\P*6<^7XG >*]S'@CO\";O>DM'2LX,H9MGWSGK2LL.B(<0,H4R6&[Y%HY/
MW>AP.R7M.<\0TGX&JF[+6E-)H+=O>$0)DQ:4HWB]8DBA4=2R6W0 HS.!8S3E
MZ:0PNNO@^A;S94%1?M,+BM-JFK22R+K+CR_/Q!+:FP5KIPE"ID2@W;H(ZC3I
MW1UIC3S->H?IXTZ2V/_1<"\[B>&C;U9&&F6+X[;%_*D-#HR$Q:"DYL0CY,]+
M;\>7D%>J^;B%\57$#37EB#(+Z,O+R*<?"UK=2?239 _ 0<Q$@*J9'M<\U\E]
M]:Q(&A3++7@/[8#0<@[6E5#,L[IEW"%0?L D2.I#_9,FCV^D7J08X3U8F\Q\
M\+^TQ'ULUS56^ N9[/XEY)6,_P%DKSTU.E=N9\# (E9Z ;9)933Y_JSKY#+@
MS:AWC_S?(Z;@E2S660A%>VIL4Q&%G[/L\8=WMND)%XJ.!=Y:N*&/L4%IRX.^
M=S(Y1RVX#!D^F1"\F='=$)J'^$'/K"2C6KWI0'D=;KP/.JXCYM6<YK2;K5;?
M4XT!,K&KH2 UJ->P/'664^:,3A,N@:]Q:L59_,H=@=IQS=^[/09^0>"0(SH:
M<$M6O2R,G3"0G$4K_<.[S+K3-ZZHF7Q%Q34RH:B5BIT( ("UL,<1W'EBAW=\
M1ZP4-6/;U.C,Z)R.? I0K(J0"G=8D*&/@_/K$Q^,H:1ZZLXQ$Z0]!7OBYU6V
M)?(ORPC_B"YJ4_O2*3[)[>/X8JC.1@TBH_MI>"=ER8W&X0WUB5!&MN.;@!@E
M(B#SN+HB4O2U#/6=7U/WTV/K.*?7&$D2K9!B(*TQV[&=*G^E"<TD8YNO0=-2
M;SNH;TF\K0J27_4TCD%7ML5]WD3X0=3O.U^15Q%+^C+!NU]FEIX<<0=)>96S
MB")RRR&;YB54&OTNZDDTQ%25;LM3K&L?9M\15:?B"A*9._CJJG+G\>LOXDH\
M$$O=IKJ&>O3">T_?5R\<-U+;A1/TF15S!XUNZ).Z!NQ>E# G9R3I,X,*H*5_
M^HX-+8V 'J6,EQX["R614D5<U'A-HI,1MMXFQ^]Q5/YY84%4"Y(=)!!VZ8.
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M;-V^:[Y?J_147X?^LS'!6=BE0^L<P(+S+W<*X!PK]SY[1?7JY>&IJF&",25
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MWB;J%I$)QCDO1U0;O[1%&WZY4\A4Y1YN^CF!@;E;(":;-#UZYK,((ON-+L4
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MHY_(9&2^<H4D^M86'W1JEUA)U_>6P4=AHMQN^%G:Z6GR<VZ^@HV;=S\^JA8
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M\N2O/@I!'$JP!C,V:)&2D@6L:BKQ*4-A+*-"%C5#@7U\_:9+(M'@73</32O
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M4F$Q)J[WFD-2M\)Z)]6L'5[E,22ES55V_/:C&(#?3D$6!?MP/7^-@TZ,NI3
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M^@(5Y\V5%_,XT1,M5<" D$;_A.A1Y?:?O&Y^E.OG!11^583H\\@BM 38O>E
MVNO\LOU-NUXC>Z8/U2^?%?R3'?.APMH8B/FMZ%2[UC1"KCT(ZKG&UI.>N(R+
M\'DSETRA9%W@F4^T4^ID8Q99\.?<<"&;K3?)M]KFY8\F[6?R;GUO7DL)S+AH
MU?TY:-XZ_[IUPIOFT]M/W4JHV;P'2BR60;J@(,)KGM =\B'2UNLC^59"13GC
M@6[^,/6@&"6>Z4[U$DR$ @\(3<U.KPM>I6GO-I02[RL.J*8JI!_(3!WRX'C/
MU3K7@;KUUDT4L7FT<Q3AIY8"BK+(IJVM@<C<DN'Y,6>>IN_:92-*Q!\FVSE-
M33@)%U26L@$7<>J8F%+X9&40"%/:GT \GZ/[U5PG.3[J+5USIJ>G>RJT8B/2
M2M!^#<D><7@B6.W$3KF3ND-?+R6YQ@-G>.O%(='P"Q"JTGM:&]6T1J;+5EE1
MAWK>P-,.\6R")6LBEJ((]4P*36M>$K7%U\N8!.S[U#1O/,Z'YDECYBO?;) 3
M,*\Q LT&4VJ ?E)M+6"I;2[G@423LTFF<5*N,OROCU@3  &L2&LXZ;=N>K1F
MN!1S#Z7)50OT6(\UQG3VRT*1@X_]!&"Y(JS-'O#^X8D?9J_/SSC!$-J#=WI$
M!7Z3+M5#!8Z4[SA@U\G ;TM$SK]LZ4J%9;0<+VR%N3'6:RT+[IL!)F$0U2]@
M&]VT%W.GI"")00F\Y971.HWB3V0-E(^DVMFZOF!RGK;,GL1=@O2>M][YW-Z8
M;A>K0HQ?R<_QFP@K.-H#=#SEESK"(R4G;GJ8-D!?;[&KO]BUF2U!M#6 ?)SO
M&T:GHB60Y_*;R&ST*O&]L$[?#8!"0;MD-]N[O'22/<ZK;8.INBU2^VW&F397
M6@&^W-=W94O'+P@[[^ 5X-:Y*H 05\K6S3\.O2I) YPV[<F5S#^8;JWGIQ./
MK+.%U547_8"-=C/.'+V?C%Z51?G$*['M7G-V]* _8XI48?,CFS-PT17ICJYI
M-.G2.]L%*#7M'3)F6ASXCC63@FJ%#CI[]/=Q?R!+?A_3LIQ+;MFNA):P0IMP
M0:[9>FJI^W$LPDTRL4NOU!K[ A69YN[E&H ,X)Q&3CL>'')EGTDYEJ1=F8GQ
M;MGO4YAASI&_(D]U?1!_[6WC?"_"J_KQAA%LGV?Z#9/4;^F?8\X/.X<))C\)
M]O(MMPTN_\*GH8#F<NJJ!,)B[!#D3D#(*\2>8  C$G4U>0'9T /GVG"*9H5_
MSSI1R,L"L-N:[ATO0Q[/2?4<!#"9RULJ$?<TO/7P(K)U@(QPK(30\+WHQ$M>
MSA, R2-%(YK\ Y[[LU,!?=R 8;+3:C[,U66]RIT<V"X*ZZ=_) U1M3$*_AMZ
ML>X8AV=S[W.-K3%Z-E],G5K\WI\!10J^[(DW3L1=?N.)9OD4'+2XH0/-CL4<
MK:]V50&#\$YUK&G@V]Y,(H6E>WY/4$DB\F4QD7P?RCL2R<;%?F->AZC^0:NP
M]:,[-BK ANOWXB$!Z_+C]Z SVT8'8N.P+!=3DB,-Q]\^=]Z%#+U+F>]R&;5O
M:XPT DA^KAMZKB*-JDWHY$=R8QPNC<V&BC Y9JUHI@6=DDF1%(X<0_NOH9Q3
M0RROV7,9W0A>BH[/2)^S18BU3;WC>?7>5'CC=?U]#4#9;A4.X4)\+*#KWYM%
MRE>L0 *8F()HEF#B#M86_2*Z;MF>2W%=^Z5""#9KAAGY[KW=\+!"_'RBX!;=
MU6?LFQ*P.;0]H^@-F5]@RL:!ILKL:0"%=L;Q/KT8AVVKOU? 489 S8:\CP/=
M@J,RH_1D#--09*<PXB#H<9)A#VH,G 'RFUBI%7X0OQS-2:EA26S@0R^T:($3
MGP=0_'(^D"V3@R27?=P^)RQ\FJMMZR]/_.!5-L*&^=-G!R%:#ZT=LR9T=QI:
M[@@9-!"T> SU:\YQ_H()'3T?N'A>4*=\J'#YD(W83)9+R5!*/=(/;Y*S\@;0
MKXZYA-('<D]%UI4*9>932%/0P)W]U,-\Z5N,?@M(F(UPI7C1L^-:%E 71JZ[
M 91^X%.E#$L9#Z\R8%HV5I1[@^Y"[A7J/&A!QO7@+6%B3G&^5*T)"NGW,W-9
M/-! +JVY\R82>"BE8X*JG;,G@]\KZ@W(/=YFNY\]^LB+5?R!:08\H*=3W8M;
MC/P3U1(MSO3;MMN9B@YDG,;JV2&6QKW[EBRZ0,UP2 M)P],E'= K7NX#_(T:
M',7*WG=!CM:TXPCKR!L ->%9P%$8Q*X:OB/A.*72MSLHV 8G!6: -N4%_P2^
MI<4C6U#F';<Y Z*V#LLWUA)DE>YW-\(VZM%+?_C=2SD<:[AF]B%M*7$RTV4#
M*GB)6@HI*FS'M> U%507](73Q7ADCE1E%U='FU96YL-A,@UUIL&H(LR>9O,]
MOLSFG(V.YM;(QTRR5@8FFX;I7+-LJES)6K4XF$*6;MFK"BF3DQL ,1Q3;XT+
M]C8?3 06QMATS+(,$'DGL^$;S7PBRU^]Q2I^/OM[J/8;P/I17X!DO]F70H*B
M,DW%N>4#QQ)0(?"0^U,_;MX3_3\YM"QN12$_ 'XO&&J4D3U]XS0;HF$BG<)(
MT:;F!.]1&.7B<E/'4]I-?KM?+BH/6;_5J U:,XG26*.M<A##[]0SPZKO_(KV
MJM9=!%5_'/A%^I)T3'OKS4(J'=V,?-S;SH,@9U;/%ZCN' >"]%)3S!96T;G&
M>J=>(9. L68N;WJ0[X5OP[/='G& @)O>*FZP4M9T([H$F-'L+'7.N<H3K>OY
MX(\U'J/]H9ZG49T53A'6 9.$S&<!1_7!'<)/3)H4F?6F:D25ILJU#.;]"[N1
MC R:H>A!XA=M*\G:%O,!L /QVEL<$#U0#)S>%=V(5F!$+$P#2:RTGCW>VI0'
M4_[<$.JD(:;%.<R31-FG;ZP06'*91&J#V+1^&I)-DJ6,,<=PI; 2V=EY&>&S
M?<Y"!!&:8:PH*WT"RBU>E[7/UI#]CN"55U4D""!\\VG=.!R\<?8)3?\18EF^
M+:>4Y?D&,4G5BP WQBUNZJJ9='C'F/11Z644?"?9,JD?//@=SS0-4Q)T%D3G
M0S,R_9[GT.4'8SF]QJHU%)VV0!MYZS(<V>(,!C)+3Q&+%A4''+C0%X0_WC?]
M_A[4M%KW&2R+6(O%ZA8L 2_L6Q"7:Y2[S6X*29ZN(%JB;30NP<&,KBMN9*_W
M!ZH06-O4M2BF0P^3N=Y#CBE2^]J0.= ..L!ZTQLV9C)IMYA\K.[_Q!7VLX+>
M H#!<Y,OPUL2UQ#\14%T/=O^X9ID3D$=27Z7(6]U'TCZV?1I4"/7O-7&J*[P
M!L3^&</2.(+1=EFLR'T/PH@6'/2Y 3#QHHR:2AVOU6M"VU=.)W(44ID?/<@9
M:VF2#U[6BO5>BQC6CZ#%V;>PC_VC"0UJU.A Y#)ON"85H*[S)<'F+YM1S9]*
MS=K TOSILV(FV*YRCHP=KC\T0J/?ZDB^=+GV]M! 5&LAK^<5^'V^F*F_*74T
M:O]P_&3?KJ4USY3^H2UA?/V3Z=<>18!?4CB[X*)8E"LQUAT=%..5&Z2:HSI=
MA54KQ,P+DR#G1#93>&>R5P4CVV*:\;K>YG@SW!FE^I1B0=^$WAN042:]EL"J
M3#=VD.IZP*RL21VI<O9R+D'/?S(:S9$\6:*3U9/4_(V3QDP_#/A!.,?T,PZ$
M%'[PZWGG,7E)WW[ZV_0B>XOXFBV.8#\6MO#9,WIZN&5Z5VYNIU%S!KKJ12\)
MOM:4!MTKS;_^<FT\:>8#S8^5DXT556*&+SJR":&5DA#.H*<;QAF'YHZV[1GV
M"9"MA543NUA['!V:D'/-QZYP&[-V5'/"QAXYVW<,^TO8@92NW"J0_5+M5:)_
M4],]MS)F?1])K;)%829Z'H\[@ !F[5B<X7%A@%N[<N\XJ>J<R^$[^]F"^O8\
M\ZSW^2W#\[I"-;8IX<^>RSZR%[B[7+>19CD,,)A2(8[]J];O ;_C_]Q*_ME?
MYS3X'0OP_Z.V+^/_95XL9 WE_]<=@=00"=2OL,^HVG#IAR?.ZDWFS6@R=)8*
M]Z'@F6%BEX1SW0T@/&?#]8KHFN(&T)<==/VDU(!E)DW7=86$NM' \?1"<%@9
M\0"S=!N,E<-N *@O^3> %+Y_>JCJ*N>P^\1:;M_OBFZ3'94& =WV@[WW!H Q
MU+L!#'\(ZM-%MUR'!Q'> !"ZRC< 3OW]-:_S@E^62=;%"K#DVU;^\_5;?RP[
MN'9!A66_ 41(W0"P,9H- ;#5L%QOGA_*#N3W^D7+)TO!85!O& P^-]\)B_-G
MPQS6T HML%GUA?/]837!Q6$)=G)4OL4;Q, 7X-?;&K=1U"\IZG7>_)CA]"]2
MMS>YV)&--+_ZX7KM&"*[AVXD!Q7Y?Z/C<4Q1^W,(<C5#5,"\%RE809SNQ*A9
MW(+BP<9!],C[F4.#::F0'.%6ECK%YTZ)(9<"&&75-$UEY_E:Y#167CGB?NCO
M2S^9+)&U93$2"5K."!=F@&V3[K\0&LN]QARTK8D*NJ:=N0'\YF$;/[?VN^NU
M4%X9.,I&.R=%0;CPI1JI**N/*JE=D!KW?SX[WEV04:)/WJ%5V;0AR!+$;U5!
ML3JBU%*XW=S--G4@-2;.NUAM0U68H9$RS+KX,?6[7ZHO=YJ5]=]X]S0*MG^*
M<"6Q6KH*7PNR,=T5K5S8IIY@ZAL]&!-/Y5YJ"W3P)C+YW$!=0<30@9I97XGJ
M)W<88$I/;*G:E0 G7C7);S?Q(U,E/?0IAT-L#'JX'5LGQ(KBCTW^CN8D'$7=
M  C>WP"BNL71#C'5I[D.+V>QND*&3H2&>?R4C=KUBB$VEH4O0'@/A]ZE.E>A
MYH,5I(N%@WNZ9H,S@(%39;H_OT-&F'1+OBJ]6FG2>/A*?T+2ROEOC$(=TGJQ
MH:];H!Y]&K$R4<F6N>%PW&2I1/KU:Q:V# DTW.(Q*=8BXBY?RFTJ",1WI,34
MG%O5=\Q)C25H3*R.&82.;G/[C.!^B![VSC0B\3Y,2$X&/!JP^5NF(-]#!";4
M0;U:BW:I4OC5!O.B*5\==W]P!E1H1;XB9.$LUJKH"CZ7AN[T-%A'-&IURLQ/
M.QE38SP-.N8:T9Z^0_G*GRPM(K9\++0\S^M5N9&?_\FPBZZI71-Z3K@PMSTA
M =X _E GV5_6=A'*[?NZ1*!:D-)#4'-7IB$;GT+PQ&_DJJ6MDQ@0EJW]:I&E
MW%4BOXG35Z 7P"7D,39"M^_7LW^.R'51CG9?L7"*SY.SE6NO7I6H)'/[ _R-
MK;")>1F6QXA.&&SH0?#\E_ZF:+%[[TAUHH.931J#@V"/9JHI]*\VM[ @72$#
M!U0;N(HP5(>ONHF7L0M&$?G@W0"$9I(^O'1&4?3/Y!K]NI7>*\'9H#ER-,#E
M\ B$7!K@2+F?4/32),WO\#ZMBT(=-YG=WYH&(>O \6NFV?T:I9F 2IVJR>HE
M<,3I6J.&*/E!.Q$BD(L*8://MO)1\%.H;TU2'SOQB=X=\!#TFO>K_XBT-56<
M=<N(YZ/D1Z&**<GB0_B7MI]L'M88_O.X8[2[96X94-+Z[:OY2V\ FT\5_W*Z
M+'MU/II7G[""1=M,1O'U3L9&<C[1%#'Z(BXM?UKL@0X$>ID_]86^KWN-%G(?
MT,V!G1&KF0A7.G I5";)\T$14CZZ1M3,UX=/O"_Y<\$W>.$+]TF>)$^+?U+[
M?V&;_K(K =N/8#:-/[H9,$']>3)HV;AW5:-[JYR.Y*<S;: ^O@SNEZR4()7G
M<GEMWX;NO[F4!.L]1\E&=/*S7%0"NUGFTLSJ?47ZG[I0;7J)++GUOZ]9P5F)
MG$!DQ_T=\9<Q/HBS-$0^%3C3O,FT>%9!58IZ=40A!Q-)%_D0ED@ID);HZZVX
MEX$JW3]"Z!$O;Q-P!079((9\I5@EKM>UG4OHR=HB<./3C>V,DCLX4VGCYX/^
MAO#3G>(%%&2.7W?ZKB\-J3J3SG(U7&7LU[B42%_;DB]ILO#A-3G!DO_9C?V?
MU4DQ,/8WQ3^+^R_B\)EK^^4/SYJAVBDKU;_AN?YOH_K_LC*V'G5?PK\Q)+#M
M6HZ_X4G^/F;XW!GV=Q1D[\3XOWL"_JFBHZ/VGQLX#H(S(VX @T%):\1-27B3
MB!ZB[;I=4;R<6=C/CT-;SU*O^M^U37SW.C+73^+1&FFRA;UTT#]6+4XJW_X<
MNRG[K_Y&]-]U*-\L_@]02P,$%     @ #J1T6FY,QUP9I0  *],  !@   !A
M<FUP+3(P,C0Q,C,Q>#$P:S Q,2YJ<&?LO'=4D]^:+_[244"D@PB(-*5*[V #
M1$0$I)<H14H$I(<:!0'I @J"]-Y"I'="K]([2 L=#(0>("0_ON?.F3/G>^9W
M9^ZL^6/NW'F3O5;6ROOLSU/W?CX[[PI^"K\(7'^JJJX*$! " ,'E"\#/ H\
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MCMD*'R/H#JI_] /VVBKTP%^&WNJ8T.M:#2_AV^HKJ[=M"+YOB,?IWP$RP^X
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MQA$K8X9(9O@3CI]Q+*3A 4(.K"VN)_#\X))V/,(#D8!99@'4JN7B% ^@.?%
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M\2'2+#K+?;)MJ7S8OJ:FT:K^C"F;O=.GXGPS_T&":UQI;W(^-R +3,K[+5-
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MKDKC*V\*4?N1AU*$52I$44^?M9ZW3,;7=;0?0,*PFHK]J$94:\MQGD5+NTG
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M,IX]DWDUR.Z=N&8G=/UM,)7@X\]?SU]C "))*GV7GF/E48<9I[76TZ*DIO[
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MVC7ME3IHTA?M:0/=[2ZH_)B*"_GKIXRS9Y"!(MCYB8 ]L9$W"P:P)#PYK,<
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M?I#>VQ&@)"24?[.D!1TVXM67)GO:&7Q10^%UWP4Z3RN*,0TRD:J:0PQ X+C
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MD$ ^;,'S0+\D?E>!>6)J(K=$D);,1(_%VF0PBX;%X*D%6X;<ZT(:8[)H[CC
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MK$Y7JY9*JCSTQCRD<ERB7>(Y^!FSJMJ]V2PNZNX.A.=_O<95]\$D,>AT. A
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M!.CD  W' (&.8+3/'?1%#-!WSM>5<0_*]S<H6UH06N<W3F'H&V:_5DKKK&.
M@9SC )1T_H]= J'P.VCS]609<I*33W^#\F?U_475H$5J+0R0ZH=]TD#W04_W
M6&,Z1;,^;9<KG\="!2$_(0CH1-]G)T/&Z;"+TFZ3EX,0&Z!Q-\C^^OD"!KBY
M 3V_7(*Z@@$^G5I$R,IXF?TMWI\TB:X8P5)%Y5W"?UO[O\W: Z))OQY&>%+Q
M\R"9DB"$U//.MOKN%X/8)+L_ @.$_6PSQE]M]O3?-OM/VZR &]G9H>:MU>;V
M#1RUZOG$E,S83[SFZ3$Q[%:++JOR[CU#&@V?QC(>,#-V",T?0_3B0!?3TQ7"
MR*QX6M)E(]*;:J.,\B:+CKU9!_9\KA=$6";?CSYA62PA:EIBC@PO6DZ<"=5E
M/X$Z<(F=:CT<2)C\<#;4RHD;+-2.#5L4>J<I)KF?-FT"JY2UF/&"148?BR*4
M^2(M>SMQ-?1E\H+XH=D4_9HK;J#]/DV5GNJHAYTQ]30<F:$QRFZ]$SNP[12?
M^37R<2L=W4S4B0K[22?8"*T(ZATYK<?UN$T1VGN'&+4(LQ:HKL^R.=;+L1UZ
M%929LD<1?70F"OFN"$ZPQ285I++M>FWUDZ7"=!M\/H3GAX8A9\)(J.&8I #R
MS>RQ_N@N7?A7&K8/$R9R%Z\_ODQ*-[]_F)O1IKZI$<)E!N-3\-KIJ/UZL>A=
MJWI;XT-+HC=5R=5:.YX3,G3K"F!#+\U_^ \_.:RIPPTZSZ#C)1K45F@I9]H=
M#* +-,E@R=-_YE*OHCT<ISU$8(!R 8-\W;#?3A[VYASZJ4+^QQ60Y8%WIH8!
MNNU@T,U?_S?X_7_[?X-/\#-=0*T00A1+P<:D8$8!>//>]SI?==*N9/5V &^E
M^@V/=@J)![/I_(S;M<KQ6E+G>,?F#.([[\BWV_(:>J( CU::F"%H>^^/U%48
M[A6U,/-BFXOCR@+TO?50=5QB)80O[>J*R(GR>)E#'C\AY91E.;*B34C4.3"[
M/E1CC#-2[^-*P.7'?L]NT::ING12:;5K'&G<RU.K$<B88-S9+#JT/J[Z=$9
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M3H-$H[7L_6D=?1HP H/%\\M08#5MVN;&88!U9\)H8LIF'OFQ2=_(G^ -5#_
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MM-GHKO(/($["-VE.DT+"GM!3:4\X51<7Y2-Y,;/5_G<\6X,8/V7%^@VF,*%
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MW@[JNU#B\ _P:[;E1UGQ$IL0CY%0X3\ C(XYY)[\1,D"F(YC@ULY05%837:
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MY%8]93,8K0$\TR7Y+\D6X-P%M"09=,Z4J:Q5P=T4A0N.5L2CA/XP/6B+QFJ
M,^P*-7A/*Y[P ?YW7^O_&/<:\HH6'1<^C<9L"K@ZN#U4E7CZQY29=OA3!-A
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MR?QKPWW?"4V\888P@(P71%1OH+$'<V%$32_140B)O''95M&V^SXAG2J8L_1
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MUGHG(V:1I:H(%H[TQLFY1+L";U"8BT\VG@AO4' +VCO&_WZ/BIG>$(O6O$&
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M]E]=,[0N^+>5$G1 ^>0O1$R5S"FP%+MBIUB6@CK*8(?/1@"I!\;41N=[D+-
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MWF#B1QX9.1]F$]]+0D>GKQ$%JO#6L>?4#).:PYKCD[SEE9D)FQ!WZ&3E^Z"
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MV>2:/9YF\1W\:U$NDV__/U!+ P04    "  .I'1:C&VP6,I4  #-WP( &
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M0RZD,BF'>&&9<9IC5@!24)%E)D^U/ QF^Z>A'GN#KY1E<VV7!I]]GL*A#.=
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M8&P0/ZGB&[."9%EJXNNSN08=%GYJ$'OEM.MBB$"NI+2F(G[N5/>69KUN-HZ
M/O<EI<+VM:IH[LA@68$-"-,-R*.]E&Y,65 /.77TEH*' BR>B.D4LS206!=R
M.V@O$2B"F& YQB(&R@Y9PC*_PY(!ND*#!)]9/L_8$ER1<#N!.>4BE2S;2HE#
M*-9%74LU@W145)R9\TSEC2*0[@GHIW,81Q(T BWK%*LS#,%7#)EJC41/\((1
M.KKV7,K;1#]?&!=TFZV!:QQZ$\MPIL'[1NGE:(:(C5%[)X;D.3B)R2N+)(:I
M^VD!(PC_A2=]^<46/SXAIT<BE$]N2+BF5^Z_4;$IIQTL(R3>':^?$0 7/@ZT
M0RDQZ)F2%8UXV)SH3GOOO+HG82O2I7W8)(86-,#<7.E':?KSN6EJ@_DW,X1$
MU<O8<TAXT^3&9&AS-I) 6H:N[0BV#P[=NP[AN-91NF&<Y>36C*\)6NIIQ0:Q
MO-VF7?EAZA<SSIQJM?1&HTH2B+%(B<:+95X<;P+Z1R/.R1W#5/!2A,.G@('A
M4V(!]"WEMTE*/'%)I-(),@4T'-&)X1+#2%.EF6$*%?QC4[%:]87M>#8QL1P7
MT&(ZT;'O(-<W;X8PX1P(E$!(D:S'G'LC>(I-2,YT@O$NV'4<K;I'V=N:D?8K
M0?+\U+\:7 S['[W3L]/M\\_O/PZ/JUUJUVI24H,FGL=/(A:-.]$1B>T]I$-7
M;ML*&+8DN$K72GMNE)!J+@_&UB^8<(:_8.)I%$XI5XN<7FXI*@?5X.#<L* P
MX@$$$1[!%!_BB:^(Y("I P7B'Q4@GC$7@NIJ,/',]=N91UHY4&F^ +(7UB0<
M@U2+L59'13@/,8[R)$=9%W[EC-!*XPK6H=,O.@>6 C(+-/<B+ZL>;)F<#(45
M&\F&(Z%=>2 MB$_C=*IL1E553[R$Y9O9&<B %^8]N.ZTTJ2!C$I%?\<;A,R4
MR*Z])C,HUA/V];F#$69L;VPQ7=JR75N$A=F%FNK1T26)J-"3)!4'KAS!V>HC
MN./]FMQ@;F^/^BV8.'!6)P!GOU8>!"FI=F^K.2)_7DC<+L;[(V.\98VNE+GW
M'+4$6*FQID"_CM'K3STD00]*BI@U:+AA4H2!HN0%4+Q_UZ;]0TJJDZ\RBJ^0
M.[Z(5 K<)<0307PZH^K N@%9%L\5:8H7F#<02RYK:/$LN.6/1A;,."UY-BMB
M8&M=AE%W?I[L_$B[M)G).!\OGR=*&#"<'>@[3.7<W*0X^V0\EII\1EF@VIPN
M+:XCVJ<CVN,R+NP6<J@B"*6R@A!22+4M=98Z9DCINTM19:3>*_P,J1?NX*Z?
M-DCYO M2=D'*#NZZ$RZM$BX6JX(2;5"4C(I@HKM,_X[JGE*E0< 9B<4Y;CE'
M'T]&$7G,*9\,/?X8 W2N#/1881DZN]'Q A^H3I?03WA#T^,ZNN[H^LGH>CA#
M[9Q3,.(O:3'/.4A4$F(4_K,( W3?SE,@2CWK&&U'D$]'D)<5EGFMHV3.SH\R
MV[R,NHR,+N#VX2:=H+QF.:,)KWE6IC0QQR[QI"QV7L^;)4%II&+&;#4IPV7O
M:I)JXZ9)*[\0@4BFKY-I99.H>K6T+%C, F.N12K95QRPM7,UT^B.87<,GT[?
MD03XM.S.RJ"RA,ECOZ/VP->F% FLQE *(-T#X%Q?.=$6_*-T%SF76I_\4N9]
MJK?Q%6!?YMMV!":G0GR?7 82Y\9O*J@^"W+;AWFNM3?3FO(;1FF(4;F)%R1^
M(;=+N8J!YL5NZ'QUYHUT?J-U%4?/P4*B52F3?KI#VAW2)S^DI;##L^'#5E(F
M'";NFK^SO A*J&GL2>&<Q(Y(.R)],B(]3Q."% VQVCPH3,65JUJA"J0Q@40"
M55BRM21%,*&$$-)$6I29;/*"BFSAQ!/G=M#:0*'J*+VC]#_"=$'.JU6*^@[I
M2?9'BX)H\0!S(#,X"@4V,*$\XR[#H*/:'T2UC(?ITF[/9C,JIDGIDP+V=/RG
MZZ36$>:/),Q/ZO>$BS JWI_;BU1<1XZH$6,WYW9,_#;0LSE[>%3 I>%T&5;F
M8VZ!%/TC_YVD:I:9BG[\C;40]-_0U=D\"O&4.#8LP7-@A<P<$]UI3%)CA$:K
M-(JOE.^/*:\W\S:+F'K)P "R0L#*N2Z 2PAL\3PG3%#3G C.8H!)L6"2\FLP
M55@2Z"CMV &B%'2?IBRVK9JW2VJ,*+[M+N*"TIG%,X5)')SE&^@HS%"(=2RA
M8PE/QA*N*"V3LCIM<OE<4YBB5H;6D6%'AC]$92K#"RRIR@)LY9G0&O']A*NU
MJ!(K[7F_)Z#J&P2WGI=K#@M30=GM\0M\XC.O$K\HHP^]FME;LGKVB2K_GT7(
M>3G<F30S:3K+)K.-.*#PR3*=.UATQNK.9')D@<-=08B]_!"H.<46?"0542@:
ML#G)H_[3-C_M#NJ/5R&YU#'6D='2>DVA!VV;C<$ E.A9V/11+2B'^F=LFCI<
MW;5 H+BT8,XU%=F92K@2NZQ6OE0ML';;,*SH'>64H854/T5A&R7%4ZG.L%49
MMY2($%>S/EX7/4(@%>KE;* " R\K9K9!1;WN+LQJY65=+O$CY!*_Z'*)NUSB
M-04\>F!1]7ZEJ/K40HRL;5EUF+FLWL5,&2]Q3_1)8-$K^2-&::*"B-H 9YH2
M9\H.?O*(,>F)"*2 KI+8(I=P@7"JQQ'7&+L0@\OURP0!8OMY%-P?[@Z1Y<R#
M@4T4^C]5!A+A)O$0"L0">P1PY%E(:M(C P>BI"8ZG"ES2L_2C*G-+S8TI*PE
M['>'.KM9#F[<:VL0+P?'/;Y\N_3IR+4W>H3%CYQK*CE"^/8>34U_E;Z_TB]X
MAJLF=XK3QZ_7%7.I#@Z@F L6D[F3; >G+)/1FQ"E2S$$]1(I&!%>EC^CM*T7
M<S.M>(R\HD99DHZT]5.Y1>RR1UY$O;L1*0>V_9XJ"Q5BQ]MF^B4Y,!BVE+ W
MJ23M/:!7@A'T[;UM'>JN-K4%&Q4SZQ7^@F57TDZ2UI)2"=#Q:= V&3(D <+A
MKK;2O][K?_O D!AJ(W+&2BS&G$/8;73BVM,H.UP"JO7LK<)!;"/(TI\)S\/Q
MX[%FHHY9O0S^,(P27V/WS(<*'M.8#KMA#0>7WL7@E_[%R?#T%Z]-J"4/G-1S
MTR8['G/76*O9-X-WM?O$5F#_"-@GK:#_K9I5)49<!_NMH2@CSQ70/6Q=UX]6
MXIP1ZII/:7,/A$XV0!P%0SM%W$$PTA/0TJB_H+FNS%HM4G2 9344M3L@_C*'
M60.["2)6!93O@\[M]GQG9I@9B\^>\A@A!NSZEDFZ/2O ')1%\@JLPH2SXX@$
M@]N*=9H8+0!S2I![-X+X_>ALY E@^V9P&ZT"HI(XN#=Z/*8F[MCM4(WUI%!I
ML&IU5H#'">@>:1F_2;-EE/AF:58]KD2L<>B\;+;A&^ [B9=9."W0&R)UT^.H
M%_V$K9T= @B=B^]+L3UNS6P@"IT#3.WB9"9+\#U 7G ?W$@9JJ"X4M@OUW-1
M)4E#SM47'4M2*_J"'=C/)77)<;Z2>&"A1G#2E7>L('E^H$$08WQ0][HX\!RD
ML:HB-W:Z?VX)R*>#1;8$<&V;/U<T3<Z!#Y=39QDEK'YA<Y\]XA\^0K(+$)O,
M 5?#5?(JD#B$XPC42R@AS"(-&=1\5 GBS^(JKG93M?<T(ZM_4--"Z3Y1@M&A
M^]^"NAK4-N7$%TQG=(JO.S)YB?8Q\! +D!4^%6_^L?K4 Q6-%Q:[T&B,9*+<
MBA3:7E+X0QI/+$H6;QH-1<2ZL6>)?,JG:5),I#4!4BGB<^H&=,Y[IWS< 0<+
M,AF$F;I1K%\A,NQ=^*\KE"U@/1;42\4&[-!VG ]"0N0WRPF_6>NE[B>(EV!0
M.U?SH[F:7W:NYL[5W$I7\R/S^$O@R01X5N&\#D>MX3N[[+3:/F9)M3:-XTCA
M-:SS+K9IM';"'^3';#(.L&&D,#?61&M-3N@UH"\FDZ200%Y"^7<Z0U7WR447
MZ+0?W-9Z9CD)]Q>73<S.,HVC65#1!52HAG'DQNI4+ZGP?:-A558?!,UXU<JZ
M]Z(W&Q:BR/7=/9+(.8</J)E0.-4;8]J6?@/N'*,=\.Q[$]/R6RIMMU<\9QDV
MO<?QA9H5Y(1G:^)YR\CG,G<&+BA[Y-1BU, R;$0&M:0Q=0'/::'*3T[OI&$=
M9%-4@17#J6.5<N.?ZCZW61]^:?5AQ\*Z'Y55D-I9T6NOIMSHE[AKGG#RP,B*
M:\IIHY>",+[34,<!8E_2G#W;O=N]GM-4;/=0'E'5VP ZM*;V5^BHJJ"WDBE,
M7R\]ANF0]V.T<*T;VBF5A9D%\Z_@S58<=:Z$F:DO:#:BS0[3,@B9R#\YKI7,
MPYB_J[WC3@G"S+_JL:]RE]+/:5O%+:T&\5L\LJ8KQ:U\C3N3F68$$C[BY&;6
MZ['M&&>=P'.(JAWX=+.R]%S3PD!<).:UG*&G$$*^YNV]:T$$J3=S;]NDO@3
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M6#3[%:RM1LZ$Y46EB_@7 ?\0,H>Q5LG1GMCZ/JK)LNZ$AS!!8":X DM5[Z1
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M=']RD_+E[OY2C^'AZ8>SBT]]_-1FJC;-D:]A=TS7.6!K['+H @"/%@ XZ (
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MXP[ZX_U!]QUT'^LQ^][YK_C'\>#SU?"X__$2M+K3XQWO<=Q";@J7]^'LPKO
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M3S5P?QTE-SWA:I,"OD,FDPF,,J&9P%RJ<Y>=77IE>UB=6XKJR![D*T!Z]=D
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MSBEB(I&JE(H8FJ/E!BF:@7,@E<"K1B*3G,NU\8YU72OZ04..,#FF,AY>J()
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MEX9S:/G )R0^@C+I\HF2<8F#@W_4.PN&\T5-=\W8WT5NN*O,OP-02P,$%
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MA55^O3ULW=/&.I($0BF1^FY+*U/S*@^:MX&/NHIVT=XYO.\<'[\Q^!_5QA_
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M*Q)/>T#4;3V,L;?X[2U^>XO?WN+70KB5D![P^P%K>;O@E^["";G2Z;#,K>K
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MY'15E9?FBXX"6WL+Q?H6BDW-$<@8K+)&/,'$6_!G7*3)J_\%4$L! A0#%
M  @ #J1T6K<(VLAV%0  T>$  !$              ( !     &%R;7 M,C R
M-#$R,S$N>'-D4$L! A0#%     @ #J1T6GYG6Z):%   RB$! !4
M     ( !I14  &%R;7 M,C R-#$R,S%?8V%L+GAM;%!+ 0(4 Q0    (  ZD
M=%K[U17^NS8  ,%H P 5              "  3(J  !A<FUP+3(P,C0Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    "  .I'1:3^D9'W=_  #<6P@ %0
M    @ $@80  87)M<"TR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @ #J1T
M6LD^+W*16@   G$& !4              ( !RN   &%R;7 M,C R-#$R,S%?
M<')E+GAM;%!+ 0(4 Q0    (  ZD=%J*5/?G)*0# #+%(  5
M  "  8X[ 0!A<FUP+3(P,C0Q,C,Q>#$P:RYH=&U02P$"% ,4    "  .I'1:
M^_!J:XZ5  "KQ@  &               @ 'EWP0 87)M<"TR,#(T,3(S,7@Q
M,&LP,#,N:G!G4$L! A0#%     @ #J1T6@_(!/'KCP  7*8  !@
M     ( !J74% &%R;7 M,C R-#$R,S%X,3!K,# T+FIP9U!+ 0(4 Q0    (
M  ZD=%JEB"'S72H! &<Q 0 8              "  <H%!@!A<FUP+3(P,C0Q
M,C,Q>#$P:S P-2YJ<&=02P$"% ,4    "  .I'1:(53L8UT'  #R!P  &
M            @ %=, < 87)M<"TR,#(T,3(S,7@Q,&LP,#8N:G!G4$L! A0#
M%     @ #J1T6H+N2HQ4!@  YP8  !@              ( !\#<' &%R;7 M
M,C R-#$R,S%X,3!K,# W+FIP9U!+ 0(4 Q0    (  ZD=%IU6"<%S08  %L'
M   8              "  7H^!P!A<FUP+3(P,C0Q,C,Q>#$P:S P."YJ<&=0
M2P$"% ,4    "  .I'1:5AGO(^P'  "6"   &               @ %]10<
M87)M<"TR,#(T,3(S,7@Q,&LP,#DN:G!G4$L! A0#%     @ #J1T6@+6^C0S
M=   T8<  !@              ( !GTT' &%R;7 M,C R-#$R,S%X,3!K,#$P
M+FIP9U!+ 0(4 Q0    (  ZD=%IN3,=<&:4  "O3   8              "
M 0C"!P!A<FUP+3(P,C0Q,C,Q>#$P:S Q,2YJ<&=02P$"% ,4    "  .I'1:
M+4F,LT(J  #I) $ &0              @ %79P@ 87)M<"TR,#(T,3(S,7AE
M>#$P9#,X+FAT;5!+ 0(4 Q0    (  ZD=%J,;;!8RE0  ,W? @ 8
M      "  ="1" !A<FUP+3(P,C0Q,C,Q>&5X,3ED,2YH=&U02P$"% ,4
M"  .I'1:66J0<^X#  !#'   &               @ '0Y@@ 87)M<"TR,#(T
M,3(S,7AE>#(Q9#$N:'1M4$L! A0#%     @ #J1T6IF\A-Q"!0  G1P  !@
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M,BYH=&U02P$"% ,4    "  .I'1:0;ZQ4PD+  "%.0  %P
M@ %$#PD 87)M<"TR,#(T,3(S,7AE>#1D.2YH=&U02P$"% ,4    "  .I'1:
MH?H2-E\8  "XG   %@              @ &"&@D 87)M<"TR,#(T,3(S,7AE
=>#DW+FAT;5!+!08     &0 9 +X&   5,PD    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>armp-20241231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:armp="http://www.armatapharma.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="armp-20241231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_reOzmK0NOUyOz-GslMRWRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K4ieWmLnSUyd7TzJckLcIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lRVURMKV0SoOkMJkefoHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TdUVPQRZ90GLDTkGnv6akw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_z3NSngTeFUqo0EjEQOAFlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1Rw3csLgjECALBKYfsINwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EqQhMtDQN0uq2op06-vOIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WYP4LOLiVE2vVMYho8f0Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H4YKiME1IEWZOdKMpzlX5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_T8FTsTcprUy8rKzW-XC3EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_gGZqSnGwP0OUUcdXV26XfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_PdC_SAUxUUK65xSOy8LXqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_NG9OliLZLUqYSqXnApcGDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_umBgF7ml2kCrfw0hSCQoPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_2hEBCqxGoUqgVYfZknvwGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_pJH1VOMu10ubY-ejaciVcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_8COWQsEZn0Wg7V4VXWyPng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GhrtbpfWc0emjiaVORy1SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_QarzicNc2kSX3wxOAwoMJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_f61X9uE-N0-LLpqFLPWZgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__36xUotZ3Emz9Qt3QZqLDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ct6tmhYJKEW98JUYWA7SAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_X0p3Xo14WU6gPCeyKpTmXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_F1-n7zRE20q0EmkRbZO3CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_aDlY3wA3nk6hKsCmJ4oMww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_TwxvP62zB0uMlwhQkUWi8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_16WVW7L1UEKVDZzpv4Vrkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Tfkx6Pkwf02KkxOhwrASHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_aI2oyISraU2WBXG-8aXVKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_3TzGv1YAjkGo6HRjhuGnGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_5Jnw-tluDEu-Kx_JvwRpgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_p7FgB_AuUke_7o5Nlzb6Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Osvcwobb1UGHl_jI9F_1uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kYqBxC16p0K1mZ2qlRBw6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_D0CIVBrcHkCADcgqae2kVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_iIfGtoSfVkOyLJgO8EHWrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_qx3dYJjAE0ynK7mpFACMVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_CQpyd18Ds0qh3m21NnuflA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_iRtQVHneb02Vlx_hfCVCVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_yrOpWPoZBU2cuEPXaihZtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6Y5SYi_BTUa8vlarva5peg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_12iaGKNXCkqYkhajskEVlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b2xRzt0_BUqhKZ6JbrdY4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_OwnershipAxis_armp_ArmataPharmaceuticalsIncMember_Gv-ymKjfckGEyekgNJZuSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">armp:ArmataPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_10_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9MsN49-EsUuh7lrZcuBNDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_RBZa_N6QqUyQ2oiWdEiprQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_lYQF9icj1kuOL4xigHQzKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_KilvybAjfU2MMseKFQN_pA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_ISHRxxWU70-yPTo0clBZbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_AUoppBe8TkmxEisCXjCy5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_XpvWEZpmi0eXkPlF_gpoDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="As_Of_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_e8KlhRKgsU2__dqtJNLl0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-29</instant>
        </period>
    </context>
    <context id="As_Of_6_15_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_2_29PgfsbkCQszk3gpXeEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="As_Of_3_13_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_HJ-pxCwh90SIPJv_UoUV2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-13</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_f3OfRucBq0qiXxxXxag-WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_9_29_2022_To_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_V-g9tOqDXE2fXuEN9aCnWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-29</startDate>
            <endDate>2022-09-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_kA-sXj9xmUyv5HjdSnfDDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_47SSxi3ckE-kheHf6e3v9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_6QVF5TJnNUu6xhAL_qid-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_6TQEKKE2Ck6FoFOmzAl5OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lY150wsNP02MP9zqV76jPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_pSgow0Qc80SpSp1cz46FaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_fPQyy0HqVEuM1qduhYrYog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_Bf3h2ZhloEidThSSRPvQFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_yDGzdtvVaUO97cPKrXci4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_PC5IfPM4Q02DNCet-1_Lag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_MIv8wWRsbkmUV0mdcTFmZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_OTR9ruU8jEO4DamnlHKFLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:CreditAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:CreditAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-10</instant>
        </period>
    </context>
    <context id="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sVGisjCvnEiEB93bLojreA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_YvPw907mK0udlp6KfJ8QZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_htSBHjfgekaRHkMRgsz1MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_7LahToXqk0ys3Hj-vViLrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_Q2agB-03uEiWytISvo0nvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_8NNrUB98dU6nTV1W_TbZEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_8bhT2JsMPEe7lORCk6OgzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_HyGAt6Tz506l49Pgkj8m9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_aSkSzFIw6E6liVy6b0eAVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_5m5du7ROvkCWkfWMS1O-UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_igNvzFb5yESqV8OvL7Pg4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_bAIh_tiMI0Kax823zmexkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_wEUJtdyPwUmF7kwBsHNYtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_FRPlVpNZ5UGLs3JJR-cB7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_rohFuA_mlUuMJvakf51DjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_SxAfTk9NBUeYICYKsOhlgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_XkThMChsq06Wh5OxvIKHaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_Zs1AsV-ToEOMh54dXGkq3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_SharesIssuableUponConversionOfConvertibleLoanMember_h0Z_P8CvIEq0cw1j1Kdi6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:SharesIssuableUponConversionOfConvertibleLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_VsjRlp7C00anCfXheLFsLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_YbvCeB-0yEWBm5JrBGygig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Wnx7hledV0aiY-1RCUHzlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kBMGpinIEUqZVp0QH9Oswg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tiRew-3WXUazY4UJ_rsE2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_28_2024_8KTFkLOAWUee7jQTUCnIkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2025_0UmROVpvLkiJOl5Q8Bvc_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_xBgryqct0E6Zilf1u8G51w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_JaLL1iLkyEWNgBPCSHnOpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_zidty5XO8kGAipBpidYvpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_8Mc5U6Ck2kSpYcYSeCnQCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_feeJaveXFUOGLBI6iniUiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_3r_X0vA_sEGsQPwLdkNqvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_elsHS6ydWEONtGpKI5VfjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_4FQlAocYb0208Y7SDKNP4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_gXm3SotZZkifgZITvucSLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_u_Te-bqUOEC1eghs9nZXfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_lvqDhuhNuUSizIHbky_dog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XXu-NcK_bkaDqHPx0csY9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_PYldRmX4ZUyocSelgjrlsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_qzQd7EpFYkq8oeUwINwivg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_hHfphnzRoUq3UB_-E3jFQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-07-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_ProstheticJointInfectionMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_cMxrWzKqB0aDivLktL7xSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:ProstheticJointInfectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_NonCysticFibrosisBronchiectasisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_Na4M3PweMUi2iIIsCkq_3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:NonCysticFibrosisBronchiectasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_CysticFibrosisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_-n5s3ugSiUWuw4UgnftWDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:CysticFibrosisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_BacteremiaMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_nENRXrCZwUmEuUIiI0n0aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:BacteremiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_ProstheticJointInfectionMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_v56oVy0tEEyLTBl6m8fpVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:ProstheticJointInfectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_NonCysticFibrosisBronchiectasisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_QTrcE4TKsUW11OtCkzUlvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:NonCysticFibrosisBronchiectasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_CysticFibrosisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_DQ9wJoe1u0-IR7_CKaA1Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:CysticFibrosisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_BacteremiaMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_O6wXLenwPkqANS08n0zSCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">armp:BacteremiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">armp:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_BApNk3n5XkaOpKH7-XGdqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_QpjN1Yhr0kCLe-x9CNhQkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_83vS_dwiSkeNsun5DvCQfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_zHKl8i7YW0il2SCbZ7ryrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_jVO24CHTHEOIiO_ECZ6bIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_q3iOc3hnOEKxXvfRp4uwBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ieNv8UfQuEu5yQKAxjemyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_-pt2ThZhNkOtRzUxqgRzhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_AE_R59dgSk29aRazyIh1uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Tan8oCbxTkeDxokgzAn6TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_wDGF0KSNh0K-ZOkC4X8kag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember__ONSzE2PXE2dEzLteS-O5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Dse-ebonN0CTM7ve3ne8_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ubx-9CKJgEWrllUJcWFg7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Nx2W3bvlQUKPamjde55oCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_jj6a-hSvJkuGs24AQOWWHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_pLXRlxUf9kGKDnBAIaplzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N9_1XuuLQ0-lsYc-TWi-NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_UqehtnWrBEGyotCU0pk1bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_N2i004GY7UqD_LBRSb5cDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_TkXtmRTW0kmojBMn9BVCTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_rOsiQMIXrkabber6Gcmk5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_T0i7nyaWzEq2E47alJJZLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_pPPFgT2uxECtGLDgw4ehFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_AyLQnVZhREiEwFcrl82R0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_kRX4vihrCkaUsg38VT2Fag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KZNkSs3clkaJtabzbT5F9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_p_w3bZ_ln0aJdZk7_GgZHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_uW8GX-eYnUeHey_7S13JXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_JqCSzztJk0uu3fT9ol6LJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_37d8n_o0P0-p2FnUWFQIOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lyiDqRxypkiQAz7M1AbxDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N0tx2XrUDkeZnYUXCzfq4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_8HLlfMA8zkmvRWpKnH3qMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_NLLKe9dPJkWGOD2819Wd7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_RangeAxis_srt_MinimumMember_1gX74jz0bEaW8OFMI4iC9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_13_2020_To_3_13_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_kfgQS3Y8DEmi378_OnwJhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">armp:AwardAgreementWithCysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-13</startDate>
            <endDate>2020-03-13</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_r5Xr-teAaUaiHHiDICZQPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2021-10-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg">
        <measure>armp:Y</measure>
    </unit>
    <unit id="Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA">
        <measure>armp:item</measure>
    </unit>
    <unit id="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_sNn8LuEmwE69rUms--yKEA">
        <measure>armp:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      id="Hidden_QxxCRg4_J0WVs2POc4bI3Q"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      id="Hidden_CgMkDhwOWkOK21k_ANT1Ew"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_tdUaBHS_U0OBCW6dE6O9oQ_2_1">0000921114</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_fLf6ZcVOL0e97AOJPQoXmg_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_NvxguUVOmku9UYunf92P4Q_6_1">false</dei:AmendmentFlag>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_6QVF5TJnNUu6xhAL_qid-w"
      id="Hidden_XOwD5nV2WEyBnp53UOQlCw">http://fasb.org/us-gaap/2024#RevenueNotFromContractWithCustomer</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_kA-sXj9xmUyv5HjdSnfDDQ"
      id="Hidden_4FqYFdy5Z0uAKDas3B1bxA">http://fasb.org/us-gaap/2024#RevenueNotFromContractWithCustomer</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      id="Hidden_-Eh2dCRyZEObk0oB6hPNcg">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2023_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_lY150wsNP02MP9zqV76jPQ"
      id="Hidden_xUrXavuJzEKCYO2cJuMBNA">http://fasb.org/us-gaap/2024#GainsLossesOnExtinguishmentOfDebt</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember__36xUotZ3Emz9Qt3QZqLDQ"
      id="Hidden_GZ0DQ00E2US7iMhH9yvSLg">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_Bf3h2ZhloEidThSSRPvQFw"
      id="Hidden_gW2qZueRtk-fdI8-fDXRnA">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_f3OfRucBq0qiXxxXxag-WQ"
      id="Hidden_jN3anHbpa0isGOdK9gp3IA">http://fasb.org/us-gaap/2024#OtherAssetsCurrent</us-gaap:GovernmentAssistanceAssetIncreaseCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_VOFMKC8dq0yx4P4Txxz-6Q">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_gKEBpBnrAkK9n1F_Z2DPzA_0_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_E65qHgZvW0W_jcM6LuXy8g">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_k9kWw8YtJk2TmF8LC7oWaA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_R9oQGsWI1kaHoLNyukb8Tg">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_dwsBEkDnjEimLTGd8cmNWA_3_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr__iqJWiZiOEqHkl17MA9hNg">001-37544</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_RXy04Js-LEK8dn6lvEXZDg">ARMATA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_htdrjDt0jUmP3q8uAyaYcA_0_0">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_fPjJxQFBoUuXD4yC1PV4Gg_0_2">91-1549568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_F-0Lic1BBUa1DV38gFSXOA">5005 McConnell Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_BgjmiSxdvUOVQZwd60vOzA">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_aUtfYb-Blk6aaMr1IztMAA">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_u_slVe-bJEee4D3DVrsF_g">90066</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_GWZdCikDkk2mLHRfuiYZkA">310</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_WHNdaiqQxUGirBSy7Ae8bw">665-2928</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_nVDDPb_XKU-ZPD6ceGzW7A">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_qdinGrhIEEiivKWG7o1YaA_1_2">ARMP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_gze0eW158Eyoj1Y8LMYzSw_1_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_hBg_0unnLki8Hrxn4L7dWw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_n8NJeeH1GkCVY_fboME6OQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_BxSL-Qzx60S6XZPiEj8NjQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_YIlIkmi450KafpP_-HFmyQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_gvaqVCxMf0-qCrK_SnQwUA">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_JHiHheS2zk2h36TqL1zVAw">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_rV30r2AwvUOKruO_kMo6Cw">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_p0Y_zaC9D0uFIbrdNJKHeQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_6IIMLrrL80SLQihq86sT8w">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_VqOpVkQG4USs0iC9m0eGrQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_28_2024_8KTFkLOAWUee7jQTUCnIkg"
      decimals="-5"
      id="Narr_QfmqYS9kyUq7mPeWfUQ5uw"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">30300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_28_2025_0UmROVpvLkiJOl5Q8Bvc_w"
      decimals="INF"
      id="Narr_adV86kWd3UaRZH65LGz8Qw"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36183067</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_rwkcKcVDAUCfuD9fioc_Wg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement relating to the 2025 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the registrant&#x2019;s fiscal&#160;year ended December&#160;31, 2024, are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_pr07zUuWBE2R0bJxs5EQDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include operational risks, intellectual property or trade secret theft, improper disclosure of confidential information, fraud, extortion, harm to employees or customers, and violation of data privacy or security laws.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Cybersecurity risks related to our business, technical operations, privacy, and compliance issues are identified and addressed through a multi-faceted approach including third-party assessments, internal information technology (&#x201c;IT&#x201d;) audits, and IT security reviews. To defend, detect, and respond to cybersecurity incidents, we perform cybersecurity reviews of systems and applications; audits of applicable data policies; vulnerability assessments and penetration testing using external third-party tools to test security control; security incident and event management; continuous monitoring, and threat intelligence gathering; conduct employee training; and implement appropriate changes. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;We leverage third-party expertise to audit and test our cybersecurity program and perform employee awareness training. These include periodic reviews of cybersecurity threats and related controls, including review of periodic penetration testing conducted by independent third parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;We maintain a cyber liability insurance plan underwritten by multiple insurance companies, which provides protection against certain potential losses arising from cybersecurity incidents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Our business strategy, results of operations and financial condition have not been materially affected by risks from cybersecurity threats, including as a result of previously identified cybersecurity incidents, but we cannot provide assurance that they will not be materially affected in the future by such risks or any future material incidents. For more information on our cybersecurity related risks, see Item 1A Risk Factors of this Annual Report on Form 10-K.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_-edTutcEbUmd3X4nG2irKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include operational risks, intellectual property or trade secret theft, improper disclosure of confidential information, fraud, extortion, harm to employees or customers, and violation of data privacy or security laws.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Cybersecurity risks related to our business, technical operations, privacy, and compliance issues are identified and addressed through a multi-faceted approach including third-party assessments, internal information technology (&#x201c;IT&#x201d;) audits, and IT security reviews. To defend, detect, and respond to cybersecurity incidents, we perform cybersecurity reviews of systems and applications; audits of applicable data policies; vulnerability assessments and penetration testing using external third-party tools to test security control; security incident and event management; continuous monitoring, and threat intelligence gathering; conduct employee training; and implement appropriate changes. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;We leverage third-party expertise to audit and test our cybersecurity program and perform employee awareness training. These include periodic reviews of cybersecurity threats and related controls, including review of periodic penetration testing conducted by independent third parties. &lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_Q0UZ6Hh9UESHeX4Ah-P8gw">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_oYSkoZ-84UywbFYJZuuVoQ">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_iqYKt4Tb9ES5pDpZKVTsAQ">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_3oWbLVd7D06D-k_YOqsABw">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_uIR60Mo6jkGea_Nkc4O1tA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cybersecurity Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Cybersecurity is an important part of our risk management processes and an area of focus for our Board of Directors (&#x201c;Board of Directors&#x201d;) and management. Our Board of Directors delegated oversight of Cybersecurity to the Audit Committee. Members of our Board of Directors receive reports and presentations on data privacy and security, which address relevant cybersecurity issues, and which can span a wide range of topics, including but not limited to, recent developments, evolving standards, vulnerability assessments, review of risks from third parties such as service providers and suppliers, and the current threat environment. These updates are presented by IT third-party experts, finance, and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;legal departments. Members of our Board of Directors also engage in ad hoc conversations with management on cybersecurity-related news events and updates to our cybersecurity risk management and strategy programs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Audit Committee&#x2019;s cybersecurity-related oversight includes the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Receiving notice of, and providing guidance with respect to, material cybersecurity incidents;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Reviewing our risks and cybersecurity programs and policies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Overseeing our management and mitigation of cybersecurity risks and potential breach incidents;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Reviewing reports and key metrics on the Company&#x2019;s cybersecurity and related risk management programs;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Reviewing the progress of major technology-related proposals, plans, projects and architecture decisions to ensure that these projects and decisions support our overall business strategy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_tesg-yqLpkqp4Vmx5OITQQ">Our Board of Directors delegated oversight of Cybersecurity to the Audit Committee. Members of our Board of Directors receive reports and presentations on data privacy and security, which address relevant cybersecurity issues, and which can span a wide range of topics, including but not limited to, recent developments, evolving standards, vulnerability assessments, review of risks from third parties such as service providers and suppliers, and the current threat environment. These updates are presented by IT third-party experts, finance, and legal departments. Members of our Board of Directors also engage in ad hoc conversations with management on cybersecurity-related news events and updates to our cybersecurity risk management and strategy programs.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_3uMo76rNQk-UvysvEl3YzQ">Audit Committee</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Group_TM2gY7NfVUGRtF7nBs40MA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Audit Committee&#x2019;s cybersecurity-related oversight includes the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Receiving notice of, and providing guidance with respect to, material cybersecurity incidents;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Reviewing our risks and cybersecurity programs and policies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Overseeing our management and mitigation of cybersecurity risks and potential breach incidents;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Reviewing reports and key metrics on the Company&#x2019;s cybersecurity and related risk management programs;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Reviewing the progress of major technology-related proposals, plans, projects and architecture decisions to ensure that these projects and decisions support our overall business strategy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_Qtb6mRT7nUuabGjV6mYz0A">Our management engages with third-party experts who have significant IT expertise and broad cybersecurity experience, including in cybersecurity threat management, cybersecurity training and education, incident response, cyber forensics, insider threats, business continuity and disaster recovery, and regulatory compliance.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_lIMoHZbsNkW7nvcXFPMwrg">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_AsCnugKohEyKu3Bqb2fhYQ">management</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_v6swIXV4EkWLEG571OIfLw">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_e4cyUP1h30a_vAGntzHcFw">individuals have significant prior work experience in various roles involving IT security, auditing, compliance, systems, and programming. These individuals are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents and design.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_4uqgdvDwQkOTeCxUDvekRQ">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_P2ZzY44jZUKmWnf2SgAG9Q">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_rjKlr9xslEKQYUBoK56meQ">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_uNE-6fZNr0a3EQtzLYKboA_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_2buloiEbxkKlm0vuKHlJ7A_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13523000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_1rU6YwLdbkijnwDVDsIFdQ_5_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1273000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_93MWJY9bs0CfdrfUfRY8AQ_5_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2265000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_DLnoBYNZFkGPUF5713aywA_6_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">744000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_c-7_Qk0oaUuKZAwGtR-LDw_6_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3363000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_yUHkfavdJ0mev1jqUkcQlA_7_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">11308000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_GdY1JLGyYkyeXxdxfYkMjw_7_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">19151000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_bxpwyAw97kS5xzakNz8WJg_8_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5480000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_It-45b0AF0WQ2lXv-jZSFg_8_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5720000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_YfNq_Q7W9Uyuvxqqo8-Rng_9_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13241000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_Ht8jbSmvAUefyi32MdnJNg_9_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">12559000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_Rk918iIdfU-RUMRmXcf3mw_10_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">41687000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_H5JRIOPzq0CQNmp-tBVoqg_10_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">44717000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_0P_CpLCE302_mvIJuGAymg_11_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">10256000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_kbFB47kBUUCqGPC1ZKh3Qg_11_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">10256000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_snSMwtq9VkiGfNGWO_UM5g_12_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3490000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_PcU0AMz0BEatJtpTMto1-w_12_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3490000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_fZ69DiJ7iESDfCrmwdJqCw_13_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">975000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_Qg_3U6ZxSUqMyADTYZ7WSA_13_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2470000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_KR0KBFMmMkWDtHUXKul7MQ_14_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">86437000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_POyTW_sEG0mlz748ibGWCA_14_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">98363000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_gd8kZiqtH0mmX3dR1SSV3A_18_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2055000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_H-HqbJbqlUaEKrDY4idchA_18_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5689000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_L-iXJTHBwUy-lUvmrgXT7A_19_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2280000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_GhDTCFfrAk6SfcG1iFFIPw_19_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">768000</us-gaap:DeferredCompensationLiabilityCurrent>
    <armp:LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_ddOONvr7VUi1_hKZ946BCQ_20_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">38954000</armp:LongTermDebtCurrentMaturitiesOtherThanConvertibleDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_s9iDHwiua020VI3C55CjJQ_21_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4431000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_Z1tu6U-mpUisZ4U5qLD3tw_21_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9481000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_xEZm9yZgQkCOe9pQLRZ0CA_22_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">529000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_4K0U2btCoU-2YKwLgBjw4A_22_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">523000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_FtVk1Gk25EuauOlJrvIDRA_23_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">48249000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_T6BVYImejUOVl33crgD2pQ_23_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">16461000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_E1XwfXdtdEW7xFslQVu5kg_24_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">32897000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_WFi0DW_D_UGHgNI0AOsrYg_24_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">58633000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_26Vjq0qf2k65s0XEml7a8g_25_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">22539000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_y-vrwM_TIEiD4byLtVathA_25_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">23674000</us-gaap:SecuredLongTermDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_rTxS1a8XgU68baZM8N5miw_26_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">27694000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_XCnAcRhoh0evYOetcF7HBQ_26_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">28583000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_EvmLTnr6gUybCLAhGm4Xvw_27_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3077000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_eGb-xqnS2UK9nGUXZy5a4Q_27_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3077000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_tDvG7uhRT0iXHYgp_1qEag_28_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">134456000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_Io6z7aWZZEilhquab2Qolg_28_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">130428000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Narr_GbK_OcWVfki6mBr-34sTDA"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Narr_gDOjAM7mQ02qS4WR91XBOg"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Narr_0dn6E5qmKUSs-bCVvX50Tw"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">217000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Narr_InAuXq19zUmAV3v0ppabHA"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">217000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Narr_HRduUbCwC0SPPfF7REUxNQ"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36183067</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Narr_E_SKvkeAtUmH-OpXLYv9qA"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36183067</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Narr_7sWDUDoutUm6iaBDlbMCcA"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36122932</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Narr_fE6zOwE5uUajM3R6Pd6BSg"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36122932</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_GZ5eyJ92aUy9F4aMZUlvtw_32_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">362000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_sq1qL0QogkiVK7FElpV_qg_32_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">361000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_9iRH3SRMUki0buWWV7FVrw_33_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">279354000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_JJgpPCu_K0eIz46on_dprQ_33_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">276393000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_K5Z9_G-6yUSKSOQPYGhYYw_34_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-327735000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_z5LlBUxp4EaagKGYEId6Uw_34_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-308819000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_QsqDGWnNdkudKxU7WHeidA_35_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-48019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_Fdl-saGMlEWS0MuTHnqetg_35_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-32065000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_0POonvvd50e1GoshoXCrWw_36_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">86437000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_VmJUFKtVkUSUfnqe4d7C0Q_36_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">98363000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_23SNBLt6CUeoo8axPU-rUQ_3_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5174000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_LUy9S44AX0WL5CopciqGfg_3_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4529000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_yFW8iOWes0Kf-yE8-qlxrQ_5_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">34426000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_X0Gec4jOmkW-1WIuZlzhRg_5_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">33770000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_dpqZrKjvKk6kpcDSE-zCnA_6_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13184000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_ZFZDbseJUUe7-dGBl48tXg_6_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">11649000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_SPpVa6ZMDkSuIOLzhB89gA_7_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">47610000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_hgOh7qTMf0KYNJeYV5_brQ_7_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">45419000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_3sCSN8XmV0K0uanuS9fQ-w_8_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-42436000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_aVZ8Twi00EaYhjYYFe6BHg_8_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-40890000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_ialMmFXzbU62AvMLE9Q--g_10_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">697000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_ywwe4kyx10C0bQXMI-wr8A_10_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">179000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_msbOZ3trN0CoF0_F0xvYSw_11_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">10742000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_ccTtdmpoJ0CKS3gTCd4E6Q_11_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2626000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_xQSZOW5iwE-LA8QRYsi1QA_12_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">31399000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_WPuf5PkR00uj08kBfcjIiQ_12_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-21845000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_t_DaX1jdu0SYni7ACDw8Ig_13_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2166000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_7fD85Kl1QkOiW__WtPcTJA_13_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-3863000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_hgUd76FKvki6DcT5G44Dzw_14_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">23520000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_C__CIlKyp0W-8ZLva7DKYQ_14_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-28155000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_YWbwpLM8D02iBRfBpNuvtQ_15_4"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-18916000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_Ik0ejmwKQ0-DSuK6ysM3rw_15_7"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-69045000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="2"
      id="Tc_YAlHXrJzN0KO-89yHdCvow_17_4"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="2"
      id="Tc_LPK8Jo4sbEa73PqBPZtFag_17_7"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">-1.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="0"
      id="Tc_3LlDBMbClUyfnMd4JxX74Q_18_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36160848</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="0"
      id="Tc_0T4zsflxYEmCAI96gfGktg_18_7"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36075555</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="2"
      id="Tc_9RH1oq9z_0ayZGJelB1O2g_19_4"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="2"
      id="Tc_ZyJpal1fh0GzopsPsuzzgw_19_7"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="0"
      id="Tc_rHXsH7fOlUqwpBYT_siuNw_20_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">59059971</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="0"
      id="Tc_cg85Bt8JS0aANxLhZeyVeg_20_7"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36075555</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WYP4LOLiVE2vVMYho8f0Pw"
      decimals="INF"
      id="Tc_xfiH2Ci5kESTpyIDdcPlLg_6_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36144706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WYP4LOLiVE2vVMYho8f0Pw"
      decimals="-3"
      id="Tc_Fnw8TZMPLUuC9PQbAtn6lA_6_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1Rw3csLgjECALBKYfsINwQ"
      decimals="-3"
      id="Tc_x-frj5Oa4EmB0IHhOksKnw_6_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">275493000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_z3NSngTeFUqo0EjEQOAFlg"
      decimals="-3"
      id="Tc_s8_X0pBZF0yXI5xxWLhs6w_6_11"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-239774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_igNvzFb5yESqV8OvL7Pg4Q"
      decimals="-3"
      id="Tc_vopHpzELrUKGk7pCMWnLLg_6_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">36080000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA"
      decimals="INF"
      id="Tc_N_UGmQ-4jEeEfzqnXYK8jg_7_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">27341</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA"
      decimals="INF"
      id="Tc_T_w_qEnUY0K4F3XBW79mWw_8_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">25933</armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_elsHS6ydWEONtGpKI5VfjQ"
      decimals="-3"
      id="Tc_Sqyrr6c-XkmffjHXxoLMlg_8_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">43000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_X3jT-ve2BUqBDMO9WVDsBw_8_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">43000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA"
      decimals="INF"
      id="Tc_Z-bcGeHDo0-b1_Vjaxg_Ow_9_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">1500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_elsHS6ydWEONtGpKI5VfjQ"
      decimals="-3"
      id="Tc_mdhJV9lc50KulNV6l461Fw_9_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_FHUzhedVUE-OEKPw_6JBfQ_9_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LiIDeeTCiECH3cIi5NjqdA"
      decimals="INF"
      id="Tc_oVaGM1hobU-UGtdtS9uR0w_10_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">30000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_elsHS6ydWEONtGpKI5VfjQ"
      decimals="-3"
      id="Tc_ZerCulkECU23uELZasQi4Q_11_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_a50PjXm-zEa5TfHm6Rww4Q_11_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b2xRzt0_BUqhKZ6JbrdY4w"
      decimals="-3"
      id="Tc_qsMd3uNWn02vizrvDpJyzA_12_11"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-69045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_FANVLm7Svk-J8ZYHXVSgYg_12_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-69045000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg"
      decimals="INF"
      id="Tc_JulQmXm4JEuQP5Oci_0CAA_13_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36122932</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg"
      decimals="-3"
      id="Tc_sJquoUbKNEGg5GmV-Xebyw_13_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TdUVPQRZ90GLDTkGnv6akw"
      decimals="-3"
      id="Tc_ayYgZONvCEeGgcSyl6aJZQ_13_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">276393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lRVURMKV0SoOkMJkefoHQ"
      decimals="-3"
      id="Tc_ShGmGvxDFEGsK6CGDltS1A_13_11"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-308819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_4ZAvMCoc5EK5i3Xm1CUeJg_13_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-32065000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg"
      decimals="INF"
      id="Tc_tBG-I2r8fUGH0g0_bmOcqQ_21_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36122932</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ymo2aZT_qUGh4fbWbiURCg"
      decimals="-3"
      id="Tc_SJTozgl9WEW9b_PDSbMoLg_21_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TdUVPQRZ90GLDTkGnv6akw"
      decimals="-3"
      id="Tc_X-dh2InPV0KDihVabrlBYw_21_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">276393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0lRVURMKV0SoOkMJkefoHQ"
      decimals="-3"
      id="Tc_iOawaIk2EU68cuwk1gKjYg_21_11"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-308819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_PqXUH1V6Uke8CE6Bw6r5fA_21_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-32065000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ"
      decimals="INF"
      id="Tc_PKEYLcvRMkquhwYjADfTTQ_22_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">37282</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ"
      decimals="-3"
      id="Tc_M7lI9ipe70OAxCsBHMswzA_22_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tiRew-3WXUazY4UJ_rsE2g"
      decimals="-3"
      id="Tc_0aMd9TMYtE-zNC17BU--PQ_22_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">129000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_wQ1NXompek6omJF1RTdRkw_22_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">130000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ"
      decimals="INF"
      id="Tc_fwwjxMSfkUqNvsHLYEl61Q_23_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">4222</armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zgKTtYxUMUuSRB9JI6oBuQ"
      decimals="INF"
      id="Tc_QRVa4-JEkkmwR6ahX1obEg_24_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">27075</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tiRew-3WXUazY4UJ_rsE2g"
      decimals="-3"
      id="Tc_o1jKrgK9cEC1ItdyEsutJA_24_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-61000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_8afPbFE7vEaGUqzYZ5DoVA_24_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-61000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tiRew-3WXUazY4UJ_rsE2g"
      decimals="-3"
      id="Tc_86WwXkpl7kCBrcfEvV2m0Q_25_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_INzCq3pCO0ew3Zg_czjTiQ_25_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_12iaGKNXCkqYkhajskEVlw"
      decimals="-3"
      id="Tc_zhMO3VsjjECuKNACTLmFYA_26_11"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-18916000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_rmvSYn4V90iARR6otgudqw_26_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-18916000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EqQhMtDQN0uq2op06-vOIg"
      decimals="INF"
      id="Tc_8mvo_f_v10mKnWzrwFxRMw_27_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36183067</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EqQhMtDQN0uq2op06-vOIg"
      decimals="-3"
      id="Tc_bZQ2y_8wJ0yBT6o2GYc2Uw_27_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K4ieWmLnSUyd7TzJckLcIw"
      decimals="-3"
      id="Tc_TuEVfyIEBEKkoIHmHBvPrA_27_8"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">279354000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_reOzmK0NOUyOz-GslMRWRg"
      decimals="-3"
      id="Tc_b3YM1yPwFEutafMhaAF3SQ_27_11"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-327735000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_NdOkFbO2-UaElA0F8DQu0g_27_14"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-48019000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_uOmIQ9VHK0WZRcPz4eLztA_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-18916000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_it_2XUtsi0W77t6HOyJWeQ_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-69045000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_vZuY1vhlgky1UopMyYli4A_6_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1325000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_Pe17rpNuxkKnjlH5VNciNQ_6_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">972000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_RprNRKijUEK-cE4oqMYz0Q_7_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2893000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_bseq1nlKIUaCdtJBTBP2Jg_7_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">938000</us-gaap:ShareBasedCompensation>
    <armp:IncreaseDecreaseFairValueOfLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_GlPE6RP2Fk-09PZNh0sKoA_8_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-31399000</armp:IncreaseDecreaseFairValueOfLiabilities>
    <armp:IncreaseDecreaseFairValueOfLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_dtdlB0ns2kCdA2TfscE8rw_8_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">21845000</armp:IncreaseDecreaseFairValueOfLiabilities>
    <us-gaap:OtherNoncashExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_giXAatDfIk6vuvjCL2kc8Q_9_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">10758000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_FnzezyXUh0KUDFPlAcmCWw_9_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2573000</us-gaap:OtherNoncashExpense>
    <armp:NoncashInterestIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_iAWRsMi-x02UJESJGbbKPQ_10_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">22000</armp:NoncashInterestIncome>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_5bgI7yR_UESDyhO0bV8HYQ_11_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2166000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_nkdT8p1rxkOnzJjRRM7EJw_11_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-3863000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <armp:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_d4bxSp6170aco9HtnRQHLQ_12_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-2053000</armp:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <armp:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_-S2mcBW1PkCvdPnkaDqOUA_12_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-1018000</armp:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_VrNWjPzBFUGLyqTOt-717A_13_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-81000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_ytcDpncspUmCzKwPz2wpeA_15_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-5106000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_K5nGZGS3Gke2hh7CW_f-xg_15_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-4826000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_tDdqcbHVzEagd9Sis4RVgw_16_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-3755000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_PYovc8xlGkOyjTqBmawJ6g_16_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">39000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_BYvLnfHyj0yjQ8GlwsWbyw_17_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1512000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_SS2NVaqv-0Cbc62vYwQi5g_17_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-1060000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_RznLkvgVUUit0B0kOOTr_Q_18_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-4962000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_Kcz5y-njsEybB_WqNG0ECg_18_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-13451000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_2XIjBdTNfU2AcN3m2t_iyQ_19_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-37551000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_C4_XM2bBlEC63epmhDFlIw_19_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-47423000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_ZxavjJVL5EaJmwv-6Bh6bw_21_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1879000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_wkatwIVi50S66U3mvXqjaQ_21_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">8144000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_Zzi3MYTKxk-nuxTl--sDwA_22_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">10000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_XOUSzK6a70quK0DyTwRGyQ_23_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-1879000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_Y48Qd4GQU0KodFEScxzT6Q_23_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-8134000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_Y_d63G3etEmREtvVdLCSzQ_25_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">29101000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_x_JsVUliuU2eVuun2iL89g_26_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">34889000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_7zJMj4CdCUuW2o6VkTIeEQ_26_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">24925000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_8CPv7dAoAECwaVh0RIczqg_27_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">61000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_uWaTg3LWZkmzcYzuslwwCg_27_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">43000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <armp:ProceedsFromExerciseOfWarrantsAndStockOptions
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_xj20aZa89USOyahNIWKP4w_28_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">130000</armp:ProceedsFromExerciseOfWarrantsAndStockOptions>
    <armp:ProceedsFromExerciseOfWarrantsAndStockOptions
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_M5LOrAsEz0ykO4kRAcwbUA_28_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5000</armp:ProceedsFromExerciseOfWarrantsAndStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_Ad2t3jkCxk-RlNrLtdPblA_29_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">34958000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_OWpCCrs6UEOv_GbZmDB9lg_29_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">53988000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_RbzKjE3uOU2fyEaZJvICfg_30_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-4472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_fHQgEuvnykeFIYRmEyFoVg_30_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-1569000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_DoJ4FwKME028benGiDG8HA_31_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">19243000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_igNvzFb5yESqV8OvL7Pg4Q"
      decimals="-3"
      id="Tc_ajLyakZ3PE-xiD4yjfiT-w_31_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">20812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_bgc5UxLFbEOgGQJhlg6PGw_32_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">14771000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_3VBfkJk4NEqSXxZiZ0ce5w_32_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">19243000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_8X7yugqphU-ls_nLBqEi4A_34_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">977000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_x16xnS-BZkid1MP5EXR3ZQ_34_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ContributionOfProperty
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_1OIkMegUMkukS7XhlQT7hw_35_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">89000</us-gaap:ContributionOfProperty>
    <us-gaap:ContributionOfProperty
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_PQuDsmDzVEG88tQAfGWIpA_35_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">217000</us-gaap:ContributionOfProperty>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_JrhEhp58Okav-d3Pf5z86w_3_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_PUgw_QiDjkijTLwCzBp_Sw_3_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13523000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_PoowoKDiq0OM7q4WTXxNeg_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5480000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_Nhs5nczoNku8CdDldSjnXw_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5720000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_UZtWWfRzYkKlXi4kukoxpA_5_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">14771000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_5ffbFeJpsEiUdxq_vrYrjQ_5_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">19243000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_mWF1A-DrNkSM0zJkJrUg-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Organization and Description of the Business &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Armata Pharmaceuticals,&#160;Inc. (&#x201c;Armata&#x201d;) together with its subsidiaries (the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company focused on &lt;/span&gt;the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;Armata&#x2019;s common stock, par value $0.01 per share (the &#x201c;Common Stock&#x201d;) is traded on the NYSE American exchange under the ticker symbol &#x201c;ARMP&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s principal stockholder, &lt;span style="font-family:'Times New Roman;"&gt;Innoviva Strategic Opportunities LLC (&#x201c;Innoviva SO&#x201d;), a wholly owned subsidiary of &lt;/span&gt;Innoviva Inc. (&#x201c;Innoviva&#x201d;), owns 69.3% of the Company&#x2019;s outstanding equity as of December 31, 2024. The Company also received $90.0 million in total debt financing from &lt;span style="font-family:'Times New Roman;"&gt;Innoviva SO&lt;/span&gt; during 2023 and in March 2024. Innoviva designees represent three out of eight seats of the Company&#x2019;s Board of Directors (&#x201c;Board of Directors&#x201d;) during the year ended December 31, 2024, and cannot vote or take any action by written consent with respect to any shares of Common Stock held by Innoviva SO that represent, in the aggregate, more than 49.5% of the total number of shares of the Company&#x2019;s Common Stock for voting on the matters related to election or removal of the Company&#x2019;s board members or amending the bylaws of the Company to reduce the maximum number of directors or setting the number of directors who may serve on the Company&#x2019;s Board of Directors in accordance with the voting agreement. The voting agreement expires on the earlier of the fifth anniversary of the agreement&#x2019;s effective date, January 26, 2021, or the approval by the Food and Drug Administration (the &#x201c;FDA&#x201d;) of any of the Company&#x2019;s product candidates for marketing and commercial distribution. Innoviva SO and Innoviva are related parties of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Narr_KbDBEU6QS0iVowraeOUI_A"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_OwnershipAxis_armp_ArmataPharmaceuticalsIncMember_Gv-ymKjfckGEyekgNJZuSg"
      decimals="3"
      id="Narr_mstPferhKES9qScFc6qXMA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.693</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_D0CIVBrcHkCADcgqae2kVQ"
      decimals="-5"
      id="Narr_hhGmNFBdOUmo6mnW1SrJeA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">90000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_iIfGtoSfVkOyLJgO8EHWrQ"
      decimals="-5"
      id="Narr_z9rLSyGCIES6PKqLXQ20Pw"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">90000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <armp:NumberOfDirectors
      contextRef="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_PYldRmX4ZUyocSelgjrlsg"
      decimals="INF"
      id="Narr_Fmw7QvaDHki3Z7AkaVeA7A"
      unitRef="Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA">3</armp:NumberOfDirectors>
    <armp:NumberOfBoardDirectors
      contextRef="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_PYldRmX4ZUyocSelgjrlsg"
      decimals="INF"
      id="Narr_WHeKZD8R2UGmlSFJekMOuA"
      unitRef="Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA">8</armp:NumberOfBoardDirectors>
    <armp:CommonStockVotingPercentageHeldPercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_RangeAxis_srt_MinimumMember_1gX74jz0bEaW8OFMI4iC9A"
      decimals="3"
      id="Narr_U4vOUBcQgE2OjjIfsntk5A"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.495</armp:CommonStockVotingPercentageHeldPercentage>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_2C971qu-40WGXv2lX5V6gQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Liquidity and Going Concern&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company has incurred significant operating losses since inception and has primarily relied on equity, debt and grant financing to fund its operations. As of December 31, 2024, the Company had an accumulated deficit of $327.7 million. The Company expects to continue to incur substantial losses, and its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until then, the Company will need to continue to raise additional capital. The existing cash and cash equivalents of $9.3 million as of December 31, 2024 will not be sufficient to fund its operations for the next 12 months from the date of these consolidated financial statements. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recent Financing:&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;i style="font-family:'Times New Roman;font-style:italic;"&gt;2025 Credit Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On March 12, 2025, the Company entered into a credit and security agreement (the &#x201c;2025 Credit Agreement&#x201d;) for a loan in an aggregate amount of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million (the &#x201c;2025 Loan&#x201d;) with &lt;/span&gt;Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA), our principal stockholder and a related party (collectively, &#x201c;Innoviva&#x201d;).&lt;span style="background:#ffffff;"&gt; The 2025 Loan bears interest at an annual rate of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;14.0%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and matures on March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2025 Loan is guaranteed by the Company&#x2019;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Concurrently with the execution of the 2025 Credit Agreement, the Company entered into amendments to (i) its existing convertible loan (the &#x201c;Convertible Loan&#x201d;) and secured credit and security agreement, dated January 10, 2023, with Innoviva (the &#x201c;Convertible Credit Agreement&#x201d;), (ii) its existing secured term loan facility (the &#x201c;2023 Loan&#x201d;) and credit and security agreement, dated July 10, 2023, with Innoviva (the &#x201c;2023 Credit Agreement&#x201d;) and (iii) its existing secured term loan facility (the &#x201c;2024 Loan&#x201d;) and credit and security agreement, dated March 4, 2024, with Innoviva (the &#x201c;2024 Credit Agreement&#x201d;), which, among other things, extended the maturity date of each loan to March 12, 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman;font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;i style="font-family:'Times New Roman;font-style:italic;"&gt;2024 Credit Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman;"&gt;On March 4, 2024, the Company entered into 2024 Credit Agreement for the 2024 Loan in an aggregate amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt;$35.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt; million. The 2024 Loan bears interest at an annual rate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt;14.0%&lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt; and was scheduled to mature on June 4, 2025. On March 12, 2025, the Company executed an amendment to the 2024 Credit Agreement which, among other things, extended the 2024 Loan maturity date to March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2024 Loan is guaranteed by the Company&#x2019;s domestic subsidiaries, and the loan is secured by substantially all of the assets &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;of the Company and the subsidiary guarantors&lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt;. &lt;/span&gt;Concurrently with the execution of the 2024 Credit Agreement, the Company amended certain provisions of the Convertible Loan and Convertible Credit Agreement and the 2023 Loan and 2023 Credit Agreement to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While the Company believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#x2019;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#x2019;s ability to achieve the development and commercialization goals would be adversely affected.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-5"
      id="Narr_rx2nVmuea0SIXrcx0TXIQA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-327700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-5"
      id="Narr_cVeKpQYEP0qmJh02jFUqvg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw"
      decimals="-5"
      id="Narr_lYPylZYIdk2wIBi0hqVZ8w"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw"
      decimals="3"
      id="Narr_KX7OiUvC30Ov6USjYARRmA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_OTR9ruU8jEO4DamnlHKFLQ"
      decimals="-5"
      id="Narr_D9m8yVEZAUeEYYbPfj4lvg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_OTR9ruU8jEO4DamnlHKFLQ"
      decimals="3"
      id="Narr_hxQNmul3CEW3W2TQ0lqiiw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_73dDRKYfj0eJ7fNKu7_Dpg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the Convertible Loan, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;"&gt;Concentration of Credit Risks and Certain Other Risks&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and restricted cash. As of December 31, 2024 and 2023, cash, cash equivalents and restricted cash were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions in accordance with the Company&#x2019;s investment policy, to a concentration limit per issuer or sector.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Other receivables represent amounts due from the Medical Technology Enterprise Consortium (&#x201c;MTEC&#x201d;) (Note 13, &#x201c;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Grants and Awards&#x201d;&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;) and reimbursement for tenant improvements (Note 12, &#x201c;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Commitments and Contingencies&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.26;margin:8pt 0pt 4pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Cash and cash equivalents consist primarily of cash deposits and marketable securities with original maturities of less than three months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of two irrevocable letters of credit with financial institutions related to the Company&#x2019;s operating leases (Note 12 , &#x201c;&lt;i style="font-style:italic;"&gt;Commitments and Contingencies&lt;/i&gt;&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;"&gt; Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, Convertible Loan and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The Convertible Loan is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#212529;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5 &#x2013; 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3 &#x2013; 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-Eh2dCRyZEObk0oB6hPNcg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. No impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2024 or 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; IPR&amp;amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#x2019;s IPR&amp;amp;D assets represent capitalized in-process bacteriophage development programs for &lt;/span&gt;&lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company tests IPR&amp;amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If and when a quantitative analysis of IPR&amp;amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#x2019;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#x2019;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2024, the Company performed the annual evaluation of its IPR&amp;amp;D assets for impairment. The Company considered the development timelines for its &lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; development program and noted no qualitative factors that would indicate potential impairment of its IPR&amp;amp;D asset. The Company also performed a quantitative analysis for impairment analysis and based on this analysis, the fair value of this bacteriophage program was greater than its carrying value as of December&#160;31, 2024. Consequently, no impairment was noted for the IPR&amp;amp;D asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company performed the annual evaluation of its IPR&amp;amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for &lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; infections was greater than its carrying value as a result of the quantitative analysis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;No impairment loss was recognized as of December 31, 2024 and 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#x2019;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted no impairment as of December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"&gt;All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#x2019;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) is determined based on the number of units granted and the closing price of the Company&#x2019;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Foreign Currency Translations and Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. &lt;span style="background:#ffffff;"&gt;Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the quarterly average exchange rate in effect during the &lt;/span&gt;year.&#160;&lt;span style="background:#ffffff;"&gt;Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#x2019;s consolidated statement of operations. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Grants Revenue and Other Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines whether agreements are within the scope of ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from contracts with customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;) or other topics at the effective date of an agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;&lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt;&#160;(&#x201c;ASC 808&#x201d;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;&lt;i style="font-style:italic;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt;, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also considers the guidance in ASC Topic 730,&#160;&lt;i style="font-style:italic;"&gt;Research and Development&#160;&lt;/i&gt;(&#x201c;ASC 730&#x201d;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability&lt;i style="font-style:italic;"&gt;.&#160;&lt;/i&gt;If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024 and 2023, the Company recognized as other receivables in its consolidated balance sheets $0.7 million and $1.5 million, respectively, related to invoiced grant amounts that have not been received. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Company&#x2019;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Comprehensive Income (Loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2024 and 2023, as such, the comprehensive income (loss) for these periods was equal to the net loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;"&gt;Basic and Diluted Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. &lt;/span&gt;Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.&lt;span style="background:#ffffff;"&gt; The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. This ASU requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 standard in the fourth quarter of 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. Refer to Note 15.&#160;&#x201c;&lt;i style="font-style:italic;"&gt;Segment Reporting&#x201d;&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"&gt;&lt;span style="color:#212529;margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;In August 2020, the FASB issued ASU 2020-06, Debt - &lt;/span&gt;&lt;i style="color:#212529;font-style:italic;background:#ffffff;"&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;&lt;span style="color:#212529;background:#ffffff;"&gt; (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted earnings (loss) per share (&#x201c;EPS&#x201d;) computation. The Company adopted this ASU as of January 1, 2024, which did not have an impact on its consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;On October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/i&gt;. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#x2019;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt;. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In November 2024, the FASB issued Accounting Standards Update ASU 2024-03 Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40):&lt;i style="font-style:italic;"&gt; Disaggregation of Income Statement Expenses&lt;/i&gt;. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#x2019;s consolidated financial statement disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_3syA4nLi7kOmuERMdUYM-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb__NNC4scwB0i4wYh-HRadwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the Convertible Loan, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_PpmQ_b6b-Ey8XRfTK0eZhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;"&gt;Concentration of Credit Risks and Certain Other Risks&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and restricted cash. As of December 31, 2024 and 2023, cash, cash equivalents and restricted cash were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions in accordance with the Company&#x2019;s investment policy, to a concentration limit per issuer or sector.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Other receivables represent amounts due from the Medical Technology Enterprise Consortium (&#x201c;MTEC&#x201d;) (Note 13, &#x201c;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Grants and Awards&#x201d;&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;) and reimbursement for tenant improvements (Note 12, &#x201c;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Commitments and Contingencies&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_jS-no4uuCE6y0lnKBkeseQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.26;margin:8pt 0pt 4pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Cash and cash equivalents consist primarily of cash deposits and marketable securities with original maturities of less than three months.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_8XmdtIqJ3E6MmRdsvC0j_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of two irrevocable letters of credit with financial institutions related to the Company&#x2019;s operating leases (Note 12 , &#x201c;&lt;i style="font-style:italic;"&gt;Commitments and Contingencies&lt;/i&gt;&#x201d;).&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <armp:NumberOfStandbyLettersOfCreditIncludedInRestrictedCash
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="INF"
      id="Narr_VH07Zbc4eUK67CUSNJRhqw"
      unitRef="Unit_Standard_item_DGQw351nRE-jSkR8ZsTCdA">2</armp:NumberOfStandbyLettersOfCreditIncludedInRestrictedCash>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_EA4KB_P64E2ucdw4PN-vjw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;"&gt; Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, Convertible Loan and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The Convertible Loan is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_V77-QbhZ7UyUssurGFK8pg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#212529;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5 &#x2013; 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3 &#x2013; 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-Eh2dCRyZEObk0oB6hPNcg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <armp:PropertyAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_o5MnEQxmhEesk1-KMGcBEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5 &#x2013; 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3 &#x2013; 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-Eh2dCRyZEObk0oB6hPNcg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</armp:PropertyAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_F1-n7zRE20q0EmkRbZO3CQ"
      id="Narr_iU2_T22x8E-diuwgoXEJeg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_TwxvP62zB0uMlwhQkUWi8Q"
      id="Narr_-PL6QDjV_UyNJX8MzTvjDQ">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_X0p3Xo14WU6gPCeyKpTmXw"
      id="Narr_CQiNFq5bH0OSZCfb9kWPMg">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_aDlY3wA3nk6hKsCmJ4oMww"
      id="Narr_h8q9wpzjh0qz60_yuCY7JQ">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_meAx8huZJEaCm8oGr4yq7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. No impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2024 or 2023. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Narr_oCvar4YJvUCTOt4pmJZ7wQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Narr_a3CKkILAkEmt7RtIgd6Iww"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_FzLFKj0VkEmbgvQeJEyqCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; IPR&amp;amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#x2019;s IPR&amp;amp;D assets represent capitalized in-process bacteriophage development programs for &lt;/span&gt;&lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company tests IPR&amp;amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If and when a quantitative analysis of IPR&amp;amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#x2019;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#x2019;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2024, the Company performed the annual evaluation of its IPR&amp;amp;D assets for impairment. The Company considered the development timelines for its &lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; development program and noted no qualitative factors that would indicate potential impairment of its IPR&amp;amp;D asset. The Company also performed a quantitative analysis for impairment analysis and based on this analysis, the fair value of this bacteriophage program was greater than its carrying value as of December&#160;31, 2024. Consequently, no impairment was noted for the IPR&amp;amp;D asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company performed the annual evaluation of its IPR&amp;amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for &lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; infections was greater than its carrying value as a result of the quantitative analysis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;No impairment loss was recognized as of December 31, 2024 and 2023. &lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Narr_PXOuOiYgsUmYg6axx7PALQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Narr_DxkDzoNbZ0aXoWNPRSP78A"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Narr_IdolUCzqv0mcYv1a3Qp1pA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_o2QaYenm6EGGuGu7IkRaeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#x2019;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted no impairment as of December 31, 2024 and 2023.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Narr_QZ4b3TjtRkecBeMFGNkj0g"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Narr_MLjo-DE4M0KdsylMFc1DuQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_9voQTVd-40CRU6U8MWpWJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"&gt;All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_NAhOMa5C6UWSNcHYZbVhYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#x2019;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) is determined based on the number of units granted and the closing price of the Company&#x2019;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_EV9_41WHdEiLxB1shMzm7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Foreign Currency Translations and Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. &lt;span style="background:#ffffff;"&gt;Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the quarterly average exchange rate in effect during the &lt;/span&gt;year.&#160;&lt;span style="background:#ffffff;"&gt;Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#x2019;s consolidated statement of operations. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <armp:GrantsAndAwardsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_YplmNsdWtkG01FRNTKwxrQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Grants Revenue and Other Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines whether agreements are within the scope of ASC Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from contracts with customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;) or other topics at the effective date of an agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;&lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt;&#160;(&#x201c;ASC 808&#x201d;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;&lt;i style="font-style:italic;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt;, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also considers the guidance in ASC Topic 730,&#160;&lt;i style="font-style:italic;"&gt;Research and Development&#160;&lt;/i&gt;(&#x201c;ASC 730&#x201d;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability&lt;i style="font-style:italic;"&gt;.&#160;&lt;/i&gt;If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024 and 2023, the Company recognized as other receivables in its consolidated balance sheets $0.7 million and $1.5 million, respectively, related to invoiced grant amounts that have not been received. &lt;/p&gt;</armp:GrantsAndAwardsPolicyTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_qx3dYJjAE0ynK7mpFACMVg"
      decimals="-5"
      id="Narr_7zqKjX0jKU2N5L_OVyXapg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">700000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_CQpyd18Ds0qh3m21NnuflA"
      decimals="-5"
      id="Narr_Swv3vtn1OEqNsMhVHvqpGA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_Qdp-TOMRJUKpKeiaCd0ARw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Company&#x2019;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_OXNcvOE-TkKHfaqWJcdi9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_Eb_a6rzslUOwDGM-XmgiQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Comprehensive Income (Loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2024 and 2023, as such, the comprehensive income (loss) for these periods was equal to the net loss. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_Wo2J8a2qB0ql788PZa9ndw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;"&gt;Basic and Diluted Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. &lt;/span&gt;Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.&lt;span style="background:#ffffff;"&gt; The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_qSIlyvhhGEWNFqz3-jUYRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. This ASU requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 standard in the fourth quarter of 2024 for annual and retrospective reporting periods with all interim disclosures to begin in the first quarter of fiscal year 2025. Refer to Note 15.&#160;&#x201c;&lt;i style="font-style:italic;"&gt;Segment Reporting&#x201d;&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"&gt;&lt;span style="color:#212529;margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;In August 2020, the FASB issued ASU 2020-06, Debt - &lt;/span&gt;&lt;i style="color:#212529;font-style:italic;background:#ffffff;"&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/i&gt;&lt;span style="color:#212529;background:#ffffff;"&gt; (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted earnings (loss) per share (&#x201c;EPS&#x201d;) computation. The Company adopted this ASU as of January 1, 2024, which did not have an impact on its consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 7.2pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;On October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/i&gt;. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#x2019;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt;. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In November 2024, the FASB issued Accounting Standards Update ASU 2024-03 Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40):&lt;i style="font-style:italic;"&gt; Disaggregation of Income Statement Expenses&lt;/i&gt;. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation, amortization and depletion expenses for each caption on the income statement where such expenses are included. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on the Company&#x2019;s consolidated financial statement disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_FNOApKF7aUq95Id6VLOgHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.27;padding-top:12pt;margin:0pt 0pt 4pt 0pt;"&gt;4. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 1:&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 2:&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 3:&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Investments in money market fund &#x2013; financial assets, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible Loan&#x2013; financial liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 32,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 32,897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible Loan&#x2013; financial liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;The Company&#x2019;s Convertible Loan (Note 7) is measured at fair value and remeasured at each measurement period, with changes in fair value recorded as other income (expense) in the consolidated statement of operations. The Company estimates the fair value of its Convertible Loan using a weighted probability model of various debt settlement scenarios during its term discounted to the reporting date. Conversion option scenarios are valued using option pricing models with assumptions and estimates such as volatility, expected term and risk-free interest rates. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;"&gt;Level 3 fair value inputs include probability and timing of various settlement scenarios and selection of comparable companies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of its Convertible Loan using the following inputs for the years ended December 31, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;15.67%-28.28%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;21.01%-45.88%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Probabilities of settlement scenarios&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%-75%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%-85%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;83.30%-111.60%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;101.1%-123.6%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.10-1.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.20-1.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;4.08%-5.33%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;4.62%-5.39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents a summary of the changes in the fair value of its Convertible Loan for the years ended December 31, 2024 and 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible Loan at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net issuance of the Convertible Loan &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Initial recognition of modified Convertible Loan &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,399)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amount exchanged &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,332)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_xUrXavuJzEKCYO2cJuMBNA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Loss on the Convertible Loan extinguishment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible Loan at the end of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 32,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:justify;margin:0pt 3pt 0pt 0pt;"&gt;(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the detemination of fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7 , &#x201c;&lt;i style="font-style:italic;"&gt;Convertible Loan&#x201d;&lt;/i&gt;).&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_6mr_Ti1z0EG99i93Mm9VCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Investments in money market fund &#x2013; financial assets, included in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible Loan&#x2013; financial liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 32,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 32,897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:49.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:50.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible Loan&#x2013; financial liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_9qcZEDh_skaFm0Zlm2Fc-A_3_2"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4955000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_bAIh_tiMI0Kax823zmexkA"
      decimals="-3"
      id="Tc_8UTzcPgHPUOw5eO6Er9Ibg_3_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4955000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_BTqaHOnVskewyfcS7vL8tw_4_2"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">32897000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sVGisjCvnEiEB93bLojreA"
      decimals="-3"
      id="Tc_JtKidOrxIUulmyrrILL1ag_4_11"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">32897000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_8AyBA_BJAkKOkyikGAxmAg_3_2"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">58633000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_YvPw907mK0udlp6KfJ8QZw"
      decimals="-3"
      id="Tc_1kvUidEXF0ipDCZjBwFeQg_3_11"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">58633000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_q41dpOoXzU2VY90IN7FsoQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;15.67%-28.28%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;21.01%-45.88%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Probabilities of settlement scenarios&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%-75%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%-85%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;83.30%-111.60%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;101.1%-123.6%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.10-1.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.20-1.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;4.08%-5.33%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;4.62%-5.39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N9_1XuuLQ0-lsYc-TWi-NA"
      decimals="2"
      id="Narr_wDm7rStjO0q7DqwLuzpqHA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">15.67</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_T0i7nyaWzEq2E47alJJZLg"
      decimals="2"
      id="Narr_BOGDL5aYwkCTGuCCR3m-tw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">28.28</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_p_w3bZ_ln0aJdZk7_GgZHA"
      decimals="4"
      id="Narr_vn3hnOy-kUCeOtEfREFI6A"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.2101</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_N0tx2XrUDkeZnYUXCzfq4w"
      decimals="4"
      id="Narr_roIYMrYlY0ejvy9YWcUQPA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.4588</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_UqehtnWrBEGyotCU0pk1bg"
      decimals="2"
      id="Narr_e9oUwUz0AUSp_n2y2z7clw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_pPPFgT2uxECtGLDgw4ehFA"
      decimals="2"
      id="Narr_ykbGo_NgUkq5d38RQMNLQA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.75</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_uW8GX-eYnUeHey_7S13JXw"
      decimals="2"
      id="Narr_9lKpU6_M0EOsCW2kOfS2kQ"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_8HLlfMA8zkmvRWpKnH3qMg"
      decimals="2"
      id="Narr_psFej-ZJbkKM460d56teNA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.85</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_jj6a-hSvJkuGs24AQOWWHA"
      decimals="2"
      id="Narr_vNzHZLiAkEWXb_zS6nInJg"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">83.3</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_TkXtmRTW0kmojBMn9BVCTg"
      decimals="2"
      id="Narr_VuBNLXg1tUifqEGw3YUc6Q"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">111.6</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_kRX4vihrCkaUsg38VT2Fag"
      decimals="3"
      id="Narr_OwRJvClQC0OK69lFlpv1qA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">1.011</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_37d8n_o0P0-p2FnUWFQIOA"
      decimals="3"
      id="Narr_A5VZpmJB8ESWaAtTystNNA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">1.236</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_pLXRlxUf9kGKDnBAIaplzQ"
      decimals="INF"
      id="Narr_Mv0c2-FbXkeOn4R7vbqrrg"
      unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg">0.1</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_rOsiQMIXrkabber6Gcmk5A"
      decimals="INF"
      id="Narr_mgJrcLnl-UewyyDWFJF3pg"
      unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg">1.2</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_KZNkSs3clkaJtabzbT5F9g"
      decimals="INF"
      id="Narr_tbmPZidUzk2h0yA-H1F9mQ"
      unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg">0.2</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lyiDqRxypkiQAz7M1AbxDg"
      decimals="INF"
      id="Narr_Lbq1LLYAaEioaUPcBejhbg"
      unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg">1.5</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Nx2W3bvlQUKPamjde55oCQ"
      decimals="2"
      id="Narr_ENc653q8902Ue241c9l9sw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">4.08</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_N2i004GY7UqD_LBRSb5cDQ"
      decimals="2"
      id="Narr_Wc8I06bkPUCThz82wi2b8A"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">5.33</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_AyLQnVZhREiEwFcrl82R0A"
      decimals="4"
      id="Narr_qRfO6cPUiEGcZBuo2KdFcw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.0462</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_JqCSzztJk0uu3fT9ol6LJA"
      decimals="4"
      id="Narr_zbfAlZSY0UO1mQ8EqXD8Fw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.0539</armp:DebtInstrumentMeasurementInputForPeriod>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_-ZSx2VYST0qkK2jk0WEpMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents a summary of the changes in the fair value of its Convertible Loan for the years ended December 31, 2024 and 2023 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible Loan at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net issuance of the Convertible Loan &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Initial recognition of modified Convertible Loan &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 35,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,399)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amount exchanged &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,332)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_xUrXavuJzEKCYO2cJuMBNA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Loss on the Convertible Loan extinguishment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:65.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible Loan at the end of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 32,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:justify;margin:0pt 3pt 0pt 0pt;"&gt;(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the detemination of fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7 , &#x201c;&lt;i style="font-style:italic;"&gt;Convertible Loan&#x201d;&lt;/i&gt;).&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_YvPw907mK0udlp6KfJ8QZw"
      decimals="-3"
      id="Tc_ohXqQoVOUkaXNaMSIzqiiw_2_2"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">58633000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug"
      decimals="-3"
      id="Tc_HxATO_niTk2SiOv0hJ4Hvg_3_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">29226000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug"
      decimals="-3"
      id="Tc_piKLxeBxu0Cp1AqIUFFAUQ_4_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">35031000</armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_pSgow0Qc80SpSp1cz46FaQ"
      decimals="-3"
      id="Tc_4fGjKjtspk2L-gft464lCw_5_2"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-31399000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug"
      decimals="-3"
      id="Tc_2qSU6khoGUq-LAVbZwftXQ_5_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">21845000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug"
      decimals="-3"
      id="Tc_AtEY7jxgNE-PpsYdA8H2aQ_6_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-31332000</armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_pSgow0Qc80SpSp1cz46FaQ"
      decimals="-3"
      id="Tc_WVGGA9rplkCMzWgIGuroQQ_7_2"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5663000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_1VZG7owi7k6CtboHgqoSug"
      decimals="-3"
      id="Tc_jeLGTTprJUy_Fh3SY1R2QA_7_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3863000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sVGisjCvnEiEB93bLojreA"
      decimals="-3"
      id="Tc_wv0genW8Ikepm7UVBl9wSQ_8_2"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">32897000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_YvPw907mK0udlp6KfJ8QZw"
      decimals="-3"
      id="Tc_QiDJcO426EyvgzsDjawpzQ_8_5"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">58633000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_OJYqMPfCa0ezVFSuP1jKEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The computation of basic EPS is based on the weighted-average number of the Company&#x2019;s Common Stock outstanding. The computation of diluted EPS is based on the weighted-average number of the Company&#x2019;s Common Stock outstanding and potential dilutive Common Stock. Diluted EPS is computed using the more dilutive of the treasury stock method, which reflects the potential dilution that would occur if securities or other contracts to issue Common Stock were exercised or converted to the Company&#x2019;s Common Stock. Common Stock options, warrants and unvested restricted stock units were not included in dilutive EPS as their impact would be antidilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the years ended December 31, 2024 and 2023 (in thousands, except share and per share data):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,916)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain from change in fair value of the Convertible Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31,399)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain on debt and the Convertible Loan extinguishments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,166)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52,481)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares outstanding, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,160,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,075,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares issuable upon the conversion of the Convertible Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22,899,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 59,059,971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,075,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.52)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following outstanding securities as of December 31, 2024 and 2023 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,755,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon the conversion of the Convertible Loan &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,293,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 23,341,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,024,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(1) The Company determined the number of shares issuable upon the conversion of the Convertible Loan as of December 2023, based on the Convertible Loan principal amount of $30.0 million, accrued and unpaid interest of $2.4 million, calculated at an annual interest rate of 8%, converted at $1.52 per share.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_ebs3r3GAo0SJ6-iOAhaiIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the years ended December 31, 2024 and 2023 (in thousands, except share and per share data):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,916)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain from change in fair value of the Convertible Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31,399)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain on debt and the Convertible Loan extinguishments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,166)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52,481)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares outstanding, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,160,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,075,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares issuable upon the conversion of the Convertible Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22,899,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 59,059,971&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,075,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.52)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_ch1atYMGSUGR2mFIGnJFOQ_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-18916000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_MJvdwVPeZkeMZLfm_3GNEw_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-69045000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_uN0lUy5mpk6jbA3eJxG5Rg_5_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-31399000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <armp:DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_Qq2eOkn1NUSn_uPV6D8aFw_6_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-2166000</armp:DilutiveSecuritiesEffectOnBasicEarningsPerShareGainOnDebtAndExtinguishmentOfDebt>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_3gvF9vFWC0eihqWYtEed3A_7_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-52481000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_EGd2i2drg0eWbC_pm0yyfQ_7_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-69045000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="0"
      id="Tc_6jWmx_OEe0eGkcJvnasCqQ_10_3"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36160848</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="0"
      id="Tc_8TP8qTYdBUejYyDKK89F9Q_10_6"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36075555</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="INF"
      id="Tc_hCVWa4IjqkGG5BoUMiWYig_11_3"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">22899123</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="0"
      id="Tc_gUt6hT8ZOUenk_Is1IK_rw_12_3"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">59059971</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="INF"
      id="Tc_gUt6hT8ZOUenk_Is1IK_rw_12_3_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">59059971</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="0"
      id="Tc_NMpk-UZ_kUimz3sxwmKaiQ_12_6"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36075555</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="INF"
      id="Tc_NMpk-UZ_kUimz3sxwmKaiQ_12_6_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">36075555</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="2"
      id="Tc_OK1xfUzw0EubmRCy5Z2gUw_14_3"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="2"
      id="Tc_NYSUo-faDk-X1PBdO2BUdg_14_6"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">-1.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="2"
      id="Tc_GxsLIA9OYEKr5fqq9aCaTQ_15_3"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="2"
      id="Tc_fjYZ_go2RECd0WL48fcn-g_15_6"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_SCZ4LUrl2Ue5p7VHoA6uLg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,755,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon the conversion of the Convertible Loan &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,293,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 23,341,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,024,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(1) The Company determined the number of shares issuable upon the conversion of the Convertible Loan as of December 2023, based on the Convertible Loan principal amount of $30.0 million, accrued and unpaid interest of $2.4 million, calculated at an annual interest rate of 8%, converted at $1.52 per share.&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_FRPlVpNZ5UGLs3JJR-cB7A"
      decimals="INF"
      id="Tc_qkw08y8rBEyaArOBbz9dPw_2_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">3755965</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_XkThMChsq06Wh5OxvIKHaw"
      decimals="INF"
      id="Tc_irdw26amokSNNZuxWxOTVQ_2_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">3165216</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_rohFuA_mlUuMJvakf51DjQ"
      decimals="INF"
      id="Tc_vcnoOYhDKUKWSbmZdGLyjw_3_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">220000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_Zs1AsV-ToEOMh54dXGkq3w"
      decimals="INF"
      id="Tc_Cj5VBp5QD0KhmZdFMpAEiQ_3_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_SharesIssuableUponConversionOfConvertibleLoanMember_h0Z_P8CvIEq0cw1j1Kdi6Q"
      decimals="INF"
      id="Tc_WetL4Q6uAE-3ZWHxTzot7Q_4_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">21293861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_wEUJtdyPwUmF7kwBsHNYtg"
      decimals="INF"
      id="Tc_D3F8ArT42UiZ6oWdeedHew_5_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">19365847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_SxAfTk9NBUeYICYKsOhlgw"
      decimals="INF"
      id="Tc_sbl7RKeoEUOL-rHscRNO9g_5_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">19365847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="INF"
      id="Tc_6f0L_5nlV0GXuXwSJ-l1jQ_6_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">23341812</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="INF"
      id="Tc_Yq78n-RIsEyJfZciyEfytA_6_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">44024924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A"
      decimals="-5"
      id="Narr_FGeB_m8UKkib3aLqJqzegQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">30000000</us-gaap:ConvertibleDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A"
      decimals="-5"
      id="Narr_YJOVxqZdAkqjg_TV7d7urw"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2400000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A"
      decimals="2"
      id="Narr_p4wDbGk_lki3eRHfTmUTSw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_eupth4UMZE2WID951M9Q9A"
      decimals="2"
      id="Narr_sl8a4s-ewE2wKXiVXTnv-w"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">1.52</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_f8rDbtmh9EqFkCVjpbfOcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Balance Sheet Details&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 438&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 26,387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,146)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,821)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation and amortization expense totaled $1.3 million and $1.0 million for the&#160;years ended December 31, 2024 and 2023, respectively. Property and equipment not in use was $8.3 million and $8.1 million as of December 31, 2024 and 2023, respectively, and is included in the laboratory equipment in the table above. These assets are not depreciated until they are placed in service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Other Receivables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Other receivables as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tenant improvement allowance receivable (Note 12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant and award receivable (Note 13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 744&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 744&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accounts Payable and Accrued Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts payable and accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,585&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_sjmepmKrd0-Y3CDvLmsr2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 438&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 26,387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,146)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,821)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_16WVW7L1UEKVDZzpv4Vrkw"
      decimals="-3"
      id="Tc_TWLNfMVgLkCwgHybDVbjug_2_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">21316000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_5Jnw-tluDEu-Kx_JvwRpgA"
      decimals="-3"
      id="Tc_alqXaeM4BkqH4fqI066TXA_2_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">19678000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_3TzGv1YAjkGo6HRjhuGnGQ"
      decimals="-3"
      id="Tc_-9ukIlvd4k6pcJY9HDahbw_3_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">831000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_kYqBxC16p0K1mZ2qlRBw6g"
      decimals="-3"
      id="Tc_sjDPtV8J20C4fFCgj1Ax9g_3_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">817000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Tfkx6Pkwf02KkxOhwrASHA"
      decimals="-3"
      id="Tc_Vv3h45jyWk27zrDmQ2745A_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">438000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_p7FgB_AuUke_7o5Nlzb6Ig"
      decimals="-3"
      id="Tc_6UGqNMiDLU6cUOZlTHYSYQ_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">438000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_aI2oyISraU2WBXG-8aXVKQ"
      decimals="-3"
      id="Tc_zFpMr9njc0agnjZFCN0mYQ_5_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3802000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Osvcwobb1UGHl_jI9F_1uQ"
      decimals="-3"
      id="Tc_B3ui9gOEckyw0-zH5WH8Dg_5_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3447000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_QXbj7ILZakChevUBfvs__g_6_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">26387000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_aDdGSoAjskCO5e-7qt7xkw_6_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">24380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_YM_1dHChwUeJ4b7DgDgL0w_7_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13146000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_mJsITpjLKU-uizkjPGVEKw_7_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">11821000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_lo7oLAfJUkyOEK1NRLiySw_8_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13241000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_WYIE4nSZjEKweUyo_hEqbQ_8_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">12559000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-5"
      id="Narr_LZniGlveckq9J3CIFNsejA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-5"
      id="Narr_ysE4F1GxFkOKUg4uDM9fIw"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-5"
      id="Narr_sUJkEkIchUyBw8N2QsRkAg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1000000</us-gaap:Depreciation>
    <armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-5"
      id="Narr_f2P2D3kUIEKCy282KfVFTg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">8300000</armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment>
    <armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-5"
      id="Narr_AwkPLHCNF0yobxjDIabx4Q"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">8100000</armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment>
    <armp:ScheduleOfOtherReceivablesCurrentTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_SNbASB4aSE23iFutTKVELQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Other receivables as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tenant improvement allowance receivable (Note 12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant and award receivable (Note 13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 744&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,528&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 744&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</armp:ScheduleOfOtherReceivablesCurrentTableTextBlock>
    <armp:TenantImprovementReceivableCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_w3vgq3C1Gk-hvH3gLJPgBg_2_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1835000</armp:TenantImprovementReceivableCurrent>
    <armp:GrantAndAwardReceivableCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_2j87f-r0q06MRR0I_LyUfQ_3_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">744000</armp:GrantAndAwardReceivableCurrent>
    <armp:GrantAndAwardReceivableCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_w31NwDm-ik2AQ_JwrT6pqw_3_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1528000</armp:GrantAndAwardReceivableCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_e1v6A9brhk2Q9-2x6VCIHQ_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">744000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_1warD_YC10u-_fk2aXI3UA_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3363000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_MXj59ivWJkWITB1__NKKQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts payable and accrued liabilities as of December 31, 2024 and 2023 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 766&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,585&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_yc2QpZcvvkS9mE2XaWY0aw_2_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">766000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_f77n35VoZEm5Jl7aEuELvw_2_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1585000</us-gaap:AccountsPayableCurrent>
    <armp:AccruedLiabilitiesClinicalTrial
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_tc6BfkEudUGgKtfEoIb1hA_3_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">828000</armp:AccruedLiabilitiesClinicalTrial>
    <armp:AccruedLiabilitiesClinicalTrial
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_0KkumMR4D0mbaOoiam3vBg_3_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3021000</armp:AccruedLiabilitiesClinicalTrial>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_SaTVq2HwuUaVSDB0YLLUnQ_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">461000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_LlTGppiycEWaqTgyjW77Pw_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1083000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_Nhe-nNL2p0SUovo8wxtKsg_5_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2055000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_Wc6sAedkaU-DGKvs6AnmgQ_5_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5689000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <armp:ConvertibleDebtDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_2PKvDvLyDkW03IHeUJ_CBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Convertible Loan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 10, 2023, the Company received the Convertible Loan in the aggregate amount of $30.0 million from Innoviva pursuant to the Convertible Credit Agreement. The Convertible Loan bears interest at a rate of 8.0% per annum and was scheduled to mature on January 10, 2024. The Convertible Credit Agreement was amended on July 10, 2023, in connection with the Company&#x2019;s entry into the 2023 Credit Agreement to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. Then, on March 12, 2025, the Company executed a subsequent amendment to the Convertible Credit Agreement which, among other things, extended the Convertible Loan maturity date to March 12, 2026. The Convertible Loan principal and accrued interest are payable at maturity. Repayment of the Convertible Loan is guaranteed by the Company&#x2019;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; The Convertible Credit Agreement provides that if there is a financing from new investors of at least &lt;/span&gt;$30.0 million (a &#x201c;Qualified Financing&#x201d;), the outstanding principal amount of and all accrued and unpaid interest on the Convertible Loan shall be converted into shares of the Company&#x2019;s Common Stock, at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in such Qualified Financing. The Convertible Credit Agreement also required the Company to file a registration statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender&#x2019;s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52 (as may be appropriately adjusted for any stock split, combination or similar act).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated authoritative guidance for accounting for the Convertible Loan and concluded that the Convertible Loan should be accounted for at fair value under ASC 480, Distinguish Liabilities from Equity, due to the fact that the Convertible Loan will predominately be settled with the Company&#x2019;s Common Stock. Consequently, the Company recorded the Convertible Loan in its entirety at fair value on its consolidated balance sheet, with changes in fair value recorded as other income (expenses) in the consolidated statements of operations during each reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On July 10, 2023, in connection with the 2023 Credit Agreement with Innoviva, as discussed below, the Company amended the terms of the Convertible Credit Agreement, to, among other changes, extend the maturity of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Convertible Loan to January 10, 2025. The Company concluded that the amendment was an extinguishment for accounting purposes. The Company recognized a $1.8 million gain as the change in fair value of the Convertible Loan before the extinguishment date, July 10, 2023. The Company estimated fair value of the combined transaction, the Loan and the Convertible Loan, before and after modification and calculated an extinguishment loss of $3.9 million, which was recognized as other income (expense) in the consolidated statement of operations for the year ended December 31, 2023. The Company recognized losses of $23.6 million from July 10, 2023 to December 31, 2023 as the change in fair value of the Convertible Loan post modification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 12, 2024, the Company amended the terms of the Convertible Credit Agreement and 2023 Credit Agreement, to, among other changes, extend the maturity of both loans to January 10, 2026. The Company concluded that the amendments were a combined transaction and an extinguishment for accounting purposes. The Company estimated fair value of the combined transaction, the 2023 Loan and the Convertible Loan, before and after modification and calculated an extinguishment gain of $2.2 million, which was recognized as other income (expense) in the consolidated statement of operations for the year ended December 31, 2024. After this amendment, the Company continued to account for the Convertible Loan at fair value on its consolidated balance sheet, with changes in fair value recorded as other income (expense) in the consolidated statements of operations during each reporting period. The Company recognized $31.4 million as the change in fair value of the Convertible Loan for the year ended December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 12, 2025, the Company executed an amendment to the Convertible Credit Agreement which, among other things, extended the Convertible Loan maturity date to March 12, 2026.&lt;/p&gt;</armp:ConvertibleDebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ"
      decimals="-5"
      id="Narr_9sMkhMMwbUKikBvcjOTSZg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ"
      decimals="3"
      id="Narr_qrQ_B2osZkeF5gNeU_YZOA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <armp:ProceedsFromQualifiedFinancingPerAgreementBenchmark
      contextRef="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_4FQlAocYb0208Y7SDKNP4Q"
      decimals="-5"
      id="Narr_9ydW1iQ_TUS2Mqq4k09xgw"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">30000000</armp:ProceedsFromQualifiedFinancingPerAgreementBenchmark>
    <armp:DebtInstrumentConversionPercentOfDiscountOnSharePrice
      contextRef="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_NLLKe9dPJkWGOD2819Wd7g"
      decimals="3"
      id="Narr_2bjVignnP0uu_vLByXN2sw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.15</armp:DebtInstrumentConversionPercentOfDiscountOnSharePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_KxgHVSnbiUauh2wyjKeSlQ"
      decimals="2"
      id="Narr_ZyT7fPxm702X4S9adfhXMA"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">1.52</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <armp:IncreaseDecreaseFairValueOfLiabilities
      contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_hHfphnzRoUq3UB_-E3jFQA"
      decimals="-5"
      id="Narr_ZzErfKYnA0KwBO4EUJKEtQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1800000</armp:IncreaseDecreaseFairValueOfLiabilities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_hHfphnzRoUq3UB_-E3jFQA"
      decimals="-5"
      id="Narr_5AyGRB4qKkuDHts0U_nfHQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="Duration_7_10_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9MsN49-EsUuh7lrZcuBNDA"
      decimals="-5"
      id="Narr_tj7iut8CSk-ugk5Q8nO1GQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-23600000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_qzQd7EpFYkq8oeUwINwivg"
      decimals="-5"
      id="Narr_n5EqYeXb5EWM7yCGb5Y8Rg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <armp:IncreaseDecreaseFairValueOfLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_qzQd7EpFYkq8oeUwINwivg"
      decimals="-5"
      id="Narr_oWEEYqT870ORBju82SjJag"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">31400000</armp:IncreaseDecreaseFairValueOfLiabilities>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_jcfJFcae8E6K5rLovLbGJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Term Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;"&gt;On July 10, 2023, the Company entered into the 2023 Credit Agreement. The 2023 Credit Agreement provides for the 2023 Loan, a secured term loan facility in an aggregate amount of $25.0&#160;million at an interest rate of&#160;14.0% per annum, and was scheduled to mature on January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the 2023 Loan is guaranteed by the Company&#x2019;s domestic subsidiaries, and the 2023 Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;"&gt;On November 12, 2024, the Company executed an amendment to the 2023 Credit Agreement, which, among other things, extended the 2023 Loan maturity date to January 10, 2026. On March 12, 2025, the Company executed a subsequent amendment to the 2023 Credit Agreement which, among other things, extended the 2023 Loan maturity date to March 12, 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The 2023 Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The 2023 Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#x201c;material adverse effect&#x201d; as set forth in the 2023 Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company&#x2019;s operating budget.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The 2023 Loan was initially recognized at fair value of $21.2&#160;million and subsequently recognized at the amortized cost net of debt issuance costs and debt discount of $3.8 million. The Company recognized $2.4 million and $0.9 million debt issuance costs and debt discount for the years ended December 31, 2024 and 2023, respectively, using the effective interest method. The Company recognized $6.7 million and $2.6 million of accrued interest expense for the years ended December 31, 2024 and 2023, respectively.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;The 2023 Loan&#x2019;s annual effective interest rate was&#160;48.76% and 27.31% as of December 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 4, 2024, the Company entered into the 2024 Credit Agreement for the 2024 Loan in an aggregate amount of $35.0 million. The 2024 Loan bears interest at an annual rate of&#160;14.0% and was scheduled to mature on June 4, 2025. On March 12, 2025, the Company executed an amendment to the 2024 Credit Agreement which, among other &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;things, extended the 2024 Loan maturity date to March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2024 Loan is guaranteed by the Company&#x2019;s domestic subsidiaries, and the 2024 Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2024 Loan was initially recognized at cash proceeds of $35.0 million net of debt issuance costs of $0.1 million, and subsequently is recognized at the amortized cost. Debt issuance costs are amortized using the effective interest method to interest expense over the term of the 2024 Loan. The Company recognized $4.1 million of accrued interest expense for the year ended December 31, 2024. The 2024 Loan&#x2019;s annual effective interest rate was 14.25% as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2023 Credit Agreement and the 2024 Credit Agreement contain customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The 2023 Credit Agreement and the 2024 Credit Agreement also include customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#x201c;material adverse effect&#x201d; as set forth in the 2023 Credit Agreement and the 2024 Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company&#x2019;s operating budget.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA"
      decimals="-5"
      id="Narr_JJSD-xR9DEuUqzsSlzExgA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA"
      decimals="3"
      id="Narr_HZ0FzPkSZ0-PWwxSIDANGw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA"
      decimals="-5"
      id="Narr_PnEnFo7B2E2HOqAGsWkCJw"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">21200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_NnRfFznq00mc3z-Jcf7_VA"
      decimals="-5"
      id="Narr_326xVe81RUOs3UKB6JsFBQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_MIv8wWRsbkmUV0mdcTFmZQ"
      decimals="-5"
      id="Narr_dvjTNJBX-0-11bP-wYED1Q"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_PC5IfPM4Q02DNCet-1_Lag"
      decimals="-5"
      id="Narr_sRJxXQt9HkmuWs9CXCabLw"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_MIv8wWRsbkmUV0mdcTFmZQ"
      decimals="-5"
      id="Narr_Bp0E0bBKCU2QKz42K7Z5yg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">900000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_PC5IfPM4Q02DNCet-1_Lag"
      decimals="-5"
      id="Narr_APsHVa_5VkS7EbDWZSCYVA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">900000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_lYQF9icj1kuOL4xigHQzKw"
      decimals="-5"
      id="Narr_hf1nM8V8tkuqFZ8Sy-DH8A"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">6700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_KilvybAjfU2MMseKFQN_pA"
      decimals="-5"
      id="Narr_AGd3Q0DjYEahakcWuOtW0g"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_PC5IfPM4Q02DNCet-1_Lag"
      decimals="4"
      id="Narr_77ajYYb8REaEGcFfe90dMw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.4876</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2023Member_MIv8wWRsbkmUV0mdcTFmZQ"
      decimals="4"
      id="Narr_ZBFnnZDciEOK0P9lbk_ThA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.2731</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA"
      decimals="-5"
      id="Narr_1ION6vt6DE6RXRAGx714fg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA"
      decimals="3"
      id="Narr_GOQs5tFOTU2c6bS_6VdmxA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA"
      decimals="-5"
      id="Narr_f9eAsRheyESHAWOFBNsXdw"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_nWxRPQO4-EGl4yZNB8CmEA"
      decimals="-5"
      id="Narr_Rp_LTcKI4k24buheEuaL3A"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_RBZa_N6QqUyQ2oiWdEiprQ"
      decimals="-5"
      id="Narr_JIlBgHFzvEmBdAqS5aIrDg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4100000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2024Member_yDGzdtvVaUO97cPKrXci4g"
      decimals="4"
      id="Narr_7JUPL6wPI0WIcF3nHYm8OA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.1425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_C6xpdjcXB0SHEa7Q5tomLg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Stockholders&#x2019; Deficit&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024 outstanding warrants to purchase shares of Common Stock were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 993,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;February 11, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,717,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 27, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,867,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;January 26, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,285,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 16, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,807,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;February 8, 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,692,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 30, 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 1,680.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;None&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Shares Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"&gt;&lt;span style="font-size:11.25pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2024 and 2023, the Company had reserved shares of its Common Stock for future issuance as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,755,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issuable under the Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,890&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares available for future grants under the 2016 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,405,908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,368,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon the conversion of the Convertible Loan&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 22,899,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,293,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares reserved&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 49,658,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46,402,832&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_NLkra1S72UaqNskI2PKFRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:36.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 993,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;February 11, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,717,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 27, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,867,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;January 26, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,285,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 16, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,807,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;February 8, 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,692,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 30, 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 1,680.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;None&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_HyGAt6Tz506l49Pgkj8m9Q"
      decimals="INF"
      id="Tc_eJfFVYo5hUyxR3DrlCGAWA_2_0"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">993139</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_HyGAt6Tz506l49Pgkj8m9Q"
      decimals="2"
      id="Tc_E6uiya2TvUuBD8IBJd38cg_2_3"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">2.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_8Mc5U6Ck2kSpYcYSeCnQCw"
      id="Tc_5jfSofCX4kyIkSyLkk5VYA_2_5">2025-02-11</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_aSkSzFIw6E6liVy6b0eAVw"
      decimals="INF"
      id="Tc_4_hDhL-YMkChpidECZEpgQ_3_0"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">7717661</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_aSkSzFIw6E6liVy6b0eAVw"
      decimals="2"
      id="Tc_QWx29fl2lkSY4LBo0hyToA_3_3"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">2.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_feeJaveXFUOGLBI6iniUiQ"
      id="Tc_lvu6w4C8p0aGpMBzCh45uA_3_5">2025-03-27</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_Q2agB-03uEiWytISvo0nvQ"
      decimals="INF"
      id="Tc_cPl-RJvFU0WaqQ3M8zlY9w_4_0"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">1867912</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_Q2agB-03uEiWytISvo0nvQ"
      decimals="2"
      id="Tc_FuOtzTvNbU2OYuIRW6w_eQ_4_3"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_xBgryqct0E6Zilf1u8G51w"
      id="Tc_aewpxdZtV06HDwINqUcP3A_4_5">2026-01-26</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_8NNrUB98dU6nTV1W_TbZEA"
      decimals="INF"
      id="Tc_b49kcgosu0CV68H_G5cc1g_5_0"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">4285935</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_8NNrUB98dU6nTV1W_TbZEA"
      decimals="2"
      id="Tc_Rfitt6gEZEubnTrrVfmdTg_5_3"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_JaLL1iLkyEWNgBPCSHnOpw"
      id="Tc_8zw8gbWAdEaNPnNAiKCo_A_5_5">2026-03-16</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_5m5du7ROvkCWkfWMS1O-UQ"
      decimals="INF"
      id="Tc_PX-t53rtOE2CXucOWhSVPw_6_0"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">1807396</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_5m5du7ROvkCWkfWMS1O-UQ"
      decimals="2"
      id="Tc_OSIvH6s2MEa0FVmPPsf6LA_6_3"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_3r_X0vA_sEGsQPwLdkNqvg"
      id="Tc_kfGYQJaT6U283IJD_VUkvg_6_5">2027-02-08</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_8bhT2JsMPEe7lORCk6OgzQ"
      decimals="INF"
      id="Tc_zbywI_3jc0WIaFKxjtKcxQ_7_0"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">2692604</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_8bhT2JsMPEe7lORCk6OgzQ"
      decimals="2"
      id="Tc_5OmQkFicsEaH36dYTPhRvw_7_3"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_zidty5XO8kGAipBpidYvpg"
      id="Tc_BnGer8CoEEmDjFjh4wVo1w_7_5">2027-03-30</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_7LahToXqk0ys3Hj-vViLrQ"
      decimals="INF"
      id="Tc_sA5SPaNn1EqXzichwaj06g_8_0"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">1200</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_7LahToXqk0ys3Hj-vViLrQ"
      decimals="2"
      id="Tc_m7O4_lTZuESgFPEJQKFCwA_8_3"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">1680</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Tc_cCA08GkY0USMgYhKgN3wyA_9_0"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">19365847</us-gaap:ClassOfWarrantOrRightOutstanding>
    <armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_qT_VQ5P75k-Kb63Mnvzdjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,755,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issuable under the Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,890&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares available for future grants under the 2016 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,405,908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,368,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon the conversion of the Convertible Loan&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 22,899,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,293,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares reserved&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 49,658,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46,402,832&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Tc_d6ueP-qASUSIXQDKa4c3hQ_2_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">3755965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Tc_QDTO1p3mikiXT4FYVV8Euw_2_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">3165216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GhrtbpfWc0emjiaVORy1SQ"
      decimals="INF"
      id="Tc_S41RfMYTI06qa71LaGfPvg_3_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_f61X9uE-N0-LLpqFLPWZgw"
      decimals="INF"
      id="Tc_9UIBDxP7TUaMl75AvX4G6Q_3_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Tc_IP6tYOsmmUiphG_-2QHBQA_4_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">11890</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Tc_VTG3SqRHs0ugM7lLwBJGsg_4_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">9748</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_PdC_SAUxUUK65xSOy8LXqA"
      decimals="INF"
      id="Tc_UAYVR2LHNk-VHa64iC1NVw_5_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">3405908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_NG9OliLZLUqYSqXnApcGDA"
      decimals="INF"
      id="Tc_V5yMO9UE4k2E7CRnsWA2MQ_5_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">2368160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Tc_Qr8oMQHZDkCJy6pIqDlF6A_6_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">19365847</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Tc_zPZ7oPy7skqQR5jSE3MWdg_6_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">19365847</us-gaap:ClassOfWarrantOrRightOutstanding>
    <armp:SharesIssuableUponConversionOfConvertibleDebt
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Tc_WCj9OgfVr0OxaXTa6PRL2g_7_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">22899123</armp:SharesIssuableUponConversionOfConvertibleDebt>
    <armp:SharesIssuableUponConversionOfConvertibleDebt
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Tc_Q403LX5BpkWAJ_xWHobjhQ_7_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">21293861</armp:SharesIssuableUponConversionOfConvertibleDebt>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Tc_3YYU0oyFvkeaGk2H0K1ehw_8_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">49658733</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Tc_N9A57T2EMUy7pPfFARXKEA_8_4"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">46402832</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_bqmixcDEukiIOHjImhIs_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Equity Incentive Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Award Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"&gt;&lt;span style="font-size:11.25pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains a 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#x2019;s Board of Directors to its employees, directors and officers and to consultants. The term of the options granted is ten years, the exercise price is the Company&#x2019;s closing price at the date of grant and the vesting period is usually four years&lt;span style="white-space:pre-wrap;"&gt;. The Company also granted RSUs under the 2016 Plan that vest over four years.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the 2016 Plan, the number of shares authorized for issuance is automatically increased by a number equal to 5% of the total number of shares of the Company&#x2019;s capital stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Board of Directors annually beginning from January 1, 2017 until January 1, 2026. As of December 31, 2024, there were 3,405,908 shares available for issuance under the 2016 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has issued restricted stock awards RSAs under certain legacy option plans that generally vested&#160;&lt;span style="-sec-ix-hidden:Hidden_GZ0DQ00E2US7iMhH9yvSLg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt;&#160;to&#160;four years&#160;based on service conditions. As of December 31, 2024, all RSAs were fully vested.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Pursuant to its 2016 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), the Company may grant or provide for the grant of rights to purchase shares of its Common Stock. The number of shares of its Common Stock reserved for issuance under the ESPP will automatically increase on January 1st of each calendar year by the lesser of 1% of the total number of shares of the Company&#x2019;s Common Stock outstanding on December 31st of the preceding calendar year and 30,000 shares, subject to the ability of the Company&#x2019;s Board of Directors to take action to reduce the size of the increase in any given year. There were no awards issued under ESPP. As of December 31, 2024, the Company had reserved 11,890 shares for future grants under the ESPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Stock option activities during the year ended December 31, 2024 are presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,859,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,282)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,231,023)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,755,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,755,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,059,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The aggregate intrinsic value of options at December 31, 2024 is based on the Company&#x2019;s closing stock price on that date of $1.85 per share. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The weighted average grant date fair value of the options granted during 2024 and 2023 was $2.54 and $1.97, respectively. The fair value of vested options during the year ended December 31, 2024 and 2023 was $2.8 million and $5.1 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Restricted stock awards and restricted stock unit award activities during the year ended December 31, 2024 are presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Avg&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 90,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2024, there was $2.6 million of total unrecognized compensation expense related to unvested stock options and restricted stock units, which the Company expects to recognize over the weighted average remaining period of approximately &lt;span style="-sec-ix-hidden:Hidden_gW2qZueRtk-fdI8-fDXRnA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1.9 years&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"&gt;&lt;span style="font-size:11.25pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.35pt;margin:0pt;"&gt;&lt;span style="font-size:7.35pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The assumptions used to estimate the options fair value were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:45.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.54%-4.25%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.54%-5.54%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;89.40%-92.50%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;75.40%-116.96%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.1-7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.1-7.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The tables below summarize the total stock-based compensation expense (reversal) included in the Company&#x2019;s consolidated statements of operations for the periods presented (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,893&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_2hEBCqxGoUqgVYfZknvwGA"
      id="Narr_mR7V3nvpk0mbaJJpbjQ4Wg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_pJH1VOMu10ubY-ejaciVcg"
      id="Narr_EJSYts7Hbk-SHSai9_7RPw">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_T8FTsTcprUy8rKzW-XC3EQ"
      decimals="2"
      id="Narr_t99IKEx2e0ieDkIKELKpUw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_gGZqSnGwP0OUUcdXV26XfA"
      decimals="INF"
      id="Narr_F0eByqI8ikCk86AZSi3eXg"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">3405908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ct6tmhYJKEW98JUYWA7SAA"
      id="Narr_XtrcRWqbd0mZ3ShsN8Xjmg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_umBgF7ml2kCrfw0hSCQoPA"
      decimals="2"
      id="Narr_PFxoYKykrE-6NzAIRkJecw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_umBgF7ml2kCrfw0hSCQoPA"
      decimals="INF"
      id="Narr_Wak6mW8WzkW6gredLHZszA"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_umBgF7ml2kCrfw0hSCQoPA"
      decimals="INF"
      id="Narr_uqmp2IRhE0-Cb10CoYvxDg"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_htSBHjfgekaRHkMRgsz1MA"
      decimals="INF"
      id="Narr_L_bTNjSQWEy7kJdXGoFJ1w"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">11890</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_hXjxA_r8yEyLk92wVR82ng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,859,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,282)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,231,023)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,755,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,755,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,059,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="INF"
      id="Tc_ns6aM8sIPkqWQvJJjcLxvA_8_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">3165216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="2"
      id="Tc_DO7dUpYh9EyU14h_LSRb3g_8_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      id="Tc_laK1aiNPoEWHj4VO-fQFVg_8_7">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_P5-58jxFDUCwu_s_XPmVPg_8_10"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">429000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="INF"
      id="Tc_CoNRiZaN306_yTHu7tQufA_9_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">1859054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="2"
      id="Tc_AzJkoQ4glkeKye2ukms7_A_9_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">3.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="INF"
      id="Tc_N6Y_azJF2UOkHuAFVwwOcw_10_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">37282</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="2"
      id="Tc_CbHHUt-B4EmuRC4YAgTMXQ_10_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">3.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_wApoDjddEEybXayZEsnRgg_10_10"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="INF"
      id="Tc_uuecdkr4xUu-qozsUm2t3Q_11_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">1231023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="2"
      id="Tc_POl9kGAlI0-RGHokZmJBqw_11_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">6.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <armp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_IkEvSVxmG0a6lmtfPG9Z2A_11_10"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4000</armp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Tc_HH6PmZs6g0K2LPTZS2oMAw_12_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">3755965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="2"
      id="Tc_7k7M2_sKZkGqKJT3FuDFzA_12_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">3.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_8Dq0VqQbQ0iqu3Raa5UNXQ_12_7">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_wvAb8jtJHk6LgpJirqktuQ_12_10"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Tc_UapZtwhwtEefipJazKJ14g_13_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">3755965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="2"
      id="Tc_OVo3uKyOCEyWshNAnTgf9Q_13_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">3.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_lx6OScVEUk6MzjRLIzITyQ_13_7">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_jJ5LIIlUMEGGF4DQrukMzw_13_10"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="INF"
      id="Tc_qQL3dAO29UO_56wtRR0EDw_14_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">2059396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="2"
      id="Tc_o9aetpSGrkKKLekAn_jvoA_14_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">4.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tc_oYN9acMUxkGZXhBacHcH-w_14_7">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_i28QqSKdLUiXKhg6VZzEgA_14_10"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H4YKiME1IEWZOdKMpzlX5Q"
      decimals="2"
      id="Narr_LbzwcVnV0EGNh590hHtcmw"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">1.85</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="2"
      id="Narr_Q_ubz7HACkmqcD61UyDA_g"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">2.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="2"
      id="Narr_0b00-Uj7kk-JO8ylsi77og"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-5"
      id="Narr_9URlzS8es0e-WsZZNeNjkg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-5"
      id="Narr_gHD2Y30-dUu-TPEExeXniA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_I25ARXKqtkCpTVIrYoar5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Avg&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 90,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:64.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 220,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_QarzicNc2kSX3wxOAwoMJQ"
      decimals="INF"
      id="Tc_jAlY8U4_fkOQU1qsK09FEw_4_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_QarzicNc2kSX3wxOAwoMJQ"
      decimals="2"
      id="Tc_of4iUZUu4ESDfk06cq2hnQ_4_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw"
      decimals="INF"
      id="Tc_Rs--Uwsaq0q-aQnVgUf-TQ_5_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw"
      decimals="2"
      id="Tc_SsZ-MmQ0dUGwNotBmcUChA_5_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw"
      decimals="INF"
      id="Tc_DvPk4JBs6EyHT-slP0qRcw_6_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw"
      decimals="2"
      id="Tc_pmPKX4r8vk6rA4jCydTTvw_6_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw"
      decimals="INF"
      id="Tc_lkUzZTzUSU2dFmwW6_nM0Q_7_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_1YkX9-ZSK0GQK0lzv2y3Yw"
      decimals="2"
      id="Tc_ehncxShDF0GED6TPHJl0WA_7_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_8COWQsEZn0Wg7V4VXWyPng"
      decimals="INF"
      id="Tc_iPrvVd67-Uy0YmIdCqCIoQ_8_2"
      unitRef="Unit_Standard_shares_RZHbnjzmNESenkP2re7Mxg">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_8COWQsEZn0Wg7V4VXWyPng"
      decimals="2"
      id="Tc_X3phwCNHOk-MUgUt-PAXMw_8_5"
      unitRef="Unit_Divide_USD_shares_DZoJzD5inUW6czUiaxzYYQ">2.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_fPQyy0HqVEuM1qduhYrYog"
      decimals="-5"
      id="Narr_LoZmz-gc7U2q6GSj9pOkqw"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_lriccVU6_0yBsVLI-a0HzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:45.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.54%-4.25%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.54%-5.54%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;89.40%-92.50%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;75.40%-116.96%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.1-7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.1-7.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_BApNk3n5XkaOpKH7-XGdqA"
      decimals="4"
      id="Narr_qfxXW8OyCUi2Iu3DYfIDKg"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.0354</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_zHKl8i7YW0il2SCbZ7ryrg"
      decimals="4"
      id="Narr_NvnPKkjIfEywtiDEIVYCag"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.0425</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_-pt2ThZhNkOtRzUxqgRzhw"
      decimals="4"
      id="Narr_Bs4caSxcMk6F-o0Yzn9__A"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.0354</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_wDGF0KSNh0K-ZOkC4X8kag"
      decimals="4"
      id="Narr_QH45xhZzU0GnYHsTia3Fwg"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.0554</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_QpjN1Yhr0kCLe-x9CNhQkg"
      decimals="3"
      id="Narr_3tOswYdcKUqP8op0pzQFmg"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.894</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_jVO24CHTHEOIiO_ECZ6bIw"
      decimals="3"
      id="Narr_e8DwmTnF5E6Kkmb2aeKg0w"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.925</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_AE_R59dgSk29aRazyIh1uA"
      decimals="4"
      id="Narr_-i9YXIG_iEuktUZS2dfDfw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.754</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember__ONSzE2PXE2dEzLteS-O5Q"
      decimals="4"
      id="Narr_N-9afHvZYEahJFBu_MzIXg"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">1.1696</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_83vS_dwiSkeNsun5DvCQfA"
      decimals="1"
      id="Narr__ZXqZgQOfUGvr4xCnQJQQg"
      unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg">5.1</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_q3iOc3hnOEKxXvfRp4uwBQ"
      decimals="1"
      id="Narr_FFg8S_ub-0291Jt9gwpLnQ"
      unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg">7</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Tan8oCbxTkeDxokgzAn6TQ"
      decimals="1"
      id="Narr_BfVJWrAchUGwkdKL2tyk3g"
      unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg">0.1</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Dse-ebonN0CTM7ve3ne8_Q"
      decimals="1"
      id="Narr_J4lHwdb9O0qmufX1kJoyRg"
      unitRef="Unit_Standard_Y_LhQEk84ZvkipFue1onJ-Zg">7</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ieNv8UfQuEu5yQKAxjemyA"
      decimals="0"
      id="Tc_knuoNMezx0K5X6rdj5UaIQ_6_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_ubx-9CKJgEWrllUJcWFg7w"
      decimals="0"
      id="Tc_mio73663r06ETYpa5l34hA_6_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0</armp:EquitySecuritiesMeasurementInput>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_7zC6flZUvkCe83zN_4zY9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The tables below summarize the total stock-based compensation expense (reversal) included in the Company&#x2019;s consolidated statements of operations for the periods presented (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,013&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,893&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_VsjRlp7C00anCfXheLFsLQ"
      decimals="-3"
      id="Tc_hZUWlQV0NUG2uPPU-Be_Zg_3_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Wnx7hledV0aiY-1RCUHzlg"
      decimals="-3"
      id="Tc_aRg27MRtCU6BcgcALQ4MWQ_3_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1013000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_YbvCeB-0yEWBm5JrBGygig"
      decimals="-3"
      id="Tc_rU6kSkHkMkOoR_qIJxldbg_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kBMGpinIEUqZVp0QH9Oswg"
      decimals="-3"
      id="Tc_6GRpOBhLmE2kW0pvc5y3jw_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_hK_IpP7shUGPM8w9kYWb0w_5_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2893000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_JR-ClKNarUWH6eo_9rc8bw_5_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_6wiN-QcwkUqlxekYcdLKJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Loss before income taxes consisted of the following components (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:7.25pt;"&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,020)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (68,182)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (896)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (863)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,916)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 53,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,431&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Depreciation and amortization &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease accounting &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,505&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest expense carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,907&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets before valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 97,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 86,767&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (84,217)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,166)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right-of-use asset &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,763)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,510)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Debt basis differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,991)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (141)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (91)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,972)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,678)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s net operating loss carryforwards at December&#160;31, 2024 are $195.3 million, $139.2 million and $12.0 for federal, state and foreign income tax purposes, respectively. Federal and state net operating loss carryforwards are available to offset future taxable income, if any, and will begin to expire in 2026 and 2029, respectively. The federal net operating loss carryforwards generated after 2017 of $140.8 million will carryforward indefinitely and can be used to offset up to 80% of future annual taxable income. The Company's foreign net operating loss carryforwards do not expire.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s net operating loss carryforwards may be subject to a substantial annual limitation as a result of ownership changes that have occurred or could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit or eliminate the amount of net operating loss carryforwards that can be utilized to offset future taxable income. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. In general, an 'ownership change' as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an &#x2018;ownership change&#x2019; of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not undergone an ownership change analysis pursuant to Internal Revenue Code Section 382 as of December 31, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.  Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of available evidence, including the Company's history of operating losses, management has determined that it is more likely than not that the Company&#x2019;s net deferred tax assets will not be realized. Accordingly, a valuation allowance has been established by the Company to fully offset these net deferred tax assets. The Company increased its valuation allowance by approximately &lt;/span&gt;$9.1 million during the year ending December 31, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustments for tax effects of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State income taxes, net of federal tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Non-deductible debt items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 25.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(3.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Return to provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(1.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Permanent differences and other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(1.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(0.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(0.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction, state of California and certain foreign jurisdictions. As of December 31, 2024, the Company is no longer subject to U.S. federal income tax examinations for tax years ended on or before December 31, 2020 or to California state income tax examinations for tax years ended on or before December 31, 2019. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses or tax credits were generated and carried forward, and make adjustments up to the amount of the net operating loss or credit carryforward.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not have a liability for unrecognized tax benefits at December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s policy is to classify interest and penalties on uncertain tax positions as a component of tax expense. As of December&#160;31, 2024 and 2023, the Company has no accrued interest or penalties related to uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred income taxes have not been provided for undistributed earnings of the Company&#x2019;s consolidated foreign subsidiary because the parent entity would not be required to include the distribution into income as the amount would be tax free.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Tax Cuts and Jobs Act subjects a U.S. stockholder to tax on GILTI earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740 No. 5. Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election either to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_lD8ThfXp006ik6qzbaB4VQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Loss before income taxes consisted of the following components (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:7.25pt;"&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,020)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (68,182)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (896)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (863)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,916)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_dS0y-VY8SkGAlvKNxNudCg_3_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-18020000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_Xu9dSTM0iUagzY7xGYFmPw_3_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-68182000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_I6tf8mFtm0eTroWlXakkow_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-896000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_9dmKT1WPpEarDQTW8tsNmQ_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-863000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_x_VsB4xge0eo3Ae7HdSUBw_5_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-18916000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_EvnstW3bvUyLtZLgk-Z2bQ_5_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-69045000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_mIcSFOZ_GkuCSYnQjsqd3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 53,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,431&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Depreciation and amortization &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease accounting &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,505&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest expense carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,907&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets before valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 97,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 86,767&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (84,217)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,166)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right-of-use asset &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,763)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,510)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Debt basis differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,991)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (141)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (91)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,972)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,678)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_NFtJzGSgzU2Grev_LYw8cQ_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">53618000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_5RqJptfdkkeK9jT-xHXufw_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">46591000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_8lVs5IG4fkqWd54CF_l0tQ_5_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">24045000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_Ru8iHUYb30W5J8MNJdOvBA_5_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">21431000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_gJXyPSMz102ZW1sDKdi3MQ_6_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1804000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_ZemoTKzDB028pkGMhHTmWA_6_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2083000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_dE1dSspDNUq00t2ofjry3g_7_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">762000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_I0kFQcMeuEKpVXAAS_hFgg_7_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">856000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <armp:DeferredTaxAssetLeaseObligation
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_13eweLS0mUyOM920m7Fz7A_8_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13505000</armp:DeferredTaxAssetLeaseObligation>
    <armp:DeferredTaxAssetLeaseObligation
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_PWm0tNgaH0aqRvJBkKNsKg_8_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13899000</armp:DeferredTaxAssetLeaseObligation>
    <armp:DeferredTaxAssetsInterestExpenseCarryForwards
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_mMsQO5vywES7C6_0T8AkHg_9_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1292000</armp:DeferredTaxAssetsInterestExpenseCarryForwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_XZhOhxgQVEman76yiMf1tg_10_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2086000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_g4ZVdYeC6k2Plj6P6LT9ig_10_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1907000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_zjUfVF4NL0m15kNHiuwrOw_11_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">97112000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_nhq4D3P8T0Oo3KSOKnsoig_11_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">86767000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_o1vlDaQBOEG1nxBSjJ6FeQ_12_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">84217000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_RsplwbL-VUqw9B4dpwnBxQ_12_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">75166000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_ADz6KDPNmkeQyPS3jdt2ag_13_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">12895000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_m_gEAkON2ky6nhKTd3627g_13_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">11601000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <armp:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_aj3BhHAh9Ey4Hh1fNZAHTQ_16_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">10763000</armp:DeferredTaxLiabilitiesRightOfUseAsset>
    <armp:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_Rr7cXwERukqiJbQMr433xg_16_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">11510000</armp:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_pCMWMuToukWzRR3NXebF6w_17_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3077000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_QfGZbXWzQU-Euts-yy6_xg_17_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3077000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <armp:DeferredTaxLiabilitiesDebtBasisDifferences
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_EgtU1kHeikGbBvSYs-27oQ_18_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1991000</armp:DeferredTaxLiabilitiesDebtBasisDifferences>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_2sqAYNU3YE6Kf8shxOatOQ_19_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">141000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_HiGFfyNCxEe-TcOVT_yPAA_19_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">91000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_KlzQjaa8NUKXfgN-DOJMeQ_20_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">15972000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_RbkaKlX2OEuDWluGuEYl_A_20_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">14678000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_RRnmgJAp8Emg2hWMOMS9aA_21_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3077000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-3"
      id="Tc_snDWGr34FUWPEpMf2FCVmA_21_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3077000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6Y5SYi_BTUa8vlarva5peg"
      decimals="-5"
      id="Narr_Y48q8P8Xpk2CP-x3Q4ViVQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">195300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_iRtQVHneb02Vlx_hfCVCVQ"
      decimals="-5"
      id="Narr_VM0BmrvdTUWSaPHkD181OQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">139200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_yrOpWPoZBU2cuEPXaihZtw"
      decimals="-5"
      id="Narr_eeIVtL0s50O0UWWhCnNNdA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">12000000</us-gaap:OperatingLossCarryforwards>
    <armp:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-5"
      id="Narr_oiqsr0yS3EyTOAjTNihLaA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">140800000</armp:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-5"
      id="Narr_DObK1BX9kEiszGjnp5lY6g"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_duc62bnKtEeVJAFsYGwpzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustments for tax effects of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State income taxes, net of federal tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Non-deductible debt items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 25.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(3.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Return to provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(1.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Permanent differences and other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(1.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(0.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(0.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="3"
      id="Tc_Y6gwwRwCeESGeg6uqS4VsQ_3_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="3"
      id="Tc_7CVmcWtXEUSvQb6nFwsZEA_3_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="3"
      id="Tc_YQyzZTRfR0yB4t250KR9LQ_5_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.096</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="3"
      id="Tc_o8ls7GtxZkS9-UBuWucm_A_5_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="3"
      id="Tc_aUGtvzY5cUGgCoWw-cxgBw_6_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.037</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="3"
      id="Tc_vUdZy3Qs1ki7zJnkh7EPIw_6_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="3"
      id="Tc_XRYg0x4_CE6dyzl4x8yFTA_7_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.253</armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent>
    <armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="3"
      id="Tc_cYa_TpKAq0eD5ReE53inyg_7_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.078</armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="3"
      id="Tc_JMfFLCefX0aSwe4EKM5bfg_8_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.497</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="3"
      id="Tc_J2uiaFwjcUunuRrCZcNhHQ_8_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.093</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="3"
      id="Tc_rnVaioqYYUyKiTUL5J9Igw_9_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="3"
      id="Tc_U4NzhceCs0iKBYOXOWPDJg_9_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <armp:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="3"
      id="Tc_WuW-D1rTwEyY4gLJVdNexw_10_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.016</armp:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <armp:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="3"
      id="Tc_7oSdk0UYzU2d33UBfVZ3zg_10_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.007</armp:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="3"
      id="Tc_gGeHUHr1tE6Wjk5N8cqKCw_11_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="3"
      id="Tc_OU5J5ZWLu02-H8Pl8iPSVA_11_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="3"
      id="Tc_sxx6L-6QnU2va4-xf_qPug_12_2"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="3"
      id="Tc_yjSfoxdMdUyr4IL80wickA_12_4"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="-5"
      id="Narr_cDcnA2oB40qAVqOu3acTTA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-5"
      id="Narr_4pZB6rpT4EmVCzDCNXMzVg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-5"
      id="Narr__-dAHyWpfUWyvMW1Pu6KIg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-5"
      id="Narr_7oA2rZGRrkCHSvY3aBQiXg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_oJcZ_C_y-0uEAwnfzaZ73g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Operating Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA, with the lease term through December 31, 2031. Annual base rent is from $1.9 million and increases by 3% annually and will be $2.5 million by the end of the term. The Company also maintains an irrevocable letter of credit in connection with this lease, which had a balance of $0.5 million as of December 31, 2024 and is reducing 20% annually through the end of the lease term&lt;span style="font-size:12pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the &#x201c;2021 Lease&#x201d;). The 2021 Lease payment start date was May 1, 2022 and the total lease term is for 16 years and runs through 2038. Monthly rent for 2022 and 2023 was fully or partially abated while the lessor and the Company completed planned tenant improvements to the facility. Base monthly rent is approximately $0.3 million in 2024. The Company was responsible for construction costs over the tenant improvements allowance of $7.2 million. The construction was completed as of December 31, 2024, and the Company received the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;full allowance. Out-of-pocket expenses to be incurred by the Company were considered noncash lease payments, and included in the lease liability and right-of-use asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;In connection with the execution of the 2021 Lease, the Company delivered an irrevocable standby letter of credit in the amount of $5.0 million to the landlord in 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum annual lease payments under the Company&#x2019;s noncancelable operating leases as of December&#160;31, 2024, are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,716&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,784&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 64,857&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: amount representing interest &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,732)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of operating lease obligations &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 32,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,431)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Noncurrent operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27,694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="color:#222222;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Operating lease expenses were $8.4 million and $7.4 million for the years ended December 31, 2024 and 2023, respectively. Variable costs related to operating expenses and taxes, which are recognized as incurred, were $1.7 million and $1.0 million for the years ended December 31, 2024 and 2023, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes supplemental cash flow information related to the Company&#x2019;s operating leases for the years ended December 31, 2024 and 2023 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 18,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company&#x2019;s operating leases as of December 31, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term, years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;11.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.8pt;text-align:right;text-indent:-0.8pt;margin:0pt 0pt 0pt -2pt;"&gt;12.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate, %&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;13.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;13.9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Legal Proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#x2019;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#x2019;s reputation and business. The Company is currently not a party to any legal proceedings, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would have a material adverse effect on its consolidated results of operations or financial position.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <armp:OperatingLeaseBaseAnnual
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_lvqDhuhNuUSizIHbky_dog"
      decimals="-5"
      id="Narr_Bl5t4-HrmESdgQYB82DW1w"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1900000</armp:OperatingLeaseBaseAnnual>
    <armp:AnnualIncreaseInRentPercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="2"
      id="Narr_ceeVlkGGbkSg8UKKZus7kA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.03</armp:AnnualIncreaseInRentPercentage>
    <armp:OperatingLeaseBaseAnnual
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XXu-NcK_bkaDqHPx0csY9A"
      decimals="-5"
      id="Narr_V936j_0x_UuxNT-HYL6GgQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2500000</armp:OperatingLeaseBaseAnnual>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="As_Of_12_31_2024_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_r5Xr-teAaUaiHHiDICZQPw"
      decimals="-5"
      id="Narr_gNIz5kR6yUSjquB6vR8jOg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">500000</us-gaap:LettersOfCreditOutstandingAmount>
    <armp:AnnualReductionOfStandbyLetterOfCredit
      contextRef="As_Of_12_31_2024_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_r5Xr-teAaUaiHHiDICZQPw"
      decimals="2"
      id="Narr_WycWm04BoUau9xll5l-PBA"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.20</armp:AnnualReductionOfStandbyLetterOfCredit>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw"
      id="Narr_8lCaBG9rHkKq7zk2sONtxw">P16Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <armp:BaseAnnualRentToBePaidYearThree
      contextRef="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw"
      decimals="-5"
      id="Narr_f7D6abN2n0iXZWc8ca2gTg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">300000</armp:BaseAnnualRentToBePaidYearThree>
    <armp:AllowanceForTenantImprovementsReceivable
      contextRef="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw"
      decimals="-5"
      id="Narr_nKyQ2BbV0kelt7Ic5pFM8Q"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">7200000</armp:AllowanceForTenantImprovementsReceivable>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="As_Of_10_28_2021_LcUKzxrTdU69jwZCYCuVzw"
      decimals="-5"
      id="Narr_rEoIXen-s0qh2XTWtzjzXA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5000000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_PUy04orVEkeamaN9Haq8-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum annual lease payments under the Company&#x2019;s noncancelable operating leases as of December&#160;31, 2024, are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,716&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,784&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,996&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 64,857&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: amount representing interest &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,732)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of operating lease obligations &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 32,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,431)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Noncurrent operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27,694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_BQYsFjYvtkim9mr4IoHfSQ_3_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4716000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_7iAj3jgTo0-fRbQNTMfkrA_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5293000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_-KJdrYoH6kOkngJNc9Mrjg_5_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5452000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_YVxQc7FAEkamDfunfEQR5g_6_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_MnWnfQCJ_UqGeY_hTELI4A_7_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5784000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_iBCxE5dA9kSKX7JvPDIFCQ_8_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">37996000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_yZpO9N8sWkCqw5EW9VIHZw_9_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">64857000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_J6EyhHIgS06Cj0xDrEBr2A_10_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">32732000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_bgHFCEIBuEOtFt1IflqEGw_11_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">32125000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_uN6v24FpWkygxzhqwbuYVw_12_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4431000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="-3"
      id="Tc_FvQ__iGWbkihhqm4DXRJrQ_13_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">27694000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-5"
      id="Narr_Htt806vxDU-UtcdZ5sa3qQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">8400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-5"
      id="Narr_e-UL90Yz4EOSEcYxzxwVbA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">7400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeasePayment
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-5"
      id="Narr_K5asiLOq-0aFm_5PV09BKA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1700000</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-5"
      id="Narr_1W2ye1-8x0mK5VlQWFir2A"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1000000</us-gaap:VariableLeasePayment>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Group_3_V2AQYjmUWJ6580uNCxVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table summarizes supplemental cash flow information related to the Company&#x2019;s operating leases for the years ended December 31, 2024 and 2023 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 18,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term, years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;11.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.8pt;text-align:right;text-indent:-0.8pt;margin:0pt 0pt 0pt -2pt;"&gt;12.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate, %&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;13.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;13.9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-3"
      id="Tc_ppWh325-0kagClTIQ8hrUw_4_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9010000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-3"
      id="Tc_j2M5b7WLsE-kcDefiofgqA_4_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">18839000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      id="Tc_B7cDwQYwYEmmWnZC0SrOrg_2_3">P11Y8M26D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      id="Tc_BUGsvz-EEUi0wExLUQCFFA_2_6">P12Y9M14D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_wY8nxbIpXkai7qaiNEvAug"
      decimals="3"
      id="Tc_phmgxM_ilUqz-ChYI0AajA_3_3"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.139</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_tz9uduCNsUWcFfmyYDPepg"
      decimals="3"
      id="Tc_JhKSBNBVhkWoGenPc14Aqw_3_6"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.139</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <armp:AwardTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_a8CvShU-5k-jD48xA6Zvtw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Grants and Awards &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;MTEC Grant&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 15, 2020, the Company entered into an agreement (the &#x201c;MTEC Agreement&#x201d;) with MTEC, pursuant to which the Company received a $15.0 million&#160;award and entered into a multi-year program administered by the DoD through MTEC and managed by the Naval Medical Research Command (&#x201c;NMRC&#x201d;) &#x2013; Naval Advanced Medical Development (&#x201c;NAMD&#x201d;) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. &lt;span style="background:#ffffff;"&gt;On September 29, 2022, the MTEC Agreement was modified to increase the total award by &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$16.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million and extend the term into the third quarter of 2024. &lt;/span&gt;In July 2024, the MTEC Agreement was modified to &lt;span style="-sec-ix-hidden:Hidden_jN3anHbpa0isGOdK9gp3IA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;increase&lt;/span&gt;&lt;/span&gt; the total award by $5.3 million to $21.6 million and extend the term into the third quarter of 2025. The Company is using the award to partially fund a Phase&#160;1b/2a, randomized, double-blind, placebo-controlled, dose escalation clinical study of the Company&#x2019;s therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;&lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt;&#160;bacteremia infections. The MTEC Agreement specifies that the award will be paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the money received is not refundable to MTEC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The MTEC Agreement is effective through August 15, 2025.&#160;The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue in the statement of operations when related costs are incurred. The Company recognized $5.2 million and $4.5 million in grant revenue from the MTEC Agreement during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the Company had $0.7&#160;million and $1.5&#160;million as awards receivable from MTEC, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CFF Therapeutics Development Award&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 13, 2020, the Company entered into an award agreement (the &#x201c;Award Agreement&#x201d;) with Cystic Fibrosis Foundation (&#x201c;CFF&#x201d;), pursuant to which the Company received a Therapeutics Development Award of up to $5.0 million (the &#x201c;CFF Award&#x201d;). The CFF Award was used to fund a portion of the Company&#x2019;s Phase 1b/2a clinical trial of the&#160;&lt;i style="font-style:italic;"&gt;Pseudomonas aeruginosa &lt;/i&gt;(&#x201c;&lt;i style="font-style:italic;"&gt;P. aeruginosa&lt;/i&gt;&#x201d;)&lt;i style="font-style:italic;"&gt; &lt;/i&gt;phage candidate, AP-PA02, as a treatment for Pseudomonas airway infections in people with cystic fibrosis (&#x201c;CF&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The first payment under the Award Agreement, in the amount of $1.0 million, became due upon signing the Award Agreement and was received in April 2020. The remainder of the CFF Award was payable to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement. The total amount of the CFF award was recognized through December 2023 and no additional payments are expected.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Award Agreement), for a period of 360 days (an &#x201c;Interruption&#x201d;) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the Product for use in treating infections in CF patients (the &#x201c;CF Field&#x201d;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company&#x2019;s material failure to achieve certain development milestones. The Company&#x2019;s payment obligations survive the termination of the Award Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the CFF Award is in the scope of ASC 808. Accordingly, as discussed in Note 3, &#x201c;&lt;i style="font-style:italic;"&gt;Significant Accounting Policies&#x201d;&lt;/i&gt;, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. During year ended December 31, 2024 and 2023, the Company recognized zero and $0.3 million as credits to research and development expenses related to the CFF Award, respectively. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred. &lt;/p&gt;</armp:AwardTextBlock>
    <us-gaap:GovernmentAssistanceAwardAmount
      contextRef="As_Of_6_15_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_2_29PgfsbkCQszk3gpXeEQ"
      decimals="-5"
      id="Narr_f8PxUNU9qE-GUJu_I2cIcg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">15000000</us-gaap:GovernmentAssistanceAwardAmount>
    <us-gaap:GovernmentAssistanceAssetIncreaseCurrent
      contextRef="Duration_9_29_2022_To_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_V-g9tOqDXE2fXuEN9aCnWA"
      decimals="-5"
      id="Narr_TyPocBydxUmcwjwr3c1l5Q"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1300000</us-gaap:GovernmentAssistanceAssetIncreaseCurrent>
    <us-gaap:GovernmentAssistanceAwardAmount
      contextRef="As_Of_9_29_2022_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_e8KlhRKgsU2__dqtJNLl0Q"
      decimals="-5"
      id="Narr_YGglFY7e40GyhV9o8JdG_Q"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">16300000</us-gaap:GovernmentAssistanceAwardAmount>
    <us-gaap:GovernmentAssistanceAssetIncreaseCurrent
      contextRef="Duration_7_1_2024_To_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_f3OfRucBq0qiXxxXxag-WQ"
      decimals="-5"
      id="Narr_svuU-YuB-EaISSjXRYoZZQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5300000</us-gaap:GovernmentAssistanceAssetIncreaseCurrent>
    <us-gaap:GovernmentAssistanceAwardAmount
      contextRef="As_Of_7_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_XpvWEZpmi0eXkPlF_gpoDw"
      decimals="-5"
      id="Narr_7KraMHh-m0eXEoUYyUUjEA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">21600000</us-gaap:GovernmentAssistanceAwardAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_kA-sXj9xmUyv5HjdSnfDDQ"
      decimals="-5"
      id="Narr_xuxzWjFEUU2_sK3mw0AVAA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5200000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_6QVF5TJnNUu6xhAL_qid-w"
      decimals="-5"
      id="Narr_5e7SkLdyzEu_v1StVMNVvg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4500000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_ISHRxxWU70-yPTo0clBZbA"
      decimals="-5"
      id="Narr_Y6uSvkq-oEukouehnQszFA"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">700000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_AUoppBe8TkmxEisCXjCy5A"
      decimals="-5"
      id="Narr_YIAnl2FGcE2vVX_AbMip0Q"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1500000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GovernmentAssistanceAwardAmount
      contextRef="As_Of_3_13_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_HJ-pxCwh90SIPJv_UoUV2w"
      decimals="-5"
      id="Narr_51y6nJYqPUmDMfk3wPXQtQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5000000</us-gaap:GovernmentAssistanceAwardAmount>
    <armp:ProceedsFromGovernmentGrants
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_gXm3SotZZkifgZITvucSLg"
      decimals="-5"
      id="Narr_hpwEA6Jt1EOfNuE2KK5vbQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1000000</armp:ProceedsFromGovernmentGrants>
    <armp:AwardAgreementInterruptionPeriod
      contextRef="Duration_3_13_2020_To_3_13_2020_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_kfgQS3Y8DEmi378_OnwJhA"
      id="Narr_nDiVxGgrF02mkVWZhDAzVA">P360D</armp:AwardAgreementInterruptionPeriod>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_47SSxi3ckE-kheHf6e3v9A"
      decimals="-5"
      id="Narr_3VOrraB8WUuuQAR1C9mbnQ"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">0</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_GovernmentAssistanceTypeAxis_armp_AwardAgreementWithCysticFibrosisFoundationMember_6TQEKKE2Ck6FoFOmzAl5OQ"
      decimals="-5"
      id="Narr_QzalmkjByEKIrL8btERZ_w"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">300000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_KR2jf0F8k0mJv0-v2n8img">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. Employee Retirement Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s employees participate in an employee retirement plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986, as amended. All of the Company&#x2019;s employees who meet minimum eligibility requirements are eligible to participate in the plan. The Company did match contributions of $0.2 million to the 401(k)&#160;plan for the&#160;years ended December 31, 2024 and 2023.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_1wfCAXsX2kqnrHRLdaSxoQ"
      decimals="-5"
      id="Narr_Mt6MWNR9mk-R5GmC0tgu6A"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="-5"
      id="Narr_CGFSeQGNdEm18utgEW-a2A"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_1TQ2J93gHEG6CeMyoCOErA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15. Segment Reporting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;one&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; reportable operating segment, which is the business of developing a pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;). The Company&#x2019;s CODM is its Chief Executive Officer, who reviews financial information on an aggregate basis for &lt;/span&gt;purposes of assessing performance, making operating decisions, &lt;span style="background:#ffffff;"&gt;allocating resources and evaluating financial performance. The long-lived assets of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$14.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, which represents &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;99.3%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the Company&#x2019;s total long-lived assets, are maintained in the United States.&lt;/span&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table includes certain segment information for the years ended December 31, 2024 and 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:37.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AP-PA02: Non-Cystic Fibrosis Bronchiectasis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,922&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AP-PA02: Cystic Fibrosis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AP-SA02: Bacteremia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AP-SA02Prosthetic Joint Infection&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt; Expenses not allocated by projects&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,042&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total external research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,647&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development personnel expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,408&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 34,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative personnel expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,649&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 47,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 45,419&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,436)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40,890)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expense), net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23,520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,155)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,916)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="INF"
      id="Narr_1ZrkB-fawkKT2UDKjXh_4w"
      unitRef="Unit_Standard_segment_sNn8LuEmwE69rUms--yKEA">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      decimals="INF"
      id="Narr_P_x5LLx78UiMdclKPuIZ-w"
      unitRef="Unit_Standard_segment_sNn8LuEmwE69rUms--yKEA">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_u_Te-bqUOEC1eghs9nZXfA"
      decimals="-5"
      id="Narr_k-Nh4Q9gBEGOgn93J7C31w"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">14000000</us-gaap:PropertyPlantAndEquipmentNet>
    <armp:PercentageOfLongLivedAssetsInGeographicalLocation
      contextRef="As_Of_12_31_2024_srt_StatementGeographicalAxis_country_US_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_u_Te-bqUOEC1eghs9nZXfA"
      decimals="3"
      id="Narr_lhs1XDSyIkaeOg2llOVAHQ"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.993</armp:PercentageOfLongLivedAssetsInGeographicalLocation>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_7KfZSSu9vkKLnETwaNGWRQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:37.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:16.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AP-PA02: Non-Cystic Fibrosis Bronchiectasis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,922&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AP-PA02: Cystic Fibrosis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AP-SA02: Bacteremia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;AP-SA02Prosthetic Joint Infection&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt; Expenses not allocated by projects&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,042&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Total external research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,647&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development personnel expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,408&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 34,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 33,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative personnel expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 9,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,649&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 47,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 45,419&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,436)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40,890)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expense), net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 23,520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,155)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,916)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_EKKLA25N1kCI4reyBhRg1Q_3_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">5174000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_eSYA_ihpNk6yPBH32QZDBA_3_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4529000</us-gaap:RevenueNotFromContractWithCustomer>
    <armp:ExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_NonCysticFibrosisBronchiectasisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_Na4M3PweMUi2iIIsCkq_3Q"
      decimals="-3"
      id="Tc_ZaxlrltZuUaWvQCiHlKR9Q_6_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">6840000</armp:ExternalResearchAndDevelopmentExpense>
    <armp:ExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_NonCysticFibrosisBronchiectasisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_QTrcE4TKsUW11OtCkzUlvw"
      decimals="-3"
      id="Tc_WCkxPY9jbUaarOQxEQjTog_6_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4922000</armp:ExternalResearchAndDevelopmentExpense>
    <armp:ExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_CysticFibrosisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_-n5s3ugSiUWuw4UgnftWDw"
      decimals="-3"
      id="Tc_yp3MDJXowkucxTopIVTqvQ_7_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">236000</armp:ExternalResearchAndDevelopmentExpense>
    <armp:ExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_CysticFibrosisMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_DQ9wJoe1u0-IR7_CKaA1Cw"
      decimals="-3"
      id="Tc_j-hdJ_DrGUSYl0JedTlCjA_7_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">1692000</armp:ExternalResearchAndDevelopmentExpense>
    <armp:ExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_BacteremiaMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_nENRXrCZwUmEuUIiI0n0aA"
      decimals="-3"
      id="Tc_EMnA5DpR50eAGoQo4nGkhg_8_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4177000</armp:ExternalResearchAndDevelopmentExpense>
    <armp:ExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_BacteremiaMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_O6wXLenwPkqANS08n0zSCw"
      decimals="-3"
      id="Tc_seZjxHyHvUup4P9O2PHAVg_8_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4789000</armp:ExternalResearchAndDevelopmentExpense>
    <armp:ExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_ProstheticJointInfectionMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_cMxrWzKqB0aDivLktL7xSw"
      decimals="-3"
      id="Tc_ISnBdoQhiE-Yvafq2BLSgA_9_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">35000</armp:ExternalResearchAndDevelopmentExpense>
    <armp:ExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_armp_ProstheticJointInfectionMember_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_v56oVy0tEEyLTBl6m8fpVg"
      decimals="-3"
      id="Tc_OFLNvOyGrEyhgidsf1Iuug_9_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">202000</armp:ExternalResearchAndDevelopmentExpense>
    <armp:UnallocatedExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_uTOu-ivL10CLPk0FJmI4HQ_10_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2408000</armp:UnallocatedExternalResearchAndDevelopmentExpense>
    <armp:UnallocatedExternalResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_ZOtXsLh_IEyeqieYuqu5Hw_10_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">3042000</armp:UnallocatedExternalResearchAndDevelopmentExpense>
    <armp:ExternalResearchAndDevelopmentExpenseTotal
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_WIbmnIPIN0GW1WrGb5A-pw_11_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13696000</armp:ExternalResearchAndDevelopmentExpenseTotal>
    <armp:ExternalResearchAndDevelopmentExpenseTotal
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_CxXkcSdzW02o3Kj6q3Vjjg_11_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">14647000</armp:ExternalResearchAndDevelopmentExpenseTotal>
    <armp:ResearchAndDevelopmentPersonnelExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_J59_SAy1g0-8SlWj9NZKCA_12_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">10764000</armp:ResearchAndDevelopmentPersonnelExpense>
    <armp:ResearchAndDevelopmentPersonnelExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_a488KCnsnE2WfFq4BMDH4A_12_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9408000</armp:ResearchAndDevelopmentPersonnelExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_CndyhQrlMkS9l5G9j4AXQw_13_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9966000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_2v68BsniSUOy33fiOSHffQ_13_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9715000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_pVZFVOGlaEWIqmPeBjCe4A_14_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">34426000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_7LOG5u26EkaIEO3oXXa4DA_14_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">33770000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_scC7dwJP70mNrkXpT73Mxg_16_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">4935000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_vjSWbTCyBke8vGs-vZo3FA_16_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">2480000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_vp7_QM0EMUGyquIHe9ra-A_17_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">8249000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_JDQlBasb-0qQA930Byc7LA_17_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">9169000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_Ziw4X9yiRE629_m9MQd80Q_18_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">13184000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_jxS2NMGTv0ishk2fet6X8A_18_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">11649000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_mmpMHSqZRk2Et6j-ER0bIA_19_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">47610000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_hziixn8VEkSp5GPC2izKnw_19_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">45419000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_okIJjMMwXkqQeXHhvo4EdA_20_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-42436000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_roMO3npmLEanC4K2ndApgQ_20_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-40890000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_fA3eyl-eCEKidO3JbR0GEA_21_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">23520000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_44jhj4ojd0uHpFmB8W4brA_21_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-28155000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_We_2X-5ASUiP-CjKzKe-nA"
      decimals="-3"
      id="Tc_rIiO7spHO0OuiMFVEYW8iQ_22_3"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-18916000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_armp_SingleReportableSegmentMember_EJJXZgNcAEK2HRMzNcCtiw"
      decimals="-3"
      id="Tc_NtSH0aWr4E-_tgSwDeZK1Q_22_6"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">-69045000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Tb_0BcivYBHtU2ByozzzOOn3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16. Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On March 12, 2025, the Company entered into the 2025 Credit Agreement for the 2025 Loan in an aggregate amount of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million.The 2025 Loan bears interest at an annual rate of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;14.0%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and matures on March 12, 2026. Principal and accrued interest are payable at maturity. Repayment of the 2025 Loan is guaranteed by the Company&#x2019;s domestic subsidiaries, and the loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Concurrently with the execution of the 2025 Credit Agreement, the Company entered into amendments to (i) the Convertible Loan and Convertible Credit Agreement, (ii) the 2023 Loan and 2023 Credit Agreement, and (iii) the 2024 Loan and 2024 Credit Agreement, which, among other things, extended the maturity date of the Convertible Loan, 2023 Loan and 2024 Loan, respectively, to March 12, 2026.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw"
      decimals="-5"
      id="Narr_P3eC552nM0O0213kQ4radg"
      unitRef="Unit_Standard_USD_2M4w7cd4H0SRNKnxUCdtNA">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_12_2025_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_CreditAgreement2025Member_HPqYoPYAkEy4u_dzwSR2Gw"
      decimals="3"
      id="Narr_ImyRZEgPoEuOvqqhpW7LVw"
      unitRef="Unit_Standard_pure_QmbFNJQm8k2MSy0ql4czBQ">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg"
      id="Narr_hNR7mqMn_UusHGZSh2vNfQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg"
      id="Narr_H5Rf9LVLdEyJQKCS6hFVhQ">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg"
      id="Narr_5BlzwmS_8UqzufBtkaJzEg">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_mqOwCc0FxUqPAIAyL9fGRg"
      id="Narr_cTE77eauWkylA9mgkHYikA">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_nF97L7cjN0CgGOoZKDqFKg"
      id="Narr_zgLawxwJWkCALjy1AosmrQ">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
